Vomiting	O
can	O
thus	O
be	O
prevented	O
by	O
prokinetic	O
agents	O
(e.g.	O
domperidone	B-Drug
or	O
metoclopramide).	O
metoclopramide	B-Drug

Actemra/RoActemra	O
(tocilizumab),	O
for	O
rheumatoid	O
arthritis.	O
Actemra	B-Drug
tocilizumab	B-Drug

As	O
Australia	O
approached	O
Federation,	O
an	O
increasing	O
number	O
of	O
bills	O
were	O
passed	O
in	O
state	O
parliaments	O
to	O
restrict	O
the	O
use	O
opium.	O
opium	B-Drug

Non-dihydropyridine	O
calcium	O
channels	O
blockers	O
such	O
as	O
diltiazem	B-Drug
and	O
verapamil	B-Drug
are	O
preferable,	O
dihydropyridine	O
agents	O
nifedipine	O
have	O
much	O
higher	O
risk	O
of	O
reflex	O
tachycardia	O
(however,	O
clinicians	O
can	O
prevent	O
by	O
administering	O
beta-blockers	O
some	O
minutes	O
before	O
using	O
the	O
latter	O
class	O
CCBs).	O

By	O
2013,	O
case	O
reports	O
of	O
25I-NBOMe	B-Drug
intoxication,	O
with	O
and	O
without	O
analytic	O
confirmation	O
the	O
drug	O
in	O
body,	O
were	O
becoming	O
increasingly	O
common	O
medical	O
literature.25I-NBOMe	O
is	O
widely	O
rumored	O
to	O
be	O
orally	O
inactive;	O
however,	O
apparent	O
overdoses	O
have	O
occurred	O
via	O
oral	O
administration.	O

the	O
drug	O
effects	O
of	O
amphetamine,	O
and	O
vice	O
versa.	O
amphetamine	B-Drug

Ketorolac,	O
sold	O
under	O
the	O
brand	O
name	O
Toradol	B-Drug
among	O
others,	O
is	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
used	O
to	O
treat	O
pain.	O
Ketorolac	B-Drug

Research	O
efforts	O
have	O
been	O
focused	O
on	O
determining	O
how	O
thalidomide	B-Drug
causes	O
birth	O
defects	O
and	O
its	O
other	O
activities	O
in	O
the	O
human	O
body,	O
to	O
develop	O
safer	O
analogs,	O
find	O
further	O
uses	O
for	O
thalidomide.	O

JWH-018	B-Drug
may	O
cause	O
intense	O
anxiety,	O
agitation,	O
and,	O
in	O
rare	O
cases	O
(generally	O
with	O
non-regular	O
JWH	O
users),	O
has	O
been	O
assumed	O
to	O
have	O
the	O
of	O
seizures	O
and	O
convulsions	O
by	O
inhibiting	O
GABA	O
neurotransmission	O
more	O
effectively	O
than	O
THC.	O
THC	B-Drug

Paracetamol	B-Drug
consists	O
of	O
a	O
benzene	O
ring	O
core,	O
substituted	O
by	O
one	O
hydroxyl	O
group	O
and	O
the	O
nitrogen	O
atom	O
an	O
amide	O
in	O
para	O
(1,4)	O
pattern.	O

However,	O
it	O
is	O
far	O
less	O
effective	O
in	O
helping	O
patients	O
maintain	O
abstinence	O
or	O
retaining	O
them	O
the	O
drug-treatment	O
system	O
(retention	O
rates	O
average	O
12%	O
at	O
90	O
days	O
for	O
naltrexone,	O
naltrexone	B-Drug

HHC	O
A-796,260	B-Drug
A-834,735	B-Drug
A-836,339	B-Drug
A-955,840	O
A-40174	O
A-41988	O
A-42574	O
AB-001	B-Drug
AB-CHFUPYCA	B-Drug
AB-CHMFUPPYCA	B-Drug
AB-CHMINACA	B-Drug
AB-FUBICA	B-Drug
AB-FUBINACA	B-Drug
2-fluorobenzyl	O
isomer	O
AB-PICA	B-Drug
AB-PINACA	B-Drug

A	O
case	O
of	O
clinically	O
significant	O
interaction	O
with	O
potent	O
CYP2D6	O
inhibitor	O
terbinafine	B-Drug
has	O
been	O
reported.	O

Patients	O
already	O
prescribed	O
oxycodone	B-Drug
will	O
receive	O
coverage	O
for	O
an	O
additional	O
year	O
OxyNeo,	O
and	O
after	O
that,	O
it	O
be	O
disallowed	O
unless	O
designated	O
under	O
the	O
exceptional	O
access	O
program.	O

LSD-Pip	O
is	O
a	O
compound	O
from	O
the	O
ergoline	O
family,	O
related	O
to	O
LSD	B-Drug
but	O
with	O
N,N-diethyl	O
substitution	O
replaced	O
by	O
piperidine	O
group.	O

For	O
comparison,	O
MOR	O
full	O
agonists	O
are	O
all	O
Schedule	O
II	O
in	O
the	O
United	O
States,	O
whereas	O
mixed	O
KOR	O
and	O
agonists/antagonists	O
butorphanol	B-Drug
pentazocine	B-Drug
IV	O
States.	O

Nicotine	B-Drug
can	O
be	O
quantified	O
in	O
blood,	O
plasma,	O
or	O
urine	O
to	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
facilitate	O
medicolegal	O
death	O
investigation.	O

Notably,	O
in	O
the	O
state	O
of	O
Florida,	O
items,	O
"designed	O
for	O
use	O
ingesting,	O
inhaling,	O
or	O
otherwise	O
introducing	O
cannabis,	O
cocaine,	O
hashish,	O
hashish	B-Drug
oil,	O
nitrous	O
oxide	O
into	O
human	O
body"	O
are	O
illegal,	O
while	O
"pipes	O
primarily	O
made	O
briar,	O
meerschaum,	O
clay,	O
corn	O
cob"	O
legal.	O
cocaine	B-Drug
oil	I-Drug

The	O
availability	O
of	O
ethylestrenol	B-Drug
is	O
very	O
limited.	O

Around	O
2011,	O
people	O
who	O
consumed	O
the	O
cocktail	O
were	O
often	O
viewed	O
more	O
negatively	O
than	O
users	O
of	O
traditional	O
kratom,	O
but	O
not	O
as	O
heroin.	O
kratom	B-Drug
heroin	B-Drug

O-Acetylpsilocin	B-Drug
can	O
be	O
considered	O
an	O
analog	O
of	O
psilocin	B-Drug
making	O
it	O
a	O
Schedule	O
9	O
prohibited	O
substance	O
in	O
Australia	O
under	O
the	O
Poisons	O
Standard	O
(October	O
2015).	O

The	O
drug	O
was	O
subsequently	O
reinvented	O
from	O
a	O
failed	O
contraceptive,	O
to	O
become	O
tamoxifen,	O
the	O
gold	O
standard	O
for	O
adjuvant	O
treatment	O
of	O
breast	O
cancer	O
and	O
pioneering	O
medicine	O
chemprevention	O
high	O
risk	O
women.	O
tamoxifen	B-Drug

The	O
Dutch,	O
British	O
and	O
French	O
system	O
called	O
the	O
System	O
of	O
Objectified	O
Judgement	O
Analysis	O
for	O
assessing	O
whether	O
drugs	O
should	O
be	O
included	O
in	O
drug	O
formularies	O
based	O
on	O
clinical	O
efficacy,	O
adverse	O
effects,	O
pharmacokinetic	O
properties,	O
toxicity,	O
interactions	O
was	O
used	O
to	O
assess	O
nitrazepam.	O
nitrazepam	B-Drug

Life-threatening	O
adverse	O
reactions	O
have	O
been	O
observed	O
at	O
doses	O
of	O
only	O
3	O
mg	O
flubromazolam.	O
flubromazolam	B-Drug

Dextroamphetamine	B-Drug
is	O
a	O
central	O
nervous	O
system	O
(CNS)	O
stimulant	O
and	O
an	O
amphetamine	B-Drug
enantiomer	O
that	O
prescribed	O
for	O
the	O
treatment	O
of	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(ADHD)	O
narcolepsy.	O

Nimetazepam	B-Drug
has	O
a	O
reputation	O
for	O
being	O
particularly	O
subject	O
to	O
abuse	O
(known	O
as	O
'Happy	O
5',	O
sold	O
an	O
ecstasy	B-Drug
replacement	O
without	O
hangover).	O

These	O
effects	O
appear	O
to	O
be	O
due	O
their	O
local	O
anesthetic	O
activity	O
and	O
are	O
not	O
reversed	O
by	O
naloxone.	O
naloxone	B-Drug

Globally,	O
bromazepam	B-Drug
is	O
contraindicated	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
women	O
who	O
are	O
pregnant,	O
the	O
elderly,	O
patients	O
a	O
history	O
of	O
alcohol	O
or	O
other	O
substance	O
abuse	O
disorders	O
children.	O

Similarly,	O
octreotide	B-Drug
can	O
be	O
used	O
to	O
treat	O
refractory	O
chronic	O
hypotension.	O

She	O
took	O
the	O
standard	O
prescribed	O
dose,	O
however	O
experienced	O
nausea	O
and	O
dizziness	O
while	O
she	O
was	O
taking	O
codeine.	O
codeine	B-Drug

Desipramine	B-Drug
was	O
developed	O
by	O
Geigy.	O

While	O
MDMA-related	O
compounds	O
possess	O
a	O
structure	O
similar	O
to	O
mescaline	B-Drug
and	O
has	O
hallucinogenic	O
properties	O
on	O
top	O
of	O
pyschostimulant	O
properties.	O

Methyltestosterone	B-Drug
has	O
also	O
been	O
marketed	O
in	O
many	O
other	O
countries	O
throughout	O
the	O
world.	O

While	O
researching	O
lysergic	O
acid	B-Drug
derivatives,	O
Hofmann	O
first	O
synthesized	O
LSD	O
on	O
November	O
16,	O
1938.	O

If	O
consumed	O
with	O
alcohol,	O
cocaine	B-Drug
combines	O
alcohol	O
in	O
the	O
liver	O
to	O
form	O
cocaethylene.	O
cocaethylene	B-Drug

It	O
has	O
been	O
implicated	O
in	O
addictions	O
to	O
alcohol,	O
cannabinoids,	O
cocaine,	O
methylphenidate,	O
nicotine,	O
opioids,	O
phencyclidine,	O
propofol,	O
and	O
substituted	O
amphetamines,	O
among	O
others.	O
cocaine	B-Drug
methylphenidate	B-Drug
nicotine	B-Drug
phencyclidine	B-Drug
propofol	B-Drug

Large	O
seizures	O
of	O
cocaine	B-Drug
are	O
not	O
only	O
a	O
success	O
for	O
local	O
and	O
national	O
authorities	O
in	O
getting	O
off	O
the	O
streets,	O
but	O
also	O
prevent	O
it	O
from	O
continuing	O
illegal	O
supply	O
chain	O
to	O
other	O
countries.	O

The	O
price	O
of	O
opium	B-Drug
paste	O
is	O
fixed	O
by	O
the	O
government	O
according	O
to	O
quality	O
and	O
quantity	O
tendered.	O

Levothyroxine	B-Drug
is	O
available	O
as	O
a	O
generic	O
medication.	O

Linagliptin	B-Drug
is	O
the	O
INN.	O

Roughly	O
90%	O
of	O
ingested	O
amphetamine	B-Drug
is	O
eliminated	O
3	O
days	O
after	O
the	O
last	O
oral	O
dose.	O

Benzodiazepines,	O
such	O
as	O
alprazolam,	O
clonazepam,	O
lorazepam	B-Drug
and	O
diazepam,	O
can	O
cause	O
both	O
depression	O
mania.	O
alprazolam	B-Drug
clonazepam	B-Drug
diazepam	B-Drug

The	O
role	O
of	O
the	O
therapist	O
was	O
minimized	O
in	O
favor	O
patient	O
self-discovery	O
accompanied	O
by	O
MDMA	B-Drug
induced	O
feelings	O
empathy.	O

In	O
the	O
United	O
Kingdom,	O
MDMA	B-Drug
was	O
made	O
illegal	O
in	O
1977	O
by	O
a	O
modification	O
order	O
to	O
existing	O
Misuse	O
of	O
Drugs	O
Act	O
1971.	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

The	O
locomotor	O
enhancing	O
properties	O
of	O
cocaine	B-Drug
may	O
be	O
attributable	O
to	O
its	O
enhancement	O
dopaminergic	O
transmission	O
from	O
the	O
substantia	O
nigra.	O

Diazepam	B-Drug
also	O
increases	O
the	O
volume	O
of	O
alcohol	O
consumed	O
by	O
problem	O
drinkers.	O

If	O
taken	O
together	O
with	O
drugs	O
that	O
induce	O
the	O
CYP3A4	O
cytochrome	O
P450	O
liver	O
enzyme,	O
levonorgestrel	B-Drug
may	O
be	O
metabolized	O
faster	O
and	O
have	O
lower	O
effectiveness.	O

The	O
figures	O
for	O
the	O
6,020	O
powder	O
cocaine	B-Drug
convictions,	O
in	O
contrast,	O
were	O
as	O
follows:	O
17%	O
of	O
these	O
offenders	O
white,	O
28%	O
black,	O
and	O
53%	O
Hispanic.	O

Compared	O
to	O
testosterone	O
and	O
many	O
other	O
AAS,	O
oxandrolone	B-Drug
is	O
less	O
androgenic	O
relative	O
its	O
strength	O
as	O
an	O
anabolic.	O

,	O
animal	O
studies	O
and	O
at	O
least	O
three	O
human	O
case	O
reports	O
have	O
found	O
no	O
interaction	O
between	O
ketamine	B-Drug
the	O
monoamine	O
oxidase	O
inhibitor	O
(MAOI)	O
tranylcypromine,	O
which	O
is	O
of	O
importance	O
as	O
combination	O
a	O
reuptake	O
with	O
an	O
MAOI	O
can	O
produce	O
severe	O
toxicity	O
such	O
serotonin	O
syndrome	O
or	O
hypertensive	O
crisis.	O
tranylcypromine	B-Drug

-methyl-thiofentanyl	O
is	O
an	O
opioid	O
analgesic	O
that	O
analogue	O
of	O
fentanyl.	O
fentanyl	B-Drug

The	O
adrenal	O
medulla	O
is	O
a	O
minor	O
contributor	O
to	O
total	O
circulating	O
catecholamines	O
(L-DOPA	O
at	O
higher	O
concentration	O
in	O
the	O
plasma),	O
though	O
it	O
contributes	O
over	O
90%	O
of	O
adrenaline.	O
L-DOPA	B-Drug

It	O
is	O
possible	O
that	O
other	O
manufacturers	O
distribute	O
10	O
mg	O
tablets	O
and	O
concentrations	O
of	O
injectable	O
nicomorphine	B-Drug
in	O
ampoules	O
multidose	O
vials.	O

However,	O
a	O
handful	O
of	O
biologic	O
medicines,	O
including	O
biosynthetic	O
insulin,	O
growth	O
hormone,	O
glucagon,	O
calcitonin,	O
and	O
hyaluronidase	B-Drug
are	O
grandfathered	O
under	O
governance	O
the	O
Federal	O
Food	O
Drug	O
Cosmetics	O
Act,	O
because	O
these	O
products	O
were	O
already	O
approved	O
when	O
legislation	O
to	O
regulate	O
biotechnology	O
medicines	O
later	O
passed	O
as	O
part	O
Public	O
Health	O
Services	O
Act.	O

heroin	B-Drug
and	O
cocaine	B-Drug
MDMA	B-Drug
(2010)	O

Clonazepam	B-Drug
is	O
also	O
effective	O
in	O
the	O
management	O
of	O
acute	O
mania.	O

JWH-018	B-Drug
is	O
one	O
of	O
these	O
compounds,	O
with	O
studies	O
showing	O
an	O
affinity	O
for	O
the	O
cannabinoid	O
(CB1)	O
receptor	O
five	O
times	O
greater	O
than	O
that	O
THC.	O
THC	B-Drug

The	O
major	O
metabolite	O
of	O
bromazepam	B-Drug
is	O
hydroxybromazepam,	O
which	O
an	O
active	O
agent	O
too	O
and	O
has	O
a	O
half-life	O
approximately	O
equal	O
to	O
that	O
bromazepam.	O

In	O
addition,	O
students	O
who	O
associated	O
with	O
the	O
rave	O
culture	O
admit	O
to	O
struggling	O
psychedelic	O
substance	O
abuse	O
such	O
as	O
LSD	B-Drug
and	O
psilocybin	O
mushrooms.	O

Mannitol	B-Drug
is	O
a	O
type	O
of	O
sugar	O
alcohol	O
used	O
as	O
sweetener	O
and	O
medication.	O

Virola	O
multinervia,	O
DMT,	O
5-MeO-DMT	B-Drug
in	O
bark	O
and	O
roots	O

presumably	O
exhibits	O
functional	O
selectivity	O
at	O
the	O
5HT2A	O
receptor	O
similar	O
to	O
other	O
phenethylamine	B-Drug
hallucinogens,	O
activating	O
Phospholipase	O
A2	O
signal	O
cascade,	O
which	O
is	O
responsible	O
for	O
release	O
of	O
Thromboxane	O
A2,	O
triggering	O
blood	O
platelet	O
aggregation.	O

Sofosbuvir	B-Drug
in	O
combination	O
with	O
velpatasvir	B-Drug
is	O
recommended	O
for	O
all	O
genotypes	O
a	O
cure	O
rate	O
greater	O
than	O
90%,	O
and	O
close	O
to	O
100%	O
most	O
cases.	O

As	O
hashish	B-Drug
is	O
a	O
derivative	O
of	O
cannabis,	O
it	O
possesses	O
identical	O
psychoactive	O
and	O
biological	O
effects.	O

(amiloride	O
hydrochloride	O
with	O
furosemide)	O
amiloride	B-Drug

Large-scale	O
international	O
heroin	B-Drug
production	O
effectively	O
ended	O
in	O
China	O
with	O
the	O
victory	O
of	O
communists	O
civil	O
war	O
late	O
1940s.	O

Subsequently,	O
other	O
benzomorphans,	O
such	O
as	O
pentazocine	B-Drug
(an	O
N-dimethylallylbenzomorphan),	O
cyclazocine	O
N-cyclopropylmethylbenzomorphan),	O
and	O
phenazocine	B-Drug
N-phenylethylbenzomorphan),	O
were	O
developed,	O
some	O
have	O
been	O
marketed	O
for	O
use	O
analgesics.	O

As	O
of	O
17	O
October	O
2018	O
when	O
recreational	O
use	O
cannabis	O
was	O
legalized	O
in	O
Canada,	O
dietary	O
supplements	O
for	O
human	O
and	O
veterinary	O
health	O
products	O
containing	O
not	O
more	O
than	O
10	O
parts	O
per	O
million	O
THC	B-Drug
extract	O
were	O
approved	O
marketing;	O
Nabiximols	B-Drug
(as	O
Sativex)	O
is	O
used	O
as	O
a	O
prescription	O
drug	O
Canada.	O
Sativex	B-Drug

In	O
September	O
1965,	O
Stanley	O
became	O
the	O
primary	O
LSD	B-Drug
supplier	O
to	O
Ken	O
Kesey	O
and	O
Merry	O
Pranksters.	O

Lysergic	O
acid,	O
also	O
known	O
as	O
D-lysergic	O
acid	B-Drug
and	O
(+)-lysergic	O
is	O
a	O
precursor	O
for	O
wide	O
range	O
of	O
ergoline	O
alkaloids	O
that	O
are	O
produced	O
by	O
the	O
ergot	O
fungus	O
found	O
in	O
seeds	O
Turbina	O
corymbosa	O
(ololiuhqui),	O
Argyreia	O
nervosa	O
(Hawaiian	O
baby	O
woodrose),	O
Ipomoea	O
tricolor	O
(morning	O
glories,	O
tlitliltzin).	O

The	O
most	O
common	O
salt	O
of	O
MDMA	B-Drug
is	O
the	O
hydrochloride	O
salt;	O
pure	O
water-soluble	O
and	O
appears	O
as	O
a	O
white	O
or	O
off-white	O
powder	O
crystal.	O

Synthetic	O
cocaine	B-Drug
would	O
be	O
highly	O
desirable	O
to	O
the	O
illegal	O
drug	O
industry	O
as	O
it	O
eliminate	O
high	O
visibility	O
and	O
low	O
reliability	O
of	O
offshore	O
sources	O
international	O
smuggling,	O
replacing	O
them	O
with	O
clandestine	O
domestic	O
laboratories,	O
are	O
common	O
for	O
illicit	O
methamphetamine.	O
methamphetamine	B-Drug

Due	O
to	O
its	O
effects	O
on	O
increasing	O
Na+	O
levels,	O
and	O
therefore	O
blood	O
volume,	O
fludrocortisone	B-Drug
is	O
the	O
first	O
line	O
of	O
treatment	O
for	O
orthostatic	O
intolerance	O
postural	O
tachycardia	O
syndrome	O
(POTS).	O

Pure	O
morphine	B-Drug
and	O
heroin	B-Drug
are	O
both	O
fine	O
powders.	O

A	O
randomized	O
controlled	O
trial	O
found	O
greater	O
improvement	O
from	O
two	O
sachets	O
(26	O
grams)	O
of	O
PEG	B-Drug
versus	O
(20	O
lactulose.	O
lactulose	B-Drug

Ro4-1539	B-Drug

Natural	O
opioids:	O
codeine	B-Drug
alkaloid	O
contained	O
in	O
opium	O
and	O
poppy	O
strawSemisynthetic	O
acetyldihydrocodeine	B-Drug
dihydrocodeine	B-Drug
ethylmorphine	B-Drug
nicocodine	B-Drug
nicodicodine	B-Drug
pholcodineNatural	O
metabolite:	O
norcodeineSynthetic	O
open	O
chain	O
opioids	O

Hash	B-Drug
oil	I-Drug
can	O
be	O
the	O
most	O
potent	O
of	O
main	O
cannabis	O
products	O
because	O
its	O
high	O
level	O
psychoactive	O
compound	O
per	O
volume,	O
which	O
vary	O
depending	O
on	O
plant's	O
mix	O
essential	O
oils	O
and	O
compounds.	O

"	O
The	O
abbreviation	O
"LSD"	O
is	O
from	O
the	O
German	O
"Lysergsurediethylamid".	O
LSD	B-Drug

At	O
very	O
high	O
doses	O
it	O
has	O
also	O
been	O
demonstrated	O
to	O
induce	O
glutathione	O
S-transferase	O
A1/glutathione	O
A2	O
in	O
rats,	O
although	O
the	O
required	O
achieve	O
this	O
effect	O
a	O
clinically	O
significant	O
degree	O
fall	O
within	O
range	O
of	O
butalbital's	O
LD50,	O
making	O
its	O
use	O
for	O
purpose	O
impractical	O
and	O
highly	O
dangerous	O
(this	O
not	O
yet	O
tested	O
human	O
models,	O
is	O
therefore	O
unknown	O
whether	O
or	O
GS-T	O
induction	O
plays	O
role	O
effects	O
humans,	O
even	O
occurs	O
at	O
all).	O
butalbital	B-Drug

The	O
Guadalajara	O
Cartel	O
managed	O
to	O
traffic	O
cocaine	B-Drug
the	O
U.S.	O
in	O
multi-ton	O
shipments	O
each	O
month.	O

Spironolactone	B-Drug
has	O
not	O
been	O
well	O
studied	O
in	O
pregnancy	O
and	O
should	O
be	O
used	O
to	O
treat	O
high	O
blood	O
pressure	O
of	O
pregnancy.	O

Based	O
on	O
in	O
vitro	O
research,	O
ethisterone	O
and	O
norethisterone	B-Drug
are	O
about	O
equipotent	O
their	O
EC50	O
values	O
for	O
activation	O
of	O
the	O
androgen	O
receptor	O
(AR),	O
whereas,	O
conversely,	O
shows	O
markedly	O
increased	O
potency	O
relative	O
to	O
terms	O
its	O
progesterone	O
receptor.	O

Dexamethasone	B-Drug
is	O
used	O
to	O
treat	O
many	O
inflammatory	O
and	O
autoimmune	O
disorders,	O
such	O
as	O
rheumatoid	O
arthritis	O
bronchospasm.	O

Ketamine	B-Drug
is	O
used	O
in	O
chemsex	O
encounters	O
to	O
"improve	O
the	O
experience	O
of	O
receptive	O
anal	O
intercourse	O
or	O
fisting".	O

Nicodicodeine	B-Drug
is	O
not	O
assigned	O
an	O
ACSCN	O
and	O
presumably	O
controlled	O
as	O
either	O
ester	O
of	O
dihydromorphine	B-Drug
or	O
derivative	O
nicomorphine.	O
nicomorphine	B-Drug

According	O
to	O
David	O
Nutt,	O
MDMA	B-Drug
was	O
widely	O
used	O
in	O
the	O
western	O
US	O
couples	O
counseling,	O
and	O
called	O
empathy.	O

Additionally,	O
apremilast	B-Drug
was	O
approved	O
by	O
the	O
FDA	O
in	O
March	O
2014.	O

Oldham	O
Kelsey	O
was	O
given	O
a	O
Presidential	O
award	O
for	O
distinguished	O
service	O
from	O
the	O
federal	O
government	O
not	O
allowing	O
thalidomide	B-Drug
to	O
be	O
approved	O
sale	O
in	O
US.In	O
Canada,	O
history	O
of	O
dates	O
back	O
April	O
1,	O
1961.	O

For	O
much	O
of	O
the	O
20th	O
century,	O
pethidine	B-Drug
was	O
opioid	O
choice	O
for	O
many	O
physicians;	O
in	O
1975,	O
60%	O
doctors	O
prescribed	O
it	O
acute	O
pain	O
and	O
22%	O
chronic	O
severe	O
pain.	O

Melatonin	B-Drug
a	O
hypnotic	O
used	O
to	O
treat	O
insomnia.	O

Naloxone	B-Drug
injection	O
and	O
the	O
nasal	O
spray	O
are	O
both	O
commonly	O
used	O
in	O
adults	O
children	O
who	O
going	O
through	O
drug	O
overdose	O
because	O
it	O
is	O
successful	O
reversing	O
effects	O
As	O
a	O
safety	O
precaution,	O
patients	O
taking	O
opioids	O
recommended	O
to	O
always	O
carry	O
naloxone	B-Drug
with	O
them	O
should	O
replace	O
regularly,	O
via	O
reference	O
expiration	O
date.	O

In	O
January	O
2018,	O
9	O
individuals	O
were	O
hospitalized	O
in	O
Perth,	O
Western	O
Australia,	O
after	O
reportedly	O
ingesting	O
hyoscine.	O
hyoscine	B-Drug

Amphetamine	B-Drug
was	O
first	O
synthesized	O
in	O
1887	O
Germany	O
by	O
Romanian	O
chemist	O
Lazr	O
Edeleanu	O
who	O
named	O
it	O
phenylisopropylamine;	O
its	O
stimulant	O
effects	O
remained	O
unknown	O
until	O
1927,	O
when	O
independently	O
resynthesized	O
Gordon	O
Alles	O
and	O
reported	O
to	O
have	O
sympathomimetic	O
properties.	O

In	O
animal	O
studies	O
the	O
IC50	O
or	O
half	O
maximal	O
inhibitory	O
concentration	O
for	O
acrylfentanyl	B-Drug
to	O
displace	O
naloxone	B-Drug
is	O
1.4	O
nM,	O
being	O
slightly	O
more	O
potent	O
than	O
fentanyl	B-Drug
itself	O
(1.6	O
nM)	O
as	O
well	O
having	O
a	O
longer	O
duration	O
of	O
action.	O

I	O
cannabinoids	O
such	O
as	O
CP-47,497,	O
and	O
therefore	O
sales	O
or	O
possession	O
could	O
potentially	O
be	O
prosecuted	O
under	O
the	O
Federal	O
Analogue	O
Act.	O
CP-47,497	B-Drug

As	O
of	O
October	O
2015,	O
MDMB-FUBINACA	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
Belarus,	O
Russia,	O
and	O
China.	O

As	O
a	O
result	O
of	O
several	O
expert	O
witnesses	O
testifying	O
that	O
MDMA	B-Drug
had	O
an	O
accepted	O
medical	O
usage,	O
the	O
administrative	O
law	O
judge	O
presiding	O
over	O
hearings	O
recommended	O
be	O
classified	O
as	O
Schedule	O
III	O
substance.	O

General	O
practitioners	O
are	O
now	O
advised	O
to	O
prescribe	O
it	O
as	O
generic	O
dipipanone/cyclizine	O
tablets.	O
dipipanone	B-Drug
cyclizine	B-Drug

Similarly,	O
oxandrolone	B-Drug
has	O
as	O
much	O
6	O
times	O
the	O
anabolic	O
potency	O
of	O
testosterone	O
and	O
significantly	O
reduced	O
androgenic	O
in	O
comparison.	O

The	O
etizolam	B-Drug
molecule	O
differs	O
from	O
a	O
benzodiazepine	O
in	O
that	O
the	O
benzene	O
ring	O
has	O
been	O
replaced	O
by	O
thiophene	O
and	O
triazole	O
fused,	O
making	O
drug	O
thienotriazolodiazepine.	O

The	O
effectiveness	O
of	O
spironolactone	B-Drug
in	O
the	O
treatment	O
both	O
acne	O
and	O
hirsutism	O
appears	O
to	O
be	O
dose-dependent,	O
with	O
higher	O
doses	O
being	O
more	O
effective	O
than	O
lower	O
doses.	O

Marks	O
and	O
Plinston	O
persuaded	O
McCann	O
to	O
smuggle	O
hashish	B-Drug
into	O
Ireland	O
from	O
Kabul,	O
which	O
the	O
pair	O
would	O
then	O
ferry	O
over	O
Wales	O
England;	O
get	O
drugs	O
through	O
freeport	O
at	O
Shannon	O
Airport	O
using	O
his	O
IRA	O
connections.	O

Acetorphine	B-Drug
is	O
illegal	O
in	O
Germany	O
(Anlage	O
I)	O

Thus,	O
over	O
90%	O
of	O
the	O
world	O
production	O
legal	O
opiates,	O
including	O
medical	O
morphine,	O
now	O
is	O
produced	O
from	O
poppy	O
straw.	O
morphine	B-Drug

This	O
is	O
not	O
a	O
common	O
practice	O
anymore,	O
however,	O
owing	O
to	O
the	O
dangers	O
of	O
long-term	O
use	O
barbiturates;	O
they	O
have	O
been	O
replaced	O
by	O
benzodiazepines	O
and	O
Z-drugs	O
such	O
as	O
zolpidem,	O
zaleplon	B-Drug
eszopiclone	B-Drug
for	O
sleep.	O
zolpidem	B-Drug

Cyclobarbital	B-Drug
(5-(1-cyclohexen-1-yl)-5-ethylbarbituric	O
acid)	O

On	O
September	O
19,	O
1966,	O
Leary	O
reorganized	O
the	O
IFIF/Castalia	O
Foundation	O
under	O
nomenclature	O
of	O
League	O
for	O
Spiritual	O
Discovery,	O
a	O
religion	O
with	O
LSD	B-Drug
as	O
its	O
holy	O
sacrament,	O
in	O
part	O
an	O
unsuccessful	O
attempt	O
to	O
maintain	O
legal	O
status	O
use	O
and	O
other	O
psychedelics	O
religion's	O
adherents,	O
based	O
on	O
"freedom	O
religion"	O
argument.	O

The	O
treatment	O
was	O
attempted	O
despite	O
the	O
ban	O
on	O
thalidomide's	O
use,	O
and	O
results	O
were	O
favourable:	O
patient	O
slept	O
for	O
hours	O
able	O
to	O
get	O
out	O
of	O
bed	O
without	O
aid	O
upon	O
awakening.	O
thalidomide	B-Drug

They	O
first	O
marketed	O
naproxen	B-Drug
sodium	I-Drug
under	O
the	O
brand	O
name	O
Anaprox	B-Drug
in	O
1980.	O

Sodium	B-Drug
oxybate	I-Drug
is	O
approved	O
by	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
cataplexy	O
associated	O
with	O
narcolepsy	O
excessive	O
daytime	O
sleepiness	O
(EDS)	O
narcolepsy.	O

presumably	O
exhibits	O
functional	O
selectivity	O
at	O
the	O
5HT2A	O
receptor	O
similar	O
to	O
other	O
phenethylamine	B-Drug
hallucinogens,	O
activating	O
Phospholipase	O
A2	O
signal	O
cascade,	O
which	O
is	O
responsible	O
for	O
release	O
of	O
Thromboxane	O
A2,	O
triggering	O
blood	O
platelet	O
aggregation.	O

The	O
longer	O
half-life	O
of	O
quazepam	B-Drug
may	O
have	O
the	O
advantage	O
however,	O
causing	O
less	O
rebound	O
insomnia	O
than	O
shorter	O
acting	O
subtype	O
selective	O
nonbenzodiazepines.	O

Studies	O
have	O
shown	O
that	O
alcohol	O
and	O
tobacco	B-Drug
may	O
additionally	O
be	O
regarded	O
as	O
gateway	O
drugs;	O
however,	O
a	O
more	O
parsimonious	O
explanation	O
could	O
cannabis	O
is	O
simply	O
readily	O
available	O
(and	O
at	O
an	O
earlier	O
age)	O
than	O
illegal	O
hard	O
drugs.	O

Information	O
on	O
their	O
use	O
is	O
largely	O
anecdotal	O
with	O
reports	O
of	O
increased	O
sexual	O
pleasure	O
and	O
the	O
effects	O
drug	O
lasting	O
longer,	O
though	O
as	O
methamphetamine	B-Drug
centrally	O
active	O
in	O
brain,	O
these	O
are	O
likely	O
experienced	O
through	O
higher	O
bioavailability	O
bloodstream	O
faster	O
onset	O
action	O
than	O
many	O
other	O
routes	O
administration.	O

In	O
1992,	O
Eric	O
Taub	O
brought	O
ibogaine	B-Drug
to	O
an	O
offshore	O
location	O
close	O
the	O
United	O
States,	O
where	O
he	O
began	O
providing	O
treatments	O
and	O
popularizing	O
its	O
use.	O

The	O
oral	O
bioavailability	O
of	O
gabapentin	B-Drug
is	O
approximately	O
80%	O
at	O
100	O
mg	O
administered	O
three	O
times	O
daily	O
once	O
every	O
8	O
hours,	O
but	O
decreases	O
to	O
60%	O
300	O
mg,	O
47%	O
400	O
34%	O
800	O
33%	O
1,200	O
and	O
27%	O
1,600	O
all	O
with	O
the	O
same	O
dosing	O
schedule.	O

The	O
Marihuana	B-Drug
Tax	O
Act	O
of	O
1937	O
effectively	O
made	O
possession	O
or	O
transfer	O
marijuana	O
illegal	O
throughout	O
the	O
United	O
States	O
under	O
federal	O
law,	O
excluding	O
medical	O
and	O
industrial	O
uses,	O
through	O
imposition	O
an	O
excise	O
tax	O
on	O
all	O
sales	O
hemp.	O

troublesome	O
side	O
effects	O
of	O
oral	O
morphine,	O
hydromorphone,	O
or	O
oxycodone.	O
morphine	B-Drug
hydromorphone	B-Drug
oxycodone	B-Drug

In	O
low	O
doses,	O
methamphetamine	B-Drug
can	O
cause	O
an	O
elevated	O
mood	O
and	O
increase	O
alertness,	O
concentration,	O
energy	O
in	O
fatigued	O
individuals.	O

Additionally,	O
research	O
on	O
the	O
neurobiological	O
effects	O
of	O
physical	O
exercise	O
suggests	O
that	O
daily	O
aerobic	O
exercise,	O
especially	O
endurance	O
(e.g.,	O
marathon	O
running),	O
prevents	O
development	O
drug	O
addiction	O
and	O
is	O
an	O
effective	O
adjunct	O
therapy	O
(i.e.,	O
a	O
supplemental	O
treatment)	O
for	O
amphetamine	B-Drug
addiction.	O

While	O
ketamine	B-Drug
is	O
legally	O
marketed	O
in	O
many	O
countries	O
worldwide,	O
it	O
also	O
a	O
controlled	O
substance	O
countries.	O

Sufentanil,	O
sold	O
under	O
the	O
brand	O
names	O
Dsuvia	O
and	O
Sufenta,	O
is	O
a	O
synthetic	O
opioid	O
analgesic	O
drug	O
approximately	O
5	O
to	O
10	O
times	O
as	O
potent	O
its	O
parent	O
drug,	O
fentanyl,	O
500	O
morphine.	O
Sufentanil	B-Drug
fentanyl	B-Drug
morphine	B-Drug

The	O
concentration	O
of	O
naphyrone	B-Drug
required	O
to	O
inhibit	O
the	O
transporters	O
by	O
50%	O
is	O
46.0nM	O
5.5	O
for	O
SERT,	O
40.0nM	O
13	O
DAT	O
and	O
11.7nM	O
0.9	O
NET.	O

U-47700	B-Drug
was	O
emergency	O
scheduled	O
in	O
Florida	O
on	O
September	O
27,	O
2016	O
by	O
an	O
rule	O
of	O
Attorney	O
General	O
Pam	O
Bondi.	O

Fentanyl	B-Drug
was	O
often	O
produced	O
in	O
China	O
and	O
exported	O
illegally	O
to	O
the	O
U.S.	O

The	O
average	O
THC	B-Drug
level	O
in	O
coffee	O
shops	O
the	O
Netherlands	O
is	O
about	O
1819%.The	O
levels	O
of	O
cannabis	O
sold	O
United	O
States	O
rose	O
dramatically	O
between	O
1970s	O
and	O
2000.	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

1P-LSD	B-Drug
is	O
a	O
derivative	O
and	O
functional	O
analogue	O
of	O
LSD	B-Drug
homologue	O
ALD-52.	O
ALD-52	B-Drug

LABAs	O
should	O
not	O
be	O
used	O
as	O
a	O
monotherapy,	O
instead,	O
they	O
concurrently	O
with	O
an	O
inhaled	O
corticosteroid,	O
such	O
beclometasone	B-Drug
dipropionate	I-Drug
or	O
fluticasone	B-Drug
propionate	I-Drug
in	O
the	O
treatment	O
of	O
asthma	O
to	O
minimize	O
serious	O
reactions	O
asthma-related	O
deaths.	O

A	O
neonatal	O
withdrawal	O
syndrome	O
can	O
also	O
occur	O
if	O
nitrazepam	B-Drug
or	O
other	O
benzodiazepines	O
are	O
used	O
during	O
pregnancy	O
with	O
symptoms	O
such	O
as	O
hyperexcitability,	O
tremor,	O
and	O
gastrointestinal	O
upset	O
(diarrhea	O
vomiting)	O
occurring.	O

When	O
taken	O
orally,	O
heroin	B-Drug
undergoes	O
extensive	O
first-pass	O
metabolism	O
via	O
deacetylation,	O
making	O
it	O
a	O
prodrug	O
for	O
the	O
systemic	O
delivery	O
of	O
morphine.	O
morphine	B-Drug

Ketamine	B-Drug
was	O
first	O
synthesized	O
in	O
1962	O
by	O
Calvin	O
L.	O
Stevens,	O
a	O
professor	O
of	O
Chemistry	O
at	O
Wayne	O
State	O
University	O
and	O
Parke-Davis	O
consultant.	O

25I-NBOMe	B-Drug
acts	O
as	O
a	O
highly	O
potent	O
full	O
agonist	O
for	O
the	O
human	O
5-HT2A	O
receptor,	O
with	O
dissociation	O
constant	O
(Ki)	O
of	O
0.044	O
nM,	O
making	O
it	O
some	O
sixteen	O
times	O
potency	O
2C-I	O
itself	O
at	O
this	O
receptor.	O

The	O
Drug	O
Enforcement	O
Administration	O
(DEA)	O
classified	O
pregabalin	B-Drug
as	O
a	O
depressant	O
and	O
placed	O
pregabalin,	O
including	O
its	O
salts,	O
all	O
products	O
containing	O
into	O
Schedule	O
V	O
of	O
the	O
Controlled	O
Substances	O
Act.	O

Major	O
sources	O
of	O
human	O
oral	O
exposure	O
to	O
aluminium	O
include	O
food	O
(due	O
its	O
use	O
in	O
additives,	O
and	O
beverage	O
packaging,	O
cooking	O
utensils),	O
drinking	O
water	O
municipal	O
treatment),	O
aluminium-containing	O
medications	O
(particularly	O
antacid/antiulcer	O
buffered	O
aspirin	B-Drug
formulations).	O

Uniquely	O
among	O
AAS,	O
mesterolone	B-Drug
has	O
very	O
high	O
affinity	O
for	O
human	O
serum	O
sex	O
hormone-binding	O
globulin	O
(SHBG),	O
about	O
440%	O
that	O
of	O
DHT	O
in	O
one	O
study	O
and	O
82%	O
another	O
study.	O

Reports	O
of	O
deaths	O
and	O
significant	O
injuries	O
have	O
been	O
attributed	O
to	O
the	O
use	O
25I-NBOMe,	O
prompting	O
some	O
governments	O
control	O
its	O
possession,	O
production,	O
sale.	O
25I-NBOMe	B-Drug

Sulpiride's	O
primary	O
use	O
in	O
medicine	O
is	O
the	O
management	O
of	O
symptoms	O
schizophrenia.	O
Sulpiride	B-Drug

Ephedrine	B-Drug
is	O
the	O
N-methyl	O
analogue	O
of	O
PPA.	O

The	O
country	O
saw	O
a	O
1213%	O
decline	O
in	O
coca	B-Drug
cultivation	O
2011	O
under	O
Morales,	O
who	O
has	O
used	O
growers'	O
federations	O
to	O
ensure	O
compliance	O
with	O
the	O
law	O
rather	O
than	O
providing	O
primary	O
role	O
for	O
security	O
forces.	O

A	O
number	O
of	O
sources	O
incorrectly	O
state	O
that	O
mesterolone	B-Drug
was	O
synthesized	O
or	O
introduced	O
for	O
medical	O
use	O
in	O
1934.	O

The	O
quantity	O
of	O
poppy	O
straw	O
produced	O
is	O
typically	O
given	O
as	O
"opium	O
equivalents".	O
opium	B-Drug

With	O
oral	O
administration	O
of	O
nandrolone	B-Drug
in	O
rodents,	O
it	O
had	O
about	O
one-tenth	O
the	O
potency	O
subcutaneous	O
injection	O
nandrolone.	O

Abnormalities	O
in	O
white	O
blood	O
cell	O
formation,	O
including	O
aplastic	O
anemia,	O
are	O
rare,	O
yet	O
the	O
cause	O
of	O
majority	O
deaths	O
attributable	O
to	O
dapsone	B-Drug
therapy.	O

Starting	O
in	O
1967,	O
Isbell	O
and	O
associates	O
published	O
a	O
few	O
studies	O
on	O
THC	B-Drug
marijuana	O
(cannabis).	O

It	O
uses	O
a	O
medication	O
delivery	O
technology	O
called	O
BEMA	O
(BioErodible	O
MucoAdhesive),	O
small	O
dissolvable	O
polymer	O
film	O
containing	O
various	O
fentanyl	B-Drug
doses	O
applied	O
to	O
the	O
inner	O
lining	O
of	O
cheek.	O

The	O
generalized	O
structural	O
motif	O
required	O
for	O
PCP-like	O
activity	O
is	O
derived	O
from	O
structure-activity	O
relationship	O
studies	O
of	O
PCP	B-Drug
derivatives.	O

Over	O
the	O
following	O
years,	O
Zeff	O
traveled	O
around	O
United	O
States	O
and	O
occasionally	O
to	O
Europe,	O
eventually	O
training	O
an	O
estimated	O
four	O
thousand	O
psychotherapists	O
in	O
therapeutic	O
use	O
of	O
MDMA.	O
MDMA	B-Drug

Due	O
to	O
its	O
progestogenic	O
activity,	O
norethisterone	B-Drug
suppresses	O
the	O
hypothalamicpituitarygonadal	O
axis	O
(HPG	O
axis)	O
and	O
hence	O
has	O
antigonadotropic	O
effects.	O

THC	B-Drug
also	O
potentiates	O
the	O
effects	O
of	O
glycine	O
receptors.	O

Its	O
use	O
has	O
caused	O
a	O
spike	O
in	O
deaths	O
among	O
users	O
of	O
heroin	B-Drug
and	O
prescription	O
painkillers,	O
while	O
becoming	O
easier	O
to	O
obtain	O
conceal.	O

The	O
entire	O
stock	O
was	O
purchased	O
by	O
Carl	O
Waltenburg,	O
who	O
distributed	O
it	O
under	O
the	O
name	O
"Indra	O
extract"	O
and	O
used	O
in	O
1982	O
to	O
treat	O
heroin	B-Drug
addicts	O
community	O
of	O
Christiania.	O

The	O
precise	O
mechanism	O
of	O
action	O
for	O
thalidomide	B-Drug
is	O
not	O
known,	O
although	O
efforts	O
to	O
identify	O
thalidomide's	O
teratogenic	O
generated	O
2,000	O
research	O
papers	O
and	O
the	O
proposal	O
15	O
or	O
16	O
plausible	O
mechanisms	O
by	O
year	O
2000.	O

When	O
club	O
drug	O
users	O
are	O
in	O
a	O
liquor-licensed	O
nightclub,	O
may	O
mix	O
pills	O
or	O
powders	O
(MDMA,	O
2C-B,	O
GHB,	O
ketamine)	O
with	O
consumption	O
of	O
alcoholic	O
drinks	O
such	O
as	O
beer,	O
wine	O
hard	O
liquor.	O
MDMA	B-Drug
2C-B	B-Drug
GHB	B-Drug
ketamine	B-Drug

LSD,	O
Oxycontin,	O
Xanax,	O
cannabis	O
Goodfellas	O
(1990)	O
LSD	B-Drug
Oxycontin	B-Drug
Xanax	B-Drug

Due	O
to	O
its	O
C17	O
methyl	O
group,	O
unlike	O
androstanolone,	O
mestanolone	B-Drug
is	O
orally	O
active.	O

According	O
to	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
pregnancy	O
categories,	O
levothyroxine	B-Drug
has	O
been	O
assigned	O
category	O
A.	O

This	O
may	O
follow	O
after	O
a	O
small	O
dose	O
of	O
20	O
mg,	O
on	O
condition	O
no	O
phenobarbital	B-Drug
administered	O
in	O
previous	O
days.	O

Patients	O
dependent	O
on	O
clonazepam	B-Drug
should	O
be	O
slowly	O
titrated	O
off	O
under	O
the	O
supervision	O
of	O
a	O
qualified	O
healthcare	O
professional	O
to	O
reduce	O
intensity	O
withdrawal	O
or	O
rebound	O
symptoms.	O

Many	O
people	O
who	O
smoke	O
cannabis	O
also	O
tobacco.	O
tobacco	B-Drug

The	O
efficacy	O
of	O
noscapine	B-Drug
in	O
the	O
treatment	O
certain	O
hematological	O
malignancies	O
has	O
been	O
explored	O
clinic.	O

Bromazepam,	O
sold	O
under	O
many	O
brand	O
names,	O
is	O
a	O
benzodiazepine.	O
Bromazepam	B-Drug

Lisdexamfetamine	B-Drug
was	O
developed	O
by	O
New	O
River	O
Pharmaceuticals,	O
who	O
were	O
bought	O
Takeda	O
Pharmaceuticals	O
through	O
its	O
acquisition	O
of	O
Shire	O
shortly	O
before	O
it	O
began	O
being	O
marketed.	O

Cyproheptadine	B-Drug
has	O
weak	O
antiandrogenic	O
activity.	O

His	O
discovery	O
of	O
the	O
alkaloid	O
led	O
to	O
development	O
a	O
generation	O
antitussive	O
and	O
antidiarrheal	O
medicines	O
based	O
on	O
codeine.	O
codeine	B-Drug

Some	O
fentanyl	B-Drug
analogues	O
such	O
as	O
carfentanil	B-Drug
are	O
up	O
to	O
~10,000	O
times	O
stronger	O
than	O
morphine.	O
morphine	B-Drug

Fentanyl	B-Drug
has	O
a	O
therapeutic	O
index	O
of	O
270.	O

Anticholinergic	O
drugs	O
and	O
deliriants:	O
Atropine,	O
racemic	O
hyoscyamine,	O
from	O
the	O
deadly	O
nightshade	O
hyoscyamine	B-Drug

Studies	O
differ	O
in	O
how	O
they	O
define	O
heavy	O
or	O
light	O
cocaine	B-Drug
use	O
during	O
pregnancy,	O
and	O
the	O
time	O
period	O
of	O
exposure	O
pregnancy	O
on	O
which	O
focus	O
(e.g.	O
first,	O
second,	O
third	O
trimester.	O

PCP	B-Drug
is	O
self-administered	O
and	O
induces	O
FosB	O
expression	O
in	O
the	O
D1-type	O
medium	O
spiny	O
neurons	O
of	O
nucleus	O
accumbens,	O
accordingly,	O
excessive	O
use	O
known	O
to	O
cause	O
addiction.	O

Cocaine	O
reverse	O
ester,	O
(also	O
known	O
as	O
Reverse	O
ester	O
cocaine	B-Drug
or	O
REC)	O
is	O
a	O
tropane	O
derivative	O
drug	O
which	O
of	O
cocaine,	O
with	O
the	O
2-COOCH3	O
methoxycarbonyl	O
group	O
swapped	O
to	O
an	O
isomeric	O
OCOCH3	O
acetoxy	O
group.	O

Enzalutamide	B-Drug
is	O
eliminated	O
71.0%	O
in	O
urine,	O
13.6%	O
bile,	O
and	O
0.39%	O
feces.	O

However,	O
PCP	B-Drug
has	O
little	O
affinity	O
for	O
the	O
human	O
monoamine	O
transporters,	O
including	O
dopamine	O
transporter	O
(DAT).	O

Commonly	O
used	O
hypnotics	O
include	O
thiopental,	O
propofol	B-Drug
and	O
etomidate.	O
thiopental	B-Drug
etomidate	B-Drug

Outside	O
the	O
US,	O
Novartis	O
markets	O
drug	O
ranibizumab	B-Drug
(trade	O
name	O
Lucentis),	O
which	O
is	O
a	O
monoclonal	O
antibody	O
fragment	O
derived	O
from	O
same	O
parent	O
mouse	O
as	O
bevacizumab	B-Drug
(Avastin).	O
Lucentis	B-Drug
Avastin	B-Drug

Additionally,	O
apremilast	B-Drug
was	O
approved	O
by	O
the	O
FDA	O
in	O
March	O
2014.	O

A	O
2009	O
Cochrane	O
review	O
found	O
methadone	B-Drug
was	O
effective	O
in	O
retaining	O
people	O
treatment	O
and	O
the	O
reduction	O
or	O
cessation	O
of	O
heroin	B-Drug
use	O
as	O
measured	O
by	O
self-report	O
urine/hair	O
analysis	O
but	O
did	O
not	O
affect	O
criminal	O
activity	O
risk	O
death.	O

Despite	O
the	O
side	O
effects,	O
thalidomide	B-Drug
was	O
sold	O
in	O
pharmacies	O
Canada	O
until	O
1962.	O

Withdrawal	O
from	O
chlordiazepoxide	B-Drug
or	O
other	O
benzodiazepines	O
often	O
leads	O
to	O
withdrawal	O
symptoms	O
that	O
are	O
similar	O
those	O
seen	O
with	O
alcohol	O
and	O
barbiturates.	O

Benzodiazepines	O
such	O
as	O
chlordiazepoxide	B-Drug
(Librium),	O
diazepam	B-Drug
(Valium),	O
lorazepam	B-Drug
(Ativan)	O
or	O
oxazepam	B-Drug
(Serax)	O
are	O
the	O
most	O
commonly	O
used	O
drugs	O
to	O
reduce	O
alcohol	O
withdrawal	O
symptoms.	O
Librium	B-Drug
Valium	B-Drug
Ativan	B-Drug
Serax	B-Drug

is	O
therefore	O
no	O
longer	O
preferred;	O
phenothiazines	O
are	O
particularly	O
risky,	O
as	O
they	O
may	O
lower	O
the	O
seizure	O
threshold,	O
worsen	O
hyperthermia,	O
and	O
boost	O
anticholinergic	O
effects	O
of	O
PCP.	O
PCP	B-Drug

There	O
are,	O
therefore,	O
diversified	O
drug	O
trafficking	O
routes	O
available	O
today,	O
particularly	O
in	O
the	O
heroin	B-Drug
trade	O
and	O
these	O
thrive	O
due	O
to	O
continuous	O
development	O
of	O
new	O
markets.	O

The	O
earliest	O
clear	O
description	O
of	O
the	O
use	O
opium	B-Drug
as	O
a	O
recreational	O
drug	O
in	O
China	O
came	O
from	O
Xu	O
Boling,	O
who	O
wrote	O
1483	O
that	O
was	O
"mainly	O
used	O
to	O
aid	O
masculinity,	O
strengthen	O
sperm	O
and	O
regain	O
vigor",	O
it	O
"enhances	O
art	O
alchemists,	O
sex	O
court	O
ladies".	O

Tetrahydrogestrinone	B-Drug
(THG),	O
known	O
by	O
the	O
nickname	O
The	O
Clear,	O
is	O
a	O
synthetic	O
and	O
orally	O
active	O
anabolicandrogenic	O
steroid	O
(AAS)	O
which	O
was	O
never	O
marketed	O
for	O
medical	O
use.	O
THG	B-Drug

Extended-release	O
methylphenidate	B-Drug
products	O
include:	O
Concerta	B-Drug
tablets	O
are	O
marked	O
with	O
the	O
letters	O
"ALZA"	O
and	O
followed	O
by:	O
"18",	O
"27",	O
"36",	O
or	O
"54",	O
relating	O
to	O
mg	O
dosage	O
strength.	O

The	O
medicinal	O
chemistry	O
work	O
turned	O
to	O
improving	O
the	O
lead	O
compound	O
into	O
a	O
suitable	O
drug:	O
result	O
was	O
thalidomide.	O
thalidomide	B-Drug

The	O
mind-	O
and	O
judgment-altering	O
effects	O
of	O
zaleplon	B-Drug
are	O
similar	O
to	O
those	O
many	O
benzodiazepines,	O
but	O
the	O
fast-acting	O
nature	O
short	O
half-life	O
chemical	O
mean	O
high	O
doses	O
set	O
on	O
much	O
more	O
quickly	O
last	O
for	O
periods	O
time	O
(usually	O
from	O
45	O
60	O
minutes).	O

Dexamethasone	B-Drug
is	O
commonly	O
given	O
as	O
a	O
treatment	O
for	O
croup	O
in	O
children,	O
single	O
dose	O
can	O
reduce	O
the	O
swelling	O
of	O
airway	O
to	O
improve	O
breathing	O
and	O
discomfort.	O

In	O
October	O
2010,	O
GlaxoSmithKline	O
sold	O
the	O
rights	O
for	O
Dexedrine	B-Drug
Spansule	O
to	O
Amedra	O
Pharmaceuticals	O
(a	O
subsidiary	O
of	O
CorePharma).The	O
U.S.	O
Air	O
Force	O
uses	O
dextroamphetamine	B-Drug
as	O
one	O
its	O
"go	O
pills",	O
given	O
pilots	O
on	O
long	O
missions	O
help	O
them	O
remain	O
focused	O
and	O
alert.	O

PCP	B-Drug
is	O
self-administered	O
and	O
induces	O
FosB	O
expression	O
in	O
the	O
D1-type	O
medium	O
spiny	O
neurons	O
of	O
nucleus	O
accumbens,	O
accordingly,	O
excessive	O
use	O
known	O
to	O
cause	O
addiction.	O

Sonata	O
(zaleplon)	O
a	O
non-benzodiazepine	O
hypnotic.	O
zaleplon	B-Drug

There	O
are	O
a	O
number	O
of	O
broad	O
classes	O
opioids:	O
Natural	O
opiates:	O
alkaloids	O
contained	O
in	O
the	O
resin	B-Drug
opium	O
poppy,	O
primarily	O
morphine,	O
codeine,	O
and	O
thebaine,	O
but	O
not	O
papaverine	B-Drug
noscapine	B-Drug
which	O
have	O
different	O
mechanism	O
action;	O
morphine	B-Drug
codeine	B-Drug

In	O
July	O
2009,	O
the	O
German	O
Bundestag	O
passed	O
a	O
law	O
allowing	O
diamorphine	B-Drug
prescription	O
as	O
standard	O
treatment	O
for	O
addicts;	O
large-scale	O
trial	O
of	O
had	O
been	O
authorized	O
in	O
country	O
2002.On	O
26	O
August	O
2016,	O
Health	O
Canada	O
issued	O
regulations	O
amending	O
prior	O
it	O
under	O
Controlled	O
Drugs	O
and	O
Substances	O
Act;	O
"New	O
Classes	O
Practitioners	O
Regulations",	O
"Narcotic	O
Control	O
"Food	O
Drug	O
to	O
allow	O
doctors	O
prescribe	O
people	O
who	O
have	O
severe	O
opioid	O
addiction	O
not	O
responded	O
other	O
treatments.	O

In	O
Chemistry	O
World,	O
John	O
Mann,	O
professor	O
of	O
chemistry	O
at	O
Queen's	O
University	O
Belfast,	O
suggested	O
the	O
UK	O
create	O
a	O
law	O
similar	O
to	O
Federal	O
Analog	O
Act	O
United	O
States,	O
which	O
would	O
have	O
made	O
mephedrone	B-Drug
illegal	O
as	O
an	O
analog	O
cathinone.	O
cathinone	B-Drug

In	O
the	O
late	O
1960s,	O
illegal	O
cocaine	B-Drug
trade	O
became	O
a	O
significant	O
problem	O
and	O
major	O
source	O
of	O
profit.	O

,	O
mescaline	B-Drug
and	O
other	O
phenethylamines.	O

It	O
is	O
a	O
potent	O
analgesic,	O
around	O
60	O
times	O
stronger	O
than	O
morphine	B-Drug
and	O
produces	O
significantly	O
less	O
constipation.	O

Diazepam	B-Drug
was	O
detected	O
in	O
26%	O
of	O
cases	O
people	O
suspected	O
driving	O
under	O
the	O
influence	O
drugs	O
Sweden,	O
and	O
its	O
active	O
metabolite	O
nordazepam	B-Drug
28%	O
cases.	O

Experiments	O
included	O
administering	O
LSD	B-Drug
to	O
CIA	O
employees,	O
military	O
personnel,	O
doctors,	O
other	O
government	O
agents,	O
prostitutes,	O
mentally	O
ill	O
patients,	O
and	O
members	O
of	O
the	O
general	O
public	O
in	O
order	O
study	O
their	O
reactions,	O
usually	O
without	O
subjects'	O
knowledge.	O

The	O
various	O
benzodiazepines	O
differ	O
in	O
their	O
toxicity;	O
temazepam	B-Drug
appears	O
most	O
toxic	O
overdose	O
and	O
when	O
used	O
with	O
other	O
drugs.	O

The	O
mechanism	O
that	O
produces	O
the	O
purported	O
hallucinogenic	O
and	O
entheogenic	O
effects	O
of	O
5-MeO-DiPT	B-Drug
is	O
thought	O
to	O
result	O
primarily	O
from	O
5-HT2A	O
receptor	O
agonism,	O
although	O
additional	O
mechanisms	O
action	O
such	O
as	O
monoamine	O
oxidase	O
inhibition	O
(MAOI)	O
may	O
be	O
involved	O
also.	O

heroin	B-Drug

Benzodiazepines,	O
such	O
as	O
lorazepam,	O
are	O
the	O
drugs	O
of	O
choice	O
to	O
control	O
agitation	O
and	O
seizures	O
(when	O
present).	O
lorazepam	B-Drug

Dr.	O
Reddy's	O
Laboratories,	O
and	O
other	O
companies	O
have	O
received	O
FDA	O
approval	O
for	O
generic	O
versions	O
of	O
sumatriptan	B-Drug
tablets	O
in	O
25-,	O
50-,	O
100-mg	O
doses	O
since	O
2009.	O

In	O
1928	O
he	O
discovered	O
the	O
physiological	O
properties	O
of	O
benzedrine	B-Drug
(amphetamine)	O
and	O
contributed	O
to	O
its	O
development	O
as	O
a	O
drug.	O
amphetamine	B-Drug

When	O
he	O
tried	O
the	O
drug	O
in	O
1977,	O
Zeff	O
was	O
impressed	O
with	O
effects	O
of	O
MDMA	B-Drug
and	O
came	O
out	O
his	O
semi-retirement	O
to	O
promote	O
its	O
use	O
therapy.	O

The	O
binding	O
affinity	O
of	O
JWH-116	B-Drug
for	O
the	O
CB1	O
receptor	O
is	O
reported	O
as	O
Ki	O
=	O

Also,	O
most	O
synthetic	O
cannabinoids	O
are	O
agonists	O
of	O
both	O
cannabinoid	O
receptors,	O
CB1	O
and	O
CB2,	O
like	O
THC;	O
however,	O
they	O
often	O
have	O
greater	O
binding	O
affinity	O
therefore	O
potency	O
than	O
THC,	O
as	O
seen	O
in	O
table	O
two.	O
THC	B-Drug

cocaine,	O
cannabis	O
Domino	O
(2005)	O
cocaine	B-Drug

From	O
the	O
results	O
seen	O
in	O
humans	O
with	O
drugs	O
such	O
as	O
Epidyolex	O
and	O
Sativex	B-Drug
scientific	O
studies	O
reviews,	O
it	O
could	O
be	O
expected	O
that	O
CBD-based	O
products	O
would	O
helpful	O
to	O
manage	O
seizures	O
dogs.	O

Traces	O
of	O
the	O
drug	O
have	O
also	O
been	O
found	O
in	O
other	O
recreational	O
drugs	O
including	O
cocaine,	O
MDMA,	O
and	O
heroin.	O
cocaine	B-Drug
MDMA	B-Drug
heroin	B-Drug

The	O
actions	O
of	O
THC	B-Drug
result	O
from	O
its	O
partial	O
agonist	O
activity	O
at	O
the	O
cannabinoid	O
receptor	O
CB1	O

It	O
is	O
specifically	O
nandrolone	B-Drug
with	O
two	O
additional	O
double	O
bonds	O
in	O
the	O
steroid	O
nucleus.	O

The	O
mechanism	O
of	O
action	O
mupirocin	B-Drug
differs	O
from	O
other	O
clinical	O
antibiotics,	O
rendering	O
cross-resistance	O
to	O
antibiotics	O
unlikely.	O

The	O
accused	O
owned	O
a	O
tablet	O
press	O
and	O
ordered	O
fentanyl	B-Drug
in	O
powder	O
form	O
from	O
China.	O

Additive	O
vasoconstricting	O
effects	O
occur	O
with	O
ergot	O
alkaloids,	O
and	O
oxytocin.	O
oxytocin	B-Drug

Amphetamine	B-Drug
and	O
related	O
sympathomimetic	O
medications	O
(such	O
as	O
benzphetamine)	O
are	O
thought	O
to	O
stimulate	O
the	O
release	O
of	O
norepinephrine	O
and/or	O
dopamine	O
from	O
storage	O
sites	O
in	O
nerve	O
terminals	O
lateral	O
hypothalamic	O
feeding	O
center,	O
thereby	O
producing	O
a	O
decrease	O
appetite.	O
benzphetamine	B-Drug

Norethisterone	B-Drug
is	O
bound	O
to	O
a	O
considerable	O
extent	O
(36%)	O
SHBG	O
in	O
circulation.	O

It	O
is	O
unclear	O
whether	O
dexamethasone	B-Drug
in	O
this	O
condition	O
significantly	O
better	O
than	O
other	O
glucocorticoids.	O

One	O
researcher	O
has	O
documented	O
that	O
"Laudanum,	O
as	O
listed	O
in	O
the	O
London	O
Pharmacopoeia	O
(1618),	O
was	O
a	O
pill	O
made	O
from	O
opium,	O
saffron,	O
castor,	O
ambergris,	O
musk	O
and	O
nutmeg".	O
Laudanum	B-Drug
opium	B-Drug

As	O
of	O
2018	O
fentanyl	B-Drug
was	O
the	O
most	O
commonly	O
listed	O
opioid	O
in	O
overdose	O
drug	O
deaths,	O
surpassing	O
heroin.	O
heroin	B-Drug

Natural	O
cannabinoids	O
(e.g.,	O
THC,	O
hashish	B-Drug
and	O
marijuana)	O
THC	B-Drug

In	O
Canada,	O
fentanyl	B-Drug
is	O
considered	O
a	O
Schedule	O
I	O
drug	O
as	O
listed	O
in	O
Canada's	O
Controlled	O
Drugs	O
and	O
Substances	O
Act.	O

This	O
was	O
largely	O
based	O
on	O
the	O
VIGOR	O
(Vioxx	O
GI	O
Outcomes	O
Research)	O
study,	O
which	O
compared	O
efficacy	O
and	O
adverse	O
effect	O
profiles	O
of	O
rofecoxib	O
naproxen.	O
naproxen	B-Drug

It	O
takes	O
15	O
to	O
60	O
minutes	O
for	O
the	O
effects	O
of	O
PCP	B-Drug
manifest.	O

Ketamine	B-Drug
is	O
also	O
used	O
as	O
a	O
recreational	O
drug	O
for	O
its	O
hallucinogenic	O
and	O
dissociative	O
effects.	O

Combustion	O
products	O
are	O
not	O
present	O
when	O
using	O
a	O
vaporizer,	O
consuming	O
THC	B-Drug
in	O
pill	O
form,	O
or	O
cannabis	O
foods.	O

The	O
elimination	O
half-life	O
of	O
oxymorphone	B-Drug
is	O
much	O
faster	O
intravenously,	O
and	O
as	O
such,	O
the	O
drug	O
most	O
commonly	O
used	O
orally.	O

Zolpidem	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
1992.	O

The	O
team	O
concluded	O
that	O
the	O
Russian	O
military	O
used	O
an	O
aerosol	O
mist	O
of	O
carfentanil	B-Drug
and	O
remifentanil	B-Drug
to	O
subdue	O
Chechen	O
hostage	O
takers.	O

The	O
rights	O
to	O
Quaalude	B-Drug
were	O
held	O
by	O
the	O
JB	O
Roerig	O
&	O
Company	O
division	O
of	O
Pfizer,	O
before	O
drug	O
was	O
discontinued	O
in	O
United	O
States	O
1985,	O
mainly	O
due	O
its	O
psychological	O
addictiveness,	O
widespread	O
abuse,	O
and	O
illegal	O
recreational	O
use.	O

Herceptin	B-Drug
therapy	O
(trastuzumab)	O
Tyrosine	O
kinase	O
inhibitors	O
such	O
as	O
imatinib	B-Drug
(marketed	O
Gleevec)	O
have	O
been	O
developed	O
to	O
treat	O
chronic	O
myeloid	O
leukemia	O
(CML),	O
in	O
which	O
the	O
BCR-ABL	O
fusion	O
gene	O
(the	O
product	O
of	O
a	O
reciprocal	O
translocation	O
between	O
chromosome	O
9	O
and	O
22)	O
is	O
present	O
>95%	O
cases	O
produces	O
hyperactivated	O
abl-driven	O
protein	O
signaling.	O
trastuzumab	B-Drug
Gleevec	B-Drug

Notable	O
side	O
effects	O
of	O
enzalutamide	B-Drug
seen	O
in	O
clinical	O
trials	O
have	O
included	O
gynecomastia,	O
breast	O
pain/tenderness,	O
fatigue,	O
diarrhea,	O
hot	O
flashes,	O
headache,	O
sexual	O
dysfunction,	O
and,	O
less	O
commonly,	O
seizures.	O

In	O
August	O
2018,	O
the	O
United	O
States	O
used	O
fentanyl	B-Drug
for	O
first	O
time	O
to	O
execute	O
a	O
prisoner.	O

The	O
peak	O
plasma	O
delay	O
of	O
loprazolam,	O
therefore,	O
may	O
not	O
be	O
relevant	O
to	O
loprazolam's	O
efficacy	O
as	O
a	O
hypnotic.	O
loprazolam	B-Drug

Jung	O
was	O
a	O
part	O
of	O
the	O
Medelln	O
Cartel,	O
which	O
responsible	O
for	O
up	O
to	O
90%	O
cocaine	B-Drug
smuggled	O
into	O
United	O
States.	O

JWH-307	B-Drug
is	O
an	O
analgesic	O
drug	O
used	O
in	O
scientific	O
research,	O
which	O
acts	O
as	O
a	O
cannabinoid	O
agonist	O
at	O
both	O
the	O
CB1	O
and	O
CB2	O
receptors.	O

Use	O
of	O
oral	O
meloxicam	B-Drug
following	O
a	O
high-fat	O
breakfast	O
increases	O
the	O
mean	O
peak	O
drug	O
levels	O
by	O
about	O
22%;	O
however,	O
manufacturer	O
does	O
not	O
make	O
any	O
specific	O
meal	O
recommendations.	O

(e.g.,	O
before	O
endoscopic	O
or	O
surgical	O
procedures)	O
Treatment	O
of	O
complications	O
with	O
a	O
hallucinogen	O
crisis	O
and	O
stimulant	O
overdoses	O
psychosis,	O
such	O
as	O
LSD,	O
cocaine,	O
methamphetamineUsed	O
in	O
treatment	O
organophosphate	O
poisoning	O
reduces	O
the	O
risk	O
seizure	O
induced	O
brain	O
cardiac	O
damage.	O
LSD	B-Drug
cocaine	B-Drug

5F-ADB	B-Drug
is	O
believed	O
to	O
be	O
extremely	O
potent	O
based	O
on	O
the	O
very	O
low	O
levels	O
detected	O
in	O
tissue	O
samples,	O
and	O
appears	O
significantly	O
more	O
toxic	O
than	O
earlier	O
synthetic	O
cannabinoid	O
drugs	O
that	O
had	O
previously	O
been	O
sold.	O

Phenytoin	B-Drug
has	O
been	O
known	O
to	O
cause	O
drug-induced	O
lupus.	O

Conversion	O
of	O
androstenedione	B-Drug
to	O
estrone	O
requires	O
the	O
enzyme	O
aromatase.	O

For	O
example,	O
the	O
reduction	O
rate	O
used	O
in	O
Heather	O
Ashton	O
protocol	O
calls	O
for	O
eliminating	O
10%	O
of	O
remaining	O
dose	O
every	O
two	O
to	O
four	O
weeks,	O
depending	O
on	O
severity	O
and	O
response	O
reductions	O
with	O
final	O
at	O
0.5	O
mg	O
diazepam	B-Drug
or	O
2.5	O
chlordiazepoxide.	O
chlordiazepoxide	B-Drug

(Femilar)	O
Estradiol	B-Drug
valerate/dienogest	I-Drug
(Natazia,	O
Qlaira)	O
Ethinylestradiol/chlormadinone	O
acetate	O
Natazia	B-Drug

A	O
kilogram	O
of	O
heroin	B-Drug
laced	O
with	O
fentanyl	B-Drug
may	O
sell	O
for	O
more	O
than	O
US$100,000,	O
but	O
the	O
itself	O
be	O
produced	O
far	O
cheaply	O
about	O
US$6,000	O
per	O
kilogram.	O

Crude	O
laboratories	O
in	O
the	O
field	O
are	O
capable	O
of	O
refining	O
opium	B-Drug
into	O
morphine	B-Drug
base	O
by	O
a	O
simple	O
acid-base	O
extraction.	O

The	O
bioavailability	O
and	O
elimination	O
half-life	O
of	O
methadone	B-Drug
are	O
subject	O
to	O
substantial	O
interindividual	O
variability.	O

Secobarbital	B-Drug
is	O
indicated	O
for:	O
Treatment	O
of	O
epilepsy	O
Temporary	O
treatment	O
insomnia	O
Use	O
as	O
a	O
preoperative	O
medication	O
to	O
produce	O
anaesthesia	O
and	O
anxiolysis	O
in	O
short	O
surgical,	O
diagnostic,	O
or	O
therapeutic	O
procedures	O
which	O
are	O
minimally	O
painful.	O

The	O
demand	O
for	O
this	O
combination	O
in	O
Philadelphia,	O
Pittsburgh,	O
Newark,	O
NYC,	O
Boston,	O
Baltimore,	O
and	O
surrounding	O
areas	O
of	O
other	O
states	O
perhaps	O
elsewhere,	O
has	O
led	O
to	O
small-scale	O
clandestine	O
synthesis	O
glutethimide	B-Drug
since	O
1984,	O
a	O
process	O
that	O
is,	O
like	O
methaqualone	B-Drug
(Quaalude)	O
synthesis,	O
somewhat	O
difficult	O
fraught	O
with	O
potential	O
bad	O
outcomes	O
when	O
amateur	O
chemists	O
manufacture	O
the	O
drugs	O
industrial-grade	O
precursors	O
without	O
adequate	O
quality	O
control.	O
Quaalude	B-Drug

Heterocodeine	B-Drug
was	O
first	O
synthesised	O
in	O
1932	O
and	O
patented	O
1935.	O

Antagonists	O
of	O
the	O
5-HT2A	O
receptor	O
like	O
cyproheptadine	B-Drug
and	O
chlorpromazine	B-Drug
are	O
able	O
to	O
reverse	O
mediate	O
recovery	O
from	O
serotonin	O
syndrome.	O

It	O
is	O
also	O
contraindicated	O
in	O
patients	O
that	O
have	O
experienced	O
hypersensitivity	O
to	O
hydrocodone,	O
acetaminophen	B-Drug
or	O
any	O
other	O
component	O
the	O
formulation.	O
hydrocodone	B-Drug

Methamphetamine	B-Drug
withdrawal	O
symptoms	O
can	O
include	O
anxiety,	O
drug	O
craving,	O
dysphoric	O
mood,	O
fatigue,	O
increased	O
appetite,	O
movement	O
or	O
decreased	O
movement,	O
lack	O
of	O
motivation,	O
sleeplessness	O
sleepiness,	O
and	O
vivid	O
lucid	O
dreams.	O

Vistaril	B-Drug
(hydroxyzine)	O
an	O
antihistamine	O
for	O
the	O
treatment	O
of	O
itches	O
and	O
irritations,	O
antiemetic,	O
as	O
a	O
weak	O
analgesic,	O
opioid	O
potentiator,	O
anxiolytic.	O
hydroxyzine	B-Drug

The	O
following	O
drugs	O
listed	O
as	O
"centrally-acting	O
antiobesity	O
preparations"	O
in	O
the	O
Anatomical	O
Therapeutic	O
Chemical	O
Classification	O
System:	O
Amfepramone	B-Drug
(also	O
known	O
diethylpropion)	O
Bupropion	B-Drug
and	O
naltrexone	B-Drug
(combination)	O
Cathine	B-Drug
Clobenzorex	O
Dexfenfluramine	B-Drug
(the	O
D-enantiomer	O
of	O
fenfluramine;	O
withdrawn	O
for	O
same	O
reason	O
its	O
racemate)	O
Ephedrine	B-Drug
(combinations)	O
diethylpropion	B-Drug
fenfluramine	B-Drug

The	O
group,	O
able	O
to	O
save	O
nearly	O
1,800	O
overdosing	O
people	O
in	O
2019,	O
is	O
currently	O
challenged	O
by	O
the	O
rise	O
fentanyl	B-Drug
and	O
methamphetamine	B-Drug
use.	O

Desogestrel	B-Drug
was	O
synthesized	O
in	O
1972	O
by	O
Organon	O
International	O
the	O
Netherlands	O
and	O
first	O
described	O
literature	O
1975.	O

The	O
side	O
effect	O
profile	O
of	O
bicalutamide	B-Drug
is	O
highly	O
dependent	O
on	O
sex;	O
that	O
is,	O
whether	O
the	O
person	O
male	O
or	O
female.	O

Because	O
the	O
effect	O
was	O
weak	O
when	O
consuming	O
it	O
due	O
to	O
its	O
low	O
THC	B-Drug
levels,	O
autoflowers	O
weren't	O
popular	O
among	O
recreational	O
users.	O

As	O
a	O
prodrug,	O
psilocybin	O
is	O
quickly	O
converted	O
by	O
the	O
body	O
to	O
psilocin,	O
which	O
has	O
mind-altering	O
effects	O
similar,	O
in	O
some	O
aspects,	O
those	O
of	O
LSD,	O
mescaline,	O
and	O
DMT.	O
psilocin	B-Drug
LSD	B-Drug
mescaline	B-Drug

The	O
total	O
lack	O
of	O
photographic	O
evidence	O
opium	B-Drug
smoking	O
in	O
Britain,	O
as	O
opposed	O
to	O
the	O
relative	O
abundance	O
historical	O
photos	O
depicting	O
North	O
America	O
and	O
France,	O
indicates	O
infamous	O
Limehouse	O
opium-smoking	O
scene	O
was	O
little	O
more	O
than	O
fantasy	O
on	O
part	O
British	O
writers	O
day,	O
who	O
were	O
intent	O
scandalizing	O
their	O
readers	O
while	O
drumming	O
up	O
threat	O
"yellow	O
peril".	O

Via	O
CB1	O
receptor	O
activation,	O
THC	B-Drug
indirectly	O
increases	O
dopamine	O
release	O
and	O
produces	O
psychotropic	O
effects.	O

Modafinil	B-Drug
is	O
a	O
highly	O
researched	O
compound,	O
with	O
many	O
derivatives	O
created	O
and	O
studied,	O
some	O
examples	O
their	O
differences	O
between	O
dopamine,	O
serotonin	O
&	O
norepinephrine	O
affect	O
given	O
in	O
bundled	O
table	O
form	O
below.	O

In	O
the	O
mid-1990s,	O
Janssen	O
Pharmaceutica	O
developed	O
and	O
introduced	O
into	O
clinical	O
trials	O
Duragesic	B-Drug
patch,	O
which	O
is	O
a	O
formulation	O
of	O
an	O
inert	O
alcohol	O
gel	O
infused	O
with	O
select	O
fentanyl	B-Drug
doses,	O
are	O
worn	O
to	O
provide	O
constant	O
administration	O
opioid	O
over	O
period	O
48	O
72	O
hours.	O

Fludiazepam	B-Drug
has	O
been	O
used	O
recreationally.	O

I	O
fear	O
there	O
may	O
be	O
a	O
more	O
sinister	O
explanation	O
for	O
why	O
the	O
bottom	O
has	O
not	O
fallen	O
out	O
of	O
opium	B-Drug
market:	O
major	O
traffickers	O
are	O
withholding	O
significant	O
amounts.	O

Although	O
the	O
title	O
of	O
their	O
one-page	O
publication	O
is	O
The	O
total	O
synthesis	O
quinine	B-Drug
it	O
oddly	O
not	O

By	O
the	O
1880s,	O
oriental-style	O
hashish	B-Drug
parlors	O
were	O
flourishing	O
alongside	O
opium	B-Drug
dens,	O
to	O
point	O
that	O
one	O
could	O
be	O
found	O
in	O
every	O
major	O
city	O
on	O
east	O
coast.	O

According	O
to	O
DSM-V	O
criteria,	O
9%	O
of	O
those	O
who	O
are	O
exposed	O
cannabis	O
develop	O
use	O
disorder,	O
compared	O
20%	O
for	O
cocaine,	O
23%	O
alcohol	O
and	O
68%	O
nicotine.	O
cocaine	B-Drug
nicotine	B-Drug

Between	O
one	O
and	O
three	O
percent	O
of	O
people	O
in	O
the	O
developed	O
world	O
have	O
used	O
cocaine	B-Drug
at	O
some	O
point	O
their	O
life.	O

People	O
can	O
be	O
exposed	O
to	O
nicotine	B-Drug
in	O
the	O
workplace	O
by	O
breathing	O
it	O
in,	O
skin	O
absorption,	O
swallowing	O
it,	O
or	O
eye	O
contact.	O

NMDA	O
receptor	O
antagonists	O
such	O
as	O
ketamine	B-Drug
SNRIs	O
milnacipran	B-Drug
Anticonvulsants	O
gabapentin	B-Drug
or	O
pregabalin	B-Drug
Clinical	O
studies	O
have	O
consistently	O
associated	O
medical	O
and	O
recreational	O
opioid	O
use	O
with	O
hypogonadism	O
(low	O
sex	O
hormone	O
levels)	O
in	O
different	O
sexes.	O

THC	B-Drug
and	O
its	O
major	O
(inactive)	O
metabolite,	O
THC-COOH,	O
can	O
be	O
measured	O
in	O
blood,	O
urine,	O
hair,	O
oral	O
fluid	O
or	O
sweat	O
using	O
chromatographic	O
techniques	O
as	O
part	O
of	O
a	O
drug	O
use	O
testing	O
program	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
offense.	O

All	O
of	O
these	O
derivatives	O
are	O
likely	O
to	O
share	O
some	O
their	O
psychoactive	O
effects	O
with	O
PCP	B-Drug
itself,	O
although	O
a	O
range	O
potencies	O
and	O
varying	O
mixtures	O
anesthetic,	O
dissociative,	O
stimulant	O
known,	O
depending	O
on	O
the	O
particular	O
drug	O
its	O
substituents.	O

Nabilone	B-Drug
had	O
a	O
slower	O
onset	O
of	O
peak	O
action	O
and	O
greater	O
dose-dependence	O
effects,	O
which	O
the	O
investigators	O
attributed	O
to	O
bioavailability.	O

It	O
also	O
aimed	O
to	O
better	O
inform	O
consumers	O
on	O
the	O
risks	O
associated	O
with	O
smoking,	O
while	O
preventing	O
those	O
under	O
age	O
of	O
18	O
from	O
purchasing	O
tobacco	B-Drug
products.	O

In	O
June	O
2020,	O
the	O
Australian	O
Therapeutic	O
Goods	O
Administration	O
(TGA)	O
published	O
a	O
consultation	O
on	O
proposal	O
to	O
pave	O
way	O
make	O
"low	O
dose"	O
CBD	B-Drug
available	O
consumer/patients	O
via	O
pharmacists	O
only	O
through	O
moving	O
products	O
from	O
Schedule	O
4	O
3.	O

Raw	O
opium	B-Drug
may	O
be	O
sold	O
to	O
a	O
merchant	O
or	O
broker	O
on	O
the	O
black	O
market,	O
but	O
it	O
usually	O
does	O
not	O
travel	O
far	O
from	O
field	O
before	O
is	O
refined	O
into	O
morphine	B-Drug
base,	O
because	O
pungent,	O
jelly-like	O
raw	O
bulkier	O
and	O
harder	O
smuggle.	O

It	O
is	O
also	O
included	O
in	O
combination	O
drugs,	O
lumacaftor/ivacaftor	B-Drug
and	O
tezacaftor/ivacaftor,	O
which	O
are	O
used	O
to	O
treat	O
people	O
with	O
cystic	O
fibrosis.	O
tezacaftor	B-Drug
ivacaftor	B-Drug

Parahexyl	B-Drug
is	O
similar	O
in	O
both	O
structure	O
and	O
activity	O
to	O
THC,	O
differing	O
only	O
the	O
position	O
of	O
one	O
double	O
bond,	O
lengthening	O
3-pentyl	O
chain	O
by	O
CH2	O
group	O
n-hexyl.	O
THC	B-Drug

Some	O
studies	O
found	O
that,	O
like	O
other	O
NMDA	O
receptor	O
antagonists,	O
PCP	B-Drug
can	O
cause	O
a	O
kind	O
of	O
brain	O
damage	O
called	O
Olney's	O
lesions	O
in	O
rats.	O

In	O
the	O
2008	O
Summer	O
Olympics,	O
50-metre	O
pistol	O
silver	O
medalist	O
and	O
10-metre	O
air	O
bronze	O
Kim	O
Jong-su	O
tested	O
positive	O
for	O
propranolol	B-Drug
was	O
stripped	O
of	O
his	O
medals.	O

It	O
has	O
been	O
implicated	O
in	O
addictions	O
to	O
alcohol,	O
cannabinoids,	O
cocaine,	O
methylphenidate,	O
nicotine,	O
opioids,	O
phencyclidine,	O
propofol,	O
and	O
substituted	O
amphetamines,	O
among	O
others.	O
cocaine	B-Drug
methylphenidate	B-Drug
nicotine	B-Drug
phencyclidine	B-Drug
propofol	B-Drug

The	O
presence	O
of	O
mannitol	B-Drug
preserves	O
renal	O
function	O
during	O
the	O
times	O
low	O
blood	O
flow	O
and	O
pressure,	O
while	O
patient	O
is	O
on	O
bypass.	O

PCP	B-Drug
works	O
primarily	O
as	O
an	O
NMDA	O
receptor	O
antagonist.	O

Characteristics	O
of	O
this	O
valproate	B-Drug
syndrome	O
include	O
facial	O
features	O
that	O
tend	O
to	O
evolve	O
with	O
age,	O
including	O
a	O
triangle-shaped	O
forehead,	O
tall	O
forehead	O
bifrontal	O
narrowing,	O
epicanthic	O
folds,	O
medial	O
deficiency	O
eyebrows,	O
flat	O
nasal	O
bridge,	O
broad	O
root,	O
anteverted	O
nares,	O
shallow	O
philtrum,	O
long	O
upper	O
lip	O
and	O
thin	O
vermillion	O
borders,	O
thick	O
lower	O
small	O
downturned	O
mouth.	O

In	O
December	O
2005,	O
Wyeth	O
and	O
Progenics	O
entered	O
into	O
an	O
exclusive,	O
worldwide	O
agreement	O
for	O
the	O
joint	O
development	O
commercialization	O
of	O
methylnaltrexone	B-Drug
treatment	O
opioid-induced	O
side	O
effects,	O
including	O
constipation	O
post-operative	O
ileus	O
(POI),	O
a	O
prolonged	O
dysfunction	O
gastrointestinal	O
tract	O
following	O
surgery.	O

In	O
late	O
1959,	O
it	O
was	O
noticed	O
that	O
peripheral	O
neuritis	O
developed	O
in	O
patients	O
who	O
took	O
the	O
drug	O
over	O
a	O
period	O
of	O
time,	O
and	O
only	O
after	O
this	O
point	O
thalidomide	B-Drug
ceased	O
to	O
be	O
provided	O
counter.	O

This	O
helps	O
avoid	O
detection	O
but	O
reduces	O
the	O
CBD	B-Drug
production	O
of	O
plant.	O

Short-term	O
addiction	O
studies	O
by	O
the	O
same	O
researchers	O
demonstrated	O
that	O
tolerance	O
developed	O
at	O
a	O
similar	O
rate	O
to	O
both	O
heroin	B-Drug
and	O
morphine.	O
morphine	B-Drug

The	O
sustained-release	O
formulation,	O
Contrave,	O
is	O
marketed	O
by	O
Takeda	O
under	O
license	O
from	O
the	O
combination	O
medication's	O
developer,	O
Orexigen	O
Therapeutics.	O
Contrave	B-Drug

In	O
accordance	O
with	O
the	O
notion	O
that	O
suppression	O
of	O
SHBG	O
is	O
involved	O
in	O
androgenic	O
effects	O
danazol,	O
drug	O
has	O
synergistic	O
rather	O
than	O
additive	O
combination	O
testosterone	O
bioassays	O
(which	O
most	O
likely	O
secondary	O
to	O
increased	O
free	O
levels).It	O
noteworthy	O
2-hydroxymethylethisterone,	O
a	O
major	O
metabolite	O
circulates	O
at	O
concentrations	O
510	O
times	O
greater	O
those	O
danazol	B-Drug
and	O
twice	O
as	O
potent	O
displacing	O
from	O
SHBG.	O

Valcyte	B-Drug
(valganciclovir),	O
for	O
cytomegalovirus	O
infection.	O
valganciclovir	B-Drug

For	O
a	O
number	O
of	O
years,	O
the	O
most	O
prevalent	O
drug	O
was	O
oxycodone,	O
synthetic	O
opiate	O
known	O
colloquially	O
as	O
oxys	O
and	O
hillbilly	O
heroin,	O
because	O
drug's	O
association	O
with	O
Appalachian	O
areas	O
Kentucky,	O
Ohio,	O
Pennsylvania,	O
Virginia,	O
West	O
Virginia.	O
oxycodone	B-Drug
heroin	B-Drug

Coca	B-Drug
leaves,	O
except	O
coca	B-Drug
leaves	I-Drug
and	O
extracts	O
of	O
from	O
which	O
cocaine,	O
ecgonine	O
derivatives	O
or	O
their	O
salts	O
have	O
been	O
removed.	O
cocaine	B-Drug

As	O
of	O
2017,	O
fentanyl	B-Drug
was	O
the	O
most	O
widely	O
used	O
synthetic	O
opioid	O
in	O
medicine.	O

The	O
study,	O
which	O
eventually	O
came	O
to	O
be	O
headed	O
by	O
Pahnke	O
and	O
Grof,	O
resulted	O
in	O
the	O
treatment	O
of	O
over	O
100	O
terminal	O
patients,	O
including	O
31	O
a	O
controlled	O
LSD	B-Drug
psychotherapy	O
study.	O

Adderall	B-Drug
is	O
peculiarly	O
well	O
suited	O
to	O
the	O
medium,	O
where	O
victory	O
depends	O
on	O
a	O
competitor's	O
alertness,	O
ability	O
concentrate	O
and	O
hand-to-eye-coordination.	O

Desogestrel	B-Drug
and	O
etonogestrel	B-Drug
have	O
no	O
affinity	O
for	O
the	O
estrogen	O
receptor,	O
hence	O
estrogenic	O
activity.	O

The	O
sedating	O
and	O
anxiolytic	O
properties	O
of	O
tetrahydrocannabinol	B-Drug
(THC)	O
in	O
some	O
users	O
might	O
make	O
the	O
use	O
cannabis	O
an	O
attempt	O
to	O
self-medicate	O
personality	O
or	O
psychiatric	O
disorders.	O
THC	B-Drug

The	O
EMCDDA	O
reported	O
mephedrone	B-Drug
can	O
cause	O
various	O
unintended	O
side	O
effects	O
including:	O
dilated	O
pupils,	O
poor	O
concentration,	O
teeth	O
grinding,	O
problems	O
focusing	O
visually,	O
short-term	O
memory,	O
hallucinations,	O
delusions,	O
and	O
erratic	O
behaviour.	O

One	O
of	O
the	O
most	O
notable	O
interactions	O
is	O
that	O
EE	O
strongly	O
increases	O
levels	O
selegiline,	O
a	O
substrate	O
CYP2B6	O
and	O
CYP2C19.	O
selegiline	B-Drug

Phenytoin	B-Drug
therapy	O
has	O
been	O
linked	O
to	O
the	O
life-threatening	O
skin	O
reactions	O
StevensJohnson	O
syndrome	O
(SJS)	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN).	O

The	O
purity	O
of	O
street	O
heroin	B-Drug
varies	O
greatly,	O
leading	O
to	O
overdoses	O
when	O
the	O
is	O
higher	O
than	O
they	O
expected.	O

It	O
is	O
related	O
to	O
other	O
acetylated	O
morphone	O
derivatives,	O
including	O
3,6-diacetyloxymorphone,	O
3,8,14-triacetyloxymorphone,	O
3,6,8,14-tetraacetyloxymorphone,	O
noroxymorphone	B-Drug
analogs	O
of	O
all	O
or	O
most	O
the	O
above,	O
and	O
3,6,14-triacetyloxymorphone,	O
a	O
derivative	O
oxymorphone	B-Drug
whose	O
structure-activity	O
relationship	O
suggests	O
800%	O
potency	O
parent	O
drug	O
versus	O
250%	O
for	O
3,14-diacetyoxymorphone.	O

As	O
carnitine	B-Drug
is	O
a	O
key	O
lysine-derived	O
metabolite	O
involved	O
in	O
fatty	O
acid	O
metabolism,	O
substandard	O
diet	O
lacking	O
sufficient	O
and	O
lysine	O
can	O
lead	O
to	O
decreased	O
levels,	O
which	O
have	O
significant	O
cascading	O
effects	O
on	O
an	O
individual's	O
health.	O

The	O
stalks	O
and	O
seeds	O
have	O
"much	O
lower	O
THC	B-Drug
levels".	O

The	O
inhibition	O
of	O
these	O
enzymes	O
can	O
thus	O
alter	O
the	O
efficacy	O
and	O
tolerability	O
profile	O
tilidine.	O
tilidine	B-Drug

According	O
to	O
the	O
US	O
Food	O
and	O
Drug	O
Administration,	O
"Piracetam	O
is	O
not	O
a	O
vitamin,	O
mineral,	O
amino	O
acid,	O
herb	O
or	O
other	O
botanical,	O
dietary	O
substance	O
for	O
use	O
by	O
humans	O
supplement	O
diet	O
increasing	O
total	O
intake.	O
Piracetam	B-Drug

If	O
oxymorphone	B-Drug
is	O
absolutely	O
indicated,	O
smaller	O
initial	O
doses	O
should	O
be	O
started	O
for	O
this	O
population.	O

Commonly	O
known	O
as	O
ecstasy,	O
it	O
is	O
a	O
common	O
club	O
drug	O
in	O
the	O
rave	O
scene.	O
ecstasy	B-Drug

Several	O
forms	O
of	O
memory	O
are	O
impaired	O
by	O
chronic	O
ecstasy	B-Drug
use;	O
however,	O
the	O
effects	O
for	O
impairments	O
in	O
users	O
generally	O
small	O
overall.	O

Steady	O
state	O
levels	O
of	O
tamoxifen	B-Drug
are	O
reached	O
typically	O
after	O
3	O
to	O
4	O
weeks	O
but	O
possibly	O
up	O
16	O
daily	O
administration.	O

In	O
2013,	O
a	O
CNN	O
program	O
that	O
featured	O
Charlotte's	O
Web	O
cannabis	O
brought	O
increased	O
attention	O
to	O
the	O
use	O
of	O
CBD	B-Drug
in	O
treatment	O
seizure	O
disorders.	O

Although	O
the	O
stimulant	O
and	O
hunger-suppressant	O
properties	O
of	O
coca	B-Drug
had	O
been	O
known	O
for	O
many	O
centuries,	O
isolation	O
cocaine	B-Drug
alkaloid	O
was	O
not	O
achieved	O
until	O
1855.	O

Desmethylprodine	B-Drug
has	O
been	O
labeled	O
by	O
the	O
DEA	O
as	O
a	O
Schedule	O

A	O
binding	O
study	O
assessed	O
PCP	B-Drug
at	O
56	O
sites	O
including	O
neurotransmitter	O
receptors	O
and	O
transporters	O
found	O
that	O
had	O
Ki	O
values	O
of	O
>10,000	O
nM	O
all	O
except	O
the	O
dizocilpine	O
(MK-801)	O
site	O
NMDA	O
receptor	O

Kief	O
is	O
a	O
powder,	O
rich	O
in	O
trichomes,	O
which	O
can	O
be	O
sifted	O
from	O
the	O
leaves,	O
flowers	O
and	O
fruits	O
of	O
cannabis	O
plants	O
either	O
consumed	O
powder	O
form	O
or	O
compressed	O
to	O
produce	O
cakes	O
hashish.	O
hashish	B-Drug

In	O
early	O
1928,	O
Merck	O
introduced	O
a	O
combination	O
product	O
containing	O
scopolamine,	O
oxycodone,	O
and	O
ephedrine	B-Drug
under	O
the	O
German	O
initials	O
for	O
ingredients	O
SEE,	O
which	O
was	O
later	O
renamed	O
Scophedal	O
(SCOpolamine,	O
ePHEDrine	O
eukodAL)	O
in	O
1942.	O
scopolamine	B-Drug
oxycodone	B-Drug
eukodAL	B-Drug

This	O
means	O
LSD	B-Drug
is	O
illegal	O
to	O
manufacture,	O
buy,	O
possess,	O
process,	O
or	O
distribute	O
without	O
a	O
license	O
from	O
the	O
Drug	O
Enforcement	O
Administration	O
(DEA).	O

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression.	O

According	O
to	O
one	O
participant	O
in	O
an	O
ethnographic	O
study,	O
the	O
Texas	O
Group	O
produced	O
more	O
MDMA	B-Drug
eighteen	O
months	O
than	O
all	O
other	O
distribution	O
networks	O
combined	O
across	O
their	O
entire	O
histories.	O

Methylphenidate	B-Drug
was	O
originally	O
available	O
as	O
an	O
immediate-release	O
racemic	O
mixture	O
formulation	O
under	O
the	O
Novartis	O
trademark	O
name	O
Ritalin,	O
although	O
a	O
variety	O
of	O
generics	O
are	O
now	O
available,	O
some	O
other	O
brand	O
names.	O
Ritalin	B-Drug

Fludrocortisone	B-Drug
was	O
described	O
in	O
the	O
literature	O
1953	O
and	O
introduced	O
for	O
medical	O
use	O
(as	O
acetate	O
ester)	O
1954.	O

Cocaine's	O
acute	O
effect	O
in	O
the	O
central	O
nervous	O
system	O
is	O
to	O
raise	O
amount	O
of	O
dopamine	O
and	O
serotonin	O
nucleus	O
accumbens	O
(the	O
pleasure	O
center	O
brain).	O
Cocaine	B-Drug

In	O
the	O
book,	O
Rosenbaum	O
illuminates	O
several	O
aspects	O
of	O
this	O
re-revisionist	O
Western:	O
from	O
Neil	O
Young's	O
haunting	O
score	O
to	O
role	O
tobacco,	O
Johnny	O
Depp's	O
performance,	O
film's	O
place	O
in	O
acid-Western	O
genre.	O
tobacco	B-Drug

Among	O
these	O
metabolites,	O
the	O
active	O
sympathomimetics	O
are	O
4-hydroxyamphetamine,	O
4-hydroxynorephedrine,	O
and	O
norephedrine.	O
norephedrine	B-Drug

speed,	O
MDMA,	O
cocaine	B-Drug
Black	O
Cat,	O
White	O
Cat	O
(1998)	O
MDMA	B-Drug

Medical	O
grade	O
diamorphine	B-Drug
is	O
used	O
as	O
a	O
pure	O
hydrochloride	O
salt	O
which	O
distinguished	O
from	O
black	O
tar	O
heroin,	O
variable	O
admixture	O
of	O
morphine	B-Drug
derivativespredominantly	O
6-MAM	O
(6-monoacetylmorphine),	O
the	O
result	O
crude	O
acetylation	O
during	O
clandestine	O
production	O
street	O
heroin.	O
6-monoacetylmorphine	B-Drug
heroin	B-Drug

In	O
1994,	O
Zurich	O
started	O
a	O
pilot	O
project	O
using	O
prescription	O
heroin	B-Drug
in	O
heroin-assisted	O
treatment	O
(HAT)	O
which	O
allowed	O
users	O
to	O
obtain	O
and	O
inject	O
it	O
under	O
medical	O
supervision.	O

whilst	O
most	O
studies	O
employing	O
basic	O
testing	O
paradigms	O
show	O
that	O
modafinil	B-Drug
intake	O
enhances	O
executive	O
function,	O
only	O
half	O
improvements	O
in	O
attention	O
and	O
learning	O
memory,	O
a	O
few	O
even	O
report	O
impairments	O
divergent	O
creative	O
thinking.	O

In	O
Australia,	O
both	O
pure	O
dextropropoxyphene	B-Drug
capsules	O
(as	O
napsylate,	O
100	O
mg),	O
marketed	O
as	O
Doloxene,	O
and	O
combination	O
tablets	O
(with	O
paracetamol)	O
all	O
containing	O
32.5	O
mg	O
HCl	O
with	O
325	O
paracetamol,	O
which	O
are	O
currently	O
available	O
on	O
prescription	O
were	O
supposed	O
to	O
be	O
withdrawn	O
from	O
1	O
March	O
2012,	O
but	O
Aspen	O
Pharma	O
sought	O
a	O
review	O
in	O
the	O
Administrative	O
Appeals	O
Tribunal	O
ruled	O
2013	O
that	O
drugs	O
could	O
sold	O
under	O
strict	O
conditions.	O
paracetamol	B-Drug

Assembling	O
phenethylamine	B-Drug
structures	O
for	O
synthesis	O
of	O
compounds	O
such	O
as	O
epinephrine,	O
amphetamines,	O
tyrosine,	O
and	O
dopamine	O
by	O
adding	O
the	O
beta-aminoethyl	O
side	O
chain	O
to	O
phenyl	O
ring	O
is	O
possible.	O

PCP's	O
rewarding	O
and	O
reinforcing	O
effects	O
are	O
at	O
least	O
partly	O
mediated	O
by	O
blocking	O
the	O
NMDA	O
receptors	O
in	O
glutamatergic	O
inputs	O
to	O
D1-type	O
medium	O
spiny	O
neurons	O
nucleus	O
accumbens.	O
PCP	B-Drug

On	O
January	O
17,	O
2018,	O
several	O
senators,	O
including	O
New	O
Hampshire	O
Senator	O
Maggie	O
Hassan,	O
wrote	O
a	O
letter	O
to	O
President	O
Trump	O
expressing	O
extreme	O
concern	O
regarding	O
his	O
lack	O
of	O
commitment	O
the	O
White	O
House	O
Office	O
National	O
Drug	O
Control	O
Policy,	O
which	O
plays	O
critical	O
role	O
in	O
coordinating	O
federal	O
government's	O
response	O
fentanyl,	O
heroin,	O
and	O
opioid	O
epidemic.	O
fentanyl	B-Drug
heroin	B-Drug

Morphine	B-Drug
and	O
its	O
ester	O
salt	O
morphine	B-Drug
diacetate	O
(diamorphine	O
or	O
heroin)	O
have	O
greater	O
addiction	O
potential	O
when	O
compared	O
to	O
oxymorphone.	O
diamorphine	B-Drug
heroin	B-Drug
oxymorphone	B-Drug

In	O
2004,	O
according	O
to	O
the	O
United	O
Nations,	O
589	O
tonnes	O
of	O
cocaine	B-Drug
were	O
seized	O
globally	O
by	O
law	O
enforcement	O
authorities.	O

In	O
2013,	O
overdose	O
on	O
amphetamine,	O
methamphetamine,	O
and	O
other	O
compounds	O
implicated	O
in	O
an	O
"amphetamine	O
use	O
disorder"	O
resulted	O
estimated	O
3,788	O
deaths	O
worldwide	O
(3,4254,145	O
deaths,	O
95%	O
confidence).	O
amphetamine	B-Drug
methamphetamine	B-Drug

However,	O
the	O
short	O
duration	O
of	O
these	O
studies	O
limits	O
conclusions	O
on	O
influence	O
nandrolone	B-Drug
decanoate	I-Drug
bone	O
in	O
men.	O

Other	O
drugs	O
of	O
the	O
same	O
type	O
have	O
included	O
in	O
opium	B-Drug
alkaloid	O
hydrobromides,	O
sulfates,	O
phosphates,	O
and	O
valerates.	O

In	O
turn,	O
alcohol	O
and	O
tobacco	B-Drug
are	O
typically	O
easier	O
to	O
obtain	O
at	O
an	O
earlier	O
age	O
than	O
is	O
cannabis	O
(though	O
the	O
reverse	O
may	O
be	O
true	O
in	O
some	O
areas),	O
thus	O
leading	O
"gateway	O
sequence"	O
those	O
individuals,	O
since	O
they	O
most	O
likely	O
experiment	O
with	O
any	O
drug	O
offered.	O

No	O
acute	O
overdosing	O
of	O
triamcinolone	B-Drug
has	O
been	O
described.	O

Unsteadiness	O
after	O
taking	O
bromazepam	B-Drug
is,	O
however,	O
less	O
pronounced	O
than	O
other	O
benzodiazepines	O
such	O
as	O
lorazepam.	O
lorazepam	B-Drug

It	O
is	O
made	O
from	O
salvinorin	B-Drug
B,	O
which	O
most	O
conveniently	O
A	I-Drug
by	O
deacetylation.	O

These	O
uses	O
include	O
aids	O
to	O
relieve	O
the	O
panic	O
or	O
distress	O
of	O
dysphoric	O
("bad	O
trip")	O
reactions	O
psychedelic	O
drugs,	O
such	O
as	O
LSD,	O
and	O
drug-induced	O
agitation	O
insomnia	O
in	O
"comedown"	O
stages	O
stimulant	O
use,	O
amphetamine,	O
cocaine,	O
MDMA	B-Drug
allowing	O
sleep.	O
LSD	B-Drug
amphetamine	B-Drug
cocaine	B-Drug

A	O
certified	O
opioid	O
treatment	O
program	O
is	O
required	O
under	O
federal	O
law	O
(42	O
CFR	O
8.12)	O
when	O
dispensing	O
methadone	B-Drug
for	O
the	O
of	O
addiction	O
or	O
detoxification.	O

Increasing	O
the	O
dosage	O
of	O
naloxone	B-Drug
or	O
its	O
frequency	O
administration	O
may	O
be	O
required	O
to	O
counteract	O
respiratory	O
depression.	O

Laudanum	B-Drug
is	O
portrayed	O
as	O
the	O
surgical	O
drug	O
of	O
choice	O
for	O
fifteenth-century	O
physicians	O
in	O
Lawrence	O
Schoonover's	O
novel	O
The	O
Burnished	O
Blade	O
(1948),	O
plot	O
which	O
deals	O
part	O
with	O
smuggling	O
expensive	O
raw	O
opium	B-Drug
into	O
France	O
from	O
Empire	O
Trebizond.	O

AMPA	O
receptors	O
modulated	O
by	O
aniracetam	B-Drug
and	O
CX614	B-Drug
will	O
deactivate	O
slower,	O
facilitate	O
more	O
overall	O
cation	O
transport.	O

In	O
2018,	O
the	O
World	O
Health	O
Organization	O
recommended	O
that	O
CBD	B-Drug
remain	O
unscheduled.	O

Use	O
of	O
MDMA	B-Drug
individually	O
or	O
in	O
small	O
groups	O
a	O
quiet	O
environment	O
and	O
when	O
concentrating,	O
is	O
associated	O
with	O
increased	O
lucidity,	O
concentration,	O
sensitivity	O
to	O
aesthetic	O
aspects	O
the	O
environment,	O
enhanced	O
awareness	O
emotions,	O
improved	O
capability	O
communication.	O

Peak	O
plasma	O
concentrations	O
of	O
the	O
morphine	B-Drug
content	O
are	O
reached	O
in	O
about	O
one	O
hour,	O
and	O
nearly	O
75%	O
opium	B-Drug
tincture	O
is	O
excreted	O
urine	O
within	O
48	O
hours	O
after	O
oral	O
administration.	O

Such	O
was	O
the	O
tobacco	B-Drug
consumption	O
of	O
its	O
troops	O
that	O
US	O
Government	O
became	O
single-largest	O
purchaser	O
cigarettes,	O
including	O
cigarettes	O
in	O
troops'	O
rations	O
and	O
at	O
discounted	O
prices	O
post	O
exchanges.	O

In	O
the	O
1660s,	O
laudanum	B-Drug
was	O
recommended	O
for	O
pain,	O
sleeplessness,	O
and	O
diarrhea	O
by	O
Thomas	O
Sydenham,	O
renowned	O
"father	O
of	O
English	O
medicine"	O
or	O
"English	O
Hippocrates",	O
to	O
whom	O
is	O
attributed	O
quote,	O
"Among	O
remedies	O
which	O
it	O
has	O
pleased	O
Almighty	O
God	O
give	O
man	O
relieve	O
his	O
sufferings,	O
none	O
so	O
universal	O
efficacious	O
as	O
opium.	O
opium	B-Drug

Chlorpromazine	B-Drug
does	O
also	O
act	O
as	O
FIASMA	O
(functional	O
inhibitor	O
of	O
acid	O
sphingomyelinase).	O

The	O
program	O
was	O
counted	O
as	O
a	O
substantial	O
success,	O
with	O
cessation	O
of	O
direct	O
British	O
opium	B-Drug
exports	O
to	O
China	O
(but	O
not	O
Hong	O
Kong)	O
and	O
most	O
provinces	O
declared	O
free	O
production.	O

An	O
18	O
m	O
(59	O
ft)	O
long	O
narco-submarine	O
can	O
reach	O
speeds	O
of	O
km/h	O
(9.7	O
knots)	O
and	O
carry	O
up	O
to	O
10	O
tons	O
cocaine.	O
cocaine	B-Drug

Androstenedione	B-Drug
can	O
be	O
biosynthesized	O
in	O
one	O
of	O
two	O
ways.	O

The	O
metabolites	O
of	O
nicodicodeine	B-Drug
include	O
dihydromorphine	B-Drug
where	O
nicocodeine	B-Drug
is	O
turned	O
into	O
morphine	B-Drug
as	O
noted	O
above.	O

PCP	B-Drug
hydrochloride	O
can	O
be	O
insufflated	O
(snorted),	O
depending	O
upon	O
the	O
purity.	O

Blunts	O
also	O
come	O
as	O
ready	O
made	O
tobacco	B-Drug
wraps	O
with	O
hundreds	O
of	O
flavors	O
across	O
numerous	O
brands.	O

Naloxone	B-Drug
is	O
extensively	O
inactivated	O
by	O
first-pass	O
metabolism	O
in	O
the	O
liver,	O
meaning	O
that	O
use	O
of	O
buprenorphine/naloxone	B-Drug
as	O
prescribed	O
should	O
not	O
lead	O
to	O
active	O
naloxone	B-Drug
blood	O
(which,	O
an	O
opioid	O
antagonist,	O
would	O
reverse	O
effect	O
buprenorphine	B-Drug
or	O
other	O
opioids).	O

Tramadol	B-Drug
exists	O
as	O
a	O
racemic	O
mixture,	O
the	O
positive	O
enantiomer	O
inhibits	O
serotonin	O
reuptake	O
while	O
negative	O
noradrenaline	O
re-uptake,	O
by	O
binding	O
to	O
and	O
blocking	O
transporters.	O

When	O
entheogenic	O
preparations	O
of	O
these	O
plants	O
were	O
used,	O
hyoscine	B-Drug
was	O
considered	O
to	O
be	O
the	O
main	O
psychoactive	O
compound	O
and	O
largely	O
responsible	O
for	O
hallucinogenic	O
effects,	O
particularly	O
when	O
preparation	O
made	O
into	O
a	O
topical	O
ointment	O
(most	O
notably	O
flying	O
ointment).	O

Androstenedione	B-Drug
is	O
produced	O
in	O
the	O
adrenal	O
glands	O
and	O
gonads.	O

Nuno	O
Maulide	O
and	O
his	O
team	O
report	O
the	O
total	O
synthesis	O
of	O
quinine	B-Drug
via	O
CH	O
activation,	O
including	O
analogues	O
with	O
improved	O
antimalarial	O
activity	O

When	O
fentanyl	B-Drug
binds,	O
downstream	O
signaling	O
leads	O
to	O
the	O
inhibitory	O
effects,	O
such	O
as	O
decreased	O
cAMP	O
production,	O
calcium	O
ion	O
influx,	O
and	O
increased	O
potassium	O
efflux.	O

We	O
knew	O
we	O
couldn't	O
make	O
it	O
illegal	O
to	O
be	O
either	O
against	O
the	O
war	O
or	O
black,	O
but	O
by	O
getting	O
public	O
associate	O
hippies	O
with	O
marijuana	O
and	O
blacks	O
heroin,	O
then	O
criminalizing	O
both	O
heavily,	O
could	O
disrupt	O
those	O
communities.	O
heroin	B-Drug

Valproate	B-Drug
in	O
elderly	O
people	O
with	O
dementia	O
caused	O
increased	O
sleepiness.	O

This	O
helps	O
avoid	O
detection	O
but	O
reduces	O
the	O
CBD	B-Drug
production	O
of	O
plant.	O

The	O
National	O
Comprehensive	O
Cancer	O
Network	O
recommends	O
bevacizumab	B-Drug
as	O
standard	O
first-line	O
treatment	O
in	O
combination	O
with	O
any	O
platinum-based	O
chemotherapy,	O
followed	O
by	O
maintenance	O
until	O
disease	O
progression.	O

The	O
risk	O
of	O
bleeding	O
increases	O
with	O
the	O
concurrent	O
medications	O
clopidogrel,	O
cefoperazone,	O
valproic	O
acid,	O
cefotetan,	O
eptifibatide,	O
tirofiban,	O
and	O
ticlopidine.	O
clopidogrel	B-Drug
cefotetan	B-Drug
eptifibatide	B-Drug

The	O
mechanism	O
of	O
alcohol-related	O
psychosis	O
is	O
due	O
to	O
distortions	O
neuronal	O
membranes,	O
gene	O
expression,	O
as	O
well	O
thiamin	B-Drug
deficiency.	O

It	O
has	O
been	O
implicated	O
in	O
addictions	O
to	O
alcohol,	O
cannabinoids,	O
cocaine,	O
methylphenidate,	O
nicotine,	O
opioids,	O
phencyclidine,	O
propofol,	O
and	O
substituted	O
amphetamines,	O
among	O
others.	O
cocaine	B-Drug
methylphenidate	B-Drug
nicotine	B-Drug
phencyclidine	B-Drug
propofol	B-Drug

Orally,	O
5-MeO-MiPT	B-Drug
is	O
active	O
at	O
4-6	O
mg.	O

The	O
reaction	O
occurs	O
with	O
retention	O
of	O
stereochemistry,	O
so	O
the	O
product	O
lisdexamfetamine	B-Drug
exists	O
as	O
a	O
single	O
stereoisomer.	O

All	O
drugs	O
in	O
the	O
NBOMe	O
family,	O
including	O
25I-NBOMe,	O
are	O
illegal.	O
25I-NBOMe	B-Drug

In	O
the	O
post	O
9/11	O
era,	O
trading	O
between	O
borders	O
became	O
difficult	O
and	O
because	O
new	O
international	O
laws	O
were	O
set	O
into	O
place,	O
opium	B-Drug
trade	O
more	O
diffused.	O

SARs	O
have	O
shown	O
that	O
4,4-difluorination	O
is	O
an	O
excellent	O
way	O
to	O
boost	O
DAT	O
activity	O
of	O
benztropine,	O
and	O
gives	O
selectivity	O
over	O
the	O
SERT	O
NET.Furthermore,	O
replacing	O
N-Me	O
with,	O
e.g.	O
n-phenylpropyl	O
helps	O
bring	O
muscarinic	O
down	O
something	O
same	O
as	O
DRI	O
affinity.	O
benztropine	B-Drug

The	O
leg	O
that	O
had	O
been	O
immersed	O
in	O
the	O
cocaine	B-Drug
solution	O
reacted	O
very	O
differently	O
from	O
salt	O
water.	O

It	O
was	O
shown	O
to	O
be	O
more	O
effective	O
than	O
maprotiline	B-Drug
in	O
a	O
group	O
of	O
people	O
with	O
co-existing	O
depression	O
and	O
anxiety.	O

5.8	O
million	O
thalidomide	B-Drug
pills	O
were	O
distributed	O
throughout	O
Brazil	O
in	O
this	O
time	O
period,	O
largely	O
to	O
poor	O
Brazilians	O
areas	O
with	O
access	O
healthcare,	O
and	O
these	O
cases	O
have	O
occurred	O
despite	O
the	O
controls.	O

Actual	O
full	O
synthesis	O
of	O
cocaine	B-Drug
is	O
rarely	O
done.	O

Contraindications	O
of	O
dexamethasone	B-Drug
include,	O
but	O
are	O
not	O
limited	O
to:	O
Uncontrolled	O
infections	O
Known	O
hypersensitivity	O
to	O
Cerebral	O
malaria	O
Systemic	O
fungal	O
infection	O
Concurrent	O
treatment	O
with	O
live	O
virus	O
vaccines	O
(including	O
smallpox	B-Drug
vaccine)	O
vaccine	I-Drug

Temazepam	B-Drug
is	O
a	O
drug	O
with	O
high	O
potential	O
for	O
misuse.	O

Mescaline	B-Drug
was	O
first	O
isolated	O
and	O
identified	O
in	O
1897	O
by	O
the	O
German	O
chemist	O
Arthur	O
Heffter	O
synthesized	O
1918	O
Ernst	O
Spth.	O

Inhibition	O
of	O
11-HSD2	O
by	O
fluoxymesterone	B-Drug
may	O
result	O
in	O
mineralocorticoid	O
receptor	O
overactivation	O
and	O
associated	O
side	O
effects	O
such	O
as	O
hypertension	O
fluid	O
retention,	O
has	O
been	O
hypothesized	O
to	O
be	O
involved	O
the	O
cardiovascular	O
other	O
adverse	O
fluoxymesterone.	O

The	O
six	O
biggest	O
tobacco	B-Drug
companies	O
made	O
a	O
combined	O
profit	O
of	O
$35.1	O
billion	O
(Jha	O
et	O
al.,	O
2014)	O
in	O
2010.	O

Harsher	O
sentences	O
are	O
given	O
for	O
those	O
convicted	O
of	O
manufacturing	O
amphetamines	O
such	O
as	O
methamphetamine.	O
methamphetamine	B-Drug

Carlos	O
Santana	O
told	O
in	O
1989	O
about	O
his	O
mescaline	B-Drug
use	O
a	O
Rolling	O
Stone	O
interview.	O

Like	O
other	O
AAS,	O
drostanolone	B-Drug
is	O
an	O
agonist	O
of	O
the	O
androgen	O
receptor	O
(AR).	O

Meperidine;	O
Demerol)	O
Meperidine	B-Drug
Demerol	B-Drug

Amitriptyline	B-Drug
is	O
probably	O
effective	O
for	O
the	O
prevention	O
of	O
periodic	O
migraine	O
in	O
adults.	O

Buprenorphine	B-Drug
and	O
methadone	B-Drug
work	O
by	O
reducing	O
opioid	O
cravings,	O
easing	O
withdrawal	O
symptoms,	O
blocking	O
the	O
euphoric	O
effects	O
of	O
opioids	O
via	O
cross-tolerance,	O
in	O
case	O
buprenorphine,	O
a	O
high-affinity	O
partial	O
agonist,	O
also	O
due	O
to	O
receptor	O
saturation.	O
buprenorphine	B-Drug

In	O
a	O
study	O
on	O
slices	O
of	O
rat	O
corpus	O
striatum	O
and	O
substantia	O
nigra	O
fencamfamin	B-Drug
acted	O
as	O
an	O
indirect	O
dopamine	O
agonist.	O

A	O
synthetic	O
derivative	O
of	O
ibogaine,	O
18-methoxycoronaridine	B-Drug
(18-MC),	O
is	O
a	O
selective	O
34	O
antagonist	O
that	O
was	O
developed	O
collaboratively	O
by	O
the	O
neurologist	O
Stanley	O
D.	O
Glick	O
(Albany)	O
and	O
chemist	O
Martin	O
E.	O
Kuehne	O
(Vermont).	O
ibogaine	B-Drug
18-MC	B-Drug

LSD	B-Drug
Run!	O

Because	O
THC	B-Drug
production	O
drops	O
off	O
once	O
pollination	O
occurs,	O
the	O
male	O
plants	O
(which	O
produce	O
little	O
themselves)	O
are	O
eliminated	O
before	O
they	O
shed	O
pollen	O
to	O
prevent	O
pollination,	O
thus	O
inducing	O
development	O
of	O
parthenocarpic	O
fruits	O
gathered	O
in	O
dense	O
infructescences.	O

On	O
June	O
18,	O
2019,	O
federal	O
authorities	O
seized	O
39,525	O
pounds	O
or	O
nearly	O
20	O
tons	O
of	O
cocaine	B-Drug
at	O
the	O
Port	O
Philadelphia's	O
Packer	O
Marine	O
Terminal.	O

However,	O
it	O
is	O
often	O
high	O
in	O
cannabidiol	B-Drug
(CBD).	O
CBD	B-Drug

ALD-52	B-Drug
is	O
technically	O
not	O
illegal	O
but	O
it	O
may	O
fall	O
in	O
the	O
NPSG	O
(Neue-Psychoaktive-Substanzen-Gesetz	O
sterreich)	O
as	O
an	O
analogue	O
of	O
LSD	B-Drug
listed	O
substance	O
Denmark	O
April,	O
2019,	O
and	O
its	O
chemical	O
class	O
'lysergamide'	O
banned	O
under	O
Analogue	O
Act	O
(Some	O
analogues	O
are,	O
however,	O
prohibited).	O

PCP	B-Drug
may	O
cause	O
hallucinations,	O
distorted	O
perceptions	O
of	O
sounds,	O
and	O
violent	O
behavior.	O

3,4-Methylenedioxyamphetamine	B-Drug
(MDA)	O

A	O
subsequent	O
PET	O
scan	O
following	O
a	O
three	O
day	O
cocaine	B-Drug
binge	O
showed	O
decrease	O
in	O
KOR	O
availability,	O
interpreted	O
as	O
increased	O
endogenous	O
dynorphin	O
competing	O
with	O
the	O
radioligand	O
at	O
binding	O
sites.	O

The	O
agency	O
also	O
took	O
issue	O
with	O
the	O
businesses	O
marketing	O
CBD	B-Drug
products	O
as	O
dietary	O
supplements".	O

In	O
any	O
case,	O
pregabalin	B-Drug
is	O
2	O
to	O
4	O
times	O
more	O
potent	O
than	O
gabapentin	B-Drug
as	O
an	O
analgesic	O
and,	O
in	O
animals,	O
appears	O
be	O
3	O
10	O
anticonvulsant.	O

Early	O
medical	O
trials	O
of	O
humans	O
taking	O
desomorphine	B-Drug
have	O
resulted	O
in	O
the	O
finding	O
that	O
like	O
morphine	B-Drug
and	O
most	O
other	O
analgesics	O
type,	O
small	O
amounts	O
are	O
highly	O
addictive	O
tolerance	O
to	O
drug	O
develops	O
quickly.	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

Lorazepam	B-Drug
is	O
sometimes	O
used	O
as	O
an	O
alternative	O
to	O
haloperidol	B-Drug
when	O
there	O
the	O
need	O
for	O
rapid	O
sedation	O
of	O
violent	O
or	O
agitated	O
individuals,	O
but	O
plus	O
promethazine	B-Drug
preferred	O
due	O
better	O
effectiveness	O
and	O
lorazepam's	O
adverse	O
effects	O
on	O
respiratory	O
function.	O
lorazepam	B-Drug

However,	O
due	O
to	O
the	O
large	O
decrease	O
in	O
sex	O
hormone-binding	O
globulin	O
(SHBG)	O
levels	O
and	O
hence	O
increase	O
free	O
unbound	O
testosterone	O
caused	O
by	O
methyltestosterone,	O
androgenic	O
effects	O
may	O
be	O
greater	O
than	O
reflected	O
merely	O
methyltestosterone	B-Drug
levels.	O

Some	O
historians	O
and	O
sociologists	O
have	O
suggested	O
that	O
the	O
meanings	O
uses	O
attributed	O
to	O
anti-craving	O
medicine,	O
such	O
as	O
naltrexone,	O
is	O
context-dependent.	O
naltrexone	B-Drug

For	O
people	O
with	O
resistant	O
hypertension,	O
already	O
taking	O
a	O
thiazide	O
diuretic,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
(ACE-i)	O
or	O
II	O
receptor	O
blocker	O
(ARB),	O
and	O
calcium	O
channel	O
blocker,	O
the	O
addition	O
of	O
amiloride	B-Drug
(or	O
spironolactone)	O
was	O
better	O
at	O
reducing	O
blood	O
pressure	O
than	O
adding	O
beta-blocker	O
(bisoprolol)	O
alpha-1	O
(doxazosin).	O
spironolactone	B-Drug

Using	O
formaldehyde	O
and	O
sulfuric	O
acid,	O
the	O
solution	O
will	O
turn	O
purple	O
when	O
introduced	O
to	O
opium	B-Drug
drugs.	O

In	O
the	O
United	O
States,	O
methamphetamine's	O
levorotary	O
form	O
is	O
available	O
in	O
some	O
over-the-counter	O
(OTC)	O
nasal	O
decongestant	O
products.	O
methamphetamine	B-Drug

Janssen	O
Pharmaceuticals	O
has	O
developed	O
and	O
brought	O
to	O
the	O
market	O
about	O
70	O
new	O
active	O
substances	O
(NCE),	O
of	O
which	O
most	O
well-known	O
are	O
(name	O
may	O
differ):	O
Imodium	B-Drug
(against	O
diarrhoea.	O

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself,	O
which	O
include	O
itching,	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression,	O
can	O
be	O
life-threatening.	O

The	O
program	O
showed	O
an	O
fMRI	O
study	O
on	O
the	O
effects	O
of	O
MDMA	B-Drug
(ecstasy)	O
brain,	O
which	O
was	O
funded	O
by	O
Channel	O
4.	O
ecstasy	B-Drug

As	O
of	O
October	O
2020,	O
CBD	B-Drug
was	O
not	O
an	O
FDA-approved	O
drug	O
eligible	O
for	O
interstate	O
commerce,	O
and	O
the	O
FDA	O
encouraged	O
manufacturers	O
to	O
follow	O
procedures	O
approval.	O

The	O
chemical	O
compound	O
tetrahydrocannabinol	B-Drug
(THC),	O
which	O
is	O
found	O
in	O
cannabis,	O
has	O
many	O
depressant	O
effects	O
such	O
as	O
muscle	O
relaxation,	O
sedation,	O
decreased	O
alertness,	O
and	O
less	O
tiredness.	O
THC	B-Drug

Sulfonamide-trimethoprim	O
combinations	O
(co-trimoxazole)	O
are	O
still	O
used	O
extensively	O
against	O
opportunistic	O
infections	O
in	O
patients	O
with	O
AIDS,	O
urinary	O
and	O
the	O
treatment	O
of	O
burns.	O
co-trimoxazole	B-Drug

Following	O
the	O
European	O
rule	O
from	O
2014,	O
25I-NBOMe	B-Drug
was	O
put	O
in	O
class	O
4	O
of	O
prohibited	O
substances.	O

MDAI	B-Drug
is	O
only	O
non-neurotoxic	O
in	O
isolation	O
but	O
may	O
become	O
neurotoxic	O
when	O
mixed	O
with	O
other	O
drugs.	O

Internationally,	O
heroin	B-Drug
is	O
controlled	O
under	O
Schedules	O
I	O
and	O
IV	O
of	O
the	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs,	O
it	O
generally	O
illegal	O
to	O
make,	O
possess,	O
or	O
sell	O
without	O
a	O
license.	O

During	O
the	O
1960s	O
and	O
early	O
1970s,	O
drug	O
culture	O
adopted	O
LSD	B-Drug
as	O
psychedelic	O
of	O
choice,	O
particularly	O
amongst	O
hippie	O
community.	O

One	O
unpublished	O
study	O
by	O
Frank	O
Sharp	O
reportedly	O
showed	O
no	O
damage	O
the	O
NDMA	O
antagonist	O
ketamine,	O
a	O
structurally	O
similar	O
drug,	O
far	O
beyond	O
recreational	O
doses,	O
but	O
due	O
to	O
never	O
having	O
been	O
published,	O
its	O
validity	O
is	O
controversial.	O
ketamine	B-Drug

Nitrazepam	B-Drug
is	O
not	O
recommended	O
for	O
use	O
in	O
those	O
under	O
18	O
years	O
of	O
age.	O

Coca	O
herbal	O
infusion	O
(also	O
referred	O
to	O
as	O
coca	B-Drug
tea)	O
is	O
used	O
in	O
coca-leaf	O
producing	O
countries	O
much	O
any	O
medicinal	O
would	O
elsewhere	O
the	O
world.	O

The	O
stimulant	O
effects	O
of	O
MDMA	B-Drug
include	O
hypertension,	O
anorexia	O
(appetite	O
loss),	O
euphoria,	O
social	O
disinhibition,	O
insomnia	O
(enhanced	O
wakefulness/inability	O
to	O
sleep),	O
improved	O
energy,	O
increased	O
arousal,	O
and	O
perspiration,	O
among	O
others.	O

As	O
of	O
2019,	O
there	O
was	O
limited	O
high-quality	O
evidence	O
for	O
cannabidiol	B-Drug
having	O
a	O
neurological	O
effect	O
in	O
people.	O

Naloxone	B-Drug
works	O
by	O
reversing	O
the	O
effects	O
of	O
hydromorphone,	O
and	O
only	O
is	O
administered	O
in	O
presence	O
significant	O
respiratory	O
depression	O
circulatory	O
depression.	O
hydromorphone	B-Drug

On	O
the	O
27th,	O
an	O
anonymous	O
source	O
reported	O
that	O
Murray	O
had	O
administered	O
propofol	B-Drug
within	O
24	O
hours	O
of	O
Jackson's	O
death.	O

Heroin	B-Drug
is	O
an	O
opiate	O
that	O
highly	O
addictive.	O

The	O
cocaine	B-Drug
is	O
then	O
broken	O
down	O
into	O
smaller	O
loads	O
for	O
smuggling	O
across	O
the	O
U.S.Mexico	O
border.	O

Although	O
nalbuphine	B-Drug
possesses	O
opioid	O
antagonist	O
activity,	O
there	O
is	O
evidence	O
that	O
in	O
nondependent	O
patients	O
it	O
will	O
not	O
antagonize	O
an	O
analgesic	O
administered	O
just	O
before,	O
concurrently,	O
or	O
after	O
injection.	O

,	O
hyoscine	B-Drug
can	O
cause	O
significant	O
unwanted	O
side	O
effects	O
when	O
taken	O
with	O
other	O
medications.	O

Within	O
the	O
INN,	O
USAN,	O
BAN,	O
and	O
AAN	O
naming	O
systems	O
this	O
drug	O
is	O
known	O
as	O
butorphanol,	O
while	O
within	O
JAN	O
it	O
named	O
torbugesic.	O
butorphanol	B-Drug

Hyperkalemia	O
can	O
occur	O
following	O
an	O
overdose	O
of	O
spironolactone,	O
and	O
this	O
is	O
especially	O
so	O
in	O
people	O
with	O
decreased	O
kidney	O
function.	O
spironolactone	B-Drug

Trace	O
aminergic	O
hypo-function	O
is	O
particularly	O
relevant	O
to	O
ADHD,	O
since	O
urinary	O
and	O
plasma	O
phenethylamine	B-Drug
concentrations	O
are	O
significantly	O
lower	O
in	O
ADHD	O
individuals	O
relative	O
controls	O
the	O
two	O
most	O
commonly	O
prescribed	O
drugs	O
for	O
amphetamine	B-Drug
methylphenidate,	O
increase	O
biosynthesis	O
treatment-responsive	O
with	O
ADHD.	O
methylphenidate	B-Drug

While	O
researching	O
lysergic	O
acid	B-Drug
derivatives,	O
Hofmann	O
first	O
synthesized	O
LSD	O
on	O
16	O
November	O
1938.	O

User-specific	O
products	O
include	O
glass	O
hashish	B-Drug
pipes,	O
crack	O
cocaine	B-Drug
smoking	O
masks,	O
bongs,	O
freebase	O
kits,	O
syringes,	O
roach	O
clips	O
for	O
holding	O
the	O
burning	O
end	O
of	O
a	O
marijuana	O
joint.	O

Cannabidiol	B-Drug
(CBD)	O
is	O
another	O
major	O
constituent	O
of	O
the	O
plant.	O
CBD	B-Drug

Because	O
of	O
fentanyl's	O
high	O
lipid	O
solubility,	O
its	O
effects	O
are	O
more	O
localized	O
than	O
morphine,	O
and	O
some	O
clinicians	O
prefer	O
to	O
use	O
morphine	B-Drug
get	O
a	O
wider	O
spread	O
analgesia.	O
fentanyl	B-Drug

Today,	O
the	O
focus	O
of	O
world's	O
drug	O
policy	O
reform	O
organisations	O
is	O
on	O
promotion	O
harm	O
reduction	O
in	O
Western	O
World,	O
and	O
attempting	O
to	O
prevent	O
catastrophic	O
loss	O
human	O
life	O
developing	O
countries	O
where	O
much	O
supply	O
heroin,	O
cocaine,	O
marijuana	O
are	O
produced.	O
heroin	B-Drug
cocaine	B-Drug

On	O
January	O
19,	O
2012,	O
the	O
European	O
Medicines	O
Agency	O
withdrew	O
marketing	O
authorization	O
in	O
Union	O
for	O
all	O
medicines	O
containing	O
meprobamate,	O
"due	O
to	O
serious	O
side	O
effects	O
seen	O
with	O
medicine."	O
meprobamate	B-Drug

A	O
single	O
dose	O
of	O
dexamethasone	B-Drug
or	O
another	O
steroid	O
speeds	O
improvement	O
a	O
sore	O
throat.	O

The	O
proposed	O
changes	O
included	O
other	O
similar	O
blanket	O
bans	O
for	O
substances,	O
such	O
as	O
a	O
ban	O
on	O
any	O
and	O
all	O
plants	O
containing	O
Mescaline	B-Drug
or	O
Ephedrine.	O
Ephedrine	B-Drug

Trimeperidine	B-Drug
(Promedol)	O
is	O
an	O
opioid	O
analgesic	O
that	O
analogue	O
of	O
prodine.	O
prodine	B-Drug

Cetrorelix	B-Drug
is	O
marketed	O
by	O
Merck	O
Serono	O
for	O
use	O
in	O
in-vitro	O
fertilization	O
all	O
countries	O
except	O
Japan,	O
where	O
it	O
Shionogi	O
and	O
Nippon	O
Kayaku.	O

Quinbolone	B-Drug
can	O
be	O
prepared	O
from	O
testosterone.	O

Adverse	O
neuroplastic	O
changes	O
to	O
brain	O
microvasculature	O
and	O
white	O
matter	O
also	O
occur	O
in	O
humans	O
using	O
low	O
doses	O
of	O
MDMA.	O
MDMA	B-Drug

Additionally,	O
nociceptin	O
may	O
have	O
lower	O
tolerance	O
development	O
than	O
drugs	O
such	O
as	O
morphine.	O
morphine	B-Drug

"Can't	O
You	O
Hear	O
Me	O
Knocking"	O
on	O
the	O
album	O
Sticky	O
Fingers	O
("Y'all	O
got	O
cocaine	B-Drug
eyes	O
/	O

lisinopril	B-Drug
+	O
amlodipine)	O
amlodipine	B-Drug

Fentanyl	B-Drug
is	O
a	O
highly	O
lipophilic	O
compound,	O
which	O
well	O
absorbed	O
sublingually	O
and	O
generally	O
tolerated.	O

Children	O
in	O
households	O
where	O
cocaine	B-Drug
is	O
abused	O
are	O
at	O
risk	O
of	O
violence	O
and	O
neglect,	O
those	O
foster	O
care	O
may	O
experience	O
problems	O
due	O
to	O
unstable	O
family	O
situations.	O

Bupropion	B-Drug
is	O
also	O
known	O
to	O
act	O
as	O
a	O
non-competitive	O
antagonist	O
of	O
the	O
32,	O
34,	O
42,	O
and,	O
very	O
weakly,	O
7	O
nACh	O
receptors,	O
and	O
these	O
actions	O
appear	O
be	O
importantly	O
involved	O
in	O
its	O
beneficial	O
properties	O
not	O
only	O
smoking	O
cessation,	O
but	O
depression	O
well.	O

Like	O
other	O
2C-X-NBOMe	O
molecules,	O
25I-NBOMe	B-Drug
is	O
a	O
derivative	O
of	O
the	O
2C	O
family	O
phenethylamines	O
described	O
by	O
chemist	O
Alexander	O
Shulgin	O
in	O
his	O
book	O
PiHKAL.	O

In	O
Canada,	O
diamorphine	B-Drug
is	O
a	O
controlled	O
substance	O
under	O
Schedule	O
I	O
of	O
the	O
Controlled	O
Drugs	O
and	O
Substances	O
Act	O
(CDSA).	O

At	O
a	O
dose	O
of	O
250	O
milligrams,	O
2C-F	B-Drug
produces	O
modest	O
closed-eye	O
visuals	O
accompanied	O
by	O
lethargy.	O

Phenomorphan	B-Drug
is	O
an	O
opioid	O
analgesic.	O

Some	O
of	O
these	O
agents	O
are	O
used	O
as	O
analgesics,	O
including	O
pentazocine,	O
phenazocine,	O
dezocine,	O
and	O
eptazocine.	O
pentazocine	B-Drug
phenazocine	B-Drug

In	O
2004,	O
the	O
FDA	O
issued	O
a	O
"Patient	O
Safety"	O
news	O
bulletin	O
stating	O
that	O
"To	O
help	O
resolve	O
confusion	O
[between	O
opium	B-Drug
tincture	O
and	O
paregoric],	O
will	O
be	O
working	O
with	O
manufacturers	O
of	O
these	O
two	O
drugs	O
to	O
clarify	O
labeling	O
on	O
containers	O
in	O
package	O
inserts."	O

Charles	O
Bradley	O
gave	O
the	O
children	O
with	O
behavioral	O
disorders	O
Benzedrine	B-Drug
and	O
found	O
it	O
improved	O
academic	O
performance	O
behavior.	O

Modafinil	B-Drug
has	O
been	O
used	O
non-medically	O
as	O
a	O
"smart	O
drug"	O
by	O
students,	O
office	O
workers,	O
soldiers	O
and	O
transhumanists.	O

Stelazine	B-Drug
(trifluoperazine)	O
a	O
typical	O
antipsychotic,	O
only	O
rarely	O
used	O
nowadays.	O
trifluoperazine	B-Drug

The	O
solid	O
form	O
of	O
imatinib	B-Drug
mesylate	I-Drug
in	O
Gleevec	B-Drug
is	O
beta	O
crystalline.	O

Delorazepam	B-Drug
is	O
contraindicated	O
in	O
those	O
with	O
severe	O
schizophrenia	O
or	O
schizo-affective	O
disorders,	O
a	O
known	O
allergy	O
hypersensitivity	O
to	O
delorazepam	O
related	O
benzodiazepines,	O
and	O
moderate	O
renal	O
impairment	O
(delorazepam	O
sometimes	O
administered	O
at	O
reduced	O
dose	O
patients	O
mild	O
impairment).	O

Demand	O
remains	O
high,	O
and	O
consequently,	O
black	O
market	O
cocaine	B-Drug
is	O
quite	O
expensive.	O

Zaleplon	B-Drug
or	O
other	O
nonimpairing	O
sleep	O
aids	O
were	O
recommended	O
be	O
used	O
instead	O
of	O
zopiclone	B-Drug
to	O
reduce	O
traffic	O
accidents.	O

Most	O
of	O
the	O
side	O
effects	O
are	O
due	O
to	O
a	O
high	O
dopamine	O
signaling,	O
and	O
can	O
be	O
alleviated	O
by	O
reducing	O
dose	O
levodopa.	O
levodopa	B-Drug

L-DOPA	B-Drug
given	O
without	O
carbidopa	B-Drug
may	O
cause	O
hypertensive	O
crisis.	O

In	O
the	O
developing	O
world,	O
tobacco	B-Drug
consumption	O
is	O
rising	O
by	O
3.4%	O
per	O
year.	O

However	O
while	O
THC's	O
pharmacodynamic	O
tolerance	O
may	O
limit	O
the	O
maximal	O
effects	O
of	O
certain	O
drugs,	O
evidence	O
suggests	O
that	O
this	O
mitigates	O
undesirable	O
effects,	O
thus	O
enhancing	O
drug's	O
therapeutic	O
window.	O
THC	B-Drug

Buspirone	B-Drug
acts	O
as	O
an	O
agonist	O
of	O
the	O
serotonin	O
5-HT1A	O
receptor	O
with	O
high	O
affinity.	O

Naltrexone	B-Drug
should	O
not	O
be	O
confused	O
with	O
naloxone,	O
which	O
is	O
used	O
in	O
emergency	O
cases	O
of	O
opioid	O
overdose.	O
naloxone	B-Drug

The	O
UNODC	O
states	O
that	O
cannabis	O
often	O
contains	O
5%	O
THC	B-Drug
content,	O
resin	O
"can	O
contain	O
up	O
to	O
20%	O
content",	O
and	O
"Cannabis	O
oil	I-Drug
may	O
more	O
than	O
60%	O
content.	O
Cannabis	B-Drug

Of	O
the	O
many	O
drugs	O
in	O
this	O
class,	O
only	O
a	O
few	O
are	O
used	O
to	O
treat	O
epilepsy:	O
Clobazam	B-Drug
(1979).	O

Remaining	O
opium	B-Drug
production	O
shifted	O
south	O
of	O
the	O
Chinese	O
border	O
into	O
Golden	O
Triangle	O
region.	O

Ibogaine	B-Drug
was	O
first	O
isolated	O
from	O
T.	O
iboga	O
in	O
1901	O
by	O
Dybowski	O
and	O
Landrin	O
independently	O
Haller	O
Heckel	O
the	O
same	O
year	O
using	O
samples	O
Gabon.	O

PCP	B-Drug
is	O
most	O
commonly	O
used	O
in	O
the	O
United	O
States.	O

In	O
2009,	O
Ohio	O
approved	O
the	O
use	O
of	O
an	O
intramuscular	O
injection	O
500	O
mg	O
hydromorphone	B-Drug
and	O
a	O
supratherapeutic	O
dose	O
midazolam	B-Drug
as	O
backup	O
means	O
carrying	O
out	O
executions	O
when	O
suitable	O
vein	O
cannot	O
be	O
found	O
for	O
intravenous	O
injection.	O

In	O
2001,	O
levacetylmethadol	B-Drug
was	O
removed	O
from	O
the	O
European	O
market	O
due	O
to	O
reports	O
of	O
life-threatening	O
ventricular	O
rhythm	O
disorders.	O

Domperidone	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN,	O
USAN,	O
BAN,	O
JAN.	O

Transdermal	O
fentanyl	B-Drug
has	O
also	O
been	O
used	O
for	O
many	O
years	O
in	O
dogs	O
and	O
cats	O
post-operative	O
analgesia.	O

There	O
was	O
also	O
a	O
misconception	O
about	O
the	O
intoxicating	O
effects	O
of	O
hemp	O
because	O
it	O
has	O
same	O
active	O
substance,	O
THC,	O
which	O
is	O
in	O
all	O
cannabis	O
strains.	O
THC	B-Drug

Long-term	O
use	O
of	O
laudanum	B-Drug
in	O
nonterminal	O
diseases	O
is	O
discouraged	O
due	O
to	O
the	O
possibility	O
drug	O
tolerance	O
and	O
addiction.	O

A	O
small	O
pilot	O
randomized	O
controlled	O
trial	O
in	O
2011	O
found	O
that	O
clascoterone	B-Drug
cream	O
decreased	O
acne	O
symptoms	O
to	O
a	O
similar	O
or	O
significantly	O
greater	O
extent	O
than	O
tretinoin	B-Drug
0.05%	O
cream.	O

Celecoxib	B-Drug
is	O
predominantly	O
metabolized	O
by	O
cytochrome	O
P450	O
2C9.	O

Triamcinolone	B-Drug
injections	O
can	O
cause	O
bruising	O
and	O
joint	O
swelling.	O

Cocaine,	O
heroin,	O
cannabis,	O
and	O
other	O
such	O
drugs	O
continued	O
to	O
be	O
legally	O
available	O
without	O
prescription	O
as	O
long	O
they	O
were	O
labeled.	O
Cocaine	B-Drug
heroin	B-Drug

Steady-state	O
concentrations	O
of	O
enzalutamide	B-Drug
are	O
achieved	O
within	O
28	O
days	O
treatment	O
initiation.	O

Flubromazolam	B-Drug
has	O
been	O
classified	O
as	O
an	O
illegal	O
substance	O
in	O
Sweden	O
after	O
seizures	O
by	O
customs	O
and	O
police,	O
well	O
indications	O
from	O
the	O
EMCDDA	O
of	O
wider	O
use	O
a	O
recreational	O
drug.	O

Raw	O
opium	B-Drug
contains	O
about	O
814%	O
morphine	B-Drug
by	O
dry	O
weight,	O
or	O
more	O
in	O
high-yield	O
cultivars.	O

Pethidine	B-Drug
has	O
serious	O
interactions	O
that	O
can	O
be	O
dangerous	O
with	O
monoamine	O
oxidase	O
inhibitors	O
(e.g.,	O
furazolidone,	O
isocarboxazid,	O
moclobemide,	O
phenelzine,	O
procarbazine,	O
selegiline,	O
tranylcypromine).	O
isocarboxazid	B-Drug
moclobemide	B-Drug
phenelzine	B-Drug
selegiline	B-Drug
tranylcypromine	B-Drug

The	O
normal	O
adulterants	O
for	O
profit	O
are	O
inactive	O
sugars,	O
usually	O
mannitol,	O
creatine	O
or	O
glucose,	O
so	O
introducing	O
active	O
gives	O
the	O
illusion	O
of	O
purity	O
and	O
to	O
'stretch'	O
make	O
it	O
a	O
dealer	O
can	O
sell	O
more	O
product	O
than	O
without	O
adulterants.	O
mannitol	B-Drug

However,	O
phenibut	B-Drug
uniquely	O
also	O
binds	O
to	O
and	O
acts	O
as	O
an	O
agonist	O
of	O
the	O
GABAB	O
receptor	O
with	O
lower	O
affinity	O
(~5-	O
10-fold	O
in	O
one	O
study).	O

One	O
unpublished	O
study	O
by	O
Frank	O
Sharp	O
reportedly	O
showed	O
no	O
damage	O
the	O
NDMA	O
antagonist	O
ketamine,	O
a	O
structurally	O
similar	O
drug,	O
far	O
beyond	O
recreational	O
doses,	O
but	O
due	O
to	O
never	O
having	O
been	O
published,	O
its	O
validity	O
is	O
controversial.	O
ketamine	B-Drug

The	O
electroencephalogram	O
(EEG)	O
of	O
a	O
person	O
with	O
phenobarbital	B-Drug
overdose	O
may	O
show	O
marked	O
decrease	O
in	O
electrical	O
activity,	O
to	O
the	O
point	O
mimicking	O
brain	O
death.	O

In	O
1938,	O
outside	O
scientists	O
including	O
H.	O
Houston	O
Merritt	O
and	O
Tracy	O
Putnam	O
discovered	O
phenytoin's	O
usefulness	O
for	O
controlling	O
seizures,	O
without	O
the	O
sedative	O
effects	O
associated	O
with	O
phenobarbital.	O
phenytoin	B-Drug
phenobarbital	B-Drug

Norethisterone	B-Drug
has	O
an	O
elimination	O
half-life	O
of	O
5.2	O
to	O
12.8	O
hours,	O
with	O
a	O
mean	O
8.0	O
hours.	O

In	O
addition	O
to	O
these	O
indications,	O
ciclosporin	B-Drug
is	O
also	O
used	O
in	O
severe	O
atopic	O
dermatitis,	O
Kimura	O
disease,	O
pyoderma	O
gangrenosum,	O
chronic	O
hives,	O
acute	O
systemic	O
mastocytosis,	O
and	O
posterior	O
or	O
intermediate	O
uveitis	O
with	O
noninfective	O
cause.	O

The	O
trial,	O
carried	O
out	O
between	O
1946	O
and	O
1947,	O
aimed	O
to	O
test	O
the	O
efficacy	O
of	O
chemical	O
streptomycin	B-Drug
for	O
curing	O
pulmonary	O
tuberculosis.	O

An	O
additional	O
example	O
is	O
the	O
usefulness	O
of	O
spironolactone	B-Drug
as	O
an	O
antiandrogen	O
in	O
transgender	O
women.	O

CBD	B-Drug
Concentrate	O
CannaVest	O
-	O
SimpleBest	O
Product	O

Testosterone	B-Drug
propionate	I-Drug
was	O
introduced	O
in	O
1937	O
by	O
Schering	O
AG	O
Germany	O
under	O
the	O
brand	O
name	O
Testoviron.	O

to	O
the	O
October	O
2013	O
Esquire	O
article,	O
"Between	O
1982	O
and	O
1989,	O
federal	O
prosecutors	O
estimated,	O
Ross	O
bought	O
resold	O
several	O
metric	O
tons	O
of	O
cocaine.	O
cocaine	B-Drug

In	O
4,560	O
women,	O
after	O
35	O
months,	O
the	O
administration	O
of	O
exemestane	B-Drug
at	O
a	O
dose	O
25	O
mg/day	O
resulted	O
in	O
65%	O
reduction	O
risk	O
breast	O
cancer	O
compared	O
with	O
placebo;	O
annual	O
incidence	O
rates	O
were	O
0.19%	O
and	O
0.55%,	O
respectively	O

An	O
abrupt	O
and	O
major	O
increase	O
in	O
the	O
rate	O
of	O
hospitalization	O
due	O
to	O
hyperkalemia	O
from	O
0.2%	O
11%	O
death	O
0.3	O
per	O
1,000	O
2.0	O
between	O
early	O
1994	O
late	O
2001	O
has	O
been	O
attributed	O
a	O
parallel	O
rise	O
number	O
prescriptions	O
written	O
for	O
spironolactone	B-Drug
upon	O
publication	O
Randomized	O
Aldactone	O
Evaluation	O
Study	O
(RALES)	O
July	O
1999.	O

Serum	O
JWH-018	B-Drug
concentrations	O
are	O
generally	O
in	O
the	O
110	O
g/L	O
range	O
during	O
first	O
few	O
hours	O
after	O
recreational	O
usage.	O

Further,	O
cocaine	B-Drug
binds	O
in	O
such	O
a	O
way	O
as	O
to	O
inhibit	O
hydrogen	O
bond	O
innate	O
DAT.	O

As	O
such,	O
nandrolone-like	O
AAS,	O
namely	O
nandrolone	B-Drug
esters,	O
are	O
the	O
most	O
frequently	O
used	O
AAS	O
in	O
clinical	O
settings	O
which	O
anabolic	O
effects	O
desired;	O
for	O
instance,	O
treatment	O
of	O
AIDS-associated	O
cachexia,	O
severe	O
burns,	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease.	O

Androstenedione	B-Drug
has	O
been	O
shown	O
to	O
increase	O
serum	O
testosterone	O
levels	O
over	O
an	O
eight-hour	O
period	O
in	O
men	O
when	O
taken	O
as	O
a	O
single	O
oral	O
dose	O
of	O
300	O
mg	O
per	O
day,	O
but	O
100	O
had	O
no	O
significant	O
effect	O
on	O
testosterone.	O

Captagon	B-Drug
is	O
most	O
common	O
in	O
Arab	O
countries	O
and	O
counterfeit	O
versions	O
of	O
the	O
drug	O
continue	O
to	O
be	O
available	O
despite	O
its	O
illegality.	O

In	O
order	O
to	O
curb	O
misuse,	O
many	O
health	O
insurers	O
have	O
begun	O
require	O
precertification	O
and/or	O
quantity	O
limits	O
for	O
Actiq	B-Drug
prescriptions.	O

Amiloride	B-Drug
works	O
in	O
the	O
same	O
way.	O

Parahexyl	B-Drug
PF-03550096	O
PF-04457845	B-Drug
PF-622	O
PF-750	O
PF-3845	B-Drug

Lespedeza	O
capitata,	O
bicolor,	O
DMT,	O
5-MeO-DMT	B-Drug
in	O
leaves	O
and	O
roots	O
bicolor	O
var.	O

demonstrated	O
reduction	O
in	O
cocaine	B-Drug
self-administration	O
rats	O
1993,	O
and	O
Rezvani	O
reported	O
reduced	O
alcohol	O
dependence	O
three	O
strains	O
of	O
"alcohol-preferring"	O
1995.As	O

(MAM-2201)	O
MAM-2201	B-Drug

Only	O
later	O
was	O
the	O
term	O
ecstasy	B-Drug
used	O
for	O
it,	O
coinciding	O
with	O
rising	O
opposition	O
to	O
its	O
use.	O

"	O
Morphine	B-Drug
was	O
the	O
first	O
pharmaceutical	O
isolated	O
from	O
a	O
natural	O
product,	O
and	O
this	O
success	O
encouraged	O
isolation	O
of	O
other	O
alkaloids:	O
by	O
1820,	O
isolations	O
noscapine,	O
strychnine,	O
veratrine,	O
colchicine,	O
caffeine,	O
quinine	B-Drug
were	O
reported.	O
noscapine	B-Drug
colchicine	B-Drug

This	O
recommendation	O
was	O
followed	O
by	O
the	O
placement	O
of	O
Etizolam	B-Drug
into	O
Schedule	O
IV	O
in	O
March	O
2020	O

In	O
adrenocortical	O
insufficiency,	O
it	O
may	O
be	O
used	O
in	O
combination	O
with	O
a	O
mineralocorticoid	O
medication	O
such	O
as	O
fludrocortisone.	O
fludrocortisone	B-Drug

Examples	O
of	O
classical	O
psychedelics	O
include	O
DMT,	O
LSD,	O
mescaline,	O
and	O
psilocybin.	O
LSD	B-Drug
mescaline	B-Drug

The	O
drug	O
organization	O
Norconon	O
states	O
that	O
other	O
synthetic	O
drugs	O
used	O
in	O
clubs,	O
or	O
which	O
are	O
sold	O
as	O
"Ecstasy"	O
include	O
harmaline;	O
piperazines	O
(e.g.,	O
BZP	B-Drug
and	O
TFMPP);	O
PMA/PMMA;	O
harmaline	B-Drug
TFMPP	B-Drug
PMA	B-Drug
PMMA	B-Drug

Fentanyl	B-Drug
citrate	O
entered	O
medical	O
use	O
as	O
a	O
general	O
anaesthetic	O
in	O
1968,	O
manufactured	O
by	O
McNeil	O
Laboratories	O
under	O
the	O
trade	O
name	O
Sublimaze.	O

Co-Renitec	O
(with	O
enalapril),	O
Capozide	O
captopril),	O
Accuretic	O
quinapril),	O
Monopril	O
HCT	O
fosinopril),	O
Lotensin	O
benazepril),	O
etc.	O
enalapril	B-Drug

Fentanyl	B-Drug
in	O
injectable	O
formulation	O
is	O
commonly	O
used	O
for	O
analgesia	O
and	O
as	O
a	O
component	O
of	O
balanced	O
sedation	O
general	O
anesthesia	O
small	O
animal	O
patients.	O

Tetrahydrocannabinol	B-Drug
(THC)	O
is	O
the	O
main	O
psychoactive	O
component	O
of	O
cannabis,	O
which	O
one	O
483	O
known	O
compounds	O
in	O
plant,	O
including	O
at	O
least	O
65	O
other	O
cannabinoids,	O
cannabidiol	B-Drug
(CBD).	O
THC	B-Drug
CBD	B-Drug

Many	O
commercial	O
immunoassay	O
screening	O
tests	O
directed	O
at	O
the	O
amphetamines	O
cross-react	O
appreciably	O
with	O
ephedrine,	O
but	O
chromatographic	O
techniques	O
can	O
easily	O
distinguish	O
ephedrine	B-Drug
from	O
other	O
phenethylamine	O
derivatives.	O

It	O
was	O
first	O
sold	O
by	O
Allen	O
&	O
Hanburys	O
(UK)	O
under	O
the	O
brand	O
name	O
Ventolin,	O
and	O
has	O
been	O
used	O
for	O
treatment	O
of	O
asthma	O
ever	O
since.	O
Ventolin	B-Drug

Side	O
effects	O
of	O
nandrolone	B-Drug
decanoate	I-Drug
may	O
include	O
symptoms	O
masculinization	O
like	O
acne,	O
increased	O
hair	O
growth,	O
voice	O
changes,	O
and	O
decreased	O
sexual	O
desire	O
due	O
to	O
its	O
ability	O
suppress	O
endogenous	O
testosterone	O
synthesis	O
while	O
not	O
being	O
a	O
sufficient	O
androgen	O
itself.	O

Belsomra	B-Drug
(Suvorexant)	O
used	O
to	O
treat	O
insomnia.	O
Suvorexant	B-Drug

Other	O
steroidogenesis	O
inhibitors	O
besides	O
ketoconazole	B-Drug
and	O
levoketoconazole	O
include	O
the	O
nonsteroidal	O
compound	O
aminoglutethimide	O
steroidal	O
abiraterone	O
acetate.	O

New	O
research	O
has	O
arisen	O
suggesting	O
that	O
Olney's	O
lesions	O
do	O
not	O
occur	O
in	O
humans,	O
however,	O
and	O
similar	O
drugs	O
such	O
as	O
ketamine	B-Drug
are	O
now	O
believed	O
to	O
be	O
acutely	O
neurotoxic.	O

In	O
addition	O
to	O
the	O
relief	O
of	O
pain,	O
drug	O
has	O
been	O
studied	O
as	O
a	O
treatment	O
for	O
morphine	B-Drug
induced	O
pruritus	O
(itching).	O

Rifampicin	B-Drug
causes	O
a	O
very	O
notable	O
reduction	O
in	O
half-life	O
of	O
zopiclone	B-Drug
and	O
peak	O
plasma	O
levels,	O
which	O
results	O
large	O
the	O
hypnotic	O
effect	O
zopiclone.	O

Although	O
usually	O
used	O
as	O
an	O
ester	O
including	O
clostebol	B-Drug
acetate	O
(Macrobin,	O
Steranabol,	O
Alfa-Trofodermin,	O
Megagrisevit),	O
caproate	O
(Macrobin-Depot),	O
or	O
propionate	O
(Yonchlon),	O

For	O
this	O
reason	O
many	O
insist	O
that	O
the	O
illegality	O
of	O
traditional	O
coca	B-Drug
cultivation	O
is	O
unjust.	O

Butabarbital	B-Drug
(5-sec-butyl-5-ethylbarbituric	O
acid)	O
acid	B-Drug

In	O
January	O
2013,	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC)	O
reported	O
an	O
illness	O
associated	O
with	O
intravenous	O
(IV)	O
abuse	O
of	O
oral	O
Opana	B-Drug
ER	I-Drug
(oxymorphone)	O
in	O
Tennessee.	O
oxymorphone	B-Drug

Many	O
studies	O
are	O
going	O
on	O
to	O
determine	O
whether	O
celecoxib	B-Drug
might	O
be	O
useful	O
for	O
this	O
latter	O
condition.	O

Naloxone	B-Drug
can	O
completely	O
or	O
partially	O
reverse	O
an	O
opioid	O
overdose.	O

Female	O
cannabis	O
plants	O
contain	O
at	O
least	O
113	O
cannabinoids,	O
including	O
cannabidiol	B-Drug
(CBD),	O
thought	O
to	O
be	O
the	O
major	O
anticonvulsant	O
that	O
helps	O
people	O
with	O
multiple	O
sclerosis;	O
and	O
cannabichromene	O
(CBC),	O
an	O
anti-inflammatory	O
which	O
may	O
contribute	O
pain-killing	O
effect	O
of	O
cannabis.	O
CBD	B-Drug

Starting	O
in	O
1956,	O
Isbell	O
and	O
associates	O
published	O
studies	O
on	O
LSD,	O
psilocybin,	O
psilocin,DMT,	O
bufotenine,	O
morning	O
glory	O
seeds	O
(ololiuqui),	O
mescaline;	O
these	O
substances	O
were	O
sometimes	O
described	O
as	O
"psychotomimetic".	O
LSD	B-Drug
psilocin	B-Drug
bufotenine	B-Drug
mescaline	B-Drug

GBL	O
is	O
not	O
active	O
in	O
its	O
own	O
right;	O
mechanism	O
of	O
action	O
stems	O
from	O
identity	O
as	O
a	O
prodrug	O
GHB.	O
GHB	B-Drug

Though	O
sometimes	O
referred	O
to	O
as	O
a	O
deliriant	O
and	O
while	O
muscarine	O
was	O
first	O
isolated	O
from	O
A.	O
muscaria	O
such	O
is	O
its	O
namesake,	O
muscimol	O
does	O
not	O
have	O
action,	O
either	O
an	O
agonist	O
or	O
antagonist,	O
at	O
the	O
muscarinic	O
acetylcholine	O
receptor	O
site,	O
therefore	O
atropine	O
physostigmine	B-Drug
antidote	O
recommended.	O

-Methylfentanyl	O
is	O
an	O
opioid	O
analgesic	O
that	O
analogue	O
of	O
fentanyl.	O
fentanyl	B-Drug

DIMP	O
is	O
the	O
lead	O
antiandrogen	O
of	O
phthalimide	O
group	O
nonsteroidal	O
AR	O
ligands,	O
and	O
a	O
variety	O
ligands	O
with	O
higher	O
affinity	O
for	O
have	O
been	O
derived	O
from	O
thalidomide.	O
thalidomide	B-Drug

Peak	O
plasma	O
concentrations	O
during	O
treatment	O
with	O
clinical	O
dosages	O
of	O
tramadol	B-Drug
have	O
generally	O
been	O
found	O
to	O
be	O
in	O
the	O
range	O
70	O
592	O
ng/ml	O
(2662,250	O
nM)	O
for	O
and	O
55	O
143	O
(221573	O
desmetramadol.	O

AG	O
has	O
largely	O
been	O
superseded	O
by	O
medications	O
with	O
better	O
effectiveness	O
and	O
tolerability	O
reduced	O
toxicity,	O
such	O
as	O
ketoconazole,	O
abiraterone	O
acetate,	O
other	O
aromatase	O
inhibitors.	O
ketoconazole	B-Drug

One	O
of	O
the	O
most	O
common	O
drugs	O
derived	O
from	O
salicylates	O
is	O
aspirin,	O
also	O
known	O
as	O
acetylsalicylic	O
acid,	O
with	O
anti-inflammatory	O
and	O
anti-pyretic	O
properties.	O
aspirin	B-Drug

troublesome	O
side	O
effects	O
of	O
oral	O
morphine,	O
hydromorphone,	O
or	O
oxycodone.	O
morphine	B-Drug
hydromorphone	B-Drug
oxycodone	B-Drug

The	O
half-life	O
of	O
naloxone	B-Drug
is	O
shorter	O
than	O
some	O
opioids,	O
such	O
that	O
it	O
may	O
need	O
to	O
be	O
given	O
multiple	O
times	O
until	O
the	O
opioid	O
has	O
been	O
metabolized	O
by	O
body.	O

The	O
oral	O
bioavailability	O
of	O
cannabidiol	B-Drug
is	O
approximately	O
6%	O
in	O
humans,	O
while	O
its	O
via	O
inhalation	O
11	O
to	O
45%	O
(mean	O
31%).	O

1,3-Benzodioxolylbutanamine	B-Drug
is	O
illegal	O
in	O
Germany	O
(Anlage	O
I)	O

Vendors	O
would	O
import	O
25I-NBOMe	B-Drug
in	O
bulk	O
(E.G	O
1	O
kilogram	O
containers)	O
and	O
resell	O
individual	O
doses	O
for	O
a	O
considerable	O
profit.	O

Severe	O
manifestations	O
are	O
often	O
treated	O
with	O
Cyclophosphamide	B-Drug
or	O
Rituximab	B-Drug
and	O
three	O
doses	O
of	O
methylprednisolone	B-Drug
IV-pulse	O
treatment	O
(as	O
recommended	O
by	O
ACR	O
guidelines)	O
prior	O
to	O
switching	O
oral	O
prednisolone	B-Drug
azathioprine	B-Drug
for	O
maintenance.	O

Unlike	O
19-nortestosterone	B-Drug
progestins,	O
CMA	O
does	O
not	O
inhibit	O
enzymes	O
in	O
the	O
cytochrome	O
P450	O
system,	O
which	O
may	O
give	O
it	O
a	O
lower	O
risk	O
of	O
drug	O
interactions.	O

mescaline	B-Drug
in	O
raw	O
form	O
and	O
dried	O
mescaline-containing	O
cacti	O
are	O
considered	O
an	O
illegal	O
drug.	O

Androstanedione	O
is	O
a	O
5-reduced	O
metabolite	O
of	O
4-androstenedione	B-Drug
which	O
serves	O
as	O
an	O
intermediate	O
in	O
the	O
biosynthesis	O
androgen	O
and	O
neurosteroid	O
androsterone.	O

In	O
1909,	O
Ernest	O
Shackleton	O
took	O
"Forced	O
March"	O
brand	O
cocaine	B-Drug
tablets	O
to	O
Antarctica,	O
as	O
did	O
Captain	O
Scott	O
a	O
year	O
later	O
on	O
his	O
ill-fated	O
journey	O
the	O
South	O
Pole.	O

Non-drug	O
plants	O
produce	O
relatively	O
low	O
levels	O
of	O
THC	B-Drug
and	O
high	O
CBD,	O
while	O
drug	O
CBD.	O
CBD	B-Drug

Morphinone	O
itself	O
is	O
an	O
active	O
opioid	O
although	O
its	O
potency	O
closer	O
to	O
codeine	B-Drug
than	O
morphine.	O
morphine	B-Drug

mescaline	B-Drug
Beta-carbolines	O
are	O
"reversible"	O
MAO-A	O
inhibitors.	O

Another	O
study	O
delivered	O
a	O
dose	O
of	O
50	O
mg	O
prasterone	B-Drug
for	O
10	O
months	O
with	O
no	O
serious	O
adverse	O
events	O
reported.	O

Israel	O
banned	O
25I-NBOMe	B-Drug
in	O
2013.	O

I	O
illicit	O
drugs	O
in	O
1970.MAPS	O
is	O
committed	O
to	O
exploring	O
the	O
potential	O
use	O
of	O
LSD	B-Drug
and	O
psilocybin-assisted	O
psychotherapy	O
treatment	O
patients	O
suffering	O
with	O
deep	O
anxiety	O
associated	O
life-threatening	O
illness.	O

The	O
main	O
component	O
of	O
cannabis	O
is	O
THC	B-Drug
formed	O
from	O
decarboxylation	O
THCA.	O

(zopiclone	O
is	O
not	O
commercially	O
available	O
in	O
the	O
U.S.)	O
zopiclone	B-Drug

Legal	O
opium	B-Drug
production	O
in	O
India	O
is	O
much	O
more	O
traditional.	O

This	O
was	O
lower	O
than	O
cannabis-induced	O
psychosis	O
(34%)	O
but	O
higher	O
amphetamine	B-Drug
(22%),	O
opioid	O
(12%),	O
alcohol	O
(10%)	O
and	O
sedative	O
(9%)	O
induced	O
psychoses.	O

Phenethylamine	B-Drug
also	O
appears	O
to	O
induce	O
acetylcholine	O
release	O
via	O
a	O
glutamate-mediated	O
mechanism.	O

imaging	O
study	O
found	O
that	O
200	O
mg	O
and	O
300	O
doses	O
of	O
modafinil	B-Drug
resulted	O
in	O
DAT	O
occupancy	O
51.4%	O
56.9%,	O
respectively,	O
which	O
was	O
described	O
as	O
"close	O
to	O
methylphenidate".	O
methylphenidate	B-Drug

Studies	O
on	O
rats	O
indicate	O
that	O
PCP	B-Drug
interacts	O
indirectly	O
with	O
opioid	O
receptors	O
(endorphin	O
and	O
enkephalin)	O
to	O
produce	O
analgesia.	O

Resultantly	O
teams	O
moved	O
to	O
using	O
ketorolac	B-Drug
as	O
the	O
drug	O
is	O
certainly	O
powerful	O
enough	O
numb	O
players	O
pain,	O
but	O
not	O
a	O
commonly	O
abused	O
with	O
bad	O
reputation.	O

Following	O
administration	O
of	O
cimetidine,	O
the	O
elimination	O
half-life	O
and	O
area-under-curve	O
zolmitriptan	B-Drug
its	O
active	O
metabolites	O
were	O
roughly	O
doubled.	O
cimetidine	B-Drug

The	O
sodium	B-Drug
salt	O
of	O
the	O
acid	O
is	O
valproate	B-Drug
and	O
a	O
coordination	O
complex	O
two	O
known	O
as	O
semisodium.	O
semisodium	I-Drug

Various	O
physical	O
and	O
psychological	O
adverse	O
effects	O
have	O
been	O
reported	O
from	O
JWH-018	B-Drug
use.	O

No	O
active	O
comparator	O
was	O
used	O
in	O
the	O
phase	O
III	O
clinical	O
trials	O
of	O
clascoterone	B-Drug
for	O
acne.	O

Conversely,	O
drugs	O
such	O
as	O
isoniazid	B-Drug
are	O
acetylated	O
within	O
the	O
liver	O
during	O
drug	O
metabolism.	O

When	O
researchers	O
control	O
for	O
use	O
of	O
other	O
drugs,	O
many	O
the	O
seeming	O
effects	O
cocaine	B-Drug
on	O
head	O
size,	O
birth	O
weight,	O
Apgar	O
scores,	O
and	O
prematurity	O
disappear.	O

The	O
marketing	O
of	O
prasterone	B-Drug
over-the-counter	O
as	O
a	O
supplement	O
is	O
allowed	O
in	O
the	O
United	O
States	O
but	O
banned	O
many	O
other	O
countries.	O

Sigma	O
receptors	O
are	O
affected	O
by	O
cocaine,	O
as	O
cocaine	B-Drug
functions	O
a	O
sigma	O
ligand	O
agonist.	O

The	O
company	O
promised	O
that	O
its	O
cocaine	B-Drug
products	O
would	O
"supply	O
the	O
place	O
of	O
food,	O
make	O
coward	O
brave,	O
silent	O
eloquent	O
and	O
render	O
sufferer	O
insensitive	O
to	O
pain."	O

P450scc,	O
CYP11A1)	O
inhibitors	O
such	O
as	O
aminoglutethimide,	O
ketoconazole,	O
and	O
mitotane	O
inhibit	O
the	O
production	O
of	O
pregnenolone	O
from	O
cholesterol	O
thereby	O
prevent	O
synthesis	O
all	O
steroid	O
hormones.	O
ketoconazole	B-Drug

Baudelaire's	O
opinion	O
of	O
the	O
drug	O
was	O
generally	O
negative,	O
believing	O
that	O
it	O
weakened	O
and	O
dampened	O
artistic	O
capacities,	O
personal	O
Will	O
even	O
very	O
identity	O
hashish	B-Drug
eater.	O

Nabilone	B-Drug
(Cesamet)	O
A	O
synthetic	O
cannabinoid.	O
Cesamet	B-Drug

Lofentanil	B-Drug
is	O
one	O
of	O
the	O
most	O
potent	O
opioid	O
analgesics	O
known	O
and	O
an	O
analogue	O
fentanyl,	O
which	O
was	O
developed	O
in	O
1960.	O
fentanyl	B-Drug

The	O
most	O
dangerous	O
adverse	O
effect	O
of	O
fentanyl	B-Drug
is	O
respiratory	O
depression,	O
that	O
is,	O
decreased	O
sensitivity	O
to	O
carbon	O
dioxide	O
leading	O
reduced	O
rate	O
breath	O
intake,	O
which	O
can	O
cause	O
complications	O
or	O
suffocation.	O

Aeruginascin	B-Drug
is	O
the	O
N-trimethyl	O
analogue	O
of	O
psilocybin.	O

The	O
oral	O
bioavailability	O
of	O
CBD	B-Drug
varies	O
greatly	O
across	O
species	O
and	O
it	O
is	O
linked	O
to	O
the	O
presentation	O
time	O
administration.	O

Urine	O
was	O
collected	O
for	O
24	O
hours,	O
followed	O
by	O
extraction	O
of	O
JWH-018	B-Drug
metabolites	O
using	O
both	O
liquid-liquid	O
and	O
solid-phase	O
extraction.	O

Crack	O
is	O
a	O
lower	O
purity	O
form	O
of	O
free-base	O
cocaine	B-Drug
that	O
usually	O
produced	O
by	O
neutralization	O
hydrochloride	O
with	O
solution	O
baking	O
soda	O
(sodium	O
bicarbonate,	O
NaHCO3)	O
and	O
water,	O
producing	O
very	O
hard/brittle,	O
off-white-to-brown	O
colored,	O
amorphous	O
material	O
contains	O
sodium	O
carbonate,	O
entrapped	O
other	O
by-products	O
as	O
the	O
main	O
impurities.	O

4-MTA	B-Drug
is	O
a	O
strong	O
serotonin	O
releaser	O
similar	O
to	O
paramethoxyamphetamine	B-Drug
(PMA),	O
which	O
can	O
cause	O
pronounced	O
hyperthermia	O
potentially	O
resulting	O
in	O
organ	O
failure	O
and	O
death.[5][6][7][8]	O
PMA	B-Drug

The	O
bioavailability	O
of	O
some	O
vitamins	O
such	O
as	O
thiamin,	O
vitamin	O
B6,	O
niacin,	O
folate,	O
and	O
carotenoids	O
are	O
increased	O
with	O
cooking	O
by	O
being	O
freed	O
from	O
the	O
food	O
microstructure.	O
thiamin	B-Drug
niacin	B-Drug
folate	B-Drug

The	O
user	O
consumed	O
JWH-018	B-Drug
daily	O
for	O
eight	O
months.	O

MDMA	B-Drug
is	O
particularly	O
expensive	O
in	O
Australia,	O
costing	O
A$15A$30	O
per	O
tablet.	O

In	O
rats,	O
alcohol	O
increased	O
the	O
probability	O
of	O
later	O
addiction	O
to	O
cocaine	B-Drug
and	O
again	O
relevant	O
alterations	O
in	O
reward	O
system	O
were	O
identified.	O

Macromerine	O
is	O
a	O
phenethylamine	B-Drug
derivative.	O

CYP2D6	O
metabolizers	O
had	O
similar	O
physiological	O
and	O
subjective	O
responses	O
to	O
hydrocodone,	O
inhibitor	O
quinidine	B-Drug
did	O
not	O
change	O
the	O
of	O
extensive	O
metabolizers,	O
suggesting	O
that	O
inhibition	O
metabolism	O
hydrocodone	B-Drug
has	O
no	O
practical	O
importance.	O

The	O
coroner	O
stated	O
that	O
Jackson	O
died	O
from	O
the	O
combination	O
of	O
drugs	O
in	O
his	O
body,	O
with	O
most	O
significant	O
being	O
anesthetic	B-Drug
propofol	B-Drug
and	O
anxiolytic	O
lorazepam.	O
lorazepam	B-Drug

SSRI	O
and	O
SNRI	O
antidepressants	O
such	O
as	O
paroxetine	B-Drug
venlafaxine	B-Drug
may	O
cause	O
jaw	O
pain/jaw	O
spasm	O
reversible	O
syndrome	O
(although	O
it	O
is	O
not	O
common),	O
buspirone	B-Drug
appears	O
to	O
be	O
successful	O
in	O
treating	O
bruxism	O
on	O
SSRI/SNRI-induced	O
clenching.	O

PCP	B-Drug
can	O
be	O
ingested	O
through	O
smoking.	O

As	O
of	O
2015,	O
amphetamines,	O
especially	O
Adderall,	O
were	O
increasingly	O
being	O
used	O
by	O
young	O
white-collar	O
workers	O
who	O
work	O
long	O
hours	O
at	O
demanding	O
work.	O
Adderall	B-Drug

In	O
November	O
2016,	O
the	O
DEA	O
uncovered	O
an	O
operation	O
making	O
counterfeit	O
oxycodone	B-Drug
and	O
Xanax	B-Drug
from	O
a	O
home	O
in	O
Cottonwood	O
Heights,	O
Utah.	O

Abbott's	O
Nembutal	B-Drug
brand	O
of	O
Pentobarbital	B-Drug
capsules	O
were	O
widely	O
abused	O
and	O
known	O
on	O
the	O
streets	O
as	O
"yellow	O
jackets".	O

Decomposition	O
also	O
made	O
it	O
difficult	O
to	O
estimate	O
pre-death	O
levels	O
of	O
hydrocodone	B-Drug
and	O
alprazolam,	O
found	O
in	O
"therapeutic	O
levels"	O
her	O
body.	O
alprazolam	B-Drug

In	O
one	O
case,	O
seven	O
volunteers	O
in	O
Kentucky	O
were	O
given	O
LSD	B-Drug
for	O
seventy-seven	O
consecutive	O
days.	O

He	O
reported	O
that	O
the	O
seeds	O
of	O
Ipomoea	O
violacea	O
were	O
used	O
as	O
sacraments	O
by	O
certain	O
Zapotecs,	O
sometimes	O
in	O
conjunction	O
with	O
Rivea	O
corymbosa,	O
another	O
species	O
which	O
has	O
a	O
similar	O
chemical	O
composition,	O
lysergol	O
instead	O
ergometrine.	O
ergometrine	B-Drug

4-Fluoroamphetamine	B-Drug
is	O
a	O
releasing	O
agent	O
and	O
reuptake	O
inhibitor	O
of	O
dopamine,	O
serotonin,	O
norepinephrine.	O

This	O
was	O
shown	O
when	O
nociceptin	O
compounds	O
were	O
used	O
as	O
a	O
pain	O
medication	O
substitution	O
for	O
morphine.	O
morphine	B-Drug

Treatment	O
of	O
the	O
ethynyl	O
enol	O
ether	O
with	O
strong	O
acid	O
leads	O
to	O
norethisterone	B-Drug
(	O

The	O
artists	O
almost	O
unanimously	O
reported	O
LSD	B-Drug
to	O
be	O
an	O
enhancement	O
their	O
creativity.	O

In	O
vivo,	O
it	O
may	O
have	O
fewer	O
adverse	O
effects	O
(including	O
respiratory	O
depression	O
and	O
constipation)	O
compared	O
with	O
morphine.	O
morphine	B-Drug

Naldemedine	B-Drug
is	O
mainly	O
metabolized	O
by	O
the	O
enzyme	O
CYP3A4	O
to	O
nor-naldemedine	O
(which	O
makes	O
up	O
about	O
913%	O
of	O
circulating	O
substance),	O
and	O
a	O
much	O
lesser	O
extent	O
UGT1A3	O

It	O
is	O
the	O
fluorinated	O
N-methyl	O
derivative	O
of	O
nitrazepam.	O
nitrazepam	B-Drug

PCP	B-Drug
is	O
a	O
Schedule	O
II	O
substance	O
in	O
the	O
United	O
States	O
and	O
its	O
ACSCN	O
7471.	O

Loperamide	B-Drug
should	O
not	O
be	O
used	O
as	O
the	O
primary	O
treatment	O
in	O
cases	O
of	O
bloody	O
diarrhea,	O
acute	O
exacerbation	O
ulcerative	O
colitis,	O
or	O
bacterial	O
enterocolitis.	O

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects,	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood.	O

In	O
2014,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
made	O
triamcinolone	B-Drug
acetonide	O
an	O
over-the-counter	O
drug	O
in	O
United	O
States	O
nasal	O
spray	O
form	O
under	O
brand	O
name	O
Nasacort.	O

The	O
contribution	O
of	O
these	O
receptors	O
to	O
the	O
overall	O
pharmacology	O
heroin	B-Drug
remains	O
unknown.	O

Mianserin,	O
sold	O
under	O
the	O
brand	O
name	O
Tolvon	O
among	O
others,	O
is	O
an	O
atypical	O
antidepressant	O
which	O
used	O
primarily	O
in	O
treatment	O
of	O
depression	O
Europe	O
and	O
elsewhere	O
world.	O
Mianserin	B-Drug

Due	O
to	O
a	O
successful	O
marketing	O
campaign,	O
thalidomide	B-Drug
was	O
widely	O
used	O
by	O
pregnant	O
women	O
during	O
the	O
first	O
trimester	O
of	O
pregnancy.	O

During	O
the	O
110th	O
United	O
States	O
Congress,	O
seven	O
crack	O
cocaine	B-Drug
sentencing	O
reform	O
bills	O
were	O
introduced	O
that	O
would	O
have	O
reduced	O
disparity	O
between	O
and	O
powder	O
offenses	O
without	O
increasing	O
mandatory	O
sentences.	O

According	O
to	O
a	O
2014	O
survey,	O
25I-NBOMe	B-Drug
was	O
the	O
most	O
frequently	O
used	O
of	O
NBOMe	O
series.	O

Constipation	O
and	O
central	O
nervous	O
system	O
(CNS)	O
effects	O
are	O
seen	O
less	O
frequently	O
than	O
with	O
morphine.	O
morphine	B-Drug

Two	O
other	O
3,6	O
diesters	O
of	O
morphine	B-Drug
invented	O
in	O
187475	O
along	O
with	O
diamorphine,	O
dibenzoylmorphine	O
and	O
acetylpropionylmorphine,	O
were	O
made	O
as	O
substitutes	O
after	O
it	O
was	O
outlawed	O
1925	O
and,	O
therefore,	O
sold	O
the	O
first	O
"designer	O
drugs"	O
until	O
they	O
by	O
League	O
Nations	O
1930.	O
diamorphine	B-Drug
acetylpropionylmorphine	B-Drug

Zaleplon	B-Drug
significantly	O
reduces	O
the	O
time	O
required	O
to	O
fall	O
asleep	O
by	O
improving	O
sleep	O
latency	O
and	O
may	O
therefore	O
facilitate	O
induction	O
rather	O
than	O
maintenance.	O

4-Methoxyamphetamine	B-Drug
(PMA)	O
PMA	B-Drug

A	O
controlled	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
stability	O
of	O
LSD	B-Drug
in	O
pooled	O
urine	O
samples.	O

Benzodiazepines	O
and,	O
in	O
particular,	O
temazepam	B-Drug
are	O
sometimes	O
used	O
intravenously,	O
which,	O
if	O
done	O
incorrectly	O
or	O
an	O
unsterile	O
manner,	O
can	O
lead	O
to	O
medical	O
complications	O
including	O
abscesses,	O
cellulitis,	O
thrombophlebitis,	O
arterial	O
puncture,	O
deep	O
vein	O
thrombosis,	O
and	O
gangrene.	O

MDMA	B-Drug
is	O
commonly	O
associated	O
with	O
dance	O
parties,	O
raves,	O
and	O
electronic	O
music.	O

A	O
fentanyl	B-Drug
patient-controlled	O
transdermal	O
system	O
(PCTS)	O
is	O
under	O
development,	O
which	O
aims	O
to	O
allow	O
patients	O
control	O
administration	O
of	O
through	O
the	O
skin	O
treat	O
postoperative	O
pain.	O

Thalidomide	B-Drug
was	O
studied	O
in	O
a	O
Phase	O
II	O
trial	O
for	O
Kaposi's	O
sarcoma,	O
rare	O
soft-tissue	O
cancer	O
most	O
commonly	O
seen	O
the	O
immunocompromised,	O
that	O
is	O
caused	O
by	O
sarcoma-associated	O
herpesvirus	O
(KSHV).	O

FDU-PB-22	B-Drug
is	O
an	O
derivative	O
of	O
JWH-018	B-Drug
that	O
presumed	O
to	O
be	O
a	O
potent	O
agonist	O
the	O
CB1	O
receptor	O
and	O
has	O
been	O
sold	O
online	O
as	O
designer	O
drug.	O

Crack	O
cocaine	B-Drug
is	O
a	O
smokeable	O
form	O
of	O
made	O
into	O
small	O
"rocks"	O
by	O
processing	O
with	O
sodium	O
bicarbonate	O
(baking	O
soda)	O
and	O
water.	O

Oxycodone	B-Drug
is	O
diverted	O
through	O
doctor	O
shopping,	O
prescription	O
forgery,	O
pharmacy	O
theft,	O
and	O
overprescribing.	O

Ketamine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist,	O
and	O
that	O
accounts	O
for	O
most	O
of	O
its	O
actions	O
except	O
the	O
antidepressive	O
effect,	O
mechanism	O
which	O
a	O
matter	O
much	O
research	O
debate.	O

Drugs	O
purported	O
to	O
be	O
methaqualone	B-Drug
are	O
in	O
a	O
significant	O
majority	O
of	O
cases	O
found	O
inert,	O
or	O
contain	O
diphenhydramine	B-Drug
benzodiazepines.	O

In	O
2006,	O
ibuprofen	B-Drug
lysine	I-Drug
was	O
approved	O
in	O
the	O
U.S.	O
by	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
for	O
closure	O
of	O
patent	O
ductus	O
arteriosus	O
premature	O
infants	O
weighing	O
between	O
500	O
1,500	O
grams	O
(1	O
3	O
lb),	O
who	O
are	O
no	O
more	O
than	O
32	O
weeks'	O
gestational	O
age	O
when	O
usual	O
medical	O
management	O
(such	O
as	O
fluid	O
restriction,	O
diuretics,	O
respiratory	O
support)	O
is	O
not	O
effective.	O

EEG	O
tests	O
showed	O
decreased	O
alpha	O
activity	O
and	O
increased	O
the	O
beta	O
activity,	O
according	O
to	O
blood	O
plasma	O
levels	O
of	O
nitrazepam.	O
nitrazepam	B-Drug

Other	O
examples	O
include	O
Assassin	O
of	O
Youth	O
(1937),	O
Marihuana	B-Drug
(1936)	O
and	O
She	O
Shoulda	O

Efavirenz	B-Drug
also	O
affects	O
antifungal	O
drugs,	O
which	O
are	O
used	O
for	O
fungal	O
infections	O
such	O
as	O
urinary	O
tract	O
infections.	O

Medical	O
marijuana	O
refers	O
to	O
the	O
use	O
of	O
Cannabis	O
plant	O
as	O
a	O
physician-recommended	O
herbal	O
therapy	O
well	O
synthetic	O
THC	B-Drug
and	O
cannabinoids.	O

Those	O
with	O
THC	B-Drug
in	O
their	O
system	O
are	O
from	O
three	O
to	O
seven	O
times	O
more	O
likely	O
be	O
the	O
cause	O
of	O
accident	O
than	O
those	O
who	O
had	O
not	O
used	O
either	O
cannabis	O
or	O
alcohol,	O
although	O
its	O
role	O
is	O
necessarily	O
causal	O
because	O
stays	O
bloodstream	O
for	O
days	O
weeks	O
after	O
intoxication.	O

Clonitazene	B-Drug
is	O
not	O
currently	O
marketed.	O

Other	O
popular	O
medicines,	O
based	O
on	O
opium,	O
included	O
Paregoric,	O
a	O
much	O
milder	O
liquid	O
preparation	O
for	O
children;	O
Black-drop,	O
stronger	O
preparation;	O
and	O
Dover's	O
powder.	O
opium	B-Drug

His	O
hostility	O
to	O
opium	B-Drug
stemmed	O
from	O
the	O
effects	O
of	O
brought	O
upon	O
his	O
sister	O
Helen.	O

Norpethidine	B-Drug
is	O
a	O
controlled	O
drug	O
because	O
of	O
its	O
potential	O
uses	O
in	O
manufacturing	O
both	O
pethidine	B-Drug
itself	O
and	O
range	O
N-substituted	O
derivatives,	O
but	O
it	O
has	O
little	O
opioid	O
activity	O
own	O
right.	O

Dapsone	B-Drug
is	O
commonly	O
used	O
in	O
combination	O
with	O
rifampicin	B-Drug
and	O
clofazimine	B-Drug
for	O
the	O
treatment	O
of	O
leprosy.	O

The	O
risks	O
are	O
similar	O
to	O
other	O
NSAIDs,	O
such	O
as	O
ibuprofen	B-Drug
and	O
naproxen.	O
naproxen	B-Drug

It	O
is	O
similar	O
both	O
structurally	O
and	O
pharmacologically	O
to	O
the	O
second-generation	O
NSAA	O
enzalutamide,	O
but	O
shows	O
some	O
advantages,	O
including	O
higher	O
antiandrogenic	O
activity	O
as	O
well	O
several-fold	O
reduced	O
central	O
nervous	O
system	O
distribution.	O
enzalutamide	B-Drug

Benzoylecgonine,	O
i.e.	O
compound	O
197e,	O
(differing	O
from	O
its	O
cocaine	B-Drug
parent	O
only	O
by	O
de-methylation	O
of	O
the	O
C2	O
carbmethoxy	O
to	O
that	O
a	O
carboxy)	O
has	O
an	O
extreme	O
loss	O
in	O
potency	O
(its	O
approximate	O
affinity	O
being	O
195,000	O
nM)	O
as	O
displayed	O
vitro	O
methodologies	O
for	O
determining	O
binding	O
efficacy	O
(wherein	O
BBB	O
penetration	O
does	O
not	O
factor-in	O
on	O
matter	O
manner	O
vivo	O
studies)	O
and	O
is	O
posited	O
be	O
due	O
possibly	O
zwitterion	O
formation.	O

Flumazenil	B-Drug
is	O
very	O
effective	O
at	O
reversing	O
the	O
CNS	O
depression	O
associated	O
with	O
benzodiazepines	O
but	O
less	O
respiratory	O
depression.	O

In	O
an	O
infamous	O
experiment	O
in	O
1884,	O
he	O
experimented	O
upon	O
himself	O
by	O
applying	O
a	O
cocaine	B-Drug
solution	O
to	O
his	O
own	O
eye	O
and	O
then	O
pricking	O
it	O
with	O
pins.	O

In	O
contrast	O
to	O
the	O
SAA	O
spironolactone,	O
bicalutamide	B-Drug
does	O
not	O
have	O
antimineralocorticoid	O
effects,	O
and	O
hence	O
is	O
associated	O
with	O
hyperkalemia,	O
urinary	O
frequency,	O
dehydration,	O
hypotension,	O
or	O
other	O
related	O
side	O
effects.	O
spironolactone	B-Drug

Pulmozyme	B-Drug
(dornase	O
alfa),	O
for	O
the	O
improvement	O
of	O
pulmonary	O
function	O
in	O
cystic	O
fibrosis.	O
dornase	B-Drug
alfa	I-Drug

ATS	O
such	O
as	O
detroamphetamine	O
are	O
used	O
in	O
the	O
treatment	O
of	O
narcolepsy	O
when	O
another	O
CNS	O
stimulant,	O
modafinil	B-Drug
is	O
not	O
effective.	O

For	O
IBS,	O
hyoscine	B-Drug
butylbromide	I-Drug
(Buscopan	O
in	O
the	O
UK)	O
and	O
mebeverine	B-Drug
hydrochloride	O
(Colofac)	O
can	O
be	O
effective	O
with	O
or	O
without	O
an	O
opium	B-Drug
related	O
compound.	O
Buscopan	B-Drug

Fexinidazole	O
Pentamidine	O
Suramin	B-Drug
sodium	I-Drug
Eflornithine	O
Melarsoprol	O
Nifurtimox	B-Drug
Benznidazole	B-Drug
Ivermectin	B-Drug
Acetylsalicylic	B-Drug
acid	I-Drug
(aspirin)	O
aspirin	B-Drug

Distillers	O
Co.	O
Ltd	O
(now	O
part	O
of	O
Diageo	O
plc),	O
marketed	O
thalidomide	B-Drug
throughout	O
the	O
UK,	O
Australia	O
and	O
New	O
Zealand,	O
under	O
brand	O
name	O
Distaval,	O
as	O
a	O
remedy	O
for	O
morning	O
sickness.	O

Dimethyltryptamine	B-Drug
is	O
an	O
indole	O
alkaloid	O
derived	O
from	O
the	O
shikimate	O
pathway.	O

"Cid",	O
"Lucy",	O
"Sidney",	O
"Blotters",	O
"Droppers",	O
"Sugar	O
Cubes")	O
psilocin	B-Drug
(found	O
in	O
psilocybin	O
mushrooms)	O
(also	O
found	O
mushrooms;	O
prodrug	O
to	O
psilocin)	O
ibogaine	B-Drug
Tabernanthe	O
iboga	O
("Iboga"))	O

In	O
contrast	O
to	O
recreational	O
nicotine	B-Drug
products,	O
which	O
have	O
been	O
designed	O
maximize	O
the	O
likelihood	O
of	O
addiction,	O
replacement	O
products	O
(NRTs)	O
are	O
minimize	O
addictiveness.	O

Ergine	B-Drug
is	O
thought	O
to	O
be	O
a	O
serotonergic	O
psychedelic	O
and	O
its	O
effects	O
due	O
it	O
being	O
partial	O
agonist	O
of	O
the	O
5-HT2A	O
receptor.	O

Thalidomide	B-Drug
is	O
racemic;	O
while	O
R-thalidomide	O
the	O
bioactive	O
form	O
of	O
molecule,	O
individual	O
enantiomers	O
can	O
racemize	O
to	O
each	O
other	O
due	O
acidic	O
hydrogen	O
at	O
chiral	O
centre,	O
which	O
carbon	O
glutarimide	O
ring	O
bonded	O
phthalimide	O
substituent.	O

Noracymethadol	B-Drug
(INN)	O
is	O
a	O
synthetic	O
opioid	O
analgesic	O
related	O
to	O
methadone	B-Drug
that	O
was	O
never	O
marketed.	O

JWH-203	B-Drug

If	O
based	O
on	O
clinical	O
decision,	O
normal	O
precautions	O
should	O
be	O
exercised	O
and	O
the	O
dosages	O
of	O
mianserin	B-Drug
any	O
concurrent	O
therapy	O
kept	O
under	O
review	O
adjusted	O
as	O
needed.	O

Hydrocodone	B-Drug
has	O
a	O
terminal	O
half-life	O
that	O
averages	O
3.8	O
hours	O
(range	O
3.34.4	O
hours).	O

4-bromo-2,5-dimethoxybenzeneethanamine	O
(2C-B)	O
2C-B	B-Drug

It	O
will	O
however	O
antagonize	O
the	O
action	O
of	O
non-benzodiazepine	O
z-drugs,	O
such	O
as	O
zolpidem	B-Drug
and	O
zopiclone,	O
because	O
they	O
act	O
via	O
benzodiazepine	O
site	O
GABA	O
receptor	O
-	O
it	O
has	O
been	O
used	O
to	O
successfully	O
treat	O
z-drug	O
overdose.	O
zopiclone	B-Drug

2C-H	O
2C-x	O
N-acetylanthranilic	O
acid	B-Drug
methaqualone	B-Drug
anthranilic	O
benzaldehyde	O
amphetamine	B-Drug
phenyl-2-propanone	O
benzyl	O
cyanide	O
ephedrine	B-Drug
and	O
pseudoephedrine	B-Drug
methamphetamine	B-Drug
methcathinone	B-Drug
ergocristine,	O
ergonovine	B-Drug
ergotamine	B-Drug
LSD	B-Drug
ethylamine	O
ethylamphetamine	B-Drug
GBL	O
GHB	B-Drug
safrole,	O
isosafrole	O
3,4-methylenedioxyphenylpropan-2-one	O
MDMA,	O
MDEA,	O
ergocristine	B-Drug
MDMA	B-Drug

In	O
excessive	O
quantities,	O
supplementation	O
can	O
interfere	O
with	O
the	O
production	O
of	O
serotonin	O
and	O
other	O
aromatic	O
amino	O
acids	O
as	O
well	O
nitric	O
oxide	O
due	O
to	O
overuse	O
(eventually,	O
limited	O
availability)	O
associated	O
cofactors,	O
iron	O
or	O
tetrahydrobiopterin.	O
tetrahydrobiopterin	B-Drug

Chemically,	O
PCP	B-Drug
is	O
a	O
member	O
of	O
the	O
arylcyclohexylamine	O
class,	O
and	O
pharmacologically,	O
it	O
dissociative	O
anesthetic.	O

This	O
protracted	O
downregulation	O
of	O
GnRH	O
receptor	O
activity	O
is	O
the	O
targeted	O
objective	O
leuprorelin	B-Drug
therapy	O
and	O
ultimately	O
results	O
in	O
decreased	O
LH	O
FSH	O
secretion,	O
leading	O
to	O
hypogonadism	O
thus	O
a	O
dramatic	O
reduction	O
estradiol	O
testosterone	O
levels	O
regardless	O
sex.	O

He	O
was	O
surprised	O
to	O
find	O
the	O
active	O
compound	O
of	O
ololiuhqui,	O
ergine	B-Drug
(LSA,	O
lysergic	B-Drug
acid	I-Drug
amide)	O
be	O
closely	O
related	O
LSD.	O
amide	I-Drug

Codeine	B-Drug
was	O
once	O
viewed	O
as	O
the	O
"gold	O
standard"	O
in	O
cough	O
suppressants,	O
but	O
this	O
position	O
is	O
now	O
questioned.	O

To	O
induce	O
lactation,	O
domperidone	B-Drug
is	O
used	O
at	O
a	O
dosage	O
of	O
10	O
to	O
20	O
mg	O
3	O
or	O
4	O
times	O
per	O
day	O
by	O
mouth.	O

Valproate	B-Drug
is	O
known	O
to	O
cause	O
serious	O
abnormalities	O
in	O
babies	O
if	O
taken	O
during	O
pregnancy,	O
and	O
as	O
such	O
it	O
not	O
typically	O
recommended	O
for	O
women	O
of	O
childbearing	O
age	O
who	O
have	O
migraines.	O

The	O
World	O
Health	O
Organization	O
estimates	O
that	O
tobacco	B-Drug
caused	O
5.4	O
million	O
deaths	O
in	O
2004	O
and	O
100	O
over	O
the	O
course	O
of	O
20th	O
century.	O

As	O
with	O
many	O
aromatic	O
terpenoids,	O
THC	B-Drug
has	O
a	O
very	O
low	O
solubility	O
in	O
water,	O
but	O
good	O
most	O
organic	O
solvents,	O
specifically	O
lipids	O
and	O
alcohols.	O

The	O
U.S.	O
National	O
Institute	O
for	O
Occupational	O
Safety	O
and	O
Health,	O
a	O
branch	O
of	O
the	O
Centers	O
Disease	O
Control,	O
rated	O
hallucinogen	O
psilocybin	O
(Schedule	O
I)	O
less	O
toxic	O
than	O
aspirin.	O
aspirin	B-Drug

For	O
example,	O
the	O
combination	O
of	O
amiloride	B-Drug
with	O
angiotensin-converting	O
enzyme	O
(ACE)	O
inhibitors	O
like	O
lisinopril,	O
or	O
angiotensin	O
II	O
receptor	O
type	O
1	O
(AT1)	O
antagonists	O
losartan,	O
may	O
lead	O
to	O
high	O
levels	O
potassium	O
in	O
blood,	O
requiring	O
frequent	O
monitoring.	O
lisinopril	B-Drug
losartan	B-Drug

Similarly,	O
patients	O
who	O
were	O
dependent	O
on	O
high	O
doses	O
of	O
benzodiazepines	O
(median	O
dosage	O
333	O
mg	O
diazepam-equivalent)	O
able	O
to	O
be	O
stabilised	O
a	O
low	O
dose	O
clonazepam	B-Drug
after	O
78	O
days	O
treatment	O
with	O
flumazenil.	O
flumazenil	B-Drug

In	O
2016,	O
the	O
FDA	O
granted	O
Mylan	O
rights	O
for	O
first	O
generic	O
version	O
of	O
Cephalon's	O
Nuvigil	B-Drug
to	O
be	O
marketed	O
in	O
U.S.Because	O
armodafinil	B-Drug
has	O
a	O
longer	O
half-life	O
than	O
modafinil	B-Drug
does,	O
it	O
may	O
more	O
effective	O
at	O
improving	O
wakefulness	O
patients	O
with	O
excessive	O
daytime	O
sleepiness.	O

It	O
is	O
a	O
prodrug	O
of	O
the	O
free	O
form,	O
beclometasone	B-Drug
(INN).	O

This	O
is	O
likely	O
accomplished	O
by	O
aniracetam	B-Drug
or	O
CX614	B-Drug
binding	O
to	O
the	O
back	O
of	O
"clam	O
shell"	O
that	O
contains	O
site	O
for	O
glutamate,	O
stabilizing	O
closed	O
conformation	O
associated	O
with	O
activation	O
AMPA	O
receptor.	O

Known	O
hypersensitivity	O
to	O
trimethoprim	B-Drug
History	O
of	O
megaloblastic	O
anemia	O
due	O
folate	O
deficiency	O
1020%	O
is	O
metabolized	O
by	O
the	O
liver	O
and	O
rest	O
excreted	O
in	O
urine.	O

Several	O
commonly	O
used	O
opioid	O
drugs	O
including	O
etorphine	B-Drug
and	O
buprenorphine	B-Drug
have	O
been	O
demonstrated	O
to	O
bind	O
nociceptin	O
receptors,	O
but	O
this	O
binding	O
is	O
relatively	O
insignificant	O
compared	O
their	O
activity	O
at	O
other	O
receptors	O
in	O
the	O
acute	O
setting	O
(however	O
non-analgesic	O
NOPr	O
antagonist	O
SB-612,111	O
was	O
potentiate	O
therapeutic	O
benefits	O
of	O
morphine).	O
morphine	B-Drug

This	O
is	O
usually	O
done	O
with	O
off-label	O
fentanyl	B-Drug
patches	O
manufactured	O
for	O
humans	O
chronic	O
pain.	O

If,	O
therefore,	O
under	O
LSD	B-Drug
we	O
can	O
have	O
a	O
temporary	O
reduction,	O
so	O
that	O
better	O
see	O
what	O
are	O
and	O
where	O
goingwell,	O
might	O
be	O
of	O
some	O
help.	O

Oral	O
anticoagulants	O
(blood	O
thinners),	O
lithium,	O
captopril,	O
triamterene	B-Drug
and	O
antihypertensives	O
may	O
also	O
interact	O
with	O
metamizole,	O
as	O
other	O
pyrazolones	O
are	O
known	O
to	O
adversely	O
these	O
substances.	O

The	O
Golden	O
Triangle	O
(Southeast	O
Asia),	O
specifically	O
Shan	O
State,	O
Myanmar,	O
is	O
the	O
world's	O
leading	O
producer	O
of	O
methamphetamine	B-Drug
as	O
production	O
has	O
shifted	O
to	O
Yaba	O
and	O
crystalline	O
methamphetamine,	O
including	O
for	O
export	O
United	O
States	O
across	O
East	O
Southeast	O
Asia	O
Pacific.	O

A	O
Cochrane	O
review	O
found	O
little	O
evidence	O
to	O
help	O
guide	O
decisions	O
about	O
the	O
best	O
treatment	O
for	O
gastrointestinal	O
hypomotility	O
caused	O
by	O
clozapine	B-Drug
and	O
other	O
antipsychotic	O
medication.	O

Anticonvulsants	O
(Topiramate,	O
carbamazepine,	O
lamotrigine,	O
etc.)	O
Topiramate	B-Drug
carbamazepine	B-Drug
lamotrigine	B-Drug

There	O
are	O
reports	O
of	O
intravenous	O
injection	O
25I-NBOMe	B-Drug
solution	O
and	O
smoking	O
the	O
drug	O
in	O
powdered	O
form.	O

Cyproheptadine	B-Drug
is	O
a	O
second	O
line	O
treatment	O
for	O
pituitary	O
pars	O
intermedia	O
dysfunction	O
in	O
horses.	O

Acetaminophen	B-Drug
metabolites	O
are	O
also	O
eliminated	O
in	O
the	O
urine.	O

Metandienone	B-Drug
was	O
originally	O
developed	O
in	O
1955	O
by	O
CIBA	O
and	O
marketed	O
Germany	O
the	O
United	O
States.	O

The	O
last	O
FDA	O
approved	O
study	O
of	O
LSD	B-Drug
in	O
patients	O
ended	O
1980,	O
while	O
a	O
healthy	O
volunteers	O
was	O
made	O
the	O
late	O
1980s.	O

Examples	O
are	O
plants	O
from	O
the	O
genus	O
Anadenanthera	O
that	O
used	O
in	O
hallucinogenic	O
yopo	O
snuff.	O
snuff	B-Drug

Once	O
it	O
has	O
passed	O
first-pass	O
metabolism,	O
6-MAM	O
is	O
then	O
metabolized	O
into	O
morphine	B-Drug
or	O
excreted	O
in	O
urine.	O

It	O
is	O
also	O
available	O
in	O
a	O
quadriphasic	O
birth	O
control	O
pill	O
combined	O
with	O
estradiol	O
valerate,	O
marketed	O
as	O
Natazia	B-Drug
the	O
United	O
States	O
and	O
Qlaira	O
some	O
European	O
countries	O
Russia.	O

Fentanyl	B-Drug
is	O
sometimes	O
given	O
intrathecally	O
as	O
part	O
of	O
spinal	O
anesthesia	O
or	O
epidurally	O
for	O
epidural	O
anaesthesia	O
and	O
analgesia.	O

Law	O
enforcement	O
manuals	O
describe	O
it	O
as	O
one	O
of	O
the	O
drugs	O
most	O
commonly	O
implicated	O
in	O
drug-facilitated	O
sexual	O
assaults,	O
but	O
according	O
to	O
research	O
conducted	O
by	O
Michael	O
Robertson	O
from	O
San	O
Diego	O
Medical	O
Examiner's	O
office	O
and	O
Dr.	O
Mahmoud	O
El	O
Sohly	O
Laboratories,	O
test	O
results	O
indicated	O
that	O
flunitrazepam	B-Drug
was	O
only	O
used	O
around	O
1%	O
reported	O
date	O
rapes	O
0.33%	O
urine	O
lab	O
tests	O
done	O
Sohly,	O
rape-kits	O
actually	O
get	O
tested	O
time.	O

-DPT	O
5-MeO-DiPT,	O
also	O
known	O
as	O
'Foxy	O
Methoxy'	O
5-MeO-DALT	B-Drug
5-MeO-MT,	O
has	O
entactogenic	O
properties	O
5-MeO-ET,	O
5-MeO-DiPT	B-Drug

Mibolerone	B-Drug
(17-hydroxy-7,17-dimethylestr-4-en-3-one)	O

However,	O
androstenedione	B-Drug
was	O
legally	O
defined	O
as	O
an	O
anabolic	O
steroid,	O
even	O
though	O
there	O
is	O
scant	O
evidence	O
that	O
itself	O
in	O
nature.	O

Fenethylline	B-Drug
was	O
considered	O
to	O
have	O
fewer	O
side	O
effects	O
and	O
less	O
potential	O
for	O
abuse	O
than	O
amphetamine.	O
amphetamine	B-Drug

A	O
forensic	O
standard	O
of	O
EAM-2201	B-Drug
is	O
available	O
and	O
commonly	O
used	O
in	O
mass	O
spectrometry.	O

Researchers	O
at	O
Chemie	O
Grnenthal	O
found	O
that	O
thalidomide	B-Drug
was	O
a	O
particularly	O
effective	O
antiemetic	O
had	O
an	O
inhibitory	O
effect	O
on	O
morning	O
sickness.	O

The	O
tetrahydrocannabinol	B-Drug
(THC)	O
content	O
ranges	O
from	O
15	O
to	O
20%,	O
with	O
some	O
phenotypes	O
testing	O
as	O
high	O
25%.	O
THC	B-Drug

In	O
addition,	O
in	O
the	O
combination	O
preparations	O
with	O
naloxone,	O
inactivation	O
of	O
same	O
can	O
only	O
be	O
insufficient.	O
naloxone	B-Drug

The	O
production,	O
distribution,	O
sale,	O
and	O
possession	O
of	O
methamphetamine	B-Drug
is	O
restricted	O
or	O
illegal	O
in	O
many	O
jurisdictions.	O

estazolam	B-Drug
(Prosom,	O
Eurodin)	O
a	O
benzodiazepine	O
derivative	O
with	O
anxiolytic,	O
anticonvulsant,	O
hypnotic,	O
sedative	O
and	O
skeletal	O
muscle	O
relaxant	O
properties,	O
commonly	O
prescribed	O
for	O
short-term	O
treatment	O
of	O
insomnia.	O
Prosom	B-Drug

Alexander	O
Shulgin	O
wrote	O
of	O
the	O
former:	O
"[Methylone]	O
has	O
almost	O
same	O
potency	O
MDMA,	O
but	O
it	O
does	O
not	O
produce	O
effects.	O
Methylone	B-Drug
MDMA	B-Drug

In	O
one	O
of	O
the	O
only	O
double-blind,	O
randomized	O
studies	O
to	O
date,	O
those	O
given	O
microdoses	O
LSD	B-Drug
did	O
not	O
perform	O
better	O
than	O
placebo	O
on	O
cognitive	O
tasks.	O

Johnson	O
was	O
not	O
the	O
only	O
participant	O
whose	O
success	O
questioned:	O
Lewis	O
had	O
tested	O
positive	O
at	O
Olympic	O
Trials	O
for	O
pseudoephedrine,	O
ephedrine	B-Drug
and	O
phenylpropanolamine.	O
pseudoephedrine	B-Drug
phenylpropanolamine	B-Drug

However,	O
trenbolone	B-Drug
acetate's	O
androgenic	O
effect	O
activates	O
a	O
variety	O
of	O
lipid-like	O
active	O
compounds	O
which	O
are	O
called	O
prostaglandins.	O

It	O
has	O
been	O
found	O
to	O
be	O
more	O
effective	O
than	O
clonazepam	B-Drug
in	O
the	O
treatment	O
of	O
West	O
syndrome,	O
which	O
is	O
an	O
age-dependent	O
epilepsy,	O
affecting	O
very	O
young.	O

Levels	O
of	O
testosterone	O
have	O
been	O
found	O
to	O
increase	O
1.5-	O
2-fold	O
(5997%	O
increase)	O
and	O
levels	O
estradiol	O
about	O
2.5-fold	O
(65146%	O
in	O
men	O
treated	O
with	O
150	O
mg/day	O
bicalutamide	B-Drug
monotherapy.	O

Dr.	O
George	O
Greer,	O
Lester	O
Grinspoon,	O
Professor	O
James	O
Bakalar,	O
and	O
Thomas	O
Roberts	O
contributed	O
to	O
the	O
argument	O
that	O
MDMA	B-Drug
belonged	O
in	O
Schedule	O
III,	O
a	O
category	O
would	O
more	O
readily	O
enable	O
future	O
research	O
permit	O
continuation	O
of	O
its	O
use	O
psychotherapy.	O

Over-the-counter	O
preparations	O
containing	O
dextromethorphan	B-Drug
have	O
been	O
used	O
in	O
manners	O
inconsistent	O
with	O
their	O
labeling,	O
often	O
as	O
a	O
recreational	O
drug.	O

Water	O
looping	O
is	O
when	O
a	O
user	O
places	O
the	O
heroin	B-Drug
in	O
an	O
empty	O
eye	O
dropper	O
bottle,	O
or	O
syringe	O
with	O
needle	O
removed.	O

Enzalutamide	B-Drug
may	O
cause	O
seizures	O
in	O
overdose.	O

In	O
2013,	O
Mexican	O
boxer	O
Erik	O
Morales	O
was	O
suspended	O
for	O
two	O
years	O
after	O
testing	O
positive	O
clenbuterol.	O
clenbuterol	B-Drug

The	O
National	O
Drug	O
Strategy	O
Household	O
Survey	O
2016	O
by	O
the	O
Australian	O
Institute	O
of	O
Health	O
and	O
Welfare	O
revealed	O
that	O
smoking	O
is	O
an	O
increasingly	O
favored	O
route	O
administration	O
among	O
methamphetamine	B-Drug
users	O
in	O
Australia.	O

In	O
use	O
longer	O
than	O
one	O
to	O
two	O
weeks,	O
tolerance	O
will	O
rapidly	O
develop	O
towards	O
the	O
ability	O
of	O
temazepam	B-Drug
maintain	O
sleep,	O
resulting	O
in	O
a	O
loss	O
effectiveness.	O

In	O
2019,	O
the	O
cannabis	O
manufacturer,	O
Canopy	O
Growth,	O
acquired	O
majority	O
ownership	O
of	O
BioSteel	O
Sports	O
Nutrition,	O
which	O
is	O
developing	O
CBD	B-Drug
products	O
under	O
endorsement	O
by	O
numerous	O
professional	O
athletes.	O

Studies	O
show	O
that	O
prenatal	O
cocaine	O
exposure	O
(independent	O
of	O
other	O
effects	O
such	O
as,	O
for	O
example,	O
alcohol,	O
tobacco,	O
or	O
physical	O
environment)	O
has	O
no	O
appreciable	O
effect	O
on	O
childhood	O
growth	O
and	O
development.	O
tobacco	B-Drug

Hence,	O
acetylmethadol	B-Drug
has	O
four	O
possible	O
optical	O
isomers.	O

Several	O
physicians,	O
including	O
John	O
Jones,	O
Brown,	O
and	O
George	O
Young,	O
the	O
last	O
of	O
whom	O
published	O
a	O
comprehensive	O
medical	O
text	O
entitled	O
Treatise	O
on	O
Opium,	O
extolled	O
virtues	O
laudanum	B-Drug
recommended	O
drug	O
for	O
practically	O
every	O
ailment.	O
"	O

Bicalutamide	B-Drug
was	O
patented	O
in	O
1982	O
and	O
approved	O
for	O
medical	O
use	O
1995.	O

China	O
is	O
also	O
a	O
leading	O
exporter	O
of	O
bulk	O
ephedrine	B-Drug
and	O
has	O
been	O
source	O
country	O
for	O
much	O
the	O
pseudoephedrine	B-Drug
imported	O
into	O
Mexico;	O
these	O
precursor	O
chemicals	O
are	O
subsequently	O
used	O
to	O
manufacture	O
methamphetamine	B-Drug
destined	O
United	O
States.	O

Regular	O
lorazepam	B-Drug
use	O
during	O
late	O
pregnancy	O
(the	O
third	O
trimester),	O
carries	O
a	O
definite	O
risk	O
of	O
benzodiazepine	O
withdrawal	O
syndrome	O
in	O
the	O
neonate.	O

When	O
nalmefene	B-Drug
is	O
used	O
to	O
treat	O
an	O
opioid	O
overdose,	O
doses	O
of	O
greater	O
than	O
1.5	O
mg	O
do	O
not	O
appear	O
give	O
any	O
benefit	O
only	O
mg.	O

Erythromycin,	O
clarithromycin,	O
ritonavir,	O
itraconazole,	O
ketoconazole,	O
nefazodone,	O
cimetidine,	O
and	O
grapefruit	O
juice	O
are	O
inhibitors	O
of	O
CYP3A4	O
can	O
affect	O
the	O
metabolism	O
benzodiazepines.	O
Erythromycin	B-Drug
ritonavir	B-Drug
itraconazole	B-Drug
ketoconazole	B-Drug
nefazodone	B-Drug
cimetidine	B-Drug

Jerry	O
Garcia	O
took	O
peyote	O
prior	O
to	O
forming	O
The	O
Grateful	O
Dead	O
but	O
later	O
switched	O
LSD	B-Drug
and	O
DMT	O
since	O
they	O
were	O
easier	O
on	O
the	O
stomach.	O

It	O
is	O
also	O
found	O
as	O
a	O
component	O
of	O
the	O
combination	O
analgesic	O
Stopayne	O
capsules	O
(along	O
with	O
paracetamol	B-Drug
(acetaminophen),	O
caffeine,	O
and	O
codeine	B-Drug
phosphate).	O
acetaminophen	B-Drug
phosphate	I-Drug

A	O
study	O
published	O
in	O
2014	O
reported	O
the	O
biosynthesis	O
of	O
N,N-dimethyltryptamine	B-Drug
(DMT)	O
human	O
melanoma	O
cell	O
line	O
SK-Mel-147	O
including	O
details	O
on	O
its	O
metabolism	O
by	O
peroxidases.	O

Other	O
medications	O
that	O
have	O
been	O
investigated	O
for	O
this	O
purpose	O
include	O
acetylcysteine,	O
baclofen,	O
and	O
vanoxerine.	O
acetylcysteine	B-Drug
baclofen	B-Drug
vanoxerine	B-Drug

Further	O
trials	O
took	O
place	O
in	O
1972	O
when	O
clozapine	B-Drug
was	O
released	O
Switzerland	O
and	O
Austria	O
as	O
Leponex.	O

In	O
order	O
to	O
induce	O
a	O
stronger	O
immune	O
response,	O
some	O
versions	O
of	O
human	O
chorionic	O
gonadotropin-based	O
anti-fertility	O
vaccines	O
were	O
designed	O
as	O
conjugates	O
the	O
subunit	O
HCG	O
covalently	O
linked	O
tetanus	B-Drug
toxoid.	O
toxoid	I-Drug

In	O
the	O
mid-1990s,	O
Janssen	O
Pharmaceutica	O
developed	O
and	O
introduced	O
into	O
clinical	O
trials	O
Duragesic	B-Drug
patch,	O
which	O
is	O
a	O
formulation	O
of	O
an	O
inert	O
alcohol	O
gel	O
infused	O
with	O
select	O
fentanyl	B-Drug
doses,	O
are	O
worn	O
to	O
provide	O
constant	O
administration	O
opioid	O
over	O
period	O
48	O
72	O
hours.	O

He	O
notes	O
that	O
Paul	O
Rabe	O
was	O
an	O
extremely	O
experienced	O
alkaloid	O
chemist,	O
he	O
had	O
ample	O
opportunity	O
to	O
compare	O
his	O
quinine	B-Drug
reaction	O
product	O
with	O
authentic	O
samples	O
and	O
the	O
described	O
1918	O
chemistry	O
repeated	O
by	O
although	O
not	O
quinotoxine	O
itself	O
but	O
still	O
closely	O
related	O
derivatives.	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	B-Drug
and	O
may	O
have	O
higher	O
cannabidiol	B-Drug
(CBD),	O
which	O
decreases	O
or	O
eliminates	O
its	O
psychoactive	O
effects.	O
CBD	B-Drug

Alprazolam	B-Drug
is	O
recommended	O
by	O
the	O
World	O
Federation	O
of	O
Societies	O
Biological	O
Psychiatry	O
(WFSBP)	O
for	O
treatment-resistant	O
cases	O
panic	O
disorder	O
where	O
there	O
no	O
history	O
tolerance	O
or	O
dependence.	O

Though	O
it	O
possesses	O
an	O
appreciable	O
in	O
vitro	O
profile,	O
animal	O
drug	O
discrimination	O
studies	O
was	O
not	O
found	O
to	O
substitute	O
for	O
MMAI	O
or	O
amphetamine	B-Drug
and	O
only	O
partially	O
MBDB.	O
MBDB	B-Drug

Medical	O
marijuana	O
researchers	O
typically	O
prefer	O
to	O
use	O
high-potency	O
marijuana,	O
but	O
NIDA's	O
National	O
Advisory	O
Council	O
on	O
Drug	O
Abuse	O
has	O
been	O
reluctant	O
provide	O
cannabis	O
with	O
high	O
THC	B-Drug
levels,	O
citing	O
safety	O
concerns:	O
Most	O
clinical	O
studies	O
have	O
conducted	O
using	O
cigarettes	O
a	O
potency	O
of	O
24%	O
THC.	O

The	O
ratio	O
of	O
testosterone	O
to	O
estradiol	O
is	O
also	O
decreased	O
during	O
oral	O
ketoconazole	B-Drug
therapy	O
in	O
men.	O

In	O
females,	O
due	O
to	O
the	O
minimal	O
biological	O
importance	O
of	O
androgens	O
in	O
this	O
sex,	O
side	O
effects	O
pure	O
antiandrogens	O
or	O
NSAAs	O
are	O
few,	O
and	O
bicalutamide	B-Drug
has	O
been	O
found	O
be	O
very	O
well	O
tolerated.	O

Phenytoin	B-Drug
is	O
primarily	O
metabolized	O
to	O
its	O
inactive	O
form	O
by	O
the	O
enzyme	O
CYP2C9.	O

Heroin	B-Drug
is	O
rapidly	O
metabolized	O
by	O
esterase	O
enzymes	O
in	O
the	O
brain	O
and	O
has	O
an	O
extremely	O
short	O
half-life.	O

Several	O
cases	O
of	O
progressive	O
bilateral	O
hearing	O
loss	O
unresponsive	O
to	O
steroid	O
therapy	O
have	O
been	O
described	O
as	O
an	O
infrequent	O
adverse	O
reaction	O
hydrocodone/paracetamol	B-Drug
misuse.	O

After	O
menopause,	O
androstenedione	B-Drug
production	O
is	O
about	O
halved,	O
due	O
primarily	O
to	O
the	O
reduction	O
of	O
steroid	O
secreted	O
by	O
ovary.	O

Antibacterials:	O
increased	O
risk	O
of	O
ototoxicity	O
with	O
aminoglycosides,	O
polymyxins	O
and	O
vancomycin;	O
avoid	O
concomitant	O
use	O
lymecycline	B-Drug
Antidepressants:	O
hypokalemia	O
reboxetine;	O
enhanced	O
hypotensive	O
effect	O
MAOIs;	O
postural	O
hypotension	O
tricyclic	O
antidepressants	O
Antiepileptics:	O
hyponatremia	O
carbamazepine	B-Drug
Antifungals:	O
amphotericin	O
Antihypertensives:	O
effect;	O
vancomycin	B-Drug
reboxetine	B-Drug

It	O
is	O
the	O
dimethyl	O
carbamate	O
ester	O
of	O
temazepam,	O
a	O
metabolite	O
diazepam.	O
temazepam	B-Drug
diazepam	B-Drug

based	O
hand	O
rub	O
Chlorine	O
base	O
compound	O
Chloroxylenol	O
Glutaral	O
Amiloride	B-Drug
Furosemide	O
Hydrochlorothiazide	B-Drug
Mannitol	B-Drug
Spironolactone	B-Drug
Pancreatic	O
enzymes	O

FosB	O
levels	O
have	O
been	O
found	O
to	O
increase	O
upon	O
the	O
use	O
of	O
cocaine.	O
cocaine	B-Drug

The	O
promethazine	B-Drug
and	O
codeine	B-Drug
concoction	O
first	O
gained	O
popularity	O
in	O
the	O
underground	O
hip	O
hop	O
scene	O
Houston,	O
where	O
musician	O
Big	O
Hawk	O
said	O
it	O
was	O
consumed	O
as	O
early	O
1960s	O
1970s,	O
becoming	O
more	O
widely	O
used	O
1990s.	O

The	O
use	O
of	O
mannitol,	O
when	O
inhaled,	O
as	O
a	O
bronchial	O
irritant	O
an	O
alternative	O
method	O
diagnosis	O
exercise-induced	O
asthma	O
has	O
been	O
proposed.	O
mannitol	B-Drug

However,	O
combined	O
oral	O
contraceptives	O
that	O
contain	O
the	O
particularly	O
androgenic	O
progestin	O
levonorgestrel	B-Drug
have	O
been	O
found	O
to	O
increase	O
SHBG	O
levels	O
by	O
only	O
50	O
100%,	O
which	O
is	O
likely	O
because	O
activation	O
of	O
AR	O
in	O
liver	O
has	O
opposite	O
effect	O
estrogen	O
and	O
suppresses	O
production	O
SHBG.	O

The	O
core	O
group	O
at	O
Millbrook	O
wanted	O
to	O
cultivate	O
the	O
divinity	O
within	O
each	O
person	O
and	O
regularly	O
joined	O
LSD	B-Drug
sessions	O
facilitated	O
by	O
Leary.	O

Urgent	O
action	O
by	O
national	O
governments	O
has	O
been	O
recommended	O
to	O
improve	O
prescribing	O
patterns	O
of	O
benzodiazepines	O
such	O
as	O
diazepam.	O
diazepam	B-Drug

About	O
13,000	O
people	O
in	O
Sweden	O
have	O
been	O
diagnosed	O
with	O
multiple	O
sclerosis	O
(MS),	O
about	O
50	O
of	O
them	O
used	O
Sativex	B-Drug
December	O
2011.	O

Although	O
prohibited	O
by	O
statute,	O
the	O
use	O
of	O
kratom	B-Drug
remains	O
widely	O
spread	O
because	O
tree	O
grows	O
natively	O
and	O
tea	O
decoctions	O
are	O
readily	O
available	O
in	O
local	O
communities.	O

The	O
two	O
active	O
components	O
of	O
the	O
drug,	O
ibuprofen	B-Drug
and	O
hydrocodone,	O
do	O
not	O
affect	O
each	O
other's	O
absorption	O
characteristics	O
or	O
other	O
pharmacokinetic	O
parameters.	O
hydrocodone	B-Drug

Non-medical	O
use	O
of	O
fentanyl	B-Drug
by	O
individuals	O
without	O
opiate	O
tolerance	O
can	O
be	O
very	O
dangerous	O
and	O
has	O
resulted	O
in	O
numerous	O
deaths.	O

Both	O
enantiomers	O
are	O
stimulants,	O
but	O
differ	O
enough	O
to	O
give	O
Adderall	B-Drug
an	O
effects	O
profile	O
distinct	O
from	O
those	O
of	O
racemic	O
amphetamine	B-Drug
or	O
dextroamphetamine,	O
which	O
marketed	O
as	O
Evekeo	B-Drug
and	O
Dexedrine/Zenzedi,	O
respectively.	O
dextroamphetamine	B-Drug
Dexedrine	B-Drug

In	O
the	O
past,	O
trifluoperazine	B-Drug
was	O
used	O
in	O
fixed	O
combinations	O
with	O
MAO	O
inhibitor	O
(antidepressant)	O
tranylcypromine	B-Drug
(tranylcypromine/trifluoperazine)	O
to	O
attenuate	O
strong	O
stimulating	O
effects	O
of	O
this	O
antidepressant.	O
tranylcypromine/trifluoperazine	B-Drug

GHB	B-Drug
became	O
known	O
to	O
the	O
general	O
public	O
as	O
a	O
date-rape	O
drug	O
by	O
late	O
1990s.	O

However,	O
cocaine	B-Drug
does	O
often	O
cause	O
involuntary	O
tooth	O
grinding,	O
known	O
as	O
bruxism,	O
which	O
can	O
deteriorate	O
enamel	O
and	O
lead	O
to	O
gingivitis.	O

As	O
of	O
2008,	O
opium	B-Drug
was	O
collected	O
by	O
farmers	O
who	O
were	O
licensed	O
to	O
grow	O
0.1	O
hectares	O
(0.25	O
acres)	O
poppies,	O
maintain	O
their	O
licences	O
needed	O
sell	O
56	O
kilograms	O
unadulterated	O
raw	O
paste.	O

Hypotension	O
may	O
be	O
treated	O
with	O
levarterenol	O
or	O
metaraminol.	O
metaraminol	B-Drug

Delorazepam	B-Drug
(7-chloro-5-(o-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)	O

She	O
goes	O
on	O
to	O
say	O
that	O
she	O
hopes	O
the	O
ACMD	O
will	O
do	O
this	O
as	O
a	O
part	O
of	O
review	O
ketamine,	O
"including	O
its	O
analogues"	O
and	O
be	O
completed	O
"within	O
12	O
months	O
from	O
making	O
current	O
order".	O
ketamine	B-Drug

Shortly	O
thereafter,	O
in	O
1937,	O
testosterone	B-Drug
first	O
became	O
commercially	O
available	O
as	O
a	O
pharmaceutical	O
drug	O
the	O
form	O
of	O
pellets	O
and	O
then	O
ester	O
for	O
intramuscular	O
injection	O
relatively	O
short-acting	O
propionate.	O
propionate	I-Drug

In	O
1993,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
approved	O
gabapentin	B-Drug
(Neurontin,	O
Pfizer)	O
only	O
for	O
treatment	O
of	O
seizures.	O
Neurontin	B-Drug

Hash	B-Drug
oil	I-Drug
is	O
a	O
resinous	O
matrix	O
of	O
cannabinoids	O
obtained	O
from	O
the	O
Cannabis	O
plant	O
by	O
solvent	O
extraction,	O
formed	O
into	O
hardened	O
or	O
viscous	O
mass.	O

Alfentanil	B-Drug
is	O
a	O
restricted	O
drug	O
which	O
classified	O
as	O
Schedule	O
II	O
in	O
the	O
US,	O
according	O
to	O
U.S.	O
DEA	O
website.	O

It	O
was	O
first	O
introduced,	O
as	O
nandrolone	B-Drug
phenylpropionate,	O
in	O
1959,	O
and	O
then	O
decanoate	I-Drug
1962,	O
followed	O
by	O
additional	O
esters.	O
phenylpropionate	I-Drug

Importation	O
of	O
opium	B-Drug
peaked	O
in	O
1879	O
at	O
6,700	O
tons,	O
and	O
by	O
1906,	O
China	O
was	O
producing	O
85	O
percent	O
the	O
world's	O
opium,	O
some	O
35,000	O
27	O
its	O
adult	O
male	O
population	O
regularly	O
used	O
opium13.5	O
million	O
people	O
consuming	O
39,000	O
tons	O
yearly.	O

According	O
to	O
DSM-V	O
criteria,	O
9%	O
of	O
those	O
who	O
are	O
exposed	O
cannabis	O
develop	O
use	O
disorder,	O
compared	O
20%	O
for	O
cocaine,	O
23%	O
alcohol	O
and	O
68%	O
nicotine.	O
cocaine	B-Drug
nicotine	B-Drug

Fentanyl	B-Drug
may	O
be	O
measured	O
in	O
blood	O
or	O
urine	O
to	O
monitor	O
for	O
abuse,	O
confirm	O
a	O
diagnosis	O
of	O
poisoning,	O
assist	O
medicolegal	O
death	O
investigation.	O

Desomorphine	B-Drug
has	O
a	O
molecular	O
weight	O
of	O
271.35	O
g/mol	O
and	O
three	O
salts	O
are	O
known:	O
hydrobromide	O
(as	O
in	O
the	O
original	O
Permonid	O
brand;	O
free-base	O
conversion	O
ratio	O
0.770),	O
hydrochloride	O
(0.881)	O
sulfate	O
(0.802).	O

25I-NBOMe	B-Drug
is	O
a	O
relatively	O
new	O
substance,	O
and	O
little	O
known	O
about	O
its	O
pharmacological	O
risks	O
or	O
interaction	O
with	O
other	O
substances.	O

Medical	O
marijuana	O
refers	O
to	O
the	O
use	O
of	O
Cannabis	O
plant	O
as	O
a	O
physician-recommended	O
herbal	O
therapy	O
well	O
synthetic	O
THC	B-Drug
and	O
cannabinoids.	O

Drowsiness	O
Dizziness	O
Somnolence	O
Physostigmine,	O
a	O
cholinergic	O
drug	O
that	O
readily	O
crosses	O
the	O
blood-brain	O
barrier,	O
has	O
been	O
used	O
as	O
an	O
antidote	O
to	O
treat	O
central	O
nervous	O
system	O
depression	O
symptoms	O
of	O
hyoscine	B-Drug
overdose.	O
Physostigmine	B-Drug

Androgenic	O
progestins	O
like	O
levonorgestrel	B-Drug
have	O
been	O
found	O
to	O
inhibit	O
the	O
procoagulatory	O
effects	O
of	O
estrogens	O
ethinylestradiol	O
on	O
hepatic	O
synthesis	O
coagulation	O
factors,	O
whereas	O
this	O
may	O
occur	O
less	O
or	O
not	O
at	O
all	O
with	O
weakly	O
androgenic	O
desogestrel	B-Drug
and	O
antiandrogenic	O
drospirenone.	O

The	O
generalized	O
structural	O
motif	O
required	O
for	O
PCP-like	O
activity	O
is	O
derived	O
from	O
structure-activity	O
relationship	O
studies	O
of	O
PCP	B-Drug
derivatives.	O

Many	O
pharmaceutical	O
manufacturers	O
were	O
vigorously	O
competing	O
for	O
market	O
shares	O
by	O
continuously	O
developing	O
new	O
combinations	O
and	O
dosage	O
formulations,	O
at	O
the	O
time	O
of	O
1973	O
recall,	O
estimated	O
annual	O
distribution	O
these	O
pills	O
was	O
equivalent	O
to	O
480	O
million	O
units	O
Obetrol	B-Drug
10mg	O
tablets.	O

Propylketobemidone	O
is	O
so	O
named	O
because	O
it	O
the	O
propyl	O
ketone	O
analogue	O
of	O
bemidone	B-Drug
(hydroxypethidine).	O
hydroxypethidine	B-Drug

The	O
role	O
of	O
NMDAR	O
antagonism	O
in	O
the	O
effect	O
PCP,	O
ketamine,	O
and	O
related	O
dissociative	O
agents	O
was	O
first	O
published	O
early	O
1980s	O
by	O
David	O
Lodge	O
colleagues.	O
PCP	B-Drug
ketamine	B-Drug

CP	B-Drug
55,940	I-Drug
was	O
created	O
by	O
Pfizer	O
in	O
1974	O
but	O
never	O
marketed.	O

According	O
to	O
David	O
Nutt,	O
MDMA	B-Drug
was	O
widely	O
used	O
in	O
the	O
western	O
US	O
couples	O
counseling,	O
and	O
called	O
empathy.	O

cannabis	O
and	O
hashish	B-Drug
Mask	O
(1985)	O

For	O
example,	O
a	O
2017	O
analysis	O
of	O
cannabidiol	B-Drug
content	O
in	O
oil,	O
tincture,	O
or	O
liquid	O
vape	O
products	O
purchased	O
online	O
the	O
United	O
States	O

In	O
Poland,	O
JWH-019	B-Drug
is	O
I-N	O
(Poland).	O

Norbuprenorphine-3-glucuronide	O
(N3G)	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
the	O
opioid	O
modulator	O
buprenorphine.	O
buprenorphine	B-Drug

In	O
June	O
2012,	O
two	O
teens	O
in	O
Grand	O
Forks,	O
North	O
Dakota	O
and	O
East	O
Minnesota	O
fatally	O
overdosed	O
on	O
a	O
substance	O
that	O
was	O
allegedly	O
25I-NBOMe,	O
resulting	O
lengthy	O
sentences	O
for	O
of	O
the	O
parties	O
involved	O
Federal	O
indictment	O
against	O
Texas-based	O
online	O
vendor.	O
25I-NBOMe	B-Drug

Naloxone	B-Drug
opposes	O
the	O
effects	O
of	O
opioids	O
but	O
is	O
poorly	O
absorbed	O
into	O
body	O
when	O
given	O
orally,	O
meaning	O
almost	O
all	O
dose	O
stays	O
within	O
gastrointestinal	O
tract	O
and	O
reduces	O
local	O
side	O
from	O
oxycodone.	O
oxycodone	B-Drug

These	O
effects	O
were	O
not	O
noted	O
in	O
its	O
medicinal	O
use	O
the	O
1950s	O
and	O
1960s	O
however,	O
reports	O
of	O
physical	O
violence	O
on	O
PCP	B-Drug
have	O
often	O
been	O
shown	O
to	O
be	O
unfounded.	O

Richwood	O
submitted	O
this	O
formulation	O
as	O
NDA	O
11-522	O
and	O
Adderall	B-Drug
gained	O
FDA	O
approval	O
for	O
the	O
treatment	O
of	O
attention-deficit/hyperactivity	O
disorder	O
therapy	O
on	O
February	O
13,	O
1996.By	O
1980s,	O
use	O
amphetaminesparticularly	O
methamphetamineas	O
an	O
adjunct	O
to	O
diet	O
exercise	O
in	O
exogenous	O
obesity	O
had	O
become	O
frowned	O
upon	O
by	O
many	O
medical	O
community.	O

These	O
effects	O
were	O
not	O
noted	O
in	O
its	O
medicinal	O
use	O
the	O
1950s	O
and	O
1960s	O
however,	O
reports	O
of	O
physical	O
violence	O
on	O
PCP	B-Drug
have	O
often	O
been	O
shown	O
to	O
be	O
unfounded.	O

Each	O
mL	O
contains	O
10	O
mg	O
of	O
anhydrous	O
morphine	B-Drug
(the	O
equivalent	O
100	O
powdered	O
opium),	O
other	O
opium	B-Drug
alkaloids	O
(except	O
noscapine),	O
and	O
ethanol,	O
19%.	O
noscapine	B-Drug

In	O
1906,	O
41,000	O
tons	O
were	O
produced,	O
but	O
because	O
39,000	O
of	O
that	O
year's	O
opium	B-Drug
consumed	O
in	O
China,	O
overall	O
usage	O
the	O
rest	O
world	O
was	O
much	O
lower.	O

The	O
price	O
per	O
kilogram	O
of	O
black	O
tar	O
heroin	B-Drug
has	O
increased	O
from	O
one-tenth	O
that	O
South	O
American	O
powder	O
in	O
the	O
mid-1990s	O
to	O
between	O
one-half	O
and	O
three-quarters	O
2003	O
due	O
distributional	O
acumen	O
combined	O
with	O
demand	O
tar's	O
traditional	O
realm	O
distribution.	O

This	O
is	O
in	O
accordance	O
with	O
the	O
fact	O
that	O
sebum	O
secretion	O
appears	O
to	O
be	O
entirely	O
under	O
control	O
of	O
5-reductase	O
type	O
I.	O
5-Reductase	O
inhibitors	O
like	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
inhibit	O
II	O
and/or	O
other	O
isoforms	O
are	O
able	O
decrease	O
circulating	O
DHT	O
levels	O
by	O
65	O
98%	O
depending	O
on	O
inhibitor	O
question.	O

They	O
lived	O
there	O
during	O
a	O
period	O
in	O
the	O
late	O
1980s	O
and	O
early	O
1990s	O
when	O
Detroit	O
many	O
other	O
major	O
American	O
cities	O
were	O
gaining	O
widespread	O
reputations	O
for	O
crime	O
violence,	O
largely	O
due	O
to	O
an	O
influx	O
of	O
cocaine	B-Drug
emergence	O
crack	O
epidemic.	O

This	O
is	O
because	O
nandrolone	B-Drug
metabolized	O
by	O
5-reductase	O
to	O
the	O
much	O
weaker	O
AR	O
ligand	O
5-dihydronandrolone	O
(DHN),	O
which	O
has	O
both	O
reduced	O
affinity	O
for	O
androgen	O
receptor	O
(AR)	O
relative	O
in	O
vitro	O
and	O
agonistic	O
potency	O
vivo.	O

CB-13	B-Drug

Embutramide	B-Drug
is	O
formulated	O
as	O
a	O
combination	O
product	O
under	O
the	O
brand	O
name	O
Tributame,	O
which	O
also	O
contains	O
chloroquine	B-Drug
and	O
lidocaine.	O
lidocaine	B-Drug

However,	O
cocaine	B-Drug
is	O
more	O
active	O
in	O
the	O
dopaminergic	O
neurons	O
of	O
ventral	O
tegmental	O
area	O
than	O
substantia	O
nigra.	O

Levonorgestrel	B-Drug
as	O
a	O
contraceptive	O
intrauterine	O
device	O
is	O
associated	O
with	O
higher	O
risk	O
of	O
breast	O
cancer	O
than	O
non-use.	O

Thus,	O
endorphin	O
is	O
a	O
contraction	O
of	O
'endo(genous)	O
(mo)rphin'	O
(morphin	O
being	O
the	O
old	O
spelling	O
morphine).	O
morphine	B-Drug

N-Phenethyl-14-ethoxymetopon	O
is	O
a	O
drug	O
that	O
derivative	O
of	O
metopon.	O
metopon	B-Drug

Nordazepam	B-Drug
and	O
other	O
sedative-hypnotic	O
drugs	O
are	O
detected	O
frequently	O
in	O
cases	O
of	O
people	O
suspected	O
driving	O
under	O
the	O
influence	O
drugs.	O

Apalutamide	B-Drug
is	O
marketed	O
under	O
the	O
brand	O
names	O
Erleada	O
and	O
Erlyand.	O

Nausea,	O
vomiting,	O
respiratory	O
depression	O
and	O
constipation	O
are	O
believed	O
to	O
be	O
less	O
frequent	O
with	O
piritramide	B-Drug
than	O
morphine	B-Drug
(the	O
gold	O
standard	O
opioid	O
against	O
which	O
other	O
opioids	O
compared	O
contrasted),	O
it	O
produces	O
more	O
rapid-onset	O
analgesia	O
(pain	O
relief)	O
when	O
pethidine.	O
pethidine	B-Drug

Thus,	O
17,20-lyase	O
is	O
required	O
for	O
the	O
synthesis	O
of	O
androstenedione,	O
whether	O
immediately	O
or	O
one	O
step	O
removed.	O
androstenedione	B-Drug

Naloxone	B-Drug
and	O
naltrexone	B-Drug
have	O
both	O
been	O
studied	O
in	O
the	O
treatment	O
of	O
depersonalization	O
disorder.	O

Snorting	O
cocaine	B-Drug
produces	O
maximum	O
physiological	O
effects	O
within	O
40	O
minutes	O
and	O
psychotropic	O
20	O
minutes,	O
however,	O
a	O
more	O
realistic	O
activation	O
period	O
is	O
closer	O
to	O
5	O
10	O
minutes.	O

Several	O
of	O
the	O
immediate	O
metabolites	O
oxycodone	B-Drug
are	O
subsequently	O
conjugated	O
with	O
glucuronic	O
acid	O
and	O
excreted	O
in	O
urine.	O

In	O
1993,	O
a	O
new	O
drug	O
was	O
introduced	O
to	O
the	O
US	O
market	O
called	O
venlafaxine,	O
serotoninnorepinephrine	O
reuptake	O
inhibitor.	O
venlafaxine	B-Drug

Anxiety,	O
tremor,	O
and	O
depression	O
have	O
been	O
documented	O
in	O
a	O
case	O
report	O
following	O
administration	O
of	O
nitrazepam	B-Drug
triazolam.	O
triazolam	B-Drug

It	O
is	O
more	O
lipid-soluble	O
than	O
morphine,	O
resulting	O
in	O
a	O
faster	O
onset	O
of	O
action.	O
morphine	B-Drug

The	O
term	O
and	O
concept	O
of	O
"research	O
chemicals"	O
was	O
coined	O
by	O
some	O
marketers	O
designer	O
drugs	O
(in	O
particular,	O
psychedelic	O
in	O
the	O
tryptamine	O
phenethylamine	B-Drug
family).	O

It	O
has	O
been	O
reported	O
to	O
be	O
almost	O
as	O
virilizing	O
comparable	O
doses	O
of	O
testosterone	B-Drug
propionate	I-Drug
and	O
methyltestosterone	B-Drug
in	O
women.	O

Looking	O
to	O
replicate	O
the	O
effects	O
of	O
nerve	O
gas	O
created	O
by	O
Germans	O
during	O
World	O
War	O
II	O
without	O
toxicity,	O
LSD	B-Drug
was	O
sought	O
for	O
use	O
under	O
pretense	O
that	O
it	O
could	O
induce	O
hysteria	O
and	O
psychoses,	O
or	O
at	O
least	O
an	O
inability	O
fight	O
wholesale	O
destruction	O
enemy	O
their	O
properties.	O

Androstenedione	B-Drug
can	O
be	O
biosynthesized	O
in	O
one	O
of	O
two	O
ways.	O

salvinorin	O
C.	O
Salvinorin	B-Drug
A	I-Drug
is	O
a	O
trans-neoclerodane	O
diterpenoid	O
with	O
the	O
chemical	O
formula	O
C23H28O8.	O

Fentanyl	B-Drug
is	O
sometimes	O
sold	O
on	O
the	O
black	O
market	O
in	O
form	O
of	O
transdermal	O
fentanyl	B-Drug
patches	O
such	O
as	O
Duragesic,	O
diverted	O
from	O
legitimate	O
medical	O
supplies.	O
Duragesic	B-Drug

One	O
report	O
found	O
that	O
550,000	O
people	O
abused	O
methamphetamine	B-Drug
in	O
the	O
12	O
years	O
after	O
end	O
of	O
World	O
War	O
II.	O

Studies	O
have	O
found	O
that	O
Duloxetine	B-Drug
can	O
increase	O
liver	O
function	O
tests	O
three	O
times	O
above	O
their	O
upper	O
normal	O
limit.	O

In	O
May	O
2020,	O
the	O
company	O
further	O
announced	O
that	O
it	O
was	O
in	O
discussions	O
with	O
several	O
generics	O
companies	O
to	O
provide	O
rights	O
produce	O
remdesivir	B-Drug
for	O
developing	O
countries,	O
and	O
Medicines	O
Patent	O
Pool	O
broader	O
generic	O
access.	O

Jackson	O
had	O
been	O
administered	O
propofol	B-Drug
and	O
anti-anxiety	O
benzodiazepines	O
lorazepam	B-Drug
midazolam	B-Drug
by	O
his	O
doctor.	O

In	O
the	O
United	O
Kingdom,	O
LSD	B-Drug
is	O
a	O
Schedule	O
1	O
Class	O
'A'	O
drug.	O

Mebicar	B-Drug
(mebicarum)	O
is	O
an	O
anxiolytic	O
produced	O
in	O
Latvia	O
and	O
used	O
Eastern	O
Europe.	O

In	O
August	O
2018,	O
the	O
United	O
States	O
used	O
fentanyl	B-Drug
for	O
first	O
time	O
to	O
execute	O
a	O
prisoner.	O

Lorazepam	B-Drug
by	O
mouth	O
is	O
given	O
90	O
to	O
120	O
minutes	O
before	O
procedures,	O
and	O
intravenous	O
lorazepam	B-Drug
as	O
late	O
10	O
procedures.	O

Phencyclidine	B-Drug
enters	O
the	O
ion	O
channel	O
and	O
binds,	O
reversibly	O
non-competitively,	O
inside	O
pore	O
to	O
block	O
entry	O
of	O
positive	O
ions	O
cell,	O
thereby	O
inhibiting	O
cell	O
depolarisation.	O

Trade	O
names	O
in	O
other	O
countries	O
include	O
Dimedrol,	O
Daedalon,	O
and	O
Nytol.	O
Nytol	B-Drug

dienogest	B-Drug
(3040%)	O

The	O
synthesis	O
of	O
methasterone	B-Drug
is	O
first	O
mentioned	O
in	O
the	O
literature	O
1956	O
connection	O
with	O
research	O
conducted	O
by	O
Syntex	O
Corporation	O
order	O
to	O
discover	O
a	O
compound	O
anti-tumor	O
properties.	O

In	O
humans,	O
intravenous	O
administration	O
of	O
bufotenin	B-Drug
results	O
in	O
excretion	O
(70%)	O
injected	O
drug	O
the	O
form	O
5-HIAA,	O
an	O
endogenous	O
metabolite	O
serotonin,	O
while	O
roughly	O
4%	O
is	O
eliminated	O
unmetabolized	O
urine.	O

25I-NBOMe	B-Drug
is	O
a	O
relatively	O
new	O
substance,	O
and	O
little	O
known	O
about	O
its	O
pharmacological	O
risks	O
or	O
interaction	O
with	O
other	O
substances.	O

A	O
method	O
reported	O
in	O
microgram	O
replaced	O
the	O
need	O
for	O
a	O
separate	O
addition	O
of	O
hydrochloric	O
acid	O
by	O
starting	O
with	O
hydrochloride	O
salt	O
dl-phenylpropanolamine	B-Drug
but	O
side-products	O
are	O
noted.	O

During	O
this	O
time	O
the	O
use	O
of	O
opium	B-Drug
had	O
little	O
stigma;	O
drug	O
was	O
used	O
freely	O
until	O
1882	O
when	O
a	O
law	O
passed	O
to	O
confine	O
smoking	O
specific	O
dens.	O

Animal	O
studies	O
suggest	O
that	O
nicotine	B-Drug
may	O
adversely	O
affect	O
cognitive	O
development	O
in	O
adolescence,	O
but	O
the	O
relevance	O
of	O
these	O
findings	O
to	O
human	O
brain	O
is	O
disputed.	O

Etodesnitazene	O
(Desnitroetonitazene,	O
Etazen,	O
Etazene,	O
Etazone)	O
is	O
a	O
benzimidazole	O
derived	O
opioid	O
analgesic	O
drug,	O
which	O
was	O
originally	O
developed	O
in	O
the	O
late	O
1950s	O
alongside	O
etonitazene	B-Drug
and	O
range	O
of	O
related	O
derivatives.	O

Because	O
of	O
the	O
extremely	O
high	O
strength	O
pure	O
fentanyl	B-Drug
powder,	O
it	O
is	O
very	O
difficult	O
to	O
dilute	O
appropriately,	O
and	O
often	O
resulting	O
mixture	O
may	O
be	O
far	O
too	O
strong	O
and,	O
therefore,	O
dangerous.	O

Punishment	O
for	O
contravention	O
in	O
relation	O
to	O
opium	B-Drug
poppy	O
and	O
opiumAny	O
person	O
who	O
contravenes	O
any	O
provision	O
of	O
this	O
Act,	O
or	O
rule	O
order	O
made	O
condition	O
license	O
granted	O
thereunder	O
cultivates	O
the	O
produces,	O
manufactures,	O
possesses,	O
sells,	O
purchases,	O
transports,	O
imports	O
inter-State,	O
exports	O
inter-State	O
uses	O
shall	O
be	O
punishable	O
with	O
rigorous	O
imprisonment	O
a	O
term	O
which	O
not	O
less	O
than	O
ten	O
years	O
but	O
may	O
extend	O
twenty	O
also	O
liable	O
fine	O
one	O
lakh	O
rupees	O
two	O
rupees.	O

Buprenorphine-3-glucuronide	O
(B3G)	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
the	O
opioid	O
modulator	O
buprenorphine.	O
buprenorphine	B-Drug

As	O
a	O
result,	O
cimetidine	B-Drug
has	O
the	O
potential	O
for	O
large	O
number	O
of	O
pharmacokinetic	O
interactions.	O

Since	O
2015,	O
several	O
reports	O
of	O
sometimes-fatal	O
cardiotoxicity	O
due	O
to	O
high-dose	O
loperamide	B-Drug
abuse	O
have	O
been	O
published.	O

Chadeayne	O
et	O
al.	O
solved	O
the	O
crystal	O
structure	O
of	O
freebase	O
form	O
5-MeO-DALT.	O
5-MeO-DALT	B-Drug

In	O
the	O
setting	O
of	O
prolonged	O
use,	O
high	O
dosage,	O
and/or	O
kidney	O
dysfunction,	O
hydromorphone	B-Drug
has	O
been	O
associated	O
with	O
neuroexcitatory	O
symptoms	O
such	O
as	O
tremor,	O
myoclonus,	O
agitation,	O
and	O
cognitive	O
dysfunction.	O

the	O
cyclosporin	B-Drug
synthetase,	O
SimB	O
(CAA02484.1)	O
is	O
alanine	O
racemase,	O
and	O
SimG	O
(similar	O
to	O
ATQ39432.1)	O
polyketide	O
synthase.	O

"Meth	O
oil"	O
refers	O
to	O
the	O
crude	O
methamphetamine	B-Drug
base	O
produced	O
by	O
several	O
synthesis	O
procedures.	O

In	O
1885	O
the	O
U.S.	O
manufacturer	O
Parke-Davis	O
sold	O
cocaine	B-Drug
in	O
various	O
forms,	O
including	O
cigarettes,	O
powder,	O
and	O
even	O
a	O
mixture	O
that	O
could	O
be	O
injected	O
directly	O
into	O
user's	O
veins	O
with	O
included	O
needle.	O

Though	O
this	O
is	O
somewhat	O
controversial	O
among	O
proponents	O
of	O
a	O
zero-tolerance	O
drug	O
policy,	O
it	O
has	O
proven	O
superior	O
to	O
methadone	B-Drug
in	O
improving	O
the	O
social	O
and	O
health	O
situations	O
addicts.	O

The	O
hydrochloride	O
salt	O
is	O
soluble	O
in	O
three	O
parts	O
of	O
water,	O
whereas	O
a	O
gram	O
morphine	B-Drug
dissolves	O
16	O
ml	O
water;	O
for	O
all	O
common	O
purposes,	O
the	O
pure	O
powder	O
hospital	O
use	O
can	O
be	O
used	O
to	O
produce	O
solutions	O
virtually	O
arbitrary	O
concentration.	O

In	O
the	O
1980s,	O
they	O
branched	O
out	O
into	O
cocaine	B-Drug
trafficking.	O

Some	O
studies	O
found	O
that,	O
like	O
other	O
NMDA	O
receptor	O
antagonists,	O
PCP	B-Drug
can	O
cause	O
a	O
kind	O
of	O
brain	O
damage	O
called	O
Olney's	O
lesions	O
in	O
rats.	O

PEA	B-Drug
reduces	O
the	O
expression	O
of	O
cyclooxygenase-2	O
(COX-2)	O
and	O
inducible	O
nitric	O
oxide	O
synthase	O
(iNOS)	O
prevents	O
IkB-alpha	O
degradation	O
p65	O
NF-kappaB	O
nuclear	O
translocation,	O
latter	O
related	O
to	O
as	O
an	O
endogenous	O
PPAR-alpha	O
agonist.	O

Clobazam,	O
sold	O
under	O
the	O
brand	O
name	O
Frisium	O
among	O
others,	O
is	O
a	O
benzodiazepine	O
class	O
medication	O
that	O
was	O
patented	O
in	O
1968.	O
Clobazam	B-Drug

A	O
popular	O
legend	O
dating	O
back	O
to	O
the	O
1960s,	O
it	O
has	O
been	O
claimed	O
that	O
several	O
people	O
took	O
LSD	B-Drug
and	O
stared	O
at	O
sun,	O
going	O
blind	O
as	O
a	O
result.	O

Because	O
of	O
the	O
low	O
social	O
status	O
immigrant	O
workers,	O
contemporary	O
writers	O
and	O
media	O
had	O
little	O
trouble	O
portraying	O
opium	B-Drug
dens	O
as	O
seats	O
vice,	O
white	O
slavery,	O
gambling,	O
knife-	O
revolver-fights,	O
a	O
source	O
for	O
drugs	O
causing	O
deadly	O
overdoses,	O
with	O
potential	O
to	O
addict	O
corrupt	O
population.	O

There	O
is	O
a	O
sharp	O
spike	O
in	O
nandrolone	B-Drug
levels	O
24	O
to	O
48	O
hours	O
after	O
an	O
intramuscular	O
injection	O
of	O
decanoate,	O
followed	O
by	O
steady	O
decline	O
baseline	O
within	O
approximately	O
two	O
or	O
three	O
weeks.	O
decanoate	I-Drug

Some	O
racetam	O
based	O
drugs	O
such	O
as	O
aniracetam	B-Drug
can	O
have	O
an	O
antianxiety	O
effect.	O

Pentobarbital	B-Drug
can	O
occur	O
as	O
a	O
free	O
acid,	O
but	O
is	O
usually	O
formulated	O
the	O
sodium	I-Drug
salt,	O
pentobarbital	B-Drug
sodium.	O

Via	O
CB1	O
receptor	O
activation,	O
THC	B-Drug
indirectly	O
increases	O
dopamine	O
release	O
and	O
produces	O
psychotropic	O
effects.	O

The	O
mechanism	O
of	O
action	O
for	O
salvinorin	B-Drug
A	I-Drug
on	O
ileal	O
tissue	O
has	O
been	O
described	O
as	O
'prejunctional',	O
it	O
was	O
able	O
to	O
modify	O
electrically	O
induced	O
contractions,	O
but	O
not	O
those	O
exogenous	O
acetylcholine.	O

These	O
varieties	O
are	O
bred	O
mostly	O
for	O
the	O
medicinal	O
cannabis	O
market,	O
since	O
they	O
not	O
very	O
appreciated	O
by	O
recreational	O
users	O
because	O
ruderalis	O
lower	O
in	O
THC	B-Drug
and	O
impart	O
a	O
slightly	O
unpleasant	O
taste.	O

Before	O
long,	O
however,	O
it	O
had	O
become	O
clear	O
that	O
glutethimide	B-Drug
was	O
just	O
as	O
likely	O
to	O
cause	O
addiction	O
and	O
caused	O
similar	O
withdrawal	O
symptoms.	O

A	O
cytochrome	O
P450	O
classified	O
as	O
Cyp80F1	O
oxidizes	O
and	O
rearranges	O
littorine	O
to	O
hyoscyamine	B-Drug
aldehyde.	O

Androstenedione	B-Drug
is	O
a	O
substrate	O
for	O
estrogen	O
production	O
in	O
granulosa	O
cells	O
which	O
produce	O
aromatase.	O

In	O
the	O
U.S.,	O
fentanyl	B-Drug
is	O
a	O
Schedule	O
II	O
controlled	O
substance	O
per	O
Controlled	O
Substance	O
Act.	O

Production	O
and	O
prescription	O
of	O
methylphenidate	B-Drug
rose	O
significantly	O
in	O
the	O
1990s,	O
especially	O
United	O
States,	O
as	O
ADHD	O
diagnosis	O
came	O
to	O
be	O
better	O
understood	O
more	O
generally	O
accepted	O
within	O
medical	O
mental	O
health	O
communities.	O

Based	O
on	O
the	O
results	O
of	O
3	O
high	O
quality	O
trials	O
and	O
5	O
lower	O
quality,	O
oral	O
cannabis	O
extract	O
was	O
rated	O
as	O
effective,	O
THC	B-Drug
probably	O
for	O
improving	O
people's	O
subjective	O
experience	O
spasticity.	O

As	O
of	O
October	O
2015	O
Butylone	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

As	O
with	O
other	O
3-substituted	O
fentanyl	B-Drug
derivatives	O
such	O
as	O
ohmefentanyl,	O
the	O
stereoisomerism	O
of	O
lofentanil	B-Drug
is	O
very	O
important,	O
some	O
stereoisomers	O
being	O
much	O
more	O
potent	O
than	O
others.	O
ohmefentanyl	B-Drug

Levonorgestrel	B-Drug
was	O
first	O
studied	O
in	O
humans	O
by	O
1970,	O
and	O
introduced	O
for	O
medical	O
use	O
Germany	O
as	O
a	O
combined	O
birth	O
control	O
pill	O
with	O
ethinylestradiol	O
under	O
the	O
brand	O
name	O
Neogynon	O
August	O
1970.	O

Ketamine	B-Drug
is	O
primarily	O
sold	O
throughout	O
the	O
world	O
under	O
brand	O
name	O
Ketalar.	O

Nabiximols	B-Drug
is	O
a	O
branded	O
product	O
name	O
from	O
tincture	O
manufacturing	O
pharmaceutical	O
company.	O

Abrupt	O
or	O
over	O
rapid	O
withdrawal	O
from	O
bromazepam	B-Drug
after	O
chronic	O
use	O
even	O
at	O
therapeutic	O
prescribed	O
doses	O
can	O
lead	O
to	O
a	O
severe	O
syndrome	O
including	O
status	O
epilepticus	O
and	O
condition	O
resembling	O
delerium	O
tremens.	O

Valproate	B-Drug
was	O
first	O
made	O
in	O
1881	O
and	O
came	O
into	O
medical	O
use	O
1962.	O

Early	O
carbon	O
dioxide	O
retention	O
causing	O
cutaneous	O
vasodilation	O
(releasing	O
more	O
fentanyl),	O
together	O
with	O
acidosis,	O
which	O
reduces	O
protein	O
binding	O
of	O
fentanyl,	O
releasing	O
yet	O
fentanyl.	O
fentanyl	B-Drug

(e.g.,	O
K2	O
and	O
Spice)	O
Cocaine	B-Drug
LSD	B-Drug
Opiates	O
fentanyl,	O
oxycodone,	O
heroin,	O
codeine,	O
morphine)	O
fentanyl	B-Drug
oxycodone	B-Drug
heroin	B-Drug
codeine	B-Drug
morphine	B-Drug

In	O
Australia,	O
packets	O
of	O
275	O
mg	O
tablets	O
naproxen	B-Drug
sodium	I-Drug
are	O
Schedule	O
2	O
pharmacy	O
medicines,	O
with	O
a	O
maximum	O
daily	O
dose	O
five	O
or	O
1375	O
mg.	O

(JWH-073	O
JWH-073	B-Drug

Schedule	O
IV:	O
sedatives	O
such	O
as	O
barbiturates	O
and	O
benzodiazepine	O
compounds,	O
with	O
the	O
exception	O
of	O
flunitrazepam.	O
flunitrazepam	B-Drug

Arnold	O
produced	O
desoxymethyltestosterone	B-Drug
and	O
supplied	O
it	O
to	O
Victor	O
Conte	O
of	O
Bay	O
Area	O
Laboratory	O
Co-operative	O
(BALCO),	O
an	O
American	O
nutritional	O
supplement	O
company	O
steroid	O
supplier.	O

It	O
is	O
illegal	O
to	O
possess	O
TFMPP	B-Drug
in	O
any	O
quantity	O
Texas.	O

In	O
contrast	O
to	O
oxycodone	B-Drug
and	O
oxymorphone,	O
noroxycodone	O
noroxymorphone,	O
while	O
also	O
potent	O
MOR	O
agonists,	O
poorly	O
cross	O
the	O
bloodbrain	O
barrier	O
into	O
central	O
nervous	O
system,	O
for	O
this	O
reason	O
are	O
only	O
minimally	O
analgesic	O
in	O
comparison.	O
oxymorphone	B-Drug
noroxymorphone	B-Drug

When	O
compared	O
to	O
the	O
opioids	O
hydromorphone,	O
fentanyl,	O
oxycodone,	O
and	O
pethidine	B-Drug
(meperidine),	O
former	O
addicts	O
showed	O
a	O
strong	O
preference	O
for	O
heroin	B-Drug
morphine,	O
suggesting	O
that	O
morphine	B-Drug
are	O
particularly	O
susceptible	O
misuse	O
causing	O
dependence.	O
hydromorphone	B-Drug
fentanyl	B-Drug
oxycodone	B-Drug
meperidine	B-Drug

Some	O
research	O
chemicals	O
on	O
the	O
market	O
were	O
not	O
psychoactive,	O
but	O
can	O
be	O
used	O
as	O
precursors	O
in	O
synthesis	O
of	O
other	O
potentially	O
psychoactive	O
substances,	O
for	O
example,	O
2C-H,	O
which	O
could	O
to	O
make	O
2C-B	B-Drug
and	O
2C-I	O
among	O
others.	O

The	O
well-established	O
brand	O
name	O
Proviron	O
had	O
previously	O
been	O
used	O
by	O
Schering	O
for	O
testosterone	B-Drug
propionate	I-Drug
starting	O
in	O
1936.	O

Scopolamine,	O
also	O
known	O
as	O
hyoscine,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
motion	O
sickness	O
and	O
postoperative	O
nausea	O
vomiting.	O
Scopolamine	B-Drug
hyoscine	B-Drug

On	O
January	O
19,	O
2018,	O
the	O
medical	O
examiner-coroner	O
for	O
county	O
of	O
Los	O
Angeles	O
said	O
musician	O
Tom	O
Petty	O
died	O
from	O
an	O
accidental	O
drug	O
overdose	O
as	O
a	O
result	O
mixing	O
medications	O
that	O
included	O
fentanyl,	O
acetyl	O
fentanyl	B-Drug
and	O
despropionyl	O
(among	O
others).	O

Because	O
PMA	B-Drug
is	O
given	O
out	O
through	O
the	O
same	O
venues	O
and	O
distribution	O
channels	O
that	O
MDMA	B-Drug
tablets	O
are,	O
risk	O
of	O
being	O
severely	O
injured,	O
hospitalized	O
or	O
even	O
dying	O
from	O
use	O
ecstasy	B-Drug
increases	O
significantly	O
when	O
a	O
batch	O
pills	O
containing	O
starts	O
to	O
be	O
sold	O
in	O
particular	O
area.	O

Mifepristone	B-Drug
is	O
a	O
19-nor	O
steroid	O
with	O
bulky	O
p-(dimethylamino)	O

Mometasone	B-Drug
and	O
other	O
corticosteroids	O
circulate	O
in	O
the	O
blood	O
easily,	O
crossing	O
cellular	O
membranes	O
binding	O
with	O
cytoplasmic	O
receptors,	O
resulting	O
transcription	O
synthesis	O
of	O
proteins.	O

Unfortunately,	O
whereas	O
systemic	O
administration	O
of	O
antiandrogens	O
is	O
very	O
effective	O
in	O
treating	O
these	O
conditions,	O
topical	O
has	O
disappointingly	O
been	O
found	O
generally	O
to	O
possess	O
limited	O
and	O
only	O
modest	O
effectiveness,	O
even	O
when	O
high-affinity	O
steroidal	O
AR	O
antagonists	O
like	O
cyproterone	O
acetate	O
spironolactone	B-Drug
have	O
employed.	O

cocaine,	O
nitrous	O
oxide,	O
cannabis,	O
LSD,	O
MDMA	B-Drug
True	O
Romance	O
(1993)	O
cocaine	B-Drug
LSD	B-Drug

There	O
is	O
some	O
clinical	O
evidence	O
that	O
tolerance	O
to	O
analgesia	O
less	O
with	O
methadone	B-Drug
compared	O
other	O
opioids;	O
this	O
may	O
be	O
due	O
its	O
activity	O
at	O
the	O
NMDA	O
receptor.	O

Internationally,	O
pentazocine	B-Drug
is	O
a	O
Schedule	O
III	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances.	O

Semax	B-Drug
has	O
undergone	O
extensive	O
study	O
in	O
Russia	O
and	O
is	O
on	O
the	O
Russian	O
List	O
of	O
Vital	O
&	O
Essential	O
Drugs	O
approved	O
by	O
Federation	O
government	O
December	O
7,	O
2011.	O

Nefazodone	B-Drug
operates	O
by	O
blocking	O
post-synaptic	O
serotonin	O
type-2A	O
receptors	O
and	O
to	O
a	O
lesser	O
extent	O
inhibiting	O
pre-synaptic	O
norepinephrine	O

Interpretation	O
of	O
this	O
data	O
is	O
generally	O
complicated	O
by	O
factors	O
such	O
as	O
the	O
unknown	O
chemical	O
composition	O
street	O
LSD,	O
concurrent	O
use	O
other	O
psychoactive	O
drugs,	O
and	O
diseases	O
hepatitis	O
in	O
sampled	O
populations.	O
LSD	B-Drug

Phenylpiracetam	B-Drug
has	O
been	O
researched	O
for	O
the	O
treatment	O
of	O
Parkinson's	O
disease.	O

A	O
2018	O
report	O
by	O
The	O
Guardian	O
indicated	O
that	O
many	O
major	O
drug	O
suppliers	O
on	O
the	O
dark	O
web	O
have	O
voluntarily	O
banned	O
trafficking	O
of	O
fentanyl.	O
fentanyl	B-Drug

Metolazone	O
is	O
around	O
ten	O
times	O
as	O
potent	O
hydrochlorothiazide.	O
hydrochlorothiazide	B-Drug

Once	O
CBGVA	O
is	O
created,	O
the	O
process	O
continues	O
exactly	O
same	O
as	O
it	O
would	O
for	O
THC.	O
THC	B-Drug

The	O
study	O
mentions	O
the	O
ways	O
in	O
which	O
levels	O
of	O
THC	B-Drug
and	O
THCA	O
impact	O
variability	O
composition	O
by	O
changing	O
bioactivity	O
beverage.	O

Despite	O
this,	O
cases	O
of	O
thalidomide	B-Drug
embryopathy	O
continue,	O
with	O
at	O
least	O
100	O
identified	O
in	O
Brazil	O
between	O
2005	O
and	O
2010.	O

A	O
seizure	O
of	O
a	O
record	O
amount	O
fentanyl	B-Drug
occurred	O
on	O
February	O
2,	O
2019,	O
by	O
U.S.	O
Customs	O
and	O
Border	O
Protection	O
in	O
Nogales,	O
Arizona.	O

The	O
free	O
base	O
is	O
then	O
dissolved	O
in	O
an	O
organic	O
solvent,	O
sulfuric	O
acid	O
added,	O
and	O
amphetamine	B-Drug
precipitates	O
out	O
as	O
the	O
sulfate	O
salt.	O

Brand	O
name	O
Dianabol	B-Drug
is	O
no	O
longer	O
produced	O
but	O
the	O
drug	O
methandrostenolone	B-Drug
itself	O
still	O
made	O
in	O
many	O
countries	O
and	O
other,	O
similar	O
drugs	O
are	O
elsewhere.	O

Malana,	O
India	O
is	O
famous	O
for	O
its	O
production	O
of	O
Indian	O
hashish	B-Drug
or	O
so	O
called	O
Malana	O
Cream,	O
attracting	O
foreign	O
tourists.	O

(2005)	O
reported	O
the	O
case	O
of	O
a	O
72-year-old	O
man,	O
described	O
as	O
professionally	O
successful,	O
intelligent,	O
and	O
cultivated,	O
with	O
polymyalgia	O
rheumatica,	O
who	O
after	O
being	O
treated	O
prednisone	B-Drug
developed	O
psychosis	O
dementia,	O
which	O
several	O
behavioral	O
neurology	O
neuropsychiatry	O
consultants	O
initially	O
diagnosed	O
early	O
dementia	O
or	O
Alzheimer's	O
disease.	O

Between	O
1880	O
and	O
1900	O
was	O
the	O
peak	O
of	O
medicinal	O
use,	O
where	O
hashish	B-Drug
compounds	O
were	O
most	O
commonplace	O
in	O
almost	O
all	O
European	O
countries	O
USA.	O

Mercdes	O
Benegbi,	O
born	O
with	O
phocomelia	O
of	O
both	O
arms,	O
drove	O
the	O
successful	O
campaign	O
for	O
compensation	O
from	O
her	O
government	O
Canadians	O
who	O
were	O
affected	O
by	O
thalidomide.	O
thalidomide	B-Drug

These	O
drugs	O
include	O
aminoglutethimide,	O
ketoconazole,	O
and	O
abiraterone	O
acetate.	O
ketoconazole	B-Drug

Prednisolone	B-Drug
Tetracaine	B-Drug
Acetazolamide	B-Drug
Latanoprost	B-Drug
Pilocarpine	B-Drug
Timolol	B-Drug
Atropine	O
Epinephrine	O
(adrenaline)	O

In	O
the	O
Netflix	O
adaptation	O
of	O
Julia	O
Quinn's	O
novels,	O
Bridgerton	O
(2020),	O
when	O
Baron	O
Featherington,	O
Featherington	O
patriarch	O
is	O
ambushed	O
by	O
gambling	O
bookies,	O
a	O
bottle	O
laudanum	B-Drug
poison	O
shown	O
on	O
table	O
and	O
later	O
family	O
learns	O
his	O
off-screen	O
death,	O
presumably	O
murdered.	O

In	O
2017,	O
the	O
government	O
made	O
changes	O
to	O
regulations	O
so	O
that	O
restrictions	O
would	O
be	O
removed,	O
which	O
meant	O
a	O
doctor	O
was	O
able	O
prescribe	O
cannabidiol	B-Drug
patients.	O

Stimulants	O
such	O
as	O
amphetamine	B-Drug
can	O
improve	O
performance	O
on	O
difficult	O
and	O
boring	O
tasks	O
are	O
used	O
by	O
some	O
students	O
a	O
study	O
test-taking	O
aid.	O

The	O
DEA's	O
ACSCN	O
for	O
dihydrocodeine	B-Drug
free	O
base	O
and	O
all	O
salts	O
is	O
9120.	O

Murdoch	O
also	O
continued	O
to	O
paint	O
as	O
an	O
artist	O
while	O
on	O
LSD,	O
including	O
most	O
of	O
his	O
underwater	O
paintings.	O
LSD	B-Drug

Desogestrel	B-Drug
is	O
available	O
widely	O
throughout	O
the	O
world,	O
including	O
in	O
United	O
States,	O
Canada,	O
Kingdom,	O
Ireland,	O
many	O
other	O
European	O
countries,	O
Australia,	O
New	O
Zealand,	O
South	O
Africa,	O
Latin	O
America,	O
South,	O
East,	O
and	O
Southeast	O
Asia,	O
elsewhere	O
world.	O

It	O
is	O
around	O
100	O
times	O
stronger	O
than	O
morphine,	O
about	O
50	O
heroin.	O
morphine	B-Drug
heroin	B-Drug

The	O
benzoyl	O
moiety	O
required	O
for	O
the	O
formation	O
of	O
cocaine	B-Drug
diester	O
is	O
synthesized	O
from	O
phenylalanine	O
via	O
cinnamic	O
acid.	O

cannabis,	O
crack/cocaine	O
Summer	O
of	O
Sam	O
(1999)	O
cocaine	B-Drug

Other	O
NMDA	O
receptor	O
antagonists	O
include	O
ketamine,	O
tiletamine,	O
dextromethorphan,	O
nitrous	O
oxide,	O
and	O
dizocilpine	O
(MK-801).	O
ketamine	B-Drug
tiletamine	B-Drug
dextromethorphan	B-Drug

Cannabis	O
impairs	O
a	O
person's	O
driving	O
ability,	O
and	O
THC	B-Drug
was	O
the	O
illicit	O
drug	O
most	O
frequently	O
found	O
in	O
blood	O
of	O
drivers	O
who	O
have	O
been	O
involved	O
vehicle	O
crashes.	O

Internationally,	O
cathinone	B-Drug
is	O
a	O
Schedule	O

The	O
half-life	O
of	O
the	O
active	O
metabolite	O
is	O
about	O
same	O
as	O
parent	O
compound	O
loprazolam.	O
loprazolam	B-Drug

Fentanyl	B-Drug
was	O
first	O
made	O
by	O
Paul	O
Janssen	O
in	O
1960	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1968.	O

The	O
work	O
describes	O
many	O
drugs	O
known	O
to	O
be	O
effective,	O
including	O
aconite,	O
aloes,	O
colocynth,	O
colchicum,	O
henbane,	O
opium	B-Drug
and	O
squill.	O

Albert	O
Hofmann	O
and	O
his	O
colleagues	O
at	O
Sandoz	O
Laboratories	O
were	O
convinced	O
immediately	O
after	O
its	O
discovery	O
in	O
1943	O
of	O
the	O
power	O
promise	O
LSD.	O
LSD	B-Drug

Since	O
the	O
early	O
1970s,	O
Cannabis	O
plants	O
have	O
been	O
categorized	O
by	O
their	O
chemical	O
phenotype	O
or	O
"chemotype",	O
based	O
on	O
overall	O
amount	O
of	O
THC	B-Drug
produced,	O
and	O
ratio	O
to	O
CBD.	O
CBD	B-Drug

Ocfentanil	B-Drug
(INN;	O
also	O
called	O
A-3217)	O
is	O
a	O
potent	O
synthetic	O
opioid	O
structurally	O
related	O
to	O
fentanyl	B-Drug
that	O
was	O
developed	O
in	O
the	O
early	O
1990s	O
as	O
one	O
of	O
series	O
naloxone-reversible	O
opioids	O
an	O
attempt	O
obtain	O
had	O
better	O
therapeutic	O
indices	O
terms	O
cardiovascular	O
effects	O
and	O
respiratory	O
depression	O
compared	O
fentanyl.	O

A	O
1985	O
study	O
found	O
that	O
temazepam	B-Drug
and	O
triazolam	B-Drug
maintained	O
significantly	O
higher	O
rates	O
of	O
self-injection	O
than	O
a	O
variety	O
other	O
benzodiazepines.	O

THC	B-Drug
and	O
its	O
11-OH-THC	O
THC-COOH	O
metabolites	O
can	O
be	O
detected	O
quantified	O
in	O
blood,	O
urine,	O
hair,	O
oral	O
fluid	O
or	O
sweat	O
using	O
a	O
combination	O
of	O
immunoassay	O
chromatographic	O
techniques	O
as	O
part	O
drug	O
use	O
testing	O
program	O
forensic	O
investigation.	O

Examples	O
include	O
itraconazole	B-Drug
(which	O
increased	O
naldemedine	O
exposure	O
2.9-fold	O
in	O
a	O
study),	O
ketoconazole,	O
clarithromycin	O
and	O
grapefruit	O
juice.	O
ketoconazole	B-Drug

It	O
was	O
originally	O
a	O
Schedule	O
III	O
drug	O
in	O
the	O
United	O
States	O
under	O
Controlled	O
Substances	O
Act,	O
but	O
1991	O
it	O
upgraded	O
to	O
II,	O
several	O
years	O
after	O
discovered	O
that	O
misuse	O
combined	O
with	O
codeine	B-Drug
increased	O
effect	O
of	O
and	O
deaths	O
had	O
resulted	O
from	O
combination.	O

Since	O
2002,	O
the	O
U.S.	O
FDA	O
has	O
required	O
special	O
labeling	O
warning	O
against	O
use	O
of	O
multiple	O
products	O
that	O
contain	O
diphenhydramine.	O
diphenhydramine	B-Drug

5F-PCN	B-Drug
(also	O
known	O
as	O
5F-MN-21)	O
is	O
an	O
azaindole-based	O
synthetic	O
cannabinoid	O
that	O
presumed	O
to	O
be	O
a	O
potent	O
agonist	O
of	O
the	O
CB1	O
receptor	O
and	O
has	O
been	O
sold	O
online	O
designer	O
drug.	O

As	O
of	O
October	O
2015	O
JWH-122	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

As	O
such,	O
fluoxymesterone	B-Drug
has	O
a	O
relatively	O
poor	O
ratio	O
of	O
anabolic	O
to	O
androgenic	O
activity	O
similarly	O
testosterone	O
and	O
methyltestosterone.	O
methyltestosterone	B-Drug

Around	O
1984,	O
powder	O
cocaine	B-Drug
was	O
available	O
on	O
the	O
street	O
at	O
an	O
average	O
of	O
55	O
percent	O
purity	O
for	O
$100	O
per	O
gram	O
(equivalent	O
to	O
$246	O
in	O
2019),	O
and	O
crack	O
sold	O
levels	O
80-plus	O
same	O
price.	O

Diphenhydramine	B-Drug
is	O
deemed	O
to	O
have	O
limited	O
abuse	O
potential	O
in	O
the	O
United	O
States	O
owing	O
its	O
potentially	O
serious	O
side-effect	O
profile	O
and	O
euphoric	O
effects,	O
not	O
a	O
controlled	O
substance.	O

Methylphenidate	B-Drug
improves	O
measures	O
of	O
somnolence	O
on	O
standardized	O
tests,	O
such	O
as	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
(MSLT),	O
but	O
performance	O
does	O
not	O
improve	O
to	O
levels	O
comparable	O
healthy	O
people.	O

Isoniazid/rifampicin	B-Drug
(isoniazid	O
+	O
rifampicin)	O
isoniazid	B-Drug
rifampicin	B-Drug

In	O
2020,	O
Bulgaria	O
became	O
the	O
first	O
country	O
in	O
European	O
Union	O
to	O
allow	O
retail	O
sales	O
of	O
food	O
products	O
and	O
supplements	O
containing	O
CBD,	O
despite	O
ongoing	O
discussion	O
within	O
EU	O
about	O
classification	O
CBD	B-Drug
as	O
a	O
novel	O
food.	O

However,	O
intravenous	O
lorazepam	B-Drug
has	O
advantages	O
over	O
diazepam,	O
including	O
a	O
higher	O
rate	O
of	O
terminating	O
seizures	O
and	O
more	O
prolonged	O
anticonvulsant	O
effect.	O
diazepam	B-Drug

Mestanolone	B-Drug
is	O
an	O
AAS,	O
with	O
both	O
androgenic	O
and	O
anabolic	O
effects.	O

The	O
most	O
frequently	O
prescribed	O
stimulants	O
as	O
of	O
2013	O
were	O
lisdexamfetamine,	O
methylphenidate,	O
and	O
amphetamine.	O
lisdexamfetamine	B-Drug
methylphenidate	B-Drug
amphetamine	B-Drug

In	O
1964,	O
the	O
Brain	O
Committee	O
recommended	O
that	O
only	O
selected	O
approved	O
doctors	O
working	O
at	O
specialized	O
centres	O
be	O
allowed	O
to	O
prescribe	O
diamorphine	B-Drug
and	O
cocaine	B-Drug
users.	O

However,	O
later	O
studies	O
using	O
more	O
modern	O
techniques	O
assigned	O
a	O
value	O
of	O
504	O
times	O
the	O
potency	O
morphine	B-Drug
for	O
active	O
trans-isomer.	O

Restoril	B-Drug
(temazepam)	O
a	O
benzodiazepine	O
used	O
to	O
treat	O
insomnia.	O
temazepam	B-Drug

A	O
number	O
of	O
medications	O
including	O
ondansetron	B-Drug
appear	O
to	O
be	O
effective	O
in	O
controlling	O
postoperative	O
nausea	O
and	O
vomiting.	O

In	O
2015	O
GW	O
Pharmaceutical	O
initiated	O
Phase	O
3	O
clinical	O
trials	O
of	O
cannabidiol	B-Drug
oral	O
solution	O
for	O
treatment	O
two	O
orphan	O
conditions	O
in	O
children	O
Dravet	O
and	O
Lennox-Gastaut	O
syndromes.	O

Fentanyl,	O
like	O
other	O
opioids,	O
acts	O
on	O
opioid	O
receptors.	O
Fentanyl	B-Drug

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects,	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood.	O

MDPV	B-Drug
remained	O
an	O
obscure	O
stimulant	O
until	O
around	O
2004	O
when	O
it	O
was	O
reportedly	O
sold	O
as	O
a	O
designer	O
drug.	O

After	O
menopause,	O
androstenedione	B-Drug
production	O
is	O
about	O
halved,	O
due	O
primarily	O
to	O
the	O
reduction	O
of	O
steroid	O
secreted	O
by	O
ovary.	O

Official	O
Chinese	O
resistance	O
to	O
opium	B-Drug
was	O
renewed	O
on	O
September	O
20,	O
1906,	O
with	O
an	O
antiopium	O
initiative	O
intended	O
eliminate	O
the	O
drug	O
problem	O
within	O
10	O
years.	O

For	O
individuals	O
who	O
wish	O
to	O
completely	O
move	O
away	O
from	O
drugs,	O
they	O
can	O
start	O
a	O
methadone	B-Drug
reduction	O
program.	O

Midazolam	B-Drug
is	O
poorly	O
absorbed	O
orally,	O
with	O
only	O
50	O
percent	O
of	O
the	O
drug	O
reaching	O
bloodstream.	O

German	O
researchers	O
F.	O
Franzen	O
and	O
H.	O
Gross	O
report	O
to	O
have	O
evidenced	O
quantified	O
DMT,	O
along	O
with	O
its	O
structural	O
analog	O
bufotenin	B-Drug
(5-HO-DMT),	O
in	O
human	O
blood	O
urine.	O

(AM-2201)	O
AM-2201	B-Drug

MDMA	B-Drug
has	O
been	O
used	O
as	O
an	O
adjunct	O
to	O
New	O
Age	O
spiritual	O
practices.	O

It	O
is	O
important	O
to	O
note	O
that	O
"recreational	O
use"	O
of	O
opium	B-Drug
was	O
part	O
a	O
civilized	O
and	O
mannered	O
ritual	O
prior	O
the	O
extensive	O
prohibitions	O
came	O
later.	O

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects,	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood.	O

According	O
to	O
Haslam,	O
"[MDMA]	O
use	O
changed	O
clubs	O
forever;	O
a	O
night	O
at	O
the	O
Haienda	O
went	O
from	O
being	O
great	O
out	O
an	O
intense,	O
life	O
changing	O
experience.	O
MDMA	B-Drug

In	O
contrast	O
to	O
hydrocodone/acetaminophen	O
combination	O
analgesics	O
such	O
as	O
Vicodin,	O
this	O
hydrocodone/ibuprofen	B-Drug
avoids	O
some	O
of	O
the	O
liver	O
toxicity	O
which	O
may	O
occur	O
from	O
acetaminophen,	O
but	O
still	O
presents	O
significant	O
dangers	O
in	O
hydrocodone	B-Drug
overdose,	O
namely	O
respiratory	O
depression.	O
acetaminophen	B-Drug
Vicodin	B-Drug

A	O
later	O
study	O
confirmed	O
the	O
d-threo-methylphenidate	B-Drug
(dexmethylphenidate)	O
binding	O
to	O
5HT1A	O
receptor,	O
but	O
no	O
significant	O
activity	O
on	O
5HT2B	O
receptor	O
was	O
found.	O
dexmethylphenidate	B-Drug

The	O
Riksdag	O
added	O
25I-NBOMe	B-Drug
to	O
Narcotic	O
Drugs	O
Punishments	O
Act	O
under	O
Swedish	O
schedule	O

These	O
include	O
tetracycline,	O
doxycycline,	O
and	O
erythromycin.	O
doxycycline	B-Drug
erythromycin	B-Drug

In	O
South	O
Carolina,	O
a	O
woman	O
who	O
used	O
crack	O
in	O
her	O
third	O
trimester	O
of	O
pregnancy	O
was	O
sentenced	O
to	O
prison	O
for	O
eight	O
years	O
when	O
child	O
born	O
with	O
cocaine	B-Drug
metabolites	O
its	O
system.	O

There	O
are	O
no	O
expected	O
pharmacokinetic	O
interactions	O
between	O
thalidomide	B-Drug
and	O
other	O
medicines	O
due	O
to	O
its	O
neutral	O
effects	O
on	O
P-glycoprotein	O
the	O
cytochrome	O
P450	O
family.	O

The	O
market	O
for	O
MDMA	B-Drug
in	O
the	O
United	O
States	O
is	O
relatively	O
small	O
compared	O
to	O
methamphetamine,	O
cocaine,	O
and	O
heroin.	O
methamphetamine	B-Drug
cocaine	B-Drug
heroin	B-Drug

Men	O
in	O
the	O
U.S.	O
and	O
Canada	O
concerned	O
about	O
persistent	O
sexual	O
side	O
effects	O
"coined	O
phrase	O
'post-finasteride	O
syndrome',	O
which	O
they	O
say	O
is	O
characterized	O
by	O
sexual,	O
neurological,	O
hormonal	O
psychological	O
that	O
can	O
persist	O
men	O
who	O
have	O
taken	O
finasteride	B-Drug
for	O
hair	O
loss	O
or	O
an	O
enlarged	O
prostate".	O
post-finasteride	B-Drug
syndrome	I-Drug

Because	O
of	O
thalidomide's	O
potential	O
for	O
causing	O
birth	O
defects,	O
the	O
drug	O
may	O
be	O
distributed	O
only	O
under	O
tightly	O
controlled	O
conditions.	O
thalidomide	B-Drug

It	O
can	O
also	O
be	O
considered	O
a	O
substituted	O
amphetamine,	O
with	O
an	O
ethyl	O
group	O
on	O
the	O
amphetamine	B-Drug
backbone.	O

This	O
explains	O
how	O
harmaline	B-Drug
elicits	O
its	O
wakefulness-promoting	O
effects.	O

Alkaloid	O
extraction	O
yielded	O
approximately	O
2%	O
of	O
the	O
alkaloids	O
including	O
mescaline	B-Drug
in	O
both	O
samples.	O

Domperidone	B-Drug
moderately	O
increases	O
the	O
volume	O
of	O
expressed	O
breast	O
milk	O
in	O
mothers	O
preterm	O
babies	O
where	O
expression	O
was	O
inadequate,	O
and	O
appears	O
to	O
be	O
safe	O
for	O
short-term	O
use	O
this	O
purpose.	O

"Diclofenac	O
is	O
similar	O
in	O
COX-2	O
selectivity	O
to	O
celecoxib.	O
Diclofenac	B-Drug
celecoxib	B-Drug

Venlafaxine	B-Drug
1998:	O
Sibutramine	B-Drug
2004:	O
Duloxetine	B-Drug
2008:	O

Cocaine	B-Drug
is	O
now	O
predominantly	O
used	O
for	O
nasal	O
and	O
lacrimal	O
duct	O
surgery.	O

Benzylmorphine	B-Drug
is	O
now	O
a	O
Schedule	O
I	O
Controlled	O
Substance	O
in	O
the	O
US	O
and	O
regulated	O
internationally	O
under	O
UN	O
drug	O
conventions.	O

The	O
degree	O
of	O
tolerance	O
is	O
more	O
pronounced	O
with	O
clonazepam	B-Drug
than	O
chlordiazepoxide.	O
chlordiazepoxide	B-Drug

Norethisterone	B-Drug
and	O
5-DHNET	O
have	O
been	O
found	O
to	O
act	O
as	O
weak	O
irreversible	O
aromatase	O
inhibitors	O
(Ki	O
=	O
1.7	O
M	O
9.0	O
M,	O
respectively).	O

Ritonavir,	O
lopinavir/ritonavir,	O
and	O
efavirenz	B-Drug
have	O
been	O
shown	O
to	O
decrease	O
levels	O
of	O
bupropion	B-Drug
and/or	O
its	O
metabolites.	O
Ritonavir	B-Drug
lopinavir/ritonavir	B-Drug

There	O
have	O
been	O
no	O
reported	O
deaths	O
or	O
hospitalizations	O
from	O
EiPT,	O
but	O
its	O
safety	O
profile	O
is	O
unknown.	O
EiPT	B-Drug

Mirtazapine	B-Drug
may	O
be	O
used	O
as	O
an	O
inexpensive	O
antiemetic	O
alternative	O
to	O
Ondansetron.	O
Ondansetron	B-Drug

Symptoms	O
of	O
a	O
moderate	O
and	O
extremely	O
large	O
overdose	O
are	O
listed	O
below;	O
fatal	O
amphetamine	B-Drug
poisoning	O
usually	O
also	O
involves	O
convulsions	O
coma.	O

The	O
profitability	O
of	O
this	O
drug	O
has	O
led	O
dealers	O
to	O
adulterate	O
other	O
drugs	O
with	O
fentanyl	B-Drug
without	O
the	O
knowledge	O
user.	O

Around	O
1804,	O
German	O
pharmacologist	O
Friedrich	O
Sertrner	O
isolated	O
morphine	B-Drug
from	O
opium.	O
opium	B-Drug

illegal	O
weight	O
loss	O
products	O
imported	O
into	O
Ireland	O
have	O
been	O
found	O
to	O
contain	O
sibutramine.	O
sibutramine	B-Drug

The	O
major	O
metabolite	O
was	O
the	O
O-conjugate	O
of	O
temazepam	B-Drug
(90%);	O
N-desmethyl	O
a	O
minor	O
(7%).	O

THG	B-Drug
is	O
a	O
highly	O
potent	O
agonist	O
of	O
the	O
androgen	O
and	O
progesterone	O
receptors,	O
around	O
10	O
times	O
more	O
than	O
comparison	O
drugs	O
nandrolone	B-Drug
or	O
trenbolone,	O
but	O
with	O
no	O
estrogenic	O
activity.	O
trenbolone	B-Drug

In	O
July	O
2014,	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
(MHRA)	O
of	O
UK	O
issued	O
a	O
warning	O
about	O
potential	O
for	O
life-threatening	O
harm	O
from	O
accidental	O
exposure	O
to	O
transdermal	O
fentanyl	B-Drug
patches,	O
particularly	O
in	O
children,	O
advised	O
that	O
they	O
should	O
be	O
folded,	O
with	O
adhesive	O
side	O
in,	O
before	O
being	O
discarded.	O

The	O
relatively	O
short	O
context-sensitive	O
half-life	O
of	O
Remifentanil	B-Drug
allows	O
the	O
desired	O
blood	O
plasma	O
level	O
to	O
be	O
achieved	O
quickly	O
and	O
also	O
for	O
same	O
reason,	O
recovery	O
occurs	O
quickly.	O

In	O
advanced	O
disease,	O
tamoxifen	B-Drug
is	O
now	O
only	O
recognized	O
as	O
effective	O
in	O
ER+	O
patients,	O
but	O
the	O
early	O
trials	O
did	O
not	O
select	O
and	O
by	O
mid	O
1980s	O
clinical	O
trial	O
picture	O
was	O
showing	O
a	O
major	O
advantage	O
for	O
tamoxifen.	O

The	O
traditional	O
synthesis	O
of	O
desomorphine	B-Drug
starts	O
from	O
-chlorocodide,	O
which	O
is	O
itself	O
obtained	O
by	O
treating	O
thionyl	O
chloride	O
with	O
codeine.	O
codeine	B-Drug

Alfaxalone	B-Drug
binds	O
to	O
3050%	O
of	O
plasma	O
proteins,	O
and	O
has	O
a	O
terminal	O
half-life	O
25	O
minutes	O
in	O
dogs	O
45	O
cats	O
when	O
given	O
at	O
clinical	O
doses	O
(2	O
mg/kg	O
5	O
respectively).	O

In	O
1956,	O
Roger	O
Heim	O
identified	O
the	O
hallucinogenic	O
mushroom	O
that	O
Wassons	O
had	O
brought	O
back	O
from	O
Mexico	O
as	O
Psilocybe	O
and	O
in	O
1958,	O
Albert	O
Hofmann	O
first	O
reported	O
psilocin	B-Drug
psilocybin	O
active	O
compound	O
these	O
mushrooms.	O

A	O
few	O
psychotherapists	O
continue	O
to	O
use	O
MDMA	B-Drug
in	O
therapy	O
despite	O
the	O
drug's	O
legal	O
status.	O

Phencyclidine	B-Drug
enters	O
the	O
ion	O
channel	O
and	O
binds,	O
reversibly	O
non-competitively,	O
inside	O
pore	O
to	O
block	O
entry	O
of	O
positive	O
ions	O
cell,	O
thereby	O
inhibiting	O
cell	O
depolarisation.	O

The	O
relationship	O
between	O
tobacco	B-Drug
and	O
other	O
drug	O
use	O
has	O
been	O
well-established,	O
however	O
the	O
nature	O
of	O
this	O
association	O
remains	O
unclear.	O

Nevertheless,	O
the	O
number	O
of	O
cocaine	B-Drug
users	O
remain	O
high,	O
with	O
a	O
large	O
concentration	O
among	O
urban	O
youth.	O

THC	B-Drug
acetate	O
ester	O
can	O
reportedly	O
be	O
synthesized	O
from	O
or	O
THCA.	O

For	O
example,	O
Michigan	O
law	O
allowed	O
over-the-counter	O
(non-prescription)	O
sale	O
of	O
paregoric	O
until	O
April	O
1964,	O
but	O
still	O
OTC	O
sales	O
certain	O
exempt	O
cough	O
medication	O
preparations	O
that	O
contain	O
60	O
mg	O
codeine	B-Drug
per	O
fluid	O
ounce."	O

Illustrative	O
of	O
the	O
drugs	O
prepared	O
from	O
aniline	O
is	O
paracetamol	B-Drug
(acetaminophen,	O
Tylenol).	O
acetaminophen	B-Drug
Tylenol	B-Drug

No	O
studies	O
regarding	O
psychosis	O
and	O
4F-MPH	O
or	O
isopropylphenidate	B-Drug
have	O
been	O
conducted	O
but	O
given	O
their	O
high	O
DAT	O
binding	O
cellular	O
uptake	O
activity,	O
the	O
possibility	O
of	O
stimulant	O
exists.	O

Chlorphentermine	B-Drug
(trade	O
names	O
Apsedon,	O
Desopimon,	O
Lucofen)	O
is	O
a	O
serotonergic	O
appetite	O
suppressant	O
of	O
the	O
amphetamine	O
family.	O

Hashish	B-Drug
(also	O
spelled	O
hasheesh,	O
hashisha,	O
or	O
simply	O
hash)	O
is	O
a	O
concentrated	O
resin	O
cake	O
ball	O
produced	O
from	O
pressed	O
kief,	O
the	O
detached	O
trichomes	O
and	O
fine	O
material	O
that	O
falls	O
off	O
cannabis	O
fruits,	O
flowers	O
leaves.	O
hash	B-Drug

Most	O
heroin	B-Drug
deaths	O
result	O
not	O
from	O
overdose	O
per	O
se,	O
but	O
combination	O
with	O
other	O
depressant	O
drugs	O
such	O
as	O
alcohol	O
or	O
benzodiazepines.	O

Larger	O
markets	O
developed	O
in	O
the	O
late	O
1960s	O
and	O
early	O
1970s	O
when	O
most	O
of	O
hashish	B-Drug
was	O
imported	O
from	O
Pakistan	O
Afghanistan.	O

Under	O
normal	O
circumstances,	O
the	O
patch	O
will	O
reach	O
its	O
full	O
effect	O
within	O
12	O
to	O
24	O
hours;	O
thus,	O
fentanyl	B-Drug
patches	O
are	O
often	O
prescribed	O
with	O
a	O
fast-acting	O
opioid	O
(such	O
as	O
morphine	B-Drug
or	O
oxycodone)	O
handle	O
breakthrough	O
pain.	O
oxycodone	B-Drug

It	O
was	O
also	O
evaluated	O
whether	O
thalidomide	B-Drug
can	O
be	O
combined	O
with	O
melphalan	O
and	O
prednisone	B-Drug
for	O
patients	O
multiple	O
myeloma.	O

In	O
February	O
2009	O
the	O
UK	O
government	O
was	O
accused	O
by	O
its	O
most	O
senior	O
expert	O
drugs	O
adviser	O
Professor	O
David	O
Nutt	O
of	O
making	O
a	O
political	O
decisions	O
with	O
regard	O
to	O
drug	O
classification	O
in	O
rejecting	O
scientific	O
advice	O
downgrade	O
ecstasy	B-Drug
from	O
class	O
A	O
drug.	O

Nabilone	B-Drug
is	O
used	O
to	O
treat	O
nausea	O
and	O
vomiting	O
in	O
people	O
under	O
chemotherapy.	O

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself,	O
which	O
include	O
itching,	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression,	O
can	O
be	O
life-threatening.	O

The	O
dose	O
of	O
heroin	B-Drug
used	O
for	O
recreational	O
purposes	O
is	O
dependent	O
on	O
the	O
frequency	O
and	O
level	O
use:	O
thus	O
a	O
first-time	O
user	O
may	O
use	O
between	O
5	O
20	O
mg,	O
while	O
an	O
established	O
addict	O
require	O
several	O
hundred	O
mg	O
per	O
day.	O

The	O
antimuscarinic	O
action	O
of	O
trifluoperazine	B-Drug
can	O
cause	O
excessive	O
dilation	O
the	O
pupils	O
(mydriasis),	O
which	O
increases	O
chances	O
patients	O
with	O
hyperopia	O
developing	O
glaucoma.	O

It	O
was	O
also	O
evaluated	O
whether	O
thalidomide	B-Drug
can	O
be	O
combined	O
with	O
melphalan	O
and	O
prednisone	B-Drug
for	O
patients	O
multiple	O
myeloma.	O

THJ-018	B-Drug
is	O
an	O
Anlage	O
II	O
controlled	O
drug	O
in	O
Germany.	O

Because	O
of	O
the	O
extremely	O
high	O
strength	O
pure	O
fentanyl	B-Drug
powder,	O
it	O
is	O
very	O
difficult	O
to	O
dilute	O
appropriately,	O
and	O
often	O
resulting	O
mixture	O
may	O
be	O
far	O
too	O
strong	O
and,	O
therefore,	O
dangerous.	O

Then,	O
until	O
around	O
2004,	O
the	O
majority	O
of	O
world's	O
heroin	B-Drug
was	O
produced	O
in	O
an	O
area	O
known	O
as	O
Golden	O
Triangle.	O

Mercdes	O
Benegbi,	O
born	O
with	O
phocomelia	O
of	O
both	O
arms,	O
drove	O
the	O
successful	O
campaign	O
for	O
compensation	O
from	O
her	O
government	O
Canadians	O
who	O
were	O
affected	O
by	O
thalidomide.	O
thalidomide	B-Drug

USAF	O
Pararescue	O
combat	O
medics	O
in	O
Afghanistan	O
use	O
fentanyl	B-Drug
lozenges	O
the	O
form	O
of	O
lollipops	O
on	O
casualties	O
from	O
IED	O
blasts	O
and	O
other	O
trauma.	O

This	O
is	O
the	O
most	O
widely	O
consumed	O
form,	O
containing	O
3%	O
to	O
20%	O
THC,	O
with	O
reports	O
of	O
up	O
33%	O
THC.	O
THC	B-Drug

Buspirone,	O
sold	O
under	O
the	O
brand	O
name	O
Buspar,	O
among	O
others,	O
is	O
a	O
medication	O
primarily	O
used	O
to	O
treat	O
anxiety	O
disorders,	O
particularly	O
generalized	O
disorder.	O
Buspirone	B-Drug
Buspar	B-Drug

Reports	O
indicate	O
that	O
acetic	O
anhydride	O
is	O
diverted	O
from	O
China	O
to	O
morphine	B-Drug
and	O
heroin	B-Drug
refineries	O
in	O
the	O
Golden	O
Triangle.	O

Diazepam	B-Drug
has	O
a	O
shelf	O
life	O
of	O
five	O
years	O
for	O
oral	O
tablets	O
and	O
three	O
IV/IM	O
solutions.	O

MEGX	O
has	O
a	O
longer	O
half-life	O
than	O
lidocaine,	O
but	O
also	O
is	O
less	O
potent	O
sodium	O
channel	O
blocker.	O
lidocaine	B-Drug

One	O
meth	B-Drug
legend	O
refers	O
to	O
the	O
method	O
of	O
administration	O
in	O
which	O
user	O
will	O
heat/melt	O
crystal	B-Drug
methamphetamine	B-Drug
and	O
inhale	O
resulting	O
vapor.	O

The	O
duration	O
of	O
cocaine's	O
effects	O
depends	O
on	O
the	O
amount	O
taken	O
and	O
route	O
administration.	O
cocaine	B-Drug

He	O
boiled	O
anhydrous	O
morphine	B-Drug
alkaloid	O
with	O
acetic	O
anhydride	O
for	O
several	O
hours	O
and	O
produced	O
a	O
more	O
potent,	O
acetylated	O
form	O
of	O
which	O
is	O
now	O
called	O
diacetylmorphine	B-Drug
or	O
diacetate.	O

Typically,	O
the	O
base	O
for	O
lean	O
has	O
been	O
prescription	O
cold	O
medicine,	O
specifically	O
cough	O
syrup,	O
one	O
that	O
contains	O
both	O
promethazine	B-Drug
and	O
codeine,	O
but	O
over-the-counter	O
medicine	O
lists	O
dextromethorphan	B-Drug
as	O
active	O
ingredient	O
also	O
used,	O
it	O
can	O
produce	O
similar	O
effects	O
eliminate	O
need	O
a	O
doctor's	O
visit.	O
codeine	B-Drug

PCP	B-Drug
not	O
only	O
produced	O
symptoms	O
similar	O
to	O
schizophrenia,	O
it	O
also	O
yielded	O
electroencephalogram	O
changes	O
in	O
the	O
thalamocortical	O
pathway	O
(increased	O
delta	O
decreased	O
alpha)	O
and	O
hippocampus	O
(increase	O
theta	O
bursts)	O
that	O
were	O
those	O
schizophrenia.	O

Opium	O
tincture	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
severe	O
fulminant	O
(intense,	O
prolific)	O
diarrhea	O
that	O
does	O
not	O
respond	O
to	O
standard	O
therapy	O
(e.g.,	O
Imodium	B-Drug
or	O
Lomotil).	O
Lomotil	B-Drug

Because	O
of	O
thalidomide's	O
potential	O
for	O
causing	O
birth	O
defects,	O
the	O
drug	O
may	O
be	O
distributed	O
only	O
under	O
tightly	O
controlled	O
conditions.	O
thalidomide	B-Drug

Recognised	O
risk	O
factors	O
for	O
tramadol	B-Drug
overdose	O
include	O
depression,	O
addiction,	O
and	O
seizures.	O

It	O
is	O
often	O
administered	O
in	O
post-operative	O
laparoscopy	O
patients	O
as	O
an	O
alternative	O
to	O
fentanyl.	O
fentanyl	B-Drug

Lorazepam	B-Drug
may	O
also	O
inhibit	O
fetal	O
liver	O
bilirubin	O
glucuronidation,	O
leading	O
to	O
neonatal	O
jaundice.	O

Estonia	O
in	O
known	O
to	O
have	O
been	O
home	O
the	O
world's	O
longest	O
documented	O
fentanyl	B-Drug
epidemic,	O
especially	O
following	O
Taliban	O
ban	O
on	O
opium	O
poppy	O
cultivation	O
Afghanistan.	O

Beginning	O
in	O
1915,	O
Chinese	O
nationalist	O
groups	O
came	O
to	O
describe	O
the	O
period	O
of	O
military	O
losses	O
and	O
Unequal	O
Treaties	O
as	O
"Century	O
National	O
Humiliation",	O
later	O
defined	O
end	O
with	O
conclusion	O
Civil	O
War	O
1949.In	O
northern	O
provinces	O
Ningxia	O
Suiyuan	O
China,	O
Muslim	O
General	O
Ma	O
Fuxiang	O
both	O
prohibited	O
engaged	O
opium	B-Drug
trade.	O

Clascoterone	B-Drug
is	O
rapidly	O
hydrolyzed	O
into	O
cortexolone	O
(11-deoxycortisol)	O
and	O
this	O
compound	O
a	O
possible	O
primary	O
metabolite	O
of	O
clascoterone	B-Drug
based	O
on	O
in-vitro	O
studies	O
in	O
human	O
liver	O
cells.	O

3-Methylfentanyl	B-Drug
(N-(3-methyl-1-phenethyl-4-piperidyl)	O
propionanilide)	O

Heroin	B-Drug
also	O
produces	O
profound	O
degrees	O
of	O
tolerance	O
and	O
physical	O
dependence.	O

The	O
attorneys	O
general	O
of	O
Connecticut	O
and	O
Pennsylvania	O
have	O
launched	O
investigations	O
into	O
its	O
diversion	O
from	O
the	O
legitimate	O
pharmaceutical	O
market,	O
including	O
Cephalon's	O
"sales	O
promotional	O
practices	O
for	O
Provigil,	O
Actiq	B-Drug
Gabitril".	O
Provigil	B-Drug
Gabitril	B-Drug

The	O
anticonvulsant	O
effects	O
of	O
diazepam	B-Drug
can	O
help	O
in	O
the	O
treatment	O
seizures	O
due	O
to	O
a	O
drug	O
overdose	O
or	O
chemical	O
toxicity	O
as	O
result	O
exposure	O
sarin,	O
VX,	O
soman	O
(or	O
other	O
organophosphate	O
poisons),	O
lindane,	O
chloroquine,	O
physostigmine,	O
pyrethroids.	O
chloroquine	B-Drug
physostigmine	B-Drug

The	O
officers	O
said	O
the	O
cups	O
and	O
bottle	O
all	O
emitted	O
"strong	O
odors	O
of	O
codeine"	O
even	O
though	O
codeine	B-Drug
is	O
odorless	O
according	O
to	O
National	O
Institutes	O
Health.	O

On	O
decarboxylation	O
the	O
following	O
major	O
cannabinoids	O
THC,	O
CBD,	O
CBC,	O
CBCV,	O
CBDV,	O
CBGV,	O
THCV	O
are	O
formed.	O
THC	B-Drug
CBD	B-Drug

The	O
knowledge	O
that	O
consuming	O
foods	O
containing	O
vitamin	B-Drug
C	I-Drug
is	O
a	O
cure	O
for	O
scurvy	O
has	O
been	O
repeatedly	O
forgotten	O
and	O
rediscovered	O
into	O
the	O
early	O
20th	O
century.	O

In	O
the	O
community,	O
intravenous	O
administration	O
is	O
not	O
practical	O
and	O
so	O
rectal	O
diazepam	B-Drug
or	O
buccal	O
midazolam	B-Drug
are	O
used,	O
with	O
a	O
preference	O
for	O
as	O
its	O
easier	O
more	O
socially	O
acceptable.	O

In	O
the	O
1950s	O
new	O
psychiatric	O
drugs,	O
notably	O
antipsychotic	O
chlorpromazine,	O
were	O
designed	O
in	O
laboratories	O
and	O
slowly	O
came	O
into	O
preferred	O
use.	O
chlorpromazine	B-Drug

In	O
case	O
of	O
serious	O
medical	O
reasons,	O
nordazepam	B-Drug
can	O
be	O
given	O
in	O
late	O
pregnancy,	O
but	O
the	O
foetus,	O
due	O
to	O
pharmacological	O
action	O
drug,	O
may	O
experience	O
side	O
effects	O
such	O
as	O
hypothermia,	O
hypotonia,	O
and	O
sometimes	O
mild	O
respiratory	O
depression.	O

Clonazepam,	O
a	O
benzodiazepine	O
is	O
used	O
to	O
treat	O
many	O
forms	O
of	O
parasomnia.	O
Clonazepam	B-Drug

Propranolol	B-Drug
is	O
a	O
highly	O
lipophilic	O
drug	O
achieving	O
high	O
concentrations	O
in	O
the	O
brain.	O

Further	O
minor	O
metabolites	O
of	O
cocaine	B-Drug
include	O
norcocaine,	O
p-hydroxycocaine,	O
m-hydroxycocaine,	O
p-hydroxybenzoylecgonine	O
(pOHBE),	O
and	O
m-hydroxybenzoylecgonine.	O

Colombia	O
replaced	O
Bolivia	O
and	O
Peru	O
as	O
the	O
primary	O
producer	O
of	O
coca	B-Drug
leaf	O
between	O
1996	O
1997,	O
but	O
fell	O
back	O
behind	O
again	O
in	O
2012.	O

As	O
the	O
name	O
implies,	O
"freebase"	O
is	O
base	O
form	O
of	O
cocaine,	O
as	O
opposed	O
to	O
salt	O
form.	O
cocaine	B-Drug

JWH-018	B-Drug
may	O
cause	O
intense	O
anxiety,	O
agitation,	O
and,	O
in	O
rare	O
cases	O
(generally	O
with	O
non-regular	O
JWH	O
users),	O
has	O
been	O
assumed	O
to	O
have	O
the	O
of	O
seizures	O
and	O
convulsions	O
by	O
inhibiting	O
GABA	O
neurotransmission	O
more	O
effectively	O
than	O
THC.	O
THC	B-Drug

An	O
article	O
in	O
the	O
Annals	O
of	O
Emergency	O
Medicine	O
compared	O
sedating	O
dose	O
and	O
toxic	O
or	O
lethal	O
fentanyl	B-Drug
those	O
its	O
derivatives	O
found	O
that	O
while	O
carfentanil	B-Drug
remifentanil	B-Drug
have	O
dramatically	O
shorter	O
biological	O
half-lives	O
are	O
more	O
potent	O
than	O
fentanyl,	O
lipophilic	O
(readily	O
taken	O
up	O
into	O
body	O
fat)	O
can	O
re-enter	O
circulation	O
after	O
an	O
overdose	O
is	O
first	O
treated,	O
causing	O
severe	O
delayed	O
effects	O
even	O
death	O
if	O
correct	O
antidote	O
not	O
administered	O
when	O
drugs	O
act	O
again.	O

XLR-11	B-Drug
was	O
banned	O
in	O
New	O
Zealand	O
by	O
being	O
added	O
to	O
the	O
temporary	O
class	O
drug	O
schedule,	O
effective	O
from	O
13	O
July	O
2012.The	O
U.S.	O
Drug	O
Enforcement	O
Administration	O
(DEA)	O
made	O
synthetic	O
cannabinoids	O
UR-144,	O
XLR11,	O
and	O
AKB48	O
Schedule	O
I,	O
illegal	O
drugs	O
under	O
Controlled	O
Substances	O
Act	O
(CSA)	O
for	O
next	O
two	O
years	O
as	O
of	O
UR-144	B-Drug

Analogues	O
of	O
OHPC	O
include	O
other	O
17-hydroxyprogesterone	O
derivatives	O
such	O
as	O
algestone	O
acetophenide	O
(dihydroxyprogesterone	O
acetophenide),	O
chlormadinone	O
acetate,	O
cyproterone	O
hydroxyprogesterone	O
heptanoate,	O
medroxyprogesterone	B-Drug
and	O
megestrol	O
well	O
the	O
caproate	O
esters	O
caproate,	O
gestonorone	O
(norhydroxyprogesterone	O
caproate),	O
methenmadinone	O
caproate.	O
acetate	I-Drug

They	O
feature	O
a	O
phenethylamine	B-Drug
core	O
with	O
an	O
alkyl	O
group	O
attached	O
to	O
the	O
alpha	O
carbon,	O
and	O
ketone	O
beta	O
along	O
additional	O
substitutions.	O

In	O
2016,	O
the	O
FAAH-inhibitor	O
drug	O
BIA	B-Drug
10-2474	I-Drug
was	O
withdrawn	O
from	O
human	O
trials	O
in	O
France	O
due	O
to	O
adverse	O
effects.	O

As	O
of	O
2019,	O
48	O
states	O
allow	O
for	O
a	O
pharmacist	O
to	O
have	O
the	O
authority	O
distribute	O
naloxone	B-Drug
without	O
an	O
individual	O
prescription.	O

These	O
side	O
effects	O
tend	O
to	O
be	O
significantly	O
worsened	O
when	O
the	O
BZP/TFMPP	O
mix	O
is	O
consumed	O
alongside	O
alcohol,	O
especially	O
headache,	O
nausea,	O
and	O
hangover.	O
BZP	B-Drug
TFMPP	B-Drug

Low	O
doses	O
of	O
AAS	O
such	O
as	O
oxandrolone	B-Drug
are	O
used	O
in	O
the	O
treatment	O
idiopathic	O
short	O
stature,	O
but	O
this	O
may	O
only	O
quicken	O
maturation	O
rather	O
than	O
increasing	O
adult	O
height.	O

Dexamethasone	B-Drug
is	O
inexpensive.	O

Due	O
to	O
the	O
ease	O
of	O
manufacturing	O
methamphetamine,	O
methcathinone,	O
and	O
certain	O
other	O
stimulants,	O
control	O
measures	O
are	O
focusing	O
less	O
on	O
preventing	O
drugs	O
from	O
crossing	O
borders.	O
methamphetamine	B-Drug
methcathinone	B-Drug

Ketamine	B-Drug
infusions	O
are	O
used	O
for	O
the	O
acute	O
pain	O
treatment	O
in	O
emergency	O
departments	O
and	O
perioperative	O
period	O
individuals	O
with	O
refractory	O
pain.	O

Desogestrel	B-Drug
is	O
the	O
C3	O
deketo	O
analogue	O
of	O
etonogestrel	B-Drug
and	O
C11	O
methylene	O
levonorgestrel.	O
levonorgestrel	B-Drug

Whereas	O
the	O
reduced	O
metabolites	O
of	O
progesterone	O
enhance	O
binding	O
benzodiazepine	O
flunitrazepam	B-Drug
to	O
GABAA	O
receptor	O
in	O
vitro,	O
MPA	O
can	O
partially	O
inhibit	O
by	O
up	O
40%	O
with	O
half-maximal	O
inhibition	O
at	O

Fludrocortisone	B-Drug
was	O
also	O
the	O
first	O
fluorine-containing	O
pharmaceutical	O
drug	O
to	O
be	O
marketed.	O

Jerry	O
Garcia	O
stated	O
in	O
a	O
July	O
3,	O
1989	O
interview	O
for	O
Relix	O
Magazine,	O
response	O
to	O
the	O
question	O
"Have	O
your	O
feelings	O
about	O
LSD	B-Drug
changed	O
over	O
years?,"	O
"They	O
haven't	O
much.	O

According	O
to	O
Alexander	O
Cockburn	O
and	O
Jeffrey	O
St.	O
Clair,	O
in	O
order	O
prevent	O
Communist	O
party	O
members	O
from	O
being	O
elected	O
Italy	O
following	O
World	O
War	O
II,	O
the	O
CIA	O
worked	O
closely	O
with	O
Sicilian	O
Mafia,	O
protecting	O
them	O
assisting	O
their	O
worldwide	O
heroin	B-Drug
smuggling	O
operations.	O

AB-CHFUPYCA	B-Drug
(also	O
AB-CHMFUPPYCA)	O
is	O
a	O
compound	O
that	O
was	O
first	O
identified	O
as	O
component	O
of	O
synthetic	O
cannabis	O
products	O
in	O
Japan	O
2015.	O
AB-CHMFUPPYCA	B-Drug

1980	O
saw	O
the	O
publication	O
of	O
first	O
trial	O
to	O
show	O
that	O
tamoxifen	B-Drug
given	O
in	O
addition	O
chemotherapy	O
improved	O
survival	O
for	O
patients	O
with	O
early	O
breast	O
cancer.	O

Cutting	O
or	O
"stepping	O
on"	O
the	O
drug	O
is	O
commonplace,	O
using	O
compounds	O
which	O
simulate	O
ingestion	O
effects,	O
such	O
as	O
Novocain	B-Drug
(procaine)	O
producing	O
temporary	O
anesthaesia,	O
many	O
users	O
believe	O
a	O
strong	O
numbing	O
effect	O
result	O
of	O
and/or	O
pure	O
cocaine,	O
ephedrine	B-Drug
similar	O
stimulants	O
that	O
are	O
to	O
produce	O
an	O
increased	O
heart	O
rate.	O
procaine	B-Drug
cocaine	B-Drug

In	O
Australia,	O
and	O
the	O
United	O
States,	O
Armodafinil	B-Drug
is	O
considered	O
to	O
be	O
a	O
Schedule	O
4	O
prescription-only	O
medicine	O
or	O
prescription	O
animal	O
remedy.	O

(generic)	O
Testosterone	B-Drug
propionate:	O
propionate	I-Drug

This	O
proposal	O
is	O
based	O
on	O
an	O
initial	O
literature	O
review	O
the	O
safety	O
of	O
low	O
dose	O
CBD	B-Drug
published	O
by	O
TGA	O
in	O
April	O
2020.	O

Side	O
effects	O
from	O
finasteride	B-Drug
are	O
rare,	O
however	O
some	O
men	O
experience	O
sexual	O
dysfunction,	O
depression,	O
and	O
breast	O
enlargement.	O

This	O
does	O
not	O
deter	O
the	O
use	O
of	O
single	O
doses	O
difenoxin	B-Drug
to	O
potentiate	O
another	O
opiate,	O
anticholingeric	O
activity	O
a	O
tablet	O
is	O
actually	O
likely	O
increase	O
pleasurable	O
effects	O
opioid	O
in	O
manner	O
similar	O
combining	O
one	O
or	O
more	O
opioids	O
with	O
orphenadrine.	O
orphenadrine	B-Drug

When	O
examined	O
in	O
particular	O
pharmacological	O
assays	O
for	O
psychomotor	O
stimulant-like	O
activity,	O
both	O
the	O
dextrorotary	O
and	O
levorotary	O
enantiomeric	O
forms	O
of	O
methcathinone	B-Drug
hydrochloride	O
have	O
been	O
found	O
to	O
be	O
pharmacologically	O
active.	O

Both	O
of	O
these	O
metabolites	O
have	O
been	O
described	O
as	O
inactive,	O
and	O
neither	O
appear	O
to	O
contribute	O
the	O
wakefulness-promoting	O
effects	O
modafinil.	O
modafinil	B-Drug

The	O
full	O
profile	O
of	O
amphetamine's	O
short-term	O
drug	O
effects	O
in	O
humans	O
is	O
mostly	O
derived	O
through	O
increased	O
cellular	O
communication	O
or	O
neurotransmission	O
dopamine,	O
serotonin,	O
norepinephrine,	O
epinephrine,	O
histamine,	O
CART	O
peptides,	O
endogenous	O
opioids,	O
adrenocorticotropic	O
hormone,	O
corticosteroids,	O
and	O
glutamate,	O
which	O
it	O
interactions	O
with	O
CART,	O
5-HT1A,	O
EAAT3,	O
TAAR1,	O
VMAT1,	O
VMAT2,	O
possibly	O
other	O
biological	O
targets.	O
amphetamine	B-Drug

Methadone	B-Drug
was	O
developed	O
in	O
1937	O
Germany	O
by	O
scientists	O
working	O
for	O
I.G.	O
Farbenindustrie	O
AG	O
at	O
the	O
Farbwerke	O
Hoechst	O
who	O
were	O
looking	O
a	O
synthetic	O
opioid	O
that	O
could	O
be	O
created	O
with	O
readily	O
available	O
precursors,	O
to	O
solve	O
Germany's	O
opium	B-Drug
shortage	O
problem.	O

Anecdotal	O
reports	O
from	O
human	O
users	O
suggest	O
25C-NBOMe	B-Drug
to	O
be	O
an	O
active	O
hallucinogen	O
at	O
a	O
dose	O
of	O
as	O
little	O
200-500	O
g	O
insufflated	O
and	O
300-600	O
buccally	O
(with	O
threshold	O
doses	O
even	O
lower),	O
making	O
it	O
only	O
half	O
third	O
the	O
potency	O
LSD.	O
LSD	B-Drug

For	O
example,	O
both	O
methamphetamine	B-Drug
and	O
MDMA	B-Drug
are	O
substituted	O
amphetamines,	O
but	O
has	O
a	O
much	O
stronger	O
stimulant	O
action	O
than	O
MDMA,	O
with	O
none	O
of	O
the	O
latter's	O
empathogenic	O
effects.	O

Delta-9-THC	B-Drug
is	O
the	O
primary	O
molecule	O
responsible	O
for	O
effects	O
of	O
cannabis.	O

Vendors	O
would	O
import	O
25I-NBOMe	B-Drug
in	O
bulk	O
(E.G	O
1	O
kilogram	O
containers)	O
and	O
resell	O
individual	O
doses	O
for	O
a	O
considerable	O
profit.	O

About	O
3040%	O
of	O
individuals	O
with	O
cocaine	B-Drug
dependence	O
will	O
turn	O
to	O
other	O
substances	O
such	O
as	O
medication	O
and	O
alcohol	O
after	O
giving	O
up	O
cocaine.	O

The	O
Pranksters	O
helped	O
popularize	O
LSD	B-Drug
use,	O
through	O
their	O
road	O
trips	O
across	O
America	O
in	O
a	O
psychedelically-decorated	O
converted	O
school	O
bus,	O
which	O
involved	O
distributing	O
the	O
drug	O
and	O
meeting	O
with	O
major	O
figures	O
of	O
beat	O
movement,	O
publications	O
about	O
activities	O
such	O
as	O
Tom	O
Wolfe's	O
Electric	O
Kool-Aid	O
Acid	O
Test	O
(1968).In	O
San	O
Francisco's	O
Haight-Ashbury	O
neighborhood,	O
brothers	O
Ron	O
Jay	O
Thelin	O
opened	O
Psychedelic	O
Shop	O
January	O
1966.	O

However,	O
although	O
no	O
reports	O
of	O
gynecomastia	O
were	O
made	O
in	O
spite	O
widespread	O
use,	O
oxandrolone	B-Drug
was	O
reported	O
a	O
publication	O
1991	O
to	O
have	O
been	O
associated	O
with	O
33	O
cases	O
adolescent	O
boys	O
treated	O
it	O
for	O
short	O
stature.	O

Methasterone	B-Drug
resurfaced	O
in	O
2005	O
as	O
a	O
designer	O
steroid.	O

In	O
Mexico,	O
Rohypnol	B-Drug
is	O
legally	O
available	O
and	O
approved	O
for	O
medical	O
use.	O

It	O
was	O
once	O
believed	O
to	O
be	O
a	O
major	O
component	O
of	O
the	O
psychoactive	O
effects	O
snuff,	O
although	O
this	O
has	O
recently	O
been	O
shown	O
unlikely,	O
due	O
limited	O
or	O
sometimes	O
even	O
non-existent	O
quantity	O
contained	O
within	O
seeds,	O
which	O
instead	O
achieve	O
their	O
psychoactivity	O
from	O
O-demethylated	O
metabolite	O
5-MeO-DMT,	O
bufotenin.	O
snuff	B-Drug
5-MeO-DMT	B-Drug
bufotenin	B-Drug

In	O
some	O
patients,	O
however,	O
and/or	O
early	O
in	O
therapy,	O
carisoprodol	B-Drug
can	O
have	O
the	O
full	O
spectrum	O
of	O
sedative	O
side	O
effects	O
and	O
impair	O
patient's	O
ability	O
to	O
operate	O
a	O
firearm,	O
motor	O
vehicles,	O
other	O
machinery	O
various	O
types,	O
especially	O
when	O
taken	O
with	O
medications	O
containing	O
alcohol,	O
which	O
case	O
an	O
alternative	O
medication	O
would	O
be	O
considered.	O

Methadone	B-Drug
is	O
also	O
regulated	O
internationally	O
as	O
a	O
Schedule	O

In	O
a	O
separate	O
study	O
conducted	O
by	O
the	O
CDC,	O
82%	O
of	O
fentanyl	B-Drug
overdose	O
deaths	O
involved	O
illegally	O
manufactured	O
fentanyl,	O
while	O
only	O
4%	O
were	O
suspected	O
to	O
originate	O
from	O
prescription.	O

25I-NBOMe	B-Drug
is	O
a	O
relatively	O
new	O
substance,	O
and	O
little	O
known	O
about	O
its	O
pharmacological	O
risks	O
or	O
interaction	O
with	O
other	O
substances.	O

No	O
serious	O
harmful	O
effects	O
have	O
been	O
reported	O
with	O
overdose	O
of	O
desogestrel.	O
desogestrel	B-Drug

By	O
the	O
late	O
Victorian	O
era,	O
cocaine	B-Drug
use	O
had	O
appeared	O
as	O
a	O
vice	O
in	O
literature.	O

A	O
1962	O
issue	O
of	O
the	O
Commission	O
on	O
Narcotic	O
Drugs'	O
Bulletin	O
Narcotics	O
proudly	O
announced	O
that	O
"after	O
a	O
definite	O
transitional	O
period,	O
all	O
non-medical	O
use	O
narcotic	O
drugs,	O
such	O
as	O
opium	B-Drug
smoking,	O
eating,	O
consumption	O
cannabis	O
(hashish,	O
marijuana)	O
and	O
chewing	O
coca	B-Drug
leaves,	O
will	O
be	O
outlawed	O
everywhere.	O
hashish	B-Drug

Benzylmorphine	B-Drug
is	O
used	O
in	O
much	O
the	O
same	O
way	O
as	O
codeine	B-Drug
and	O
ethylmorphine,	O
primarily	O
a	O
moderate	O
strength	O
analgesic,	O
for	O
eye	O
surgery	O
1	O
to	O
2%	O
solution,	O
cough	O
suppressant.	O
ethylmorphine	B-Drug

JWH-081.	O
JWH-081	B-Drug

In	O
the	O
United	O
States,	O
midazolam	B-Drug
(DEA	O
number	O
2884)	O
is	O
on	O
Schedule	O
IV	O
list	O
of	O
Controlled	O
Substances	O
Act	O
as	O
a	O
non-narcotic	O
agent	O
with	O
low	O
potential	O
for	O
abuse.	O

Emergency-scheduling	O
power	O
was	O
used	O
for	O
the	O
first	O
time	O
MDMA.	O
MDMA	B-Drug

Brand	O
names	O
for	O
these	O
solutions	O
include	O
GoLytely,	O
GlycoLax,	O
CoLyte,	O
Miralax,	O
Movicol,	O
NuLytely,	O
Suprep,	O
and	O
Fortrans.	O
Miralax	B-Drug
NuLytely	B-Drug

This	O
spike	O
is	O
a	O
reflection	O
of	O
the	O
increase	O
in	O
heroin	B-Drug
supplies	O
United	O
States	O
and	O
decrease	O
prices,	O
which	O
encouraged	O
large	O
proportion	O
individuals	O
with	O
an	O
established	O
dependency	O
tolerance	O
on	O
opioids	O
to	O
transition	O
towards	O
more	O
concentrated	O
cheaper	O
alternative.	O

The	O
promethazine	B-Drug
and	O
codeine	B-Drug
concoction	O
first	O
gained	O
popularity	O
in	O
the	O
underground	O
hip	O
hop	O
scene	O
Houston,	O
where	O
musician	O
Big	O
Hawk	O
said	O
it	O
was	O
consumed	O
as	O
early	O
1960s	O
1970s,	O
becoming	O
more	O
widely	O
used	O
1990s.	O

Cephalon's	O
2011	O
attempt	O
to	O
merge	O
with	O
Teva	O
was	O
approved	O
by	O
the	O
FTC	O
under	O
a	O
number	O
of	O
conditions,	O
including	O
granting	O
generic	O
US	O
rights	O
another	O
company;	O
ultimately,	O
Par	O
Pharmaceutical	O
acquired	O
modafinil	B-Drug
as	O
well	O
some	O
others.	O

Venlafaxine	B-Drug
blocks	O
the	O
neuronal	O
reuptake	O
of	O
serotonin,	O
noradrenaline,	O
and,	O
to	O
a	O
lesser	O
extent,	O
dopamine	O
in	O
central	O
nervous	O
system.	O

Zaleplon	B-Drug
is	O
a	O
full	O
agonist	O
for	O
the	O
benzodiazepine	O
1	O
receptor	O
located	O
on	O
GABAA	O
complex	O
in	O
body,	O
with	O
lower	O
affinity	O
2	O
and	O
3	O
subsites.	O

A	O
more	O
widely	O
used	O
formulation,	O
containing	O
lower	O
doses	O
of	O
ethinylestradiol	O
and	O
levonorgestrel,	O
was	O
introduced	O
under	O
the	O
brand	O
name	O
Microgynon	O
by	O
1973.	O
levonorgestrel	B-Drug

Meta-DOT	O
Ortho-DOT	O
DOTFM	B-Drug
Phenylcyclopropylamine	O
derivatives	O
(technically	O
not	O
amphetamines)	O
amphetamines	B-Drug

Hash	B-Drug
oil	I-Drug
can	O
be	O
the	O
most	O
potent	O
of	O
main	O
cannabis	O
products	O
because	O
its	O
high	O
level	O
psychoactive	O
compound	O
per	O
volume,	O
which	O
vary	O
depending	O
on	O
plant's	O
mix	O
essential	O
oils	O
and	O
compounds.	O

The	O
first	O
quarter	O
of	O
sales	O
for	O
Contrave	B-Drug
(Q1	O
2015)	O
showed	O
net	O
US$11,500,000.Despite	O
having	O
been	O
approved	O
use	O
in	O
Europe	O
March	O
2015,	O
have	O
not	O
begun	O
as	O
Orexigen	O
has	O
yet	O
found	O
a	O
marketing	O
partner.	O

Following	O
chlordiazepoxide,	O
in	O
1963	O
diazepam	B-Drug
hit	O
the	O
market	O
under	O
brand	O
name	O
Valiumand	O
was	O
followed	O
by	O
many	O
further	O
benzodiazepine	O
compounds	O
over	O
subsequent	O
years	O
and	O
decades.	O
chlordiazepoxide	B-Drug

This	O
method	O
is	O
more	O
cost	O
effective,	O
and	O
therefore	O
prevalent	O
on	O
the	O
inner-city	O
streets,	O
while	O
powder	O
cocaine	B-Drug
remains	O
popular	O
in	O
white	O
suburbia.	O

Lidocaine	B-Drug
is	O
one	O
of	O
the	O
most	O
commonly	O
used	O
local	O
anaesthetics	O
in	O
dentistry.	O

Alfaxalone	B-Drug
can	O
be	O
used	O
instead	O
of	O
gas	O
anesthetics	O
in	O
surgeries	O
that	O
are	O
under	O
30	O
minutes,	O
where	O
it	O
is	O
given	O
at	O
a	O
constant	O
rate	O
via	O
IV	O
(constant	O
infusion);	O
this	O
especially	O
useful	O
procedures	O
such	O
as	O
bronchoscopies	O
or	O
repairing	O
tracheal	O
tears,	O
there	O
no	O
endotracheal	O
tube	O
the	O
way.	O

Pure	O
morphine	B-Drug
and	O
heroin	B-Drug
are	O
both	O
fine	O
powders.	O

Thalidomide	B-Drug
can	O
prevent	O
menstruation.	O

Naphyrone	B-Drug
analogues	O
were	O
subsequently	O
banned	O
in	O
July	O
2010	O
following	O
a	O
further	O
review	O
by	O
the	O
ACMD,	O
along	O
with	O
broad	O
based	O
structure	O
ban	O
even	O
more	O
expansive	O
than	O
last.	O

Selegiline	B-Drug
has	O
been	O
used	O
in	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(ADHD).	O

THC	B-Drug
has	O
been	O
shown	O
to	O
inhibit	O
GABA	O
receptor	O
neurotransmission	O
in	O
the	O
brain	O
via	O
several	O
pathways.	O

MDMA	B-Drug
tablets	O
typically	O
have	O
low	O
purity	O
due	O
to	O
bulking	O
agents	O
that	O
are	O
added	O
dilute	O
the	O
drug	O
and	O
increase	O
profits	O
(notably	O
lactose)	O
binding	O
agents.	O

In	O
June	O
2012,	O
two	O
teens	O
in	O
Grand	O
Forks,	O
North	O
Dakota	O
and	O
East	O
Minnesota	O
fatally	O
overdosed	O
on	O
a	O
substance	O
that	O
was	O
allegedly	O
25I-NBOMe,	O
resulting	O
lengthy	O
sentences	O
for	O
of	O
the	O
parties	O
involved	O
Federal	O
indictment	O
against	O
Texas-based	O
online	O
vendor.	O
25I-NBOMe	B-Drug

It	O
is	O
also	O
used	O
by	O
itself,	O
or	O
in	O
combination	O
with	O
complementary	O
agents	O
such	O
as	O
phenytoin,	O
commercial	O
animal	O
euthanasia	O
injectable	O
solutions.	O
phenytoin	B-Drug

lysergic	O
acid	B-Drug
diethylamide	O
(LSD;	O
L;	O
Delysid;	O
"Acid",	O
"Sid".	O

Abrupt	O
or	O
over-rapid	O
discontinuation	O
of	O
prazepam	B-Drug
after	O
long-term	O
use,	O
even	O
at	O
low	O
dosage,	O
may	O
result	O
in	O
a	O
protracted	O
withdrawal	O
syndrome.	O

NFL	O
punter	O
Todd	O
Sauerbrun	O
of	O
the	O
Denver	O
Broncos	O
was	O
suspended	O
for	O
first	O
month	O
2006	O
season	O
after	O
testing	O
positive	O
ephedrine.	O
ephedrine	B-Drug

Due	O
to	O
the	O
availability	O
of	O
precursor	O
chemicals,	O
traffickers	O
produce	O
large	O
amounts	O
crystal	B-Drug
methamphetamine.	O
methamphetamine	I-Drug

Leading	O
names	O
included	O
The	O
Joshua	O
Light	O
Show/Joe's	O
Lights/Sensefex	O
located	O
in	O
NY,	O
Tony	O
Martin	O
(SF,	O
NYC),	O
Elias	O
Romero	O
(SF),	O
Mike	O
Leonard	O
(lights	O
for	O
Pink	O
Floyd)	O
(UK),	O
Heavy	O
Water	O
Show,	O
Mark	O
Boyle's	O
Lights/Joan	O
Hill	O
Lymbic	O
System	O
(Mark	O
Hanau)	O
Glen	O
McKay's	O
Headlights,	O
Pig	O
Show	O
(NY),	O
Lights	O
by	O
Pablo	O
Brotherhood	O
of	O
Little	O
Princess	O
109	O
LSD,	O
Ed's	O
Amazing	O
Liquid	O
Abercrombe	O
the	O
Single	O
Wing	O
Turquoise	O
Bird	O
light	O
show	O
(California),	O
Sector	O
(Alberto	O
Zanotti)	O
and	O
Anna	O
Patti	O
(Italy).	O
LSD	B-Drug

The	O
total	O
synthesis	O
of	O
quinine,	O
a	O
naturally-occurring	O
antimalarial	O
drug,	O
was	O
developed	O
over	O
150-year	O
period.	O
quinine	B-Drug

NSAIDs	O
such	O
as	O
ibuprofen	B-Drug
work	O
by	O
inhibiting	O
the	O
cyclooxygenase	O
(COX)	O
enzymes,	O
which	O
convert	O
arachidonic	O
acid	O
to	O
prostaglandin	O
H2	O
(PGH2).	O

Common	O
side	O
effects	O
of	O
bupropion	B-Drug
include	O
a	O
dry	O
mouth,	O
difficulty	O
sleeping,	O
agitation,	O
and	O
headaches.	O

In	O
addition,	O
viqualine	O
displaces	O
diazepam	B-Drug
from	O
the	O
GABAA	O
receptor	O
and	O
produces	O
benzodiazepine-like	O
effects,	O
indicating	O
that	O
it	O
is	O
also	O
a	O
positive	O
allosteric	O
modulator	O
of	O
benzodiazepine	O
site	O
receptor.	O

There	O
have	O
been	O
no	O
reports	O
of	O
adverse	O
or	O
toxic	O
effects	O
MBDB	B-Drug
in	O
humans.	O

For	O
this	O
reason,	O
glucocorticoid	O
analogue	O
drugs	O
such	O
as	O
prednisone	B-Drug
down-regulate	O
the	O
natural	O
synthesis	O
of	O
glucocorticoids.	O

As	O
with	O
other	O
17-alkylated	O
AAS,	O
metandienone	B-Drug
is	O
hepatotoxic.	O

In	O
Sweden,	O
physicians	O
had	O
long	O
been	O
discouraged	O
by	O
the	O
medical	O
products	O
agency	O
to	O
prescribe	O
dextropropoxyphene	B-Drug
due	O
risk	O
of	O
respiratory	O
depression	O
and	O
even	O
death	O
when	O
taken	O
with	O
alcohol.	O

Elevations	O
in	O
brain	O
temperature	O
from	O
MDMA	B-Drug
use	O
are	O
positively	O
correlated	O
with	O
MDMA-induced	O
neurotoxicity.	O

As	O
of	O
2018	O
fentanyl	B-Drug
was	O
the	O
most	O
commonly	O
listed	O
opioid	O
in	O
overdose	O
drug	O
deaths,	O
surpassing	O
heroin.	O
heroin	B-Drug

Products	O
containing	O
a	O
relatively	O
small	O
proportion	O
of	O
certain	O
substances	O
listed	O
in	O
schedules	O
1-4	O
(e.g.	O
cough	O
medicines	O
codeine)	O
and	O
are	O
usually	O
administered	O
by	O
doctor	O
or	O
pharmacist.	O
codeine	B-Drug

GHB	B-Drug
is	O
only	O
detectable	O
in	O
urine	O
for	O
six	O
to	O
twelve	O
hours	O
after	O
ingestion.	O

As	O
part	O
of	O
the	O
deal,	O
Israel	O
drug	O
manufacturer	O
Teva	O
will	O
also	O
provide	O
US$20	O
million	O
in	O
cash	O
and	O
US$25	O
worth	O
Suboxone,	O
an	O
opioid	O
addiction	O
treatment.	O
Suboxone	B-Drug

The	O
corresponding	O
alcohol,	O
cathine,	O
is	O
a	O
less	O
powerful	O
stimulant.	O
cathine	B-Drug

The	O
concentrations	O
of	O
MDA	O
in	O
the	O
blood	O
or	O
urine	O
a	O
person	O
who	O
has	O
taken	O
only	O
MDMA	B-Drug
are,	O
general,	O
less	O
than	O
10%	O
those	O
parent	O
drug.	O

The	O
weakness	O
of	O
the	O
government	O
in	O
China	O
and	O
conditions	O
civil	O
war	O
enabled	O
heroin	B-Drug
production	O
to	O
take	O
root	O
there.	O

Spironolactone	B-Drug
bodies	O
are	O
eosinophilic,	O
round,	O
concentrically	O
laminated	O
cytoplasmic	O
inclusions	O
surrounded	O
by	O
clear	O
halos	O
in	O
preparations	O
stained	O
with	O
hematoxylin	O
and	O
eosin.	O

In	O
2008,	O
Chief	O
Sanitary	O
Inspector	O
of	O
Russia	O
Gennadiy	O
Onishchenko,	O
claimed	O
that	O
Russian	O
health	O
officials	O
are	O
not	O
convinced	O
the	O
methadone's	O
efficacy	O
in	O
treating	O
heroin	B-Drug
and/or	O
opioid	O
addicts.	O
methadone	B-Drug

In	O
Canada,	O
fentanyl	B-Drug
is	O
considered	O
a	O
Schedule	O
I	O
drug	O
as	O
listed	O
in	O
Canada's	O
Controlled	O
Drugs	O
and	O
Substances	O
Act.	O

In	O
addition	O
to	O
functioning	O
as	O
an	O
endogenous	O
prohormone,	O
androstenedione	B-Drug
also	O
has	O
weak	O
androgenic	O
activity	O
in	O
its	O
own	O
right.	O

In	O
1999,	O
Marinol	O
was	O
rescheduled	O
from	O
Schedule	O
II	O
to	O
III	O
of	O
the	O
Controlled	O
Substances	O
Act,	O
reflecting	O
a	O
finding	O
that	O
THC	B-Drug
had	O
potential	O
for	O
abuse	O
less	O
than	O
cocaine	B-Drug
and	O
heroin.	O
heroin	B-Drug

As	O
a	O
result,	O
bicalutamide	B-Drug
appears	O
to	O
not	O
be	O
able	O
compete	O
with	O
testosterone	O
in	O
this	O
sole	O
part	O
of	O
the	O
body	O
an	O
extent	O
sufficient	O
considerably	O
interfere	O
androgen	O
signaling	O
and	O
function.	O

Darolutamide	B-Drug
is	O
a	O
nonsteroidal	O
compound	O
and	O
structurally	O
distinct	O
from	O
other	O
marketed	O
NSAAs,	O
including	O
enzalutamide	B-Drug
apalutamide.	O
apalutamide	B-Drug

The	O
study	O
involved	O
108	O
intravenous	O
substance	O
abusers	O
and	O
88%	O
of	O
them	O
had	O
injected	O
methylphenidate	B-Drug
within	O
the	O
last	O
30	O
days	O
for	O
63%	O
them,	O
was	O
most	O
preferred	O
substance.	O

1-Phenylcyclohexylamine	O
or	O
any	O
compound	O
(not	O
being	O
ketamine,	O
tiletamine	B-Drug
a	O
for	O
the	O
time	O
specified	O
in	O
paragraph	O
1(a)	O
of	O
Part	O
1	O
this	O
Schedule)	O
structurally	O
derived	O
from	O
1-phenylcyclohexylamine	O
2-amino-2-phenylcyclohexanone	O
by	O
modification	O
following	O
ways,	O
that	O
is	O
to	O
say,	O
(i)	O
substitution	O
at	O
nitrogen	O
atom	O
extent	O
alkyl,	O
alkenyl	O
hydroxyalkyl	O
groups,	O
replacement	O
amino	O
group	O
with	O
1-piperidyl,	O
1-pyrrolidyl	O
1-azepyl	O
group,	O
whether	O
not	O
containing	O
ring	O
further	O
substituted	O
one	O
more	O
alkyl	O
groups;	O
ketamine	B-Drug

(7-HMG)	O
compose	O
significant	O
proportions	O
of	O
the	O
natural	O
products	O
isolable	O
from	O
M.	O
speciosa;	O
e.g.,	O
in	O
one	O
study,	O
mitragynine	B-Drug
was	O
12%	O
by	O
weight	O
Malaysian	O
leaf	O
sources,	O
versus	O
66%	O
Thai	O
and	O
7-hydroxymitragynine	O
constituted	O
~2%	O
weight.	O

signaling	O
mediated	O
resistance	O
Enzalutamide	B-Drug
is	O
reported	O
to	O
be	O
a	O
strong	O
inducer	O
of	O
the	O
enzyme	O
CYP3A4	O
and	O
moderate	O
CYP2C9	O
CYP2C19,	O
can	O
affect	O
circulating	O
concentrations	O
drugs	O
that	O
are	O
metabolized	O
by	O
these	O
enzymes.	O

After	O
being	O
taken	O
by	O
mouth,	O
paracetamol	B-Drug
is	O
rapidly	O
absorbed	O
the	O
gastrointestinal	O
(GI)	O
tract	O
(although	O
absorption	O
through	O
stomach	O
negligible);	O
its	O
volume	O
of	O
distribution	O
roughly	O
50	O
L.	O

Propylhexedrine	B-Drug
is	O
used	O
recreationally	O
in	O
a	O
manner	O
similar	O
to	O
amphetamine,	O
methamphetamine,	O
and	O
dextroamphetamine.	O
amphetamine	B-Drug
methamphetamine	B-Drug
dextroamphetamine	B-Drug

,	O
5F-APINACA,	O
EAM-2201,	O
JWH-018,	O
JWH-122,	O
MAM-2201,	O
5F-APINACA	B-Drug
EAM-2201	B-Drug
JWH-018	B-Drug
JWH-122	B-Drug
MAM-2201	B-Drug

Sofosbuvir	B-Drug
allows	O
most	O
people	O
to	O
be	O
treated	O
successfully	O
without	O
the	O
use	O
of	O
peginterferon,	O
an	O
injectable	O
drug	O
with	O
severe	O
side	O
effects	O
that	O
is	O
a	O
key	O
component	O
older	O
combinations	O
for	O
treatment	O
hepatitis	O
C	O
virus.	O

In	O
2016,	O
Australian	O
heavyweight	O
boxing	O
champion	O
Lucas	O
Browne	O
tested	O
positive	O
for	O
clenbuterol.	O
clenbuterol	B-Drug

Tapentadol	B-Drug
is	O
Pregnancy	O
Category	O
C.	O

After	O
receiving	O
a	O
bolus	O
dose	O
of	O
fentanyl,	O
people	O
can	O
also	O
experience	O
paradoxical	O
coughing,	O
which	O
is	O
phenomenon	O
that	O
not	O
well	O
understood.	O
fentanyl	B-Drug

In	O
surveys,	O
the	O
number	O
of	O
high	O
school	O
students	O
admitting	O
to	O
trying	O
PCP	B-Drug
at	O
least	O
once	O
fell	O
from	O
13%	O
in	O
1979	O
less	O
than	O
3%	O
1990.	O

Salvinorin	B-Drug
A	I-Drug
is	O
soluble	O
in	O
organic	O
solvents	O
such	O
as	O
ethanol	O
and	O
acetone,	O
but	O
not	O
especially	O
so	O
water.	O

In	O
addition	O
to	O
the	O
CSA,	O
due	O
pseudoephedrine	B-Drug
(PSE)	O
and	O
ephedrine	B-Drug
being	O
widely	O
used	O
in	O
manufacture	O
of	O
methamphetamine,	O
U.S.	O
Congress	O
passed	O
Methamphetamine	B-Drug
Precursor	O
Control	O
Act	O
which	O
places	O
restrictions	O
on	O
sale	O
any	O
medicine	O
containing	O
pseudoephedrine.	O
methamphetamine	B-Drug

"Paracetamol	O
is	O
metabolized	O
by	O
the	O
liver	O
and	O
hepatotoxic;	O
side	O
effects	O
are	O
multiplied	O
when	O
combined	O
with	O
alcoholic	O
drinks,	O
very	O
likely	O
in	O
chronic	O
alcoholics	O
or	O
people	O
damage.	O
Paracetamol	B-Drug

Flunitrazepam	B-Drug
has	O
been	O
referred	O
to	O
as	O
a	O
date	O
rape	O
drug,	O
though	O
the	O
percentage	O
of	O
reported	O
cases	O
in	O
which	O
it	O
is	O
involved	O
small.	O

One	O
potential	O
cause	O
of	O
death	O
from	O
GHB	B-Drug
consumption	O
is	O
polydrug	O
toxicity.	O

However,	O
when	O
used	O
in	O
combination	O
with	O
ribavirin	B-Drug
or	O
peginterferon	O
alfa/ribavirin,	O
others,	O
the	O
contraindications	O
applicable	O
to	O
these	O
agents	O
are	O
applied.	O

As	O
such,	O
fatalities	O
involving	O
mitragynine	B-Drug
tend	O
to	O
involve	O
additional	O
drugs	O
including	O
other	O
opioids	O
and	O
cough	O
suppressants.	O

Analogues	O
of	O
diphenhydramine	B-Drug
include	O
orphenadrine,	O
an	O
anticholinergic,	O
nefopam,	O
analgesic,	O
and	O
tofenacin,	O
antidepressant.	O
orphenadrine	B-Drug
nefopam	B-Drug

The	O
agonist	O
substitution	O
approach	O
is	O
one	O
that	O
draws	O
upon	O
the	O
analogy	O
of	O
success	O
nicotine	B-Drug
replacement	O
therapy	O
for	O
addiction.	O

Recreational	O
use	O
of	O
5-APB	B-Drug
has	O
been	O
associated	O
with	O
death	O
in	O
combination	O
other	O
drugs	O
and	O
solely	O
as	O
the	O
result	O
5-APB.	O

Aghajanian	O
and	O
Bing	O
(1964)	O
found	O
LSD	B-Drug
had	O
an	O
elimination	O
half-life	O
of	O
only	O
175	O
minutes	O
(about	O
3	O
hours).	O

After	O
using	O
mescaline	B-Drug
in	O
1953,	O
Aldous	O
Huxley	O
wrote	O
The	O
Doors	O
of	O
Perception	O
where	O
he	O
advanced	O
the	O
theory	O
that	O
psychedelic	O
compounds	O
could	O
produce	O
mystical	O
experiences	O
and	O
knowledge,	O
"what	O
visionary,	O
medium,	O
even	O
mystic	O
were	O
talking	O
about"	O
what	O
eastern	O
philosophy	O
described	O
with	O
terms	O
like	O
Satcitananda,	O
Godhead,	O
Suchness,	O
Void,	O
Not-self	O
Dharmakaya.	O

The	O
researchers	O
concluded	O
that	O
statutes	O
requiring	O
naloxone	B-Drug
prescriptions	O
for	O
individuals	O
at	O
risk	O
opioid	O
overdose	O
and	O
those	O
people	O
actually	O
receiving	O
resulted	O
in	O
...further	O
reduction	O
of	O
opioid-related	O
harm.	O

Dextropropoxyphene	B-Drug
was	O
successfully	O
tested	O
in	O
1954	O
as	O
part	O
of	O
US	O
Navy	O
and	O
CIA-funded	O
research	O
on	O
nonaddictive	O
substitutes	O
for	O
codeine.	O
codeine	B-Drug

items	O
can	O
be	O
infused	O
with	O
CBD	B-Drug
as	O
an	O
alternative	O
means	O
of	O
ingesting	O
the	O
substance.	O

JWH-081	B-Drug

in	O
a	O
pharmacokinetic	O
study	O
topiramate	B-Drug
only	O
increased	O
the	O
level	O
of	O
amitriptyline	B-Drug
by	O
20%	O
and	O
nortriptyline	B-Drug
33%.Amitriptiline	O
counteracts	O
antihypertensive	O
action	O
guanethidine.	O

Valproate	B-Drug
products	O
are	O
also	O
used	O
to	O
treat	O
manic	O
or	O
mixed	O
episodes	O
of	O
bipolar	O
disorder.	O

Nevertheless,	O
the	O
number	O
of	O
cocaine	B-Drug
users	O
remain	O
high,	O
with	O
a	O
large	O
concentration	O
among	O
urban	O
youth.	O

Lorazepam	B-Drug
is	O
used	O
in	O
the	O
short-term	O
management	O
of	O
severe	O
anxiety.	O

A	O
combination	O
of	O
20	O
g/day	O
EE	O
and	O
0.25	O
mg/day	O
levonorgestrel,	O
a	O
progestin	O
with	O
relatively	O
high	O
androgenicity,	O
decreases	O
SHBG	O
levels	O
by	O
50%;	O
30	O
levonorgestrel	B-Drug
has	O
no	O
effect	O
on	O
levels;	O
0.15	O
increases	O
30%;	O
triphasic	O
COCs	O
containing	O
increase	O
100	O
to	O
150%.	O

In	O
terms	O
of	O
purity	O
data	O
for	O
Australian	O
MDMA,	O
the	O
average	O
is	O
around	O
34%,	O
ranging	O
from	O
less	O
than	O
1%	O
to	O
about	O
85%.	O
MDMA	B-Drug

As	O
such,	O
5-reductase	O
inhibitors	O
like	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
do	O
not	O
reduce	O
the	O
androgenic	O
effects	O
of	O
metandienone.	O
metandienone	B-Drug

DOB,	O
DOI,	O
and	O
other	O
closely	O
related	O
drugs	O
are	O
sometimes	O
sold	O
as	O
LSD.	O
LSD	B-Drug

Propylhexedrine,	O
sold	O
under	O
the	O
brand	O
names	O
Benzedrex	B-Drug
and	O
Obesin	O
among	O
others,	O
is	O
a	O
nasal	O
decongestant,	O
appetite	O
suppressant,	O
psychostimulant	O
medication.	O
Propylhexedrine	B-Drug

esters	O
of	O
oxymorphone	B-Drug
were	O
developed	O
in	O
the	O
1930s	O
but	O
are	O
not	O
used	O
medicine	O
at	O
this	O
time.	O

BZP	B-Drug
has	O
been	O
shown	O
to	O
have	O
a	O
mixed	O
mechanism	O
of	O
action,	O
acting	O
on	O
the	O
serotonergic	O
and	O
dopaminergic	O
receptor	O
systems	O
in	O
similar	O
fashion	O
MDMA.	O
MDMA	B-Drug

As	O
a	O
cough	O
suppressant,	O
opium	B-Drug
was	O
used	O
to	O
treat	O
bronchitis,	O
tuberculosis,	O
and	O
other	O
respiratory	O
illnesses.	O

A	O
particularly	O
novel,	O
high-yielding	O
synthesis	O
of	O
etonitazene	B-Drug
was	O
developed	O
by	O
FI	O
Carroll	O
and	O
MC	O
Coleman	O
in	O
the	O
mid-1970s	O

Since	O
heroin	B-Drug
can	O
cause	O
nausea	O
and	O
vomiting,	O
a	O
significant	O
number	O
of	O
deaths	O
attributed	O
to	O
overdose	O
are	O
caused	O
by	O
aspiration	O
vomit	O
an	O
unconscious	O
person.	O

As	O
the	O
active	O
ingredient	O
of	O
hashish	B-Drug
is	O
THC,	O
it	O
has	O
same	O
effects	O
as	O
cannabis.	O
THC	B-Drug

It	O
is	O
also	O
available	O
in	O
generic	O
dexamfetamine	B-Drug
sulfate	O
5	O
mg/ml	O
oral	O
sugar-free	O
syrup.	O

heroin	B-Drug
American	O
Gangster	O
(2007)	O

Tramadol	B-Drug
may	O
interact	O
with	O
other	O
medications	O
and	O
increase	O
the	O
risk	O
for	O
adverse	O
events.	O

5-MeO-DMT	B-Drug
is	O
being	O
developed	O
and	O
evaluated	O
for	O
potential	O
therapeutic	O
effects	O
in	O
patients	O
suffering	O
from	O
Treatment-Resistant	O
Depression	O
(TRD).	O

The	O
warning	O
also	O
applied	O
to	O
hemp	O
CBD	B-Drug
capsules	O
and	O
oil	O
that	O
were	O
being	O
marketed	O
illegally	O
while	O
not	O
adhering	O
the	O
federal	O
definition	O
of	O
a	O
dietary	O
supplement.	O

PCP	B-Drug
is	O
self-administered	O
and	O
induces	O
FosB	O
expression	O
in	O
the	O
D1-type	O
medium	O
spiny	O
neurons	O
of	O
nucleus	O
accumbens,	O
accordingly,	O
excessive	O
use	O
known	O
to	O
cause	O
addiction.	O

Metoclopramide	B-Drug
is	O
contraindicated	O
in	O
pheochromocytoma.	O

Four	O
analogues	O
of	O
PMA	B-Drug
have	O
been	O
reported	O
to	O
be	O
sold	O
on	O
the	O
black	O
market,	O
including	O
PMMA,	O
PMEA,	O
4-ETA	B-Drug
and	O
4-MTA.	O
PMMA	B-Drug
4-MTA	B-Drug

Naltrexone	B-Drug
has	O
been	O
shown	O
to	O
decrease	O
the	O
amount	O
and	O
frequency	O
of	O
drinking.	O

In	O
Australia,	O
ketamine	B-Drug
is	O
listed	O
as	O
a	O
schedule	O
8	O
controlled	O
drug	O
under	O
the	O
Poisons	O
Standard	O
(October	O
2015).	O

Propiram	B-Drug
is	O
currently	O
a	O
Schedule	O
I/Narcotic	O
controlled	O
substance	O
in	O
the	O
United	O
States	O
with	O
an	O
ACSCN	O
of	O
9649	O
and	O
zero	O
annual	O
aggregate	O
manufacturing	O
quota	O
as	O
2014.	O

McKnight	O
stated	O
at	O
sentencing	O
that	O
when	O
he	O
first	O
met	O
Demetrius	O
Flenory,	O
did	O
not	O
show	O
him	O
"the	O
other	O
side	O
of	O
his	O
world",	O
in	O
reference	O
to	O
the	O
cocaine	B-Drug
trafficking.	O

Most	O
women	O
who	O
use	O
cocaine	B-Drug
while	O
pregnant	O
other	O
drugs	O
too;	O
one	O
study	O
found	O
that	O
93%	O
of	O
those	O
or	O
opiates	O
also	O
tobacco,	O
marijuana,	O
alcohol.	O
tobacco	B-Drug

Because	O
THC	B-Drug
production	O
drops	O
off	O
once	O
pollination	O
occurs,	O
the	O
male	O
plants	O
(which	O
produce	O
little	O
themselves)	O
are	O
eliminated	O
before	O
they	O
shed	O
pollen	O
to	O
prevent	O
pollination,	O
thus	O
inducing	O
development	O
of	O
parthenocarpic	O
fruits	O
gathered	O
in	O
dense	O
infructescences.	O

In	O
both	O
music	O
and	O
art,	O
the	O
influence	O
of	O
LSD	B-Drug
was	O
soon	O
being	O
more	O
widely	O
seen	O
heard	O
thanks	O
to	O
bands	O
that	O
participated	O
in	O
Acid	O
Tests	O
related	O
events,	O
including	O
Grateful	O
Dead,	O
Jefferson	O
Airplane	O
Big	O
Brother	O
Holding	O
Company,	O
through	O
inventive	O
poster	O
album	O
art	O
San	O
Francisco-based	O
artists	O
like	O
Rick	O
Griffin,	O
Victor	O
Moscoso,	O
Bonnie	O
MacLean,	O
Stanley	O
Mouse	O
&	O
Alton	O
Kelley,	O
Wes	O
Wilson,	O
meant	O
evoke	O
visual	O
experience	O
an	O
trip.	O

Apalutamide	B-Drug
shows	O
potent	O
induction	O
potential	O
of	O
cytochrome	O
P450	O
enzymes	O
similarly	O
to	O
enzalutamide.	O
enzalutamide	B-Drug

DOET	B-Drug
is	O
an	O
extremely	O
rare	O
compound	O
and	O
reports	O
of	O
its	O
effects	O
toxicology	O
in	O
humans	O
are	O
sparse.	O

Fluorophen,	O
or	O
fluorofen,	O
is	O
a	O
fluorinated	O
analogue	O
of	O
phenazocine,	O
an	O
opioid	O
drug	O
the	O
benzomorphan	O
group,	O
which	O
was	O
developed	O
as	O
radioligand	O
for	O
purpose	O
labeling	O
receptors	O
during	O
PET	O
scans	O
(with	O
18F).	O
phenazocine	B-Drug

Interdiction	O
efforts,	O
using	O
current	O
armed	O
forces	O
resources,	O
would	O
have	O
almost	O
no	O
effect	O
on	O
cocaine	B-Drug
importation	O
into	O
the	O
United	O
States,	O
report	O
concluded.	O

In	O
the	O
UK	O
to	O
avoid	O
being	O
controlled	O
by	O
Medicines	O
Act,	O
designer	O
drugs	O
such	O
as	O
mephedrone	B-Drug
have	O
been	O
described	O
"plant	O
food,"	O
despite	O
compounds	O
having	O
no	O
history	O
of	O
used	O
for	O
these	O
purposes.	O

The	O
combination	O
of	O
BZP	B-Drug
and	O
TFMPP	B-Drug
has	O
been	O
associated	O
with	O
a	O
range	O
side	O
effects,	O
including	O
insomnia,	O
anxiety,	O
nausea	O
vomiting,	O
headaches	O
muscle	O
aches	O
which	O
may	O
resemble	O
migraine,	O
seizures,	O
impotence,	O
rarely	O
psychosis,	O
as	O
well	O
prolonged	O
unpleasant	O
hangover	O
effect.	O

Hashish	B-Drug
5	O
grams	O
Magic	O
mushrooms	O
40	O
pieces	O

In	O
June	O
2013,	O
the	O
United	O
States	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC)	O
issued	O
a	O
health	O
advisory	O
to	O
emergency	O
departments	O
alerting	O
14	O
overdose	O
deaths	O
among	O
intravenous	O
drug	O
users	O
in	O
Rhode	O
Island	O
associated	O
with	O
acetylfentanyl,	O
synthetic	O
opioid	O
analog	O
of	O
fentanyl	B-Drug
that	O
has	O
never	O
been	O
licensed	O
medical	O
use.	O

In	O
addition,	O
it	O
tends	O
to	O
cause	O
less	O
vomiting	O
and	O
regurgitation	O
than	O
other	O
pure-opiate	O
(codeine,	O
morphine)	O
synthetic	O
pure-opioid	O
agonists	O
(oxycodone,	O
hydromorphone)	O
when	O
given	O
as	O
a	O
continuous	O
post-operative	O
infusion.	O
codeine	B-Drug
morphine	B-Drug
oxycodone	B-Drug
hydromorphone	B-Drug

Also,	O
coca	B-Drug
leaves	O
have	O
been	O
used	O
by	O
South	O
American	O
Indians	O
since	O
ancient	O
times.	O

The	O
recent	O
generation	O
of	O
rat,	O
zebrafish,	O
maize	O
and	O
tobacco	B-Drug
ZFN-mediated	O
mutants	O
the	O
improvements	O
in	O
TALEN-based	O
approaches	O
testify	O
to	O
significance	O
methods,	O
list	O
is	O
expanding	O
rapidly.	O

An	O
opioid-dependent	O
person	O
should	O
not	O
receive	O
naltrexone	B-Drug
before	O
detoxification.	O

Transdermal	O
fentanyl	B-Drug
has	O
also	O
been	O
used	O
for	O
many	O
years	O
in	O
dogs	O
and	O
cats	O
post-operative	O
analgesia.	O

The	O
1993	O
Domestic	O
Chemical	O
Diversion	O
and	O
Control	O
Act	O
(effective	O
on	O
April	O
16,	O
1994)	O
in	O
response	O
to	O
methamphetamine	B-Drug
trafficking.	O

The	O
average	O
THC	B-Drug
level	O
in	O
coffee	O
shops	O
the	O
Netherlands	O
is	O
about	O
1819%.The	O
levels	O
of	O
cannabis	O
sold	O
United	O
States	O
rose	O
dramatically	O
between	O
1970s	O
and	O
2000.	O

Norgestrel	B-Drug
is	O
sometimes	O
referred	O
to	O
as	O
a	O
"second-generation"	O
progestin.	O

THJ-2201	B-Drug
is	O
an	O
indazole-based	O
synthetic	O
cannabinoid	O
that	O
presumably	O
acts	O
as	O
a	O
potent	O
agonist	O
of	O
the	O
CB1	O
receptor	O
and	O
has	O
been	O
sold	O
online	O
designer	O
drug.	O

Colonic	O
hypomotility	O
has	O
been	O
shown	O
to	O
occur	O
in	O
up	O
80%	O
of	O
people	O
prescribed	O
clozapine	B-Drug
when	O
gastrointestinal	O
function	O
is	O
measured	O
objectively	O
using	O
radiopaque	O
markers.	O

On	O
December	O
13th	O
2019,	O
the	O
World	O
Health	O
Organization	O
recommended	O
Etizolam	B-Drug
be	O
placed	O
in	O
Schedule	O
4	O
of	O
1971	O
Convention	O
on	O
Psychotropic	O
Substances.	O

The	O
risk	O
of	O
toxicity	O
to	O
the	O
kidneys	O
increases	O
when	O
ketorolac	B-Drug
is	O
taken	O
with	O
cyclosporine.	O
cyclosporine	B-Drug

Since	O
the	O
final	O
active	O
metabolite	O
is	O
slightly	O
stronger	O
opiate	O
dihydromorphine	B-Drug
rather	O
than	O
morphine,	O
nicodicodine	B-Drug
can	O
be	O
expected	O
to	O
marginally	O
more	O
potent	O
and	O
longer	O
acting	O
nicocodeine.	O
morphine	B-Drug
nicocodeine	B-Drug

Among	O
young	O
adults,	O
1.8%	O
had	O
used	O
MDMA	B-Drug
in	O
the	O
last	O
year.	O

The	O
UK	O
Home	O
Office	O
accepted	O
the	O
recommendation	O
and	O
enacted	O
legislation	O
to	O
ban	O
UR-144	B-Drug
as	O
a	O
class	O
B	O
drug	O
along	O
with	O
number	O
of	O
other	O
drugs	O
on	O
February	O
26,	O
2013	O
part	O
Misuse	O
Drugs	O
Act	O
1971	O
(Amendment)	O
Order	O
2013.	O

Amphetamine	B-Drug
is	O
still	O
illegally	O
synthesized	O
today	O
in	O
clandestine	O
labs	O
and	O
sold	O
on	O
the	O
black	O
market,	O
primarily	O
European	O
countries.	O

The	O
word	O
"oxycodone"	O
should	O
not	O
be	O
confused	O
with	O
"oxandrolone",	O
"oxazepam",	O
"oxybutynin",	O
"oxytocin",	O
or	O
"Roxanol".	O
oxycodone	B-Drug
oxandrolone	B-Drug
oxazepam	B-Drug
oxybutynin	B-Drug
Roxanol	B-Drug

In	O
addition	O
to	O
their	O
medical	O
use,	O
metenolone	B-Drug
esters	O
are	O
used	O
improve	O
physique	O
and	O
performance.	O

Methadone	B-Drug
intermediate	I-Drug
is	O
also	O
controlled,	O
under	O
ACSCN	O
9226	O
Schedule	O
II,	O
with	O
a	O
quota	O
of	O
38,875	O
kilos.	O

Spironolactone	B-Drug
has	O
been	O
reported	O
to	O
produce	O
a	O
50	O
100%	O
improvement	O
in	O
acne	O
at	O
sufficiently	O
high	O
doses.	O

Whereas	O
the	O
surrealist	O
was	O
fascinated	O
by	O
Freud's	O
theory	O
of	O
unconscious,	O
psychedelic	O
artist	O
has	O
been	O
literally	O
"turned	O
on"	O
Albert	O
Hofmann's	O
discovery	O
LSD.	O
LSD	B-Drug

The	O
plasma	O
protein	O
binding	O
of	O
norethisterone	B-Drug
is	O
97%.	O

Prednisone	B-Drug
is	O
a	O
glucocorticoid	O
medication	O
mostly	O
used	O
to	O
suppress	O
the	O
immune	O
system	O
and	O
decrease	O
inflammation	O
in	O
conditions	O
such	O
as	O
asthma,	O
COPD,	O
rheumatologic	O
diseases.	O

Increased	O
alertness	O
Loss	O
of	O
any	O
sleepiness	O
stereoscopic	O
vision	O
Noscapine	B-Drug
can	O
increase	O
the	O
effects	O
centrally	O
sedating	O
substances	O
such	O
as	O
alcohol	O
and	O
hypnotics.	O

The	O
antiandrogen	O
rosterolone	O
(17-propylmesterolone)	O
is	O
also	O
closely	O
related	O
to	O
mesterolone.	O
mesterolone	B-Drug

Like	O
with	O
cytochrome	O
P450	O
inhibition,	O
gestodene	O
was	O
more	O
potent	O
in	O
this	O
action	O
compared	O
to	O
other	O
progestins,	O
including	O
desogestrel	B-Drug
and	O
levonorgestrel.	O
levonorgestrel	B-Drug

Intranasal	O
fentanyl	B-Drug
appears	O
to	O
be	O
as	O
equally	O
effective	O
IV	O
morphine	B-Drug
and	O
superior	O
intramuscular	O
for	O
management	O
of	O
acute	O
hospital	O
pain.	O

Fentanyl	B-Drug
was	O
first	O
synthesized	O
in	O
Belgium	O
by	O
Paul	O
Janssen	O
under	O
the	O
label	O
of	O
his	O
relatively	O
newly	O
formed	O
Pharmaceutica	O
1959.	O

As	O
such,	O
as	O
tramadol	B-Drug
is	O
related	O
to	O
venlafaxine,	O
the	O
same	O
conditions	O
apply.	O
venlafaxine	B-Drug

Crack	O
cocaine	B-Drug
is	O
popularly	O
thought	O
to	O
be	O
the	O
most	O
addictive	O
form	O
of	O
cocaine.	O

Per	O
one	O
study,	O
tamoxifen	B-Drug
had	O
7%	O
and	O
6%	O
of	O
the	O
affinity	O
estradiol	O
for	O
ER	O
ER,	O
respectively,	O
whereas	O
afimoxifene	O
178%	O
338%	O
respectively.	O

Foremost	O
amongst	O
these	O
are	O
nefopam,	O
orphenadrine,	O
and	O
perhaps	O
phenyltoloxamine	O
or	O
some	O
other	O
antihistamines.	O
nefopam	B-Drug
orphenadrine	B-Drug

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
"[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine".	O
promethazine	B-Drug

After	O
receiving	O
a	O
bolus	O
dose	O
of	O
fentanyl,	O
people	O
can	O
also	O
experience	O
paradoxical	O
coughing,	O
which	O
is	O
phenomenon	O
that	O
not	O
well	O
understood.	O
fentanyl	B-Drug

BU-LAD	B-Drug
is	O
a	O
psychedelic	O
drug	O
similar	O
to	O
LSD,	O
but	O
significantly	O
less	O
potent	O
than	O
with	O
dose	O
of	O
500	O
micrograms	O
producing	O
only	O
mild	O
effects.	O
LSD	B-Drug

In	O
the	O
United	O
States,	O
cannabidiol	B-Drug
drug	O
Epidiolex	B-Drug
was	O
approved	O
by	O
Food	O
and	O
Drug	O
Administration	O
in	O
2018	O
for	O
treatment	O
of	O
two	O
epilepsy	O
disorders.	O

Desogestrel	B-Drug
is	O
sometimes	O
referred	O
to	O
as	O
a	O
"third-generation"	O
progestin.	O

In	O
October	O
2018,	O
cannabidiol	B-Drug
became	O
legal	O
for	O
recreational	O
and	O
medical	O
use	O
by	O
the	O
federal	O
Cannabis	O
Act.	O

In	O
certain	O
countries,	O
triazolam,	O
flunitrazepam,	O
flutoprazepam	B-Drug
and	O
midazolam	B-Drug
are	O
also	O
restricted	O
or	O
controlled	O
to	O
degrees.	O
triazolam	B-Drug
flunitrazepam	B-Drug

Cocaine	B-Drug
use	O
also	O
promotes	O
the	O
formation	O
of	O
blood	O
clots.	O

As	O
of	O
2015	O
China	O
had	O
the	O
largest	O
methadone	B-Drug
maintenance	O
treatment	O
program	O
with	O
over	O
250,000	O
people	O
in	O
650	O
clinics	O
27	O
provinces.	O

The	O
penalty	O
for	O
trafficking	O
or	O
manufacturing	O
diamorphine	B-Drug
is	O
a	O
$5,000,000	O
(HKD)	O
fine	O
and	O
life	O
imprisonment.	O

For	O
example,	O
heroin	B-Drug
is	O
regulated	O
almost	O
everywhere;	O
substances	O
such	O
as	O
qat,	O
codeine	B-Drug
are	O
in	O
some	O
places,	O
but	O
not	O
others.	O

The	O
various	O
formulations	O
combined	O
with	O
codeine	B-Drug
are	O
FDA-approved	O
for	O
the	O
treatment	O
of	O
tension	O
headaches.	O

Chinese	O
triad	O
gangs	O
eventually	O
came	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
illicit	O
heroin	B-Drug
trade.	O

25C-NBOMe	B-Drug
has	O
been	O
found	O
on	O
blotter	O
mimics	O
sold	O
as	O
LSD.	O
LSD	B-Drug

PCP	B-Drug
comes	O
in	O
both	O
powder	O
and	O
liquid	O
forms	O
(PCP	O
base	O
is	O
dissolved	O
most	O
often	O
ether),	O
but	O
typically	O
it	O
sprayed	O
onto	O
leafy	O
material	O
such	O
as	O
cannabis,	O
mint,	O
oregano,	O
tobacco,	O
parsley,	O
or	O
ginger	O
leaves,	O
then	O
smoked.	O
tobacco	B-Drug

Some	O
studies	O
found	O
that,	O
like	O
other	O
NMDA	O
receptor	O
antagonists,	O
PCP	B-Drug
can	O
cause	O
a	O
kind	O
of	O
brain	O
damage	O
called	O
Olney's	O
lesions	O
in	O
rats.	O

Morphine's	O
solubility	O
in	O
water	O
is	O
around	O
10mgs/ml.	O
Morphine	B-Drug

Cannabis	O
produces	O
CBD-carboxylic	O
acid	O
through	O
the	O
same	O
metabolic	O
pathway	O
as	O
THC,	O
until	O
next	O
to	O
last	O
step,	O
where	O
CBDA	O
synthase	O
performs	O
catalysis	O
instead	O
of	O
THCA	O
synthase.	O
THC	B-Drug

Conversion	O
of	O
androstenedione	B-Drug
to	O
estrone	O
requires	O
the	O
enzyme	O
aromatase.	O

The	O
first	O
amphetamine	B-Drug
pharmaceutical	O
was	O
Benzedrine,	O
a	O
brand	O
which	O
used	O
to	O
treat	O
variety	O
of	O
conditions.	O

It	O
is	O
closely	O
related	O
to	O
natural	O
cannabinoids	O
of	O
the	O
tetrahydrocannabinol	B-Drug
(THC)	O
group,	O
differing	O
mainly	O
by	O
its	O
longer	O
and	O
branched	O
side	O
chain,	O
replacement	O
9-position	O
carbon	O
with	O
a	O
nitrogen.	O
THC	B-Drug

Common	O
side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself,	O
which	O
include	O
itching,	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression,	O
can	O
be	O
life-threatening.	O

In	O
his	O
ruling	O
the	O
trial	O
judge	O
wrote:	O
"Plaintiff's	O
evidence	O
shows	O
Purdue	O
could	O
have	O
tested	O
safety	O
and	O
efficacy	O
of	O
OxyContin	B-Drug
at	O
eight	O
hours,	O
amended	O
their	O
label,	O
but	O
did	O
not."	O

Illicit	O
use	O
of	O
pharmaceutical	O
fentanyl	B-Drug
and	O
its	O
analogues	O
first	O
appeared	O
in	O
the	O
mid-1970s	O
medical	O
community	O
continues	O
present.	O

It	O
is	O
in	O
the	O
oxicam	O
family	O
of	O
chemicals	O
and	O
closely	O
related	O
to	O
piroxicam.	O
piroxicam	B-Drug

In	O
a	O
randomized	O
controlled	O
trial	O
trace	O
contamination	O
of	O
androstenedione	B-Drug
with	O
bolandione	B-Drug
was	O
sufficient	O
for	O
users	O
to	O
test	O
positive	O
nandrolone.	O
nandrolone	B-Drug

If	O
high	O
boluses	O
of	O
fentanyl	B-Drug
are	O
administered	O
quickly,	O
muscle	O
rigidity	O
the	O
vocal	O
cords	O
can	O
make	O
bag-mask	O
ventilation	O
very	O
difficult.	O

5.8	O
million	O
thalidomide	B-Drug
pills	O
were	O
distributed	O
throughout	O
Brazil	O
in	O
this	O
time	O
period,	O
largely	O
to	O
poor	O
Brazilians	O
areas	O
with	O
access	O
healthcare,	O
and	O
these	O
cases	O
have	O
occurred	O
despite	O
the	O
controls.	O

Ziegler's	O
work	O
resulted	O
in	O
the	O
production	O
of	O
methandrostenolone,	O
which	O
Ciba	O
Pharmaceuticals	O
marketed	O
as	O
Dianabol.	O
methandrostenolone	B-Drug
Dianabol	B-Drug

Toward	O
the	O
middle	O
20th	O
century,	O
use	O
of	O
opiates	O
was	O
generally	O
limited	O
to	O
treatment	O
pain,	O
and	O
opium	B-Drug
no	O
longer	O
a	O
medically	O
accepted	O
"cure-all".	O

In	O
response,	O
New	O
Zealand	O
experts	O
called	O
for	O
wider	O
availability	O
of	O
naloxone.	O
naloxone	B-Drug

Naltrexone	B-Drug
by	O
mouth	O
remains	O
an	O
ideal	O
treatment	O
for	O
a	O
small	O
number	O
of	O
people	O
with	O
opioid	O
use,	O
usually	O
those	O
stable	O
social	O
situation	O
and	O
motivation.	O

Like	O
lidocaine,	O
bupivacaine	B-Drug
is	O
an	O
amino-amide	O
anesthetic;	O
the	O
aromatic	O
head	O
and	O
hydrocarbon	O
chain	O
are	O
linked	O
by	O
amide	O
bond	O
rather	O
than	O
ester	O
as	O
in	O
earlier	O
local	O
anesthetics.	O
lidocaine	B-Drug
anesthetic	B-Drug

"Pulmonary	O
hypertension	O
has	O
been	O
associated	O
with	O
ingestion	O
of	O
the	O
appetite	O
suppressant	O
aminorex.	O
aminorex	B-Drug

The	O
remains	O
of	O
coca	B-Drug
leaves	O
have	O
been	O
found	O
with	O
ancient	O
Peruvian	O
mummies,	O
and	O
pottery	O
from	O
the	O
time	O
period	O
depicts	O
humans	O
bulged	O
cheeks,	O
indicating	O
presence	O
something	O
on	O
which	O
they	O
are	O
chewing.	O

carbon-14	O
(codeine	O
has	O
just	O
a	O
hydrogen	O
in	O
its	O
place)	O
codeine	B-Drug

Per	O
the	O
1972	O
Physicians'	O
Desk	O
Reference,	O
Obetrol	B-Drug
contained	O
(per	O
10	O
mg	O
tablet):	O
2.5	O
methamphetamine	B-Drug
saccharate	O

Like	O
all	O
opioids,	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone,	O
or	O
other	O
opiate	O
antagonists.	O
naloxone	B-Drug

The	O
known	O
active	O
constituent	O
of	O
Salvia	O
divinorum	O
is	O
a	O
trans-neoclerodane	O
diterpenoid	O
as	O
salvinorin	B-Drug
A	I-Drug
(chemical	O
formula	O
C23H28O8).	O

In	O
tests	O
on	O
mice	O
it	O
was	O
found	O
to	O
be	O
an	O
active	O
psychedelic,	O
though	O
with	O
only	O
around	O
1/7th	O
the	O
potency	O
of	O
LSD	B-Drug
itself.	O

the	O
conversion	O
of	O
pregnenolone	O
and	O
progesterone	O
to	O
their	O
17-hydroxy	O
derivatives	O
by	O
its	O
17-hydroxylase	O
activity,	O
(b)	O
subsequent	O
formation	O
dehydroepiandrosterone	O
(DHEA)	O
androstenedione,	O
respectively,	O
17,20-lyase	O
activity.	O
androstenedione	B-Drug

Around	O
10%	O
(range	O
814%)	O
of	O
a	O
dose	O
oxycodone	B-Drug
is	O
excreted	O
essentially	O
unchanged	O
(unconjugated	O
or	O
conjugated)	O
in	O
the	O
urine.	O

The	O
free	O
and	O
legal	O
commercialization	O
of	O
dried	O
coca	B-Drug
leaves	O
under	O
the	O
form	O
filtration	O
bags	O
to	O
be	O
used	O
as	O
"coca	O
tea"	O
has	O
been	O
actively	O
promoted	O
by	O
governments	O
Peru	O
Bolivia	O
for	O
many	O
years	O
a	O
drink	O
having	O
medicinal	O
powers.	O

Its	O
texture	O
will	O
also	O
depend	O
on	O
the	O
adulterants,	O
origin	O
and	O
processing	O
of	O
powdered	O
cocaine,	O
method	O
converting	O
base.	O
cocaine	B-Drug

Although	O
desogestrel	B-Drug
was	O
introduced	O
in	O
1981	O
and	O
widely	O
used	O
Europe	O
from	O
this	O
time,	O
it	O
not	O
the	O
United	O
States	O
until	O
1992.	O

Like	O
all	O
opioids,	O
the	O
effects	O
of	O
fentanyl	B-Drug
can	O
be	O
reversed	O
with	O
naloxone,	O
or	O
other	O
opiate	O
antagonists.	O
naloxone	B-Drug

Xyrem	B-Drug
is	O
in	O
Schedule	O
III	O
but	O
with	O
a	O
restricted	O
distribution	O
system.	O

Virtually	O
all	O
commercially	O
available	O
baby	O
formulas	O
contain	O
added	O
vitamin	B-Drug
C,	O
preventing	O
infantile	O
scurvy.	O
C	I-Drug

Fentanyl,	O
like	O
other	O
opioids,	O
acts	O
on	O
opioid	O
receptors.	O
Fentanyl	B-Drug

The	O
strong	O
androgenic	O
nature	O
of	O
trenbolone	B-Drug
acetate	O
facilitates	O
its	O
tendency	O
to	O
produce	O
virilization	O
and	O
this	O
is	O
why	O
it	O
not	O
recommended	O
for	O
women	O
physique-	O
or	O
performance-enhancing	O
purposes.	O

Naloxone	B-Drug
kits	O
are	O
recommended	O
for	O
laypersons	O
who	O
may	O
witness	O
an	O
opioid	O
overdose,	O
individuals	O
with	O
large	O
prescriptions	O
opioids,	O
those	O
in	O
substance	O
use	O
treatment	O
programs,	O
or	O
have	O
been	O
recently	O
released	O
from	O
incarceration.	O

Tamoxifen	B-Drug
binds	O
to	O
ER,	O
the	O
ER/tamoxifen	O
complex	O
recruits	O
other	O
proteins	O
known	O
as	O
co-repressors,	O
and	O
then	O
DNA	O
modulate	O
gene	O
expression.	O
tamoxifen	B-Drug

Over-the-counter	O
use	O
of	O
substituted	O
amphetamines	O
was	O
initiated	O
in	O
the	O
early	O
1930s	O
by	O
pharmaceutical	O
company	O
Smith,	O
Kline	O
&	O
French	O
(now	O
part	O
GlaxoSmithKline),	O
as	O
a	O
medicine	O
(Benzedrine)	O
for	O
colds	O
and	O
nasal	O
congestion.	O
Benzedrine	B-Drug

Fentanyl	B-Drug
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family,	O
which	O
includes	O
sufentanil,	O
alfentanil,	O
remifentanil,	O
and	O
carfentanil.	O
sufentanil	B-Drug
alfentanil	B-Drug
remifentanil	B-Drug
carfentanil	B-Drug

The	O
distribution	O
half-life	O
of	O
diazepam	B-Drug
is	O
two	O
to	O
13	O
minutes.	O

Patients	O
taking	O
the	O
SSRIs;	O
Celexa	B-Drug
(citalopram),	O
Lexapro	B-Drug
(escitalopram),	O
and	O
Luvox	B-Drug
(fluvoxamine),	O
did	O
not	O
have	O
an	O
increased	O
risk	O
of	O
recurrence,	O
due	O
to	O
their	O
lack	O
competitive	O
metabolism	O
for	O
CYP2D6	O
enzyme.	O
citalopram	B-Drug
escitalopram	B-Drug
fluvoxamine	B-Drug

Phentermine	B-Drug
is	O
a	O
substituted	O
amphetamine	B-Drug
which	O
has	O
methyl	O
group	O
on	O
amphetamine's	O
alpha	O
carbon.	O

Most	O
modern	O
formulations	O
of	O
opium	B-Drug
tincture	O
do	O
not	O
contain	O
the	O
alkaloid	O
narcotine	B-Drug
(also	O
known	O
as	O
noscapine),	O
which	O
has	O
antitussive	O
properties.	O
noscapine	B-Drug

However,	O
the	O
affinity	O
of	O
cimetidine	B-Drug
for	O
AR	O
is	O
very	O
weak;	O
in	O
one	O
study,	O
it	O
showed	O
only	O
0.00084%	O
anabolic	O
steroid	O
metribolone	O
(100%)	O
human	O
(Ki	O
=	O
140	O
M	O
and	O
1.18	O
nM,	O
respectively).	O

crystal	B-Drug
meth	I-Drug
(methamphetamine)	O
City	O
by	O
the	O
Sea	O
(2002)	O
crack	O
Of	O
God	O
methamphetamine	B-Drug

Heavy	O
drinking,	O
tobacco	B-Drug
use,	O
and	O
use	O
of	O
illegal	O
drugs	O
are	O
common	O
in	O
the	O
US	O
military.	O

As	O
of	O
2014	O
there	O
was	O
no	O
good	O
evidence	O
for	O
a	O
difference	O
between	O
trifluoperazine	B-Drug
and	O
placebo	O
with	O
respect	O
to	O
the	O
risk	O
experiencing	O
intensified	O
symptoms	O
over	O
16-week	O
period	O
nor	O
in	O
reducing	O
significant	O
agitation	O
or	O
distress.	O

For	O
children,	O
PEG	B-Drug
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
lactulose.	O
lactulose	B-Drug

Mimosa	O
verrucosa,	O
DMT	O
in	O
root	O
bark	O
Mucuna	O
pruriens,	O
"The	O
leaves,	O
seeds,	O
stems	O
and	O
roots	O
contain	O
L-Dopa,	O
Serotonin,	O
5-HTP,	O
Nicotine,	O
as	O
well	O
N,N-DMT,	O
Bufotenine,	O
5-MeO-DMT.	O
L-Dopa	B-Drug
Nicotine	B-Drug
N,N-DMT	B-Drug
Bufotenine	B-Drug
5-MeO-DMT	B-Drug

Unlike	O
other	O
synthetic	O
opioids	O
which	O
are	O
hepatically	O
metabolized,	O
remifentanil	B-Drug
has	O
an	O
ester	O
linkage	O
undergoes	O
rapid	O
hydrolysis	O
by	O
non-specific	O
tissue	O
and	O
plasma	O
esterases.	O

Fentanyl	B-Drug
patches	O
for	O
cancer	O
pain	O
are	O
on	O
the	O
World	O
Health	O
Organization's	O
List	O
of	O
Essential	O
Medicines.	O

Estazolam	B-Drug
exerts	O
its	O
therapeutic	O
effects	O
via	O
benzodiazepines	O
receptor	O
agonist	O
properties.	O

Cocaine	B-Drug
also	O
causes	O
vasoconstriction,	O
thus	O
reducing	O
bleeding	O
during	O
minor	O
surgical	O
procedures.	O

Salvinorin	B-Drug
A	I-Drug
is	O
active	O
at	O
doses	O
as	O
low	O
200	O
g.	O
Synthetic	O
chemicals,	O
such	O
LSD	B-Drug
(active	O
2030	O
g	O
doses),	O
can	O
be	O
more	O
potent.	O

An	O
analysis	O
of	O
samples	O
acquired	O
four	O
weeks	O
after	O
the	O
German	O
prohibition	O
JWH-018	B-Drug
took	O
place	O
found	O
that	O
manufacturers	O
had	O
shortened	O
alkyl	O
chain	O
by	O
one	O
carbon	O
to	O
circumvent	O
ban.	O

Bacampicillin	O
Metampicillin	O
(formaldehyde	O
ester	O
of	O
ampicillin)	O
ampicillin	B-Drug

Brands	O
as	O
of	O
that	O
date	O
for	O
the	O
combination	O
with	O
medazepam	B-Drug
included	O
Nobritol.	O

The	O
birth	O
defects	O
caused	O
by	O
thalidomide	B-Drug
led	O
to	O
the	O
development	O
of	O
greater	O
drug	O
regulation	O
and	O
monitoring	O
in	O
many	O
countries.	O

The	O
subject	O
of	O
the	O
work	O
is	O
psychoactive	O
phenethylamine	B-Drug
chemical	O
derivatives,	O
notably	O
those	O
that	O
act	O
as	O
psychedelics	O
and/or	O
empathogen-entactogens.	O

The	O
use	O
of	O
"marihuana"	O
in	O
American	O
English	O
increased	O
dramatically	O
the	O
1930s,	O
when	O
it	O
was	O
preferred	O
as	O
an	O
exotic-sounding	O
alternative	O
name	O
during	O
debates	O
on	O
drug's	O
use.	O
marihuana	B-Drug

Used	O
for	O
the	O
treatment	O
of	O
addiction	O
in	O
limited	O
countries,	O
ibogaine	B-Drug
has	O
become	O
an	O
icon	O
management	O
among	O
certain	O
underground	O
circles.	O

Gabapentin	B-Drug
decreases	O
the	O
frequency	O
of	O
hot	O
flashes	O
in	O
both	O
menopausal	O
women	O
and	O
patients	O
with	O
breast	O
cancer.	O

heroin,	O
references	O
to	O
morphine,	O
biphetamine,	O
methamphetamine	B-Drug
and	O
cocaine	B-Drug
Another	O
Happy	O
Day	O
(2011)	O
fentanyl	B-Drug
heroin	B-Drug
morphine	B-Drug

This	O
research	O
was	O
fueled	O
by	O
revenues	O
from	O
the	O
sale	O
of	O
morphine,	O
an	O
alkaloid	O
found	O
in	O
opium,	O
first	O
identified	O
a	O
German	O
chemist	O
early	O
19th	O
century	O
and	O
patented	O
Merck	O
soon	O
afterward.	O
morphine	B-Drug
opium	B-Drug

The	O
endogenous	O
opioid	O
system	O
may	O
play	O
a	O
role	O
in	O
some	O
of	O
the	O
pharmacological	O
properties	O
nitrazepam	B-Drug
rats.	O

Hash	B-Drug
oil	I-Drug
is	O
a	O
resinous	O
matrix	O
of	O
cannabinoids	O
obtained	O
from	O
the	O
Cannabis	O
plant	O
by	O
solvent	O
extraction,	O
formed	O
into	O
hardened	O
or	O
viscous	O
mass.	O

The	O
program	O
relied	O
on	O
the	O
turning	O
of	O
public	O
sentiment	O
against	O
opium,	O
with	O
mass	O
meetings	O
at	O
which	O
opium	B-Drug
paraphernalia	O
were	O
publicly	O
burned,	O
as	O
well	O
coercive	O
legal	O
action	O
and	O
granting	O
police	O
powers	O
to	O
organizations	O
such	O
Fujian	O
Anti-Opium	O
Society.	O

On	O
March	O
27,	O
1965,	O
Beatles	O
members	O
John	O
Lennon	O
and	O
George	O
Harrison	O
(and	O
their	O
wives)	O
were	O
dosed	O
with	O
LSD	B-Drug
without	O
permission	O
by	O
dentist,	O
Dr.	O
Riley.	O

The	O
5-HT2	O
receptor	O
(particularly	O
the	O
subtypes	O
5-HT2A,	O
5-HT2B	O
and	O
5-HT2C)	O
are	O
involved	O
in	O
locomotor-activating	O
effects	O
of	O
cocaine.	O
cocaine	B-Drug

Sofosbuvir	B-Drug
may	O
reactivate	O
hepatitis	O
B	O
in	O
those	O
who	O
have	O
been	O
previously	O
infected.	O

PCP	B-Drug
hydrochloride	O
can	O
be	O
insufflated	O
(snorted),	O
depending	O
upon	O
the	O
purity.	O

LEAP	O
supports	O
harm	O
reduction	O
programs,	O
which	O
reduce	O
the	O
negative	O
personal	O
and	O
societal	O
consequences	O
of	O
drug	O
use,	O
including	O
Supervised	O
Injection	O
Facilities,	O
Law	O
Enforcement	O
Assisted	O
Diversion	O
(LEAD),	O
heroin-assisted	O
treatment,	O
Medication	O
Treatment,	O
syringe	O
exchange	O
expanded	O
naloxone	B-Drug
access,	O
treatment	O
on	O
demand.	O

The	O
bioavailability	O
of	O
spironolactone	B-Drug
when	O
taken	O
by	O
mouth	O
is	O
60	O
to	O
90%.	O

Eight	O
Janssen	O
drugs	O
have	O
been	O
included	O
on	O
the	O
WHO	O
Model	O
List	O
of	O
Essential	O
Medicines:	O
Imodium	B-Drug
(loperamide)	O
Haldol	B-Drug
(haloperidol)	O
loperamide	B-Drug
haloperidol	B-Drug

Mirtazapine	B-Drug
Examples	O
of	O
antipsychotics	O
with	O
sedation	O
as	O
a	O
side	O
effect:	O
First-generationChlorpromazineSecond-generationClozapine	O

Depo-Provera	B-Drug
is	O
the	O
brand	O
name	O
for	O
a	O
150	O
mg	O
microcrystalline	O
aqueous	O
suspension	O
of	O
DMPA	O
that	O
administered	O
by	O
intramuscular	O
injection.	O

Also,	O
opium	B-Drug
trade	O
proved	O
to	O
be	O
more	O
cost-efficient	O
than	O
livestock	O
trade,	O
since	O
large	O
amounts	O
of	O
are	O
easier	O
transport	O
livestock.	O

Imipramine	B-Drug
pamoate	O
is	O
marketed	O
under	O
the	O
brand	O
name	O
Tofranil-PM	O
for	O
intramuscular	O
injection.	O

In	O
one	O
study	O
of	O
long-term	O
efficacy,	O
nortriptyline	B-Drug
showed	O
a	O
higher	O
relapse	O
rate	O
in	O
comparison	O
with	O
phenelzine	B-Drug
individuals	O
being	O
treated	O
for	O
depression,	O
possibly	O
due	O
to	O
the	O
toxic	O
metabolite	O
10-hydroxynortriptyline	O
produced.	O

German	O
researchers	O
F.	O
Franzen	O
and	O
H.	O
Gross	O
report	O
to	O
have	O
evidenced	O
quantified	O
DMT,	O
along	O
with	O
its	O
structural	O
analog	O
bufotenin	B-Drug
(5-HO-DMT),	O
in	O
human	O
blood	O
urine.	O

Many	O
sympathetic	O
hormones	O
and	O
neurotransmitters	O
are	O
based	O
on	O
the	O
phenethylamine	B-Drug
skeleton,	O
function	O
generally	O
in	O
"fight	O
or	O
flight"	O
type	O
responses,	O
such	O
as	O
increasing	O
heart	O
rate,	O
blood	O
pressure,	O
dilating	O
pupils,	O
increased	O
energy,	O
drying	O
of	O
mucous	O
membranes,	O
sweating,	O
a	O
significant	O
number	O
additional	O
effects.	O

In	O
a	O
study	O
of	O
10	O
healthy	O
volunteers	O
taking	O
orally	O
administered	O
mitragynine	B-Drug
from	O
whole	O
leaf	O
preparations,	O
appeared	O
to	O
have	O
much	O
longer	O
half-life	O
than	O
typical	O
opioid	O
agonists	O
(739	O
hours)	O
and	O
reached	O
peak	O
plasma	O
concentration	O
within	O
1	O
hour	O
administration.	O

In	O
the	O
final	O
step	O
C9	O
hydroxyl	O
group	O
was	O
introduced	O
by	O
oxidation	O
with	O
sodium	O
hydride,	O
dimethylsulfoxide	O
and	O
oxygen	O
quinine	B-Drug
to	O
epiquinine	O
ratio	O
of	O
14:1.	O

According	O
to	O
David	O
Nutt,	O
MDMA	B-Drug
was	O
widely	O
used	O
in	O
the	O
western	O
US	O
couples	O
counseling,	O
and	O
called	O
empathy.	O

Examples	O
of	O
inducers	O
include	O
anticonvulsants	O
like	O
phenytoin,	O
primidone,	O
ethosuximide,	O
phenobarbital,	O
and	O
carbamazepine;	O
azole	O
antifungals	O
fluconazole;	O
rifamycin	B-Drug
antibiotics	O
rifampin	B-Drug
(rifampicin).	O
phenytoin	B-Drug
primidone	B-Drug
ethosuximide	B-Drug
phenobarbital	B-Drug
carbamazepine	B-Drug
fluconazole	B-Drug
rifampicin	B-Drug

Naloxone	B-Drug
can	O
completely	O
or	O
partially	O
reverse	O
an	O
opioid	O
overdose.	O

Their	O
results	O
indicate	O
significantly	O
higher	O
levels	O
of	O
bufotenin	B-Drug
in	O
the	O
urine	O
ASD	O
and	O
schizophrenic	O
groups	O
when	O
compared	O
to	O
asymptomatic	O
individuals.	O

The	O
experiments	O
suggested	O
a	O
relation	O
to	O
dopamine	O
D1	O
receptors,	O
and	O
also	O
opioid	O
receptors	O
in	O
the	O
reinforcement	O
produced	O
by	O
fencamfamin,	O
as	O
place	O
preference	O
was	O
blocked	O
selective	O
antagonist	O
SCH	O
23390	O
naloxone.	O
fencamfamin	B-Drug
naloxone	B-Drug

It	O
is	O
the	O
C17	O
undecylenate	O
(undecenoate)	O
ester	O
of	O
boldenone	B-Drug
(1-testosterone,	O
1-dehydrotestosterone,	O
or	O
androsta-1,4-dien-17-ol-3-one),	O
which	O
itself	O
C1(2)	O
dehydrogenated	O
analogue	O
testosterone	O
and	O
a	O
naturally	O
occurring	O
androgen	O
found	O
in	O
scent	O
gland	O
Ilybius	O
fenestratus	O
(a	O
species	O
aquatic	O
beetle).	O
1-testosterone	B-Drug

Unlike	O
phenmetrazine,	O
ethcathinone	B-Drug
(and	O
therefore	O
amfepramone	B-Drug
as	O
well)	O
are	O
mostly	O
selective	O
noradrenaline	O
releasing	O
agents.	O
phenmetrazine	B-Drug

However,	O
there	O
have	O
been	O
multiple	O
studies	O
verifying	O
the	O
ability	O
of	O
methadone	B-Drug
maintenance	O
patients	O
to	O
drive.	O

For	O
example,	O
a	O
2017	O
analysis	O
of	O
cannabidiol	B-Drug
content	O
in	O
oil,	O
tincture,	O
or	O
liquid	O
vape	O
products	O
purchased	O
online	O
the	O
United	O
States	O

Alternatively,	O
coca	B-Drug
leaves	O
can	O
be	O
infused	O
in	O
liquid	O
and	O
consumed	O
like	O
tea.	O

There	O
have	O
been	O
no	O
reports	O
of	O
adverse	O
or	O
toxic	O
effects	O
MBDB	B-Drug
in	O
humans.	O

Amides	O
of	O
lysergic	O
acid	B-Drug
are	O
collectively	O
known	O
as	O
lysergamides,	O
and	O
include	O
a	O
number	O
compounds	O
with	O
potent	O
agonist	O
and/or	O
antagonist	O
activity	O
at	O
various	O
serotonin	O
dopamine	O
receptors.	O

The	O
other	O
group	O
comprises	O
those	O
that	O
are	O
metabolized	O
through	O
glucuronidation,	O
such	O
as	O
lorazepam,	O
oxazepam,	O
and	O
temazepam,	O
and,	O
in	O
general,	O
have	O
few	O
drug	O
interactions.	O
lorazepam	B-Drug
oxazepam	B-Drug
temazepam	B-Drug

Pseudomorphine	O
(also	O
known	O
as	O
oxydimorphine	O
or	O
dehydromorphine)	O
is	O
an	O
inactive,	O
natural	O
dimerisation	O
product	O
of	O
the	O
morphine	B-Drug
molecule	O
in	O
tandem	O
and	O
thus	O
a	O
common	O
impurity	O
concentrations.	O

These	O
included	O
dismantling	O
the	O
Medelln	O
and	O
Cali	O
drug	O
cartels,	O
interdicting	O
coca	B-Drug
coming	O
into	O
Colombian	O
processing	O
facilities,	O
using	O
certification	O
requirements	O
to	O
pressure	O
government	O
attack	O
cartels	O
allow	O
aerial	O
fumigation	O
of	O
crops.	O

Trileptal	B-Drug
(oxcarbazepine)	O
an	O
anticonvulsant	O
used	O
as	O
a	O
mood	O
stabilizer.	O
oxcarbazepine	B-Drug

A	O
similar	O
place	O
preference,	O
which	O
was	O
blocked	O
by	O
naloxone	B-Drug
and	O
SCH	O
23390	O
raclopride,	O
has	O
been	O
seen	O
in	O
a	O
study	O
on	O
rats	O
with	O
drinking	O
water.	O

"	O
Following	O
use	O
by	O
34,000	O
women	O
in	O
France	O
from	O
April	O
1988	O
to	O
February	O
1990	O
of	O
mifepristone	B-Drug
distributed	O
free	O
charge,	O
Roussel-Uclaf	O
began	O
selling	O
Mifegyne	O
(mifepristone)	O
hospitals	O
at	O
a	O
price	O
(negotiated	O
with	O
the	O
French	O
government)	O
US$48	O
(equivalent	O
$93.93	O
2019)	O
per	O
600-mg	O
dose.	O

The	O
best	O
studied	O
cannabinoids	O
include	O
tetrahydrocannabinol	B-Drug
(THC),	O
cannabidiol	B-Drug
(CBD)	O
and	O
cannabinol	B-Drug
(CBN).	O
THC	B-Drug
CBD	B-Drug
CBN	B-Drug

While	O
the	O
FDA	O
approved	O
use	O
of	O
generic	O
levothyroxine	B-Drug
for	O
brand-name	O
in	O
2004,	O
decision	O
was	O
met	O
with	O
disagreement	O
by	O
several	O
medical	O
associations.	O

In	O
Hong	O
Kong,	O
diamorphine	B-Drug
is	O
regulated	O
under	O
Schedule	O
1	O
of	O
Kong's	O
Chapter	O
134	O
Dangerous	O
Drugs	O
Ordinance.	O

4-HO-MiPT	B-Drug
was	O
presumably	O
first	O
synthesized	O
by	O
Alexander	O
Shulgin.	O

"	O
In	O
this	O
context,	O
octreotide	B-Drug
suppresses	O
the	O
excessive	O
release	O
of	O
insulin	O
and	O
may	O
increase	O
its	O
action,	O
thereby	O
inhibiting	O
adipose	O
storage.	O

Ketamine	B-Drug
is	O
a	O
chiral	O
compound.	O

Studies	O
have	O
subsequently	O
distinguished	O
between	O
enkephalins,	O
endorphins,	O
and	O
endogenously-produced	O
morphine,	O
which	O
is	O
not	O
a	O
peptide.	O
morphine	B-Drug

Flumazenil	B-Drug
was	O
also	O
shown	O
to	O
produce	O
significantly	O
fewer	O
withdrawal	O
symptoms	O
than	O
saline	O
in	O
a	O
randomized,	O
placebo-controlled	O
study	O
with	O
benzodiazepine-dependent	O
subjects.	O

Data	O
presented	O
by	O
the	O
Prescription	O
Drug	O
Abuse	O
Policy	O
System	O
indicates	O
that,	O
in	O
49	O
states	O
(every	O
state	O
except	O
Nebraska),	O
pharmacists	O
are	O
allowed	O
to	O
dispense	O
naloxone	B-Drug
without	O
a	O
"patient-specific	O
prescription	O
from	O
another	O
medical	O
professional.	O

Ibuprofen	B-Drug
was	O
discovered	O
in	O
1961	O
by	O
Stewart	O
Adams	O
at	O
Boots	O
UK	O
Limited	O
and	O
initially	O
marketed	O
as	O
Brufen.	O

These	O
findings	O
suggest	O
little	O
to	O
no	O
risk	O
of	O
androgenic	O
side	O
effects	O
with	O
norethisterone	B-Drug
at	O
a	O
dosage	O
5	O
mg/day.	O

It	O
has	O
a	O
pharmacology	O
similar	O
to	O
THC,	O
although	O
its	O
structure	O
is	O
quite	O
different.	O
THC	B-Drug

On	O
more	O
degradation	O
CBN	B-Drug
is	O
formed.	O

A	O
similar	O
and	O
connected	O
nexus	O
of	O
LSD	B-Drug
use	O
in	O
the	O
creative	O
arts	O
developed	O
around	O
same	O
time	O
London.	O

In	O
2019,	O
there	O
was	O
a	O
case	O
of	O
desomorphine	B-Drug
abuse	O
in	O
the	O
UK	O
with	O
41-year-old	O
shoplifter	O
and	O
drug	O
addict	O
becoming	O
victim	O
to	O
severe	O
skin	O
damage	O
as	O
result	O
abusing	O
drug.	O

The	O
metabolite	O
was	O
identified	O
after	O
10	O
days	O
and	O
the	O
AMB-FUBINACA	B-Drug
only	O
confirmed	O
17	O
incident.	O

Like	O
other	O
AAS,	O
mesterolone	B-Drug
is	O
an	O
agonist	O
of	O
the	O
androgen	O
receptor	O
(AR).	O

This	O
is	O
particularly	O
dangerous,	O
as	O
DOC	O
not	O
known	O
to	O
have	O
the	O
safety	O
profile	O
of	O
LSD.	O
LSD	B-Drug

THC	B-Drug
was	O
first	O
discovered	O
and	O
isolated	O
by	O
Bulgarian-born	O
chemist	O
Raphael	O
Mechoulam	O
in	O
Israel	O
1964.	O

Imipramine	B-Drug
is	O
marketed	O
throughout	O
the	O
world	O
mainly	O
under	O
brand	O
name	O
Tofranil.	O
Tofranil	B-Drug

It	O
is	O
a	O
full	O
agonist	O
with	O
around	O
the	O
same	O
potency	O
as	O
CP	B-Drug
55,940	I-Drug
in	O
animal	O
studies,	O
and	O
has	O
fairly	O
high	O
affinity	O
for	O
both	O
CB1	O
CB2	O
receptors,	O
Ki	O
values	O
of	O
2.91nM	O
at	O
4.24nM	O
CB2.	O

Testosterone	B-Drug
propionate	I-Drug
(Testoviron,	O
numerous	O
others)	O
(component	O
of	O
Omnadren,	O
Sustanon	O
100,	O
250,	O
and	O
Testoviron	B-Drug
Depot)	O
Depot	I-Drug

Acetazolamide	B-Drug
is	O
available	O
as	O
a	O
generic	O
medication.	O

The	O
half	O
life	O
of	O
sofosbuvir	B-Drug
is	O
0.4	O
hours,	O
and	O
the	O
GS-331077	O
27	O
hours.	O

In	O
Canada,	O
GHB	B-Drug
has	O
been	O
a	O
Schedule	O

Injecting	O
diamorphine	B-Drug
users	O
are	O
encouraged	O
to	O
use	O
new	O
needles,	O
syringes,	O
spoons/steri-cups,	O
and	O
filters	O
every	O
time	O
they	O
inject	O
not	O
share	O
these	O
with	O
other	O
users.	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

In	O
January	O
2016,	O
it	O
was	O
announced	O
scientists	O
had	O
developed	O
a	O
way	O
to	O
detect	O
GHB,	O
among	O
other	O
things,	O
in	O
saliva.	O
GHB	B-Drug

However,	O
Brunt	O
and	O
colleagues	O
stated,	O
"extreme	O
caution"	O
should	O
be	O
used	O
when	O
inferring	O
the	O
toxicity	O
of	O
mephedrone	B-Drug
from	O
methcathinone,	O
noting	O
some	O
associated	O
with	O
methcathinone	B-Drug
is	O
due	O
to	O
manganese	O
impurities	O
related	O
its	O
synthesis,	O
rather	O
than	O
compound	O
itself.	O

The	O
medication	O
was	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
for	O
treatment	O
of	O
acne	O
in	O
August	O
2020.The	O
FDA	O
clascoterone	B-Drug
based	O
on	O
evidence	O
from	O
two	O
clinical	O
trials	O
(Trial	O
1/NCT02608450	O
Trial	O
2/NCT02608476)	O
1,440	O
participants	O
9	O
to	O
58	O
years	O
age	O
with	O
vulgaris.	O

It	O
was	O
tested	O
in	O
pigeons	O
and	O
other	O
experiments	O
which	O
contrasted	O
compared	O
its	O
analgesic	O
effects	O
to	O
those	O
of	O
the	O
phenazepine	O
opioid	O
ethoheptazine	B-Drug
phenalkoxam	O
open	O
chain	O
propoxyphene,	O
pethidine	B-Drug
as	O
well.	O
propoxyphene	B-Drug

In	O
preparation	O
for	O
dental	O
work,	O
withdrawal	O
from	O
phenelzine	B-Drug
is	O
specifically	O
advised;	O
since	O
this	O
takes	O
two	O
weeks,	O
however,	O
it	O
not	O
always	O
a	O
desirable	O
or	O
practical	O
option.	O

In	O
studies	O
conducted	O
on	O
primates,	O
pemoline	B-Drug
fails	O
to	O
demonstrate	O
a	O
potential	O
for	O
self-administration.	O

Suppression	O
of	O
the	O
cough	O
reflex:	O
Fentanyl	B-Drug
can	O
decrease	O
struggle	O
against	O
an	O
endotracheal	O
tube	O
and	O
excessive	O
coughing	O
by	O
decreasing	O
reflex,	O
becoming	O
useful	O
when	O
intubating	O
people	O
who	O
are	O
awake	O
have	O
compromised	O
airways.	O

QT-prolonging	O
drugs	O
like	O
amiodarone	B-Drug
Side	O
effects	O
associated	O
with	O
domperidone	B-Drug
include	O
dry	O
mouth,	O
abdominal	O
cramps,	O
diarrhea,	O
nausea,	O
rash,	O
itching,	O
hives,	O
and	O
hyperprolactinemia	O
(the	O
symptoms	O
of	O
which	O
may	O
breast	O
enlargement,	O
galactorrhea,	O
pain/tenderness,	O
gynecomastia,	O
hypogonadism,	O
menstrual	O
irregularities).	O

It	O
was	O
developed	O
by	O
screening	O
chemicals	O
similar	O
to	O
pethidine	B-Drug
(meperidine)	O
for	O
opioid	O
activity.	O
meperidine	B-Drug

On	O
May	O
30,	O
2018	O
the	O
United	O
States	O
Drug	O
Enforcement	O
Administration,	O
Department	O
of	O
Justice	O
published	O
a	O
notice	O
intent	O
to	O
place	O
NM-2201	B-Drug
and	O
4	O
other	O
synthetic	O
cannabinoids	O
in	O
schedule	O
I	O
Controlled	O
Substances	O
Act.	O

Tisagenlecleucel	B-Drug
is	O
an	O
adoptive	O
cell	O
transfer	O
therapy	O
for	O
B-cell	O
acute	O
lymphoblastic	O
leukemia;	O
T	O
cells	O
from	O
a	O
person	O
with	O
cancer	O
are	O
removed,	O
genetically	O
engineered	O
to	O
make	O
specific	O
T-cell	O
receptor	O
(a	O
chimeric	O
receptor,	O
or	O
"CAR-T")	O
that	O
reacts	O
the	O
cancer,	O
and	O
administered	O
back	O
person.	O

Due	O
to	O
a	O
successful	O
marketing	O
campaign,	O
thalidomide	B-Drug
was	O
widely	O
used	O
by	O
pregnant	O
women	O
during	O
the	O
first	O
trimester	O
of	O
pregnancy.	O

Only	O
of	O
a	O
few	O
these	O
compounds	O
were	O
widely	O
used	O
including	O
rolicyclidine	B-Drug
(PCPy),	O
eticyclidine	B-Drug
(PCE),	O
and	O
tenocyclidine	B-Drug
(TCP).	O
PCE	B-Drug
TCP	B-Drug

Until	O
2011,	O
Colombia	O
remained	O
the	O
world's	O
largest	O
cocaine	B-Drug
producer.	O

Accidental	O
ingestion	O
can	O
cause	O
a	O
fatal	O
overdose	O
of	O
hydrocodone.	O
hydrocodone	B-Drug

glue,	O
Ritalin,	O
solvents,	O
cocaine	B-Drug
La	O
Haine	O
(1995)	O
Ritalin	B-Drug

A	O
large	O
scale	O
opium	B-Drug
prohibition	O
attempt	O
began	O
in	O
1729,	O
when	O
the	O
Qing	O
Yongzheng	O
Emperor,	O
disturbed	O
by	O
madak	O
smoking	O
at	O
court	O
and	O
carrying	O
out	O
government's	O
role	O
of	O
upholding	O
Confucian	O
virtues,	O
officially	O
prohibited	O
sale	O
opium,	O
except	O
for	O
a	O
small	O
amount	O
medicinal	O
purposes.	O

Preferences	O
between	O
opium	B-Drug
and	O
heroin/morphine,	O
methods	O
of	O
administration,	O
differ	O
from	O
region	O
to	O
within	O
China.	O
heroin	B-Drug
morphine	B-Drug

Cocaine	B-Drug
has	O
a	O
short	O
half	O
life	O
of	O
0.7-1.5	O
hours	O
and	O
is	O
extensively	O
metabolized	O
by	O
cholinesterase	O
enzymes	O
(primarily	O
in	O
the	O
liver	O
plasma),	O
with	O
only	O
about	O
1%	O
excreted	O
unchanged	O
urine.	O

It	O
is	O
the	O
4-chloro-substituted	O
derivative	O
of	O
metandienone	B-Drug
(dehydromethyltestosterone).	O

Isolation	O
of	O
ephedrine	B-Drug
from	O
Ephedra	O
vulgaris	O
in	O
1885.	O

Dosages	O
of	O
LSD	B-Drug
are	O
measured	O
in	O
micrograms	O
(g),	O
or	O
millionths	O
a	O
gram.	O

In	O
addition	O
to	O
its	O
medical	O
use,	O
testosterone	B-Drug
propionate	I-Drug
is	O
used	O
improve	O
physique	O
and	O
performance.	O

In	O
2017,	O
the	O
U.S.	O
Coast	O
Guard	O
detained	O
a	O
privately-owned	O
semi-submersible	O
off	O
coast	O
of	O
Texas	O
carrying	O
1.7	O
tonnes	O
(3,800	O
lb)	O
cocaine,	O
and	O
on	O
13	O
November	O
US	O
located	O
seized	O
another	O
one	O
Panama.	O
cocaine	B-Drug

The	O
Persian	O
physician	O
Ab	O
Al	O
al-Husayn	O
ibn	O
Sina	O
("Avicenna")	O
described	O
opium	B-Drug
as	O
the	O
most	O
powerful	O
of	O
stupefacients,	O
in	O
comparison	O
to	O
mandrake	O
and	O
other	O
highly	O
effective	O
herbs,	O
Canon	O
Medicine.	O

Rifampin	B-Drug
significantly	O
increases	O
the	O
clearance	O
of	O
nitrazepam,	O
while	O
probenecid	O
decreases	O
its	O
clearance.	O
nitrazepam	B-Drug

Concerns	O
about	O
possible	O
induction	O
of	O
desmosterolosis	O
and	O
associated	O
symptoms	O
such	O
as	O
cataracts	O
ichthyosis	O
with	O
extended	O
exposure	O
precluded	O
the	O
use	O
clomifene	B-Drug
in	O
treatment	O
breast	O
cancer.	O

One	O
example	O
of	O
an	O
antibiotic	O
that	O
may	O
be	O
applied	O
topically	O
is	O
chloramphenicol.	O
chloramphenicol	B-Drug

The	O
Napoleonic	O
campaigns	O
introduced	O
French	O
troops	O
to	O
hashish	B-Drug
in	O
Egypt	O
and	O
the	O
first	O
description	O
of	O
usefulness	O
stems	O
from	O
1830	O
by	O
pharmacist	O
botanist	O
Theodor	O
Friedrich	O
Ludwig	O
Nees	O
von	O
Esenbeck.	O

This	O
is	O
usually	O
done	O
with	O
off-label	O
fentanyl	B-Drug
patches	O
manufactured	O
for	O
humans	O
chronic	O
pain.	O

Dexamethasone	B-Drug
has	O
also	O
been	O
used	O
with	O
antibiotics	O
to	O
treat	O
acute	O
endophthalmitis.	O

It	O
includes	O
a	O
proposal	O
that	O
cannabis	O
with	O
more	O
than	O
15	O
percent	O
THC	B-Drug
should	O
be	O
labeled	O
as	O
hard	O
drugs.	O

Further	O
research	O
is	O
therefore	O
needed	O
to	O
compare	O
nalbuphine	B-Drug
with	O
other	O
postoperative	O
opioids.	O

cannabis,	O
hashish,	O
LSD,	O
DMT,	O
psilocybin,	O
cocaine,	O
alcohol,	O
amphetamines,	O
barbiturates	O
The	O
Stoned	O
Age	O
(1994)	O
hashish	B-Drug
LSD	B-Drug
cocaine	B-Drug

It	O
is	O
sometimes	O
thought	O
that	O
heroin	B-Drug
users	O
can	O
walk	O
into	O
a	O
clinic	O
and	O
out	O
with	O
prescription,	O
but	O
the	O
process	O
takes	O
many	O
weeks	O
before	O
prescription	O
for	O
diamorphine	B-Drug
issued.	O

This	O
study	O
suggested	O
that	O
25I-NBOMe	B-Drug
is	O
approximately	O
14-fold	O
more	O
potent	O
than	O
2C-I	O
in-vivo.	O

MDMA	B-Drug
is	O
in	O
the	O
substituted	O
methylenedioxyphenethylamine	O
and	O
amphetamine	O
classes	O
of	O
chemicals.	O

Tryptophan	O
and	O
5-hydroxy-tryptophan,	O
for	O
instance,	O
can	O
be	O
used	O
to	O
help	O
the	O
body	O
replenish	O
serotonin	O
levels	O
in	O
brain	O
after	O
use	O
of	O
MDMA,	O
vitamin	O
supplements	O
are	O
appropriate	O
users	O
stimulants	O
such	O
as	O
amphetamine.	O
MDMA	B-Drug
amphetamine	B-Drug

It	O
binds	O
to	O
the	O
androgen	O
receptor	O
more	O
strongly	O
than	O
older	O
drugs	O
such	O
as	O
andarine	B-Drug
with	O
a	O
Ki	O
of	O
1.7	O
nM,	O
and	O
in	O
animal	O
studies	O
it	O
showed	O
both	O
good	O
ratio	O
anabolic	O
androgenic	O
effects,	O
dose-dependent	O
suppression	O
spermatogenesis	O
spontaneous	O
recovery	O
after	O
cessation	O
treatment.	O

Ibogaine	B-Drug
-	O
Natural	O
Tramadol"	O
(2021)	O
Tramadol	B-Drug

All	O
drugs	O
in	O
the	O
NBOMe	O
series,	O
including	O
25I-NBOMe,	O
became	O
illegal	O
Russia	O
October	O
2011.	O
25I-NBOMe	B-Drug

Indian	O
law	O
enforcement	O
agencies	O
seized	O
a	O
total	O
of	O
182,622	O
kg	O
ganja	O
and	O
2,489	O
hashish	B-Drug
in	O
2016.	O

These	O
populations	O
should	O
be	O
treated	O
with	O
second-generation	O
antihistamines	O
such	O
as	O
loratadine,	O
desloratadine,	O
fexofenadine,	O
cetirizine,	O
levocetirizine,	O
and	O
azelastine.	O
loratadine	B-Drug
desloratadine	B-Drug
fexofenadine	B-Drug
cetirizine	B-Drug
levocetirizine	B-Drug
azelastine	B-Drug

Spironolactone	B-Drug
has	O
been	O
studied	O
at	O
extremely	O
high	O
oral	O
doses	O
of	O
up	O
to	O
2,400	O
mg	O
per	O
day	O
in	O
clinical	O
trials.	O

Codoxime	B-Drug
(dihydrocodeinone	O
O-(carboxymethyl)	O

Because	O
of	O
its	O
increasing	O
popularity	O
with	O
young	O
party	O
goers	O
in	O
Beijing,	O
Shanghai,	O
Nanjing,	O
Guangzhou,	O
and	O
Shenzhen,	O
Chinese	O
law	O
enforcement	O
officials	O
report	O
significant	O
increases	O
the	O
domestic	O
production	O
MDMA	B-Drug
(Ecstasy).	O

In	O
November	O
2014	O
nalmefene	B-Drug
was	O
appraised	O
and	O
approved	O
as	O
a	O
treatment	O
supplied	O
by	O
Britain's	O
National	O
Health	O
Service	O
(NHS)	O
for	O
reducing	O
alcohol	O
consumption	O
in	O
people	O
with	O
dependence.	O

When	O
compared	O
with	O
oxycodone,	O
hydromorphone,	O
and	O
placebo,	O
pethidine	B-Drug
was	O
consistently	O
associated	O
more	O
euphoria,	O
difficulty	O
concentrating,	O
confusion,	O
impaired	O
psychomotor	O
cognitive	O
performance	O
when	O
administered	O
to	O
healthy	O
volunteers.	O
oxycodone	B-Drug
hydromorphone	B-Drug

However,	O
they	O
require	O
compromises	O
in	O
borderline	O
cases;	O
for	O
example,	O
nicotine	B-Drug
contains	O
a	O
pyridine	O
fragment	O
from	O
nicotinamide	B-Drug
and	O
pyrrolidine	O
part	O
ornithine	O
therefore	O
can	O
be	O
assigned	O
to	O
both	O
classes.	O

Rats	O
which	O
were	O
treated	O
by	O
octreotide	B-Drug
experienced	O
erectile	O
dysfunction	O
in	O
a	O
1998	O
study.	O

Hydrocodone	B-Drug
was	O
first	O
marketed	O
by	O
Knoll	O
as	O
Dicodid,	O
starting	O
in	O
February	O
1924	O
Germany.	O

This	O
intervention	O
has	O
demonstrated	O
success	O
in	O
many	O
psychiatric	O
conditions	O
(e.g.,	O
depression)	O
and	O
substance	O
use	O
disorders	O
tobacco).	O
tobacco	B-Drug

Conversely,	O
peak	O
urine	O
flow	O
rates	O
and	O
pressure	O
examinations	O
were	O
not	O
significantly	O
different	O
between	O
bicalutamide	B-Drug
placebo.	O

Serum	O
JWH-018	B-Drug
concentrations	O
are	O
generally	O
in	O
the	O
110	O
g/L	O
range	O
during	O
first	O
few	O
hours	O
after	O
recreational	O
usage.	O

Cisapride	B-Drug
and	O
tegaserod	O
are	O
5-HT4	O
receptor	O
partial	O
agonists	O
that	O
were	O
used	O
to	O
treat	O
disorders	O
of	O
gastrointestinal	O
motility.	O

Opioid	O
effects	O
(adverse	O
or	O
otherwise)	O
can	O
be	O
reversed	O
with	O
an	O
opioid	O
antagonist	O
such	O
as	O
naloxone	B-Drug
naltrexone.	O
naltrexone	B-Drug

The	O
Thelins	O
opened	O
the	O
store	O
to	O
promote	O
safe	O
use	O
of	O
LSD,	O
which	O
was	O
then	O
still	O
legal	O
in	O
California.	O
LSD	B-Drug

A	O
2014	O
editorial	O
in	O
Lab	O
Times	O
online	O
contested	O
the	O
notion	O
that	O
tramadol	B-Drug
tree	O
roots	O
was	O
result	O
of	O
anthropogenic	O
contamination,	O
stating	O
samples	O
were	O
taken	O
from	O
trees	O
which	O
grew	O
national	O
parks,	O
where	O
livestock	O
forbidden;	O
it	O
also	O
quoted	O
researcher	O
Michel	O
de	O
Waard,	O
who	O
stated	O
"thousands	O
and	O
thousands	O
tramadol-treated	O
cattle	O
sitting	O
around	O
a	O
single	O
urinating	O
there"	O
would	O
be	O
required	O
to	O
produce	O
concentrations	O
discovered.	O

Paracetamol	B-Drug
is	O
available	O
as	O
a	O
generic	O
medication,	O
with	O
brand	O
names	O
including	O
Tylenol	B-Drug
and	O
Panadol	O
among	O
others.	O

Further	O
backlash	O
against	O
LSD	B-Drug
usage	O
swept	O
psilocybin	O
along	O
with	O
it	O
into	O
the	O
Schedule	O

Alprazolam	B-Drug
is	O
a	O
triazole	O
and	O
benzodiazepine	O
derivative	O
substituted	O
with	O
phenyl	O
group	O
at	O
position	O
6,	O
chlorine	O
atom	O
8	O
methyl	O
1.	O

Thalidomide	B-Drug
was	O
studied	O
in	O
a	O
Phase	O
II	O
trial	O
for	O
Kaposi's	O
sarcoma,	O
rare	O
soft-tissue	O
cancer	O
most	O
commonly	O
seen	O
the	O
immunocompromised,	O
that	O
is	O
caused	O
by	O
sarcoma-associated	O
herpesvirus	O
(KSHV).	O

The	O
recreational	O
use	O
is	O
not	O
particularly	O
widespread	O
in	O
the	O
EU	O
with	O
exception	O
of	O
Tallinn,	O
Estonia,	O
where	O
it	O
has	O
largely	O
replaced	O
heroin.	O
heroin	B-Drug

Adderall	B-Drug
contains	O
equal	O
amounts	O
of	O
four	O
amphetamine	B-Drug
salts:	O

As	O
the	O
CIBA	O
product	O
Dianabol,	O
metandienone	B-Drug
quickly	O
became	O
first	O
widely	O
used	O
AAS	O
among	O
professional	O
and	O
amateur	O
athletes,	O
remains	O
most	O
common	O
orally	O
active	O
for	O
non-medical	O
use.	O
Dianabol	B-Drug

PCP's	O
rewarding	O
and	O
reinforcing	O
effects	O
are	O
at	O
least	O
partly	O
mediated	O
by	O
blocking	O
the	O
NMDA	O
receptors	O
in	O
glutamatergic	O
inputs	O
to	O
D1-type	O
medium	O
spiny	O
neurons	O
nucleus	O
accumbens.	O
PCP	B-Drug

Peak	O
levels	O
of	O
tamoxifen	B-Drug
after	O
a	O
single	O
40	O
mg	O
oral	O
dose	O
were	O

At	O
the	O
same	O
time,	O
research	O
on	O
use	O
of	O
GHB	B-Drug
in	O
form	O
sodium	B-Drug
oxybate	I-Drug
had	O
formalized,	O
as	O
a	O
company	O
called	O
Orphan	O
Medical	O
filed	O
an	O
investigational	O
new	O
drug	O
application	O
and	O
was	O
running	O
clinical	O
trials	O
with	O
intention	O
gaining	O
regulatory	O
approval	O
for	O
to	O
treat	O
narcolepsy.	O

To	O
detect	O
GHB	B-Drug
in	O
urine,	O
the	O
sample	O
must	O
be	O
taken	O
within	O
four	O
hours	O
of	O
ingestion,	O
and	O
cannot	O
tested	O
at	O
home.	O

The	O
concentration	O
of	O
methylphenidate	B-Drug
or	O
ritalinic	O
acid,	O
its	O
major	O
metabolite,	O
may	O
be	O
quantified	O
in	O
plasma,	O
serum	O
whole	O
blood	O
order	O
to	O
monitor	O
compliance	O
those	O
receiving	O
the	O
drug	O
therapeutically,	O
confirm	O
diagnosis	O
potential	O
poisoning	O
victims	O
assist	O
forensic	O
investigation	O
a	O
case	O
fatal	O
overdosage.	O

The	O
biosynthesis	O
begins	O
with	O
L-Glutamine,	O
which	O
is	O
derived	O
to	O
L-ornithine	O
in	O
plants.	O
L-Glutamine	B-Drug

(the	O
purity	O
of	O
the	O
cocaine	B-Drug
is	O
also	O
a	O
factor),	O
but	O
one	O
line	O
generally	O
considered	O
to	O
be	O
single	O
dose.	O

TFMPP	B-Drug
has	O
affinity	O
for	O
the	O
5-HT1A	O

Phenobarbital,	O
phenytoin,	O
rifampin,	O
carbamazepine	B-Drug
and	O
barbiturates,	O
increase	O
hepatic	O
enzymes	O
rate	O
of	O
elimination,	O
thus	O
reducing	O
the	O
immunosuppressive	O
effect	O
methylprednisolone.	O
Phenobarbital	B-Drug
phenytoin	B-Drug
rifampin	B-Drug
methylprednisolone	B-Drug

Its	O
popularity	O
with	O
recreational	O
drug	O
users,	O
compared	O
to	O
morphine,	O
reportedly	O
stems	O
from	O
its	O
perceived	O
different	O
effects.	O
morphine	B-Drug

Dihydrocodeine	B-Drug
is	O
metabolised	O
by	O
the	O
CYP450	O
system	O
isoenzyme	O
2D6	O
to	O
dihydromorphine,	O
which	O
mediates	O
majority	O
of	O
its	O
analgesic	O
effects.	O
dihydromorphine	B-Drug

Coadministration	O
of	O
ritonavir	B-Drug
and	O
fluticasone	B-Drug
may	O
lead	O
to	O
increased	O
levels	O
in	O
the	O
body,	O
which	O
Cushing's	O
Syndrome	O
adrenal	O
insufficiency.	O

Additionally,	O
the	O
Minister	O
of	O
Health	O
issued	O
an	O
order	O
to	O
change	O
basic	O
life	O
support	O
provider's	O
medical	O
scope,	O
within	O
EMS,	O
administer	O
naloxone	B-Drug
in	O
event	O
a	O
suspected	O
narcotic	O
overdose.	O

It	O
is	O
unlikely	O
that	O
a	O
person	O
would	O
overdose	O
on	O
nicotine	B-Drug
through	O
smoking	O
alone.	O

Researchers	O
confirmed	O
that	O
THC	B-Drug
exerts	O
its	O
most	O
prominent	O
effects	O
via	O
actions	O
on	O
two	O
types	O
of	O
cannabinoid	O
receptors,	O
the	O
CB1	O
receptor	O
and	O
CB2	O
receptor,	O
both	O
which	O
are	O
G	O
protein-coupled	O
receptors.	O

The	O
number	O
of	O
instances	O
fatal	O
MDMA	B-Drug
intoxication	O
is	O
low	O
relative	O
to	O
its	O
usage	O
rates.	O

Healthcare	O
institution-based	O
naloxone	B-Drug
prescription	O
programs	O
have	O
also	O
helped	O
reduce	O
rates	O
of	O
opioid	O
overdose	O
in	O
the	O
U.S.	O
state	O
North	O
Carolina,	O
and	O
been	O
replicated	O
military.	O

There	O
are	O
no	O
expected	O
pharmacokinetic	O
interactions	O
between	O
thalidomide	B-Drug
and	O
other	O
medicines	O
due	O
to	O
its	O
neutral	O
effects	O
on	O
P-glycoprotein	O
the	O
cytochrome	O
P450	O
family.	O

Nitrobenzodiazepines	O
such	O
as	O
nitrazepam,	O
nimetazepam,	O
flunitrazepam,	O
and	O
clonazepam	B-Drug
are	O
more	O
toxic	O
to	O
the	O
liver	O
than	O
other	O
benzodiazepines	O
they	O
metabolically	O
activated	O
by	O
CYP3A4	O
which	O
can	O
result	O
in	O
cytotoxicity.	O
nitrazepam	B-Drug
nimetazepam	B-Drug
flunitrazepam	B-Drug

Lidocaine	B-Drug
can	O
further	O
interact	O
with	O
other	O
drugs	O
such	O
as	O
amiodarone	B-Drug
and	O
monoamine	O
oxidase	O
inhibitor	O
to	O
cause	O
hypotension,	O
dronedarone	B-Drug
arrhythmia.	O

The	O
process	O
continued	O
until	O
1817,	O
when	O
Sertrner	O
published	O
the	O
isolation	O
of	O
pure	O
morphine	B-Drug
from	O
opium	B-Drug
after	O
at	O
least	O
thirteen	O
years	O
research	O
and	O
a	O
nearly	O
disastrous	O
trial	O
on	O
himself	O
three	O
boys.	O

Erowid	O
has	O
been	O
providing	O
expertise	O
and	O
work	O
developing	O
coordinating	O
construction	O
of	O
an	O
online	O
MDMA	B-Drug
Reference	O
library	O
MAPS	O
begun	O
working	O
on	O
doing	O
a	O
similar	O
project	O
with	O
the	O
Albert	O
Hofmann	O
Foundation's	O
LSD	B-Drug
Psilocybin	O
Library.	O

On	O
October	O
1,	O
1957,	O
the	O
company	O
launched	O
thalidomide	B-Drug
and	O
began	O
marketing	O
it	O
under	O
trade	O
name	O
Contergan.	O
Contergan	B-Drug

In	O
the	O
event	O
of	O
an	O
overdose	O
oral	O
ketoconazole,	O
treatment	O
should	O
be	O
supportive	O
and	O
based	O
on	O
symptoms.	O
ketoconazole	B-Drug

Enzalutamide,	O
sold	O
under	O
the	O
brand	O
name	O
Xtandi,	O
is	O
a	O
nonsteroidal	O
antiandrogen	O
(NSAA)	O
medication	O
which	O
used	O
in	O
treatment	O
of	O
prostate	O
cancer.	O
Enzalutamide	B-Drug

FUB-APINACA	B-Drug
(also	O
known	O
as	O
AFUBINACA	O
and	O
FUB-AKB48)	O
is	O
an	O
indazole-based	O
synthetic	O
cannabinoid	O
that	O
presumed	O
to	O
be	O
a	O
potent	O
agonist	O
of	O
the	O
CB1	O
receptor	O
has	O
been	O
sold	O
online	O
designer	O
drug.	O

The	O
1990s	O
"soap	O
bars"	O
disappeared	O
and	O
the	O
physical	O
shapes	O
of	O
hashish	B-Drug
changed	O
to	O
melon	O
shaped,	O
tablets	O
or	O
olive	O
shaped	O
pellets.	O

As	O
a	O
result	O
of	O
the	O
growing	O
popularity	O
LSD	B-Drug
and	O
disdain	O
for	O
hippies	O
with	O
whom	O
it	O
was	O
heavily	O
associated,	O
banned	O
in	O
United	O
States	O
1967.	O

In	O
the	O
same	O
month,	O
in	O
Sweden,	O
another	O
man	O
died	O
from	O
ecstasy	B-Drug
laced	O
with	O
PMMA.In	O

It	O
is	O
therefore	O
not	O
scheduled	O
at	O
the	O
federal	O
level	O
in	O
United	O
States,	O
but	O
it	O
possible	O
that	O
NBOMe-mescaline	B-Drug
could	O
legally	O
be	O
considered	O
an	O
analog	O
of	O
mescaline,	O
and	O
sales	O
or	O
possession	O
potentially	O
prosecuted	O
under	O
Federal	O
Analogue	O
Act.	O
mescaline	B-Drug

Birth	O
control	O
pills	O
containing	O
estradiol	B-Drug
valerate/dienogest	I-Drug
are	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
venous	O
thromboembolism.	O

A	O
major	O
shortcoming	O
of	O
hydralazine	B-Drug
monotherapy	O
was	O
that	O
it	O
lost	O
its	O
effectiveness	O
over	O
time	O
(tachyphylaxis).	O

Phenethylamine	B-Drug
instead	O
regulates	O
monoamine	O
neurotransmission	O
by	O
binding	O
to	O
trace	O
amine-associated	O
receptor	O
1	O
(TAAR1),	O
which	O
plays	O
a	O
significant	O
role	O
in	O
regulating	O
dopamine,	O
norepinephrine,	O
and	O
serotonin	O
neurons	O
the	O
CNS	O
inhibiting	O
vesicular	O
transporter	O
2	O
(VMAT2)	O
neurons.	O

In	O
1863,	O
Mariani	O
started	O
marketing	O
a	O
wine	O
called	O
Vin	O
Mariani,	O
which	O
had	O
been	O
treated	O
with	O
coca	B-Drug
leaves,	O
to	O
become	O
cocawine.	O

The	O
UNODC	O
states	O
that	O
cannabis	O
often	O
contains	O
5%	O
THC	B-Drug
content,	O
resin	O
"can	O
contain	O
up	O
to	O
20%	O
content",	O
and	O
"Cannabis	O
oil	I-Drug
may	O
more	O
than	O
60%	O
content.	O
Cannabis	B-Drug

Compared	O
to	O
THC,	O
which	O
is	O
a	O
partial	O
agonist	O
at	O
CB1	O
receptors,	O
JWH-018,	O
and	O
many	O
synthetic	O
cannabinoids,	O
are	O
full	O
agonists.	O
THC	B-Drug
JWH-018	B-Drug

According	O
to	O
the	O
International	O
Programme	O
on	O
Chemical	O
Safety	O
(IPCS)	O
and	O
United	O
States	O
Food	O
Drug	O
Administration	O
(USFDA),	O
amphetamine	B-Drug
is	O
contraindicated	O
in	O
people	O
with	O
a	O
history	O
of	O
drug	O
abuse,	O
cardiovascular	O
disease,	O
severe	O
agitation,	O
or	O
anxiety.	O

Finasteride	B-Drug
is	O
a	O
5-reductase	O
inhibitor	O
and	O
therefore	O
an	O
antiandrogen.	O

Sedative	O
drugs	O
and	O
sleeping	O
pills,	O
including	O
lorazepam,	O
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death.	O
lorazepam	B-Drug

In	O
contrast	O
to	O
WAY-267,464,	O
carbetocin,	O
a	O
close	O
analogue	O
of	O
oxytocin	O
and	O
peptide	O
receptor	O
agonist,	O
notably	O
does	O
produce	O
antidepressant-like	O
effects	O
in	O
animals.	O
carbetocin	B-Drug

In	O
the	O
Leuckart	O
reaction,	O
one	O
equivalent	O
of	O
phenylacetone	O
is	O
reacted	O
with	O
two	O
equivalents	O
N-methylformamide	O
to	O
produce	O
formyl	O
amide	O
methamphetamine	B-Drug
plus	O
carbon	O
dioxide	O
and	O
methylamine	O
as	O
side	O
products.	O

The	O
FDA	O
launched	O
a	O
post-marketing	O
safety	O
study	O
regarding	O
the	O
reformulation	O
of	O
Opana	B-Drug
ER	I-Drug
in	O
2012	O
and	O
Indiana	O
state	O
government	O

Alprazolam,	O
like	O
other	O
benzodiazepines,	O
acts	O
through	O
the	O
GABAA	O
receptor.	O
Alprazolam	B-Drug

An	O
example	O
is	O
the	O
relaunch	O
of	O
use	O
ciclosporin	B-Drug
as	O
an	O
immunosuppressor	O
to	O
facilitate	O
organ	O
transplant.	O

Clonazepam	B-Drug
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
acute	O
control	O
of	O
non-convulsive	O
status	O
epilepticus;	O
however,	O
benefits	O
tended	O
transient	O
many	O
people,	O
and	O
addition	O
phenytoin	B-Drug
for	O
lasting	O
was	O
required	O
these	O
patients.	O

Three-quarters	O
of	O
the	O
world's	O
annual	O
yield	O
cocaine	B-Drug
has	O
been	O
produced	O
in	O
Colombia,	O
both	O
from	O
base	O
imported	O
Peru	O
(primarily	O
Huallaga	O
Valley)	O
and	O
Bolivia,	O
locally	O
grown	O
coca.	O
coca	B-Drug

Richard	O
Davenport-Hines,	O
in	O
his	O
book	O
The	O
Pursuit	O
of	O
Oblivion,	O
criticized	O
the	O
efficacy	O
War	O
on	O
Drugs	O
by	O
pointing	O
out	O
that	O
1015%	O
illicit	O
heroin	B-Drug
and	O
30%	O
cocaine	B-Drug
is	O
intercepted.	O

Heroin	B-Drug
prepared	O
for	O
the	O
European	O
market	O
is	O
insoluble	O
in	O
water	O
and	O
usually	O
requires	O
addition	O
of	O
an	O
acid	O
such	O
as	O
citric	O
or	O
ascorbic	O
(Vitamin	O
C)	O
powder	O
to	O
dissolve	O
drug.	O
Vitamin	B-Drug
C	I-Drug

Pure	O
zaleplon	B-Drug
in	O
its	O
solid	O
state	O
is	O
a	O
white	O
to	O
off-white	O
powder	O
with	O
very	O
low	O
solubility	O
water,	O
as	O
well	O
ethanol	O
and	O
propylene	O
glycol.	O

On	O
July	O
5,	O
2010,	O
former	O
Oakland	O
Raiders	O
quarterback	O
JaMarcus	O
Russell	O
was	O
arrested	O
at	O
his	O
home	O
in	O
Mobile,	O
Alabama,	O
for	O
possession	O
of	O
codeine	B-Drug
syrup	O
without	O
a	O
prescription.	O

Cocaine	B-Drug
hydrochloride	O
(Goprelto),	O
an	O
ester	O
local	O
anesthetic,	O
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
December	O
2017,	O
and	O
is	O
indicated	O
introduction	O
of	O
anesthesia	O
mucous	O
membranes	O
diagnostic	O
procedures	O
surgeries	O
on	O
or	O
through	O
nasal	O
cavities	O
adults.	O

Vyvanse	B-Drug
is	O
available	O
as	O
capsules,	O
and	O
chewable	O
tablets,	O
in	O
seven	O
strengths;	O
10	O
mg,	O
20	O
30	O
40	O
50	O
60	O
70	O
mg.	O

While	O
studies	O
are	O
as	O
yet	O
unavailable	O
of	O
various	O
samples	O
krokodil	O
seized	O
in	O
different	O
regions,	O
it	O
is	O
likely	O
that	O
the	O
drug	O
fact	O
not	O
a	O
single	O
chemical,	O
recipe,	O
or	O
'designer'	O
drug,	O
but	O
rather	O
medical	O
symptoms	O
caused	O
by	O
injection	O
toxic	O
chemical	O
used	O
variety	O
'home-bake'	O
synthesis	O
methods,	O
although	O
traditionally	O
such	O
processes	O
methamphetamine	B-Drug
home	O
producers.	O

Prescription	O
of	O
dipipanone	B-Drug
is	O
discouraged	O
apart	O
from	O
in	O
exceptional	O
circumstances,	O
because	O
the	O
perceived	O
risk	O
abuse	O
-	O
BNF	O
marks	O
substance	O
as	O
"less	O
suitable	O
for	O
prescribing"	O
along	O
with	O
other	O
older	O
compounds	O
such	O
pethidine	B-Drug
and	O
pentazocine	B-Drug
unusual	O
patterns.	O

The	O
user	O
consumed	O
JWH-018	B-Drug
daily	O
for	O
eight	O
months.	O

In	O
animal	O
models,	O
the	O
result	O
of	O
NOP	O
activation	O
in	O
central	O
nervous	O
system	O
has	O
been	O
shown	O
to	O
eliminate	O
conditioned	O
place	O
preference	O
induced	O
by	O
morphine,	O
cocaine,	O
alcohol,	O
and	O
methamphetamine.	O
morphine	B-Drug
cocaine	B-Drug
methamphetamine	B-Drug

In	O
Taiwan,	O
amphetamines	O
including	O
Adderall	B-Drug
are	O
Schedule	O
2	O
drugs	O
with	O
a	O
minimum	O
five	O
years	O
prison	O
term	O
for	O
possession.	O

It	O
is	O
the	O
triazole	O
analogue	O
of	O
Flunitrazepam	B-Drug
(Rohypnol).	O
Rohypnol	B-Drug

It	O
is	O
bound	O
to	O
albumin,	O
and	O
both	O
tibolone	B-Drug
its	O
metabolites	O
have	O
low	O
affinity	O
for	O
SHBG.	O

The	O
high	O
risk-factor	O
obtained	O
is	O
a	O
product	O
not	O
of	O
the	O
fact	O
that	O
so	O
many	O
marijuana	O
users	O
use	O
cocaine	B-Drug
but	O
used	O
previously.	O

Tetracaine,	O
also	O
known	O
as	O
amethocaine,	O
is	O
an	O
ester	O
local	O
anesthetic	O
used	O
to	O
numb	O
the	O
eyes,	O
nose,	O
or	O
throat.	O
Tetracaine	B-Drug

One	O
gram	O
of	O
oxymorphone	B-Drug
hydrochloride	I-Drug
is	O
soluble	O
in	O
4	O
ml	O
water	O
and	O
it	O
sparingly	O
alcohol	O
ether.	O

Morphine-N-oxide	O
(morphine	O
oxide)	O
Myrophine	B-Drug
(benzylmorphine	O
myristate)	O
morphine	B-Drug
benzylmorphine	B-Drug

Though	O
this	O
is	O
somewhat	O
controversial	O
among	O
proponents	O
of	O
a	O
zero-tolerance	O
drug	O
policy,	O
it	O
has	O
proven	O
superior	O
to	O
methadone	B-Drug
in	O
improving	O
the	O
social	O
and	O
health	O
situations	O
addicts.	O

Based	O
on	O
heroin	B-Drug
production	O
statistics	O
compiled	O
by	O
the	O
United	O
Nations	O
Office	O
Drugs	O
and	O
Crime,	O
in	O
2006,	O
Bagcho's	O
activities	O
accounted	O
for	O
approximately	O
20	O
percent	O
of	O
world's	O
total	O
that	O
year.	O

Additionally,	O
several	O
reports	O
of	O
mitragynine	B-Drug
pharmacology	O
indicate	O
potential	O
biased	O
agonism	O
activity	O
favoring	O
G	O
protein	O
signaling	O
pathways	O
independent	O
beta	O
-	O
arrestin	O
recruitment,	O
a	O
primary	O
component	O
in	O
opioid	O
induced	O
respiratory	O
depression.	O

A	O
common	O
but	O
untrue	O
belief	O
is	O
that	O
the	O
smoking	O
of	O
cocaine	B-Drug
chemically	O
breaks	O
down	O
tooth	O
enamel	O
and	O
causes	O
decay.	O

Dapsone	B-Drug
also	O
find	O
uses	O
as	O
a	O
curing	O
agent	O
in	O
the	O
manufacture	O
of	O
paints,	O
adhesives,	O
composites,	O
powder	O
coats	O
and	O
printed	O
circuit	O
boards.	O

Methadone,	O
itself	O
an	O
opioid	O
and	O
a	O
psychoactive	O
substance,	O
is	O
common	O
treatment	O
for	O
heroin	O
addiction,	O
as	O
another	O
opioid,	O
buprenorphine.	O
Methadone	B-Drug
buprenorphine	B-Drug

Metandienone,	O
along	O
with	O
other	O
AAS,	O
is	O
a	O
schedule	O
III	O
controlled	O
substance	O
in	O
the	O
United	O
States	O
under	O
Controlled	O
Substances	O
Act.	O
Metandienone	B-Drug

An	O
amphetamine	B-Drug
overdose	O
can	O
result	O
in	O
a	O
stimulant	O
psychosis	O
that	O
may	O
involve	O
variety	O
of	O
symptoms,	O
such	O
as	O
delusions	O
and	O
paranoia.	O

The	O
Rodriguez-Orejuela	O
family	O
alone	O
amassed	O
a	O
fortune	O
of	O
more	O
than	O
$250	O
billion	O
in	O
worldwide	O
assets,	O
according	O
to	O
the	O
DEA.Santacruz	O
Londoo's	O
cocaine	B-Drug
distribution	O
and	O
money	O
laundering	O
operations	O
were	O
based	O
New	O
York	O
metropolitan	O
area,	O
but	O
he	O
Cali	O
cartel	O
operated	O
most	O
major	O
cities	O
United	O
States	O
including	O
City,	O
Miami,	O
Los	O
Angeles,	O
San	O
Francisco,	O
Houston,	O
Las	O
Vegas,	O
Chicago.	O

UR-144	B-Drug

The	O
salts	O
of	O
methadone	B-Drug
in	O
use	O
are	O
the	O
hydrobromide	O
(free	O
base	O
conversion	O
ratio	O
0.793),	O
hydrochloride	O
(0.894),	O
and	O
HCl	O
monohydrate	O
(0.850).	O

Related	O
drugs	O
include	O
carisoprodol	B-Drug
and	O
tybamate	O
(prodrugs	O
of	O
meprobamate),	O
felbamate,	O
mebutamate,	O
methocarbamol.	O
meprobamate	B-Drug
mebutamate	B-Drug
methocarbamol	B-Drug

Oxymorphone	B-Drug
plays	O
only	O
a	O
minor	O
role,	O
being	O
responsible	O
for	O
15.8%	O
and	O
4.5%	O
of	O
the	O
analgesic	O
effect	O
oxycodone	B-Drug
after	O
oral	O
intravenous	O
administration,	O
respectively.	O

The	O
generation	O
of	O
antibodies	O
against	O
androstenedione	B-Drug
by	O
these	O
agents	O
is	O
thought	O
to	O
decrease	O
circulating	O
levels	O
and	O
its	O
metabolites	O
(e.g.,	O
testosterone	O
estrogens),	O
which	O
in	O
turn	O
increases	O
the	O
activity	O
HPG	O
axis	O
via	O
reduced	O
negative	O
feedback	O
rate	O
ovulation,	O
resulting	O
greater	O
fertility	O
fecundity.	O

Certain	O
other	O
aspects	O
of	O
the	O
usage	O
hyoscine	B-Drug
in	O
crimes	O
have	O
equally	O
been	O
described	O
as	O
"exaggerated"	O
or	O
even	O
implausible.	O

25I-NBOMe,	O
25B-NBOMe	B-Drug
and	O
25C-NBOMe	B-Drug
are	O
currently	O
Schedule	O
1	O
Substances	O
according	O
to	O
21	O
CFR	O
1308.11(d)	O
25I-NBOMe	B-Drug

In	O
2011,	O
21,649	O
emergency	O
room	O
visits	O
in	O
the	O
United	O
States	O
were	O
related	O
to	O
tramadol.	O
tramadol	B-Drug

Some	O
carbon	O
monoxide	O
binds	O
to	O
hemoglobin	O
when	O
smoking	O
tobacco.	O
tobacco	B-Drug

Amitriptyline	B-Drug
prolongs	O
QT	O
interval.	O

Inclusion	O
of	O
duplicate	O
reports	O
led	O
to	O
a	O
23%	O
overestimation	O
ondansetron's	O
antiemetic	O
efficacy.	O
ondansetron	B-Drug

Naloxone	B-Drug
has	O
little	O
to	O
no	O
effect	O
if	O
opioids	O
are	O
not	O
present.	O

A	O
2019	O
review	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
(which	O
included	O
PCP)	O
to	O
schizophrenia	O
was	O
26%.	O
PCP	B-Drug

A	O
single	O
oral	O
dose	O
of	O
bicalutamide	B-Drug
in	O
humans	O
that	O
results	O
symptoms	O
overdose	O
or	O
is	O
considered	O
to	O
be	O
life-threatening	O
has	O
not	O
been	O
established.	O

When	O
omeprazole	B-Drug
and	O
ranitidine	B-Drug
were	O
compared	O
in	O
a	O
study	O
of	O
144	O
people	O
with	O
severe	O
inflammation	O
erosions	O
or	O
ulcers	O
the	O
oesophagus,	O
85%	O
those	O
treated	O
healed	O
within	O
eight	O
weeks,	O
50%	O
given	O
ranitidine.	O

Antipyretics	O
work	O
by	O
inhibiting	O
the	O
enzyme	O
COX,	O
which	O
causes	O
general	O
inhibition	O
of	O
prostanoid	O
biosynthesis	O
(PGE2)	O
within	O
hypothalamus.	O
PGE2	B-Drug

in	O
order	O
to	O
be	O
bioactivated;	O
this	O
makes	O
6-MAM	O
somewhat	O
more	O
potent	O
than	O
heroin.	O
heroin	B-Drug

PCP's	O
rewarding	O
and	O
reinforcing	O
effects	O
are	O
at	O
least	O
partly	O
mediated	O
by	O
blocking	O
the	O
NMDA	O
receptors	O
in	O
glutamatergic	O
inputs	O
to	O
D1-type	O
medium	O
spiny	O
neurons	O
nucleus	O
accumbens.	O
PCP	B-Drug

When	O
examination	O
of	O
Novartis'	O
patent	O
application	O
began	O
in	O
2005,	O
it	O
came	O
under	O
immediate	O
attack	O
from	O
oppositions	O
initiated	O
by	O
generic	O
companies	O
that	O
were	O
already	O
selling	O
Gleevec	B-Drug
India	O
and	O
advocacy	O
groups.	O

In	O
terminal	O
diseases,	O
there	O
is	O
no	O
ceiling	O
dose	O
for	O
opium	B-Drug
tincture;	O
the	O
increased	O
slowly	O
until	O
diarrhea	O
controlled.	O

Due	O
to	O
difficulties	O
in	O
procuring	O
heroin,	O
combined	O
with	O
easy	O
and	O
cheap	O
access	O
over-the-counter	O
pharmacy	O
products	O
containing	O
codeine	B-Drug
Russia,	O
use	O
of	O
krokodil	O
increased	O
until	O
2012.	O
heroin	B-Drug

Subsequent	O
legally-approved	O
MDMA	B-Drug
studies	O
in	O
humans	O
have	O
taken	O
place	O
the	O
US.	O

As	O
demand	O
for	O
more	O
and	O
better	O
cocaine	B-Drug
increased,	O
Escobar	O
began	O
working	O
with	O
Roberto	O
Surez	O
Gomz,	O
helping	O
to	O
further	O
the	O
product	O
other	O
countries	O
in	O
Americas	O
Europe,	O
as	O
well	O
being	O
rumored	O
reach	O
far	O
Asia.	O

Unused	O
fentanyl	B-Drug
patches	O
should	O
be	O
kept	O
in	O
a	O
secure	O
location	O
out	O
of	O
children's	O
sight	O
and	O
reach,	O
such	O
as	O
locked	O
cabinet.	O

This	O
helps	O
avoid	O
detection	O
but	O
reduces	O
the	O
CBD	B-Drug
production	O
of	O
plant.	O

The	O
pH	O
of	O
diazepam	B-Drug
is	O
neutral	O
(i.e.,	O
=	O
7).	O

Norepinephrine	O
reuptake	O
inhibitors	O
(NRIs):	O
atomoxetine,	O
mazindol,	O
reboxetine.	O
atomoxetine	B-Drug
mazindol	B-Drug
reboxetine	B-Drug

Possession	O
of	O
few	O
modafinil	B-Drug
pills	O
can	O
lead	O
to	O
310	O
years	O
imprisonment.	O

For	O
heroin	B-Drug
withdrawal,	O
symptoms	O
are	O
typically	O
greatest	O
at	O
two	O
to	O
four	O
days,	O
and	O
can	O
last	O
for	O
up	O
weeks.	O

EM-5854	O
and	O
its	O
metabolite	O
EM-5855	O
show	O
3.7-fold	O
94-fold	O
higher	O
affinity	O
for	O
the	O
human	O
AR	O
than	O
bicalutamide	B-Drug
(0.66%	O
17%	O
of	O
RBA	O
metribolone,	O
respectively,	O
compared	O
to	O
0.18%	O
bicalutamide).	O

Pete	O
Doherty	O
is	O
also	O
a	O
self-confessed	O
user	O
of	O
heroin.	O
heroin	B-Drug

Nalbuphine,	O
sold	O
under	O
the	O
brand	O
names	O
Nubain	B-Drug
among	O
others,	O
is	O
an	O
opioid	O
analgesic	O
which	O
used	O
in	O
treatment	O
of	O
pain.	O
Nalbuphine	B-Drug

In	O
psychotherapeutic	O
settings,	O
MDMA	B-Drug
effects	O
have	O
been	O
characterized	O
by	O
infantile	O
ideas,	O
mood	O
lability,	O
and	O
memories	O
moods	O
connected	O
with	O
childhood	O
experiences.	O

This	O
network	O
also	O
supplied	O
Europe	O
with	O
cocaine	B-Drug
from	O
the	O
Cali	O
KGB	O
cartel.	O

In	O
1573,	O
for	O
instance,	O
a	O
Venetian	O
visitor	O
to	O
the	O
Ottoman	O
Empire	O
observed	O
many	O
of	O
Turkish	O
natives	O
Constantinople	O
regularly	O
drank	O
"certain	O
black	O
water	O
made	O
with	O
opium"	O
that	O
makes	O
them	O
feel	O
good,	O
but	O
which	O
they	O
become	O
so	O
addicted,	O
if	O
try	O
go	O
without,	O
will	O
"quickly	O
die".	O
opium	B-Drug

Additionally,	O
apremilast	B-Drug
was	O
approved	O
by	O
the	O
FDA	O
in	O
March	O
2014.	O

The	O
regulatory	O
authorities	O
in	O
East	O
Germany	O
did	O
not	O
approve	O
thalidomide.	O
thalidomide	B-Drug

These	O
include	O
airdrops	O
of	O
500	O
to	O
700	O
kg	O
(1,100	O
1,500	O
lb)	O
in	O
the	O
Bahama	O
Islands	O
or	O
off	O
coast	O
Puerto	O
Rico,	O
mid-ocean	O
boat-to-boat	O
transfers	O
2,000	O
4,400	O
lb),	O
and	O
commercial	O
shipment	O
tonnes	O
cocaine	B-Drug
through	O
port	O
Miami.	O

N-Desmethylenzalutamide	O
is	O
formed	O
from	O
enzalutamide	B-Drug
in	O
the	O
liver	O
by	O
cytochrome	O
P450	O
enzymes	O
CYP2C8	O
and	O
CYP3A4.	O

Ketamine	B-Drug
has	O
been	O
found	O
to	O
increase	O
dopaminergic	O
neurotransmission	O
in	O
the	O
brain,	O
but	O
instead	O
of	O
being	O
due	O
dopamine	O
reuptake	O
inhibition,	O
this	O
may	O
be	O
via	O
indirect/downstream	O
mechanisms,	O
namely	O
through	O
antagonism	O
NMDA	O
receptor.	O

Street	O
users	O
of	O
LSD	B-Drug
are	O
often	O
under	O
the	O
impression	O
that	O
blotter	O
paper	O
which	O
is	O
actively	O
hallucinogenic	O
can	O
only	O
be	O
because	O
chemical	O
with	O
low	O
enough	O
doses	O
to	O
fit	O
on	O
a	O
small	O
square	O
paper.	O

Recreational	O
drug	O
users	O
commonly	O
use	O
nicotine	B-Drug
for	O
its	O
mood-altering	O
effects.	O

Hydrocortisone	B-Drug
1%	O
(Many	O
over-the-counter	O
brands)	O

Many	O
bodybuilders	O
and	O
athletes	O
use	O
oxandrolone	B-Drug
for	O
its	O
muscle-building	O
effects.	O

It	O
is	O
also	O
now	O
generally	O
accepted	O
that	O
MDMA	B-Drug
neurotoxicity	O
results	O
from	O
a	O
variety	O
of	O
different	O
causes	O
and	O
not	O
solely	O
due	O
to	O
accumulation	O
alpha-methyldopamine,	O
making	O
it	O
unclear	O
how	O
much	O
less	O
neurotoxic	O
DFMDA	O
related	O
drugs	O
would	O
be	O
in	O
practice.	O

Trials	O
of	O
chlortalidone	B-Drug
for	O
high	O
blood	O
pressure	O
found	O
that	O
lower	O
doses	O
(e.g.,	O
12.5	O
mg	O
daily	O
in	O
ALLHAT	O
study)	O
had	O
maximal	O
lowering	O
effect	O
and	O
higher	O
did	O
not	O
it	O
more.	O

Ciclosporin,	O
may	O
increase	O
plasma	O
levels	O
of	O
ciclosporin.	O
Ciclosporin	B-Drug
ciclosporin	B-Drug

The	O
synthesis	O
and	O
structure	O
elucidation	O
of	O
cocaine	B-Drug
was	O
reported	O
by	O
Richard	O
Willsttter	O
in	O
1898.	O

Dexamyl	O
utilized	O
its	O
enantiopure	O
isomer	O
of	O
greater	O
central	O
nervous	O
system	O
(CNS)	O
selectivity,	O
dextroamphetamine	B-Drug
sulfate,	O
to	O
elevate	O
mood	O
and	O
suppress	O
appetite,	O
whereas	O
the	O
concomitant	O
barbiturate	O
was	O
included	O
broadly	O
counteract	O
potential	O
adverse	O
effects	O
from	O
dextroamphetamine.	O
sulfate	I-Drug

PCP	B-Drug
may	O
induce	O
feelings	O
of	O
strength,	O
power,	O
and	O
invulnerability	O
as	O
well	O
a	O
numbing	O
effect	O
on	O
the	O
mind.	O

'	O
Benzoxazines	O
(more	O
specifically	O
cyclopropylethynylated	O
benzoxazines)	O
Substituted	O
benzoxazines	O
Efavirenz,	O
the	O
active	O
constituent	O
of	O
Sustiva,	O
Stocrin,	O
and	O
Efavir	O
Efavirenz	B-Drug
Sustiva	B-Drug

Levothyroxine	B-Drug
for	O
systemic	O
administration	O
is	O
available	O
as	O
an	O
oral	O
tablet,	O
intramuscular	O
injection,	O
and	O
a	O
solution	O
intravenous	O
infusion.	O

The	O
FDA	O
initially	O
did	O
not	O
approve	O
Sugammadex	B-Drug
due	O
to	O
concerns	O
over	O
potential	O
allergic	O
reactions,	O
however	O
it	O
was	O
subsequently	O
approved	O
on	O
December	O
15,	O
2015	O
for	O
use	O
in	O
the	O
United	O
States.	O

The	O
mean	O
elimination	O
half-life	O
of	O
apalutamide	B-Drug
at	O
steady-state	O
is	O
3	O
to	O
4	O
days.	O

Phencyclidine	B-Drug
or	O
phenylcyclohexyl	O
piperidine	O
(PCP),	O
also	O
known	O
as	O
angel	B-Drug
dust	I-Drug
among	O
other	O
names,	O
is	O
a	O
drug	O
used	O
for	O
its	O
mind-altering	O
effects.	O
PCP	B-Drug

Also	O
in	O
1884,	O
Jellinek	O
demonstrated	O
the	O
effects	O
of	O
cocaine	B-Drug
as	O
a	O
respiratory	O
system	O
anesthetic.	O

Various	O
enhancements	O
exist	O
in	O
the	O
California	O
Health	O
and	O
Safety	O
Code	O
for	O
dealing	O
cocaine	B-Drug
which	O
may	O
result	O
very	O
long	O
prison	O
terms,	O
such	O
as	O
selling	O
to	O
a	O
minor,	O
school	O
zone,	O
large	O
quantities	O
of	O
drug.	O

Racecadotril	B-Drug
also	O
has	O
no	O
influence	O
on	O
the	O
time	O
substances,	O
bacteria	O
or	O
virus	O
particles	O
stay	O
in	O
intestine.	O

Morphine-N-oxide	O
(genomorphine)	O
is	O
an	O
active	O
opioid	O
metabolite	O
of	O
morphine.	O
morphine	B-Drug

PCP,	O
like	O
ketamine,	O
also	O
acts	O
as	O
a	O
potent	O
dopamine	O
D2High	O
receptor	O
partial	O
agonist	O
in	O
rat	O
brain	O
homogenate	O
and	O
has	O
affinity	O
for	O
the	O
human	O
cloned	O
receptor.	O
PCP	B-Drug
ketamine	B-Drug

Like	O
many	O
other	O
first-generation	O
antihistamines,	O
diphenhydramine	B-Drug
is	O
also	O
a	O
potent	O
antimuscarinic	O
(a	O
competitive	O
antagonist	O
of	O
muscarinic	O
acetylcholine	O
receptors)	O
and,	O
as	O
such,	O
at	O
high	O
doses	O
can	O
cause	O
anticholinergic	O
syndrome.	O

Tetrahydrocannabinol	B-Drug
(THC)	O
is	O
the	O
main	O
psychoactive	O
component	O
of	O
cannabis,	O
which	O
one	O
483	O
known	O
compounds	O
in	O
plant,	O
including	O
at	O
least	O
65	O
other	O
cannabinoids,	O
cannabidiol	B-Drug
(CBD).	O
THC	B-Drug
CBD	B-Drug

Vehicle	O
or	O
4-methylaminorex	B-Drug
doses	O
were	O
substituted	O
for	O
cocaine.	O
cocaine	B-Drug

In	O
Iceland,	O
Flunitrazepam	B-Drug
is	O
a	O
controlled	O
substance	O
available	O
from	O
Mylan.	O

The	O
Professional	O
(1994)	O
cocaine	B-Drug
Leprechaun	O
in	O
the	O
Hood	O
(2000)	O

Chlortalidone	B-Drug
is	O
eliminated	O
from	O
the	O
body	O
mostly	O
by	O
kidney,	O
as	O
unchanged	O
drug.	O

One	O
published	O
study	O
that	O
analysed	O
samples	O
of	O
mephedrone	B-Drug
bought	O
using	O
the	O
internet	O
in	O
UK	O
2010	O
found	O
it	O
was	O
racemic	O
(a	O
mixture	O
both	O
stereoisomers)	O
and	O
high	O
purity.	O

The	O
DEA	O
lists	O
oxycodone	B-Drug
both	O
for	O
sale	O
and	O
use	O
in	O
manufacturing	O
other	O
opioids	O
as	O
ACSCN	O
9143	O
2013	O
approved	O
the	O
following	O
annual	O
aggregate	O
quotas:	O
131.5	O
metric	O
tons	O
sale,	O
down	O
from	O
153.75	O
2012,	O
10.25	O
conversion,	O
unchanged	O
previous	O
year.	O

Because	O
of	O
its	O
relatively	O
long	O
duration	O
action,	O
and	O
evidence	O
safety	O
efficacy,	O
diazepam	B-Drug
is	O
preferred	O
over	O
other	O
benzodiazepines	O
for	O
treatment	O
persons	O
experiencing	O
moderate	O
to	O
severe	O
alcohol	O
withdrawal.	O

New	O
products	O
containing	O
CBD	B-Drug
after	O
this	O
deadline	O
will	O
require	O
a	O
fully	O
approved	O
application.	O

Tolerance	O
to	O
opioids	O
is	O
attenuated	O
by	O
a	O
number	O
of	O
substances,	O
including:	O
calcium	O
channel	O
blockers	O
intrathecal	O
magnesium	O
and	O
zinc	O
NMDA	O
antagonists,	O
such	O
as	O
dextromethorphan,	O
ketamine,	O
memantine.	O
dextromethorphan	B-Drug
ketamine	B-Drug
memantine	B-Drug

The	O
price	O
of	O
illicit	O
opium	B-Drug
far	O
exceeds	O
that	O
licit,	O
(in	O
India,	O
in	O
2000,	O
the	O
for	O
licit	O
was	O
US$1329	O
per	O
kilo,	O
but	O
US$155206).	O

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms,	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O

Finally,	O
independent	O
testing	O
of	O
the	O
tetanus	B-Drug
vaccine	I-Drug
by	O
Kenya's	O
health	O
authorities	O
has	O
revealed	O
no	O
traces	O
human	O
chorionic	O
gonadotropin	O
hormone.	O

Governments	O
that	O
support	O
a	O
harm	O
reduction	O
approach	O
usually	O
fund	O
needle	O
and	O
syringe	O
exchange	O
programs,	O
which	O
supply	O
new	O
needles	O
syringes	O
on	O
confidential	O
basis,	O
as	O
well	O
education	O
proper	O
filtering	O
before	O
injection,	O
safer	O
injection	O
techniques,	O
safe	O
disposal	O
of	O
used	O
injecting	O
gear	O
other	O
equipment	O
when	O
preparing	O
diamorphine	B-Drug
for	O
may	O
also	O
be	O
supplied	O
including	O
citric	O
acid	O
sachets/vitamin	O
C	I-Drug
sachets,	O
steri-cups,	O
filters,	O
alcohol	O
pre-injection	O
swabs,	O
sterile	O
water	O
ampules	O
tourniquets	O
(to	O
stop	O
the	O
use	O
shoelaces	O
or	O
belts).	O
vitamin	B-Drug

Only	O
one	O
other	O
drug,	O
Anipryl	B-Drug
(veterinary	O
brand	O
name)	O
selegiline,	O
is	O
FDA-approved	O
to	O
treat	O
Cushing's	O
disease	O
in	O
dogs,	O
but	O
only	O
uncomplicated,	O
pituitary-dependent	O
Cushing's.	O
selegiline	B-Drug

Naloxone	B-Drug
is	O
useful	O
for	O
treating	O
an	O
opioid	O
overdose	O
and	O
giving	O
those	O
at	O
risk	O
naloxone	B-Drug
to	O
take	O
home	O
beneficial.	O

When	O
referring	O
to	O
stimulants,	O
the	O
parent	O
drug	O
(e.g.,	O
amphetamine)	O
will	O
always	O
be	O
expressed	O
in	O
singular;	O
with	O
word	O
"substituted"	O
placed	O
before	O
(substituted	O
amphetamines).	O
amphetamine	B-Drug

Twenty-three	O
ADB-FUBINACA	B-Drug
major	O
metabolites	O
were	O
identified	O
in	O
several	O
incubations	O
with	O
cryopreserved	O
human	O
hepatocytes.	O

Because	O
the	O
price	O
of	O
Lucentis	B-Drug
is	O
much	O
higher	O
than	O
Avastin,	O
many	O
ophthalmologists	O
began	O
having	O
compounding	O
pharmacies	O
formulate	O
Avastin	B-Drug
for	O
administration	O
to	O
eye,	O
and	O
treating	O
their	O
patients	O
with	O
Avastin.	O

By	O
1905,	O
there	O
were	O
many	O
laws	O
in	O
place	O
which	O
prohibited	O
the	O
import	O
and	O
use	O
of	O
smoking	O
grade	O
opium;	O
however,	O
by	O
1930s,	O
Australia	O
had	O
developed	O
world's	O
highest	O
per	O
capita	O
rate	O
heroin	B-Drug
consumption.	O
opium	B-Drug

O-Acetylpsilocin	B-Drug
is	O
illegal	O
in	O
Italy	O
as	O
it	O
an	O
ester	O
of	O
a	O
prohibited	O
substance.	O

Codeine	B-Drug
is	O
the	O
natural	O
mono-methyl	O
ether,	O
but	O
must	O
be	O
metabolized	O
for	O
activity	O
(that	O
is,	O
it	O
a	O
prodrug).	O

HHC	O
A-796,260	B-Drug
A-834,735	B-Drug
A-836,339	B-Drug
A-955,840	O
A-40174	O
A-41988	O
A-42574	O
AB-001	B-Drug
AB-CHFUPYCA	B-Drug
AB-CHMFUPPYCA	B-Drug
AB-CHMINACA	B-Drug
AB-FUBICA	B-Drug
AB-FUBINACA	B-Drug
2-fluorobenzyl	O
isomer	O
AB-PICA	B-Drug
AB-PINACA	B-Drug

Approximate	O
cocaine	B-Drug
purity	O
can	O
be	O
determined	O
using	O
1	O
mL	O
2%	O
cupric	O
sulfate	O
pentahydrate	O
in	O
dilute	O
HCl,	O
potassium	O
thiocyanate	O
and	O
2	O
of	O
chloroform.	O

In	O
1903,	O
he	O
published	O
observations	O
that	O
barbital	B-Drug
(then	O
known	O
as	O
diethyl-barbituric	O
acid)	O
has	O
sedative	O
properties	O
in	O
humans.	O

THC	B-Drug
appears	O
to	O
alter	O
mood	O
and	O
cognition	O
through	O
its	O
agonist	O
actions	O
on	O
the	O
CB1	O
receptors,	O
which	O
inhibit	O
a	O
secondary	O
messenger	O
system	O
(adenylate	O
cyclase)	O
in	O
dose-dependent	O
manner.	O

In	O
Russia,	O
desomorphine	B-Drug
was	O
declared	O
an	O
illegal	O
narcotic	O
analgesic	O
in	O
1998.	O

"	O
The	O
three	O
main	O
forms	O
of	O
cannabis	O
products	O
are	O
the	O
flower/fruit,	O
resin	O
(hashish),	O
and	O
oil	I-Drug
(hash	O
oil).	O
hashish	B-Drug
hash	B-Drug

Phenylpropanolamine	B-Drug
(PPA)	O
is	O
a	O
sympathomimetic	O
agent	O
which	O
used	O
as	O
decongestant	O
and	O
appetite	O
suppressant.	O

Hardening	O
of	O
Canadian	O
attitudes	O
toward	O
Chinese-Canadian	O
opium	B-Drug
users	O
and	O
fear	O
a	O
spread	O
the	O
drug	O
into	O
white	O
population	O
led	O
to	O
effective	O
criminalization	O
for	O
nonmedical	O
use	O
in	O
Canada	O
between	O
1908	O
mid-1920s.	O

Fentanyl	B-Drug
has	O
a	O
therapeutic	O
index	O
of	O
270.	O

Nociceptin	O
is	O
a	O
peptide	O
related	O
to	O
the	O
opioid	O
class	O
of	O
compounds	O
(ex.	O
morphine	B-Drug
and	O
codeine),	O
but	O
it	O
does	O
not	O
act	O
at	O
classic	O
receptors	O
(namely,	O
mu,	O
kappa,	O
delta	O
receptors)	O
which	O
typically	O
as	O
pain	O
relievers.	O
codeine	B-Drug

FDA	O
also	O
reported	O
that	O
if	O
individuals	O
comprehend	O
instructions,	O
administer	O
naloxone	B-Drug
and	O
call	O
911,	O
many	O
lives	O
will	O
be	O
saved.	O

As	O
of	O
October	O
31,	O
2016;	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
(Schedule	O
III)	O
in	O
Canada.	O

the	O
4-position	O
as	O
in	O
JWH-081.	O
JWH-081	B-Drug

Methcathinone	B-Drug
production	O
utilizes	O
the	O
oxidation	O
of	O
pseudoephedrine	B-Drug
or	O
ephedrine,	O
former	O
being	O
preferred	O
because	O
much	O
higher	O
yields	O
achieved.	O
ephedrine	B-Drug

There	O
has	O
been	O
a	O
report	O
of	O
hepatitis	O
caused	O
by	O
clotiazepam.	O
clotiazepam	B-Drug

a	O
District	O
Court	O
in	O
Liberec	O
was	O
deciding	O
case	O
of	O
person	O
that	O
accused	O
criminal	O
possession	O
for	O
having	O
3.25	O
grams	O
methamphetamine	B-Drug
(1.9	O
straight	O
base),	O
well	O
over	O
the	O
Regulation's	O
limit	O
2	O
grams.	O

Diacetylnalorphine	O
may	O
behave	O
as	O
a	O
prodrug	O
to	O
nalorphine,	O
similarly	O
the	O
cases	O
of	O
heroin	B-Drug
(diacetylmorphine)	O
morphine	B-Drug
and	O
diacetyldihydromorphine	B-Drug
dihydromorphine.	O
nalorphine	B-Drug
diacetylmorphine	B-Drug
dihydromorphine	B-Drug

In	O
contrast	O
the	O
semi-synthetic	O
mono-methyl	O
ether,	O
heterocodeine	B-Drug
is	O
a	O
direct	O
agonist.	O

Fentanyl	B-Drug
is	O
sometimes	O
sold	O
on	O
the	O
black	O
market	O
in	O
form	O
of	O
transdermal	O
fentanyl	B-Drug
patches	O
such	O
as	O
Duragesic,	O
diverted	O
from	O
legitimate	O
medical	O
supplies.	O
Duragesic	B-Drug

Drying	O
is	O
done	O
in	O
a	O
dark	O
place,	O
as	O
THC	B-Drug
resins	O
deteriorate	O
if	O
exposed	O
to	O
light	O
and	O
the	O
degradation	O
product	O
CBN	B-Drug
forms,	O
significantly	O
altering	O
cannabinoid	O
profile	O
of	O
dried	O
flowers.	O

No	O
double	O
blind	O
studies	O
had	O
yet	O
been	O
conducted	O
as	O
to	O
the	O
efficacy	O
of	O
MDMA	B-Drug
for	O
therapy.	O

25I-NBOMe,	O
25B-NBOMe	B-Drug
and	O
25C-NBOMe	B-Drug
are	O
currently	O
Schedule	O
1	O
Substances	O
according	O
to	O
21	O
CFR	O
1308.11(d)	O
25I-NBOMe	B-Drug

Nabiximols	B-Drug
is	O
a	O
branded	O
product	O
name	O
from	O
tincture	O
manufacturing	O
pharmaceutical	O
company.	O

Propranolol	B-Drug
is	O
not	O
recommended	O
for	O
the	O
treatment	O
of	O
high	O
blood	O
pressure	O
by	O
Eighth	O
Joint	O
National	O
Committee	O
(JNC	O
8)	O
because	O
a	O
higher	O
rate	O
primary	O
composite	O
outcome	O
cardiovascular	O
death,	O
myocardial	O
infarction,	O
or	O
stroke	O
compared	O
to	O
an	O
angiotensin	O
receptor	O
blocker	O
was	O
noted	O
in	O
one	O
study.	O

Although	O
25I-NBOMe	B-Drug
was	O
discovered	O
in	O
2003,	O
it	O
did	O
not	O
emerge	O
as	O
a	O
common	O
recreational	O
drug	O
until	O
2010,	O
when	O
first	O
sold	O
by	O
vendors	O
specializing	O
the	O
supply	O
of	O
designer	O
drugs.	O

Whereas	O
opioids	O
like	O
codeine,	O
hydrocodone,	O
oxycodone,	O
and	O
hydromorphone	B-Drug
are	O
synthesized	O
by	O
simple	O
modifications	O
of	O
morphine,	O
fentanyl	B-Drug
its	O
relatives	O
meperidine.	O
codeine	B-Drug
hydrocodone	B-Drug
oxycodone	B-Drug
morphine	B-Drug
meperidine	B-Drug

The	O
original	O
Mexican	O
Spanish	O
used	O
forms	O
with	O
the	O
letter	O
h	O
(marihuana),	O
and	O
is	O
famously	O
in	O
Revolutionary	O
era	O
(1910-1920)	O
version	O
of	O
lyrics	O
La	O
Cucaracha.	O
marihuana	B-Drug

Nitrazepam	B-Drug
has	O
been	O
found	O
to	O
be	O
dangerous	O
in	O
elderly	O
patients	O
due	O
a	O
significantly	O
increased	O
risk	O
of	O
falls.	O

JWH-018	B-Drug
usage	O
is	O
readily	O
detected	O
in	O
urine	O
using	O
"spice"	O
screening	O
immunoassays	O
from	O
several	O
manufacturers	O
focused	O
on	O
both	O
the	O
parent	O
drug	O
and	O
its	O
omega-hydroxy	O
carboxyl	O
metabolites.	O

In	O
August	O
2018,	O
the	O
United	O
States	O
used	O
fentanyl	B-Drug
for	O
first	O
time	O
to	O
execute	O
a	O
prisoner.	O

The	O
International	O
Narcotics	O
Control	O
Board	O
estimated	O
11.5	O
short	O
tons	O
(10.4	O
t)	O
of	O
oxycodone	B-Drug
were	O
manufactured	O
worldwide	O
in	O
1998;	O
by	O
2007	O
this	O
figure	O
had	O
grown	O
to	O
75.2	O
(68.2	O
t).	O

Clorazepate	B-Drug
is	O
prescribed	O
principally	O
in	O
the	O
treatment	O
of	O
alcohol	O
withdrawal	O
and	O
epilepsy,	O
although	O
it	O
also	O
a	O
useful	O
anxiolytic	O
because	O
its	O
long	O
half-life.	O

In	O
the	O
US,	O
fentanyl	B-Drug
and	O
analogs	O
caused	O
over	O
29,000	O
deaths	O
in	O
2017,	O
a	O
large	O
increase	O
previous	O
four	O
years.	O

25I-NBOMe	B-Drug
(2C-I-NBOMe,	O
Cimbi-5,	O
also	O
shortened	O
to	O
"25I")	O
is	O
a	O
synthetic	O
hallucinogen	O
that	O
used	O
in	O
biochemistry	O
research	O
for	O
mapping	O
the	O
brain's	O
usage	O
of	O
type	O
2A	O
serotonin	O
receptor;	O
it	O
sometimes	O
recreational	O
purposes.	O
2C-I-NBOMe	B-Drug

The	O
effectiveness	O
increases	O
to	O
greater	O
than	O
90%	O
if	O
misoprostol	B-Drug
is	O
given	O
after	O
the	O
mifepristone.	O
mifepristone	B-Drug

It	O
is	O
unclear,	O
however,	O
whether	O
the	O
increase	O
in	O
THC	B-Drug
content	O
has	O
caused	O
people	O
to	O
consume	O
more	O
or	O
if	O
users	O
adjust	O
based	O
on	O
potency	O
of	O
cannabis.	O

JWH-018	B-Drug

Norpropoxyphene	O
is	O
a	O
more	O
potent	O
local	O
anesthetic	O
than	O
propoxyphene,	O
and	O
they	O
are	O
both	O
lidocaine.	O
propoxyphene	B-Drug
lidocaine	B-Drug

In-utero	O
exposure	O
to	O
cocaine	B-Drug
is	O
associated	O
with	O
behavioral	O
abnormalities,	O
cognitive	O
impairment,	O
cardiovascular	O
malformations,	O
intrauterine	O
growth	O
restriction,	O
preterm	O
birth,	O
urinary	O
tract	O
and	O
cleft	O
lip	O
palate.	O

Cocaine's	O
desired	O
euphoric	O
effects	O
are	O
delayed	O
when	O
snorted	O
through	O
the	O
nose	O
by	O
about	O
five	O
minutes.	O
Cocaine	B-Drug

The	O
World	O
Health	O
Organization	O
(WHO)	O
states	O
that	O
"Much	O
of	O
the	O
disease	O
burden	O
and	O
premature	O
mortality	O
attributable	O
to	O
tobacco	B-Drug
use	O
disproportionately	O
affect	O
poor".	O

Brands	O
as	O
of	O
that	O
date	O
for	O
the	O
combination	O
with	O
perphenazine	B-Drug
included	O
Levazine,	O
Minitran,	O
Mutabase,	O
Mutabon,	O
Pertriptyl,	O
Triavil,	O
and	O
Triptafen.	O

Norethisterone	B-Drug
enanthate	I-Drug
(norethindrone	O
enanthate;	O
Noristerat,	O
Norigest)	O

Extrapyramidal	O
symptoms	O
may	O
subside	O
somewhat	O
after	O
a	O
person	O
switches	O
from	O
another	O
antipsychotic	O
to	O
clozapine.	O
clozapine	B-Drug

Androstenedione	B-Drug
was	O
legal	O
and	O
able	O
to	O
be	O
purchased	O
over	O
the	O
counter,	O
and,	O
as	O
a	O
consequence,	O
it	O
in	O
common	O
use	O
Major	O
League	O
Baseball	O
throughout	O
1990s	O
by	O
record-breaking	O
sluggers	O
like	O
Mark	O
McGwire.	O

It	O
uses	O
a	O
medication	O
delivery	O
technology	O
called	O
BEMA	O
(BioErodible	O
MucoAdhesive),	O
small	O
dissolvable	O
polymer	O
film	O
containing	O
various	O
fentanyl	B-Drug
doses	O
applied	O
to	O
the	O
inner	O
lining	O
of	O
cheek.	O

BIM-018	B-Drug

Fentanyl	B-Drug
use	O
has	O
also	O
been	O
associated	O
with	O
aphasia.	O

A	O
large	O
hairpin	O
was	O
used	O
to	O
make	O
a	O
hole	O
in	O
the	O
skin	O
and	O
dropper	O
containing	O
drug	O
(usually	O
heroin)	O
inserted	O
bulb	O
squeezed,	O
releasing	O
it	O
into	O
tissues.	O
heroin	B-Drug

Heptabarbital	B-Drug
(5-(1-cyclohepten-1-yl)-5-ethylbarbituric	O
acid)	O

The	O
lawsuit	O
alleged	O
that	O
Murray	O
repeatedly	O
lied	O
to	O
cover	O
up	O
his	O
use	O
of	O
propofol,	O
did	O
not	O
keep	O
sufficient	O
medical	O
records	O
and	O
was	O
negligent	O
in	O
medications	O
on	O
Jackson.	O
propofol	B-Drug

Medical	O
examiners	O
concluded	O
that	O
musician	O
Prince	O
died	O
on	O
April	O
21,	O
2016,	O
from	O
an	O
accidental	O
fentanyl	B-Drug
overdose.	O

Methamphetamine	B-Drug
may	O
counteract	O
the	O
effects	O
of	O
antihypertensives	O
and	O
antipsychotics	O
due	O
to	O
its	O
on	O
cardiovascular	O
system	O
cognition	O
respectively.	O

Two	O
reviews	O
noted	O
a	O
study	O
where	O
the	O
mean	O
24	O
hour	O
urinary	O
phenylacetic	O
acid	O
concentration	O
following	O
just	O
30	O
minutes	O
of	O
intense	O
exercise	O
rose	O
77%	O
above	O
its	O
base	O
level;	O
suggest	O
that	O
phenethylamine	B-Drug
synthesis	O
sharply	O
increases	O
during	O
physical	O
which	O
it	O
is	O
rapidly	O
metabolized	O
due	O
to	O
short	O
half-life	O
roughly	O
seconds.	O

Most	O
are	O
lipid-soluble,	O
non-polar,	O
small	O
molecules	O
(usually	O
20-26	O
carbon	O
atoms)	O
that	O
fairly	O
volatile,	O
making	O
them	O
"smokable,"	O
like	O
THC.	O
THC	B-Drug

Nicotiana	O
rustica	O
follows	O
as	O
second	O
containing	O
higher	O
concentrations	O
of	O
nicotine.	O
nicotine	B-Drug

There	O
are	O
no	O
expected	O
pharmacokinetic	O
interactions	O
between	O
thalidomide	B-Drug
and	O
other	O
medicines	O
due	O
to	O
its	O
neutral	O
effects	O
on	O
P-glycoprotein	O
the	O
cytochrome	O
P450	O
family.	O

Alphaprodine	B-Drug
was	O
sold	O
under	O
several	O
brand	O
names,	O
mainly	O
Nisentil	O
and	O
Prisilidine.	O

Japan	O
is	O
the	O
sole	O
manufacturer	O
of	O
nimetazepam	B-Drug
in	O
world.	O

In	O
2007	O
piperazine	O
based	O
party-pill	O
formulations	O
started	O
to	O
become	O
widely	O
available	O
nationwide	O
which	O
has	O
caused	O
concern	O
with	O
local	O
authorities	O
such	O
as	O
Health	O
Canada	O
and	O
subsequently	O
BZP	B-Drug
gained	O
much	O
media	O
attention	O
in	O
2008.	O

Naltrexone	B-Drug
can	O
be	O
described	O
as	O
a	O
substituted	O
oxymorphone	B-Drug
here	O

Lysergic	O
acid	I-Drug
is	O
made	O
by	O
alkaline	O
hydrolysis	O
of	O
lysergamides	O
like	O
ergotamine,	O
a	O
substance	O
usually	O
derived	O
from	O
the	O
ergot	O
fungus	O
on	O
agar	O
plate;	O
or,	O
theoretically	O
possible,	O
but	O
impractical	O
and	O
uncommon,	O
ergine	B-Drug
(lysergic	O
amide,	O
LSA)	O
extracted	O
morning	O
glory	O
seeds.	O
ergotamine	B-Drug
lysergic	B-Drug
amide	I-Drug

A	O
review	O
of	O
the	O
literature	O
found	O
that	O
long-term	O
use	O
benzodiazepines	O
such	O
as	O
estazolam	B-Drug
is	O
associated	O
with	O
drug	O
tolerance,	O
dependence,	O
rebound	O
insomnia	O
and	O
CNS	O
related	O
adverse	O
effects.	O

Melatonin	B-Drug
augmentation	O
was	O
found	O
to	O
statistically	O
increase	O
the	O
discontinuation	O
success	O
rate	O
for	O
people	O
with	O
insomnia.	O

Fentanyl	B-Drug
decreases	O
the	O
heart	O
rate	O
by	O
increasing	O
vagal	O
nerve	O
tone	O
in	O
brainstem,	O
which	O
increases	O
parasympathetic	O
drive.	O

-Methylacetylfentanyl	O
(or	O
alphamethylacetylfentanyl)	O
is	O
an	O
opioid	O
analgesic	O
that	O
analog	O
of	O
fentanyl.	O
fentanyl	B-Drug

In	O
2015,	O
Governor	O
Pat	O
McCrory	O
signed	O
into	O
law	O
HB766,	O
allowing	O
those	O
with	O
intractable	O
epilepsy	O
to	O
use	O
CBD	B-Drug
oil.	O
oil	I-Drug

On	O
April	O
19,	O
1943,	O
Hofmann	O
performed	O
a	O
self-experiment	O
to	O
determine	O
the	O
true	O
effects	O
of	O
LSD,	O
intentionally	O
ingesting	O
0.25	O
milligrams	O
(250	O
micrograms)	O
substance,	O
an	O
amount	O
he	O
predicted	O
be	O
threshold	O
dose	O
(an	O
actual	O
is	O
0.02	O
milligrams).	O
LSD	B-Drug

More	O
than	O
12	O
different	O
analogues	O
of	O
fentanyl,	O
all	O
unapproved	O
and	O
clandestinely	O
produced,	O
have	O
been	O
identified	O
in	O
the	O
U.S.	O
drug	O
traffic.	O
fentanyl	B-Drug

With	O
sulfamethoxazole	B-Drug
or	O
dapsone	B-Drug
it	O
may	O
be	O
used	O
for	O
Pneumocystis	O
pneumonia	O
in	O
people	O
with	O
HIV/AIDS.	O

Common	O
adverse	O
drug	O
reactions	O
(ADRs)	O
associated	O
with	O
metoclopramide	B-Drug
therapy	O
include	O
restlessness	O
(akathisia),	O
and	O
focal	O
dystonia.	O

heroin,	O
methamphetamine	B-Drug
A	O
Bucket	O
of	O
Blood	O
(1959)	O
heroin	B-Drug
Buffalo	O
Soldiers	O
(2001)	O

amobarbital	B-Drug
>	O

A	O
university-led	O
study	O
(including	O
several	O
authors	O
who	O
are	O
advisors	O
to	O
companies	O
such	O
as	O
Pfizer)	O
in	O
103	O
women	O
comparing	O
alfatradiol	B-Drug
minoxidil,	O
another	O
topical	O
hair	O
loss	O
treatment,	O
found	O
the	O
latter	O
be	O
more	O
effective.	O
minoxidil	B-Drug

Clomifene	B-Drug
is	O
a	O
triphenylethylene	O
derivative.	O

Soon	O
the	O
lines	O
between	O
legitimate	O
research	O
and	O
personal	O
experimentation	O
began	O
to	O
blur	O
for	O
some,	O
as	O
early	O
1962	O
fellow	O
faculty	O
members	O
at	O
Harvard	O
openly	O
criticized	O
Leary	O
Alpert	O
abandoning	O
scientific	O
principles	O
experimenting	O
with	O
LSD	B-Drug
outside	O
official	O
settings.	O

butorphanol	B-Drug
(agonist-antagonist	O

Methamphetamine	B-Drug
properly	O
refers	O
to	O
a	O
specific	O
chemical,	O
the	O
racemic	O
free	O
base,	O
which	O
is	O
an	O
equal	O
mixture	O
of	O
levomethamphetamine	B-Drug
and	O
dextromethamphetamine	B-Drug
in	O
their	O
pure	O
amine	O
forms.	O

Once	O
benzodiazepine	O
dependence	O
has	O
been	O
established,	O
a	O
clinician	O
usually	O
converts	O
the	O
patient	O
to	O
an	O
equivalent	O
dose	O
of	O
diazepam	B-Drug
before	O
beginning	O
gradual	O
reduction	O
program.	O

In	O
the	O
United	O
States,	O
immediate	O
and	O
extended	O
release	O
formulations	O
of	O
Adderall	B-Drug
are	O
both	O
available	O
as	O
generic	O
drugs,	O
while	O
Mydayis	O
is	O
only	O
a	O
brand-name	O
drug.	O

1P-ETH-LAD	B-Drug
(1-propionyl-6-ethyl-6-nor-lysergic	O
acid	B-Drug
diethyamide)	O
is	O
an	O
analog	O
of	O
LSD.	O
LSD	B-Drug

Some	O
studies	O
indicate	O
repeated	O
recreational	O
use	O
of	O
ecstasy	B-Drug
is	O
associated	O
with	O
depression	O
and	O
anxiety,	O
even	O
after	O
quitting	O
the	O
drug.	O

Tolerance	O
to	O
the	O
anticonvulsant	O
effects	O
of	O
clonazepam	B-Drug
occurs	O
in	O
both	O
animals	O
and	O
humans.	O

In	O
2016,	O
about	O
21	O
million	O
people	O
between	O
the	O
ages	O
of	O
15	O
and	O
64	O
used	O
ecstasy	B-Drug
(0.3%	O
world	O
population).	O

Clonazepam,	O
when	O
used	O
late	O
in	O
pregnancy,	O
may	O
result	O
the	O
development	O
of	O
a	O
severe	O
benzodiazepine	O
withdrawal	O
syndrome	O
neonate.	O
Clonazepam	B-Drug

Meptazinol	B-Drug
is	O
a	O
3-phenylazepane	O
derivative,	O
whereas	O
the	O
other	O
phenazepanes	O
like	O
ethoheptazine	B-Drug
and	O
proheptazine	B-Drug
are	O
4-phenylazepanes.	O

Ketamine	B-Drug
is	O
associated	O
with	O
nightmares,	O
delirium,	O
and	O
hallucinations.	O

Formation	O
of	O
inactive	O
stereoisomers	O
(cocaine	O
has	O
4	O
chiral	O
centres	O
1R,	O
2R,	O
3S,	O
and	O
5S,	O
2	O
them	O
dependent,	O
hence	O
a	O
total	O
potential	O
8	O
possible	O
stereoisomers)	O
plus	O
synthetic	O
by-products	O
limits	O
the	O
yield	O
purity.	O
cocaine	B-Drug

It	O
has	O
been	O
used	O
as	O
an	O
intermediate	O
in	O
the	O
preparation	O
of	O
radiolabeled	O
diethyltryptamine.	O
diethyltryptamine	B-Drug

People	O
who	O
harvest	O
or	O
cultivate	O
tobacco	B-Drug
may	O
experience	O
Green	O
Tobacco	O
Sickness	O
(GTS),	O
a	O
type	O
of	O
nicotine	O
poisoning	O
caused	O
by	O
dermal	O
exposure	O
to	O
wet	O
leaves.	O

Gastrointestinal	O
alkalizing	O
(acidifying)	O
agents	O
increase	O
the	O
absorption	O
of	O
amphetamine.	O
amphetamine	B-Drug

The	O
medication	O
is	O
a	O
prodrug	O
of	O
norethisterone	B-Drug
in	O
the	O
body,	O
with	O
etynodiol	O
occurring	O
as	O
an	O
intermediate.	O

In	O
addition,	O
about	O
a	O
six-fold	O
increase	O
in	O
mortality,	O
necrotizing	O
enterocolitis,	O
and	O
infection	O
such	O
as	O
sepsis,	O
pneumonia,	O
urinary	O
tract	O
was	O
reported	O
patients	O
receiving	O
ranitidine	B-Drug
cohort	O
analysis	O
of	O
274	O
VLBW	O
neonates.	O

Sodium	B-Drug
oxybate	I-Drug
is	O
also	O
used	O
therapeutically	O
in	O
Italy	O
under	O
the	O
brand	O
name	O
Alcover	O
for	O
treatment	O
of	O
alcohol	O
withdrawal	O
and	O
dependence.	O

Drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
including	O
antiarrhythmics	O
such	O
as	O
quinidine,	O
antihistamines	O
astemizole	O
and	O
terfenadine,	O
some	O
antipsychotics	O
may	O
increase	O
chance	O
of	O
ventricular	O
dysrhythmias.	O
quinidine	B-Drug

The	O
FDA	O
launched	O
a	O
post-marketing	O
safety	O
study	O
regarding	O
the	O
reformulation	O
of	O
Opana	B-Drug
ER	I-Drug
in	O
2012	O
and	O
Indiana	O
state	O
government	O

Mazindol	B-Drug
is	O
a	O
sympathomimetic	O
amine,	O
which	O
similar	O
to	O
amphetamine.	O
amphetamine	B-Drug

A	O
cannabis	O
edible,	O
also	O
known	O
as	O
a	O
cannabis-infused	O
food	O
or	O
simply	O
an	O
is	O
product	O
that	O
contains	O
cannabinoids,	O
especially	O
tetrahydrocannabinol	B-Drug
(THC).	O
THC	B-Drug

In	O
contrast,	O
the	O
newer	O
NSAAs	O
nilutamide,	O
bicalutamide,	O
and	O
enzalutamide	B-Drug
all	O
have	O
much	O
longer	O
half-lives,	O
this	O
allows	O
for	O
once-daily	O
administration	O
in	O
their	O
cases.	O
bicalutamide	B-Drug

The	O
possible	O
exceptions	O
may	O
be	O
aspirin	B-Drug
and	O
naproxen	B-Drug
due	O
to	O
their	O
anti-platelet	O
aggregation	O
properties.	O

In	O
late	O
1959,	O
it	O
was	O
noticed	O
that	O
peripheral	O
neuritis	O
developed	O
in	O
patients	O
who	O
took	O
the	O
drug	O
over	O
a	O
period	O
of	O
time,	O
and	O
only	O
after	O
this	O
point	O
thalidomide	B-Drug
ceased	O
to	O
be	O
provided	O
counter.	O

In	O
the	O
United	O
States	O
where	O
patches	O
cannot	O
always	O
be	O
returned	O
through	O
a	O
medication	O
take-back	O
program,	O
flushing	O
is	O
recommended	O
for	O
fentanyl	B-Drug
because	O
it	O
fastest	O
and	O
surest	O
way	O
to	O
remove	O
them	O
from	O
home	O
prevent	O
ingestion	O
by	O
children,	O
pets	O
or	O
others	O
not	O
intended	O
use	O
them.	O

In	O
a	O
2000	O
Brookhaven	O
National	O
Laboratory	O
medical	O
department	O
study,	O
based	O
on	O
self	O
reports	O
of	O
32	O
people	O
who	O
used	O
cocaine	B-Drug
participated	O
in	O
the	O
study,"peak	O
high"	O
was	O
found	O
at	O
mean	O
1.4min	O
+/-	O

Nabilone	B-Drug
Any	O
compound	O
structurally	O
derived	O
from	O
3phenylacetylindole	O
by	O
substitution	O
at	O
the	O
nitrogen	O
atom	O
of	O
indole	O
ring	O
with	O
alkyl,	O
alkenyl,	O
cycloalkylmethyl,	O
cycloalkylethyl	O
or	O
2(4morpholinyl)ethyl,	O
whether	O
not	O
further	O
substituted	O
in	O
to	O
any	O
extent	O
and	O
phenyl	O
extent.	O

A	O
sticky,	O
brown	O
paste,	O
morphine	B-Drug
base	O
is	O
pressed	O
into	O
bricks	O
and	O
sun-dried,	O
can	O
either	O
be	O
smoked,	O
prepared	O
other	O
forms	O
or	O
processed	O
heroin.	O
heroin	B-Drug

Through	O
the	O
same	O
blockade	O
of	O
NMDA	O
receptor,	O
ketamine	B-Drug
is	O
also	O
effective	O
as	O
a	O
painkiller.	O

Valium	B-Drug
(diazepam)	O
a	O
benzodiazepine	O
used	O
to	O
treat	O
anxiety.	O
diazepam	B-Drug

Ondansetron,	O
sold	O
under	O
the	O
brand	O
name	O
Zofran	B-Drug
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
prevent	O
nausea	O
and	O
vomiting	O
caused	O
by	O
cancer	O
chemotherapy,	O
radiation	O
therapy,	O
or	O
surgery.	O
Ondansetron	B-Drug

Medical	O
grade	O
diamorphine	B-Drug
is	O
used	O
as	O
a	O
pure	O
hydrochloride	O
salt	O
which	O
distinguished	O
from	O
black	O
tar	O
heroin,	O
variable	O
admixture	O
of	O
morphine	B-Drug
derivativespredominantly	O
6-MAM	O
(6-monoacetylmorphine),	O
the	O
result	O
crude	O
acetylation	O
during	O
clandestine	O
production	O
street	O
heroin.	O
6-monoacetylmorphine	B-Drug
heroin	B-Drug

Dinalbuphine	O
sebacate	O
(DNS),	O
also	O
known	O
as	O
nalbuphine	B-Drug
or	O
sebacoyl	O
dinalbuphine	O
ester	O
(SDE)	O
and	O
sold	O
under	O
the	O
brand	O
name	O
Naldebain,	O
is	O
a	O
non-controlled	O
opioid	O
analgesic	O
which	O
used	O
7-day	O
long-acting	O
injection	O
in	O
treatment	O
of	O
moderate	O
to	O
severe	O
postoperative	O
pain.	O

The	O
proton-pump	O
inhibitors	O
(antacids)	O
omeprazole,	O
lansoprazole,	O
pantoprazole,	O
rabeprazole,	O
and	O
tenatoprazole	O
all	O
contain	O
a	O
benzimidazole	O
group.	O
omeprazole	B-Drug
lansoprazole	B-Drug
pantoprazole	B-Drug

In	O
2007,	O
about	O
42,800	O
emergency	O
room	O
visits	O
occurred	O
due	O
to	O
"episodes"	O
involving	O
oxycodone.	O
oxycodone	B-Drug

Attitudes	O
towards	O
the	O
opium	B-Drug
trade	O
were	O
initially	O
ambivalent,	O
but	O
in	O
1874	O
Society	O
for	O
Suppression	O
of	O
Opium	O
Trade	O
was	O
formed	O
England	O
by	O
Quakers	O
led	O
Rev.	O
Frederick	O
Storrs-Turner.	O

Diazepam	B-Drug
was	O
the	O
most	O
commonly	O
detected	O
benzodiazepine.	O

Harmaline	B-Drug
is	O
a	O
fluorescent	O
indole	O
alkaloid	O
from	O
the	O
group	O
of	O
harmala	O
alkaloids	O
and	O
beta-carbolines.	O

Prodilidine	O
is	O
an	O
opioid	O
analgesic	O
which	O
a	O
ring-contracted	O
analogue	O
of	O
prodine.	O
prodine	B-Drug

Iodine-123	B-Drug
has	O
a	O
half-life	O
of	O
thirteen	O
hours	O
and	O
decays	O
by	O
electron	O
capture	O
to	O
tellurium-123,	O
emitting	O
gamma	O
radiation;	O
it	O
is	O
used	O
in	O
nuclear	O
medicine	O
imaging,	O
including	O
single	O
photon	O
emission	O

In	O
the	O
Netherlands,	O
diamorphine	B-Drug
is	O
a	O
List	O

During	O
this	O
time,	O
drug	O
cartels	O
expanded	O
their	O
power	O
and	O
corruption,	O
anti-drug	O
operations	O
focused	O
mainly	O
on	O
destroying	O
marijuana	O
opium	B-Drug
crops	O
in	O
mountainous	O
regions.	O

The	O
Harrison	O
Narcotics	O
Tax	O
Act	O
of	O
1914	O
restricted	O
the	O
manufacture	O
and	O
distribution	O
opiates,	O
including	O
laudanum,	O
coca	B-Drug
derivatives	O
in	O
US.	O
laudanum	B-Drug

An	O
autopsy	O
found	O
that	O
Bigelow's	O
death	O
was	O
due	O
to	O
multiple	O
drugs	O
in	O
his	O
system	O
including	O
toxic	O
levels	O
of	O
cocaine	B-Drug
and	O
anti-anxiety	O
known	O
as	O
benzodiazepines.	O

While	O
THC	B-Drug
remains	O
illegal,	O
cannabidiol	B-Drug
is	O
not	O
subject	O
to	O
the	O
Swiss	O
Narcotic	O
Acts	O
because	O
this	O
substance	O
does	O
produce	O
a	O
comparable	O
psychoactive	O
effect.	O

Zopiclone	B-Drug
is	O
less	O
selective	O
to	O
the	O
1	O
site	O
and	O
has	O
higher	O
affinity	O
2	O
than	O
zaleplon.	O
zaleplon	B-Drug

Moore	O
received	O
a	O
lethal	O
injection,	O
administered	O
as	O
an	O
intravenous	O
series	O
of	O
four	O
drugs	O
that	O
included	O
fentanyl	B-Drug
citrate	O
to	O
inhibit	O
breathing	O
and	O
render	O
the	O
subject	O
unconscious.	O

Exceptions	O
include	O
4-MTA,	O
a	O
para-substituted,	O
non-neurotoxic	O
amphetamine.	O
4-MTA	B-Drug
amphetamine	B-Drug

A	O
review	O
of	O
benzodiazepine	O
poisonings	O
in	O
cats	O
and	O
dogs	O
from	O
1991-1994	O
found	O
bromazepam	B-Drug
to	O
be	O
responsible	O
for	O
significantly	O
more	O
than	O
any	O
other	O
benzodiazepine.	O

Tipepidine	B-Drug
(INN)	O
(brand	O
names	O
Asverin,	O
Antupex,	O
Asvelik,	O
Asvex,	O
Bitiodin,	O
Cofdenin	O
A,	O
Hustel,	O
Nodal,	O
Sotal),	O
also	O
known	O
as	O
tipepidine	B-Drug
hibenzate	O
(JAN),	O
is	O
a	O
synthetic,	O
non-opioid	O
antitussive	O
and	O
expectorant	O
of	O
the	O
thiambutene	O
class.	O

It	O
was	O
derived	O
from	O
medroxyprogesterone	B-Drug
acetate,	O
which	O
had	O
been	O
synthesized	O
at	O
Syntex	O
in	O
1957.	O
acetate	I-Drug

Levomethorphan	B-Drug
(INN,	O
BAN)	O
is	O
an	O
opioid	O
analgesic	O
of	O
the	O
morphinan	O
family	O
that	O
has	O
never	O
been	O
marketed.	O

Thalidomide,	O
sold	O
under	O
the	O
brand	O
names	O
Contergan	B-Drug
and	O
Thalomid	B-Drug
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
number	O
of	O
cancers	O
(including	O
multiple	O
myeloma),	O
graft-versus-host	O
disease,	O
skin	O
conditions	O
including	O
complications	O
leprosy.	O
Thalidomide	B-Drug

Imipramine	B-Drug
appears	O
to	O
work	O
by	O
increasing	O
levels	O
of	O
serotonin	O
and	O
norepinephrine	O
blocking	O
certain	O
serotonin,	O
adrenergic,	O
histamine,	O
cholinergic	O
receptors.	O

presumably	O
exhibits	O
functional	O
selectivity	O
at	O
the	O
5HT2A	O
receptor	O
similar	O
to	O
other	O
phenethylamine	B-Drug
hallucinogens,	O
activating	O
Phospholipase	O
A2	O
signal	O
cascade,	O
which	O
is	O
responsible	O
for	O
release	O
of	O
Thromboxane	O
A2,	O
triggering	O
blood	O
platelet	O
aggregation.	O

Leary	O
believed	O
that	O
LSD	B-Drug
showed	O
potential	O
for	O
therapeutic	O
use	O
in	O
psychiatry.	O

Hyoscine	B-Drug
also	O
inhibits	O
cholinergic-mediated	O
glutamate	O
release	O
in	O
hippocampal	O
neurons,	O
which	O
assist	O
depolarization,	O
potentiation	O
of	O
action	O
potential,	O
and	O
synaptic	O
suppression.	O

A	O
2014	O
review	O
of	O
the	O
safety	O
and	O
efficacy	O
MDMA	B-Drug
as	O
a	O
treatment	O
for	O
various	O
disorders,	O
particularly	O
PTSD,	O
indicated	O
that	O
has	O
therapeutic	O
in	O
some	O
patients;	O
however,	O
it	O
emphasized	O
issues	O
regarding	O
controlability	O
MDMA-induced	O
experiences	O
neurochemical	O
recovery	O
must	O
be	O
addressed.	O

During	O
these	O
raids,	O
the	O
DEA	O
seized	O
$3	O
million	O
in	O
cash	O
and	O
assets,	O
2.5	O
kilograms	O
of	O
cocaine,	O
numerous	O
weapons.	O
cocaine	B-Drug

The	O
first	O
clinical	O
study	O
of	O
tamoxifen	B-Drug
took	O
place	O
at	O
the	O
Christie	O
Hospital	O
in	O
1971,	O
and	O
showed	O
a	O
convincing	O
effect	O
advanced	O
breast	O
cancer,	O
but	O
nevertheless	O
ICI's	O
development	O
programme	O
came	O
close	O
to	O
termination	O
when	O
it	O
was	O
reviewed	O
1972.	O

By	O
2013,	O
case	O
reports	O
of	O
25I-NBOMe	B-Drug
intoxication,	O
with	O
and	O
without	O
analytic	O
confirmation	O
the	O
drug	O
in	O
body,	O
were	O
becoming	O
increasingly	O
common	O
medical	O
literature.25I-NBOMe	O
is	O
widely	O
rumored	O
to	O
be	O
orally	O
inactive;	O
however,	O
apparent	O
overdoses	O
have	O
occurred	O
via	O
oral	O
administration.	O

From	O
ergotamine,	O
the	O
anti-migraine	O
drugs	O
dihydroergotamine	B-Drug
and	O
methysergide	B-Drug
were	O
developed	O
by	O
Albert	O
Hofmann.	O
ergotamine	B-Drug

They	O
also	O
cited	O
a	O
review	O
of	O
the	O
Annual	O
Reports	O
American	O
Association	O
Poison	O
Control	O
Centers	O
National	O
Data	O
Collection	O
System,	O
which	O
showed	O
alprazolam	B-Drug
was	O
involved	O
in	O
34	O
fatal	O
deliberate	O
self-poisonings	O
over	O
10	O
years	O
(19922001),	O
compared	O
with	O
30	O
involving	O
diazepam.	O
diazepam	B-Drug

Even	O
with	O
no	O
drug	O
in	O
production,	O
Sanofi	O
sold	O
the	O
stanozolol	B-Drug
business	O
to	O
Ovation	O
Pharmaceuticals	O
2003,	O
along	O
two	O
other	O
drugs.	O

Dipipanone	B-Drug
is	O
a	O
Schedule	O

THC,	O
CBD	B-Drug
and	O
CBN.CB1	O
CB2	O
are	O
the	O
primary	O
cannabinoid	O
receptors	O
responsible	O
for	O
several	O
of	O
effects	O
cannabinoids,	O
although	O
other	O
may	O
play	O
a	O
role	O
as	O
well.	O
THC	B-Drug

Methamphetamine	B-Drug
is	O
a	O
CYP2D6	O
inhibitor.	O

Like	O
other	O
forms	O
of	O
cocaine,	O
smoking	O
crack	O
can	O
increase	O
heart	O
rate	O
and	O
blood	O
pressure,	O
leading	O
to	O
long-term	O
cardiovascular	O
problems.	O
cocaine	B-Drug

According	O
to	O
DSM-V	O
criteria,	O
9%	O
of	O
those	O
who	O
are	O
exposed	O
cannabis	O
develop	O
use	O
disorder,	O
compared	O
20%	O
for	O
cocaine,	O
23%	O
alcohol	O
and	O
68%	O
nicotine.	O
cocaine	B-Drug
nicotine	B-Drug

In	O
the	O
US,	O
generic	O
methadone	B-Drug
tablets	O
are	O
inexpensive,	O
with	O
retail	O
prices	O
ranging	O
from	O
$0.25	O
to	O
$2.50	O
per	O
defined	O
daily	O
dose.	O

A	O
2007	O
UK	O
study	O
ranked	O
MDMA	B-Drug
18th	O
in	O
harmfulness	O
out	O
of	O
20	O
recreational	O
drugs.	O

Other	O
examples	O
include	O
radio-labelled	O
anti-CD20	O
antibodies	O
(e.g.	O
Bexxar)	O
for	O
treating	O
lymphoma,	O
Radium-223	B-Drug
bone	O
metastases,	O
Lutetium-177	O
DOTATATE	B-Drug
neuroendocrine	O
tumours	O
and	O
PSMA	O
prostate	O
cancer.	O

The	O
blood	O
levels	O
of	O
ibuprofen	B-Drug
peak	O
1.8	O
hours	O
after	O
oral	O
administration.	O

THC	B-Drug
appears	O
to	O
alter	O
mood	O
and	O
cognition	O
through	O
its	O
agonist	O
actions	O
on	O
the	O
CB1	O
receptors,	O
which	O
inhibit	O
a	O
secondary	O
messenger	O
system	O
(adenylate	O
cyclase)	O
in	O
dose-dependent	O
manner.	O

Fludrocortisone	B-Drug
is	O
mostly	O
a	O
mineralocorticoid;	O
however,	O
it	O
also	O
has	O
glucocorticoid	O
effects.	O

The	O
formal	O
generic	O
names	O
of	O
nandrolone	B-Drug
esters	O
include	O
cyclohexylpropionate	O
(BANM),	O
cyclotate	O
(USAN),	O
decanoate	I-Drug
(USAN,	O
USP,	O
BANM,	O
JAN),	O
laurate	O
phenpropionate	I-Drug
(USP),	O
and	O
phenylpropionate	I-Drug
(BANM,	O
JAN).	O

Clorazepate	B-Drug
can	O
be	O
synthesized	O
starting	O
from	O
2-amino-5-chlorobenzonitrile,	O
which	O
upon	O
reaction	O
with	O
phenylmagnesium	O
bromide	O
is	O
transformed	O
into	O
2-amino-5-chlorbenzophenone	O
imine.	O

Licorice,	O
which	O
has	O
indirect	O
mineralocorticoid	O
activity	O
by	O
inhibiting	O
metabolism,	O
been	O
found	O
to	O
inhibit	O
the	O
antimineralocorticoid	O
effects	O
of	O
spironolactone.	O
spironolactone	B-Drug

American	O
rapper	O
Lil	O
Peep	O
also	O
died	O
of	O
an	O
accidental	O
fentanyl	B-Drug
overdose	O
on	O
November	O
15,	O
2017.	O

In	O
1838,	O
the	O
Chinese	O
Commissioner	O
Lin	O
Zexu	O
destroyed	O
20,000	O
chests	O
of	O
opium	B-Drug
in	O
Guangzhou.	O

Cannabinol	B-Drug
(CBN)	O
is	O
a	O
mildly	O
psychoactive	O
cannabinoid	O
found	O
only	O
in	O
trace	O
amounts	O
Cannabis,	O
and	O
mostly	O
aged	O
Cannabis.	O
CBN	B-Drug

The	O
most	O
common	O
adverse	O
effects	O
of	O
tramadol	B-Drug
include	O
nausea,	O
dizziness,	O
dry	O
mouth,	O
indigestion,	O
abdominal	O
pain,	O
vertigo,	O
vomiting,	O
constipation,	O
drowsiness,	O
and	O
headache.	O

Moreover,	O
nandrolone	B-Drug
is	O
metabolized	O
by	O
5-reductase,	O
but	O
unlike	O
the	O
case	O
of	O
testosterone	O
and	O
DHT,	O
5-reduced	O
metabolite	O
has	O
much	O
lower	O
affinity	O
for	O
AR	O
than	O
does	O
itself,	O
this	O
results	O
in	O
reduced	O
activation	O
5-reductase-expressing	O
tissues.	O

HIV	O
drug	O
resistance	O
is	O
growing	O
due	O
to	O
recreational	O
use	O
of	O
drugs	O
efavirenz	B-Drug
and	O
ritonavir,	O
rendering	O
them	O
ineffective	O
not	O
only	O
for	O
users	O
but	O
non-users	O
as	O
well,	O
with	O
one	O
study	O
showing	O
that	O
3%	O
5%	O
people	O
in	O
areas	O
where	O
whoonga	O
was	O
used	O
were	O
"pre-treatment	O
resistance"	O
antiretroviral	O
treat	O
HIV.	O
ritonavir	B-Drug

Acetylpropionylmorphine	B-Drug
is	O
an	O
opiate	O
analogue	O
that	O
ester	O
of	O
morphine.	O
morphine	B-Drug

In	O
some	O
cases,	O
switching	O
from	O
venlafaxine	B-Drug
to	O
fluoxetine,	O
a	O
long-acting	O
SSRI,	O
and	O
then	O
tapering	O
off	O
may	O
be	O
recommended	O
reduce	O
discontinuation	O
symptoms.	O
fluoxetine	B-Drug

In	O
the	O
experiment,	O
36	O
volunteers	O
without	O
prior	O
experience	O
with	O
hallucinogens	O
were	O
given	O
psilocybin	O
and	O
methylphenidate	B-Drug
(Ritalin)	O
in	O
separate	O
sessions;	O
sessions	O
served	O
as	O
a	O
control	O
psychoactive	O
placebo.	O
Ritalin	B-Drug

Desomorphine	B-Drug
comes	O
in	O
four	O
isoforms,	O
A,	O
B,	O
C,	O
and	O
D	O
the	O
latter	O
two	O
appear	O
to	O
be	O
more	O
researched	O
used.	O

In	O
accordance,	O
inhibition	O
of	O
2-1-containing	O
VDCCs	O
by	O
pregabalin	B-Drug
appears	O
to	O
be	O
responsible	O
for	O
its	O
anticonvulsant,	O
analgesic,	O
and	O
anxiolytic	O
effects.	O

the	O
summer	O
of	O
1964,	O
Kesey's	O
Merry	O
Pranksters	O
customized	O
a	O
bus	O
named	O
"Furthur"	O
and	O
set	O
out	O
on	O
tour	O
to	O
propagate	O
LSD	B-Drug
use.	O

Low	O
dose	O
mifepristone	B-Drug
tablets	O
for	O
emergency	O
contraception	O
are	O
available	O
by	O
prescription	O
in	O
Armenia	O
(Gynepriston),	O
Russia	O
(Agesta,	O
Gynepriston,	O
Mifepristone	B-Drug
72,	O
Negele),	O
Ukraine	O
and	O
Vietnam	O
(Mifestad	O
10,	O
Ciel	O
EC).	O

Detailed	O
sales	O
logs	O
were	O
required	O
to	O
record	O
marihuana	B-Drug
sales.	O

Even	O
though	O
these	O
benzodiazepines	O
are	O
also	O
CNS	O
depressants,	O
they	O
primarily	O
modulate	O
GABAA	O
receptors	O
whereas	O
GHB	B-Drug
is	O
a	O
GABAB	O
receptor	O
agonist,	O
and	O
so	O
do	O
not	O
worsen	O
depression	O
as	O
much	O
might	O
be	O
expected.	O

Inactivation	O
of	O
the	O
substantia	O
nigra	O
could	O
prove	O
to	O
be	O
a	O
possible	O
treatment	O
for	O
cocaine	B-Drug
addiction.	O

"	O
The	O
three	O
main	O
forms	O
of	O
cannabis	O
products	O
are	O
the	O
flower/fruit,	O
resin	O
(hashish),	O
and	O
oil	I-Drug
(hash	O
oil).	O
hashish	B-Drug
hash	B-Drug

Pethidine	B-Drug
is	O
in	O
Schedule	O
II	O
of	O
the	O
Controlled	O
Substances	O
Act	O
1970	O
United	O
States	O
as	O
a	O
Narcotic	O
with	O
ACSCN	O
9230	O
6250	O
kilo	O
aggregate	O
manufacturing	O
quota	O
2014.	O

It	O
was	O
estimated	O
in	O
2015	O
that	O
the	O
percentage	O
of	O
world	O
population	O
had	O
used	O
cocaine	B-Drug
during	O
a	O
year	O
0.4%.	O

Numerous	O
small	O
studies	O
have	O
investigated	O
the	O
effects	O
of	O
oral	O
ketoconazole	B-Drug
on	O
hormone	O
levels	O
in	O
humans.	O

The	O
2010	O
UN	O
World	O
Drug	O
Report	O
concluded	O
that	O
"it	O
appears	O
the	O
North	O
American	O
cocaine	B-Drug
market	O
has	O
declined	O
in	O
value	O
from	O
US$47	O
billion	O
1998	O
to	O
US$38	O
2008.	O

Mazindol	B-Drug
(brand	O
names	O
Mazanor,	O
Sanorex)	O
is	O
a	O
stimulant	O
drug	O
which	O
used	O
as	O
an	O
appetite	O
suppressant.	O

Amphetamine	B-Drug
addiction	O
is	O
largely	O
mediated	O
through	O
increased	O
activation	O
of	O
dopamine	O
receptors	O
and	O
co-localized	O
NMDA	O
in	O
the	O
nucleus	O
accumbens;	O
magnesium	O
ions	O
inhibit	O
by	O
blocking	O
receptor	O
calcium	O
channel.	O

Nabilone	B-Drug
is	O
another	O
cannabinoid	O
drug	O
that	O
has	O
been	O
approved	O
by	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
(MHRA),	O
but	O
a	O
synthetic	O
form	O
of	O
THC	B-Drug
not	O
naturally	O
derived	O
from	O
plant.	O

Tincture	O
of	O
Opium	O
is	O
known	O
as	O
one	O
many	O
"unapproved	O
drugs"	O
regulated	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA);	O
marketing	O
distribution	O
opium	B-Drug
tincture	O
prevails	O
today	O
only	O
because	O
was	O
sold	O
prior	O
to	O
Federal	O
Food,	O
&	O
Cosmetic	O
Act	O
1938.	O

Cocaine	B-Drug
Caffeine	O
Methamphetamine	B-Drug
hydrochloride	O
USFDA-approved	O
for	O
the	O
treatment	O
of	O
obesity	O
(as	O
a	O
short-term)	O
under	O
brand	O
name	O
"Desoxyn".	O
Desoxyn	B-Drug

Prior	O
to	O
its	O
listing	O
at	O
the	O
federal	O
level	O
in	O
2018,	O
Louisiana	O
placed	O
ADB-CHMINACA	B-Drug
on	O
Schedule	O

Methylprednisolone	B-Drug
was	O
first	O
synthesized	O
and	O
manufactured	O
by	O
The	O
Upjohn	O
Company	O
(now	O
Pfizer)	O
Food	O
Drug	O
Administration	O
(FDA)	O
approved	O
in	O
the	O
United	O
States	O
on	O
October	O
2,	O
1957.	O

While	O
retaining	O
structural	O
elements	O
from	O
both	O
families,	O
JWH-161	O
has	O
a	O
CB1	O
Ki	O
of	O
19.0nM,	O
although	O
it	O
was	O
found	O
to	O
be	O
slightly	O
weaker	O
than	O
THC	B-Drug
in	O
animal	O
tests.	O

A	O
tastier,	O
smoother	O
and	O
more	O
aromatic	O
terpenes	O
flavanoids	O
profile	O
is	O
seen	O
as	O
an	O
indicator	O
of	O
a	O
significant	O
rise	O
in	O
hashish	B-Drug
quality	O
recent	O
years.	O

Valproate	B-Drug
inhibits	O
the	O
metabolism	O
of	O
lorazepam,	O
whereas	O
carbamazepine,	O
lamotrigine,	O
phenobarbital,	O
phenytoin,	O
and	O
rifampin	B-Drug
increase	O
its	O
rate	O
metabolism.	O
lorazepam	B-Drug
carbamazepine	B-Drug
lamotrigine	B-Drug
phenobarbital	B-Drug
phenytoin	B-Drug

PEA	B-Drug
cannot	O
strictly	O
be	O
considered	O
a	O
classic	O
endocannabinoid	O
because	O
it	O
lacks	O
affinity	O
for	O
the	O
cannabinoid	O
receptors	O
CB1	O
and	O
CB2.	O

25C-NBOMe	B-Drug
is	O
derived	O
from	O
the	O
psychedelic	O
phenethylamine	B-Drug
2C-C	O
by	O
substitution	O
on	O
amine	O
with	O
a	O
2-methoxybenzyl	O
group.	O

Meloxicam	B-Drug
is	O
extensively	O
metabolized	O
in	O
the	O
liver	O
by	O
enzymes	O
CYP2C9	O
and	O
CYP3A4	O

MDMA	B-Drug
likely	O
emerged	O
as	O
a	O
substitute	O
for	O
its	O
analog	O
methylenedioxyamphetamine	O
(MDA),	O
drug	O
at	O
the	O
time	O
popular	O
among	O
users	O
of	O
psychedelics	O
which	O
was	O
made	O
Schedule	O
1	O
substance	O
in	O
United	O
States	O
1970.	O

The	O
FDA	O
reported	O
in	O
April	O
2012	O
that	O
twelve	O
young	O
children	O
had	O
died	O
and	O
more	O
made	O
seriously	O
ill	O
from	O
separate	O
accidental	O
exposures	O
to	O
fentanyl	B-Drug
skin	O
patches.	O

AM-2201	B-Drug

A	O
study	O
by	O
one	O
of	O
the	O
manufacturers	O
drug	O
found	O
risk	O
agranulocytosis	O
within	O
first	O
week	O
treatment	O
to	O
be	O
a	O
mere	O
1.1	O
in	O
million,	O
versus	O
5.92	O
million	O
for	O
diclofenac.	O
diclofenac	B-Drug

Propylhexedrine	B-Drug
has	O
also	O
seen	O
use	O
in	O
Europe	O
as	O
an	O
appetite	O
suppressant	O
under	O
the	O
trade	O
name	O
Obesin	O
and	O
anticonvulsant	O
preparation	O
barbexaclone	O
its	O
S-isomer	O
(levopropylhexedrine	O
or	O
L-propylhexedrine)	O
is	O
bonded	O
with	O
phenobarbital	B-Drug
for	O
purpose	O
of	O
offsetting	O
barbiturate-induced	O
sedation.	O

There	O
have	O
also	O
been	O
anecdotal	O
reports	O
of	O
alprazolam	B-Drug
being	O
snorted.	O

Nalbuphine	B-Drug
is	O
a	O
semisynthetic	O
mixed	O
agonist/antagonist	O
opioid	O
modulator	O
of	O
the	O
phenanthrene	O
or	O
morphinan	O
series.	O

Alkaloids	O
present	O
in	O
the	O
fresh	O
plant	O
or	O
dried	O
root	O
included	O
atropine,	O
hyoscyamine,	O
scopolamine	B-Drug
(hyoscine),	O
scopine,	O
cuscohygrine,	O
apoatropine,	O
3-alpha-tigloyloxytropane,	O
3-alpha,6-beta-ditigloyloxytropane	O
and	O
belladonnines.	O
hyoscyamine	B-Drug
hyoscine	B-Drug

In	O
a	O
study	O
about	O
bromazepam's	O
negative	O
effects	O
on	O
psychomotor	O
skills	O
and	O
driving	O
ability,	O
it	O
was	O
noted	O
that	O
3	O
mg	O
doses	O
caused	O
minimal	O
impairment.	O
bromazepam	B-Drug

Naloxone	B-Drug
by	O
mouth	O
appears	O
to	O
be	O
the	O
most	O
effective.	O

Methylphenidate	B-Drug
is	O
metabolized	O
into	O
ritalinic	O
acid	O
by	O
CES1A1,	O
enzymes	O
in	O
the	O
liver.	O

In	O
the	O
case	O
of	O
lisdexamfetamine,	O
this	O
is	O
achieved	O
by	O
reacting	O
with	O
two	O
equivalents	O
methanesulfonic	O
acid	O
to	O
produce	O
dimesylate	O
salt,	O
a	O
water-soluble	O
(792	O
mg	O
mL1)	O
powder	O
white	O
off-white	O
color.	O
lisdexamfetamine	B-Drug

Other	O
drugs,	O
including	O
the	O
benzodiazepines	O
and	O
zolpidem,	O
are	O
also	O
found	O
in	O
high	O
numbers	O
of	O
suspected	O
drugged	O
drivers.	O
zolpidem	B-Drug

MDAI	B-Drug
and	O
other	O
similar	O
drugs	O
have	O
been	O
widely	O
used	O
in	O
scientific	O
research,	O
as	O
they	O
are	O
able	O
to	O
replicate	O
many	O
of	O
the	O
effects	O
MDMA,	O
but	O
without	O
causing	O
neurotoxicity	O
which	O
may	O
be	O
associated	O
with	O
MDMA	B-Drug
some	O
related	O
drugs.	O

Like	O
other	O
2C-X-NBOMe	O
molecules,	O
25I-NBOMe	B-Drug
is	O
a	O
derivative	O
of	O
the	O
2C	O
family	O
phenethylamines	O
described	O
by	O
chemist	O
Alexander	O
Shulgin	O
in	O
his	O
book	O
PiHKAL.	O

Some	O
examples	O
of	O
synthetic	O
steroid	O
hormones:	O
Glucocorticoids:	O
alclometasone,	O
prednisone,	O
dexamethasone,	O
triamcinolone,	O
cortisone	O
Mineralocorticoid:	O
alclometasone	B-Drug
prednisone	B-Drug
dexamethasone	B-Drug
triamcinolone	B-Drug

Understanding	O
the	O
potential	O
role	O
of	O
nicotine	B-Drug
in	O
oral	O
health	O
has	O
become	O
increasingly	O
important	O
given	O
recent	O
introduction	O
novel	O
products	O
and	O
their	O
helping	O
smokers	O
quit.	O

At	O
first,	O
he	O
smuggled	O
the	O
cocaine	B-Drug
in	O
old	O
plane	O
tires,	O
and	O
a	O
pilot	O
could	O
return	O
as	O
much	O
US$500,000	O
per	O
flight,	O
dependent	O
on	O
quantity	O
smuggled.	O

Amphetamine	B-Drug
has	O
a	O
very	O
similar	O
structure	O
and	O
function	O
to	O
the	O
endogenous	O
trace	O
amines,	O
which	O
are	O
naturally	O
occurring	O
neuromodulator	O
molecules	O
produced	O
in	O
human	O
body	O
brain.	O

Neurocognitive	O
enhancing	O
effects	O
of	O
stimulants,	O
specifically	O
modafinil,	O
amphetamine	B-Drug
and	O
methylphenidate	B-Drug
have	O
been	O
documented	O
in	O
healthy	O
adolescents,	O
is	O
a	O
commonly	O
cited	O
reason	O
among	O
illicit	O
drug	O
users	O
for	O
use,	O
particularly	O
college	O
students	O
the	O
context	O
studying.	O
modafinil	B-Drug

Norethandrolone	B-Drug
(17-ethyl-17-hydroxyestr-4-en-3-one)	O

As	O
a	O
member	O
of	O
Parliament,	O
Gladstone	O
called	O
it	O
"most	O
infamous	O
and	O
atrocious"	O
referring	O
to	O
the	O
opium	B-Drug
trade	O
between	O
China	O
British	O
India	O
in	O
particular.	O

Mibolerone	B-Drug
(17-hydroxy-7,17-dimethylestr-4-en-3-one)	O

A	O
cultivar	O
for	O
opium	B-Drug
production,	O
Papaver	O
somniferum	O
L.	O
elite,	O
contains	O
91.2	O
percent	O
morphine,	O
codeine,	O
and	O
thebaine	O
in	O
its	O
latex	O
alkaloids,	O
whereas	O
the	O
of	O
condiment	O
"Marianne",	O
these	O
three	O
alkaloids	O
total	O
only	O
14.0	O
percent.	O
morphine	B-Drug
codeine	B-Drug

As	O
with	O
intestinal	O
absorption	O
of	O
gabapentin	B-Drug
mediated	O
by	O
LAT1,	O
transport	O
across	O
the	O
bloodbrain	O
barrier	O
LAT1	O
is	O
saturable.	O

The	O
degree	O
of	O
tolerance	O
is	O
more	O
pronounced	O
with	O
clonazepam	B-Drug
than	O
chlordiazepoxide.	O
chlordiazepoxide	B-Drug

Fentanyl	B-Drug
was	O
first	O
made	O
by	O
Paul	O
Janssen	O
in	O
1960	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1968.	O

Nalmefene	B-Drug
is	O
a	O
derivative	O
of	O
naltrexone	B-Drug
and	O
was	O
first	O
reported	O
in	O
1975.	O

The	O
structure	O
of	O
trenbolone	B-Drug
acetate	O
is	O
a	O
19-nor	O
classification,	O
which	O
represents	O
structural	O
change	O
the	O
testosterone	O
hormone.	O

It	O
is	O
unclear,	O
however,	O
whether	O
the	O
increase	O
in	O
THC	B-Drug
content	O
has	O
caused	O
people	O
to	O
consume	O
more	O
or	O
if	O
users	O
adjust	O
based	O
on	O
potency	O
of	O
cannabis.	O

The	O
Semitic	O
root	O
is	O
also	O
found	O
in	O
the	O
Spanish	O
word	O
mejorana	O
and	O
English	O
marjoram	O
('oregano'),	O
which	O
could	O
be	O
related	O
to	O
marihuana.	O
marihuana	B-Drug

The	O
degree	O
of	O
bluing	O
in	O
a	O
Psilocybe	O
fruit	O
body	O
roughly	O
correlates	O
with	O
the	O
concentration	O
psilocin	B-Drug
mushroom.	O

A	O
2011	O
review	O
concluded	O
that	O
risperidone	B-Drug
is	O
more	O
effective	O
in	O
relapse	O
prevention	O
than	O
other	O
first-	O
and	O
second-generation	O
antipsychotics	O
with	O
the	O
exception	O
of	O
olanzapine	B-Drug
clozapine.	O
clozapine	B-Drug

In	O
the	O
United	O
Kingdom,	O
use	O
of	O
flunitrazepam	B-Drug
and	O
other	O
"date	O
rape"	O
drugs	O
have	O
also	O
been	O
connected	O
to	O
stealing	O
from	O
sedated	O
victims.	O

Isotretinoin	B-Drug
reduces	O
inflammation	O
via	O
inhibition	O
of	O
chemotactic	O
responses	O
monocytes	O
and	O
neutrophils.	O

PCP	B-Drug
hydrochloride	O
can	O
be	O
insufflated	O
(snorted),	O
depending	O
upon	O
the	O
purity.	O

Cocaine	B-Drug
also	O
blocks	O
sodium	O
channels,	O
thereby	O
interfering	O
with	O
the	O
propagation	O
of	O
action	O
potentials;	O
thus,	O
like	O
lignocaine	B-Drug
and	O
novocaine,	O
it	O
acts	O
as	O
a	O
local	O
anesthetic.	O
novocaine	B-Drug

Chlorodehydromethyltestosterone	B-Drug
(CDMT;	O
brand	O
name	O
Oral	B-Drug
Turinabol),	O
also	O
known	O
as	O
4-chloro-17-hydroxy17-methylandrosta-1,4-dien-3-one,	O
is	O
an	O
anabolicandrogenic	O
steroid	O
(AAS).	O
Turinabol	I-Drug

Like	O
retinoic	O
acid,	O
the	O
related	O
compounds	O
do	O
not	O
have	O
full	O
vitamin	B-Drug
A	I-Drug
activity,	O
but	O
powerful	O
effects	O
on	O
gene	O
expression	O
and	O
epithelial	O
cell	O
differentiation.	O

Its	O
non-17-alkylated	O
counterpart,	O
drostanolone	B-Drug
propionate,	O
was	O
commercialized	O
by	O
Syntex	O
Corporation	O
under	O
the	O
brand	O
name	O
Masteron.	O
propionate	I-Drug

Enzalutamide	B-Drug
was	O
developed	O
and	O
marketed	O
by	O
Medivation	O
for	O
the	O
treatment	O
of	O
prostate	O
cancer.	O

Psychiatrists	O
were	O
reluctant	O
initially,	O
but	O
on	O
19	O
January	O
1952,	O
it	O
was	O
administered	O
(alongside	O
pethidine,	O
pentothal	O
and	O
ECT)	O
to	O
Jacques	O
Lh.	O
pethidine	B-Drug

As	O
his	O
distribution	O
empire	O
grew	O
to	O
include	O
forty-two	O
cities,	O
the	O
price	O
he	O
paid	O
per	O
kg	O
of	O
powder	O
cocaine	B-Drug
dropped	O
from	O
as	O
much	O
$60,000	O
low	O
$10,000."	O

This	O
includes	O
paracetamol/acetaminophen	O
or	O
NSAIDs	O
like	O
ibuprofen	B-Drug
naproxen.	O
paracetamol	B-Drug
acetaminophen	B-Drug
naproxen	B-Drug

Sofosbuvir	B-Drug
was	O
discovered	O
in	O
2007,	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
2013.	O

The	O
locomotor	O
enhancing	O
properties	O
of	O
cocaine	B-Drug
may	O
be	O
attributable	O
to	O
its	O
enhancement	O
dopaminergic	O
transmission	O
from	O
the	O
substantia	O
nigra.	O

The	O
primary	O
mechanism	O
of	O
phentermine's	O
action	O
in	O
treating	O
obesity	O
is	O
the	O
reduction	O
hunger	O
perception,	O
which	O
a	O
cognitive	O
process	O
mediated	O
primarily	O
through	O
several	O
nuclei	O
within	O
hypothalamus	O
(in	O
particular,	O
lateral	O
hypothalamic	O
nucleus,	O
arcuate	O
and	O
ventromedial	O
nucleus).	O
phentermine	B-Drug

However,	O
PCP	B-Drug
may	O
also	O
interact	O
with	O
allosteric	O
sites	O
on	O
the	O
monoamine	O
transporters	O
to	O
produce	O
inhibition	O
of	O
reuptake.	O

Systemic	O
exposure	O
to	O
excessive	O
quantities	O
of	O
lidocaine	B-Drug
mainly	O
result	O
in	O
central	O
nervous	O
system	O
(CNS)	O
and	O
cardiovascular	O
effects	O

However,	O
a	O
decision	O
by	O
an	O
American	O
representative	O
in	O
the	O
World	O
Health	O
Assembly	O
banned	O
publication	O
of	O
study,	O
because	O
it	O
seemed	O
to	O
make	O
case	O
for	O
positive	O
uses	O
cocaine.	O
cocaine	B-Drug

A	O
2012	O
review	O
focused	O
on	O
antidepressants	O
and	O
sleep	O
found	O
that	O
in	O
many	O
people	O
with	O
disorders	O
caused	O
by	O
depression,	O
mirtazapine	B-Drug
reduces	O
the	O
time	O
it	O
takes	O
to	O
fall	O
asleep	O
increases	O
quality	O
of	O
sleep,	O
but	O
some	O
can	O
disturb	O
especially	O
at	O
higher	O
doses,	O
causing	O
restless	O
leg	O
syndrome	O
8	O
28%	O
rare	O
cases	O
causes	O
REM	O
behavior	O
disorder.	O

which	O
is	O
a	O
derivative	O
of	O
anthranilic	O
acid,	O
in	O
turn	O
nitrogen	O
isostere	O
salicylic	O
the	O
active	O
metabolite	O
aspirin.	O
aspirin	B-Drug

Then,	O
using	O
7-ethyl-2-azabicyclo[2.2.2]oct-5-ene	O
and	O
cesium	O
carbonate	O
in	O
acetonitrile,	O
the	O
ibogaine	B-Drug
precursor	O
7-ethyl-2-(2-(2-iodo-1H-indol-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene	O
is	O
obtained.	O

Benzoyl-CoA	O
then	O
combines	O
the	O
two	O
units	O
to	O
form	O
cocaine.	O
cocaine	B-Drug

Brand	O
names	O
include	O
Sublimaze,	O
Actiq,	O
Durogesic,	O
Duragesic,	O
Fentora,	O
Matrifen,	O
Haldid,	O
Onsolis,	O
Instanyl,	O
Abstral,	O
Lazanda	B-Drug
and	O
others.	O
Actiq	B-Drug
Duragesic	B-Drug

Cocaine	O
intoxication	O
refers	O
to	O
the	O
subjective	O
and	O
objective,	O
desired	O
adverse,	O
effects	O
of	O
cocaine	B-Drug
on	O
body.	O

The	O
physical	O
dependence	O
and	O
withdrawal	O
syndrome	O
of	O
alprazolam	B-Drug
also	O
add	O
to	O
its	O
addictive	O
nature.	O

Like	O
many	O
other	O
drugs,	O
PCP	B-Drug
has	O
been	O
known	O
to	O
alter	O
mood	O
states	O
in	O
an	O
unpredictable	O
fashion,	O
causing	O
some	O
individuals	O
become	O
detached,	O
and	O
others	O
animated.	O

Hilleman	O
would	O
later	O
move	O
to	O
Merck	O
where	O
he	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
vaccines	O
against	O
measles,	O
mumps,	O
chickenpox,	O
rubella,	O
hepatitis	O
A,	O
B,	O
and	O
meningitis.	O
measles	B-Drug
chickenpox	B-Drug

The	O
test	O
took	O
place	O
before	O
the	O
introduction	O
of	O
modafinil	B-Drug
as	O
medication,	O
and	O
personnel	O
involved	O
was	O
not	O
informed	O
product's	O
nature.	O

We	O
knew	O
we	O
couldn't	O
make	O
it	O
illegal	O
to	O
be	O
either	O
against	O
the	O
war	O
or	O
black,	O
but	O
by	O
getting	O
public	O
associate	O
hippies	O
with	O
marijuana	O
and	O
blacks	O
heroin,	O
then	O
criminalizing	O
both	O
heavily,	O
could	O
disrupt	O
those	O
communities.	O
heroin	B-Drug

Methyltestosterone	B-Drug
is	O
used	O
in	O
the	O
treatment	O
of	O
delayed	O
puberty,	O
hypogonadism,	O
cryptorchidism,	O
and	O
erectile	O
dysfunction	O
males,	O
low	O
doses	O
to	O
treat	O
menopausal	O
symptoms	O
(specifically	O
for	O
osteoporosis,	O
hot	O
flashes,	O
increase	O
libido	O
energy),	O
postpartum	O
breast	O
pain	O
engorgement,	O
cancer	O
women.	O

A	O
2006	O
review	O
paper	O
summarized	O
several	O
studies	O
that	O
examined	O
the	O
effect	O
of	O
androstenedione	B-Drug
on	O
strength	O
training.	O

A	O
bath	O
solution	O
of	O
benzocaine	B-Drug
has	O
been	O
used	O
to	O
anesthetize	O
amphibians	O
for	O
surgery.	O

In	O
1959,	O
Wolfgang	O
Fruhstorfer	O
synthesized	O
MDMA	B-Drug
for	O
pharmacological	O
testing	O
while	O
researching	O
stimulants.	O

This	O
could	O
be	O
due	O
to	O
the	O
fact	O
that	O
norethisterone	B-Drug
induces	O
endometrial	O
proliferation	O
during	O
secretory	O
phase,	O
which	O
has	O
been	O
shown	O
alleviate	O
pain	O
complaints.	O

Methadone	B-Drug
is	O
used	O
as	O
an	O
analgesic	O
in	O
chronic	O
pain,	O
often	O
rotation	O
with	O
other	O
opioids.	O

Mannitol	B-Drug
is	O
in	O
the	O
osmotic	O
diuretic	O
family	O
of	O
medications	O
and	O
works	O
by	O
pulling	O
fluid	O
from	O
brain	O
eyes.	O

Price	O
had	O
claimed	O
that	O
buprenorphine	B-Drug
and	O
methadone	B-Drug
were	O
"simply	O
substitute[s]"	O
for	O
"illicit	O
drugs"	O
whereas	O
according	O
to	O
the	O
letter,	O
"the	O
substantial	O
body	O
of	O
research	O
evidence	O
supporting	O
these	O
treatments	O
is	O
summarized	O
in	O
guidance	O
from	O
within	O
your	O
own	O
agency,	O
including	O
Substance	O
Abuse	O
Mental	O
Health	O
Services	O
Administration,	O
US	O
Surgeon	O
General,	O
National	O
Institute	O
on	O
Drug	O
Abuse,	O
Centers	O
Disease	O
Control	O
Prevention.	O

Midazolam	B-Drug
is	O
known	O
to	O
cause	O
respiratory	O
depression.	O

Compared	O
to	O
THC,	O
which	O
is	O
a	O
partial	O
agonist	O
at	O
CB1	O
receptors,	O
JWH-018,	O
and	O
many	O
synthetic	O
cannabinoids,	O
are	O
full	O
agonists.	O
THC	B-Drug
JWH-018	B-Drug

After	O
1860,	O
opium	B-Drug
use	O
continued	O
to	O
increase	O
with	O
widespread	O
domestic	O
production	O
in	O
China.	O

Cocaine	B-Drug
also	O
blocks	O
sodium	O
channels,	O
thereby	O
interfering	O
with	O
the	O
propagation	O
of	O
action	O
potentials;	O
thus,	O
like	O
lignocaine	B-Drug
and	O
novocaine,	O
it	O
acts	O
as	O
a	O
local	O
anesthetic.	O
novocaine	B-Drug

Chinese	O
authorities	O
issued	O
edicts	O
against	O
opium	B-Drug
smoking	O
in	O
1730,	O
1796	O
and	O
1800.	O

Octreotide,	O
sold	O
under	O
the	O
brand	O
name	O
Sandostatin	B-Drug
among	O
others,	O
is	O
an	O
octapeptide	O
that	O
mimics	O
natural	O
somatostatin	O
pharmacologically,	O
though	O
it	O
a	O
more	O
potent	O
inhibitor	O
of	O
growth	O
hormone,	O
glucagon,	O
and	O
insulin	O
than	O
hormone.	O
Octreotide	B-Drug

When	O
Leah	O
Betts	O
was	O
first	O
admitted	O
to	O
hospital	O
in	O
a	O
coma,	O
her	O
family	O
released	O
image	O
the	O
national	O
media	O
as	O
an	O
example	O
of	O
dangers	O
illegal	O
drugs,	O
specifically	O
ecstasy,	O
attempt	O
deter	O
other	O
young	O
people	O
from	O
experimenting	O
with	O
drugs.	O
ecstasy	B-Drug

Since	O
2008,	O
Pfizer	O
has	O
engaged	O
in	O
extensive	O
direct-to-consumer	O
advertising	O
campaigns	O
to	O
promote	O
its	O
branded	O
product	O
Lyrica	B-Drug
for	O
fibromyalgia	O
and	O
diabetic	O
nerve	O
pain	O
indications.	O

Fresh	O
cannabis	O
contains	O
tetrahydrocannabinolic	O
acid	O
(THCA),	O
which	O
is	O
converted	O
into	O
THC	B-Drug
after	O
heating	O
and	O
then	O
metabolized	O
by	O
the	O
body	O
11-hydroxy-THC	O
11-nor-9-carboxy-THC;	O
both	O
compounds	O
can	O
be	O
glucuronidated	O
mainly	O
excreted	O
urine.	O

Nabilone	B-Drug
has	O
shown	O
modest	O
effectiveness	O
in	O
relieving	O
fibromyalgia.	O

During	O
his	O
period	O
in	O
South	O
Australia,	O
he	O
resumed	O
production	O
and	O
distribution	O
of	O
amphetamine	B-Drug
methamphetamine,	O
conjunction	O
with	O
disgraced	O
former	O
solicitor	O
Justin	O
Birk	O
Hill.	O
methamphetamine	B-Drug

PCP	B-Drug
can	O
be	O
ingested	O
through	O
smoking.	O

Pure	O
morphine	B-Drug
and	O
heroin	B-Drug
are	O
both	O
fine	O
powders.	O

In	O
2010,	O
an	O
evidence-based	O
guideline	O
sponsored	O
by	O
the	O
International	O
Association	O
for	O
Study	O
of	O
Pain	O
recommended	O
nortriptyline	B-Drug
as	O
a	O
first-line	O
medication	O
neuropathic	O
pain.	O

Russell	O
Smith	O
noted	O
that	O
the	O
association	O
of	O
drugs	O
and	O
music	O
subcultures	O
was	O
by	O
no	O
means	O
exclusive	O
to	O
electronic	O
music,	O
citing	O
previous	O
examples	O
genres	O
were	O
associated	O
with	O
certain	O
drugs,	O
such	O
as	O
psychedelic	O
rock	O
LSD,	O
disco	O
cocaine,	O
punk	O
heroin.	O
LSD	B-Drug
cocaine	B-Drug
heroin	B-Drug

Methadone	B-Drug
has	O
been	O
widely	O
used	O
for	O
pregnant	O
women	O
addicted	O
to	O
opioids.	O

In	O
South	O
Africa,	O
Rohypnol	B-Drug
is	O
classified	O
as	O
a	O
Schedule	O
6	O
drug.	O

Pregnant	O
people	O
who	O
use	O
cocaine	B-Drug
have	O
an	O
elevated	O
risk	O
of	O
placental	O
abruption,	O
a	O
condition	O
where	O
the	O
placenta	O
detaches	O
from	O
uterus	O
and	O
causes	O
bleeding.	O

In	O
addition	O
to	O
its	O
wake-promoting	O
effects	O
and	O
ability	O
increase	O
locomotor	O
activity	O
in	O
animals,	O
according	O
Nuvigil	B-Drug
prescribing	O
information	O
from	O
manufacturer	O
Cephalon,	O
armodafinil	B-Drug
produces	O
psychoactive	O
euphoric	O
effects,	O
alterations	O
mood,	O
perception,	O
thinking,	O
feelings	O
typical	O
of	O
other	O
central	O
nervous	O
system	O
(CNS)	O
stimulants	O
humans.	O

Conversely,	O
the	O
aromatase	O
inhibitor	O
letrozole	B-Drug
does	O
not	O
affect	O
metabolism	O
of	O
tamoxifen.	O
tamoxifen	B-Drug

The	O
chemical	O
half-life	O
of	O
naloxone	B-Drug
is	O
such	O
that	O
injection	O
and	O
nasal	O
forms	O
have	O
been	O
marketed	O
with	O
24-month	O
18-month	O
shelf-lives,	O
respectively.	O

However,	O
in	O
the	O
spring	O
of	O
1971,	O
two	O
congressmen	O
released	O
an	O
alarming	O
report	O
alleging	O
that	O
15%	O
servicemen	O
Vietnam	O
were	O
addicted	O
to	O
heroin.	O
heroin	B-Drug

Bayer	O
lost	O
some	O
of	O
its	O
trademark	O
rights	O
to	O
heroin	B-Drug
(as	O
well	O
as	O
aspirin)	O
under	O
the	O
1919	O
Treaty	O
Versailles	O
following	O
German	O
defeat	O
in	O
World	O
War	O
I.Use	O
by	O
jazz	O
musicians	O
particular	O
aspirin	B-Drug

The	O
bioavailability	O
of	O
intranasal	O
fentanyl	B-Drug
is	O
about	O
7090%,	O
but	O
with	O
some	O
imprecision	O
due	O
to	O
clotted	O
nostrils,	O
pharyngeal	O
swallow	O
and	O
incorrect	O
administration.	O

One	O
example	O
is	O
the	O
case	O
of	O
Big	O
Lurch,	O
a	O
former	O
rapper	O
with	O
history	O
violent	O
crime,	O
who	O
was	O
convicted	O
murdering	O
and	O
cannibalizing	O
his	O
roommate	O
while	O
under	O
influence	O
PCP.	O
PCP	B-Drug

In	O
children,	O
intranasal	O
fentanyl	B-Drug
is	O
useful	O
for	O
the	O
treatment	O
of	O
moderate	O
and	O
severe	O
pain	O
well	O
tolerated.	O

MDMA	B-Drug
has	O
been	O
described	O
as	O
an	O
"empathogenic"	O
drug	O
because	O
of	O
its	O
empathy-producing	O
effects.	O

Dapsone	B-Drug
may	O
be	O
used	O
to	O
treat	O
brown	O
recluse	O
spider	O
bites	O
that	O
become	O
necrotic.	O

The	O
intensity	O
of	O
the	O
side	O
effects	O
carisoprodol	B-Drug
tends	O
to	O
lessen	O
as	O
therapy	O
continues,	O
is	O
case	O
with	O
many	O
other	O
drugs.	O

A	O
2006	O
review	O
found	O
that	O
controlled-release	O
oxycodone	B-Drug
is	O
comparable	O
to	O
immediate-release	O
oxycodone,	O
morphine,	O
and	O
hydromorphone	B-Drug
in	O
management	O
of	O
moderate	O
severe	O
cancer	O
pain,	O
with	O
fewer	O
side	O
effects	O
than	O
morphine.	O
morphine	B-Drug

(WIN	O
55,212-2)	O
3Dimethylheptyl11hydroxyhexahydrocannabinol.	O
WIN	B-Drug
55,212-2	I-Drug

In	O
any	O
case,	O
it	O
has	O
been	O
elucidated	O
that	O
acute	O
blockade	O
of	O
NMDA	O
receptors	O
in	O
the	O
brain	O
results	O
an	O
activation	O
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic	O
acid	O
(AMPA	O
receptors),	O
which	O
turn	O
modulate	O
a	O
variety	O
downstream	O
signaling	O
pathways	O
to	O
influence	O
neurotransmission	O
limbic	O
system	O
and	O
mediate	O
antidepressant	O
effects	O
receptor	O
antagonists	O
like	O
ketamine.	O
ketamine	B-Drug

These	O
effects	O
were	O
not	O
noted	O
in	O
its	O
medicinal	O
use	O
the	O
1950s	O
and	O
1960s	O
however,	O
reports	O
of	O
physical	O
violence	O
on	O
PCP	B-Drug
have	O
often	O
been	O
shown	O
to	O
be	O
unfounded.	O

Fentanyl-laced	O
heroin	B-Drug
has	O
become	O
a	O
big	O
problem	O
for	O
major	O
cities,	O
including	O
Philadelphia,	O
Detroit	O
and	O
Chicago.	O

JWH-019	B-Drug
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family	O
that	O
acts	O
as	O
a	O
cannabinoid	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
receptors.	O

Most	O
recently,	O
in	O
2012	O
the	O
FDA	O
approved	O
Intermezzo	O
(zolpidem	O
tartate	O
sublingual),	O
which	O
is	O
marketed	O
for	O
middle-of-the-night	O
insomnia,	O
available	O
doses	O
only	O
half	O
of	O
strength	O
immediate-release	O
zolpidem	B-Drug
tartrate	O
to	O
avoid	O
residual	O
next-day	O
sedation.	O

Anti-epileptic	O
drugs,	O
benzodiazepines	O
such	O
as	O
clonazepam	B-Drug
in	O
particular,	O
should	O
be	O
reduced	O
dose	O
slowly	O
and	O
gradually	O
when	O
discontinuing	O
the	O
drug	O
to	O
mitigate	O
withdrawal	O
effects.	O

Drug	O
dealers	O
are	O
cashing	O
in	O
too,	O
selling	O
cocaine	B-Drug
to	O
visitors	O
at	O
prices	O
much	O
cheaper	O
than	O
their	O
homelands.	O

Gabitril	B-Drug
(tiagabine)	O
used	O
off-label	O
in	O
the	O
treatment	O
of	O
anxiety	O
disorders	O
and	O
panic	O
disorder.	O
tiagabine	B-Drug

Stereoselective	O
synthesis	O
of	O
tributalin	O
and	O
salbutamol	B-Drug
acetal	O
can	O
be	O
done	O
from	O
O-protected-(R)-cyanohydrins.	O

Like	O
its	O
drug	O
subcategory	O
prototype	O
methadone,	O
phenadoxone	B-Drug
can	O
be	O
used	O
as	O
the	O
opioid	O
analgesic	O
in	O
Brompton	O
cocktail.	O
methadone	B-Drug

Non-medical	O
use	O
of	O
fentanyl	B-Drug
by	O
individuals	O
without	O
opiate	O
tolerance	O
can	O
be	O
very	O
dangerous	O
and	O
has	O
resulted	O
in	O
numerous	O
deaths.	O

As	O
of	O
2017,	O
fentanyl	B-Drug
was	O
the	O
most	O
widely	O
used	O
synthetic	O
opioid	O
in	O
medicine.	O

Fentanyl	B-Drug
has	O
a	O
US	O
DEA	O
ACSCN	O
of	O
9801	O
and	O
2013	O
annual	O
aggregate	O
manufacturing	O
quota	O
2,108.75	O
kg,	O
unchanged	O
from	O
the	O
prior	O
year.	O

Apixaban	B-Drug
was	O
approved	O
for	O
the	O
prevention	O
of	O
stroke	O
in	O
people	O
with	O
atrial	O
fibrillation	O
on	O
December	O
28,	O
2012.	O

It	O
was	O
speculated	O
that	O
antifungal	O
properties	O
of	O
ketoconazole	B-Drug
reduce	O
scalp	O
microflora	O
and	O
consequently	O
may	O
follicular	O
inflammation	O
contributes	O
to	O
alopecia.	O

To	O
maintain	O
anesthesia,	O
inhaled	O
anesthetics	O
and	O
additional	O
fentanyl	B-Drug
may	O
be	O
used.	O

Sources	O
for	O
the	O
following	O
lists	O
of	O
adverse	O
effects:As	O
haloperidol	B-Drug
is	O
a	O
high-potency	O
typical	O
antipsychotic,	O
it	O
tends	O
to	O
produce	O
significant	O
extrapyramidal	O
side	O
effects.	O

This	O
rise	O
in	O
androstenedione	B-Drug
and	O
DHEA	O
is	O
hypothesized	O
to	O
play	O
a	O
crucial	O
role	O
for	O
learning	O
social,	O
cultural	O
ecological	O
skills,	O
such	O
as	O
the	O
development	O
understanding	O
of	O
sexual	O
attraction.	O

Currently	O
it	O
is	O
approved	O
in	O
more	O
than	O
80	O
countries	O
worldwide	O
but	O
not	O
the	O
US,	O
where	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
additional	O
safety	O
efficacy	O
data	O
for	O
etoricoxib	B-Drug
before	O
will	O
issue	O
approval.	O

On	O
November	O
28,	O
2013	O
the	O
ACMD	O
recommended	O
that	O
6-APB	B-Drug
and	O
related	O
benzofurans	O
should	O
become	O
Class	O
B,	O
Schedule	O
1	O
substances.	O

MBDB	B-Drug
is	O
considered	O
a	O
Schedule	O
9	O
Prohibited	O
substance	O
in	O
Australia	O
under	O
the	O
Poisons	O
Standard	O
(October	O
2015).	O

In	O
the	O
United	O
States,	O
benzodiazepines	O
are	O
Schedule	O
IV	O
drugs	O
under	O
Federal	O
Controlled	O
Substances	O
Act,	O
even	O
when	O
not	O
on	O
market	O
(for	O
example,	O
nitrazepam	B-Drug
and	O
bromazepam).	O
bromazepam	B-Drug

Nabilone,	O
a	O
first	O
generation	O
synthetic	O
THC	B-Drug
analog,	O
has	O
been	O
used	O
as	O
an	O
antiemetic	O
to	O
combat	O
vomiting	O
and	O
nausea	O
since	O
1981.	O
Nabilone	B-Drug

In	O
fact,	O
nandrolone-like	O
AAS	O
like	O
nandrolone	B-Drug
itself	O
and	O
trenbolone	B-Drug
are	O
said	O
to	O
have	O
among	O
the	O
highest	O
ratio	O
of	O
anabolic	O
androgenic	O
effect	O
all	O
AAS.	O

In	O
addition	O
to	O
its	O
medical	O
use,	O
methyltestosterone	B-Drug
is	O
used	O
improve	O
physique	O
and	O
performance,	O
although	O
it	O
not	O
as	O
commonly	O
other	O
AAS	O
for	O
such	O
purposes	O
due	O
androgenic	O
effects,	O
estrogenic	O
risk	O
of	O
liver	O
damage.	O

On	O
the	O
other	O
hand,	O
possession	O
of	O
500	O
grams	O
powder	O
cocaine	B-Drug
carries	O
same	O
sentence.	O

The	O
European	O
Food	O
Safety	O
Authority	O
reported	O
that	O
there	O
is	O
insufficient	O
information	O
to	O
determine	O
if	O
these	O
effects	O
exist	O
when	O
L-theanine	B-Drug
used	O
without	O
caffeine.	O

In	O
accordance,	O
spironolactone	B-Drug
has	O
not	O
been	O
associated	O
with	O
conventional	O
glucocorticoid	O
medication	O
effects	O
or	O
side	O
effects.	O

Methylphenidate	B-Drug
has	O
a	O
higher	O
affinity	O
for	O
the	O
dopamine	O
transporter	O
than	O
norepinephrine	O
transporter,	O
and	O
so	O
its	O
effects	O
are	O
mainly	O
due	O
to	O
elevated	O
levels	O
caused	O
by	O
inhibited	O
reuptake	O
of	O
dopamine,	O
however	O
increased	O
also	O
contribute	O
various	O
drug.	O

China	O
ceased	O
producing	O
licit	O
opium	B-Drug
after	O
2001.	O

Certain	O
other	O
aspects	O
of	O
the	O
usage	O
hyoscine	B-Drug
in	O
crimes	O
have	O
equally	O
been	O
described	O
as	O
"exaggerated"	O
or	O
even	O
implausible.	O

In	O
January	O
2020,	O
Chilean	O
ATP	O
tennis	O
singles	O
competitor	O
Nicols	O
Jarry	O
tested	O
positive	O
for	O
both	O
ligandrol	B-Drug
and	O
stanozolol.	O
stanozolol	B-Drug

The	O
apparent	O
clearance	O
(CL/F)	O
of	O
ivacaftor	B-Drug
was	O
similar	O
for	O
healthy	O
subjects	O
and	O
patients	O
with	O
CF.	O

While	O
preparing	O
reagents	O
for	O
the	O
work,	O
Mueckter's	O
assistant	O
Wilhelm	O
Kunz	O
isolated	O
a	O
by-product	O
that	O
was	O
recognized	O
by	O
pharmacologist	O
Herbert	O
Keller	O
as	O
an	O
analog	O
of	O
glutethimide,	O
sedative.	O
glutethimide	B-Drug

The	O
project	O
saw	O
a	O
decrease	O
in	O
coca	B-Drug
cultivation	O
Colombia	O
from	O
160,000	O
hectares	O
to	O
48,000	O
and	O
the	O
drug-related	O
economy	O
US$7.5	O
billion	O
US$4.5	O
2008-2013.Quelling	O
demand	O
for	O
illicit	O
drugs	O
has	O
also	O
been	O
considered	O
as	O
solution	O
environmental	O
impacts	O
involved	O
with	O
drug	O
production.	O

"Diamorphine"	O
is	O
the	O
Recommended	O
International	O
Nonproprietary	O
Name	O
and	O
British	O
Approved	O
Name.	O
Diamorphine	B-Drug

Serotonin	O
antagonists	O
and	O
dantrolene	B-Drug
may	O
be	O
used	O
as	O
required.	O

Boldenone	B-Drug
undecylenate	I-Drug
and	O
trenbolone	B-Drug
acetate	O
are	O
used	O
in	O
veterinary	O
medicine.	O

Low	O
doses	O
of	O
AAS	O
such	O
as	O
oxandrolone	B-Drug
are	O
used	O
in	O
the	O
treatment	O
idiopathic	O
short	O
stature,	O
but	O
this	O
may	O
only	O
quicken	O
maturation	O
rather	O
than	O
increasing	O
adult	O
height.	O

Under	O
acidic	O
conditions,	O
less	O
than	O
5%	O
of	O
the	O
LSD	B-Drug
was	O
converted	O
to	O
iso-LSD.	O

James	O
Taylor,	O
John	O
Lennon,	O
Eric	O
Clapton,	O
Johnny	O
Winter,	O
Keith	O
Richards	O
and	O
Janis	O
Joplin	O
also	O
used	O
heroin.	O
heroin	B-Drug

JWH-098	B-Drug
is	O
illegal	O
in	O
Russia,	O
Sweden,	O
and	O
the	O
UK,	O
although	O
it	O
unclear	O
whether	O
has	O
any	O
history	O
of	O
human	O
use.	O

Exposing	O
cells	O
to	O
aminopterin	O
(a	O
folic	O
acid	O
analogue,	O
which	O
inhibits	O
dihydrofolate	B-Drug
reductase,	O
DHFR),	O
makes	O
them	O
unable	O
use	O
the	O
de	O
novo	O
pathway	O
and	O
become	O
fully	O
auxotrophic	O
for	O
nucleic	O
acids,	O
thus	O
requiring	O
supplementation	O
survive.	O

Methyltestosterone	B-Drug
is	O
highly	O
protein-bound,	O
by	O
approximately	O
98%.	O

The	O
Manual	O
of	O
Adolescent	O
Substance	O
Abuse	O
Treatment	O
calls	O
it	O
the	O
most	O
addictive	O
form	O
cocaine.	O
cocaine	B-Drug

Presumably	O
it	O
has	O
similar	O
effects	O
to	O
other	O
opioid	O
derivatives,	O
such	O
as	O
analgesia,	O
sedation,	O
nausea	O
and	O
respiratory	O
depression,	O
however	O
unlike	O
most	O
derivatives	O
is	O
not	O
specifically	O
listed	O
an	O
illegal	O
drug,	O
although	O
would	O
probably	O
be	O
regarded	O
a	O
controlled	O
substance	O
analogue	O
of	O
pethidine	B-Drug
on	O
the	O
grounds	O
its	O
related	O
chemical	O
structure	O
in	O
some	O
jurisdictions	O
United	O
States,	O
Canada	O
Australia,	O
classified	O
"Pethidine	O
Analogue"	O
under	O
New	O
Zealand	O
Misuse	O
Drugs	O
Act	O
Class	O
C7.	O
Pethidine	B-Drug

It	O
has	O
low	O
estrogenic	O
activity	O
(via	O
aromatization	O
into	O
ethylestradiol	O
following	O
transformation	O
norethandrolone),	O
strong	O
progestogenic	O
activity,	O
and	O
a	O
high	O
ratio	O
of	O
anabolic	O
to	O
androgenic	O
similarly	O
other	O
nandrolone	B-Drug
derivatives.	O
norethandrolone	B-Drug

In	O
one	O
study,	O
some	O
long	O
term,	O
high-dosage	O
users	O
of	O
alprazolam	B-Drug
developed	O
reversible	O
depression.	O

Shulgin	O
may	O
have	O
suspected	O
he	O
played	O
a	O
role	O
in	O
the	O
emergence	O
of	O
MDMA	B-Drug
Chicago.	O

Diazepam	B-Drug
can	O
be	O
administered	O
orally,	O
intravenously	O
(must	O
diluted,	O
as	O
it	O
is	O
painful	O
and	O
damaging	O
to	O
veins),	O
intramuscularly	O
(IM),	O
or	O
a	O
suppository.	O

Ketamine	B-Drug
potentiates	O
the	O
sedative	O
effects	O
of	O
propofol	B-Drug
and	O
midazolam.	O
midazolam	B-Drug

Water	O
looping	O
is	O
when	O
a	O
user	O
places	O
the	O
heroin	B-Drug
in	O
an	O
empty	O
eye	O
dropper	O
bottle,	O
or	O
syringe	O
with	O
needle	O
removed.	O

Diphenhydramine	B-Drug
is	O
marketed	O
under	O
the	O
trade	O
name	O
Benadryl	O
by	O
McNeil	O
Consumer	O
Healthcare	O
in	O
U.S.,	O
Canada,	O
and	O
South	O
Africa.	O

There	O
are	O
no	O
specific	O
antidotes	O
available	O
for	O
ethchlorvynol,	O
and	O
treatment	O
is	O
supportive	O
with	O
protocols	O
resembling	O
those	O
the	O
of	O
barbiturate	O
overdose.	O
ethchlorvynol	B-Drug

The	O
Rodrguez	O
brothers	O
were	O
extradited	O
in	O
2006	O
to	O
the	O
United	O
States	O
and	O
pleaded	O
guilty	O
Miami,	O
Florida,	O
charges	O
of	O
conspiracy	O
import	O
cocaine	B-Drug
into	O
States.	O

Nicotine	B-Drug
can	O
form	O
carcinogenic	O
Tobacco-specific	O
nitrosamines	O
(TSNAs)	O
through	O
a	O
nitrosation	O
reaction.	O

Collaborating	O
partners	O
include	O
leading	O
institutions	O
such	O
as	O
Imperial	O
College	O
London,	O
Sant	O
Pau	O
Hospital,	O
University	O
Kings	O
and	O
Johns	O
Hopkins	O
University,	O
topics	O
have	O
covered:	O
changes	O
in	O
brain	O
structure,	O
function,	O
blood	O
supply	O
response	O
to	O
cannabis,	O
LSD,	O
psilocybin,	O
ayahuasca/DMT,	O
MDMA;	O
MDMA-assisted	O
psychotherapy	O
for	O
conditions	O
depression,	O
anxiety,	O
addiction,	O
post-traumatic	O
stress	O
disorder	O
(PTSD);	O
cannabis	O
cannabinoids	O
the	O
treatment	O
of	O
cancer;	O
LSD	B-Drug
cluster	O
headaches;	O
cerebral	O
circulation,	O
cranial	O
compliance,	O
their	O
relationship	O
age-related	O
cognitive	O
decline.	O
MDMA	B-Drug

Alphaprodine	B-Drug
has	O
a	O
duration	O
of	O
action	O
1	O
to	O
2	O
hours	O
and	O
40	O
60	O
mg	O
is	O
equal	O
10	O
morphine	B-Drug
via	O
the	O
subcutaneous	O
route.	O

Antidiabetic	O
drugs	O
can	O
become	O
less	O
effective	O
because	O
triamcinolone	B-Drug
causes	O
diabetes-like	O
symptoms.	O

Cocaine	B-Drug
acts	O
as	O
a	O
stimulant,	O
whereas	O
heroin/morphine	O
depressant.	O
heroin	B-Drug
morphine	B-Drug

Methyprylon	B-Drug
was	O
withdrawn	O
from	O
the	O
US	O
market	O
in	O
June	O
1975	O
and	O
Canadian	O
September	O
1990.	O

B&O	O
Supprettes	O
(the	O
name	O
is	O
derived	O
from	O
the	O
generic	O
term	O
'belladonna/opium	O
suppository')	O
an	O
"unapproved"	O
drug	O
according	O
to	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
opium	B-Drug

MDMA	B-Drug
El	O
hombre	O
de	O
los	O
hongos,	O
aka	O
The	O
Mushroom	O
Man	O
(1976)	O
psychedelic	O
mushrooms	O

This	O
misconception	O
was	O
likely	O
popularized	O
by	O
an	O
episode	O
of	O
MTV's	O
True	O
Life,	O
"I'm	O
on	O
Ecstasy"	O
(2000),	O
which	O
featured	O
a	O
former	O
poly-drug	O
user	O
(including	O
heavy	O
use	O
MDMA)	O
MDMA	B-Drug

Actual	O
full	O
synthesis	O
of	O
cocaine	B-Drug
is	O
rarely	O
done.	O

Its	O
effects	O
have	O
been	O
described	O
as	O
comparable	O
with	O
ethanol	O
(alcohol)	O
and	O
MDMA	B-Drug
use,	O
such	O
euphoria,	O
disinhibition,	O
enhanced	O
libido	O
empathogenic	O
states.	O

The	O
National	O
Sheriffs'	O
Association	O
(NSA)	O
opposed	O
the	O
bill,	O
stating	O
that	O
"Both	O
crack	O
and	O
powder	O
cocaine	B-Drug
are	O
dangerous	O
narcotics	O
plights	O
[sic]	O
on	O
communities	O
throughout	O
United	O
States.	O

In	O
February	O
2018,	O
the	O
U.S.	O
Drug	O
Enforcement	O
Administration	O
indicated	O
that	O
illicit	O
fentanyl	B-Drug
analogs	O
have	O
no	O
medically	O
valid	O
use,	O
and	O
thus	O
applied	O
a	O
"Schedule	O
I"	O
classification	O
to	O
them.	O

Lin	O
wrote	O
about	O
using	O
Adderall	B-Drug
in	O
his	O
novel	O
Taipei.	O

There	O
is	O
also	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
interfere	O
with	O
formation	O
of	O
various	O
kinds	O
new	O
blood	O
cells,	O
creating	O
infection	O
via	O
neutropenia,	O
leukopenia,	O
and	O
lymphopenia,	O
risks	O
will	O
not	O
clot	O
thrombocytopenia.	O

Some	O
subjects	O
had	O
negative	O
reactions	O
to	O
LSD	B-Drug
(as	O
noted	O
above),	O
but	O
others	O
found	O
the	O
experience	O
"pleasant",	O
or	O
even	O
"dearly	O
loved"	O
it	O
as	O
long	O
dosage	O
was	O
not	O
too	O
high	O
(less	O
than	O
2	O
micrograms	O
per	O
kilogram	O
of	O
body	O
weight).	O

As	O
shown	O
in	O
the	O
image	O
below,	O
N-carbethoxyphthalimide	O
(1)	O
can	O
react	O
with	O
L-glutamine	B-Drug
to	O
yield	O
N-phthaloyl-L-glutamine	O
(2).	O

Imipramine	B-Drug
is	O
available	O
in	O
the	O
form	O
of	O
oral	O
tablets	O
and	O
capsules.	O

Methyltestosterone	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
women	O
and	O
children,	O
as	O
it	O
can	O
cause	O
irreversible	O
virilization.	O

There	O
are	O
reports	O
of	O
intravenous	O
injection	O
25I-NBOMe	B-Drug
solution	O
and	O
smoking	O
the	O
drug	O
in	O
powdered	O
form.	O

A	O
review	O
of	O
benzodiazepine	O
poisonings	O
in	O
cats	O
and	O
dogs	O
from	O
1991-1994	O
found	O
bromazepam	B-Drug
to	O
be	O
responsible	O
for	O
significantly	O
more	O
than	O
any	O
other	O
benzodiazepine.	O

PCP	B-Drug
is	O
an	O
arylcyclohexylamine.	O

Tolerance,	O
dependence	O
and	O
withdrawal	O
problems	O
may	O
be	O
less	O
severe	O
than	O
with	O
other	O
benzodiazepines,	O
such	O
as	O
diazepam.	O
diazepam	B-Drug

Dexamethasone	B-Drug
decreases	O
IFN-gamma	O
stimulated	O
Fc	O
gamma	O
RI	O
expression	O
in	O
neutrophils	O
while	O
conversely	O
causing	O
an	O
increase	O
monocytes.	O

After	O
heating	O
these	O
components	O
at	O
120	O
C	O
for	O
12	O
hours	O
in	O
DMSO,	O
the	O
direct	O
etonitazene	B-Drug
precursor,	O
2-(4-Ethoxybenzyl)-5-nitro-1H-benzoimidazole,	O
was	O
formed	O
an	O
approx	O
80-90%	O
yield.	O

Clopidogrel	B-Drug
Alteplase	B-Drug
Streptokinase	O
Simvastatin	B-Drug
Miconazole	B-Drug
Selenium	O
sulfide	O
Sodium	O
thiosulfate	O
Terbinafine	B-Drug
Mupirocin	B-Drug
Potassium	O
permanganate	O

A	O
related	O
anabolic	O
steroid,	O
methylclostebol,	O
is	O
a	O
common	O
additive	O
in	O
so-called	O
dietary	O
supplements,	O
generally	O
listed	O
the	O
convoluted	O
form	O
4-chloro-17-methyl-androst-4-en-17-ol-3-one.	O
methylclostebol	B-Drug

Gabapentin	B-Drug
was	O
originally	O
marketed	O
under	O
the	O
brand	O
name	O
Neurontin.	O
Neurontin	B-Drug

Small	O
doses	O
of	O
MDMA	B-Drug
are	O
used	O
by	O
some	O
religious	O
practitioners	O
as	O
an	O
entheogen	O
to	O
enhance	O
prayer	O
or	O
meditation.	O

Under	O
normal	O
circumstances,	O
the	O
patch	O
will	O
reach	O
its	O
full	O
effect	O
within	O
12	O
to	O
24	O
hours;	O
thus,	O
fentanyl	B-Drug
patches	O
are	O
often	O
prescribed	O
with	O
a	O
fast-acting	O
opioid	O
(such	O
as	O
morphine	B-Drug
or	O
oxycodone)	O
handle	O
breakthrough	O
pain.	O
oxycodone	B-Drug

The	O
FDA	O
authorized	O
use	O
of	O
injectable	O
naltrexone	B-Drug
for	O
opioid	O
addiction	O
using	O
a	O
single	O
study	O
that	O
was	O
led	O
by	O
Evgeny	O
Krupitsky	O
at	O
Bekhterev	O
Research	O
Psychoneurological	O
Institute,	O
St	O
Petersburg	O
State	O
Pavlov	O
Medical	O
University,	O
Petersburg,	O
Russia,	O
country	O
where	O
agonists	O
such	O
as	O
methadone	B-Drug
and	O
buprenorphine	B-Drug
are	O
not	O
available.	O

The	O
intermediate	O
compound	O
-hydroxybutyraldehyde	O
(GHBAL)	O
is	O
also	O
a	O
prodrug	O
for	O
GHB;	O
however,	O
as	O
with	O
all	O
aliphatic	O
aldehydes	O
this	O
caustic	O
and	O
strong-smelling	O
foul-tasting;	O
actual	O
use	O
of	O
an	O
intoxicant	O
likely	O
to	O
be	O
unpleasant	O
result	O
in	O
severe	O
nausea	O
vomiting.	O
GHB	B-Drug

Mephedrone	B-Drug
and	O
the	O
cathinones	O
marked	O
somewhat	O
of	O
a	O
turning	O
point	O
for	O
designer	O
drugs,	O
them	O
from	O
little	O
known,	O
ineffective	O
substances	O
sold	O
in	O
head	O
shops	O
to	O
powerful	O
able	O
compete	O
with	O
classical	O
drugs	O
on	O
black	O
market.	O

In	O
England	O
Charles	O
Romley	O
Alder	O
Wright	O
developed	O
hundreds	O
of	O
opiate	O
compounds	O
in	O
his	O
search	O
for	O
a	O
nonaddictive	O
opium	B-Drug
derivative.	O

Examples	O
of	O
traditional	O
entheogens	O
include:	O
peyote,	O
psilocybin	O
and	O
Amanita	O
muscaria	O
(fly	O
agaric)	O
mushrooms,	O
uncured	O
tobacco,	O
cannabis,	O
ayahuasca,	O
Salvia	O
divinorum,	O
iboga,	O
Mexican	O
morning	O
glory.	O
tobacco	B-Drug

The	O
Wolf	O
of	O
Wall	O
Street	O
(2013)	O
cocaine,	O
crack	B-Drug
Quaaludes,	O
and	O
a	O
mention	O
cannabis,	O
Xanax	B-Drug
morphine	B-Drug
Woodstock	O
(1970)	O
cocaine	I-Drug
Quaaludes	B-Drug

Instead,	O
norpethidine	B-Drug
acts	O
as	O
a	O
stimulant	O
and	O
causes	O
convulsions.	O

Kief	O
is	O
a	O
powder,	O
rich	O
in	O
trichomes,	O
which	O
can	O
be	O
sifted	O
from	O
the	O
leaves,	O
flowers	O
and	O
fruits	O
of	O
cannabis	O
plants	O
either	O
consumed	O
powder	O
form	O
or	O
compressed	O
to	O
produce	O
cakes	O
hashish.	O
hashish	B-Drug

He	O
subsequently	O
failed	O
the	O
drug	O
test	O
when	O
stanozolol	B-Drug
was	O
found	O
in	O
his	O
urine.	O

It	O
has	O
been	O
observed	O
that	O
higher	O
serum	O
osteocalcin	O
levels	O
are	O
relatively	O
well	O
correlated	O
with	O
increases	O
in	O
bone	O
mineral	O
density	O
during	O
treatment	O
anabolic	O
formation	O
drugs	O
for	O
osteoporosis,	O
such	O
as	O
teriparatide.	O
teriparatide	B-Drug

as	O
there	O
has	O
been	O
no	O
research	O
published	O
using	O
parahexyl	B-Drug
since	O
the	O
discovery	O
of	O
CB1	O
receptor	O
this	O
not	O
definitively	O
confirmed.	O

Amphetamine	B-Drug
also	O
interacts	O
with	O
MAOIs,	O
particularly	O
monoamine	O
oxidase	O

Methamphetamine	B-Drug
is	O
used	O
to	O
create	O
euphoria,	O
"heighten	O
sexual	O
appetite",	O
and	O
increase	O
stamina.	O

Orchiectomy	O
or	O
DES	O
both	O
were	O
the	O
standard	O
initial	O
treatment	O
for	O
symptomatic	O
advanced	O
prostate	O
cancer	O
over	O
40	O
years,	O
until	O
GnRH	O
agonist	O
leuprorelin	B-Drug
was	O
found	O
to	O
have	O
efficacy	O
similar	O
without	O
estrogenic	O
effects	O
and	O
approved	O
in	O
1985.From	O
1940s	O
late	O
1980s,	O
FDA-approved	O
as	O
estrogen	O
replacement	O
therapy	O
deficiency	O
states	O
such	O
ovarian	O
dysgenesis,	O
premature	O
failure,	O
after	O
oophorectomy.	O

Methylprednisolone	B-Drug
achieves	O
this	O
primarily	O
by	O
regulating	O
the	O
number	O
and	O
function	O
of	O
leukocytes,	O
cytokines	O
chemokines.	O

Clenbuterol	B-Drug
is	O
not	O
an	O
ingredient	O
of	O
any	O
therapeutic	O
drug	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
now	O
banned	O
for	O
IOC-tested	O
athletes.	O

Heroin,	O
also	O
known	O
as	O
diacetylmorphine	B-Drug
and	O
diamorphine	B-Drug
among	O
other	O
names,	O
is	O
an	O
opioid	O
used	O
a	O
recreational	O
drug	O
for	O
its	O
euphoric	O
effects.	O
Heroin	B-Drug

More	O
reliable	O
methods	O
for	O
detecting	O
cocaine	B-Drug
exposure	O
involve	O
testing	O
the	O
newborn's	O
hair	O
or	O
meconium	O
(the	O
infant's	O
earliest	O
stool).	O

Some,	O
such	O
as	O
exogenous	O
phenethylamine,	O
amphetamine,	O
and	O
methamphetamine,	O
can	O
also	O
diffuse	O
directly	O
across	O
the	O
cell	O
membrane	O
to	O
varying	O
degrees.	O
phenethylamine	B-Drug
amphetamine	B-Drug
methamphetamine	B-Drug

Tejada	O
and	O
two	O
unnamed	O
teammates	O
provided	O
B12	B-Drug
samples	O
to	O
the	O
panel,	O
which	O
did	O
not	O
contain	O
stanozolol.	O
stanozolol	B-Drug

Hardison	O
called	O
5-MeO-DMT	B-Drug
"a	O
very	O
rare,	O
beautiful	O
experience,"	O
but	O
admitted	O
he	O
hadn't	O
done	O
any	O
since	O
the	O
night	O
Birkholz	O
died.	O
"	O

Buspirone	B-Drug
and	O
pregabalin	B-Drug
are	O
second-line	O
treatments	O
for	O
people	O
who	O
do	O
not	O
respond	O
to	O
SSRIs	O
or	O
SNRIs;	O
there	O
is	O
also	O
evidence	O
that	O
benzodiazepines	O
including	O
diazepam	B-Drug
clonazepam	B-Drug
effective	O
but	O
have	O
fallen	O
out	O
of	O
favor	O
due	O
the	O
risk	O
dependence	O
abuse.	O

early	O
20th	O
century	O
brought	O
increased	O
regulation	O
of	O
all	O
manner	O
narcotics,	O
including	O
laudanum,	O
as	O
the	O
addictive	O
properties	O
opium	B-Drug
became	O
more	O
widely	O
understood,	O
and	O
"patent	O
medicines	O
came	O
under	O
fire,	O
largely	O
because	O
their	O
mysterious	O
compositions".	O
laudanum	B-Drug

The	O
coca	B-Drug
leaf	O
was,	O
and	O
still	O
is,	O
chewed	O
almost	O
universally	O
by	O
some	O
indigenous	O
communities.	O

Additionally,	O
there	O
are	O
no	O
known	O
deaths	O
directly	O
associated	O
with	O
pharmacological	O
effects	O
of	O
ergine	B-Drug
consumption.	O

A	O
study	O
in	O
rats	O
indicated	O
that	O
the	O
major	O
metabolites	O
of	O
5-MAPB	B-Drug
are	O
5-APB	B-Drug
and	O
3-carboxymethyl-4-hydroxymethamphetamine.	O

Beginning	O
in	O
2015,	O
Canada	O
has	O
seen	O
a	O
number	O
of	O
fentanyl	B-Drug
overdoses.	O

Ethylestrenol	B-Drug
is	O
or	O
has	O
also	O
been	O
marketed	O
for	O
veterinary	O
use	O
under	O
the	O
brand	O
names	O
Nandoral,	O
Nitrotain,	O
and	O
Oestrotain.	O

DET	O
is	O
an	O
analogue	O
of	O
the	O
common	O
tryptamine	O
hallucinogen	O
N,N-Dimethyltryptamine	B-Drug
or	O
DMT.	O

Although	O
it	O
remained	O
legal	O
in	O
some	O
countries	O
until	O
after	O
World	O
War	O
II,	O
health	O
risks,	O
addiction,	O
and	O
widespread	O
recreational	O
use	O
led	O
most	O
western	O
to	O
declare	O
heroin	B-Drug
a	O
controlled	O
substance	O
by	O
the	O
latter	O
half	O
of	O
20th	O
century.	O

Codeine-6-glucuronide	O
(C6G)	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
codeine	B-Drug
and	O
may	O
be	O
responsible	O
for	O
as	O
much	O
60%	O
the	O
analgesic	O
effects	O
codeine.	O

Methylphenidate	B-Drug
is	O
considered	O
effective	O
in	O
increasing	O
wakefulness,	O
vigilance,	O
and	O
performance.	O

Alirocumab	B-Drug
is	O
the	O
International	O
nonproprietary	O
name.	O

Clozapine	B-Drug
is	O
an	O
atypical	O
antipsychotic	O
drug	O
primarily	O
used	O
in	O
people	O
who	O
are	O
unresponsive	O
to	O
or	O
intolerant	O
other	O
antipsychotics.	O

In	O
September	O
2009,	O
Pfizer	O
pleaded	O
guilty	O
to	O
the	O
illegal	O
marketing	O
of	O
arthritis	O
drug	O
Bextra	B-Drug
for	O
uses	O
unapproved	O
by	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA),	O
agreed	O
a	O
$2.3	O
billion	O
settlement,	O
largest	O
health	O
care	O
fraud	O
settlement	O
at	O
that	O
time.	O

Phenoperidine	B-Drug
was	O
first	O
synthesized	O
in	O
1957	O
by	O
Paul	O
Janssen,	O
of	O
the	O
company	O
now	O
known	O
as	O
Janssen	O
Pharmaceutica,	O
who	O
seeking	O
better	O
opioid	O
pain-killers.	O

O-Acetylpsilocin	B-Drug
is	O
ambiguously	O
legal	O
for	O
use	O
as	O
a	O
lab	O
reagent	O
or	O
research	O
chemical;	O
however,	O
it	O
an	O
acetate	O
ester	O
of	O
psilocin,	O
meaning	O
would	O
be	O
considered	O
Schedule	O
I	O
under	O
the	O
Federal	O
Analogue	O
Act	O
if	O
sold	O
human	O
consumption.	O
psilocin	B-Drug

Tamoxifen	B-Drug
binds	O
to	O
ER	O
competitively	O
(with	O
respect	O
the	O
endogenous	O
agonist	O
estrogen)	O
in	O
tumor	O
cells	O
and	O
other	O
tissue	O
targets,	O
producing	O
a	O
nuclear	O
complex	O
that	O
decreases	O
DNA	O
synthesis	O
inhibits	O
estrogen	O
effects.	O

Psychedelic	O
substances	O
which	O
may	O
have	O
therapeutic	O
uses	O
include	O
psilocybin,	O
LSD,	O
and	O
mescaline.	O
LSD	B-Drug
mescaline	B-Drug

He	O
also	O
liked	O
the	O
fact	O
that	O
there	O
was	O
virtually	O
no	O
humidity,	O
which	O
can	O
affect	O
production	O
of	O
LSD.	O
LSD	B-Drug

On	O
March	O
5,	O
2014	O
the	O
UK	O
Home	O
Office	O
announced	O
that	O
5-MAPB	B-Drug
would	O
be	O
made	O
a	O
class	O
B	O
drug	O
on	O
10	O
June	O
alongside	O
every	O
other	O
benzofuran	O
entactogen	O
and	O
many	O
structurally	O
related	O
drugs.	O

Heroin	B-Drug
is	O
also	O
known	O
by	O
many	O
street	O
names	O
including	O
dope,	O
H,	O
smack,	O
junk,	O
horse,	O
scag,	O
and	O
brown,	O
among	O
others.	O
smack	B-Drug

These	O
medications	O
could	O
potentially	O
interact	O
with	O
the	O
metabolism	O
of	O
hyoscine:	O
analgesics/pain	O
medications,	O
ethanol,	O
zolpidem,	O
thiazide	O
diuretics,	O
buprenorphine,	O
anticholinergic	O
drugs	O
such	O
as	O
tiotropium,	O
etc.	O
hyoscine	B-Drug
zolpidem	B-Drug
buprenorphine	B-Drug
tiotropium	B-Drug

After	O
World	O
War	O
II,	O
the	O
Mafia	O
took	O
advantage	O
of	O
weakness	O
postwar	O
Italian	O
government	O
and	O
set	O
up	O
heroin	B-Drug
labs	O
in	O
Sicily.	O

The	O
most	O
severe	O
side	O
effect	O
associated	O
with	O
buprenorphine	B-Drug
is	O
respiratory	O
depression	O
(insufficient	O
breathing).	O

Bicalutamide	B-Drug
influences	O
the	O
HPG	O
axis	O
and	O
increases	O
hormone	O
levels	O
only	O
in	O
men	O
not	O
also	O
women.	O

The	O
antipsychotic	O
haloperidol	B-Drug
may	O
also	O
be	O
used.	O

The	O
efficacy	O
of	O
risperidone	B-Drug
long-acting	O
injection	O
appears	O
to	O
be	O
similar	O
that	O
long	O
acting	O
injectable	O
forms	O
first	O
generation	O
antipsychotics.	O

Diclofenac	B-Drug
formulations	O
are	O
available	O
worldwide	O
under	O
many	O
different	O
trade	O
names.	O

It	O
is	O
also	O
used	O
in	O
depression	O
that	O
not	O
responsive	O
to	O
reuptake	O
inhibitor	O
antidepressants,	O
such	O
as	O
the	O
SSRIs,	O
TCAs,	O
or	O
bupropion.	O
bupropion	B-Drug

Opuntia	O
spinosior),	O
Mescaline	B-Drug
0.00004%,	O
3-methoxytyramine	O
0.001%,	O
tyramine	O

People	O
taking	O
a	O
dosage	O
of	O
cimetidine	B-Drug
greater	O
than	O
or	O
equal	O
to	O
1,000	O
mg	O
showed	O
more	O
40	O
times	O
the	O
risk	O
gynecomastia	O
non-users.	O

This	O
was	O
similar	O
to	O
the	O
increase	O
in	O
prolactin	O
levels	O
produced	O
by	O
a	O
single	O
20	O
mg	O
oral	O
dose	O
of	O
metoclopramide	B-Drug
(7.4	O
ng/mL	O
124.1	O
ng/mL;	O
16.7-fold	O
increase).	O

Zinc	O
supplementation	O
may	O
reduce	O
the	O
minimum	O
effective	O
dose	O
of	O
amphetamine	B-Drug
when	O
it	O
is	O
used	O
for	O
treatment	O
ADHD.In	O
general,	O
there	O
no	O
significant	O
interaction	O
consuming	O
with	O
food,	O
but	O
pH	O
gastrointestinal	O
content	O
and	O
urine	O
affects	O
absorption	O
excretion	O
amphetamine,	O
respectively.	O

In	O
fact,	O
regulations	O
on	O
the	O
cannabis	O
plant	O
as	O
well	O
opium	O
poppy,	O
coca	B-Drug
bush,	O
poppy	O
straw	O
and	O
tops	O
were	O
embedded	O
in	O
text	O
of	O
treaty,	O
making	O
it	O
impossible	O
to	O
deregulate	O
them	O
through	O
normal	O
Scheduling	O
process.	O

As	O
a	O
result	O
of	O
several	O
expert	O
witnesses	O
testifying	O
that	O
MDMA	B-Drug
had	O
an	O
accepted	O
medical	O
usage,	O
the	O
administrative	O
law	O
judge	O
presiding	O
over	O
hearings	O
recommended	O
be	O
classified	O
as	O
Schedule	O
III	O
substance.	O

In	O
some	O
instances,	O
designer	O
drugs	O
have	O
similar	O
effects	O
to	O
other	O
known	O
drugs,	O
but	O
completely	O
dissimilar	O
chemical	O
structures	O
(e.g.	O
JWH-018	B-Drug
vs	O
THC).	O
THC	B-Drug

MDMA:	O
MDMA	B-Drug

ADBICA	B-Drug
(also	O
known	O
as	O
ADB-PICA)	O
is	O
a	O
designer	O
drug	O
identified	O
in	O
synthetic	O
cannabis	O
blends	O
Japan	O
2013.	O

Jungla	O
commando	O
force,	O
and	O
between	O
45,000	O
60,000	O
police	O
officers	O
during	O
the	O
three-month	O
presidential	O
campaign	O
voting	O
period	O
had	O
been	O
unavailable	O
for	O
manual	O
coca	B-Drug
eradicationThe	O
aerial	O
spraying	O
of	O
glyphosate	O
herbicide	O
is	O
one	O
most	O
controversial	O
methods	O
eradication.	O

A	O
2012	O
review	O
examining	O
the	O
relation	O
of	O
cancer	O
and	O
cannabis	O
found	O
little	O
direct	O
evidence	O
that	O
cannabinoids	O
in	O
cannabis,	O
including	O
THC,	O
are	O
carcinogenic.	O
THC	B-Drug

PCP,	O
like	O
ketamine,	O
also	O
acts	O
as	O
a	O
potent	O
dopamine	O
D2High	O
receptor	O
partial	O
agonist	O
in	O
rat	O
brain	O
homogenate	O
and	O
has	O
affinity	O
for	O
the	O
human	O
cloned	O
receptor.	O
PCP	B-Drug
ketamine	B-Drug

However,	O
because	O
of	O
its	O
higher	O
alkalinity	O
(pH	O
8.5)	O
compared	O
to	O
cigarette	O
smoke	O
5.3),	O
non-ionized	O
nicotine	B-Drug
is	O
more	O
readily	O
absorbed	O
through	O
the	O
mucous	O
membranes	O
in	O
mouth.	O

LSD	B-Drug
is	O
rapidly	O
absorbed,	O
so	O
activated	O
charcoal	O
and	O
emptying	O
of	O
the	O
stomach	O
little	O
benefit,	O
unless	O
done	O
within	O
3060	O
minutes	O
ingesting	O
an	O
overdose	O
LSD.	O

In	O
individuals	O
with	O
terminal	O
cancer,	O
methylphenidate	B-Drug
can	O
be	O
used	O
to	O
counteract	O
opioid-induced	O
somnolence,	O
increase	O
the	O
analgesic	O
effects	O
of	O
opioids,	O
treat	O
depression,	O
and	O
improve	O
cognitive	O
function.	O

The	O
Riksdag	O
added	O
4-AcO-DMT	B-Drug
to	O
Narcotic	O
Drugs	O
Punishments	O
Act	O
under	O
swedish	O
schedule	O
I	O
("substances,	O
plant	O
materials	O
and	O
fungi	O
which	O
normally	O
do	O
not	O
have	O
medical	O
use"	O
)	O
as	O
of	O
January	O
25,	O
2017,	O
published	O
by	O
Medical	O
Products	O
Agency	O
(MPA)	O
in	O
regulation	O
HSLF-FS	O
2017:1	O
listed	O
4-acetoxi-N,N-dimetyltryptamin.	O

Prohibition	O
in	O
the	O
United	O
States	O
Alcohol	O
consumption	O
by	O
youth	O
Alcohol-related	O
traffic	O
crashes	O
Medical	O
cannabis	O
Decriminalization	O
of	O
non-medical	O
Legal	O
history	O
Removal	O
from	O
Schedule	O
I	O
Controlled	O
Substances	O
Act	O
History	O
commercial	O
tobacco	B-Drug
Cigarette	O
taxes	O

cocaine,	O
ketamine,	O
LSD,	O
ecstasy	B-Drug
cocaine	B-Drug
ketamine	B-Drug
LSD	B-Drug

Clonazepam,	O
which	O
is	O
a	O
GABAA	O
receptor	O
agonist,	O
shown	O
to	O
prevent	O
the	O
acquisition	O
of	O
behavioural	O
sensitization	O
methamphetamine.	O
Clonazepam	B-Drug
methamphetamine	B-Drug

Marijuana	O
use	O
is	O
also	O
linked	O
to	O
other	O
substance	O
disorders	O
including	O
nicotine	B-Drug
addiction.	O

Back	O
in	O
France,	O
he	O
continued	O
to	O
experiment	O
on	O
himself	O
and	O
published	O
an	O
1845	O
book	O
entitled	O
Hashish	B-Drug
mental	O
alienation	O
which	O
establishes	O
equivalence	O
between	O
dream,	O
hallucination,	O
hashish	B-Drug
delirium.	O

Even	O
modest	O
doses	O
of	O
narcotine	B-Drug
can	O
induce	O
profound	O
nausea	O
and	O
vomiting.	O

However,	O
PCP	B-Drug
may	O
also	O
interact	O
with	O
allosteric	O
sites	O
on	O
the	O
monoamine	O
transporters	O
to	O
produce	O
inhibition	O
of	O
reuptake.	O

The	O
starting	O
of	O
methadone	B-Drug
and	O
the	O
time	O
immediately	O
after	O
leaving	O
treatment	O
with	O
both	O
drugs	O
are	O
periods	O
particularly	O
increased	O
mortality	O
risk,	O
which	O
should	O
be	O
dealt	O
by	O
public	O
health	O
clinical	O
strategies.	O

Dienogest	B-Drug
is	O
one	O
of	O
the	O
only	O
19-nortestosterone	B-Drug
derivative	O
progestins	O
that	O
does	O
not	O
have	O
androgenic	O
properties.	O

DrugScience	O
initially	O
focused	O
on	O
reviewing	O
official	O
risk	O
estimates	O
for	O
psychedelic	O
drugs,	O
ecstasy	B-Drug
and	O
cannabis,	O
increasing	O
warnings	O
of	O
the	O
dangers	O
ketamine.	O
ketamine	B-Drug

Uncured	O
tobacco	B-Drug
is	O
also	O
a	O
deliriant	O
due	O
to	O
its	O
intoxicatingly	O
high	O
levels	O
of	O
nicotine.	O
nicotine	B-Drug

Notably,	O
the	O
amphetamine	B-Drug
contained	O
in	O
Benzedrine	B-Drug
inhaler	O
was	O
liquid	O
free-base,	O
not	O
a	O
chloride	O
or	O
sulfate	O
salt.	O

A	O
heroin	B-Drug
overdose	O
may	O
be	O
treated	O
with	O
naloxone.	O
naloxone	B-Drug

Additionally,	O
while	O
cocaine	B-Drug
overdose	O
victims	O
showed	O
a	O
large	O
increase	O
in	O
KORs	O
(doubled)	O
the	O
NAcc,	O
KOR	O
agonist	O
administration	O
is	O
shown	O
to	O
be	O
effective	O
decreasing	O
seeking	O
and	O
self-administration.	O

MBE	O
of	O
the	O
United	O
Kingdom,	O
born	O
with	O
phocomelia	O
both	O
arms	O
and	O
legs,	O
is	O
only	O
thalidomide	B-Drug
survivor	O
to	O
carry	O
Olympic	O
Torch.	O

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects,	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood.	O

This	O
drug	O
is	O
administered	O
to	O
those	O
with	O
hypotension	O
post	O
intubation	O
as	O
a	O
result	O
of	O
lidocaine,	O
midazolam,	O
fentanyl,	O
propofol,	O
and	O
ketamine.	O
lidocaine	B-Drug
midazolam	B-Drug
fentanyl	B-Drug
propofol	B-Drug
ketamine	B-Drug

Spironolactone	B-Drug
has	O
been	O
reported	O
to	O
induce	O
the	O
enzymes	O
CYP3A4	O
and	O
certain	O
UDP-glucuronosyltransferases	O
(UGTs),	O
which	O
can	O
result	O
in	O
interactions	O
with	O
various	O
medications.	O

It	O
is	O
22	O
times	O
more	O
potent	O
than	O
morphine.	O
morphine	B-Drug

Like	O
RCS-4	B-Drug
and	O
AB-001,	O
MAM-2201	B-Drug
thus	O
appears	O
to	O
be	O
a	O
novel	O
compound	O
invented	O
by	O
"research	O
chemical"	O
suppliers	O
specifically	O
for	O
grey-market	O
recreational	O
use.	O
AB-001	B-Drug

In	O
contrast,	O
paracetamol	B-Drug
(acetaminophen)	O
is	O
regarded	O
as	O
being	O
safe	O
and	O
well	O
tolerated	O
during	O
pregnancy,	O
but	O
Leffers	O
et	O
al.	O
released	O
a	O
study	O
in	O
2010,	O
indicating	O
that	O
there	O
may	O
be	O
associated	O
male	O
infertility	O
the	O
unborn.	O
acetaminophen	B-Drug

MDMA-assisted	O
psychotherapy	O
is	O
the	O
use	O
of	O
prescribed	O
doses	O
MDMA	B-Drug
as	O
an	O
adjunct	O
to	O
sessions.	O

Since	O
a	O
partial	O
cause	O
of	O
the	O
refractory	O
period	O
is	O
inhibition	O
dopamine	O
by	O
an	O
orgasm-induced	O
secretion	O
prolactin,	O
such	O
potent	O
receptor	O
agonists	O
as	O
cabergoline	B-Drug
may	O
help	O
achieve	O
multiple	O
orgasms	O
well	O
retention	O
sexual	O
arousal	O
for	O
longer	O
periods	O
time.	O

It	O
was	O
revealed	O
that	O
the	O
sale	O
of	O
meprobamate	B-Drug
earned	O
$40,000,000	O
for	O
defendants.	O

It	O
is	O
generally	O
less	O
expensive	O
than	O
other	O
forms	O
of	O
heroin.	O
heroin	B-Drug

Drugs	O
such	O
as	O
marijuana,	O
cocaine,	O
heroin,	O
and	O
methamphetamine	B-Drug
are	O
related	O
to	O
a	O
wide	O
range	O
of	O
paraphernalia.	O
cocaine	B-Drug
heroin	B-Drug

It	O
is	O
the	O
source	O
of	O
90%	O
world	O
supply	O
legal	O
morphine	B-Drug
(for	O
medical	O
and	O
scientific	O
use)	O
in	O
some	O
countries	O
it	O
also	O
a	O
illegal	O
morphine,	O
which	O
could	O
be	O
processed	O
into	O
heroin.	O
heroin	B-Drug

In	O
the	O
United	O
States,	O
acetylmethadol	B-Drug
and	O
its	O
individual	O
isomers	O
are	O
all	O
Schedule	O

In	O
animal	O
studies	O
it	O
was	O
found	O
to	O
be	O
moderately	O
addictive	O
and	O
produced	O
limited	O
physical	O
dependence,	O
but	O
not	O
as	O
severe	O
that	O
seen	O
with	O
morphine	B-Drug
or	O
pethidine.	O
pethidine	B-Drug

Not	O
all	O
addictive	O
drugs	O
are	O
associated	O
with	O
physical	O
dependence,	O
e.g.,	O
amphetamine,	O
and	O
not	O
that	O
produce	O
dependence	O
drugs,	O
caffeine.	O
amphetamine	B-Drug

Some	O
or	O
all	O
extrapyramidal	O
reactions	O
may	O
respond	O
to	O
the	O
application	O
of	O
anticholinergic	O
drugs	O
such	O
as	O
biperiden	B-Drug
benzatropine.	O
benzatropine	B-Drug

More	O
recently,	O
when	O
blood	O
samples	O
from	O
366	O
patients	O
in	O
the	O
TOPCAT	O
study	O
were	O
analyzed	O
for	O
presence	O
of	O
canrenone	O
(an	O
active	O
metabolite	O
spironolactone),	O
30%	O
Russia	O
lacked	O
detectable	O
residues	O
canrenone.	O
spironolactone	B-Drug

Spironolactone	B-Drug
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
female-pattern	O
hair	O
loss	O
(pattern	O
scalp	O
women).	O

LSD	B-Drug
was	O
also	O
given	O
to	O
artists	O
in	O
order	O
track	O
their	O
mental	O
deterioration,	O
but	O
Huxley	O
believed	O
might	O
enhance	O
creativity.	O

Some	O
athletes	O
have	O
used	O
GHB	B-Drug
or	O
its	O
analogs	O
because	O
of	O
being	O
marketed	O
as	O
anabolic	O
agents,	O
although	O
there	O
is	O
no	O
evidence	O
that	O
it	O
builds	O
muscle	O
improves	O
performance.	O

Mitragynine	B-Drug
is	O
primarily	O
metabolized	O
in	O
the	O
liver	O
producing	O
many	O
metabolites	O
during	O
both	O
phase	O
I	O
and	O
II.	O

4.0g	O
of	O
MDMA	B-Drug
is	O
the	O
amount	O
required	O
determining	O
a	O
court	O
trial,	O
2.0g	O
considered	O
presumption	O
with	O
intent	O
to	O
sell	O
or	O
supply	O
and	O
28.0g	O
trafficking	O
under	O
Australian	O
law.	O

In	O
1991,	O
Glaxo	O
received	O
approval	O
for	O
sumatriptan,	O
which	O
was	O
the	O
first	O
available	O
triptan.	O
sumatriptan	B-Drug

Specifically,	O
25I-NBOMe	B-Drug
is	O
an	O
N-benzyl	O
derivative	O
of	O
the	O
phenethylamine	B-Drug
molecule	O
2C-I,	O
formed	O
by	O
adding	O
a	O
2-methoxybenzyl	O
(BnOMe)	O
onto	O
nitrogen	O
(N)	O
backbone.	O

Molecularly,	O
this	O
is	O
seen	O
as	O
demethylenation	O
of	O
methylenedioxypyrovalerone	B-Drug
(CYP2D6),	O
followed	O
by	O
methylation	O
the	O
aromatic	O
ring	O
via	O
catechol-O-methyl	O
transferase.	O

THC	B-Drug
has	O
been	O
shown	O
to	O
inhibit	O
GABA	O
receptor	O
neurotransmission	O
in	O
the	O
brain	O
via	O
several	O
pathways.	O

However,	O
in	O
2016	O
an	O
investigation	O
by	O
the	O
Los	O
Angeles	O
Times	O
found	O
that	O
"the	O
drug	O
weans	O
off	O
hours	O
early	O
many	O
people,"	O
inducing	O
symptoms	O
of	O
opiate	O
withdrawal	O
and	O
intense	O
cravings	O
for	O
OxyContin.	O
OxyContin	B-Drug

Present	O
in	O
industrial	O
hemp,	O
cannabidiol	B-Drug
is	O
a	O
major	O
constituent	O
among	O
some	O
560	O
compounds	O
found	O
hemp.	O

One	O
such	O
memo	O
read,	O
"There	O
is	O
no	O
Q8	O
dosing	O
with	O
OxyContin...	O
OxyContin	B-Drug

See	O
for	O
example	O
the	O
list	O
of	O
phenyltropanes	O
or	O
synthesis	O
paroxetine	B-Drug
further	O
examples	O
this.	O

PCP's	O
rewarding	O
and	O
reinforcing	O
effects	O
are	O
at	O
least	O
partly	O
mediated	O
by	O
blocking	O
the	O
NMDA	O
receptors	O
in	O
glutamatergic	O
inputs	O
to	O
D1-type	O
medium	O
spiny	O
neurons	O
nucleus	O
accumbens.	O
PCP	B-Drug

Diamorphine	B-Drug
was	O
first	O
synthesized	O
in	O
1874	O
by	O
C.	O
R.	O
Alder	O
Wright,	O
an	O
English	O
chemist	O
working	O
at	O
St.	O
Mary's	O
Hospital	O
Medical	O
School	O
London	O
who	O
had	O
been	O
experimenting	O
combining	O
morphine	B-Drug
with	O
various	O
acids.	O

CBD	B-Drug
is	O
believed	O
to	O
regulate	O
the	O
metabolism	O
of	O
THC	B-Drug
by	O
inactivating	O
cytochrome	O
P450	O
enzymes	O
that	O
metabolize	O
drugs.	O

Research	O
efforts	O
have	O
been	O
focused	O
on	O
determining	O
how	O
thalidomide	B-Drug
causes	O
birth	O
defects	O
and	O
its	O
other	O
activities	O
in	O
the	O
human	O
body,	O
to	O
develop	O
safer	O
analogs,	O
find	O
further	O
uses	O
for	O
thalidomide.	O

According	O
to	O
the	O
American	O
Heart	O
Association,	O
"Nicotine	O
addiction	O
has	O
historically	O
been	O
one	O
of	O
hardest	O
addictions	O
break."	O
Nicotine	B-Drug

Indeed,	O
DHT	O
has	O
less	O
than	O
1%	O
of	O
the	O
affinity	O
testosterone	O
for	O
ZIP9,	O
and	O
synthetic	O
AAS	O
metribolone	O
mibolerone	B-Drug
are	O
ineffective	O
competitors	O
receptor	O
similarly.	O

Tasmania	O
also	O
had	O
25%	O
of	O
the	O
world's	O
opium	B-Drug
and	O
codeine	B-Drug
production.	O

Pharmacists	O
who	O
were	O
found	O
to	O
have	O
prescribed	O
opium	B-Drug
for	O
illegitimate	O
uses	O
and	O
anyone	O
sold	O
without	O
proper	O
qualifications	O
would	O
be	O
prosecuted.	O

Sufentanil,	O
a	O
powerful	O
fentanyl	B-Drug
analog,	O
is	O
the	O
only	O
drug	O
enough	O
to	O
relieve	O
pain	O
in	O
emergency	O
settings	O
because	O
it	O
opioid	O
that	O
has	O
potency	O
and	O
binding	O
affinity	O
strong	O
displace	O
buprenorphine	B-Drug
from	O
receptors	O
CNS	O
provide	O
analgesia.	O
Sufentanil	B-Drug

Although	O
Afghanistan's	O
overall	O
economy	O
is	O
being	O
boosted	O
by	O
opium	B-Drug
profits,	O
less	O
than	O
20	O
percent	O
of	O
the	O
$3	O
billion	O
in	O
profits	O
actually	O
goes	O
to	O
impoverished	O
farmers,	O
while	O
more	O
80	O
into	O
pockets	O
Afghan's	O
traffickers	O
and	O
kingpins	O
their	O
political	O
connections.	O

Methyltestosterone,	O
sold	O
under	O
the	O
brand	O
names	O
Android,	O
Metandren,	O
and	O
Testred	B-Drug
among	O
others,	O
is	O
an	O
androgen	O
anabolic	O
steroid	O
(AAS)	O
medication	O
which	O
used	O
in	O
treatment	O
of	O
low	O
testosterone	O
levels	O
men,	O
delayed	O
puberty	O
boys,	O
at	O
doses	O
as	O
a	O
component	O
menopausal	O
hormone	O
therapy	O
for	O
symptoms	O
like	O
hot	O
flashes,	O
osteoporosis,	O
sexual	O
desire	O
women,	O
to	O
treat	O
breast	O
cancer	O
women.	O
Methyltestosterone	B-Drug

Oxycodone	B-Drug
is	O
a	O
Class	O
A	O
drug	O
under	O
the	O
Misuse	O
of	O
Drugs	O
Act.	O

Methadone	B-Drug
is	O
also	O
regulated	O
internationally	O
as	O
a	O
Schedule	O

Tetrazepam	B-Drug
(is	O
marketed	O
under	O
the	O
following	O
brand	O
names,	O
Clinoxan,	O
Epsipam,	O
Myolastan,	O
Musaril,	O
Relaxam	O
and	O
Spasmorelax)	O
is	O
a	O
benzodiazepine	O
derivative	O
with	O
anticonvulsant,	O
anxiolytic,	O
muscle	O
relaxant	O
slightly	O
hypnotic	O
properties.	O

It	O
is	O
a	O
positional	O
isomer	O
of	O
methamphetamine	B-Drug
and	O
other	O
methylamphetamines.	O

In	O
the	O
United	O
States	O
in	O
1937,	O
Marihuana	B-Drug
Tax	O
Act	O
was	O
passed,	O
and	O
prohibited	O
production	O
of	O
hemp	O
addition	O
to	O
cannabis.	O

These	O
results	O
suggest	O
that	O
the	O
administration	O
of	O
coca	B-Drug
leaf	O
infusion	O
plus	O
counseling	O
would	O
be	O
an	O
effective	O
method	O
for	O
preventing	O
relapse	O
during	O
treatment	O
cocaine	B-Drug
addiction.	O

Bicalutamide	B-Drug
has	O
been	O
found	O
to	O
be	O
a	O
P-glycoprotein	O
(ABCB1)	O
inhibitor.	O

Suicide	O
by	O
laudanum	B-Drug
was	O
not	O
uncommon	O
in	O
the	O
mid-19th	O
century.	O

Hair	O
analysis,	O
however,	O
can	O
give	O
false	O
positives	O
for	O
cocaine	B-Drug
exposure,	O
and	O
a	O
newborn	O
may	O
not	O
have	O
enough	O
hair	O
to	O
test.	O

The	O
transition	O
from	O
medical	O
use	O
of	O
zolpidem	B-Drug
to	O
high-dose	O
addiction	O
or	O
drug	O
dependence	O
can	O
occur	O
with	O
use,	O
but	O
some	O
believe	O
it	O
may	O
be	O
more	O
likely	O
when	O
used	O
without	O
a	O
doctor's	O
recommendation	O
continue	O
using	O
it,	O
physiological	O
tolerance	O
leads	O
higher	O
doses	O
than	O
the	O
usual	O
5	O
mg	O
10	O
mg,	O
consumed	O
through	O
inhalation	O
injection,	O
taken	O
for	O
purposes	O
other	O
as	O
sleep	O
aid.	O

Bezitramide	B-Drug
is	O
an	O
opioid	O
analgesic.	O

As	O
such,	O
most	O
of	O
the	O
occupation	O
SHBG	O
by	O
danazol	B-Drug
may	O
actually	O
be	O
due	O
to	O
this	O
metabolite.	O

Nandrolone	B-Drug
Norandrostenediol	O
Norandrostenedione	O
Norbolethone	B-Drug
Norclostebol	O
Norethandrolone	B-Drug
Oxabolone	O
Oxandrolone	B-Drug
Oxymesterone	O
Oxymetholone	B-Drug
Prostanozol	O
Quinbolone	B-Drug
Selective	O
androgen	O
receptor	O
modulators	O
(SARMs)	O

It	O
is	O
likely	O
that	O
the	O
higher	O
THC	B-Drug
content	O
allows	O
people	O
to	O
ingest	O
less	O
tar.	O

Temazepam	B-Drug
has	O
very	O
good	O
bioavailability,	O
with	O
almost	O
100%	O
being	O
absorbed	O
following	O
taken	O
by	O
mouth.	O

Protective	O
airway	O
reflexes	O
are	O
preserved,	O
and	O
it	O
is	O
sometimes	O
possible	O
to	O
administer	O
ketamine	B-Drug
anesthesia	O
without	O
protective	O
measures	O
the	O
airways.	O

When	O
enforcement	O
efforts	O
intensified	O
in	O
South	O
Florida	O
and	O
the	O
Caribbean,	O
Colombian	O
organizations	O
formed	O
partnerships	O
with	O
Mexico-based	O
traffickers	O
to	O
transport	O
cocaine	B-Drug
by	O
land	O
through	O
Mexico	O
into	O
United	O
States.	O

The	O
committee	O
made	O
this	O
recommendation	O
on	O
the	O
basis	O
of	O
pharmacological	O
similarity	O
MDMA	B-Drug
to	O
previously	O
scheduled	O
drugs,	O
reports	O
illicit	O
trafficking	O
in	O
Canada,	O
drug	O
seizures	O
United	O
States,	O
and	O
lack	O
well-defined	O
therapeutic	O
use.	O

A	O
systematic	O
review	O
from	O
2014	O
found	O
that	O
low	O
doses	O
of	O
amphetamine	B-Drug
also	O
improve	O
memory	O
consolidation,	O
in	O
turn	O
leading	O
to	O
improved	O
recall	O
information.	O

All	O
drugs	O
in	O
the	O
NBOMe	O
series,	O
including	O
25I-NBOMe,	O
became	O
illegal	O
Russia	O
October	O
2011.	O
25I-NBOMe	B-Drug

Progress	O
and	O
promise	O
for	O
the	O
MDMA	B-Drug
drug	O
development	O
program.	O

but	O
if	O
the	O
6-7	O
bond	O
is	O
saturated,	O
isomer	O
some	O
50	O
times	O
more	O
potent	O
than	O
morphine.	O
morphine	B-Drug

Rolling	O
meth	B-Drug
labs	O
can	O
be	O
concealed	O
on	O
or	O
in	O
vehicles	O
as	O
large	O
18	O
wheelers	O
small	O
motorcycles.	O

Fentanyl	B-Drug
is	O
sometimes	O
given	O
intrathecally	O
as	O
part	O
of	O
spinal	O
anesthesia	O
or	O
epidurally	O
for	O
epidural	O
anaesthesia	O
and	O
analgesia.	O

Cannabidiol	B-Drug
is	O
classified	O
as	O
a	O
medical	O
product	O
in	O
Sweden.	O

Methylphenidate	B-Drug
taken	O
orally	O
has	O
a	O
bioavailability	O
of	O
1152%	O
with	O
duration	O
action	O
around	O
24	O
hours	O
for	O
instant	O
release	O
(i.e.	O
Ritalin),	O
38	O
sustained	O
Ritalin	B-Drug
SR),	O
and	O
812	O
extended	O
Concerta).	O
Concerta	B-Drug

Like	O
other	O
drugs	O
of	O
this	O
type,	O
nalmefene	B-Drug
may	O
precipitate	O
acute	O
withdrawal	O
symptoms	O
in	O
patients	O
who	O
are	O
dependent	O
on	O
opioid	O
drugs,	O
or	O
more	O
rarely	O
when	O
used	O
post-operatively,	O
to	O
counteract	O
the	O
effects	O
strong	O
opioids	O
surgery.	O

It	O
can	O
be	O
cut	O
into,	O
or	O
even	O
replace	O
entirely,	O
the	O
supply	O
of	O
heroin	B-Drug
and	O
other	O
opiates.	O

By	O
federal	O
law,	O
private	O
enterprises	O
developing	O
hemp-derived	O
CBD	B-Drug
are	O
obligated	O
to	O
cultivate	O
hemp	O
exclusively	O
for	O
industrial	O
purposes,	O
which	O
involve	O
the	O
fiber	O
and	O
seed,	O
but	O
not	O
flowering	O
tops	O
contain	O
THC	B-Drug
CBD.	O

Active	O
substance:	O
loperamide)	O
Motilium	O
(against	O
flatulence	O
and	O
bowel	O
impairments.	O
loperamide	B-Drug

A	O
2018	O
systematic	O
review	O
and	O
network	O
meta-analysis	O
of	O
50	O
trials	O
involving	O
12	O
different	O
psychosocial	O
interventions	O
for	O
amphetamine,	O
methamphetamine,	O
or	O
cocaine	B-Drug
addiction	O
found	O
that	O
combination	O
therapy	O
with	O
both	O
contingency	O
management	O
community	O
reinforcement	O
approach	O
had	O
the	O
highest	O
efficacy	O
(i.e.,	O
abstinence	O
rate)	O
acceptability	O
lowest	O
dropout	O
rate).	O
amphetamine	B-Drug
methamphetamine	B-Drug

Linagliptin,	O
sold	O
under	O
the	O
brand	O
name	O
Tradjenta	O
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
diabetes	O
mellitus	O
type	O
2.	O
Linagliptin	B-Drug

Another	O
popular	O
route	O
to	O
intake	O
heroin	B-Drug
is	O
insufflation	O
(snorting),	O
where	O
a	O
user	O
crushes	O
the	O
into	O
fine	O
powder	O
and	O
then	O
gently	O
inhales	O
it	O
(sometimes	O
with	O
straw	O
or	O
rolled-up	O
banknote,	O
as	O
cocaine)	O
nose,	O
absorbed	O
through	O
soft	O
tissue	O
in	O
mucous	O
membrane	O
of	O
sinus	O
cavity	O
straight	O
bloodstream.	O
cocaine	B-Drug

Classical	O
cannabinoids	O
include	O
nabilone	B-Drug
and	O
dronabinol,	O
one	O
of	O
the	O
best	O
known	O
synthetic	O
classical	O
is	O
HU-210.	O
HU-210	B-Drug

Phencyclidine	B-Drug
(PCP)	O
is	O
believed	O
to	O
be	O
the	O
first	O
arylcyclohexylamine	O
with	O
recognized	O
anesthetic	O
properties,	O
but	O
several	O
arylcyclohexylamines	O
were	O
described	O
before	O
PCP	B-Drug
in	O
scientific	O
literature,	O
beginning	O
PCA	O
(1-phenylcyclohexan-1-amine)	O

Fentanyl	B-Drug
is	O
a	O
highly	O
lipophilic	O
compound,	O
which	O
well	O
absorbed	O
sublingually	O
and	O
generally	O
tolerated.	O

Sulpiride	B-Drug
is	O
usually	O
well	O
tolerated,	O
producing	O
few	O
adverse	O
effects.	O

25B-NBOMe	B-Drug
has	O
been	O
used	O
in	O
clinical	O
trials	O
with	O
an	O
evaluation	O
dose	O
for	O
safety	O
consideration	O
to	O
humans	O
of	O
only	O
1	O
microgram.	O

Administration	O
of	O
pholcodine	B-Drug
causes	O
production	O
antibodies	O
linked	O
with	O
fatalities	O
during	O
surgery,	O
when	O
essential	O
neuromuscular	O
blocking	O
agents	O
(NMBAs)	O
are	O
administered	O
to	O
prevent	O
patient	O
movement	O
under	O
general	O
anaesthesia.	O

Fentanyl,	O
like	O
other	O
opioids,	O
acts	O
on	O
opioid	O
receptors.	O
Fentanyl	B-Drug

that	O
can	O
be	O
nearly	O
indistinguishable	O
from	O
real	O
LSD	B-Drug
before	O
use,	O
and	O
thus	O
easily	O
confused	O
with	O
"bad	O
acid."	O
acid	B-Drug

ketamine	B-Drug
(K;	O
Ketalar,	O
Ketaset,	O
Ketanest;	O
"Ket",	O
"Kit	O
Kat",	O
"Special-K",	O
"Vitamin	O
K",	O
"Jet	O
Fuel",	O
"Horse	O
Tranquilizer")	O
methoxetamine	B-Drug
(Mex,	O
Mket,	O
Mexi)	O
phencyclidine	B-Drug
(PCP;	O
Sernyl;	O
"Angel	O
Dust",	O
"Rocket	O
"Sherm",	O
"Killer	O
Weed",	O
"Super	O
Grass")	O
PCP	B-Drug

At	O
therapeutic	O
doses,	O
dextromethorphan	B-Drug
acts	O
centrally	O
(meaning	O
that	O
it	O
on	O
the	O
brain)	O
as	O
opposed	O
to	O
locally	O
(on	O
respiratory	O
tract).	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco,	O
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine.	O
tobacco	B-Drug
cocaine	B-Drug

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s.	O

racemoramide	B-Drug
moramide	B-Drug
intermediate	I-Drug

Tranylcypromine	B-Drug
is	O
a	O
propylamine	O
formed	O
from	O
the	O
cyclization	O
of	O
amphetamine's	O
side	O
chain;	O
therefore,	O
it	O
classified	O
as	O
substituted	O
amphetamine.	O
amphetamine	B-Drug

The	O
patches	O
work	O
by	O
slowly	O
releasing	O
fentanyl	B-Drug
through	O
the	O
skin	O
into	O
bloodstream	O
over	O
48	O
to	O
72	O
hours,	O
allowing	O
for	O
long-lasting	O
pain	O
management.	O

Use	O
of	O
camazepam	B-Drug
is	O
contraindicated	O
in	O
subjects	O
with	O
known	O
hypersensitivity	O
to	O
drug	O
or	O
allergy	O
other	O
drugs	O
the	O
benzodiazepine	O
class	O
any	O
excipients	O
contained	O
pharmaceutical	O
form.	O

Cannabis	O
has	O
been	O
cultivated	O
in	O
Morocco	O
for	O
centuries	O
and	O
the	O
country	O
is	O
currently	O
among	O
world's	O
top	O
producers	O
of	O
hashish.	O
hashish	B-Drug

Phencyclidine	B-Drug
is	O
used	O
for	O
its	O
ability	O
to	O
induce	O
a	O
dissociative	O
state.	O

Snorting	O
heroin	B-Drug
becomes	O
an	O
often	O
unwanted	O
route,	O
once	O
a	O
user	O
begins	O
to	O
inject	O
the	O
drug.	O

However,	O
it	O
is	O
arguably	O
an	O
analog	O
of	O
psilocin,	O
which	O
could	O
lead	O
to	O
prosecution	O
under	O
the	O
Federal	O
Analog	O
Act.	O
psilocin	B-Drug

Zaleplon	B-Drug
is	O
not	O
recommended	O
for	O
chronic	O
use	O
in	O
the	O
elderly.	O

GHB	B-Drug
induces	O
the	O
accumulation	O
of	O
either	O
a	O
derivative	O
tryptophan	O
or	O
itself	O
in	O
extracellular	O
space,	O
possibly	O
by	O
increasing	O
transport	O
across	O
bloodbrain	O
barrier.	O

Long-acting	O
benzodiazepines	O
such	O
as	O
clonazepam	B-Drug
are	O
not	O
generally	O
recommended	O
for	O
the	O
elderly	O
due	O
to	O
risk	O
of	O
drug	O
accumulation.	O

Thus,	O
some	O
say	O
Afghan	O
opium	B-Drug
would	O
contribute	O
to	O
an	O
already	O
oversupplied	O
market	O
and	O
potentially	O
cause	O
the	O
supply	O
demand	O
imbalance	O
that	O
UN	O
control	O
system	O
was	O
designed	O
prevent.	O

Stanislav	O
Grof	O
has	O
written	O
that	O
religious	O
and	O
mystical	O
experiences	O
observed	O
during	O
LSD	B-Drug
sessions	O
appear	O
to	O
be	O
phenomenologically	O
indistinguishable	O
from	O
similar	O
descriptions	O
in	O
the	O
sacred	O
scriptures	O
of	O
great	O
religions	O
world	O
texts	O
ancient	O
civilizations.	O

In	O
a	O
rat	O
study	O
Nimetazepam	B-Drug
showed	O
greater	O
damage	O
to	O
the	O
fetus,	O
as	O
did	O
nitrazepam	B-Drug
when	O
compared	O
against	O
other	O
benzodiazepines,	O
all	O
at	O
dosage	O
of	O
100	O
mg/kg.	O

Medical	O
grade	O
diamorphine	B-Drug
is	O
used	O
as	O
a	O
pure	O
hydrochloride	O
salt	O
which	O
distinguished	O
from	O
black	O
tar	O
heroin,	O
variable	O
admixture	O
of	O
morphine	B-Drug
derivativespredominantly	O
6-MAM	O
(6-monoacetylmorphine),	O
the	O
result	O
crude	O
acetylation	O
during	O
clandestine	O
production	O
street	O
heroin.	O
6-monoacetylmorphine	B-Drug
heroin	B-Drug

In	O
addition,	O
some	O
parts	O
of	O
Europe,	O
the	O
United	O
States,	O
and	O
Australia	O
allow	O
processed	O
cocaine	B-Drug
for	O
medicinal	O
uses	O
only.	O

Only	O
of	O
a	O
few	O
these	O
compounds	O
were	O
widely	O
used	O
including	O
rolicyclidine	B-Drug
(PCPy),	O
eticyclidine	B-Drug
(PCE),	O
and	O
tenocyclidine	B-Drug
(TCP).	O
PCE	B-Drug
TCP	B-Drug

There	O
is	O
also	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
interfere	O
with	O
formation	O
of	O
various	O
kinds	O
new	O
blood	O
cells,	O
creating	O
infection	O
via	O
neutropenia,	O
leukopenia,	O
and	O
lymphopenia,	O
risks	O
will	O
not	O
clot	O
thrombocytopenia.	O

Chloromorphide	O
is	O
one	O
of	O
a	O
series	O
opioids	O
known	O
as	O
morphides	O
and	O
codides,	O
which	O
are	O
important	O
precursors	O
intermediates	O
in	O
the	O
synthesis	O
semi-synthetic	O
opioid	O
analgesic	O
drugs,	O
especially	O
those	O
with	O
additions,	O
substitutions,	O
or	O
other	O
modifications	O
at	O
7,	O
8,	O
and/or	O
14	O
positions	O
on	O
morphine	B-Drug
carbon	O
skeleton.	O

the	O
earliest	O
European	O
and	O
American	O
research	O
efforts	O
investigated	O
whether	O
LSD	B-Drug
could	O
reliably	O
induce	O
psychotic	O
disorders,	O
some	O
began	O
to	O
evaluate	O
potential	O
for	O
assist	O
in	O
traditional	O
Freudian	O
psychotherapy	O
1950s.	O

Synthetic	O
cannabinoids	O
are	O
a	O
class	O
of	O
molecules	O
that	O
bind	O
to	O
the	O
same	O
receptors	O
which	O
(THC	O
and	O
CBD)	O
in	O
cannabis	O
plants	O
attach.	O
THC	B-Drug
CBD	B-Drug

The	O
prescription	O
heroin	B-Drug
can	O
be	O
accessed	O
by	O
doctors	O
through	O
Health	O
Canada's	O
Special	O
Access	O
Programme	O
(SAP)	O
for	O
"emergency	O
access	O
to	O
drugs	O
patients	O
with	O
serious	O
or	O
life-threatening	O
conditions	O
when	O
conventional	O
treatments	O
have	O
failed,	O
are	O
unsuitable,	O
unavailable."	O

Intravenous	O
infusion	O
of	O
ketamine	B-Drug
has	O
never	O
been	O
directly	O
compared	O
with	O
intranasal	O
esketamine,	O
but	O
a	O
comparative	O
meta-analysis	O
clinical	O
trials	O
indicates	O
the	O
superiority	O
intravenous	O
ketamine,	O
which	O
greater	O
overall	O
response	O
and	O
remission	O
rates,	O
lower	O
number	O
dropouts.	O
esketamine	B-Drug

The	O
most	O
commonly	O
prescribed	O
opioids	O
have	O
been	O
oxycodone	B-Drug
and	O
hydrocodone.	O
hydrocodone	B-Drug

Traces	O
of	O
the	O
drug	O
have	O
also	O
been	O
found	O
in	O
other	O
recreational	O
drugs	O
including	O
cocaine,	O
MDMA,	O
and	O
heroin.	O
cocaine	B-Drug
MDMA	B-Drug
heroin	B-Drug

Amphetamine	B-Drug
has	O
been	O
used	O
in	O
the	O
past	O
to	O
treat	O
anhedonia,	O
a	O
major	O
phenomenon	O
of	O
depression.	O

In	O
2010,	O
the	O
BBC	O
reported	O
that	O
use	O
of	O
MDMA	B-Drug
had	O
decreased	O
in	O
UK	O
previous	O
years.	O

High	O
doses	O
of	O
thiamine	B-Drug
often	O
by	O
the	O
intravenous	O
route	O
is	O
also	O
recommended.	O

The	O
most	O
common	O
salt	O
of	O
MDMA	B-Drug
is	O
the	O
hydrochloride	O
salt;	O
pure	O
water-soluble	O
and	O
appears	O
as	O
a	O
white	O
or	O
off-white	O
powder	O
crystal.	O

Unnatural	O
aphrodisiacs	O
like	O
ecstasy	B-Drug
are	O
classified	O
as	O
those	O
that	O
manufactured	O
to	O
imitate	O
a	O
natural	O
substance.	O

2C-G	O
and	O
all	O
of	O
its	O
homologs	O
are	O
unscheduled	O
in	O
the	O
United	O
States,	O
but	O
possession	O
sales	O
might	O
be	O
prosecuted	O
under	O
Federal	O
Analog	O
Act	O
because	O
their	O
close	O
structural	O
similarities	O
to	O
2C-B,	O
which	O
is	O
a	O
Schedule	O
2C-B	B-Drug

Anticonvulsants,	O
such	O
as	O
carbamazepine,	O
gabapentin,	O
lamotrigine,	O
and	O
topiramate,	O
do	O
not	O
appear	O
to	O
be	O
effective	O
treatment.	O
carbamazepine	B-Drug
gabapentin	B-Drug
lamotrigine	B-Drug
topiramate	B-Drug

This	O
continued	O
into	O
the	O
1990s,	O
when	O
Colombia	O
remained	O
chief	O
exporter	O
of	O
cocaine.	O
cocaine	B-Drug

When	O
people	O
die	O
from	O
overdosing	O
on	O
a	O
drug,	O
the	O
drug	O
is	O
usually	O
an	O
opioid	O
and	O
often	O
heroin.	O
heroin	B-Drug

In	O
2005,	O
Celgene	O
received	O
FDA	O
approval	O
for	O
lenalidomide	B-Drug
(Revlimid)	O
as	O
the	O
first	O
commercially	O
useful	O
derivative.	O
Revlimid	B-Drug

Androstenedione	B-Drug
is	O
currently	O
banned	O
by	O
the	O
U.S.	O
military.	O

Serum	O
JWH-018	B-Drug
concentrations	O
are	O
generally	O
in	O
the	O
110	O
g/L	O
range	O
during	O
first	O
few	O
hours	O
after	O
recreational	O
usage.	O

Flurazepam	B-Drug
is	O
best	O
used	O
for	O
a	O
short	O
time	O
period	O
and	O
at	O
the	O
lowest	O
possible	O
dose	O
to	O
avoid	O
complications	O
associated	O
with	O
long-term	O
use.	O

If,	O
however,	O
marijuana	O
were	O
taxed	O
similarly	O
to	O
alcohol	O
or	O
tobacco,	O
it	O
might	O
generate	O
as	O
much	O
$6.2	O
billion	O
annually....	O
tobacco	B-Drug

Professor	O
Richard	O
"Rick"	O
Silverman	O
of	O
Northwestern	O
University	O
developed	O
pregabalin	B-Drug
there.	O

Imipramine	B-Drug
is	O
the	O
English	O
and	O
French	O
generic	O
name	O
of	O
drug	O
its	O
INN,	O
BAN,	O
DCF,	O
while	O
imipramine	B-Drug
hydrochloride	O
USAN,	O
USP,	O
BANM,	O
JAN.	O

People	O
with	O
severe	O
liver	O
impairment	O
or	O
kidney	O
disease,	O
including	O
those	O
on	O
dialysis,	O
should	O
not	O
take	O
perampanel.	O
perampanel	B-Drug

In	O
the	O
US,	O
similar	O
descriptions	O
have	O
been	O
used	O
to	O
describe	O
mephedrone,	O
as	O
well	O
methylenedioxypyrovalerone	B-Drug
(MDPV).	O
mephedrone	B-Drug
MDPV	B-Drug

In	O
children	O
aged	O
6	O
to	O
8	O
years	O
old,	O
there	O
is	O
a	O
rise	O
in	O
androstenedione	B-Drug
secretion	O
along	O
with	O
DHEA	O
during	O
adrenarche.	O

Author	O
D.	O
Gold	O
provided	O
synthesis	O
instructions	O
for	O
this	O
compound	O
(calling	O
it	O
"THC	O
acetate")	O
in	O
his	O
1974	O
book	O
Cannabis	O
Alchemy:	O
Art	O
of	O
Modern	O
Hashmaking.	O
THC	B-Drug

It	O
seems	O
possible	O
that	O
the	O
small	O
number	O
of	O
genetic	O
abnormalities	O
reported	O
in	O
users	O
street	O
LSD	B-Drug
is	O
either	O
coincidental	O
or	O
related	O
to	O
factors	O
other	O
than	O
a	O
toxic	O
effect	O
pure	O
LSD.	O

Symptoms	O
of	O
mild	O
opiate	O
withdrawal	O
were	O
observed	O
following	O
abrupt	O
discontinuation	O
long-term	O
treatment	O
animals	O
with	O
loperamide.	O
loperamide	B-Drug

While	O
street	O
prices	O
of	O
cocaine	B-Drug
in	O
Canada	O
is	O
higher	O
than	O
they	O
are	O
South	O
American	O
and	O
East	O
Asian	O
countries;	O
the	O
four-year	O
period	O
1997	O
to	O
2001	O
price	O
drug	O
fell	O
by	O
almost	O
thirteen	O
US	O
dollars	O
a	O
gram,	O
from	O
$94.3/gram	O
$81.6/gram.	O

There	O
was	O
a	O
28%	O
increase	O
from	O
the	O
amount	O
of	O
potentially	O
harvestable	O
coca	B-Drug
plants	O
which	O
were	O
grown	O
in	O
Colombia	O
1998.	O

GHB	B-Drug
tends	O
to	O
cause	O
rapid	O
unconsciousness	O
at	O
doses	O
above	O
3500	O
mg,	O
with	O
single	O
over	O
7000	O
mg	O
often	O
causing	O
life-threatening	O
respiratory	O
depression,	O
and	O
higher	O
still	O
inducing	O
bradycardia	O
cardiac	O
arrest.	O

Revlimid	B-Drug
is	O
available	O
only	O
in	O
a	O
restricted	O
distribution	O
setting	O
to	O
avoid	O
its	O
use	O
during	O
pregnancy.	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

The	O
UK	O
term	O
"mandy"	O
and	O
the	O
US	O
"molly"	O
colloquially	O
refer	O
to	O
MDMA	B-Drug
in	O
a	O
crystalline	O
powder	O
form	O
that	O
is	O
thought	O
be	O
free	O
of	O
adulterants.	O

It	O
is	O
used	O
to	O
reverse	O
the	O
effects	O
of	O
super-potent	O
opioid	O
analgesics	O
such	O
as	O
etorphine	B-Drug
and	O
carfentanil	B-Drug
that	O
are	O
for	O
tranquilizing	O
large	O
animals.	O

Some	O
bacteria	O
have	O
been	O
shown	O
to	O
be	O
able	O
turn	O
morphine	B-Drug
into	O
closely	O
related	O
drugs,	O
including	O
hydromorphone	B-Drug
and	O
dihydromorphine	B-Drug
among	O
others.	O

Power	O
shifted	O
from	O
remote	O
to	O
high-end	O
smugglers	O
and	O
opium	B-Drug
traders.	O

An	O
extended-release	O
formulation	O
of	O
gabapentin	B-Drug
for	O
once-daily	O
administration	O
was	O
introduced	O
in	O
2011	O
postherpetic	O
neuralgia	O
under	O
the	O
brand	O
name	O
Gralise.	O
Gralise	B-Drug

In	O
2010,	O
1.3	O
short	O
tons	O
(1.2	O
t)	O
of	O
oxycodone	B-Drug
were	O
illegally	O
manufactured	O
using	O
a	O
fake	O
pill	O
imprint.	O

Nabiximols	B-Drug
(trade	O
name	O
Sativex)	O
is	O
a	O
botanical	O
drug	O
that	O
cannabis	O
extract,	O
administered	O
as	O
mouth	O
spray;	O
it	O
was	O
approved	O
in	O
the	O
UK	O
2010	O
treatment	O
for	O
multiple	O
sclerosis	O
(MS)	O
patients	O
to	O
alleviate	O
neuropathic	O
pain,	O
spasticity,	O
overactive	O
bladder,	O
and	O
other	O
symptoms.	O
Sativex	B-Drug

Other	O
popular	O
medicines,	O
based	O
on	O
opium,	O
included	O
Paregoric,	O
a	O
much	O
milder	O
liquid	O
preparation	O
for	O
children;	O
Black-drop,	O
stronger	O
preparation;	O
and	O
Dover's	O
powder.	O
opium	B-Drug

However,	O
one	O
placebo-controlled	O
study	O
comparing	O
3	O
weeks	O
of	O
treatment	O
for	O
insomnia	O
with	O
either	O
loprazolam	B-Drug
or	O
triazolam	B-Drug
showed	O
rebound	O
anxiety	O
and	O
occurring	O
days	O
after	O
discontinuing	O
therapy,	O
whereas	O
the	O
was	O
seen	O
next	O
day.	O

Dipipanone	B-Drug
is	O
now	O
the	O
only	O
alternative	O
opioid	O
left	O
to	O
use	O
in	O
UK	O
that	O
of	O
equal	O
strength	O
morphine	B-Drug
can	O
be	O
prescribed	O
instead.	O

Although	O
production	O
fell	O
temporarily,	O
coca	B-Drug
crops	O
rebounded	O
in	O
numerous	O
smaller	O
fields	O
Colombia,	O
rather	O
than	O
the	O
larger	O
plantations.	O

This	O
is	O
the	O
most	O
widely	O
consumed	O
form,	O
containing	O
3%	O
to	O
20%	O
THC,	O
with	O
reports	O
of	O
up	O
33%	O
THC.	O
THC	B-Drug

Animal	O
models	O
of	O
neurotoxicity	O
from	O
high-dose	O
amphetamine	B-Drug
exposure	O
indicate	O
that	O
the	O
occurrence	O
hyperpyrexia	O
(i.e.,	O
core	O
body	O
temperature	O
40	O
C)	O
is	O
necessary	O
for	O
development	O
amphetamine-induced	O
neurotoxicity.	O

Anexate	B-Drug
(flumazenil),	O
for	O
the	O
reversal	O
of	O
acute	O
benzodiazepine	O
effects.	O
flumazenil	B-Drug

The	O
combination	O
oxycodone/aspirin	B-Drug
is	O
also	O
sold	O
under	O
the	O
brand	O
name	O
Endodan.	O

A	O
series	O
of	O
injections	O
with	O
triamcinolone	B-Drug
acetonide	O
or	O
another	O
corticosteroid	O
may	O
reduce	O
keloid	O
size	O
and	O
irritation.	O

Silverman	O
is	O
best	O
known	O
for	O
identifying	O
the	O
drug	O
pregabalin	B-Drug
as	O
a	O
possible	O
treatment	O
epileptic	O
seizures.	O

Methylprednisolone	B-Drug
sodium	O
succinate	O
(Solu-Medrol)	O
is	O
the	O
ester	O
of	O
methylprednisolone.	O
methylprednisolone	B-Drug

Synthetic	O
cathinones	O
such	O
as	O
mephedrone,	O
which	O
are	O
chemically	O
similar	O
to	O
cathinone,	O
naturally	O
found	O
in	O
the	O
plant	O
Catha	O
edulis	O
(khat),	O
were	O
first	O
synthesised	O
1920s.	O
mephedrone	B-Drug
cathinone	B-Drug

al	O
(2019)	O
evaluated	O
the	O
potential	O
involvement	O
of	O
dysregulated	O
dopaminergic	O
system,	O
neuroadaption,	O
and	O
brain	O
wave	O
changes	O
which	O
may	O
contribute	O
to	O
rewarding	O
reinforcing	O
properties	O
25B-NBOMe	B-Drug
in	O
rodents.	O

Severe	O
low	O
blood	O
pressure	O
and	O
abnormal	O
heart	O
rhythms	O
can	O
be	O
seen	O
with	O
rapid	O
infusion	O
of	O
IV	O
phenytoin.	O
phenytoin	B-Drug

which	O
list	O
had	O
hitherto	O
been	O
almost	O
entirely	O
concerned	O
with	O
opium	B-Drug
and	O
its	O
derivatives.	O

Researchers	O
confirmed	O
that	O
THC	B-Drug
exerts	O
its	O
most	O
prominent	O
effects	O
via	O
actions	O
on	O
two	O
types	O
of	O
cannabinoid	O
receptors,	O
the	O
CB1	O
receptor	O
and	O
CB2	O
receptor,	O
both	O
which	O
are	O
G	O
protein-coupled	O
receptors.	O

Methenolone	B-Drug
enanthate	O
is	O
the	O
USAN	O
of	O
metenolone	B-Drug
enanthate,	O
and	O
methenolone	B-Drug
BAN	O
its	O
active	O
form,	O
metenolone.	O

Illicitly	O
synthesized	O
fentanyl	B-Drug
powder	O
has	O
also	O
appeared	O
on	O
the	O
United	O
States	O
market.	O

However,	O
for	O
those	O
adults	O
who	O
have	O
received	O
drugs	O
such	O
as	O
beta	O
blocker,	O
calcium	O
channel	O
and	O
digoxin	B-Drug
an	O
increased	O
risk	O
of	O
developing	O
bradycardia.	O

I	O
think	O
that	O
in	O
human	O
evolution	O
it	O
has	O
never	O
been	O
as	O
necessary	O
to	O
have	O
this	O
substance	O
LSD.	O
LSD	B-Drug

PCP	B-Drug
began	O
to	O
emerge	O
as	O
a	O
recreational	O
drug	O
in	O
major	O
cities	O
the	O
United	O
States	O
1960s.	O

Tamoxifen	B-Drug
is	O
marketed	O
primarily	O
under	O
the	O
brand	O
name	O
Nolvadex,	O
but	O
also	O
available	O
a	O
variety	O
of	O
other	O
names	O
throughout	O
world.	O
Nolvadex	B-Drug

Similarly	O
to	O
danazol,	O
gestrinone	O
acts	O
as	O
a	O
weak	O
antigonadotropin	O
via	O
activation	O
of	O
the	O
PR	O
and	O
AR	O
in	O
pituitary	O
gland	O
suppresses	O
mid-cycle	O
surge	O
luteinizing	O
hormone	O
(LH)	O
follicle-stimulating	O
(FSH)	O
during	O
menstrual	O
cycle	O
without	O
affecting	O
basal	O
levels	O
these	O
hormones.	O
danazol	B-Drug

Treatment	O
of	O
dutasteride	B-Drug
overdose	O
should	O
be	O
based	O
on	O
symptoms	O
and	O
supportive.	O

Opium,	O
and	O
after	O
1820,	O
morphine,	O
was	O
mixed	O
with	O
everything	O
imaginable:	O
mercury,	O
hashish,	O
cayenne	O
pepper,	O
ether,	O
chloroform,	O
belladonna,	O
whiskey,	O
wine	O
brandy."	O
morphine	B-Drug
hashish	B-Drug

In	O
2018,	O
5F-ADB	B-Drug
was	O
the	O
most	O
common	O
synthetic	O
cannabinoid	O
to	O
be	O
identified	O
in	O
Drug	O
Enforcement	O
Administration	O
seizures.	O

In	O
the	O
European	O
Union	O
as	O
of	O
2018,	O
4.1%	O
adults	O
(1564	O
years	O
old)	O
have	O
used	O
MDMA	B-Drug
at	O
least	O
once	O
in	O
their	O
life,	O
and	O
0.8%	O
had	O
it	O
last	O
year.	O

Besides	O
the	O
longer	O
duration,	O
trip	O
tends	O
to	O
be	O
more	O
energetic	O
than	O
an	O
LSD	B-Drug
trip,	O
with	O
body	O
load	O
and	O
a	O
different	O
subjective	O
visual	O
experience.	O

In	O
addition	O
to	O
its	O
well	O
explored	O
interactions	O
with	O
NMDA	O
receptors,	O
PCP	B-Drug
has	O
also	O
been	O
shown	O
inhibit	O
dopamine	O
reuptake,	O
and	O
thereby	O
leads	O
increased	O
extracellular	O
levels	O
of	O
hence	O
dopaminergic	O
neurotransmission.	O

After	O
prolonged	O
use,	O
prednisone	B-Drug
needs	O
to	O
be	O
stopped	O
gradually.	O

Phencyclidine	B-Drug
is	O
used	O
for	O
its	O
ability	O
to	O
induce	O
a	O
dissociative	O
state.	O

About	O
448	O
tons	O
of	O
heroin	B-Drug
were	O
made	O
in	O
2016.	O

The	O
serial	O
killer	O
Harold	O
Shipman	O
used	O
diamorphine	B-Drug
on	O
his	O
victims,	O
and	O
the	O
subsequent	O
Inquiry	O
led	O
to	O
a	O
tightening	O
of	O
regulations	O
surrounding	O
storage,	O
prescribing	O
destruction	O
controlled	O
drugs	O
in	O
UK.	O

In	O
addition,	O
buspirone	B-Drug
does	O
not	O
produce	O
euphoria	O
and	O
is	O
a	O
drug	O
of	O
abuse.	O

Hoping	O
MDMA	B-Drug
could	O
avoid	O
criminalization	O
like	O
LSD	B-Drug
and	O
mescaline,	O
psychotherapists	O
experimenters	O
attempted	O
to	O
limit	O
the	O
spread	O
of	O
information	O
about	O
it	O
while	O
conducting	O
informal	O
research.	O
mescaline	B-Drug

Compared	O
to	O
ingestion,	O
the	O
faster	O
absorption	O
of	O
insufflated	O
cocaine	B-Drug
results	O
in	O
quicker	O
attainment	O
maximum	O
drug	O
effects.	O

QT	O
prolongation	O
was	O
also	O
observed	O
with	O
very	O
high	O
doses	O
of	O
tamoxifen.	O
tamoxifen	B-Drug

For	O
these	O
reasons,	O
the	O
Committee	O
did	O
not	O
consider	O
abuse	O
liability	O
of	O
MBDB	B-Drug
would	O
constitute	O
a	O
significant	O
risk	O
to	O
public	O
health,	O
thereby	O
warranting	O
its	O
placement	O
under	O
international	O
control.	O

By	O
1950,	O
about	O
10%	O
of	O
the	O
poppy	O
seed	O
harvest	O
those	O
countries	O
was	O
also	O
yielding	O
morphine.	O
morphine	B-Drug

Pentobarbital	B-Drug
has	O
been	O
used	O
or	O
considered	O
as	O
a	O
substitute	O
for	O
other	O
drugs	O
traditionally	O
capital	O
punishment	O
in	O
the	O
United	O
States	O
when	O
they	O
are	O
short	O
supply.	O

Walker	O
was	O
allegedly	O
drinking	O
prior	O
to	O
his	O
emotional	O
outburst,	O
and	O
it	O
is	O
believed	O
the	O
combination	O
of	O
amobarbital	B-Drug
alcohol	O
resulted	O
in	O
a	O
severe	O
reaction.	O

The	O
name	O
"scopolamine"	O
is	O
derived	O
from	O
one	O
type	O
of	O
nightshade	O
known	O
as	O
Scopolia,	O
while	O
the	O
"hyoscine"	O
another	O
Hyoscyamus	O
niger.	O
scopolamine	B-Drug
hyoscine	B-Drug

Alternatively,	O
medroxyprogesterone	B-Drug
acetate	I-Drug
may	O
be	O
an	O
exception	O
among	O
progestogens	O
in	O
terms	O
of	O
influence	O
on	O
VTE	O
risk,	O
possibly	O
due	O
to	O
its	O
partial	O
glucocorticoid	O
activity.	O

THC	B-Drug
is	O
considered	O
the	O
primary	O
active	O
component	O
of	O
cannabis	O
plant.	O

Fentanyl	B-Drug
has	O
been	O
discovered	O
for	O
sale	O
in	O
illicit	O
markets	O
Australia	O
2017	O
and	O
New	O
Zealand	O
2018.	O

Alcohol	O
and	O
nicotine	B-Drug
also	O
prime	O
the	O
brain	O
for	O
a	O
heightened	O
response	O
to	O
other	O
drugs	O
are,	O
like	O
marijuana,	O
typically	O
used	O
before	O
person	O
progresses	O
other,	O
more	O
harmful	O
substances.	O

In	O
July	O
2019,	O
National	O
Football	O
League	O
player	O
Taylor	O
Lewan	O
failed	O
a	O
drug	O
test	O
for	O
Enobosarm,	O
which	O
claimed	O
he	O
ingested	O
accidentally	O
as	O
an	O
unlabeled	O
ingredient	O
in	O
supplement.	O
Enobosarm	B-Drug

Hydrochlorothiazide	B-Drug
is	O
available	O
as	O
a	O
generic	O
drug	O
under	O
large	O
number	O
of	O
brand	O
names,	O
including	O
Apo-Hydro,	O
Aquazide,	O
BPZide,	O
Dichlotride,	O
Esidrex,	O
Hydrochlorot,	O
Hydrodiuril,	O
HydroSaluric,	O
Hypothiazid,	O
Microzide,	O
Oretic	B-Drug
and	O
many	O
others.	O
Hydrodiuril	B-Drug

Nandrolone	B-Drug
has	O
a	O
very	O
high	O
ratio	O
of	O
anabolic	O
to	O
androgenic	O
activity.	O

It	O
is	O
weaker	O
than	O
morphine	B-Drug
as	O
an	O
analgesic	O
but	O
longer-lasting	O
in	O
effects,	O
and	O
was	O
thought	O
to	O
have	O
more	O
local	O
anesthetic	O
effect	O
morphine,	O
though	O
with	O
a	O
somewhat	O
greater	O
tendency	O
cause	O
histamine	O
reactions	O
like	O
itching	O
rash.	O

The	O
role	O
of	O
the	O
therapist	O
was	O
minimized	O
in	O
favor	O
patient	O
self-discovery	O
accompanied	O
by	O
MDMA	B-Drug
induced	O
feelings	O
empathy.	O

Hydromorphone	B-Drug
is	O
available	O
in	O
parenteral,	O
rectal,	O
subcutaneous,	O
and	O
oral	O
formulations,	O
also	O
can	O
be	O
administered	O
via	O
epidural	O
or	O
intrathecal	O
injection.	O

JWH-073	B-Drug
and	O
HU-210	B-Drug
were	O
all	O
made	O
illegal	O
in	O
Sweden	O
on	O
September	O
15,	O
2009.	O

ALD-52,	O
also	O
known	O
as	O
1-acetyl-LSD,	O
is	O
a	O
chemical	O
analogue	O
of	O
lysergic	O
acid	B-Drug
diethylamide	O
(LSD).	O
ALD-52	B-Drug
LSD	B-Drug

Adderall	B-Drug
is	O
generally	O
well	O
tolerated	O
and	O
effective	O
in	O
treating	O
the	O
symptoms	O
of	O
ADHD	O
narcolepsy.	O

In	O
the	O
United	O
States,	O
ADB-FUBINACA	B-Drug
is	O
a	O
Schedule	O

Tetrahydrocannabinol	B-Drug
(THC)	O
is	O
the	O
main	O
psychoactive	O
component	O
of	O
cannabis,	O
which	O
one	O
483	O
known	O
compounds	O
in	O
plant,	O
including	O
at	O
least	O
65	O
other	O
cannabinoids,	O
cannabidiol	B-Drug
(CBD).	O
THC	B-Drug
CBD	B-Drug

Many	O
nations	O
have	O
implemented	O
some	O
form	O
of	O
tobacco	B-Drug
taxation.	O

The	O
modern	O
pharmaceutical	O
industry	O
began	O
with	O
local	O
apothecaries	O
that	O
expanded	O
from	O
their	O
traditional	O
role	O
distributing	O
botanical	O
drugs	O
such	O
as	O
morphine	B-Drug
and	O
quinine	B-Drug
to	O
wholesale	O
manufacture	O
in	O
the	O
mid-1800s,	O
discoveries	O
resulting	O
applied	O
research.	O

It	O
is	O
a	O
structural	O
isomer	O
of	O
LSD,	O
with	O
the	O
two	O
ethyl	O
groups	O
on	O
amide	O
nitrogen	O
having	O
been	O
replaced	O
by	O
single	O
sec-butyl	O
group,	O
joined	O
at	O
2-position.	O
LSD	B-Drug

Ketamine	B-Drug
is	O
also	O
used	O
to	O
manage	O
pain	O
among	O
large	O
animals.	O

In	O
2014,	O
researchers	O
demonstrated	O
the	O
immunomodulatory	O
potential	O
of	O
DMT	O
and	O
5-MeO-DMT	B-Drug
through	O
Sigma-1	O
receptor	O
human	O
immune	O
cells.	O

Hydrocodone	B-Drug
diversion	O
and	O
recreational	O
use	O
has	O
escalated	O
in	O
recent	O
years	O
due	O
to	O
its	O
opioid	O
effects.	O

Stanley	O
was	O
charged	O
with	O
illegal	O
possession	O
of	O
narcotics,	O
dangerous	O
non-narcotics,	O
LSD,	O
and	O
barbiturates.	O
LSD	B-Drug

presumably	O
exhibits	O
functional	O
selectivity	O
at	O
the	O
5HT2A	O
receptor	O
similar	O
to	O
other	O
phenethylamine	B-Drug
hallucinogens,	O
activating	O
Phospholipase	O
A2	O
signal	O
cascade,	O
which	O
is	O
responsible	O
for	O
release	O
of	O
Thromboxane	O
A2,	O
triggering	O
blood	O
platelet	O
aggregation.	O

Atomoxetine	B-Drug
may	O
improve	O
working	O
memory	O
and	O
attention	O
when	O
used	O
at	O
certain	O
doses.	O

Good	O
Samaritan	O
laws	O
typically	O
protect	O
bystanders	O
that	O
administer	O
naloxone.	O
naloxone	B-Drug

High	O
doses	O
of	O
norethisterone	B-Drug
and	O
noretynodrel	O
have	O
been	O
associated	O
with	O
estrogenic	O
side	O
effects	O
such	O
as	O
breast	O
enlargement	O
in	O
women	O
gynecomastia	O
men,	O
but	O
also	O
alleviation	O
menopausal	O
symptoms	O
postmenopausal	O
women.	O

As	O
with	O
most	O
DiPT	B-Drug
psychedelics,	O
music	O
can	O
become	O
more	O
dissonant	O
and	O
less	O
harmonious.	O

Amphetamines	B-Drug
also	O
have	O
cross-tolerance	O
with	O
pseudoephedrine,	O
as	O
pseudoephedrine	B-Drug
can	O
block	O
dopamine	O
uptake	O
in	O
the	O
same	O
manner	O
that	O
amphetamines	B-Drug
do,	O
but	O
less	O
potently.	O

PCP	B-Drug
is	O
metabolized	O
into	O
PCHP,	O
PPC	O
and	O
PCAA.	O

His	O
20-year	O
sentence	O
will	O
run	O
concurrent	O
to	O
another	O
stemming	O
for	O
his	O
role	O
on	O
BMF	O
cocaine	B-Drug
charges.	O

However,	O
higher	O
doses	O
(18	O
milligrams	O
of	O
THC)	O
reliably	O
produced	O
what	O
Isbell	O
referred	O
to	O
as	O
a	O
"psychotic	O
reaction"	O
(e.g.,	O
"all	O
sudden	O
[the	O
subject]	O
was	O
on	O
trip	O
and	O
watching	O
his	O
own	O
burial.	O
THC	B-Drug

A	O
fentanyl	B-Drug
patient-controlled	O
transdermal	O
system	O
(PCTS)	O
is	O
under	O
development,	O
which	O
aims	O
to	O
allow	O
patients	O
control	O
administration	O
of	O
through	O
the	O
skin	O
treat	O
postoperative	O
pain.	O

Midazolam	B-Drug
was	O
patented	O
in	O
1974	O
and	O
came	O
into	O
medical	O
use	O
1982.	O

In	O
1956,	O
researchers	O
involved	O
in	O
clinical	O
trials	O
at	O
SKF	O
noted	O
that,	O
even	O
when	O
used	O
very	O
high	O
doses,	O
thalidomide	B-Drug
could	O
not	O
induce	O
sleep	O
mice.	O

Morocco	O
produces	O
a	O
substantial	O
portion	O
of	O
the	O
world's	O
hashish;	O
it	O
was	O
top	O
producer	O
for	O
2002-2010	O
period	O
before	O
2012	O
study	O
placed	O
Afghanistan	O
as	O
producer.	O
hashish	B-Drug

As	O
nicotine	B-Drug
enters	O
the	O
body,	O
it	O
is	O
distributed	O
quickly	O
through	O
bloodstream	O
and	O
crosses	O
bloodbrain	O
barrier	O
reaching	O
brain	O
within	O
1020	O
seconds	O
after	O
inhalation.	O

Aspirin,	O
the	O
only	O
NSAID	O
able	O
to	O
irreversibly	O
inhibit	O
COX-1,	O
is	O
also	O
indicated	O
for	O
antithrombosis	O
through	O
inhibition	O
of	O
platelet	O
aggregation.	O
Aspirin	B-Drug

2-TOET	O
and	O
5-TOET	O
are	O
the	O
2-	O
5-methylthio	O
analogs	O
of	O
DOET,	O
respectively.	O
DOET	B-Drug

Paracetamol	B-Drug
combined	O
with	O
NSAIDs	O
may	O
be	O
more	O
effective	O
for	O
treating	O
postoperative	O
pain	O
than	O
either	O
paracetamol	B-Drug
or	O
alone.	O

Clenbuterol	B-Drug
is	O
a	O
2	O
agonist	O
with	O
some	O
structural	O
and	O
pharmacological	O
similarities	O
to	O
epinephrine	O
salbutamol,	O
but	O
its	O
effects	O
are	O
more	O
potent	O
longer-lasting	O
as	O
stimulant	O
thermogenic	O
drug.	O
salbutamol	B-Drug

Methylphenidate	B-Drug
has	O
both	O
dopamine	O
transporter	O
and	O
norepinephrine	O
binding	O
affinity,	O
with	O
the	O
dextromethylphenidate	B-Drug
enantiomers	O
displaying	O
a	O
prominent	O
affinity	O
for	O
transporter.	O

Opioids	O
such	O
as	O
fentanyl	B-Drug
may	O
be	O
given	O
to	O
attenuate	O
the	O
responses	O
intubation	O
process	O
(accelerated	O
heart	O
rate	O
and	O
increased	O
intracranial	O
pressure).	O

Thus	O
indometacin	B-Drug

It	O
was	O
the	O
second	O
synthetic	O
AAS	O
to	O
be	O
developed,	O
following	O
mesterolone	B-Drug
(1-methyl-DHT)	O
in	O
1934,	O
and	O
first	O
17-alkylated	O
synthesized.	O

Further	O
minor	O
metabolites	O
of	O
cocaine	B-Drug
include	O
norcocaine,	O
p-hydroxycocaine,	O
m-hydroxycocaine,	O
p-hydroxybenzoylecgonine	O
(pOHBE),	O
and	O
m-hydroxybenzoylecgonine.	O

The	O
primary	O
use	O
of	O
dextromethorphan	B-Drug
is	O
as	O
a	O
cough	O
suppressant,	O
for	O
the	O
temporary	O
relief	O
caused	O
by	O
minor	O
throat	O
and	O
bronchial	O
irritation	O
(such	O
commonly	O
accompanies	O
flu	O
common	O
cold),	O
well	O
those	O
resulting	O
from	O
inhaled	O
particle	O
irritants.	O

Intranasal	O
mupirocin	B-Drug
before	O
surgery	O
is	O
effective	O
for	O
prevention	O
of	O
post-operative	O
wound	O
infection	O
with	O
Staphylcoccus	O
aureus	O
and	O
preventative	O
intranasal	O
or	O
catheter-site	O
treatment	O
reducing	O
the	O
risk	O
catheter	O
site	O
in	O
persons	O
treated	O
chronic	O
peritoneal	O
dialysis.	O

As	O
of	O
2008,	O
opium	B-Drug
was	O
collected	O
by	O
farmers	O
who	O
were	O
licensed	O
to	O
grow	O
0.1	O
hectares	O
(0.25	O
acres)	O
poppies,	O
maintain	O
their	O
licences	O
needed	O
sell	O
56	O
kilograms	O
unadulterated	O
raw	O
paste.	O

Benzphetamine	B-Drug
has	O
a	O
half-life	O
of	O
46	O
hours.	O

Forced	O
acid	O
diuresis	O
(with	O
ammonium	O
chloride	O
or,	O
more	O
safely,	O
ascorbic	O
acid)	O
may	O
increase	O
clearance	O
of	O
PCP	B-Drug
from	O
the	O
body,	O
and	O
was	O
somewhat	O
controversially	O
recommended	O
in	O
past	O
as	O
a	O
decontamination	O
measure.	O

In	O
1972,	O
band	O
member	O
John	O
Lennon	O
remarked	O
that	O
"Rubber	O
Soul	O
was	O
the	O
pot	O
album	O
and	O
Revolver	O
acid."	O
acid	B-Drug

The	O
levels	O
of	O
EE	O
formed	O
by	O
0.5	O
and	O
1	O
mg	O
norethisterone	B-Drug
have	O
been	O
estimated	O
based	O
on	O
higher	O
dosages	O
as	O
corresponding	O
to	O
2	O
10	O
g	O
EE,	O
respectively.	O

The	O
CEPD/North	O
(Study	O
Centre	O
on	O
Drug	O
Prevention/North),	O
using	O
methadone	B-Drug
as	O
the	O
substituting	O
substance,	O
was	O
only	O
unit	O
opioid	O
substitution	O
until	O
1992.	O

Its	O
affinity	O
for	O
the	O
androgen	O
receptor	O
is	O
specifically	O
about	O
64%	O
of	O
that	O
norethandrolone.	O
norethandrolone	B-Drug

Soldiers	O
returning	O
home	O
from	O
the	O
Crusades	O
in	O
11th	O
to	O
13th	O
century	O
brought	O
opium	B-Drug
with	O
them.	O

In	O
2016,	O
fentanyl	B-Drug
and	O
analogues	O
were	O
the	O
most	O
common	O
cause	O
of	O
overdose	O
deaths	O
in	O
United	O
States	O
at	O
more	O
than	O
20,000,	O
about	O
half	O
all	O
opioid-related	O
deaths.	O

Mifepristone	B-Drug
was	O
approved	O
for	O
use	O
in	O
France	O
1988	O
(initial	O
marketing	O
1989),	O
the	O
United	O
Kingdom	O
1991,	O
Sweden	O
1992,	O
then	O
Austria,	O
Belgium,	O
Denmark,	O
Finland,	O
Germany,	O
Greece,	O
Luxembourg,	O
Netherlands,	O
Spain,	O
and	O
Switzerland	O
1999.	O

In	O
2013	O
Then	O
Criminal	O
Investigation	O
and	O
Detection	O
Group	O
Chief	O
turned	O
Baguio	O
City	O
Mayor	O
Benjamin	O
Magalong	O
discovered	O
an	O
alleged	O
recyling	O
of	O
Methamphetamine	B-Drug
Hydrocloride	O
worth	O
PhP	O
648	O
million	O
setting	O
a	O
druglord	O
free	O
during	O
Anti-drug	O
operation	O
in	O
Mexico,	O
Pampanga.	O

Buprenorphine	B-Drug
binds	O
strongly	O
to	O
opioid	O
receptors	O
and	O
acts	O
as	O
a	O
pain-reducing	O
medication	O
in	O
the	O
central	O
nervous	O
system	O
(CNS).	O

And	O
this	O
is	O
a	O
much	O
better	O
way	O
to	O
prepare	O
it	O
than	O
putting	O
the	O
opium	B-Drug
into	O
alcohol,	O
or	O
any	O
other	O
spirits	O
alone,	O
for	O
in	O
that	O
case	O
of	O
does	O
not	O
dissolve.	O

Cyclization	O
of	O
N-phthaloyl-L-glutamine	O
occurs	O
using	O
carbonyldiimidazole,	O
which	O
then	O
yields	O
thalidomide	B-Drug
(3).	O

Intramuscular	O
injection	O
of	O
testosterone	B-Drug
propionate	I-Drug
as	O
an	O
oil	O
solution,	O
aqueous	O
suspension,	O
and	O
emulsion	O
has	O
been	O
compared.	O

However,	O
studies	O
suggest	O
people	O
who	O
use	O
cocaine	B-Drug
do	O
not	O
show	O
normal	O
age-related	O
loss	O
of	O
striatal	O
dopamine	O
transporter	O
(DAT)	O
sites,	O
suggesting	O
has	O
neuroprotective	O
properties	O
for	O
neurons.	O

This	O
causes	O
confounding	O
factors,	O
where	O
questions	O
arise	O
as	O
to	O
whether	O
the	O
tobacco,	O
cannabis,	O
or	O
both	O
that	O
have	O
caused	O
a	O
cancer.	O
tobacco	B-Drug

As	O
such,	O
the	O
researchers	O
stated,	O
"although	O
oxandrolone	B-Drug
cannot	O
be	O
implicated	O
as	O
stimulatory	O
[in]	O
gynecomastia",	O
a	O
possible	O
relationship	O
should	O
considered	O
in	O
clinicians	O
using	O
adolescents	O
for	O
growth	O
stimulation.	O

In	O
2005,	O
the	O
pharmaceutical	O
company	O
Sepracor	O
of	O
Marlborough,	O
Massachusetts	O
began	O
marketing	O
active	O
stereoisomer	O
eszopiclone	B-Drug
under	O
name	O
Lunesta	B-Drug
in	O
United	O
States.	O

This	O
was	O
the	O
case	O
with	O
aminorex	B-Drug
in	O
1960s,	O
and	O
again	O
1990s	O
fenfluramine	B-Drug

6-APB	B-Drug
is	O
not	O
scheduled	O
at	O
the	O
federal	O
level	O
in	O
United	O
States,	O
but	O
it	O
may	O
be	O
considered	O
an	O
analog	O
of	O
amphetamine,	O
which	O
case	O
purchase,	O
sale,	O
or	O
possession	O
could	O
prosecuted	O
under	O
Federal	O
Analog	O
Act.	O
amphetamine	B-Drug

Alectinib	B-Drug
(INN,	O
marketed	O
as	O
Alecensa)	O
is	O
an	O
oral	O
drug	O
that	O
blocks	O
the	O
activity	O
of	O
anaplastic	O
lymphoma	O
kinase	O
(ALK)	O
and	O
used	O
to	O
treat	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

There	O
are	O
numerous	O
methods	O
available	O
to	O
synthesize	O
MDMA	B-Drug
via	O
different	O
intermediates.	O

As	O
early	O
as	O
the	O
1960s,	O
research	O
into	O
medicinal	O
properties	O
of	O
LSD	B-Drug
was	O
being	O
conducted.	O

If	O
vasoconstriction	O
is	O
desired	O
for	O
a	O
procedure	O
(as	O
it	O
reduces	O
bleeding),	O
the	O
anesthetic	B-Drug
combined	O
with	O
vasoconstrictor	O
such	O
as	O
phenylephrine	B-Drug
or	O
epinephrine.	O

Miron	O
further	O
estimated	O
at	O
least	O
$46.7	O
billion	O
in	O
tax	O
revenue	O
based	O
on	O
rates	O
comparable	O
to	O
those	O
tobacco	B-Drug
and	O
alcohol:	O
$8.7	O
from	O
marijuana,	O
$32.6	O
cocaine	B-Drug
heroin,	O
$5.4	O
other	O
drugs.	O
heroin	B-Drug

cocaine,	O
cannabis	O
Cocaine	O
Cowboys	O
2	O
(2008)	O
cocaine	B-Drug
Fiends	O
(1935)	O
=	O

Though	O
a	O
contributor	O
of	O
wealth,	O
the	O
distribution	O
cocaine	B-Drug
has	O
had	O
negative	O
effects	O
on	O
socio-political	O
situation	O
Colombia	O
and	O
weakened	O
its	O
economy	O
as	O
well.	O

The	O
clinical	O
trials	O
used	O
in	O
the	O
regulatory	O
approval	O
of	O
ivacaftor	B-Drug
are	O
described	O
here.	O

Like	O
all	O
or	O
most	O
of	O
the	O
direct	O
morphine	B-Drug
derivatives,	O
halogenated	O
derivatives	O
these	O
drugs	O
and	O
their	O
hydromorphone	B-Drug
hydromorphinol	B-Drug
analogues	O
were	O
synthesized	O
in	O
1930s	O
when	O
both	O
esters	O
being	O
developed,	O
including	O
one	O
given	O
as	O
1,2-iodo-3,6,14-triacetyl-6-14-hydroxydihydromorphinone	O
a	O
footnote	O
to	O
1948	O
German	O
medical	O
journal	O
article	O
about	O
morphine.	O

Nitrazepam	B-Drug
for	O
example	O
is	O
commonly	O
abused	O
in	O
Nepal	O
and	O
the	O
United	O
Kingdom,	O
whereas	O
States	O
of	O
America	O
where	O
nitrazepam	B-Drug
not	O
available	O
on	O
prescription	O
other	O
benzodiazepines	O
are	O
more	O
abused.	O

The	O
discovery	O
of	O
Librium	B-Drug
in	O
1957	O
was	O
due	O
largely	O
to	O
the	O
dedicated	O
work	O
and	O
observational	O
ability	O
a	O
gifted	O
technician,	O
Beryl	O
Kappell.	O

Mephedrone	B-Drug
has	O
been	O
implicated	O
in	O
the	O
death	O
of	O
a	O
22-year-old	O
male,	O
who	O
had	O
also	O
injected	O
black	O
tar	O
heroin.	O

The	O
melting	O
point	O
of	O
benzocaine	B-Drug
is	O
8890	O
C,	O
and	O
the	O
boiling	O
about	O
310	O
C.	O

The	O
substance	O
was	O
used	O
together	O
with	O
its	O
phosphoryloxy-analog	O
ethocybin	B-Drug
in	O
human	O
clinical	O
trials	O
the	O
1960s	O
by	O
German	O
researchers	O
Hanscarl	O
Leuner	O
and	O
G.	O
Baer.	O

In	O
December	O
2018,	O
Greece	O
intercepted	O
a	O
Syrian	O
ship	O
sailing	O
for	O
Libya,	O
carrying	O
six	O
tonnes	O
of	O
processed	O
cannabis	O
and	O
3	O
million	O
Captagon	B-Drug
pills.	O

inhibitors	O
can	O
cause	O
a	O
fatal	O
overdose	O
of	O
hydrocodone.	O
hydrocodone	B-Drug

Chronic	O
users	O
often	O
have	O
high	O
methadone	B-Drug
and	O
EDDP	O
baseline	O
values.	O

Cannabis	O
dependence	O
develops	O
in	O
9%	O
of	O
users,	O
significantly	O
less	O
than	O
that	O
heroin,	O
cocaine,	O
alcohol,	O
and	O
prescribed	O
anxiolytics,	O
but	O
slightly	O
higher	O
for	O
psilocybin,	O
mescaline,	O
or	O
LSD.	O
heroin	B-Drug
cocaine	B-Drug
mescaline	B-Drug
LSD	B-Drug

Formally	O
known	O
as	O
the	O
National	O
Commission	O
on	O
Marihuana	B-Drug
and	O
Drug	O
Abuse,	O
Shafer	O
led	O
by	O
former	O
Pennsylvania	O
governor	O
Raymond	O
P.	O
determined	O
in	O
its	O
March	O
1972	O
report	O
to	O
President	O
Congress	O
that	O
societal	O
harms	O
caused	O
cannabis	O
were	O
limited,	O
recommended	O
removal	O
of	O
criminal	O
penalties	O
for	O
possession	O
distribution	O
small	O
amounts	O
drug.	O

Zyban	B-Drug
the	O
same	O
medication	O
but	O
marketed	O
as	O
a	O
smoking	O
cessation	O
aid.	O

Bottles	O
of	O
opium	B-Drug
tincture	O
are	O
required	O
by	O
the	O
FDA	O
to	O
bear	O
a	O
bright	O
red	O
"POISON"	O
label	O
given	O
potency	O
drug	O
and	O
potential	O
for	O
overdose	O
(see	O
discussion	O
about	O
confusion	O
with	O
Paregoric	O
below).	O

56,098	O
XLR-11	B-Drug
Yangonin	O
Harmaline,	O
harmala	O
alkaloids,	O
and	O
other	O
beta-carbolines,	O
active	O
constituents	O
of	O
ayahuasca;	O
powerful	O
MAOIs	O
(can	O
be	O
classified	O
as	O
indoles)	O
Harmaline	B-Drug

Pruritus	O
is	O
a	O
common	O
side	O
effect	O
of	O
morphine	B-Drug
or	O
other	O
pure	O
MOR	O
agonist	O
opioid	O
administration.	O

Butorphanol	B-Drug
is	O
available	O
in	O
the	O
U.S.	O
as	O
a	O
generic	O
drug;	O
it	O
various	O
nations	O
under	O
one	O
of	O
any	O
number	O
trade	O
names,	O
including	O
Moradol	O
and	O
Beforal	O
(Brand	O
name	O
Stadol	O
no	O
longer	O
US);	O
veterinary	O
names	O
include	O
Butorphic,	O
Dolorex,	O
Morphasol,	O
Torbugesic,	O
Torbutrol.	O

However,	O
thalidomide	B-Drug
is	O
a	O
teratogenic	O
substance,	O
and	O
proportion	O
of	O
children	O
born	O
during	O
the	O
1960s	O
were	O
afflicted	O
with	O
syndrome	O
known	O
as	O
embryopathy	O
(TE).	O

Other	O
side-effects	O
include	O
convulsions	O
(especially	O
when	O
combined	O
with	O
stimulants),	O
and	O
nausea/vomiting	O
alcohol).The	O
greatest	O
life	O
threat	O
due	O
to	O
GHB	B-Drug
overdose	O
(with	O
or	O
without	O
other	O
substances)	O
is	O
respiratory	O
arrest.	O

In	O
2008,	O
the	O
European	O
Monitoring	O
Centre	O
for	O
Drugs	O
and	O
Drug	O
Addiction	O
reports	O
that	O
typical	O
retail	O
price	O
of	O
cocaine	B-Drug
varied	O
between	O
50	O
75	O
per	O
gram	O
in	O
most	O
countries,	O
although	O
Cyprus,	O
Romania,	O
Sweden	O
Turkey	O
reported	O
much	O
higher	O
values.	O

It	O
is	O
a	O
ring-methylated	O
homologue	O
of	O
MDA	O
and	O
structural	O
isomer	O
MDMA.	O
MDMA	B-Drug

Additionally,	O
the	O
toxicity	O
of	O
mitragynine	B-Drug
and	O
associated	O
kratom	B-Drug
alkaloids	O
have	O
yet	O
to	O
be	O
fully	O
determined	O
in	O
humans,	O
nor	O
has	O
risk	O
overdose.	O

However,	O
currently	O
100%	O
of	O
Afghan	O
opium	B-Drug
is	O
diverted	O
to	O
the	O
illegal	O
trade	O
and	O
funds	O
in	O
some	O
cases	O
terrorist	O
activities.	O

This	O
led	O
to	O
the	O
discovery	O
of	O
domperidone	B-Drug
as	O
a	O
strong	O
anti-emetic	O
with	O
minimal	O
central	O
effects.	O

There	O
is	O
no	O
good	O
evidence	O
to	O
suggest	O
that	O
phenytoin	B-Drug
a	O
human	O
carcinogen.	O

A	O
version	O
of	O
this	O
legend	O
was	O
repeated	O
as	O
fact	O
on	O
TV's	O
Dragnet	O
series	O
in	O
1967,	O
an	O
episode	O
revolving	O
around	O
the	O
use	O
LSD	B-Drug
before	O
it	O
made	O
illegal.	O

In	O
people	O
who	O
are	O
difficult	O
to	O
treat,	O
an	O
inpatient	O
flumazenil	B-Drug
administration	O
allows	O
for	O
rapid	O
competitive	O
binding	O
of	O
GABAAreceptor	O
as	O
antagonist,	O
thus	O
stopping	O
(a	O
effectively	O
detoxifying)	O
zolpidem	B-Drug
from	O
being	O
able	O
bind	O
agonist	O
on	O
GABAAreceptor;	O
slowly	O
drug	O
dependence	O
or	O
addiction	O
will	O
wane.	O

The	O
cost	O
of	O
ivacaftor	B-Drug
is	O
US$311,000	O
per	O
year,	O
roughly	O
similar	O
to	O
the	O
price	O
other	O
drugs	O
for	O
extremely	O
rare	O
diseases.	O

Lorcaserin	B-Drug
is	O
an	O
appetite	O
suppressant	O
and	O
anti-obesity	O
drug	O
which	O
acts	O
as	O
a	O
selective	O
5-HT2C	O
receptor	O
agonist.	O

The	O
accused	O
owned	O
a	O
tablet	O
press	O
and	O
ordered	O
fentanyl	B-Drug
in	O
powder	O
form	O
from	O
China.	O

Thalidomide,	O
sold	O
under	O
the	O
brand	O
names	O
Contergan	B-Drug
and	O
Thalomid	B-Drug
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
number	O
of	O
cancers	O
(including	O
multiple	O
myeloma),	O
graft-versus-host	O
disease,	O
skin	O
conditions	O
including	O
complications	O
leprosy.	O
Thalidomide	B-Drug

The	O
user	O
consumed	O
JWH-018	B-Drug
daily	O
for	O
eight	O
months.	O

Most	O
of	O
these	O
overdose	O
deaths	O
were	O
due	O
to	O
illegally	O
made	O
fentanyl.	O
fentanyl	B-Drug

An	O
August	O
2015	O
review	O
notes	O
that	O
dapsone	B-Drug
is	O
reported	O
to	O
be	O
effective	O
against	O
generalized	O
granuloma	O
annulare.	O

Recently,	O
mitragynine	B-Drug
use	O
has	O
spread	O
throughout	O
Europe	O
and	O
the	O
Americas	O
as	O
both	O
a	O
recreational	O
medicinal	O
drug.	O

Conversely,	O
(Sigma)	O
receptors	O
are	O
no	O
longer	O
considered	O
to	O
be	O
opioid	O
because	O
their	O
activation	O
is	O
not	O
reversed	O
by	O
the	O
inverse-agonist	O
naloxone,	O
they	O
do	O
exhibit	O
high-affinity	O
binding	O
for	O
classical	O
opioids,	O
and	O
stereoselective	O
dextro-rotatory	O
isomers	O
while	O
other	O
stereo-selective	O
levo-rotatory	O
isomers.	O
naloxone	B-Drug

Paracetamol	B-Drug
hepatotoxicity	O
is	O
by	O
far	O
the	O
most	O
common	O
cause	O
of	O
acute	O
liver	O
failure	O
in	O
both	O
United	O
States	O
and	O
Kingdom.	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s.	O

it	O
is	O
eight	O
to	O
ten	O
times	O
more	O
potent	O
than	O
morphine.	O
morphine	B-Drug

The	O
use	O
of	O
danazol	B-Drug
is	O
limited	O
by	O
masculinizing	O
side	O
effects	O
such	O
as	O
acne,	O
excessive	O
hair	O
growth,	O
and	O
voice	O
deepening.	O

North	O
India	O
and	O
Nepal	O
have	O
a	O
long	O
social	O
tradition	O
in	O
the	O
production	O
of	O
hashish,	O
known	O
locally	O
as	O
charas.	O
hashish	B-Drug

Suicide	O
by	O
laudanum	B-Drug
was	O
not	O
uncommon	O
in	O
the	O
mid-19th	O
century.	O

Amphetamine	B-Drug
has	O
influenced	O
the	O
aesthetics	O
of	O
many	O
rock	O
and	O
roll	O
bands	O
(especially	O
in	O
garage	O
rock,	O
mod	O
R&B,	O
death	O
punk/hardcore,	O
gothic	O
extreme	O
metal	O
genres).	O

The	O
Thai	O
government	O
had	O
passed	O
the	O
Kratom	B-Drug
Act	O
2486,	O
effective	O
3	O
August	O
1943,	O
which	O
made	O
planting	O
tree	O
illegal,	O
in	O
response	O
to	O
a	O
rise	O
its	O
use	O
when	O
opium	B-Drug
became	O
very	O
expensive	O
Thailand	O
and	O
was	O
attempting	O
gain	O
control	O
of	O
market.	O

Following	O
the	O
appearance	O
of	O
-methylfentanyl	O
on	O
market,	O
over	O
ten	O
new	O
analogs	O
fentanyl	B-Drug
have	O
been	O
reported,	O
starting	O
with	O
para-fluorofentanyl,	O
followed	O
by	O
-methylacetylfentanyl,	O
then	O
highly	O
potent	O
3-methylfentanyl,	O
and	O
subsequently	O
many	O
others	O
such	O
as	O
-hydroxyfentanyl,	O
ohmefentanyl,	O
-hydroxythiofentanyl	O
para-fluorofentanyl	B-Drug
3-methylfentanyl	B-Drug
ohmefentanyl	B-Drug

The	O
Canadian	O
government	O
states	O
that	O
CBD	B-Drug
products	O
"are	O
subject	O
to	O
all	O
of	O
the	O
rules	O
and	O
requirements	O
apply	O
cannabis	O
under	O
Cannabis	O
Act	O
its	O
regulations.	O

Dihydromorphine's	O
onset	O
of	O
action	O
is	O
more	O
rapid	O
than	O
morphine	B-Drug
and	O
it	O
also	O
tends	O
to	O
have	O
a	O
longer	O
duration	O
action,	O
generally	O
47	O
hours.	O
Dihydromorphine	B-Drug

It	O
is	O
often	O
used	O
instead	O
of	O
THC	B-Drug
because	O
it	O
has	O
a	O
higher	O
efficacy.	O

Researchers	O
at	O
Chemie	O
Grnenthal	O
found	O
that	O
thalidomide	B-Drug
was	O
a	O
particularly	O
effective	O
antiemetic	O
had	O
an	O
inhibitory	O
effect	O
on	O
morning	O
sickness.	O

When	O
opioids	O
like	O
hydrocodone	B-Drug
are	O
taken	O
as	O
prescribed,	O
for	O
the	O
indication	O
and	O
a	O
short	O
period	O
of	O
time,	O
then	O
risk	O
abuse	O
addiction	O
is	O
small.	O

A	O
drugs	O
such	O
as	O
heroin	B-Drug
and	O
cocaine,	O
should	O
be	O
downgraded	O
to	O
class	O
B.	O
cocaine	B-Drug

By	O
the	O
early	O
1980s	O
MDMA	B-Drug
was	O
being	O
used	O
in	O
Boston	O
and	O
New	O
York	O
City	O
nightclubs	O
such	O
as	O
Studio	O
54	O
Paradise	O
Garage.	O

A	O
2017	O
UNODC	O
report	O
into	O
the	O
cultivation	O
of	O
illicit	O
crops	O
in	O
Colombia	O
showed	O
that	O
number	O
hectares	O
under	O
coca	B-Drug
leapt	O
from	O
96,000	O
2015	O
to	O
146,000	O
2016.As	O
2006,	O
production	O
employed	O
an	O
estimated	O
67,000	O
households.	O

Androstenedione	B-Drug
is	O
a	O
precursor	O
of	O
testosterone	O
and	O
other	O
androgens,	O
as	O
well	O
estrogens	O
like	O
estrone,	O
in	O
the	O
body.	O

Dexamethasone	B-Drug
intravitreal	O
steroid	O
implants	O
have	O
been	O
approved	O
by	O
the	O
FDA	O
to	O
treat	O
ocular	O
conditions	O
such	O
as	O
diabetic	O
macular	O
edema,	O
central	O
retinal	O
vein	O
occlusion,	O
and	O
uveitis.	O

Dihydrocodeine	B-Drug
is	O
available	O
in	O
suppository	O
form	O
on	O
prescription.	O

When	O
grown	O
for	O
opium	B-Drug
production,	O
the	O
skin	O
of	O
ripening	O
pods	O
these	O
poppies	O
is	O
scored	O
by	O
a	O
sharp	O
blade	O
at	O
time	O
carefully	O
chosen	O
so	O
that	O
rain,	O
wind,	O
and	O
dew	O
cannot	O
spoil	O
exudation	O
white,	O
milky	O
latex,	O
usually	O
in	O
afternoon.	O

Dependence	O
occurs	O
in	O
one-third	O
of	O
people	O
who	O
take	O
clonazepam	B-Drug
for	O
longer	O
than	O
four	O
weeks.	O

Steady-state	O
levels	O
of	O
etonogestrel	B-Drug
are	O
achieved	O
within	O
one	O
week	O
upon	O
insertion	O
as	O
an	O
implant	O
or	O
vaginal	O
ring.	O

Eight	O
individuals	O
who	O
accidentally	O
consumed	O
very	O
high	O
amounts	O
by	O
mistaking	O
LSD	B-Drug
for	O
cocaine	B-Drug
developed	O
comatose	O
states,	O
hyperthermia,	O
vomiting,	O
gastric	O
bleeding,	O
and	O
respiratory	O
problemsall	O
survived,	O
however,	O
with	O
supportive	O
care.	O

Evidence	O
from	O
ancient	O
Greece	O
indicates	O
that	O
opium	B-Drug
was	O
consumed	O
in	O
several	O
ways,	O
including	O
inhalation	O
of	O
vapors,	O
suppositories,	O
medical	O
poultices,	O
and	O
as	O
a	O
combination	O
with	O
hemlock	O
for	O
suicide.	O

As	O
of	O
October	O
2015,	O
5-MeO-DMT	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

The	O
fenethylline	B-Drug
molecule	O
results	O
when	O
theophylline	B-Drug
is	O
covalently	O
linked	O
with	O
amphetamine	B-Drug
via	O
an	O
alkyl	O
chain.	O

JWH-198	B-Drug
has	O
a	O
binding	O
affinity	O
at	O
the	O
CB1	O
receptor	O
of	O
10	O
nM,	O
around	O
four	O
times	O
more	O
tightly	O
than	O
parent	O
compound	O
JWH-200,	O
which	O
no	O
substitution	O
on	O
naphthoyl	O
ring.	O
JWH-200	B-Drug

This	O
use	O
is	O
controversial	O
since	O
the	O
Lupron	B-Drug
label	O
advises	O
against	O
using	O
drug	O
when	O
one	O
considering	O
pregnancy,	O
due	O
to	O
a	O
risk	O
of	O
birth	O
defects.	O

It	O
is	O
a	O
potent	O
analgesic,	O
around	O
60	O
times	O
stronger	O
than	O
morphine	B-Drug
and	O
produces	O
significantly	O
less	O
constipation.	O

Some	O
heroin	B-Drug
dealers	O
mix	O
fentanyl	B-Drug
powder	O
with	O
to	O
increase	O
potency	O
or	O
compensate	O
for	O
low-quality	O
heroin.	O

Amphetamines	O
like	O
MDMA,	O
MDEA,	O
MDA,	O
and	O
MBDB,	O
among	O
other	O
relatives	O
(see	O
MDxx),	O
are	O
recreational	O
drugs	O
termed	O
entactogens.	O
MDMA	B-Drug
MBDB	B-Drug

The	O
major	O
pathway	O
involves	O
the	O
formation	O
of	O
androstenedione,	O
which	O
is	O
then	O
converted	O
by	O
aromatase	O
into	O
estrone	O
and	O
subsequently	O
estradiol.	O
androstenedione	B-Drug

Buspirone	B-Drug
has	O
also	O
been	O
found	O
to	O
bind	O
with	O
much	O
higher	O
affinity	O
the	O
dopamine	O
D3	O
and	O
D4	O
receptors,	O
where	O
it	O
is	O
similarly	O
an	O
antagonist.	O

The	O
risks	O
of	O
tolerance,	O
dependence,	O
and	O
withdrawal	O
are	O
very	O
low	O
when	O
the	O
drug	O
is	O
used	O
for	O
24	O
weeks	O
only,	O
lormetazepam	B-Drug
generally	O
a	O
safe	O
effective	O
no	O
longer	O
than	O
weeks.	O

Although	O
it	O
has	O
a	O
short	O
half-life	O
(~	O
1	O
hour),	O
cocaine	B-Drug
metabolites,	O
which	O
rise	O
in	O
concentrations	O
several	O
hours	O
after	O
ingestion,	O
persist	O
circulation	O
for	O
up	O
to	O
24	O
hours,	O
and	O
may	O
cause	O
delayed	O
or	O
recurrent	O
coronary	O
vasoconstriction.	O

Androstenedione	B-Drug
is	O
a	O
precursor	O
of	O
testosterone	O
and	O
other	O
androgens,	O
as	O
well	O
estrogens	O
like	O
estrone,	O
in	O
the	O
body.	O

Androstenedione	B-Drug
is	O
currently	O
banned	O
by	O
the	O
U.S.	O
military.	O

Since	O
1994,	O
the	O
production,	O
dispensing,	O
and	O
prescription	O
of	O
thalidomide	B-Drug
have	O
been	O
strictly	O
controlled,	O
requiring	O
women	O
to	O
use	O
two	O
forms	O
birth	O
control	O
submit	O
regular	O
pregnancy	O
tests.	O

marijuana	B-Drug
Gummo	O
(1997)	O

Japan's	O
war	O
with	O
China	O
had	O
cut	O
the	O
normal	O
distribution	O
routes	O
for	O
heroin	B-Drug
and	O
generally	O
disrupted	O
movement	O
of	O
opium.	O
opium	B-Drug

Syntex	O
first	O
marketed	O
naproxen	B-Drug
in	O
1976,	O
as	O
the	O
prescription	O
drug	O
Naprosyn.	O
Naprosyn	B-Drug

There	O
soon	O
appeared	O
reports	O
of	O
abnormalities	O
in	O
children	O
being	O
born	O
to	O
mothers	O
using	O
thalidomide.	O
thalidomide	B-Drug

Some	O
of	O
these	O
substances	O
contain	O
methylone,	O
ethylone,	O
MDPV,	O
mephedrone,	O
or	O
any	O
other	O
the	O
group	O
compounds	O
commonly	O
known	O
as	O
bath	O
salts,	O
in	O
addition	O
to,	O
place	O
of,	O
MDMA.	O
methylone	B-Drug
ethylone	B-Drug
MDPV	B-Drug
mephedrone	B-Drug
MDMA	B-Drug

Overdoses	O
of	O
alprazolam	B-Drug
can	O
be	O
mild	O
to	O
severe	O
depending	O
on	O
the	O
quantity	O
ingested	O
and	O
if	O
other	O
drugs	O
are	O
taken	O
in	O
combination.	O

In	O
addition	O
to	O
low	O
NAcc	O
D2	O
binding,	O
cocaine	B-Drug
is	O
also	O
known	O
produce	O
a	O
variety	O
of	O
changes	O
the	O
primate	O
brain	O
such	O
as	O
increases	O
prodynorphin	O

Levonorgestrel	B-Drug
is	O
used	O
in	O
emergency	O
contraceptive	O
pills	O
(ECPs),	O
both	O
a	O
combined	O
Yuzpe	O
regimen	O
which	O
includes	O
estrogen,	O
and	O
as	O
levonorgestrel-only	O
method.	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	B-Drug
and	O
higher	O
CBD,	O
which	O
gives	O
lesser	O
psychoactive	O
effects.	O
CBD	B-Drug

The	O
Soviet-Afghan	O
war	O
led	O
to	O
increased	O
production	O
in	O
the	O
Pakistani-Afghan	O
border	O
regions,	O
as	O
US-backed	O
mujaheddin	O
militants	O
raised	O
money	O
for	O
arms	O
from	O
selling	O
opium,	O
contributing	O
heavily	O
modern	O
Golden	O
Crescent	O
creation.	O
opium	B-Drug

Domperidone	B-Drug
is	O
now	O
contraindicated	O
in	O
those	O
with	O
underlying	O
cardiac	O
conditions	O
and	O
other	O
risk	O
factors.	O

In	O
the	O
last	O
few	O
years	O
certain	O
strains	O
of	O
cannabis	O
plant	O
with	O
higher	O
concentrations	O
THC	B-Drug
and	O
drug	O
tourism	O
have	O
challenged	O
former	O
policy	O
in	O
Netherlands	O
led	O
to	O
a	O
more	O
restrictive	O
approach;	O
for	O
example,	O
ban	O
on	O
selling	O
tourists	O
coffeeshops	O
suggested	O
start	O
late	O
2011.	O

Gabapentin	B-Drug
is	O
eliminated	O
renally	O
in	O
the	O
urine.	O

Edible	O
CBD	B-Drug
products	O
were	O
scheduled	O
to	O
be	O
permitted	O
for	O
sale	O
in	O
Canada	O
on	O
October	O
17,	O
2019	O
human	O
consumption.	O

Despite	O
its	O
lack	O
of	O
addictive	O
properties,	O
ibogaine	B-Drug
is	O
listed	O
as	O
a	O
Schedule	O
I	O
compound	O
in	O
the	O
US	O
because	O
it	O
psychoactive	O
substance,	O
hence	O
considered	O
illegal	O
to	O
possess	O
under	O
any	O
circumstances.	O

BML-190	O
is	O
structurally	O
derived	O
from	O
the	O
NSAID	O
indomethacin	B-Drug
but	O
has	O
a	O
quite	O
different	O
biological	O
activity.	O

Other	O
examples	O
include	O
phenylephrine,	O
isoproterenol,	O
and	O
dobutamine.	O
phenylephrine	B-Drug

This	O
powder	O
often	O
contains	O
nitroglycerin,	O
a	O
drug	O
prescribed	O
for	O
heart	O
conditions,	O
which	O
might	O
cause	O
vasodilation,	O
permitting	O
the	O
cocaine	B-Drug
or	O
amphetamine	B-Drug
insufflation	O
to	O
move	O
more	O
freely	O
through	O
body.	O

The	O
BALCO	O
scandal	O
brought	O
to	O
light	O
an	O
as-yet	O
unsubstantiated	O
(but	O
widely	O
published)	O
account	O
of	O
Major	O
League	O
Baseball's	O
all-time	O
leading	O
home-run	O
hitter	O
Barry	O
Bonds'	O
supplemental	O
chemical	O
regimen	O
that	O
included	O
modafinil	B-Drug
in	O
addition	O
anabolic	O
steroids	O
and	O
human	O
growth	O
hormone.	O

This	O
makes	O
JWH-098	B-Drug
a	O
good	O
example	O
of	O
how	O
methylation	O
the	O
indole	O
2-position	O
in	O
naphthoylindole	O
series	O
tends	O
to	O
increase	O
CB2	O
affinity,	O
but	O
often	O
at	O
expense	O
CB1	O
binding.	O

Oral	O
rehydration	O
salts	O
Zinc	O
sulfate	O
Fludrocortisone	B-Drug
Hydrocortisone	B-Drug
Testosterone	O

Levonorgestrel	B-Drug
was	O
patented	O
in	O
1960	O
and	O
introduced	O
for	O
medical	O
use	O
together	O
with	O
ethinylestradiol	O
1970.	O

Unused	O
fentanyl	B-Drug
patches	O
should	O
be	O
kept	O
in	O
a	O
secure	O
location	O
out	O
of	O
children's	O
sight	O
and	O
reach,	O
such	O
as	O
locked	O
cabinet.	O

It	O
has	O
no	O
clinically	O
significant	O
interaction	O
with	O
the	O
D1	O
receptor,	O
unlike	O
metoclopramide.	O
metoclopramide	B-Drug

Unlike	O
many	O
benzodiazepines,	O
pharmacokinetic	O
interactions	O
involving	O
the	O
P450	O
system	O
have	O
not	O
been	O
observed	O
with	O
temazepam.	O
temazepam	B-Drug

According	O
to	O
the	O
United	O
Nations	O
Office	O
on	O
Drugs	O
and	O
Crime	O
(UNODC),	O
"the	O
amount	O
of	O
THC	B-Drug
present	O
in	O
a	O
cannabis	O
sample	O
is	O
generally	O
used	O
as	O
measure	O
potency.	O

that	O
JWH-018	B-Drug
was	O
found	O
as	O
one	O
of	O
the	O
active	O
components	O
in	O
at	O
least	O
three	O
versions	O
grey	O
market	O
drug	O
Spice,	O
which	O
has	O
been	O
sold	O
an	O
incense	O
a	O
number	O
countries	O
around	O
world	O
since	O
2002.	O

Clonazepam,	O
sold	O
under	O
the	O
brand	O
Klonopin	B-Drug
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
prevent	O
and	O
treat	O
seizures,	O
panic	O
disorder,	O
movement	O
disorder	O
known	O
as	O
akathisia.	O
Clonazepam	B-Drug

In	O
Canada,	O
generic	O
XR	O
bupropion	B-Drug
is	O
distributed	O
by	O
Mylan.	O

Especially	O
in	O
Mexican	O
production,	O
opium	B-Drug
may	O
be	O
converted	O
directly	O
to	O
"black	O
tar	O
heroin"	O
a	O
simplified	O
procedure.	O

In	O
November	O
2017,	O
the	O
FDA	O
cited	O
serious	O
concerns	O
over	O
marketing	O
and	O
effects	O
(including	O
death)	O
associated	O
with	O
use	O
of	O
kratom	B-Drug
in	O
United	O
States,	O
stating	O
that	O
"There	O
is	O
no	O
reliable	O
evidence	O
to	O
support	O
as	O
a	O
treatment	O
for	O
opioid	O
disorder;	O
there	O
are	O
currently	O
FDA-approved	O
therapeutic	O
uses	O
kratom...	O
has	O
show	O
significant	O
safety	O
issues	O
its	O
use.	O

Hydrochlorothiazide	B-Drug
is	O
frequently	O
used	O
for	O
the	O
treatment	O
of	O
hypertension,	O
congestive	O
heart	O
failure,	O
symptomatic	O
edema,	O
diabetes	O
insipidus,	O
renal	O
tubular	O
acidosis.	O

The	O
elimination	O
half-life	O
of	O
brotizolam	B-Drug
is	O
36	O
hours.	O

Thalidomide	B-Drug
was	O
first	O
marketed	O
in	O
1957	O
West	O
Germany,	O
where	O
it	O
available	O
over	O
the	O
counter.	O

Major	O
applications	O
of	O
drug	O
testing	O
include	O
detection	O
the	O
presence	O
performance	O
enhancing	O
steroids	O
in	O
sport,	O
employers	O
and	O
parole/probation	O
officers	O
screening	O
for	O
drugs	O
prohibited	O
by	O
law	O
(such	O
as	O
cocaine,	O
methamphetamine,	O
heroin)	O
police	O
concentration	O
alcohol	O
(ethanol)	O
blood	O
commonly	O
referred	O
to	O
BAC	O
(blood	O
content).	O
cocaine	B-Drug
methamphetamine	B-Drug
heroin	B-Drug

Steady-state	O
levels	O
of	O
clascoterone	B-Drug
occur	O
within	O
5	O
days	O
twice	O
daily	O
administration.	O

In	O
vitro	O
studies	O
of	O
tissue	O
cultured	O
cell	O
lines	O
have	O
shown	O
that	O
chronic	O
treatment	O
with	O
flumazenil	B-Drug
enhanced	O
the	O
benzodiazepine	O
binding	O
site	O
where	O
such	O
receptors	O
become	O
more	O
numerous	O
and	O
uncoupling/down-regulation	O
GABAA	O
has	O
been	O
reversed.	O

Some	O
varieties,	O
having	O
undergone	O
careful	O
selection	O
and	O
growing	O
techniques,	O
can	O
yield	O
as	O
much	O
34%	O
THC.	O
THC	B-Drug

Clonazepam	B-Drug
is	O
a	O
2'-chlorinated	O
derivative	O
of	O
nitrazepam,	O
which	O
increases	O
its	O
potency	O
due	O
to	O
electron-attracting	O
effect	O
the	O
halogen	O
in	O
ortho-position.	O
nitrazepam	B-Drug

The	O
experts	O
pointed	O
out	O
that	O
Vivitrol's	O
competitors,	O
buprenorphine	B-Drug
and	O
methadone,	O
are	O
"less	O
expensive",	O
"more	O
widely	O
used",	O
have	O
been	O
"rigorously	O
studied".	O
methadone	B-Drug

Dapsone	B-Drug
is	O
effective	O
and	O
safe	O
for	O
treatment	O
of	O
second-line	O
therapy	O
people	O
with	O
chronic	O
spontaneous	O
urticaria	O
in	O
those	O
whom	O
antihistamines	O
other	O
first-line	O
agents	O
have	O
failed.	O

Indeed,	O
combined	O
oral	O
contraceptives	O
containing	O
ethinylestradiol	O
and	O
desogestrel	B-Drug
have	O
been	O
found	O
to	O
significantly	O
decrease	O
free	O
concentrations	O
of	O
testosterone	O
possess	O
overall	O
antiandrogenic	O
effects,	O
reducing	O
symptoms	O
acne	O
hirsutism	O
in	O
women	O
with	O
hyperandrogenism.	O

Primarily,	O
fentanyl	B-Drug
provides	O
the	O
relief	O
of	O
pain	O
by	O
acting	O
on	O
brain	O
and	O
spinal	O
-receptors.	O

Hyoscine's	O
effects	O
on	O
acetylcholine	O
and	O
glutamate	O
release	O
in	O
the	O
hippocampus	O
favor	O
retrieval-dominant	O
cognitive	O
functioning.	O
Hyoscine	B-Drug

Cocaine	B-Drug
acts	O
like	O
a	O
class	O
I	O
antiarrhythmic	O
agent	O
by	O
blocking	O
sodium	O
and	O
potassium	O
channels,	O
in	O
similar	O
way	O
of	O
local	O
anesthetics	O
such	O
as	O
lidocaine,	O
interferes	O
with	O
action	O
potential	O
propagation.	O
lidocaine	B-Drug

Methaqualone	B-Drug
became	O
increasingly	O
popular	O
as	O
a	O
recreational	O
drug	O
and	O
club	O
in	O
the	O
late	O
1960s	O
1970s,	O
known	O
variously	O
"ludes"	O
or	O
"disco	O
biscuits"	O
due	O
to	O
its	O
widespread	O
use	O
during	O
popularity	O
of	O
disco	O
"sopers"	O
(also	O
"soaps")	O
United	O
States	O
"mandrakes"	O
"mandies"	O
Kingdom,	O
Australia	O
New	O
Zealand.	O

These	O
findings	O
suggest	O
that	O
the	O
progonadotropic	O
effects	O
of	O
clomifene	B-Drug
are	O
stronger	O
in	O
younger	O
men	O
than	O
older	O
men.	O

Fentanyl	B-Drug
was	O
often	O
produced	O
in	O
China	O
and	O
exported	O
illegally	O
to	O
the	O
U.S.	O

The	O
immunosuppressive	O
effect	O
of	O
the	O
natural	O
product	O
ciclosporin	B-Drug
was	O
discovered	O
in	O
December	O
1971	O
a	O
screening	O
test	O
on	O
immune	O
suppression	O
designed	O
and	O
implemented	O
by	O
Hartmann	O
F.	O
Sthelin	O
at	O
Sandoz.	O

Many	O
fentanyl	B-Drug
overdoses	O
are	O
initially	O
classified	O
as	O
heroin	B-Drug
overdoses.	O

By	O
the	O
1990s,	O
Obetrol	B-Drug
Pharmaceuticals	O
had	O
been	O
wholly	O
absorbed	O
by	O
Rexar	O
Pharmacal	O
and	O
was	O
no	O
longer	O
noted	O
as	O
a	O
"division"	O
of	O
Rexar.	O

There	O
are	O
case	O
reports	O
of	O
increased	O
liver	O
enzymes	O
involving	O
ketamine	B-Drug
treatment	O
chronic	O
pain.	O

Opium	O
prohibition	O
in	O
China	O
began	O
1729,	O
yet	O
was	O
followed	O
by	O
nearly	O
two	O
centuries	O
of	O
increasing	O
opium	B-Drug
use.	O

A	O
study	O
in	O
rats	O
found	O
temazepam	B-Drug
is	O
cross	O
tolerant	O
with	O
barbiturates	O
and	O
able	O
to	O
effectively	O
substitute	O
for	O
suppress	O
barbiturate	O
withdrawal	O
signs.	O

From	O
1971	O
on,	O
therefore,	O
returning	O
servicemen	O
were	O
required	O
to	O
take	O
a	O
mandatory	O
heroin	B-Drug
test.	O

"	O
is	O
not	O
a	O
phenyltropane	O
but	O
actually	O
belongs	O
to	O
the	O
benzatropine	B-Drug
family	O
of	O
DRIs.	O

Additionally,	O
nociceptin	O
may	O
have	O
lower	O
tolerance	O
development	O
than	O
drugs	O
such	O
as	O
morphine.	O
morphine	B-Drug

The	O
other	O
drugs	O
included	O
diazepam	B-Drug
as	O
a	O
tranquilizer,	O
cisatracurium	B-Drug
besylate	O
muscle	O
relaxant,	O
and	O
potassium	O
chloride	O
to	O
stop	O
the	O
heart.	O

Amphetamine	B-Drug
also	O
has	O
a	O
slight	O
analgesic	O
effect	O
and	O
can	O
enhance	O
the	O
pain	O
relieving	O
effects	O
of	O
opioids.	O

Numerous	O
fire	O
safe	O
cigarette	O
designs	O
have	O
been	O
proposed,	O
some	O
by	O
tobacco	B-Drug
companies	O
themselves,	O
which	O
would	O
extinguish	O
a	O
left	O
unattended	O
for	O
more	O
than	O
minute	O
or	O
two,	O
thereby	O
reducing	O
the	O
risk	O
of	O
fire.	O

Proheptazine	B-Drug
produces	O
similar	O
effects	O
to	O
other	O
opioids,	O
including	O
analgesia,	O
sedation,	O
euphoria,	O
dizziness	O
and	O
nausea.	O

LSD	B-Drug
has	O
been	O
shown	O
to	O
have	O
low	O
affinity	O
for	O
H1	O
receptors,	O
displaying	O
antihistamine	O
effects.	O

heroin,	O
Viagra	B-Drug
and	O
anorectics	O
are	O
referred	O
to	O
Little	O
Shop	O
of	O
Horrors	O
(1986)	O
heroin	B-Drug

Thalidomide	B-Drug
has	O
been	O
used	O
by	O
Brazilian	O
physicians	O
as	O
the	O
drug	O
of	O
choice	O
for	O
treatment	O
severe	O
ENL	O
since	O
1965,	O
and	O
1996,	O
at	O
least	O
33	O
cases	O
thalidomide	B-Drug
embryopathy	O
were	O
recorded	O
in	O
people	O
born	O
Brazil	O
after	O
1965.	O

Haloperidol	B-Drug
was	O
approved	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
on	O
12	O
April	O
1967;	O
it	O
later	O
marketed	O
in	O
other	O
countries	O
under	O
brand	O
name	O
Haldol	B-Drug
McNeil	O
Laboratories.	O

A	O
reduced	O
quality	O
of	O
life	O
is	O
associated	O
with	O
heavy	O
cannabis	O
use,	O
although	O
the	O
relationship	O
inconsistent	O
and	O
weaker	O
than	O
for	O
tobacco	B-Drug
other	O
substances.	O

Apixaban	B-Drug
is	O
a	O
highly	O
selective,	O
orally	O
bioavailable,	O
and	O
reversible	O
direct	O
inhibitor	O
of	O
free	O
clot-bound	O
factor	O
Xa.	O

Mibolerone,	O
also	O
known	O
as	O
dimethylnortestosterone	O
(DMNT)	O
and	O
sold	O
under	O
the	O
brand	O
names	O
Cheque	O
Drops	O
Matenon,	O
is	O
a	O
synthetic,	O
orally	O
active,	O
extremely	O
potent	O
anabolicandrogenic	O
steroid	O
(AAS)	O
17-alkylated	O
nandrolone	B-Drug
(19-nortestosterone)	O
derivative	O
which	O
was	O
marketed	O
by	O
Upjohn	O
for	O
use	O
veterinary	O
drug.	O
Mibolerone	B-Drug
19-nortestosterone	B-Drug

It	O
is	O
similar	O
in	O
effects	O
to	O
phencyclidine	B-Drug
(PCP)	O
but	O
considerably	O
more	O
potent.	O
PCP	B-Drug

Chlorothiazide,	O
sold	O
under	O
the	O
brand	O
name	O
Diuril	B-Drug
among	O
others,	O
is	O
an	O
organic	O
compound	O
used	O
as	O
a	O
diuretic	O
and	O
antihypertensive.	O
Chlorothiazide	B-Drug

Importantly,	O
these	O
results	O
also	O
suggest	O
strongly	O
that	O
the	O
primary	O
pharmacologically	O
active	O
metabolite	O
in	O
coca	B-Drug
leaf	O
infusions	O
is	O
actually	O
cocaine	B-Drug
and	O
not	O
secondary	O
alkaloids.	O

Almost	O
50	O
years	O
later,	O
Patrick	O
Kroupa	O
and	O
Hattie	O
Wells	O
released	O
the	O
first	O
treatment	O
protocol	O
for	O
concomitant	O
administration	O
of	O
ibogaine	B-Drug
with	O
opioids	O
in	O
human	O
subjects,	O
indicating	O
that	O
reduced	O
tolerance	O
to	O
opioid	O
drugs.	O

He	O
started	O
off	O
by	O
smuggling	O
marijuana	O
and	O
opium	B-Drug
into	O
the	O
U.S.,	O
was	O
first	O
Mexican	O
drug	O
chief	O
to	O
link	O
up	O
with	O
Colombia's	O
cocaine	B-Drug
cartels	O
in	O
1980s.	O

The	O
immediate	O
effect	O
of	O
KOR	O
agonism	O
leads	O
to	O
reduction	O
dopamine	O
release	O
in	O
the	O
NAcc	O
during	O
self-administration	O
cocaine	B-Drug
and	O
over	O
long	O
term	O
up-regulates	O
receptors	O
that	O
have	O
been	O
down-regulated	O
substance	O
abuse	O
such	O
as	O
MOR	O
D2	O
receptor.	O

Because	O
of	O
fentanyl's	O
high	O
lipid	O
solubility,	O
its	O
effects	O
are	O
more	O
localized	O
than	O
morphine,	O
and	O
some	O
clinicians	O
prefer	O
to	O
use	O
morphine	B-Drug
get	O
a	O
wider	O
spread	O
analgesia.	O
fentanyl	B-Drug

Compared	O
to	O
THC,	O
which	O
is	O
a	O
partial	O
agonist	O
at	O
CB1	O
receptors,	O
JWH-018,	O
and	O
many	O
synthetic	O
cannabinoids,	O
are	O
full	O
agonists.	O
THC	B-Drug
JWH-018	B-Drug

According	O
to	O
a	O
dose-response	O
study	O
in	O
human	O
subjects,	O
dimethyltryptamine	B-Drug
administered	O
intravenously	O
slightly	O
elevated	O
blood	O
pressure,	O
heart	O
rate,	O
pupil	O
diameter,	O
and	O
rectal	O
temperature,	O
addition	O
elevating	O
concentrations	O
of	O
beta-endorphin,	O
corticotropin,	O
cortisol,	O
prolactin;	O
growth	O
hormone	O
levels	O
rise	O
equally	O
response	O
all	O
doses	O
DMT,	O
melatonin	B-Drug
were	O
unaffected."	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s.	O

Hydromorphone	B-Drug
is	O
listed	O
under	O
the	O
German	O
Betubungsmittelgesetz	O
as	O
a	O
Betubungsmittel	O
in	O
most	O
restricted	O
schedule	O
for	O
medicinal	O
drugs;	O
it	O
controlled	O
similarly	O
Austria	O
(Suchtgift)	O
SMG	O
and	O
Swiss	O
BetmG.	O

Despite	O
the	O
historically	O
negative	O
view	O
of	O
opium	B-Drug
as	O
a	O
cause	O
addiction,	O
use	O
morphine	B-Drug
and	O
other	O
derivatives	O
isolated	O
from	O
in	O
treatment	O
chronic	O
pain	O
has	O
been	O
reestablished.	O

The	O
common	O
side	O
effects	O
of	O
oxymetholone	B-Drug
include	O
depression,	O
lethargy,	O
headache,	O
swelling,	O
rapid	O
weight	O
gain,	O
priapism,	O
changes	O
in	O
skin	O
color,	O
urination	O
problems,	O
nausea,	O
vomiting,	O
stomach	O
pain	O
(if	O
taken	O
on	O
an	O
empty	O
stomach),	O
loss	O
appetite,	O
jaundice,	O
breast	O
swelling	O
men,	O
feeling	O
restless	O
or	O
excited,	O
insomnia,	O
and	O
diarrhea.	O

The	O
two	O
terms	O
are	O
often	O
used	O
interchangeably,	O
but	O
acid	O
rock	O
may	O
be	O
distinguished	O
as	O
a	O
more	O
extreme	O
variation	O
that	O
was	O
heavier,	O
louder,	O
relied	O
on	O
long	O
jams,	O
focused	O
directly	O
LSD,	O
and	O
made	O
greater	O
use	O
of	O
distortion.	O
LSD	B-Drug

Laudanum	B-Drug
appears	O
in	O
Charles	O
Baudelaire's	O
prose	O
poem	O
The	O
Double	O
Room,	O
published	O
his	O
collection	O
Le	O
Spleen	O
de	O
Paris	O
1869.	O

This	O
causes	O
confounding	O
factors,	O
where	O
questions	O
arise	O
as	O
to	O
whether	O
the	O
tobacco,	O
cannabis,	O
or	O
both	O
that	O
have	O
caused	O
a	O
cancer.	O
tobacco	B-Drug

MPA	O
shows	O
weak	O
androgenic	O
effects	O
on	O
liver	O
protein	O
synthesis,	O
similarly	O
to	O
other	O
weakly	O
progestins	O
like	O
megestrol	O
acetate	O
and	O
19-nortestosterone	B-Drug
derivatives.	O

Use	O
during	O
pregnancy	O
may	O
result	O
in	O
preterm	O
birth;	O
however,	O
ciclosporin	B-Drug
does	O
not	O
appear	O
to	O
cause	O
birth	O
defects.	O

Subsequently,	O
other	O
benzomorphans,	O
such	O
as	O
pentazocine	B-Drug
(an	O
N-dimethylallylbenzomorphan),	O
cyclazocine	O
N-cyclopropylmethylbenzomorphan),	O
and	O
phenazocine	B-Drug
N-phenylethylbenzomorphan),	O
were	O
developed,	O
some	O
have	O
been	O
marketed	O
for	O
use	O
analgesics.	O

Circa	O
1994,	O
the	O
United	O
States	O
government	O
notified	O
UN	O
Secretary	O
General	O
that	O
it	O
supported	O
controlling	O
methcathinone,	O
an	O
addictive	O
stimulant	O
manufactured	O
with	O
common	O
household	O
products,	O
as	O
a	O
Schedule	O
methcathinone	B-Drug

Sometimes,	O
longer	O
duration	O
of	O
low	O
doses	O
doxycycline	B-Drug
are	O
required.	O

The	O
term,	O
originally	O
spelled	O
variously	O
as	O
"marihuana",	O
"mariguana",	O
etc.,	O
originated	O
in	O
Mexican	O
Spanish.	O
marihuana	B-Drug
mariguana	B-Drug

According	O
to	O
the	O
National	O
Drug	O
Intelligence	O
Center,	O
Mexican	O
cartels	O
are	O
predominant	O
smugglers	O
and	O
wholesale	O
distributors	O
of	O
South	O
American	O
cocaine	B-Drug
Mexico-produced	O
cannabis,	O
methamphetamine	B-Drug
heroin.	O
heroin	B-Drug

Structurally	O
it	O
closely	O
resembles	O
cannabinoid	O
compounds	O
from	O
patent	O
WO	O
2003/035005	O
but	O
with	O
a	O
5-fluoropentyl	O
chain	O
on	O
the	O
indazole	O
1-position,	O
and	O
5F-APINACA	B-Drug
falls	O
within	O
claims	O
of	O
this	O
patent,	O
as	O
despite	O
not	O
being	O
disclosed	O
an	O
example,	O
is	O
very	O
similar	O
to	O
corresponding	O
pentanenitrile	O
4-chlorobutyl	O
which	O
are	O
claimed	O
examples	O
3	O
4.5F-APINACA	O
was	O
first	O
identified	O
in	O
South	O
Korea.	O

Barbiturates	O
are	O
also	O
used	O
to	O
alleviate	O
the	O
adverse	O
or	O
withdrawal	O
effects	O
of	O
illicit	O
drug	O
use,	O
in	O
a	O
manner	O
similar	O
long-acting	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug
and	O
clonazepam.	O
clonazepam	B-Drug

MKUltra's	O
researchers	O
later	O
dismissed	O
LSD	B-Drug
as	O
too	O
unpredictable	O
in	O
its	O
results.	O

As	O
the	O
dose	O
of	O
buprenorphine	B-Drug
increases,	O
its	O
analgesic	O
effects	O
reach	O
a	O
plateau,	O
and	O
then	O
it	O
starts	O
to	O
act	O
like	O
an	O
antagonist.	O

Nutt	O
had	O
repeated	O
his	O
familiar	O
view	O
that	O
illicit	O
drugs	O
should	O
be	O
classified	O
according	O
to	O
the	O
actual	O
evidence	O
of	O
harm	O
they	O
cause	O
and	O
pointed	O
out	O
alcohol	O
tobacco	B-Drug
caused	O
more	O
than	O
LSD,	O
ecstasy	B-Drug
cannabis.	O
LSD	B-Drug

Quaaludes	B-Drug
were	O
so	O
common	O
at	O
disco	O
clubs	O
that	O
the	O
drug	O
was	O
nicknamed	O
"disco	O
biscuits".	O

Levomethamphetamine	B-Drug
is	O
a	O
sympathomimetic	O
vasoconstrictor	O
which	O
the	O
active	O
ingredient	O
in	O
some	O
over-the-counter	O
(OTC)	O
nasal	O
decongestant	O
inhalers	O
United	O
States.	O

The	O
hydrogen	O
iodide	O
is	O
used	O
to	O
reduce	O
either	O
ephedrine	B-Drug
or	O
pseudoephedrine	B-Drug
methamphetamine.	O
methamphetamine	B-Drug

The	O
provisions	O
as	O
to	O
how	O
much	O
a	O
coca	B-Drug
farmer	O
can	O
yield	O
annually	O
is	O
protected	O
by	O
laws	O
such	O
the	O
Bolivian	O
Cato	O
accord.	O

Fentanyl	B-Drug
use	O
has	O
also	O
been	O
associated	O
with	O
aphasia.	O

Atropine	O
Midazolam	B-Drug
Morphine	B-Drug
Oxygen	O

4-bromo-2,5-dimethoxybenzeneethanamine	O
(2C-B)	O
2C-B	B-Drug

Furthermore,	O
phentolamine	B-Drug
is	O
rarely	O
used,	O
not	O
readily	O
available	O
in	O
many	O
emergency	O
departments,	O
and	O
present-day	O
clinicians	O
are	O
unfamiliar	O
with	O
its	O
use.	O

Nandrolone	B-Drug
has	O
strong	O
anabolic	O
effects	O
and	O
weak	O
androgenic	O
effects,	O
which	O
give	O
them	O
a	O
mild	O
side	O
effect	O
profile	O
make	O
especially	O
suitable	O
for	O
use	O
in	O
women	O
children.	O

Many	O
countries	O
either	O
banned	O
LSD	B-Drug
outright	O
or	O
made	O
it	O
extremely	O
scarce,	O
and,	O
bowing	O
to	O
governmental	O
concerns,	O
Sandoz	O
halted	O
production	O
of	O
in	O
1965.	O

The	O
introduction	O
of	O
increasingly	O
formalised	O
testing	O
procedures,	O
especially	O
with	O
the	O
creation	O
World	O
Anti-Doping	O
Agency	O
in	O
1999,	O
made	O
it	O
much	O
more	O
difficult	O
for	O
athletes	O
to	O
get	O
away	O
using	O
these	O
drugs	O
without	O
detection,	O
which	O
then	O
led	O
synthesis	O
novel	O
and	O
potent	O
anabolic	O
steroid	O
such	O
as	O
tetrahydrogestrinone	B-Drug
(THG),	O
were	O
not	O
detectable	O
by	O
standard	O
tests.	O
THG	B-Drug

As	O
a	O
DHT	O
derivative,	O
drostanolone	B-Drug
is	O
not	O
substrate	O
for	O
aromatase	O
and	O
hence	O
cannot	O
be	O
aromatized	O
into	O
estrogenic	O
metabolites.	O

The	O
new	O
drug	O
was	O
a	O
slight	O
variant	O
of	O
pethidine.	O
pethidine	B-Drug

This	O
"de-narcotized"	O
or	O
"deodorized"	O
opium	B-Drug
tincture	O
is	O
formulated	O
using	O
a	O
petroleum	O
distillate	O
to	O
remove	O
the	O
narcotine.	O
narcotine	B-Drug

Compared	O
to	O
placebo,	O
risperidone	B-Drug
treatment	O
reduces	O
certain	O
problematic	O
behaviors	O
in	O
autistic	O
children,	O
including	O
aggression	O
toward	O
others,	O
self-injury,	O
meltdowns,	O
and	O
rapid	O
mood	O
changes.	O

As	O
with	O
a	O
home	O
lab,	O
the	O
remaining	O
fumes	O
from	O
crude	O
moving	O
methamphetamine	B-Drug
lab	O
can	O
be	O
extremely	O
toxic.	O

However,	O
intravenous	O
methylphenidate	B-Drug
(Ritalin)	O
use	O
results	O
in	O
a	O
type	O
of	O
lung	O
damage	O
commonly	O
known	O
as	O
Ritalin	B-Drug
lung.	O

The	O
article	O
links	O
Raymond	O
and	O
Arthur	O
Sackler's	O
business	O
practices	O
with	O
the	O
rise	O
of	O
direct	O
pharmaceutical	O
marketing	O
eventually	O
to	O
addiction	O
oxycodone	B-Drug
in	O
United	O
States.	O

Felbamate:	O
may	O
increase	O
plasma	O
concentrations	O
of	O
valproate.	O
valproate	B-Drug

The	O
structure	O
of	O
bufotenine	B-Drug
was	O
first	O
confirmed	O
in	O
1934	O
by	O
Heinrich	O
Wielands	O
laboratory	O
Munich,	O
and	O
the	O
reported	O
synthesis	O
Toshio	O
Hoshino	O
Kenya	O
Shimodaira	O
1935.	O

The	O
main	O
component	O
of	O
cannabis	O
is	O
THC	B-Drug
formed	O
from	O
decarboxylation	O
THCA.	O

Unlike	O
bufotenin,	O
both	O
DMT	O
and	O
5-MeO-DMT	B-Drug
are	O
relatively	O
unstable	O
begin	O
to	O
degrade	O
rather	O
quickly.	O
bufotenin	B-Drug

The	O
synthetic	O
alkaloid	O
ketazocine	O
and	O
terpenoid	O
natural	O
product	O
salvinorin	B-Drug
A	I-Drug
are	O
potent	O
selective	O
KOR	O
agonists.	O

Though	O
this	O
method	O
has	O
never	O
been	O
explored	O
with	O
5-MeO-DMT,	O
it	O
used	O
successfully	O
for	O
changing	O
DET	O
into	O
4-HO-DET	B-Drug
and	O
4-PO-DET,	O
both	O
of	O
which	O
had	O
before	O
found	O
in	O
nature.	O
5-MeO-DMT	B-Drug

While	O
there	O
are	O
currently	O
no	O
effective	O
drugs	O
for	O
treating	O
amphetamine	B-Drug
addiction,	O
regularly	O
engaging	O
in	O
sustained	O
aerobic	O
exercise	O
appears	O
to	O
reduce	O
the	O
risk	O
of	O
developing	O
such	O
an	O
addiction.	O

In	O
2013,	O
the	O
Indian	O
Supreme	O
Court	O
issued	O
a	O
decision	O
rejecting	O
Novartis'	O
patent	O
application	O
in	O
India	O
on	O
final	O
form	O
of	O
Gleevec,	O
Novartis's	O
cancer	O
drug;	O
case	O
caused	O
great	O
controversy.	O
Gleevec	B-Drug

Hydrocortisone	B-Drug
(cortisol)	O
is	O
typically	O
used	O
for	O
replacement	O
therapy,	O
e.g.	O
adrenal	O
insufficiency	O
and	O
congenital	O
hyperplasia.	O

For	O
example,	O
an	O
acid	B-Drug
trip	O
is	O
a	O
psychedelic	O
experience	O
brought	O
on	O
by	O
the	O
use	O
of	O
LSD,	O
while	O
mushroom	O
psilocybin.	O
LSD	B-Drug

Fry"	O
or	O
"sherm"	O
are	O
street	O
terms	O
for	O
marijuana	O
tobacco	B-Drug
cigarettes	O
that	O
dipped	O
in	O
PCP	B-Drug
and	O
then	O
dried.	O

All	O
other	O
cannabinoids	O
(including	O
but	O
not	O
limited	O
to	O
cannabis,	O
hashish,	O
marijuana,	O
and	O
THC)	O
are	O
prohibited	O
in-competition.	O
hashish	B-Drug
THC	B-Drug

Evekeo	B-Drug
is	O
an	O
FDA-approved	O
medication	O
that	O
contains	O
racemic	O
amphetamine	B-Drug
sulfate	I-Drug
(i.e.,	O
50%	O
levoamphetamine	O
and	O
dextroamphetamine	B-Drug
sulfate).	O

Thalidomide,	O
sold	O
under	O
the	O
brand	O
names	O
Contergan	B-Drug
and	O
Thalomid	B-Drug
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
number	O
of	O
cancers	O
(including	O
multiple	O
myeloma),	O
graft-versus-host	O
disease,	O
skin	O
conditions	O
including	O
complications	O
leprosy.	O
Thalidomide	B-Drug

Several	O
factors	O
encourage	O
opium	B-Drug
production,	O
the	O
greatest	O
being	O
economic:	O
high	O
rate	O
of	O
return	O
on	O
investment	O
from	O
poppy	O
cultivation	O
has	O
driven	O
an	O
agricultural	O
shift	O
in	O
Afghanistan	O
growing	O
traditional	O
crops	O
to	O
poppy.	O

Interim	O
phase	O
III	O
trial	O
results	O
in	O
2011	O
showed	O
that	O
adding	O
everolimus	B-Drug
to	O
exemestane	B-Drug
therapy	O
against	O
advanced	O
breast	O
cancer	O
can	O
significantly	O
improve	O
progression-free	O
survival	O
compared	O
with	O
alone.	O

The	O
effects	O
of	O
psilocybin	O
and	O
MDMA	B-Drug
on	O
between-network	O
resting	O
state	O
functional	O
connectivity	O
in	O
healthy	O
volunteers.	O

Diazepam	B-Drug
is	O
marketed	O
in	O
over	O
500	O
brands	O
throughout	O
the	O
world.	O

Certain	O
NSAIDs,	O
such	O
as	O
aspirin,	O
have	O
been	O
marketed	O
in	O
enteric-coated	O
formulations	O
that	O
manufacturers	O
claim	O
reduce	O
the	O
incidence	O
of	O
gastrointestinal	O
ADRs.	O
aspirin	B-Drug

In	O
extreme	O
situations,	O
flumazenil	B-Drug
can	O
be	O
administered	O
to	O
inhibit	O
or	O
reverse	O
the	O
effects	O
of	O
midazolam.	O
midazolam	B-Drug

Spongia	O
somnifera,	O
sponges	O
soaked	O
in	O
opium,	O
were	O
used	O
during	O
surgery.	O
opium	B-Drug

In	O
2016,	O
Imodium	B-Drug
was	O
one	O
of	O
the	O
biggest-selling	O
branded	O
over-the-counter	O
medications	O
sold	O
in	O
Great	O
Britain,	O
with	O
sales	O
GB32.7	O
million.	O

Schedule	O
III	O
includes	O
barbiturate	O
products	O
with	O
fast	O
or	O
average	O
effects,	O
which	O
have	O
been	O
the	O
object	O
of	O
serious	O
abuse	O
even	O
though	O
useful	O
therapeutically,	O
strongly	O
sedative	O
benzodiazepines	O
like	O
flunitrazepam	B-Drug
and	O
some	O
analgesics	O
buprenorphine.	O
buprenorphine	B-Drug

Examples	O
are	O
brotizolam,	O
midazolam,	O
and	O
triazolam.	O
brotizolam	B-Drug
midazolam	B-Drug
triazolam	B-Drug

Metolazone	O
is	O
sometimes	O
used	O
together	O
with	O
loop	O
diuretics	O
such	O
as	O
furosemide	O
or	O
bumetanide,	O
but	O
these	O
highly	O
effective	O
combinations	O
can	O
lead	O
to	O
dehydration	O
and	O
electrolyte	O
abnormalities.	O
bumetanide	B-Drug

In	O
1953	O
and	O
1954,	O
the	O
United	O
States	O
Army	O
commissioned	O
a	O
study	O
of	O
toxicity	O
behavioral	O
effects	O
in	O
animals	O
injected	O
with	O
mescaline	B-Drug
several	O
analogues,	O
including	O
MDMA.	O
MDMA	B-Drug

cannabis	O
and	O
MDMA	B-Drug
O	O
(2001)	O

Non-hydrazines	O
Tranylcypromine	B-Drug
(Parnate,	O
Jatrosom)	O
Parnate	B-Drug

Due	O
to	O
a	O
successful	O
marketing	O
campaign,	O
thalidomide	B-Drug
was	O
widely	O
used	O
by	O
pregnant	O
women	O
during	O
the	O
first	O
trimester	O
of	O
pregnancy.	O

If	O
this	O
approach	O
fails,	O
a	O
crossover	O
to	O
benzodiazepine	O
equivalent	O
dose	O
of	O
long-acting	O
(such	O
as	O
chlordiazepoxide	B-Drug
or	O
more	O
preferably	O
diazepam)	O
can	O
be	O
tried	O
followed	O
by	O
gradual	O
reduction	O
in	O
dosage.	O
diazepam	B-Drug

Regeneron	O
and	O
Sanofi	O
were	O
allowed	O
to	O
continue	O
marketing	O
alirocumab	B-Drug
during	O
the	O
appeals	O
process.	O

The	O
attachment	O
of	O
the	O
amino	O
acid	O
lysine	O
slows	O
down	O
relative	O
amount	O
dextroamphetamine	B-Drug
available	O
to	O
blood	O
stream.	O

Cloxazolam	B-Drug
is	O
a	O
benzodiazepine	O
derivative	O
that	O
has	O
anxiolytic,	O
sedative,	O
and	O
anticonvulsant	O
properties.	O

morphine	B-Drug
Eden	O
Lake	O
(2009)	O

However,	O
some	O
sedating	O
antihistamines	O
such	O
as	O
orphenadrine	B-Drug
can	O
produce	O
a	O
synergistic	O
pain	O
relieving	O
effect	O
permitting	O
smaller	O
doses	O
of	O
opioids	O
be	O
used.	O

Amiloride	B-Drug
was	O
developed	O
in	O
1967.	O

Concurrent	O
administration	O
of	O
P-glycoprotein	O
inhibitors	O
such	O
as	O
quinidine	B-Drug
potentially	O
allows	O
loperamide	B-Drug
to	O
cross	O
the	O
bloodbrain	O
barrier	O
and	O
produce	O
central	O
morphine-like	O
effects.	O

PCP	B-Drug
is	O
classified	O
as	O
a	O
schedule	O
II	O
drug	O
in	O
the	O
United	O
States.	O

Cocaine:	O
Cocaine	B-Drug

Abbott	O
discontinued	O
their	O
Nembutal	B-Drug
brand	O
of	O
Pentobarbital	B-Drug
capsules	O
in	O
1999,	O
largely	O
replaced	O
by	O
the	O
Benzodiazepine	O
family	O
drugs.	O

Oral	O
administered	O
nalbuphine	B-Drug
is	O
reported	O
to	O
be	O
three	O
times	O
more	O
potent	O
than	O
codeine	B-Drug

Medical	O
marijuana	O
refers	O
to	O
the	O
use	O
of	O
Cannabis	O
plant	O
as	O
a	O
physician-recommended	O
herbal	O
therapy	O
well	O
synthetic	O
THC	B-Drug
and	O
cannabinoids.	O

Few	O
studies	O
have	O
examined	O
bupropion	B-Drug
(a	O
novel	O
antidepressant)	O
for	O
cocaine	O
dependence;	O
however,	O
trials	O
performed	O
thus	O
far	O
not	O
shown	O
it	O
to	O
be	O
an	O
effective	O
form	O
of	O
treatment	O
this	O
purpose.	O

Butane	O
and	O
supercritical	O
carbon	O
dioxide	O
hash	B-Drug
oil	I-Drug
have	O
become	O
popular	O
in	O
recent	O
years.	O

Tyrosine	O
can	O
follow	O
two	O
different	O
routes:	O
by	O
tyrosine	O
hydroxylase	O
it	O
form	O
L-dopamine	O
(L-DOPA),	O
or	O
be	O
reduced	O
to	O
4-phenylhydroxyacetaldehyde	O
(4-HPAA).	O
L-DOPA	B-Drug

It	O
is	O
possible	O
that	O
the	O
action	O
of	O
ibogaine	B-Drug
at	O
kappa	O
opioid	O
receptor	O
may	O
indeed	O
contribute	O
significantly	O
to	O
psychoactive	O
effects	O
attributed	O
ingestion;	O
Salvia	O
divinorum,	O
another	O
plant	O
recognized	O
for	O
its	O
strong	O
hallucinogenic	O
properties,	O
contains	O
chemical	O
salvinorin	B-Drug
A,	O
which	O
a	O
highly	O
selective	O
agonist.	O
A	I-Drug

Bortezomib	B-Drug
is	O
PyzPheboroLeu,	O
and	O
MG132	O
ZLeuLeuLeual.	O

On	O
13	O
March	O
2012,	O
Haji	O
Bagcho,	O
with	O
ties	O
to	O
the	O
Taliban,	O
was	O
convicted	O
by	O
a	O
US	O
District	O
Court	O
of	O
conspiracy,	O
distribution	O
heroin	B-Drug
for	O
importation	O
into	O
United	O
States	O
and	O
narco-terrorism.	O

The	O
number	O
of	O
clinics	O
that	O
provide	O
treatment	O
with	O
Methadone	B-Drug
or	O
Subutex	B-Drug
has	O
increased	O
from	O
one	O
clinic	O
to	O
110	O
clinics.	O

DPT	B-Drug
is	O
a	O
Class	O
A	O
drug	O
in	O
the	O
United	O
Kingdom,	O
making	O
it	O
illegal	O
to	O
possess	O
or	O
distribute	O
.	O

Cyproheptadine	B-Drug
is	O
a	O
very	O
potent	O
antihistamine	O
or	O
inverse	O
agonist	O
of	O
the	O
H1	O
receptor.	O

The	O
first	O
extended	O
research	O
into	O
GHB	B-Drug
and	O
its	O
use	O
in	O
humans	O
was	O
conducted	O
the	O
early	O
1960s	O
by	O
Dr.	O
Henri	O
Laborit	O
to	O
studying	O
neurotransmitter	O
GABA.	O

Apart	O
from	O
its	O
controversial	O
experimental	O
use	O
in	O
psychotherapy,	O
2C-B,	O
like	O
most	O
other	O
hallucinogens,	O
does	O
not	O
have	O
any	O
known	O
therapeutic	O
usefulness....	O
2C-B	B-Drug

Because	O
ibogaine	B-Drug
is	O
one	O
of	O
the	O
many	O
drugs	O
that	O
are	O
partly	O
metabolized	O
by	O
cytochrome	O
P450	O
complex,	O
caution	O
must	O
be	O
exercised	O
to	O
avoid	O
foods	O
or	O
similarly	O
CP450,	O
in	O
particular	O
containing	O
bergamottin	O
bergamot	O
oil,	O
such	O
as	O
grapefruit	O
juice.	O

Nalbuphine	B-Drug
HCL	O
is	O
currently	O
available	O
only	O
as	O
an	O
injectable	O
in	O
the	O
US	O
and	O
European	O
Union.	O

It	O
is	O
the	O
17-alkylated	O
variant	O
of	O
clostebol	B-Drug
(4-chlorotestosterone).Rahnema,	O
Crosnoe,	O
and	O
Kim	O
(2015)	O

The	O
origins	O
of	O
the	O
present	O
international	O
illegal	O
heroin	B-Drug
trade	O
can	O
be	O
traced	O
back	O
to	O
laws	O
passed	O
in	O
many	O
countries	O
early	O
1900s	O
that	O
closely	O
regulated	O
production	O
and	O
sale	O
opium	B-Drug
its	O
derivatives	O
including	O
heroin.	O

However,	O
controlled	O
studies	O
have	O
found	O
the	O
symptomatic	O
effectiveness	O
of	O
dextromethorphan	B-Drug
similar	O
to	O
placebo.	O

Comparing	O
its	O
analgesic	O
effect,	O
remifentanil	B-Drug
is	O
superior	O
to	O
morphine	B-Drug
but	O
not	O
fentanyl.	O
fentanyl	B-Drug

clorazepate,	O
diazepam,	O
flurazepam,	O
halazepam,	O
prazepam,	O
and	O
others3-hydroxy	O
compounds:	O
clorazepate	B-Drug
diazepam	B-Drug
flurazepam	B-Drug
halazepam	B-Drug
prazepam	B-Drug

UR-144	B-Drug
(TMCP-018,	O
KM-X1,	O

Morphine	B-Drug
was	O
the	O
first	O
alkaloid	O
to	O
be	O
isolated	O
from	O
any	O
medicinal	O
plant,	O
beginning	O
of	O
modern	O
scientific	O
drug	O
discovery.	O

Shulgin	O
occasionally	O
used	O
MDMA	B-Drug
for	O
relaxation,	O
referring	O
to	O
it	O
as	O
"my	O
low-calorie	O
martini",	O
and	O
gave	O
the	O
drug	O
friends,	O
researchers,	O
others	O
who	O
he	O
thought	O
could	O
benefit	O
from	O
it.	O

She	O
came	O
to	O
the	O
United	O
States	O
with	O
Contergan	B-Drug
tablets	O
she	O
had	O
brought	O
from	O
Germany	O
and	O
a	O
prescription	O
her	O
physician.	O

Black	O
tar	O
heroin	O
is	O
impure	O
diamorphine.	O
diamorphine	B-Drug

The	O
opioid	O
antagonists	O
naloxone	B-Drug
and	O
naltrexone	B-Drug
are	O
also	O
partial	O
inverse	O
agonists	O
at	O
mu	O
receptors.	O

JWH-018	B-Drug
is	O
a	O
full	O
agonist	O
of	O
both	O
the	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptors,	O
with	O
reported	O
binding	O
affinity	O
9.00	O
5.00	O
nM	O
at	O
2.94	O
2.65	O
CB2.	O

The	O
onset	O
of	O
heroin's	O
effects	O
depends	O
upon	O
the	O
route	O
administration.	O
heroin	B-Drug

Can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
StevensJohnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
Diclofenac	B-Drug
consumption	O
has	O
been	O
associated	O
with	O
significantly	O
increased	O
vascular	O
coronary	O
risk	O
in	O
a	O
study	O
including	O
coxib,	O
diclofenac,	O
ibuprofen	B-Drug
naproxen.	O
diclofenac	B-Drug
naproxen	B-Drug

Several	O
dozen	O
centres	O
exist	O
throughout	O
the	O
country	O
and	O
heroin-dependent	O
people	O
can	O
administer	O
heroin	B-Drug
in	O
a	O
controlled	O
environment	O
at	O
these	O
locations.	O

Nitrazepam	B-Drug
is	O
a	O
long-acting	O
benzodiazepine	O
with	O
an	O
elimination	O
half-life	O
of	O
1538	O
hours	O
(mean	O
26	O
hours).[1]	O
Residual	O
"hangover"	O
effects	O
after	O
nighttime	O
administration	O
nitrazepam	B-Drug
such	O
as	O
sleepiness,	O
impaired	O
psychomotor	O
and	O
cognitive	O
functions	O
may	O
persist	O
into	O
the	O
next	O
day,	O
which	O
impair	O
ability	O
users	O
to	O
drive	O
safely	O
increases	O
risk	O
falls	O
hip	O
fractures.	O

It	O
can	O
be	O
cut	O
into,	O
or	O
even	O
replace	O
entirely,	O
the	O
supply	O
of	O
heroin	B-Drug
and	O
other	O
opiates.	O

Solutions	O
of	O
sodium	O
barbital	B-Drug
have	O
also	O
been	O
used	O
as	O
pH	O
buffers	O
for	O
biological	O
research,	O
e.g.,	O
in	O
immunoelectrophoresis	O
or	O
fixative	O
solutions.	O

Clomifene	B-Drug
can	O
lead	O
to	O
multiple	O
ovulation,	O
hence	O
increasing	O
the	O
chance	O
of	O
twins	O
(10%	O
births	O
instead	O
~1%	O
in	O
general	O
population)	O
and	O
triplets.	O

The	O
creation	O
of	O
the	O
following	O
analogues	O
cocaine	B-Drug
have	O
traditionally	O
required	O
a	O
step	O
which	O
has	O
utilized	O
2-CMT	O
as	O
an	O
intermediate	O
molecular	O
product.	O

The	O
effectiveness	O
of	O
bupropion	B-Drug
is	O
comparable	O
to	O
nicotine	O
replacement	O
therapy,	O
but	O
less	O
effective	O
than	O
varenicline.	O
varenicline	B-Drug

In	O
the	O
EU,	O
bevacizumab	B-Drug
in	O
combination	O
with	O
paclitaxel	B-Drug
is	O
indicated	O
for	O
first-line	O
treatment	O
of	O
adults	O
metastatic	O
breast	O
cancer.	O

According	O
to	O
the	O
journal	O
Clinical	O
Pharmacology	O
&	O
Therapeutics,	O
vaporizing	O
cannabis	O
is	O
a	O
safe	O
and	O
more	O
effective	O
way	O
(than	O
smoking)	O
of	O
delivering	O
THC	B-Drug
patients	O
for	O
medical	O
uses.	O

Its	O
"grandfathered"	O
status	O
protects	O
opium	B-Drug
tincture	O
from	O
being	O
required	O
to	O
undergo	O
strict	O
FDA	O
drug	O
reviews	O
and	O
subsequent	O
approval	O
processes.	O

In	O
the	O
United	O
States,	O
heroin	B-Drug
is	O
not	O
accepted	O
as	O
medically	O
useful.	O

Black	O
tar	O
heroin	B-Drug
is	O
a	O
free	O
base	O
form	O
of	O
that	O
sticky	O
like	O
or	O
hard	O
coal.	O

"	O
Etizolam	B-Drug
is	O
controlled	O
in	O
Denmark	O
under	O
the	O
Danish	O
Misuse	O
of	O
Drugs	O
Act.	O

Cocaine	B-Drug
use	O
also	O
promotes	O
the	O
formation	O
of	O
blood	O
clots.	O

Major	O
metabolites	O
of	O
buspirone	B-Drug
include	O
5-hydroxybuspirone,	O
6-hydroxybuspirone,	O
8-hydroxybuspirone,	O
and	O
1-PP.	O

After	O
20	O
years	O
of	O
intermission,	O
Strassman	O
was	O
the	O
first	O
person	O
in	O
United	O
States	O
to	O
undertake	O
human	O
research	O
with	O
psychedelic,	O
hallucinogenic,	O
or	O
entheogenic	O
substances	O
his	O
on	O
N,N-dimethyltryptamine,	O
also	O
known	O
as	O
DMT.	O
N,N-dimethyltryptamine	B-Drug

"	O
In	O
the	O
US,	O
Harrison	O
Narcotics	O
Tax	O
Act	O
was	O
passed	O
in	O
1914	O
to	O
control	O
sale	O
and	O
distribution	O
of	O
diacetylmorphine	B-Drug
other	O
opioids,	O
which	O
allowed	O
drug	O
be	O
prescribed	O
sold	O
for	O
medical	O
purposes.	O

Spironolactone	B-Drug
has	O
been	O
studied	O
in	O
fibromyalgia	O
women.	O

nandrolone,	O
trenbolone,	O
norethandrolone,	O
ethylestrenol,	O
trestolone,	O
dimethandrolone	O
5-Reduction:	O
nandrolone	B-Drug
trenbolone	B-Drug
norethandrolone	B-Drug
ethylestrenol	B-Drug

Levodopa	B-Drug
a	O
systematic	O
review	O
noted	O
that	O
it	O
improved	O
verbal	O
episodic	O
memory	O
and	O
encoding.	O

Dutasteride	B-Drug
was	O
patented	O
in	O
1993	O
by	O
GlaxoSmithKline	O
and	O
approved	O
for	O
medical	O
use	O
2001.	O

Baeocystin	B-Drug
is	O
a	O
zwitterionic	O
alkaloid	O
and	O
analog	O
of	O
psilocybin.	O

JWH-398	B-Drug
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family,	O
which	O
acts	O
as	O
a	O
cannabinoid	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
receptors.	O

A	O
police	O
officer's	O
normal	O
monthly	O
wage	O
of	O
$93	O
is	O
less	O
than	O
2%	O
the	O
value	O
1	O
kilogram	O
(2.2	O
lb)	O
cocaine	B-Drug
(7000	O
or	O
$8750).	O

Androstenedione	B-Drug
has	O
been	O
shown	O
to	O
increase	O
serum	O
testosterone	O
levels	O
over	O
an	O
eight-hour	O
period	O
in	O
men	O
when	O
taken	O
as	O
a	O
single	O
oral	O
dose	O
of	O
300	O
mg	O
per	O
day,	O
but	O
100	O
had	O
no	O
significant	O
effect	O
on	O
testosterone.	O

Neither	O
of	O
these	O
tests,	O
however,	O
is	O
specific	O
for	O
psilocybin;	O
example,	O
the	O
Marquis	O
test	O
will	O
react	O
with	O
many	O
classes	O
controlled	O
drugs,	O
such	O
as	O
those	O
containing	O
primary	O
amino	O
groups	O
and	O
unsubstituted	O
benzene	O
rings,	O
including	O
amphetamine	B-Drug
methamphetamine.	O
methamphetamine	B-Drug

Dexamethasone	B-Drug
and	O
its	O
derivatives	O
are	O
almost	O
pure	O
glucocorticoids,	O
while	O
prednisone	B-Drug
have	O
some	O
mineralocorticoid	O
action	O
in	O
addition	O
to	O
the	O
glucocorticoid	O
effect.	O

Fentanyl	B-Drug
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family,	O
which	O
includes	O
sufentanil,	O
alfentanil,	O
remifentanil,	O
and	O
carfentanil.	O
sufentanil	B-Drug
alfentanil	B-Drug
remifentanil	B-Drug
carfentanil	B-Drug

Symptoms	O
developed	O
after	O
abrupt	O
withdrawal	O
of	O
chlordiazepoxide	B-Drug
and	O
persisted	O
for	O
14	O
months.	O

The	O
discovery	O
of	O
propranolol	B-Drug
was	O
hailed	O
as	O
the	O
greatest	O
breakthrough	O
in	O
treatment	O
heart	O
disease	O
since	O
digitalis.	O

In	O
addition,	O
the	O
combination	O
of	O
bicalutamide	B-Drug
with	O
other	O
medications,	O
such	O
as	O
estrogens,	O
progestogens,	O
and	O
GnRH	O
analogues,	O
can	O
compromise	O
spermatogenesis	O
due	O
to	O
their	O
own	O
adverse	O
effects	O
on	O
male	O
fertility.	O

When	O
subcommittee	O
member	O
Senator	O
Ted	O
Kennedy	O
of	O
Massachusetts	O
asked	O
Leary	O
if	O
LSD	B-Drug
usage	O
was	O
"extremely	O
dangerous,"	O
replied,	O
"Sir,	O
the	O
motor	O
car	O
is	O
dangerous	O
used	O
improperly...	O

In	O
France,	O
car	O
accidents	O
involving	O
psychotropic	O
drugs	O
in	O
combination	O
with	O
alcohol	O
(itself	O
a	O
major	O
contributor)	O
found	O
benzodiazepines,	O
mainly	O
diazepam,	O
nordiazepam,	O
and	O
bromazepam,	O
to	O
be	O
the	O
most	O
common	O
drug	O
present	O
blood	O
stream,	O
almost	O
twice	O
that	O
of	O
next-most-common	O
cannabis.	O
diazepam	B-Drug
nordiazepam	B-Drug
bromazepam	B-Drug

The	O
price	O
per	O
kilogram	O
of	O
black	O
tar	O
heroin	B-Drug
has	O
increased	O
from	O
one-tenth	O
that	O
South	O
American	O
powder	O
in	O
the	O
mid-1990s	O
to	O
between	O
one-half	O
and	O
three-quarters	O
2003	O
due	O
distributional	O
acumen	O
combined	O
with	O
demand	O
tar's	O
traditional	O
realm	O
distribution.	O

Lemmon,	O
well	O
aware	O
of	O
Quaalude's	O
public	O
image	O
problems,	O
used	O
advertisements	O
in	O
medical	O
journals	O
to	O
urge	O
physicians	O
"not	O
permit	O
the	O
abuses	O
illegal	O
users	O
deprive	O
a	O
legitimate	O
patient	O
drug".	O
Quaalude	B-Drug

In	O
1968,	O
"[d]eeply	O
concerned	O
at	O
reports	O
of	O
serious	O
damage	O
to	O
health	O
being	O
caused	O
by	O
LSD	B-Drug
and	O
similar	O
hallucinogenic	O
substances,"	O
the	O
United	O
Nations	O
Economic	O
Social	O
Council	O
(ECOSOC)	O
passed	O
a	O
resolution	O
calling	O
on	O
nations	O
limit	O
use	O
such	O
drugs	O
scientific	O
medical	O
purposes	O
impose	O
import	O
export	O
restrictions.	O

Oxycodone	B-Drug
is	O
available	O
as	O
controlled-release	O
tablet,	O
intended	O
to	O
be	O
taken	O
every	O
12	O
hours.	O

In	O
VCaP	O
cells	O
which	O
over-express	O
the	O
AR,	O
enzalutamide	B-Drug
induced	O
apoptosis	O
whereas	O
bicalutamide	B-Drug
did	O
not.	O

Drostanolone	B-Drug
propionate	I-Drug
appears	O
to	O
no	O
longer	O
be	O
marketed.	O

4-methylaminorex	B-Drug
(a	O
stimulant)	O
amongst	O
the	O
products	O
he	O
prepares	O

Phenylpiracetam	B-Drug
(INN:	O
fonturacetam,	O
brand	O
names	O
Phenotropil	O
,	O
Carphedon),	O
is	O
a	O
phenylated	O
analog	O
of	O
the	O
drug	O
piracetam.	O
Carphedon	B-Drug
piracetam	B-Drug

Beginning	O
in	O
February	O
2010,	O
addicts	O
Copenhagen	O
and	O
Odense	O
became	O
eligible	O
to	O
receive	O
free	O
diamorphine.	O
diamorphine	B-Drug

Thalidomide	B-Drug
has	O
several	O
cardiovascular	O
adverse	O
effects,	O
including	O
risk	O
of	O
heart	O
attacks,	O
pulmonary	O
hypertension,	O
and	O
changes	O
in	O
rhythm	O
syncope,	O
bradycardia,	O
atrioventricular	O
block.	O

Ivacaftor	B-Drug
does	O
not	O
bind	O
to	O
human	O
red	O
blood	O
cells.	O

As	O
with	O
other	O
mu-opioid	O
agonists,	O
tapentadol	B-Drug
may	O
cause	O
spasms	O
of	O
the	O
sphincter	O
Oddi,	O
and	O
is	O
therefore	O
discouraged	O
for	O
use	O
in	O
patients	O
biliary	O
tract	O
disease	O
such	O
as	O
both	O
acute	O
chronic	O
pancreatitis.	O

A	O
follow-up	O
paper	O
by	O
Brodie	O
and	O
Axelrod	O
in	O
1949	O
established	O
that	O
phenacetin	O
was	O
also	O
metabolized	O
to	O
paracetamol.	O
paracetamol	B-Drug

Lidocaine	B-Drug
alters	O
signal	O
conduction	O
in	O
neurons	O
by	O
prolonging	O
the	O
inactivation	O
of	O
fast	O
voltage-gated	O
Na+	O
channels	O
neuronal	O
cell	O
membrane	O
responsible	O
for	O
action	O
potential	O
propagation.	O

Thus,	O
attachment	O
of	O
a	O
phenyl-containing	O
indole	O
molecule	O
to	O
the	O
C-ring	O
naltrexone's	O
morphinan	O
base	O
successfully	O
produced	O
drug	O
with	O
high	O
receptor	O
affinity	O
naltrexone,	O
but	O
which	O
binds	O
almost	O
exclusively	O
delta	O
opioid	O
receptor.	O
naltrexone	B-Drug

Some	O
of	O
these	O
symptoms	O
are	O
also	O
common	O
to	O
acne	O
treatment	O
with	O
Isotretinoin.	O
Isotretinoin	B-Drug

GHB	B-Drug
can	O
be	O
detected	O
in	O
hair.	O

Some	O
serve	O
as	O
electron	O
acceptors	O
in	O
transport	O
chains	O
such	O
those	O
photosynthesis	O
(plastoquinone,	O
phylloquinone),	O
and	O
aerobic	O
respiration	O
(ubiquinone).	O
phylloquinone	B-Drug

Revlimid	B-Drug
is	O
available	O
only	O
in	O
a	O
restricted	O
distribution	O
setting	O
to	O
avoid	O
its	O
use	O
during	O
pregnancy.	O

Between	O
1987	O
and	O
1992,	O
illegal	O
drug	O
use	O
sales	O
were	O
permitted	O
in	O
Platzspitz	O
park,	O
Zurich,	O
an	O
attempt	O
to	O
counter	O
the	O
growing	O
heroin	B-Drug
problem.	O

Instead,	O
the	O
experiment	O
produced	O
an	O
acetylated	O
form	O
of	O
morphine	B-Drug
one	O
and	O
a	O
half	O
to	O
two	O
times	O
more	O
potent	O
than	O
itself.	O

Methylphenidate	B-Drug
appears	O
to	O
improve	O
symptoms	O
as	O
reported	O
by	O
teachers	O
and	O
parents.	O

Starting	O
with	O
4-hydroxyindole,	O
they	O
generated	O
psilocybin	O
from	O
psilocin	B-Drug
in	O
85%	O
yield,	O
a	O
marked	O
improvement	O
over	O
yields	O
reported	O
previous	O
syntheses.	O

Research	O
also	O
indicates	O
that	O
PCP	B-Drug
inhibits	O
nicotinic	O
acetylcholine	O
receptors	O
(nAChRs)	O
among	O
other	O
mechanisms.	O

According	O
to	O
the	O
U.S.	O
National	O
Center	O
for	O
Health	O
Statistics,	O
as	O
well	O
a	O
2006	O
series	O
in	O
Charleston	O
Gazette	O
(West	O
Virginia),	O
medical	O
examiners	O
listed	O
methadone	B-Drug
contributing	O
3,849	O
deaths	O
2004.	O

People	O
with	O
normal	O
vitamin	B-Drug
B12	I-Drug
levels	O
have	O
stores	O
to	O
make	O
the	O
effects	O
of	O
nitrous	O
oxide	O
insignificant,	O
unless	O
exposure	O
is	O
repeated	O
and	O
prolonged	O
(nitrous	O
abuse).	O

AM-2201	B-Drug

Methylestradiol/methyltestosterone/reserpine	O
(Klimanosid	O
R)	O
Estradiol	B-Drug
benzoate/testosterone	I-Drug
propionate	I-Drug
(	O
methyltestosterone	B-Drug

The	O
most	O
commonly	O
used	O
agents	O
are	O
long-acting	O
benzodiazepines,	O
such	O
as	O
chlordiazepoxide	B-Drug
and	O
diazepam.	O
diazepam	B-Drug

Nitrazepam	B-Drug
is	O
recommended	O
to	O
be	O
avoided	O
in	O
patients	O
who	O
drive	O
or	O
operate	O
machinery.	O

The	O
drug	O
label	O
advises	O
that	O
bupropion	B-Drug
should	O
not	O
be	O
prescribed	O
to	O
individuals	O
with	O
epilepsy	O
or	O
other	O
conditions	O
lower	O
the	O
seizure	O
threshold,	O
such	O
as	O
anorexia	O
nervosa,	O
bulimia	O
benzodiazepine	O
abuse	O
withdrawal,	O
and	O
alcohol	O
withdrawal.	O

A	O
78-week	O
study	O
of	O
alirocumab	B-Drug
in	O
2341	O
people	O
taking	O
statins	O
who	O
were	O
at	O
high	O
risk	O
for	O
cardiovascular	O
events	O
and	O
had	O
LDL	O
cholesterol	O
levels	O
was	O
published	O
April	O
2015.	O

Flumazenil	B-Drug
has	O
been	O
found	O
to	O
stimulate	O
the	O
reversal	O
of	O
tolerance	O
and	O
normalization	O
receptor	O
function.	O

Once	O
retinol	B-Drug
has	O
been	O
taken	O
up	O
by	O
a	O
cell,	O
it	O
can	O
be	O
oxidized	O
to	O
retinal	O
(retinaldehyde)	O
dehydrogenases;	O
retinaldehyde	O
then	O
retinoic	O
acid	O
dehydrogenases.	O

Dihydrocodeine	B-Drug
was	O
developed	O
during	O
the	O
search	O
for	O
more	O
effective	O
cough	O
medication,	O
especially	O
to	O
help	O
reduce	O
spread	O
of	O
tuberculosis,	O
pertussis,	O
and	O
pneumonia	O
in	O
years	O
from	O
c.a.	O
1895	O
1915.	O

Fry"	O
or	O
"sherm"	O
are	O
street	O
terms	O
for	O
marijuana	O
tobacco	B-Drug
cigarettes	O
that	O
dipped	O
in	O
PCP	B-Drug
and	O
then	O
dried.	O

In	O
2006,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
began	O
investigating	O
several	O
respiratory	O
deaths,	O
but	O
doctors	O
in	O
United	O
Kingdom	O
were	O
not	O
warned	O
of	O
risks	O
with	O
fentanyl	B-Drug
until	O
September	O
2008.	O

Medical	O
examiners	O
concluded	O
that	O
musician	O
Prince	O
died	O
on	O
April	O
21,	O
2016,	O
from	O
an	O
accidental	O
fentanyl	B-Drug
overdose.	O

Thus,	O
17,20-lyase	O
is	O
required	O
for	O
the	O
synthesis	O
of	O
androstenedione,	O
whether	O
immediately	O
or	O
one	O
step	O
removed.	O
androstenedione	B-Drug

Inversely,	O
PCP	B-Drug
can	O
have	O
more	O
unpredictable	O
effects	O
and	O
has	O
often	O
been	O
classified	O
as	O
a	O
stimulant	O
depressant	O
in	O
some	O
texts	O
along	O
with	O
being	O
dissociative.	O

Some	O
have	O
speculated	O
that	O
6-APB's	O
structure	O
qualifies	O
it	O
as	O
a	O
Schedule	O
6-APB	B-Drug

The	O
prodrug	O
lisdexamfetamine	B-Drug
is	O
not	O
as	O
sensitive	O
to	O
pH	O
amphetamine	B-Drug
when	O
being	O
absorbed	O
in	O
the	O
gastrointestinal	O
tract;	O
following	O
absorption	O
into	O
blood	O
stream,	O
it	O
converted	O
by	O
red	O
cell-associated	O
enzymes	O
dextroamphetamine	B-Drug
via	O
hydrolysis.	O

Bromazepam	B-Drug
has	O
also	O
been	O
responsible	O
for	O
accidental	O
poisonings	O
in	O
companion	O
animals.	O

Only	O
of	O
a	O
few	O
these	O
compounds	O
were	O
widely	O
used	O
including	O
rolicyclidine	B-Drug
(PCPy),	O
eticyclidine	B-Drug
(PCE),	O
and	O
tenocyclidine	B-Drug
(TCP).	O
PCE	B-Drug
TCP	B-Drug

the	O
titular	O
character	O
becomes	O
addicted	O
to	O
laudanum.	O
laudanum	B-Drug

25I-NBOMe	B-Drug
was	O
put	O
on	O
the	O
list	O
of	O
prohibited	O
substances	O
in	O
March	O
2015.	O

Among	O
anti-convulsant	O
drugs,	O
behavioural	O
disturbances	O
occur	O
most	O
frequently	O
with	O
clonazepam	B-Drug
and	O
phenobarbital.	O
phenobarbital	B-Drug

A	O
Beckley	O
Foundation/King's	O
College	O
London	O
collaboration	O
with	O
Dr	O
Paul	O
Morrison	O
at	O
the	O
Institute	O
of	O
Psychiatry	O
is	O
investigating	O
differing	O
effects	O
delta-9-tetrahydrocannabinol	B-Drug
(THC)	O
and	O
cannabidiol	B-Drug
(CBD),	O
two	O
main	O
cannabinoids	O
found	O
in	O
cannabis	O
that	O
determine	O
its	O
subjective	O
cognitive	O
effects.	O
THC	B-Drug
CBD	B-Drug

FDA	O
panels	O
considered	O
moving	O
dextromethorphan	B-Drug
to	O
prescription	O
status	O
due	O
its	O
potential	O
for	O
abuse,	O
but	O
voted	O
against	O
the	O
recommendation	O
in	O
September	O
2010,	O
citing	O
lack	O
of	O
evidence	O
that	O
making	O
it	O
prescription-only	O
would	O
curb	O
abuse.	O

One	O
of	O
Monardes	O
most	O
well-known	O
characteristics	O
was	O
his	O
affinity	O
for	O
the	O
tobacco	B-Drug
plant.	O

Drospirenone	O
differs	O
structurally	O
from	O
spironolactone	B-Drug
only	O
in	O
that	O
the	O
C7	O
acetylthio	O
substitution	O
of	O
has	O
been	O
removed	O
and	O
two	O
methylene	O
groups	O
have	O
substituted	O
at	O
C67	O
C1516	O
positions.	O

The	O
neurotoxicity	O
of	O
pethidine's	O
metabolites	O
is	O
a	O
unique	O
feature	O
pethidine	B-Drug
compared	O
to	O
other	O
opioids.	O

Since	O
the	O
late	O
1980s,	O
there	O
has	O
also	O
been	O
a	O
revival	O
of	O
hallucinogen	O
research	O
more	O
broadly,	O
which,	O
in	O
recent	O
years,	O
included	O
preclinical	O
and	O
clinical	O
studies	O
involving	O
LSD	B-Drug
other	O
compounds	O
such	O
as	O
members	O
2C	O
family	O
psilocybin.	O

The	O
remaining	O
alkaloids	O
in	O
the	O
latter	O
cultivar	O
are	O
primarily	O
narcotoline	O
and	O
noscapine.	O
noscapine	B-Drug

Because	O
these	O
areas	O
were	O
not	O
previously	O
surveyed,	O
it	O
is	O
impossible	O
to	O
determine	O
for	O
how	O
long	O
they	O
have	O
been	O
under	O
coca	B-Drug
cultivation.	O

Hyoscine	B-Drug
is	O
used	O
as	O
a	O
research	O
tool	O
to	O
study	O
memory	O
encoding.	O

The	O
medication	O
shows	O
equivalent	O
or	O
superior	O
effectiveness	O
to	O
other	O
antiandrogens	O
including	O
spironolactone,	O
cyproterone	O
acetate,	O
and	O
finasteride	B-Drug
in	O
the	O
treatment	O
of	O
hirsutism,	O
although	O
its	O
relatively	O
high	O
risk	O
hepatotoxicity	O
makes	O
it	O
unfavorable	O
compared	O
these	O
options.	O
spironolactone	B-Drug

A	O
2019	O
review	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
(which	O
included	O
PCP)	O
to	O
schizophrenia	O
was	O
26%.	O
PCP	B-Drug

The	O
antagonist	O
prevents	O
synaptic	O
dopamine	O
released	O
by	O
cathinone	B-Drug
from	O
exerting	O
its	O
effect	O
binding	O
to	O
receptors.	O

Stanozolol	B-Drug
is	O
used	O
for	O
physique-	O
and	O
performance-enhancing	O
purposes	O
by	O
competitive	O
athletes,	O
bodybuilders,	O
powerlifters.	O

Tests	O
in	O
rats	O
showed	O
alphaprodine	B-Drug
to	O
be	O
97%	O
the	O
strength	O
of	O
morphine	B-Drug
via	O
subcutaneous	O
route	O
and	O
140%	O
methadone	B-Drug
orally.	O

The	O
intraperitoneal	O
LD50	O
of	O
bufotenin	B-Drug
is	O
between	O
200300	O

Finally,	O
lysine	O
has	O
been	O
shown	O
to	O
be	O
a	O
precursor	O
for	O
carnitine,	O
which	O
transports	O
fatty	O
acids	O
the	O
mitochondria,	O
where	O
they	O
can	O
oxidised	O
release	O
of	O
energy.	O
carnitine	B-Drug

The	O
active	O
components	O
in	O
cohoba	O
responsible	O
for	O
the	O
hallucinogenic	O
effects	O
are	O
DMT	O
(N,N-dimethyltryptamine)	O
and	O
bufotenine.	O
N,N-dimethyltryptamine	B-Drug
bufotenine	B-Drug

Despite	O
all	O
of	O
this,	O
methasterone	B-Drug
has	O
resurfaced	O
within	O
the	O
supplement	O
industry	O
on	O
several	O
occasions	O
since	O
its	O
banning	O
by	O
WADA.	O

The	O
most	O
commonly	O
used	O
antiandrogens	O
for	O
these	O
indications	O
are	O
cyproterone	O
acetate	O
and	O
spironolactone.	O
spironolactone	B-Drug

Other	O
related	O
indole-containing	O
psychedelic	O
compounds	O
include	O
dimethyltryptamine,	O
found	O
in	O
many	O
plant	O
species	O
and	O
trace	O
amounts	O
some	O
mammals,	O
bufotenine,	O
the	O
skin	O
of	O
psychoactive	O
toads.	O
dimethyltryptamine	B-Drug
bufotenine	B-Drug

An	O
average	O
cigarette	O
yields	O
about	O
2	O
mg	O
of	O
absorbed	O
nicotine.	O
nicotine	B-Drug

Most	O
commercial	O
amphetamine	O
immunoassay	O
screening	O
tests	O
cross-react	O
significantly	O
with	O
MDMA	B-Drug
or	O
its	O
major	O
metabolites,	O
but	O
chromatographic	O
techniques	O
can	O
easily	O
distinguish	O
and	O
separately	O
measure	O
each	O
of	O
these	O
substances.	O

It	O
is	O
a	O
conformationally-restricted	O
derivative	O
of	O
the	O
phenethylamine	O
2C-B,	O
also	O
hallucinogen,	O
and	O
acts	O
as	O
potent	O
agonist	O
for	O
5-HT2A	O
5-HT2C	O
receptors	O
with	O
Ki	O
0.26	O
nM	O
at	O
human	O
receptor.	O
2C-B	B-Drug

The	O
bioavailability	O
of	O
intranasal	O
fentanyl	B-Drug
is	O
about	O
7090%,	O
but	O
with	O
some	O
imprecision	O
due	O
to	O
clotted	O
nostrils,	O
pharyngeal	O
swallow	O
and	O
incorrect	O
administration.	O

This	O
study	O
suggested	O
that	O
25I-NBOMe	B-Drug
is	O
approximately	O
14-fold	O
more	O
potent	O
than	O
2C-I	O
in-vivo.	O

Flurazepam,	O
similar	O
to	O
other	O
benzodiazepines	O
and	O
nonbenzodiazepine	O
hypnotic	O
drugs	O
causes	O
impairments	O
in	O
body	O
balance	O
standing	O
steadiness	O
individuals	O
who	O
wake	O
up	O
at	O
night	O
or	O
the	O
next	O
morning.	O
Flurazepam	B-Drug

6-Methylenedihydrodesoxymorphine	O
is	O
synthesised	O
in	O
two	O
steps;	O
first	O
a	O
Wittig	O
reaction	O
used,	O
reacting	O
hydrocodone	B-Drug
with	O
methylenetriphenylphosphorane	O
and	O
an	O
alkyl	O
lithium	O
reagent	O
diethyl	O
ether	O
to	O
form	O
6-Methylenedihydrodesoxycodeine.	O

Sandoz	O
Laboratories	O
introduced	O
LSD	B-Drug
as	O
a	O
psychiatric	O
drug	O
in	O
1947	O
and	O
marketed	O
panacea,	O
hailing	O
it	O
"as	O
cure	O
for	O
everything	O
from	O
schizophrenia	O
to	O
criminal	O
behavior,	O
'sexual	O
perversions,'	O
alcoholism.	O

HU-331	O
is	O
a	O
quinone	O
anticarcinogenic	O
drug	O
synthesized	O
from	O
cannabidiol,	O
cannabinoid	O
in	O
the	O
Cannabis	O
sativa	O
plant.	O
cannabidiol	B-Drug

One	O
such	O
ester,	O
boldenone	B-Drug
undecylenate,	O
was	O
introduced	O
for	O
clinical	O
use	O
as	O
an	O
injectable	O
AAS	O
under	O
the	O
brand	O
name	O
Parenabol	O
in	O
1960s.	O
undecylenate	I-Drug

For	O
example,	O
morphine	B-Drug
is	O
a	O
Class	O
A	O
drug	O
under	O
the	O
Misuse	O
of	O
Drugs	O
Act	O
1971,	O
but	O
when	O
lawfully	O
supplied	O
falls	O
category	O
Schedule	O
2	O
controlled	O
drug.	O

In	O
veterinary	O
medicine,	O
selegiline	B-Drug
is	O
sold	O
under	O
the	O
brand	O
name	O
Anipryl	B-Drug
(manufactured	O
by	O
Zoetis).	O

Studies	O
have	O
shown	O
hydrocodone	B-Drug
is	O
stronger	O
than	O
codeine	B-Drug
but	O
only	O
one-tenth	O
as	O
potent	O
morphine	B-Drug
at	O
binding	O
to	O
receptors	O
and	O
reported	O
be	O
59%	O
in	O
analgesic	O
properties.	O

There	O
is	O
also	O
evidence	O
suggesting	O
that	O
increased	O
amounts	O
of	O
dynorphin	O
can	O
protect	O
humans	O
from	O
cocaine	B-Drug
addiction.	O

Mild	O
withdrawal	O
symptoms	O
from	O
the	O
discontinuation	O
of	O
amphetamine	B-Drug
treatment	O
at	O
therapeutic	O
doses	O
can	O
be	O
avoided	O
by	O
tapering	O
dose.	O

At	O
the	O
hospital,	O
individuals	O
with	O
hydromorphone	B-Drug
overdose	O
are	O
provided	O
supportive	O
care,	O
such	O
as	O
assisted	O
ventilation	O
to	O
provide	O
oxygen	O
and	O
gut	O
decontamination	O
using	O
activated	O
charcoal	O
through	O
a	O
nasogastric	O
tube.	O

In	O
many	O
European	O
countries	O
and	O
elsewhere	O
in	O
the	O
world,	O
most	O
commonly	O
found	O
dihydrocodeine	B-Drug
preparations	O
are	O
extended-release	O
tablets	O
made	O
by	O
encasing	O
granules	O
of	O
ingredient	O
mixture,	O
almost	O
always	O
using	O
bitartrate	O
salt	O
dihydrocodeine,	O
four	O
different	O
sizes	O
a	O
wax-based	O
binder.	O

This	O
route	O
serves	O
Hezbollah	O
in	O
making	O
a	O
profit	O
the	O
cocaine	B-Drug
smuggling	O
market	O
to	O
leverage	O
it	O
for	O
terrorist	O
activities.	O

As	O
reported	O
in	O
the	O
current	O
Nubain	B-Drug
Package	O
Insert	O
(2005),	O
most	O
frequent	O
side	O
effect	O
1066	O
patients	O
treated	O
with	O
nalbuphine	B-Drug
was	O
sedation	O
381	O
(36%).	O

Clinical	O
studies	O
regarding	O
the	O
following	O
diseases	O
have	O
been	O
conducted:	O
There	O
has	O
reports	O
on	O
potential	O
re-purposing	O
of	O
leflunomide	B-Drug
for	O
treatment	O
solid	O
tumors	O
with	O
tumor	O
suppressor,	O
PTEN,	O
loss.	O

In	O
1676	O
Sydenham	O
published	O
a	O
seminal	O
work,	O
Medical	O
Observations	O
Concerning	O
the	O
History	O
and	O
Cure	O
of	O
Acute	O
Diseases,	O
in	O
which	O
he	O
promoted	O
his	O
brand	O
opium	B-Drug
tincture,	O
advocated	O
its	O
use	O
for	O
range	O
medical	O
conditions.	O

In	O
2015,	O
however,	O
case	O
reports	O
of	O
extremely	O
high-dose	O
loperamide	B-Drug
use	O
were	O
published.	O

WIN	B-Drug
55,212-2,	O
along	O
with	O
HU-210	B-Drug
and	O
JWH-133,	O
may	O
prevent	O
the	O
inflammation	O
caused	O
by	O
amyloid	O
beta	O
proteins	O
involved	O
in	O
Alzheimer's	O
disease,	O
addition	O
to	O
preventing	O
cognitive	O
impairment	O
loss	O
of	O
neuronal	O
markers.	O
55,212-2	I-Drug

Ciclesonide,	O
cortisone	O
acetate,	O
hydrocortisone	B-Drug
aceponate,	O
buteprate,	O
butyrate,	O
valerate,	O
prednicarbate,	O
and	O
tixocortol	O
pivalate.	O
Ciclesonide	B-Drug
buteprate	I-Drug

Isoniazid	B-Drug
Isoniazid/pyrazinamide/rifampicin	O
(isoniazid	O
+	O
pyrazinamide	B-Drug
rifampicin)	O
rifampicin	B-Drug
isoniazid	B-Drug

Despite	O
drastic	O
penalties	O
and	O
continued	O
prohibition	O
of	O
opium	B-Drug
until	O
1860,	O
smuggling	O
rose	O
steadily	O
from	O
200	O
chests	O
per	O
year	O
under	O
the	O
Yongzheng	O
Emperor	O
to	O
1,000	O
Qianlong	O
Emperor,	O
4,000	O
Jiaqing	O
30,000	O
Daoguang	O
Emperor.	O

The	O
human	O
trace	O
amines	O
include:	O
Phenethylamines	O
(related	O
to	O
catecholamines):	O
Phenethylamine	B-Drug
(PEA)	O
PEA	B-Drug

UR-144	B-Drug
MN-25	B-Drug

In	O
the	O
US,	O
desomorphine	B-Drug
is	O
a	O
Schedule	O
1	O
controlled	O
substance,	O
indicating	O
that	O
United	O
States	O
FDA	O
has	O
determined	O
there	O
are	O
no	O
legal	O
medicinal	O
uses	O
for	O
in	O
States.	O

Abuse	O
of	O
homemade	O
desomorphine	B-Drug
was	O
first	O
reported	O
in	O
Siberia	O
2003	O
when	O
Russia	O
started	O
a	O
major	O
crackdown	O
on	O
heroin	B-Drug
production	O
and	O
trafficking,	O
but	O
has	O
since	O
spread	O
throughout	O
the	O
neighboring	O
former	O
Soviet	O
republics.	O

The	O
half-life	O
of	O
duloxetine	B-Drug
is	O
about	O
12	O
hours	O
(range:	O
817	O
hours),	O
and	O
steady-state	O
achieved	O
after	O
3	O
days.	O

According	O
to	O
the	O
World	O
Health	O
Organization	O
there	O
is	O
little	O
evidence	O
judge	O
abuse	O
potential	O
of	O
tapentadol.	O
tapentadol	B-Drug

Several	O
clinical	O
trials	O
have	O
demonstrated	O
the	O
effect	O
of	O
octreotide	B-Drug
as	O
acute	O
treatment	O
(abortive	O
agent)	O
in	O
cluster	O
headache,	O
where	O
it	O
has	O
been	O
shown	O
that	O
administration	O
subcutaneous	O
is	O
effective	O
when	O
compared	O
with	O
placebo.	O

Selegiline	B-Drug
and	O
its	O
metabolites	O
bind	O
extensively	O
to	O
plasma	O
proteins	O
(at	O
a	O
rate	O
of	O
94%).	O

Using	O
data	O
from	O
the	O
Philippine	O
National	O
Police	O
(PNP)	O
and	O
Drug	O
Enforcement	O
Agency	O
(PDEA),	O
Robredo	O
said,	O
"In	O
spite	O
of	O
all	O
Filipinos	O
who	O
were	O
killed	O
money	O
spent	O
by	O
government,	O
we	O
only	O
seized	O
less	O
than	O
1	O
percent	O
in	O
supply	O
shabu	B-Drug
involved	O
illegal	O
drugs."	O

These	O
alkaloids	O
include,	O
among	O
others,	O
atropine,	O
cocaine,	O
scopolamine,	O
and	O
hyoscyamine.	O
cocaine	B-Drug
scopolamine	B-Drug
hyoscyamine	B-Drug

In	O
the	O
next	O
month,	O
World	O
Health	O
Organization	O
identified	O
MDMA	B-Drug
as	O
only	O
substance	O
out	O
of	O
twenty	O
phenethylamines	O
to	O
be	O
seized	O
a	O
significant	O
number	O
times.	O

Estonia	O
has	O
the	O
highest	O
rate	O
of	O
3-methylfentanyl	B-Drug
overdose	O
deaths	O
in	O
EU,	O
due	O
to	O
its	O
high	O
recreational	O
use.	O

Recent	O
research	O
has	O
used	O
data	O
on	O
2-methyl-MDA	O
and	O
5-methyl-MDA	B-Drug
to	O
help	O
guide	O
computer	O
modeling	O
of	O
the	O
serotonin	O
transporter	O
complex.	O

This	O
helps	O
avoid	O
detection	O
but	O
reduces	O
the	O
CBD	B-Drug
production	O
of	O
plant.	O

Ethylamphetamine	O
can	O
be	O
used	O
as	O
a	O
recreational	O
drug	O
and,	O
while	O
its	O
prevalence	O
is	O
less	O
than	O
amphetamine's,	O
it	O
still	O
encountered	O
substance	O
taken	O
for	O
purposes.	O
amphetamine	B-Drug

When	O
taken	O
in	O
prescribed	O
quantities,	O
cough	O
syrup	O
is	O
quite	O
safe	O
but	O
dangers	O
arise	O
higher	O
doses	O
since	O
promethazine	B-Drug
a	O
depressant	O
of	O
the	O
central	O
nervous	O
system	O
(CNS),	O
and	O
codeine	B-Drug
respiratory	O
depressant.	O

Conversely,	O
gabapentin	B-Drug
enacarbil,	O
which	O
acts	O
as	O
a	O
prodrug	O
of	O
gabapentin,	O
must	O
undergo	O
enzymatic	O
hydrolysis	O
to	O
become	O
active.	O
enacarbil	I-Drug

Diamorphine	B-Drug
continues	O
to	O
be	O
widely	O
used	O
in	O
palliative	O
care	O
the	O
UK,	O
where	O
it	O
is	O
commonly	O
given	O
by	O
subcutaneous	O
route,	O
often	O
via	O
a	O
syringe	O
driver	O
if	O
patients	O
cannot	O
easily	O
swallow	O
morphine	B-Drug
solution.	O

Previously,	O
an	O
extended-release	O
version	O
of	O
hydromorphone,	O
Palladone,	O
was	O
available	O
before	O
being	O
voluntarily	O
withdrawn	O
from	O
the	O
market	O
after	O
a	O
July	O
2005	O
FDA	O
advisory	O
warned	O
high	O
overdose	O
potential	O
when	O
taken	O
with	O
alcohol.	O
hydromorphone	B-Drug
Palladone	B-Drug

In	O
addition	O
to	O
this	O
cocaine	B-Drug
has	O
some	O
target	O
binding	O
the	O
site	O
of	O
Kappa-opioid	O
receptor	O
as	O
well.	O

MDMA	B-Drug
may	O
have	O
been	O
in	O
non-medical	O
use	O
the	O
western	O
United	O
States	O
1968.	O

Fentanyl	B-Drug
was	O
among	O
many	O
substances	O
identified	O
in	O
counterfeit	O
pills	O
recovered	O
from	O
his	O
home,	O
especially	O
some	O
that	O
were	O
mislabeled	O
as	O
Watson	O
385,	O
a	O
combination	O
of	O
hydrocodone	B-Drug
and	O
paracetamol.	O
paracetamol	B-Drug

Pegasys,	O
(peginterferon	O
alfa-2a)	O
for	O
hepatitis	O
B	O
and	O
C.	O
Perjeta	B-Drug
(pertuzumab),	O
HER-2	O
positive	O
breast	O
cancer.	O
peginterferon	B-Drug
alfa-2a	I-Drug
pertuzumab	B-Drug

In	O
the	O
United	O
States,	O
ibogaine	B-Drug
is	O
classified	O
by	O
Controlled	O
Substances	O
Act	O
on	O
list	O
of	O
schedule	O
I	O
drugs,	O
although	O
plant	O
itself	O
remains	O
unscheduled.	O

These	O
results	O
suggest	O
that	O
PCP	B-Drug
is	O
a	O
highly	O
selective	O
ligand	O
of	O
the	O
NMDAR	O
and	O
2	O
receptor.	O

AMB-CHMINACA	B-Drug
is	O
listed	O
in	O
the	O
Fifth	O
Schedule	O
of	O
Misuse	O
Drugs	O
Act	O
(MDA)	O
and	O
therefore	O
illegal	O
Singapore	O
as	O

People	O
who	O
metabolize	O
methadone	B-Drug
rapidly,	O
on	O
the	O
other	O
hand,	O
may	O
require	O
twice	O
daily	O
dosing	O
to	O
obtain	O
sufficient	O
symptom	O
alleviation	O
while	O
avoiding	O
excessive	O
peaks	O
and	O
troughs	O
in	O
their	O
blood	O
concentrations	O
associated	O
effects.	O

According	O
to	O
the	O
United	O
Nations	O
Office	O
on	O
Drugs	O
and	O
Crime	O
(UNODC),	O
"the	O
amount	O
of	O
THC	B-Drug
present	O
in	O
a	O
cannabis	O
sample	O
is	O
generally	O
used	O
as	O
measure	O
potency.	O

Risperidone	B-Drug
is	O
effective	O
in	O
treating	O
the	O
acute	O
exacerbations	O
of	O
schizophrenia.	O

Modafinil	B-Drug
is	O
the	O
primary	O
metabolite	O
of	O
adrafinil,	O
lacking	O
polar	O
-OH	O
group	O
on	O
its	O
terminal	O
amide,	O
and	O
has	O
similar	O
activity	O
to	O
parent	O
drug	O
but	O
much	O
more	O
widely	O
used.	O
adrafinil	B-Drug

Naloxone	B-Drug
can	O
be	O
used	O
on	O
infants	O
who	O
were	O
exposed	O
to	O
intrauterine	O
opiates	O
administered	O
mothers	O
during	O
delivery.	O

In	O
a	O
1987	O
study	O
by	O
the	O
International	O
Conference	O
of	O
Symphony	O
and	O
Opera	O
Musicians,	O
it	O
was	O
shown	O
that	O
27%	O
interviewed	O
members	O
admitted	O
to	O
using	O
beta	O
blockers	O
such	O
as	O
propranolol	B-Drug
for	O
musical	O
performances.	O

The	O
law	O
allows	O
only	O
physicians,	O
dentists,	O
and	O
veterinarians	O
to	O
prescribe	O
oxycodone	B-Drug
the	O
federal	O
government	O
regulate	O
prescriptions	O
(e.g.,	O
by	O
requiring	O
reporting).	O

Cocaine	B-Drug
is	O
smoked	O
by	O
inhaling	O
the	O
vapor	O
produced	O
when	O
solid	O
cocaine	B-Drug
heated	O
to	O
point	O
that	O
it	O
sublimates.	O

In	O
the	O
United	O
States	O
where	O
patches	O
cannot	O
always	O
be	O
returned	O
through	O
a	O
medication	O
take-back	O
program,	O
flushing	O
is	O
recommended	O
for	O
fentanyl	B-Drug
because	O
it	O
fastest	O
and	O
surest	O
way	O
to	O
remove	O
them	O
from	O
home	O
prevent	O
ingestion	O
by	O
children,	O
pets	O
or	O
others	O
not	O
intended	O
use	O
them.	O

Non-medical	O
use	O
of	O
fentanyl	B-Drug
by	O
individuals	O
without	O
opiate	O
tolerance	O
can	O
be	O
very	O
dangerous	O
and	O
has	O
resulted	O
in	O
numerous	O
deaths.	O

In	O
1999,	O
Burma,	O
the	O
heartland	O
of	O
Golden	O
Triangle,	O
was	O
second-largest	O
producer	O
heroin,	O
after	O
Afghanistan.	O
heroin	B-Drug

The	O
best-selling	O
drug	O
ever,	O
Lipitor,	O
averaged	O
$13	O
billion	O
annually	O
and	O
netted	O
$141	O
total	O
over	O
its	O
lifetime	O
before	O
Pfizer's	O
patent	O
expired	O
in	O
November	O
2011.	O
Lipitor	B-Drug

A	O
loss	O
of	O
ability	O
to	O
activate	O
the	O
AR	O
is	O
also	O
seen	O
with	O
other	O
testosterone	O
derivatives	O
extended-length	O
C17	O
substitutions	O
such	O
as	O
topterone	O
(propyltestosterone)	O
(compare	O
AAS	O
ethyltestosterone	O
and	O
methyltestosterone)	O
allylestrenol	O
ethylestrenol).	O
methyltestosterone	B-Drug
ethylestrenol	B-Drug

For	O
comparison,	O
the	O
average	O
blood	O
morphine	B-Drug
concentration	O
resulting	O
from	O
deadly	O
overdoses	O
involving	O
only	O
heroin	B-Drug
is	O
around	O
0.34	O
mg/	O

Because	O
of	O
the	O
extremely	O
high	O
strength	O
pure	O
fentanyl	B-Drug
powder,	O
it	O
is	O
very	O
difficult	O
to	O
dilute	O
appropriately,	O
and	O
often	O
resulting	O
mixture	O
may	O
be	O
far	O
too	O
strong	O
and,	O
therefore,	O
dangerous.	O

He	O
mentioned	O
a	O
90-day	O
study	O
of	O
chlordiazepoxide,	O
which	O
concluded	O
that	O
the	O
automobile	O
accident	O
rate	O
among	O
68	O
users	O
was	O
10	O
times	O
higher	O
than	O
normal.	O
chlordiazepoxide	B-Drug

amphetamines,	O
painkillers,	O
cannabis,	O
MDMA	B-Drug

In	O
U.S.	O
markets,	O
naproxen	B-Drug
is	O
sold	O
with	O
boxed	O
warnings	O
about	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
or	O
bleeding.	O

An	O
exception	O
to	O
this	O
is	O
when	O
a	O
medication	O
required	O
intramuscular	O
in	O
which	O
case	O
either	O
lorazepam	B-Drug
or	O
midazolam	B-Drug
recommended.	O

Overdose	O
is	O
commonly	O
broken	O
into	O
two	O
categories	O
-	O
liver	O
toxicity	O
(from	O
paracetamol	O
poisoning)	O
and	O
dextropropoxyphene	B-Drug
overdose.	O

Isomethadone	B-Drug
is	O
also	O
regulated	O
internationally	O
as	O
a	O
Schedule	O

Estradiol	O
benzoate/gentamicin/hydrocortisone/nystatin	O
(Cridermol	O
Fem,	O
Ginabiot,	O
Ginecovan)	O
hydrocortisone	B-Drug

Availability	O
of	O
fluoxymesterone	B-Drug
aside	O
from	O
the	O
United	O
States	O
remains	O
scarce,	O
but	O
it	O
is	O
marketed	O
in	O
some	O
other	O
countries	O
such	O
as	O
Mexico,	O
Moldova,	O
and	O
Taiwan.	O

One	O
study	O
has	O
shown	O
that	O
THC	B-Drug
does	O
not	O
readily	O
deposit	O
inside	O
epithelial	O
cells	O
so	O
it	O
is	O
possible	O
for	O
cosmetic	O
and	O
other	O
forms	O
of	O
adulteration	O
to	O
reduce	O
the	O
amount	O
testable	O
cannabinoids	O
within	O
a	O
hair	O
sample.	O

Dutasteride	B-Drug
is	O
sold	O
primarily	O
under	O
the	O
brand	O
name	O
Avodart	B-Drug
and,	O
in	O
combination	O
with	O
tamsulosin	B-Drug
(see	O
dutasteride/tamsulosin),	O
names	O
Combodart	O
and	O
Duodart.	O
dutasteride	B-Drug

It	O
is	O
listed	O
under	O
the	O
Single	O
Convention	O
for	O
Control	O
of	O
Narcotic	O
Substances	O
1961	O
and	O
controlled	O
in	O
most	O
countries	O
same	O
fashion	O
as	O
morphine.	O
morphine	B-Drug

Studies	O
on	O
rats	O
indicate	O
that	O
PCP	B-Drug
interacts	O
indirectly	O
with	O
opioid	O
receptors	O
(endorphin	O
and	O
enkephalin)	O
to	O
produce	O
analgesia.	O

In	O
Hong	O
Kong,	O
dihydrocodeine	B-Drug
is	O
regulated	O
under	O
Schedule	O
1	O
of	O
Kong's	O
Chapter	O
134	O
Dangerous	O
Drugs	O
Ordinance.	O

NPP	O
is	O
a	O
nandrolone	B-Drug
ester	O
and	O
long-lasting	O
prodrug	O
of	O
in	O
the	O
body.	O

According	O
to	O
the	O
US	O
Department	O
of	O
Labor's	O
2014	O
List	O
Goods	O
Produced	O
by	O
Child	O
Labor	O
or	O
Forced	O
Labor,	O
opium	B-Drug
production	O
is	O
one	O
sectors	O
that	O
rely	O
on	O
child	O
labor	O
in	O
Afghanistan.	O

Women	O
who	O
are	O
administered	O
oxandrolone	B-Drug
may	O
experience	O
virilization,	O
irreversible	O
development	O
of	O
masculine	O
features	O
such	O
as	O
voice	O
deepening,	O
hirsutism,	O
menstruation	O
abnormalities,	O
male-pattern	O
hair	O
loss,	O
and	O
clitoral	O
enlargement.	O

Flumazenil	B-Drug
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
reducing	O
feelings	O
of	O
hostility	O
and	O
aggression	O
patients	O
who	O
had	O
been	O
free	O
benzodiazepines	O
for	O
4266	O
weeks.	O

Trenbolone	O
acetate	O
is	O
an	O
androgen	O
ester	O
and	O
a	O
long-lasting	O
prodrug	O
of	O
trenbolone	B-Drug
in	O
the	O
body.	O

Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
respiratory	O
depression	O
are:	O
High	O
fentanyl	B-Drug
doses	O

These	O
drugs	O
include	O
the	O
steroidal	O
antiandrogens	O
cyproterone	O
acetate,	O
megestrol	O
chlormadinone	O
spironolactone,	O
oxendolone,	O
and	O
osaterone	O
acetate	O
(veterinary)	O
nonsteroidal	O
flutamide,	O
bicalutamide,	O
nilutamide,	O
topilutamide,	O
enzalutamide,	O
apalutamide.	O
spironolactone	B-Drug
bicalutamide	B-Drug
enzalutamide	B-Drug
apalutamide	B-Drug

Finasteride	B-Drug
causes	O
short-term	O
sexual	O
dysfunction	O
in	O
some	O
men,	O
which	O
may	O
persist	O
men	O
after	O
stopping	O
the	O
medication.	O

Based	O
on	O
the	O
recommendation	O
of	O
EACD,	O
New	O
Zealand	O
government	O
has	O
passed	O
legislation	O
which	O
placed	O
BZP,	O
along	O
with	O
other	O
piperazine	O
derivatives	O
TFMPP,	O
mCPP,	O
pFPP,	O
MeOPP	B-Drug
and	O
MBZP,	O
into	O
Class	O
C	O
Misuse	O
Drugs	O
Act	O
1975.	O
BZP	B-Drug
TFMPP	B-Drug
mCPP	B-Drug
pFPP	B-Drug

Loperamide	B-Drug
is	O
an	O
antidiarrheal	O
agent,	O
which	O
decreases	O
intestinal	O
movement.	O

2CBCB-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
Vermont	O
as	O
of	O
January	O
2016.	O

Mesterolone	B-Drug
is	O
used	O
in	O
the	O
treatment	O
of	O
androgen	O
deficiency	O
male	O
hypogonadism,	O
anemia,	O
and	O
to	O
support	O
fertility	O
among	O
other	O
indications.	O

He	O
wrote	O
of	O
his	O
discovery:	O
"Here	O
is	O
a	O
new	O
substance	O
found	O
in	O
opium	B-Drug
...	O

The	O
most	O
common	O
side	O
effects	O
reported	O
with	O
naltrexone	B-Drug
are	O
gastrointestinal	O
complaints	O
such	O
as	O
diarrhea	O
and	O
abdominal	O
cramping.	O

Due	O
to	O
the	O
potential	O
for	O
stunted	O
growth,	O
USFDA	O
advises	O
monitoring	O
height	O
and	O
weight	O
of	O
children	O
adolescents	O
prescribed	O
amphetamines.	O
amphetamines	B-Drug

Finasteride	B-Drug
may	O
improve	O
the	O
symptoms	O
associated	O
with	O
BPH	O
such	O
as	O
difficulty	O
urinating,	O
getting	O
up	O
during	O
night	O
to	O
urinate,	O
hesitation	O
at	O
start	O
and	O
end	O
of	O
urination,	O
decreased	O
urinary	O
flow.	O

Hashish	B-Drug
can	O
also	O
contain	O
appreciable	O
amounts	O
of	O
CBD,	O
CBN	O
and	O
trace	O
other	O
cannabinoidsAs	O
mentioned	O
above,	O
there	O
has	O
been	O
a	O
general	O
increase	O
in	O
potency	O
as	O
the	O
competition	O
grown	O
bigger	O
new	O
hybrid	O
plants	O
have	O
developed.	O
CBD	B-Drug

Clonazepam,	O
when	O
used	O
late	O
in	O
pregnancy,	O
may	O
result	O
the	O
development	O
of	O
a	O
severe	O
benzodiazepine	O
withdrawal	O
syndrome	O
neonate.	O
Clonazepam	B-Drug

Early	O
CIA	O
efforts	O
focused	O
on	O
LSD-25,	O
which	O
later	O
came	O
to	O
dominate	O
many	O
of	O
MKUltra's	O
programs.	O
LSD-25	B-Drug

Due	O
to	O
its	O
potency	O
and	O
much	O
lower	O
cost	O
than	O
so-called	O
classical	O
or	O
traditional	O
psychedelics,	O
25I-NBOMe	B-Drug
blotters	O
are	O
sometimes	O
misrepresented	O
as,	O
mistaken	O
for,	O
LSD	B-Drug
blotters.	O

Researchers	O
at	O
Chemie	O
Grnenthal	O
found	O
that	O
thalidomide	B-Drug
was	O
a	O
particularly	O
effective	O
antiemetic	O
had	O
an	O
inhibitory	O
effect	O
on	O
morning	O
sickness.	O

The	O
closely	O
related	O
medication,	O
methylnaltrexone,	O
is	O
used	O
to	O
treat	O
opioid-induced	O
constipation,	O
but	O
does	O
not	O
addiction	O
as	O
it	O
cross	O
the	O
bloodbrain	O
barrier.	O
methylnaltrexone	B-Drug

Other	O
metabolites	O
detected	O
were	O
lorazepam	B-Drug
and	O
lormetazepam	B-Drug
which	O
detectable	O
in	O
urine	O
for	O
19	O
11	O
days,	O
respectively,	O
indicating	O
hydroxylation	O
by	O
cytochrome	O
P450	O
enzymes	O
occurring	O
concurrently	O
with	O
N-demethylation.	O

In	O
addition,	O
a	O
phase	O
II	O
trial	O
began	O
in	O
March	O
2011	O
comparing	O
enzalutamide	B-Drug
with	O
bicalutamide	B-Drug
prostate	O
cancer	O
patients	O
who	O
have	O
progressed	O
while	O
on	O

In	O
the	O
United	O
States,	O
mescaline	B-Drug
was	O
made	O
illegal	O
in	O
1970	O
by	O
Comprehensive	O
Drug	O
Abuse	O
Prevention	O
and	O
Control	O
Act,	O
categorized	O
as	O
a	O
Schedule	O
I	O
hallucinogen.	O

Fentanyl	B-Drug
(and	O
all	O
its	O
analogues,	O
i.e.	O
alphamethylfentanyl	B-Drug
(	O

Less	O
frequently,	O
in	O
3-10%	O
of	O
people,	O
fentanyl	B-Drug
can	O
cause	O
abdominal	O
pain,	O
headache,	O
fatigue,	O
anorexia	O
and	O
weight	O
loss,	O
dizziness,	O
nervousness,	O
hallucinations,	O
anxiety,	O
depression,	O
flu-like	O
symptoms,	O
dyspepsia	O
(indigestion),	O
shortness	O
breath,	O
hypoventilation,	O
apnoea,	O
urinary	O
retention.	O

Ketamine	B-Drug
may	O
also	O
decrease	O
suicidal	O
thoughts	O
for	O
up	O
to	O
three	O
days	O
after	O
the	O
injection.	O

The	O
volume	O
of	O
distribution	O
dienogest	B-Drug
is	O
relatively	O
low	O
at	O
40	O
L.Dienogest	O
metabolized	O
in	O
the	O
liver.	O

On	O
1	O
August	O
2013,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
issued	O
a	O
warning	O
about	O
paracetamol.	O
paracetamol	B-Drug

In	O
addition	O
to	O
its	O
well	O
explored	O
interactions	O
with	O
NMDA	O
receptors,	O
PCP	B-Drug
has	O
also	O
been	O
shown	O
inhibit	O
dopamine	O
reuptake,	O
and	O
thereby	O
leads	O
increased	O
extracellular	O
levels	O
of	O
hence	O
dopaminergic	O
neurotransmission.	O

The	O
so-called	O
"magical	O
half-dozen"	O
refers	O
to	O
Shulgin's	O
self-rated	O
most	O
important	O
phenethylamine	B-Drug
compounds,	O
all	O
of	O
which	O
except	O
mescaline	B-Drug
he	O
developed	O
and	O
synthesized	O
himself.	O

Dr.	O
Oscar	O
Janiger	O
was	O
one	O
of	O
the	O
pioneers	O
in	O
field	O
studying	O
relationship	O
between	O
LSD	B-Drug
and	O
creativity.	O

Ranitidine	B-Drug
may	O
have	O
an	O
anti-emetic	O
effect	O
when	O
administered	O
preoperatively.	O

Nandrolone	B-Drug
esters	O
were	O
first	O
described	O
and	O
introduced	O
for	O
medical	O
use	O
in	O
the	O
late	O
1950s.	O

The	O
use	O
of	O
tobacco	B-Drug
is	O
an	O
individual	O
decision,	O
it	O
yet	O
strongly	O
frowned	O
on	O
but	O
not	O
explicitly	O
forbidden.	O

Clenbuterol	B-Drug
is	O
administered	O
as	O
an	O
aerosol	O
for	O
the	O
treatment	O
of	O
allergic	O
respiratory	O
disease	O
in	O
horses	O
a	O
bronchodilator,	O
and	O
intravenously	O
cattle	O
to	O
relax	O
uterus	O
cows	O
at	O
time	O
parturition,	O
specifically	O
facilitate	O
exteriorisation	O
during	O
Caesarian	O
section	O
surgery.	O

As	O
a	O
prodrug,	O
psilocybin	O
is	O
quickly	O
converted	O
by	O
the	O
body	O
to	O
psilocin,	O
which	O
has	O
mind-altering	O
effects	O
similar,	O
in	O
some	O
aspects,	O
those	O
of	O
LSD,	O
mescaline,	O
and	O
DMT.	O
psilocin	B-Drug
LSD	B-Drug
mescaline	B-Drug

In	O
premenopausal	O
women,	O
the	O
adrenal	O
glands	O
and	O
ovaries	O
each	O
produce	O
about	O
half	O
of	O
total	O
androstenedione	B-Drug
(about	O
3	O
mg/day).	O

Simethicone	B-Drug
is	O
not	O
absorbed	O
from	O
the	O
gastrointestinal	O
tract	O
so	O
there	O
are	O
no	O
systemic	O
side	O
effects.	O

It	O
is	O
thought	O
that	O
the	O
hallucinogenic	O
and	O
dysphoric	O
effects	O
of	O
opioids	O
such	O
as	O
butorphanol,	O
nalbuphine,	O
pentazocine	B-Drug
serve	O
to	O
limit	O
their	O
abuse	O
potential.	O
butorphanol	B-Drug
nalbuphine	B-Drug

As	O
such,	O
its	O
pharmacological	O
activity	O
is	O
essentially	O
identical	O
to	O
that	O
of	O
norethisterone.	O
norethisterone	B-Drug

Both	O
were	O
developed	O
in	O
Austria	O
the	O
1920s	O
along	O
with	O
other	O
derivatives	O
of	O
strong	O
dihydromorphinones	O
and	O
these	O
drugs	O
are	O
generated	O
by	O
reacting	O
oxymorphone	B-Drug
either	O
acetic	O
anhydride	O
or	O
acetyl	O
chloride	O
at	O
various	O
temperatures	O
80-160	O
C	O
for	O
several	O
hours;	O
3,6,14-triacetyloxymorphone	O
may	O
be	O
more	O
easily	O
made	O
when	O
a	O
catalyst	O
is	O
used	O
but	O
elevated	O
pressure	O
reaction	O
vacuo	O
under	O
nitrogen	O
noble	O
gas	O
atmosphere	O
not	O
required.	O

Hoffmann	O
was	O
working	O
at	O
Bayer	O
pharmaceutical	O
company	O
in	O
Elberfeld,	O
Germany,	O
and	O
his	O
supervisor	O
Heinrich	O
Dreser	O
instructed	O
him	O
to	O
acetylate	O
morphine	B-Drug
with	O
the	O
objective	O
of	O
producing	O
codeine,	O
a	O
constituent	O
opium	O
poppy	O
that	O
is	O
pharmacologically	O
similar	O
but	O
less	O
potent	O
addictive.	O
codeine	B-Drug

In	O
the	O
United	O
States,	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
approved	O
ciclosporin	B-Drug
for	O
clinical	O
use	O
in	O
1983.	O

In	O
1992,	O
Eric	O
Taub	O
brought	O
ibogaine	B-Drug
to	O
an	O
offshore	O
location	O
close	O
the	O
United	O
States,	O
where	O
he	O
began	O
providing	O
treatments	O
and	O
popularizing	O
its	O
use.	O

THC	B-Drug
and	O
its	O
major	O
(inactive)	O
metabolite,	O
THC-COOH,	O
can	O
be	O
measured	O
in	O
blood,	O
urine,	O
hair,	O
oral	O
fluid	O
or	O
sweat	O
using	O
chromatographic	O
techniques	O
as	O
part	O
of	O
a	O
drug	O
use	O
testing	O
program	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
offense.	O

The	O
weakness	O
of	O
the	O
government	O
in	O
China	O
and	O
conditions	O
civil	O
war	O
enabled	O
heroin	B-Drug
production	O
to	O
take	O
root	O
there.	O

It	O
is	O
not	O
clear	O
whether	O
ketamine	B-Drug
alone	O
sufficient	O
for	O
the	O
antidepressive	O
action	O
or	O
its	O
metabolites	O
are	O
also	O
important.	O

Phenobarbital	B-Drug
is	O
sometimes	O
used	O
for	O
alcohol	O
detoxification	O
and	O
benzodiazepine	O
its	O
sedative	O
anti-convulsant	O
properties.	O

Fentanyl	B-Drug
is	O
used	O
orally,	O
smoked,	O
snorted,	O
or	O
injected.	O

As	O
of	O
the	O
end	O
2011,	O
seizure	O
operations	O
Colombian	O
cocaine	B-Drug
carried	O
out	O
in	O
different	O
countries	O
have	O
totaled	O
351.8	O
metric	O
tons	O
cocaine,	O
i.e.	O
121.3%	O
Colombia's	O
annual	O
production	O
according	O
to	O
U.S.	O
Department	O
State's	O
estimates.	O

In	O
the	O
US,	O
ketorolac	B-Drug
is	O
only	O
widely	O
available	O
intravenous	O
NSAID.	O

Combined	O
birth	O
control	O
pills	O
containing	O
different	O
progestins	O
result	O
in	O
SHBG	O
levels	O
that	O
are	O
increased	O
1.5-	O
to	O
2-fold	O
with	O
levonorgestrel,	O
2.5-	O
4-fold	O
desogestrel	B-Drug
and	O
gestodene,	O
3.5-	O
drospirenone	O
dienogest,	O
4-	O
5-fold	O
cyproterone	O
acetate.	O
levonorgestrel	B-Drug
dienogest	B-Drug

According	O
to	O
DSM-V	O
criteria,	O
9%	O
of	O
those	O
who	O
are	O
exposed	O
cannabis	O
develop	O
use	O
disorder,	O
compared	O
20%	O
for	O
cocaine,	O
23%	O
alcohol	O
and	O
68%	O
nicotine.	O
cocaine	B-Drug
nicotine	B-Drug

The	O
widespread	O
use	O
of	O
fentanyl	B-Drug
triggered	O
the	O
production	O
citrate	O
(the	O
salt	O
formed	O
by	O
combining	O
and	O
citric	O
acid	O
in	O
a	O
1:1	O
stoichiometric	O
ratio).	O

6-Naltrexol,	O
or	O
6-hydroxynaltrexone,	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
naltrexone	B-Drug
formed	O
by	O
hepatic	O
dihydrodiol	O
dehydrogenase	O
which	O
acts	O
as	O
potent,	O
peripherally	O
selective	O
opioid	O
neutral	O
antagonist.	O

This	O
was	O
championed	O
in	O
parliament	O
by	O
Deputy	O
Minister	O
of	O
Agriculture	O
Joe	O
Manduwa	O
who	O
argued	O
that	O
the	O
plant	O
could	O
be	O
a	O
valuable	O
alternative	O
to	O
tobacco.	O
tobacco	B-Drug

Brands	O
as	O
of	O
that	O
date	O
for	O
the	O
combination	O
with	O
chlordiazepoxide	B-Drug
included	O
Amicon	O
Forte,	O
Amitrac-CZ,	O
Amypres-C,	O
Antalin,	O
Antalin	O
Arpidox-CP,	O
Axeptyl,	O
Diapatol,	O
Diaztric-A,	O
Emotrip,	O
Klotriptyl,	O
Libotryp,	O
Limbatril,	O
Limbitrol,	O
Limbitryl,	O
Limbival,	O
Limbritol,	O
Maxitrip-CZ,	O
Mitryp	O
Morelin,	O
Ristryl,	O
and	O
Sedans.	O
Limbitrol	B-Drug

Yet	O
despite	O
lurid	O
literary	O
accounts	O
to	O
the	O
contrary,	O
19th-century	O
London	O
was	O
not	O
a	O
hotbed	O
of	O
opium	B-Drug
smoking.	O

Recent	O
enforcement	O
action	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
against	O
manufacturers	O
of	O
paregoric	O
opium	B-Drug
tincture	O
suggests	O
that	O
tincture's	O
availability	O
in	O
may	O
be	O
jeopardy.	O

Some	O
people	O
might	O
define	O
narcotics	O
as	O
substances	O
that	O
bind	O
at	O
opioid	O
receptors	O
(cellular	O
membrane	O
proteins	O
activated	O
by	O
like	O
heroin	B-Drug
or	O
morphine),	O
while	O
others	O
refer	O
to	O
any	O
illicit	O
substance	O
a	O
narcotic.	O
morphine	B-Drug

Traffickers	O
take	O
advantage	O
of	O
expanding	O
port	O
facilities	O
in	O
northeast	O
cities,	O
such	O
as	O
Qingdao,	O
Shanghai,	O
and	O
Tianjin,	O
to	O
ship	O
heroin	B-Drug
via	O
maritime	O
routes.	O

The	O
2017	O
clinical	O
practice	O
guidelines	O
of	O
the	O
American	O
College	O
Cardiology/American	O
Heart	O
Association	O
Task	O
Force	O
on	O
Clinical	O
Practice	O
Guidelines	O
list	O
amiloride	B-Drug
as	O
a	O
"secondary"	O
oral	O
antihypertensive,	O
with	O
minimal	O
efficacy.	O

The	O
remaining	O
three	O
formulas	O
are	O
copied	O
from	O
an	O
1890	O
publication	O
of	O
the	O
day:	O
Sydenham's	O
Laudanum:	O
"	O
Laudanum	B-Drug

As	O
such,	O
single	O
doses	O
of	O
injectable	O
ondansetron	B-Drug
should	O
not	O
exceed	O
16	O
mg	O
at	O
one	O
time.	O

It	O
is	O
also	O
unclear	O
if	O
this	O
medication	O
safe	O
among	O
people	O
with	O
a	O
history	O
of	O
addiction,	O
as	O
they	O
were	O
excluded	O
from	O
the	O
clinical	O
trials	O
suvorexant.	O
suvorexant	B-Drug

At	O
5	O
M	O
WIN	B-Drug
55,212-2	I-Drug
inhibits	O
ATP	O
production	O
in	O
sperm	O
a	O
CB1	O
receptor-dependent	O
fashion.	O

The	O
counterfeit	O
Avastin	B-Drug
has	O
been	O
traced	O
back	O
to	O
Egypt,	O
and	O
it	O
entered	O
legitimate	O
supply	O
chains	O
via	O
Europe	O
the	O
United	O
States.	O

Phenethylamine	B-Drug
(PEA)	O
is	O
an	O
organic	O
compound,	O
natural	O
monoamine	O
alkaloid,	O
and	O
trace	O
amine,	O
which	O
acts	O
as	O
a	O
central	O
nervous	O
system	O
stimulant	O
in	O
humans.	O
PEA	B-Drug

The	O
BBC	O
series	O
Panorama	O
featured	O
an	O
episode	O
titled	O
"Temazepam	O
Wars",	O
dealing	O
with	O
the	O
epidemic	O
of	O
temazepam	B-Drug
abuse	O
and	O
directly	O
related	O
crime	O
in	O
Paisley,	O
Scotland.	O
Temazepam	B-Drug

There	O
was	O
a	O
28%	O
increase	O
from	O
the	O
amount	O
of	O
potentially	O
harvestable	O
coca	B-Drug
plants	O
which	O
were	O
grown	O
in	O
Colombia	O
1998.	O

Some	O
bodybuilders	O
and	O
athletes	O
use	O
trenbolone	B-Drug
esters	O
for	O
their	O
muscle-building	O
otherwise	O
performance-enhancing	O
effects.	O

Tramadol	B-Drug
can	O
interact	O
with	O
other	O
medications	O
similar	O
mechanisms	O
of	O
action.	O

Commercial	O
cannabinoid	O
immunoassays,	O
often	O
employed	O
as	O
the	O
initial	O
screening	O
method	O
when	O
testing	O
physiological	O
specimens	O
for	O
marijuana	O
presence,	O
have	O
different	O
degrees	O
of	O
cross-reactivity	O
with	O
THC	B-Drug
and	O
its	O
metabolites.	O

Venlafaxine	B-Drug
blocks	O
the	O
neuronal	O
reuptake	O
of	O
serotonin,	O
noradrenaline,	O
and,	O
to	O
a	O
lesser	O
extent,	O
dopamine	O
in	O
central	O
nervous	O
system.	O

As	O
sofosbuvir	B-Drug
clinical	O
development	O
progressed,	O
physicians	O
began	O
to	O
"warehouse"	O
people	O
in	O
anticipation	O
of	O
its	O
availability.	O

Also	O
in	O
2018,	O
the	O
FDA	O
supervised	O
voluntary	O
destruction	O
of	O
kratom	B-Drug
dietary	O
supplements	O
by	O
a	O
nationwide	O
distributor	O
Missouri,	O
and	O
encouraged	O
all	O
companies	O
involved	O
commerce	O
to	O
remove	O
their	O
products	O
from	O
market.	O

Ibogaine	B-Drug
catalyzes	O
an	O
altered	O
state	O
of	O
consciousness	O
reminiscent	O
dreaming	O
while	O
fully	O
conscious	O
and	O
aware	O
so	O
that	O
memories,	O
life	O
experiences,	O
issues	O
trauma	O
can	O
be	O
processed.	O

Chinese	O
organizations	O
tried	O
to	O
purchase	O
mifepristone	B-Drug
from	O
Roussel	O
Uclaf,	O
which	O
refused	O
sell	O
it	O
them,	O
so	O
in	O
1992	O
China	O
began	O
its	O
own	O
domestic	O
production	O
of	O
mifepristone.	O

Dextroamphetamine	B-Drug
is	O
considered	O
to	O
have	O
a	O
high	O
potential	O
for	O
misuse	O
in	O
recreational	O
manner	O
since	O
individuals	O
typically	O
report	O
feeling	O
euphoric,	O
more	O
alert,	O
and	O
energetic	O
after	O
taking	O
the	O
drug.	O

Heroin,	O
the	O
first	O
semi-synthetic	O
opioid,	O
was	O
synthesized	O
in	O
1874,	O
but	O
not	O
pursued	O
until	O
its	O
rediscovery	O
1897	O
by	O
Felix	O
Hoffmann	O
at	O
Bayer	O
pharmaceutical	O
company	O
Elberfeld,	O
Germany.	O
Heroin	B-Drug

Marijuana	O
concentrates	O
contain	O
extraordinarily	O
high	O
THC	B-Drug
levels	O
that	O
could	O
once	O
range	O
from	O
40	O
to	O
80%,	O
up	O
four	O
times	O
stronger	O
in	O
content	O
than	O
grade	O
or	O
top	O
shelf	O
marijuana,	O
which	O
normally	O
measures	O
around	O
20%	O
levels.	O

Users	O
report	O
an	O
intense	O
rush,	O
acute	O
transcendent	O
state	O
of	O
euphoria,	O
which	O
occurs	O
while	O
diamorphine	B-Drug
is	O
being	O
metabolized	O
into	O
6-monoacetylmorphine	B-Drug
(6-MAM)	O
and	O
morphine	B-Drug
in	O
the	O
brain.	O

This	O
detail	O
became	O
less	O
relevant	O
after	O
bolandione	B-Drug
and	O
4-androstenedione	B-Drug
were	O
banned	O
by	O
major	O
sporting	O
bodies.	O

However,	O
not	O
all	O
pharmacies	O
stock	O
or	O
dispense	O
naloxone.	O
naloxone	B-Drug

Teens	O
abused	O
prescription	O
drugs	O
more	O
than	O
any	O
illicit	O
drug	O
except	O
cannabis,	O
cocaine,	O
heroin,	O
and	O
methamphetamine	B-Drug
combined.	O
cocaine	B-Drug
heroin	B-Drug

The	O
bust	O
also	O
uncovered	O
large	O
quantities	O
of	O
DMT,	O
2C-B,	O
MDMA,	O
and	O
$500,000	O
worth	O
cash	O
gold.	O
2C-B	B-Drug
MDMA	B-Drug

In	O
Denmark,	O
temazepam	B-Drug
is	O
listed	O
as	O
a	O
Class	O
D	O
substance	O
under	O
the	O
Executive	O
Order	O
698	O
of	O
1993	O
on	O
Euphoric	O
Substances	O
which	O
means	O
it	O
has	O
high	O
potential	O
for	O
abuse,	O
but	O
used	O
medical	O
and	O
scientific	O
purposes.	O

Dienogest	B-Drug
was	O
discovered	O
in	O
1979	O
and	O
introduced	O
for	O
medical	O
use	O
1995.	O

Sveriges	O
riksdags	O
health	O
ministry	O
Statens	O
folkhlsoinstitut	O
classified	O
salvinorin	B-Drug
A	I-Drug
(and	O
Salvia	O
divinorum)	O
as	O
"health	O
hazard"	O
under	O
the	O
act	O
Lagen	O
om	O
frbud	O
mot	O
vissa	O
hlsofarliga	O
varor	O
(translated	O
Act	O
on	O
Prohibition	O
of	O
Certain	O
Goods	O
Dangerous	O
to	O
Health)	O
Apr	O
1,	O
2006,	O
in	O
their	O
regulation	O
SFS	O
2006:167	O
listed	O
"salvinorin	O
A",	O
making	O
it	O
illegal	O
sell	O
or	O
possess.	O

Dermorphin	O
is	O
about	O
3040	O
times	O
more	O
potent	O
than	O
morphine	B-Drug
but	O
theoretically	O
may	O
be	O
less	O
likely	O
to	O
produce	O
drug	O
tolerance	O
and	O
addiction	O
(due	O
its	O
high	O
potency).	O

Unexpectedly	O
despite	O
its	O
weaker	O
CB1	O
Ki	O
in	O
vitro,	O
the	O
2-methylindole	O
derivative	O
JWH-204	O
is	O
actually	O
more	O
potent	O
than	O
JWH-203	B-Drug
animal	O
tests	O
for	O
cannabinoid	O
activity,	O
though	O
it	O
still	O
JWH-249.	O
JWH-249	B-Drug

The	O
metabolic	O
half	O
life	O
of	O
methadone	B-Drug
differs	O
from	O
its	O
duration	O
action.	O

Clobazam	B-Drug
is	O
sometimes	O
used	O
for	O
refractory	O
epilepsies.	O

Tramadol	B-Drug
(Ultram),	O
an	O
opioid	O
analgesic	O
Carisoprodol	B-Drug
(Soma)	O
has	O
become	O
a	O
Schedule	O
IV	O
medication	O
as	O
of	O
11	O
January	O
2012	O
Suvorexant	B-Drug
and	O
Lemborexant,	O
orexinergic	O
sedatives	O
V	O
substances	O
are	O
those	O
that	O
have	O
the	O
following	O
findings:	O
No	O
controlled	O
substance	O
in	O
which	O
is	O
drug	O
may	O
be	O
distributed	O
or	O
dispensed	O
other	O
than	O
for	O
medical	O
purpose.	O
Ultram	B-Drug
Soma	B-Drug
Lemborexant	B-Drug

In	O
2019,	O
German	O
authorities	O
in	O
Hamburg	O
seized	O
1.5	O
tonnes	O
of	O
cocaine	B-Drug
at	O
a	O
port	O
Hamburg.	O

In	O
a	O
brain	O
sample	O
of	O
fatal	O
nitrazepam	B-Drug
poisoning	O
high	O
concentrations	O
and	O
its	O
metabolite	O
were	O
found	O
in	O
the	O
deceased	O
person.	O

PEA	B-Drug
also	O
has	O
affinity	O
to	O
cannabinoid-like	O
G-coupled	O
receptors	O
GPR55	O
and	O
GPR119.	O

MDMP	O
produces	O
few	O
to	O
no	O
effects,	O
and	O
is	O
slightly	O
similar	O
MDMA.	O
MDMA	B-Drug

Like	O
other	O
opioids,	O
diphenoxylate	B-Drug
acts	O
by	O
slowing	O
intestinal	O
contractions,	O
allowing	O
the	O
body	O
to	O
consolidate	O
contents	O
and	O
prolong	O
transit	O
time,	O
thus	O
intestines	O
draw	O
moisture	O
out	O
of	O
them	O
at	O
a	O
normal	O
or	O
higher	O
rate	O
therefore	O
stop	O
formation	O
loose	O
liquid	O
stools;	O
atropine	O
is	O
an	O
anticholinergic	O
present	O
prevent	O
drug	O
abuse	O
overdose.	O

Metabolism	O
of	O
JWH-018	B-Drug
was	O
assessed	O
using	O
Wistar	O
rats	O
which	O
had	O
been	O
administered	O
an	O
ethanolic	O
extract	O
containing	O
JWH-018.	O

This	O
only	O
prevented	O
Genentech	O
from	O
marketing	O
bevacizumab	B-Drug
for	O
breast	O
cancer.	O

However,	O
there	O
is	O
consistent	O
evidence	O
of	O
structural	O
and	O
functional	O
deficits	O
in	O
MDMA	B-Drug
users	O
with	O
high	O
lifetime	O
exposure.	O

It	O
is	O
no	O
longer	O
used	O
due	O
mainly	O
to	O
safety	O
concerns,	O
as	O
it	O
has	O
a	O
serotonergic	O
effects	O
profile	O
similar	O
other	O
withdrawn	O
appetite	O
suppressants	O
such	O
fenfluramine	B-Drug
and	O
aminorex	B-Drug
which	O
were	O
found	O
cause	O
pulmonary	O
hypertension	O
cardiac	O
fibrosis	O
following	O
prolonged	O
use.	O

In	O
July	O
2014,	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
(MHRA)	O
of	O
UK	O
issued	O
a	O
warning	O
about	O
potential	O
for	O
life-threatening	O
harm	O
from	O
accidental	O
exposure	O
to	O
transdermal	O
fentanyl	B-Drug
patches,	O
particularly	O
in	O
children,	O
advised	O
that	O
they	O
should	O
be	O
folded,	O
with	O
adhesive	O
side	O
in,	O
before	O
being	O
discarded.	O

However,	O
high	O
amphetamine	B-Drug
doses	O
that	O
are	O
above	O
the	O
therapeutic	O
range	O
can	O
interfere	O
with	O
working	O
memory	O
and	O
other	O
aspects	O
of	O
cognitive	O
control.	O

Over	O
the	O
past	O
two	O
decades,	O
public	O
service	O
advertisements	O
have	O
grown	O
to	O
target	O
other	O
drugs	O
like	O
heroin,	O
methamphetamine,	O
ecstasy,	O
and	O
others.	O
heroin	B-Drug
methamphetamine	B-Drug
ecstasy	B-Drug

It	O
was	O
recently	O
found	O
that	O
D-amino	O
acid	O
oxidase,	O
the	O
enzyme	O
catalyses	O
breakdown	O
of	O
acids	O
(e.g.	O
D-alanine	O
and	O
D-serine	O
neurotransmitters)	O
is	O
inhibited	O
by	O
risperidone.	O
risperidone	B-Drug

PMA	B-Drug
first	O
came	O
into	O
circulation	O
in	O
the	O
early	O
1970s,	O
where	O
it	O
was	O
used	O
intentionally	O
as	O
a	O
substitute	O
for	O
hallucinogenic	O
properties	O
of	O
LSD.	O
LSD	B-Drug

The	O
aim	O
of	O
this	O
trial	O
was	O
determine	O
the	O
safety	O
and	O
effectiveness	O
enzalutamide	B-Drug
in	O
patients	O
who	O
have	O
previously	O
failed	O
chemotherapy	O
treatment	O
with	O
docetaxel.	O
docetaxel	B-Drug

Phenobarbital	B-Drug
is	O
a	O
cytochrome	O
P450	O
inducer,	O
and	O
used	O
to	O
reduce	O
the	O
toxicity	O
of	O
some	O
drugs.	O

MDAI	B-Drug
has	O
been	O
shown	O
to	O
inhibit	O
the	O
reuptake	O
of	O
serotonin,	O
dopamine,	O
and	O
norepinephrine	O
with	O
IC50	O
values	O
512	O
nM,	O
5,920	O
1,426	O
respectively.	O

After	O
oxycodone	B-Drug
binds	O
to	O
the	O
MOR,	O
a	O
G	O
protein-complex	O
is	O
released,	O
which	O
inhibits	O
release	O
of	O
neurotransmitters	O
by	O
cell	O
decreasing	O
amount	O
cAMP	O
produced,	O
closing	O
calcium	O
channels,	O
and	O
opening	O
potassium	O
channels.	O

Butenolide	O
Diethylpropion	B-Drug

The	O
first	O
step	O
is	O
an	O
oxidation	O
of	O
testosterone	O
with	O
Jones	O
reagent	O
to	O
afford	O
androst-4-ene-3,17-dione	B-Drug
a	O
73%	O
yield.	O

Harm	O
to	O
bystanders	O
was	O
perceived	O
as	O
a	O
motivator	O
for	O
stricter	O
regulation	O
of	O
tobacco	B-Drug
products.	O

Notable	O
compounds	O
include	O
dimethylthiambutene,	O
diethylthiambutene,	O
ethylmethylthiambutene,	O
pyrrolidinylthiambutene	O
and	O
piperidylthiambutene.	O
dimethylthiambutene	B-Drug
diethylthiambutene	B-Drug
ethylmethylthiambutene	B-Drug

Samuel	O
Caldwell	O
A	O
former	O
alcohol	O
peddler	O
during	O
prohibition,	O
(18801941)	O
was	O
one	O
of	O
the	O
first	O
people	O
convicted	O
in	O
1937	O
under	O
federal	O
marihuana	B-Drug
prohibition	O
law.	O

Despite	O
the	O
fact	O
that	O
pregabalin	B-Drug
is	O
a	O
GABA	O
analogue,	O
it	O
does	O
not	O
bind	O
to	O
receptors,	O
convert	O
into	O
or	O
another	O
receptor	O
agonist	O
in	O
vivo,	O
and	O
directly	O
modulate	O
transport	O
metabolism.	O

Dissociation	O
and	O
psychotomimetic	O
effects	O
are	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	B-Drug
at	O
plasma	O
concentrations	O
of	O
around	O
100	O
to	O
250	O
ng	O

Additionally,	O
the	O
Government	O
further	O
improved	O
regulations	O
to	O
strengthen	O
control	O
of	O
ephedrine	B-Drug
during	O
1999	O
and	O
2000.	O

Hyoscine	B-Drug
enters	O
breast	O
milk	O
by	O
secretion.	O

Commercial	O
cannabinoid	O
immunoassays,	O
often	O
employed	O
as	O
the	O
initial	O
screening	O
method	O
when	O
testing	O
physiological	O
specimens	O
for	O
marijuana	O
presence,	O
have	O
different	O
degrees	O
of	O
cross-reactivity	O
with	O
THC	B-Drug
and	O
its	O
metabolites.	O

Classifying	O
stimulants	O
is	O
difficult,	O
because	O
of	O
the	O
large	O
number	O
classes	O
drugs	O
occupy,	O
and	O
fact	O
that	O
they	O
may	O
belong	O
to	O
multiple	O
classes;	O
for	O
example,	O
ecstasy	B-Drug
can	O
be	O
classified	O
as	O
a	O
substituted	O
methylenedioxyphenethylamine,	O
amphetamine	O
consequently,	O
phenethylamine.	O

It	O
has	O
been	O
found	O
to	O
be	O
33	O
per	O
cent	O
the	O
analgesic	O
potency	O
of	O
morphine	B-Drug
with	O
a	O
substantially	O
longer	O
duration	O
action.	O

Long-term	O
use	O
of	O
morphine	B-Drug
in	O
palliative	O
care	O
and	O
the	O
management	O
chronic	O
pain	O
always	O
entails	O
a	O
risk	O
that	O
patient	O
develops	O
tolerance	O
or	O
physical	O
dependence.	O

The	O
risks	O
are	O
dose-dependent,	O
and	O
appear	O
to	O
be	O
greatest	O
with	O
high/very	O
high	O
doses	O
via	O
intravenous	O
administration	O
in	O
the	O
elderly,	O
as	O
well	O
drugs	O
that	O
interact	O
domperidone	B-Drug
increase	O
its	O
circulating	O
concentrations	O
(namely	O
CYP3A4	O
inhibitors).	O

The	O
severity	O
of	O
these	O
developmental	O
delays	O
increases	O
with	O
heavier	O
MDMA	B-Drug
use.	O

Psilocin	B-Drug
is	O
glucuronated	O
by	O
the	O
glucuronosyltransferase	O
enzymes	O
UGT1A9	O
in	O
liver,	O
and	O
UGT1A10	O
small	O
intestine.	O

Opioids	O
can	O
also	O
increase	O
the	O
risk	O
of	O
becoming	O
psychologically	O
dependent	O
on	O
zolpidem.	O
zolpidem	B-Drug

Urine	O
was	O
collected	O
for	O
24	O
hours,	O
followed	O
by	O
extraction	O
of	O
JWH-018	B-Drug
metabolites	O
using	O
both	O
liquid-liquid	O
and	O
solid-phase	O
extraction.	O

Furthermore,	O
it	O
is	O
not	O
clear	O
yet	O
whether	O
"typical"	O
users	O
of	O
MDMA	B-Drug
(1	O
to	O
2	O
pills	O
75	O
125	O
mg	O
or	O
analogue	O
every	O
1	O
4	O
weeks)	O
will	O
develop	O
neurotoxic	O
brain	O
lesions.	O

Triamterene	B-Drug
is	O
best	O
avoided	O
in	O
patients	O
with	O
chronic	O
kidney	O
disease	O
due	O
to	O
the	O
possibility	O
of	O
hyperkalemia.	O

associated	O
with	O
other	O
early	O
LSD	B-Drug
producers,	O
Tim	O
Scully	O
and	O
Nicholas	O
Sand.	O

Fentanyl	B-Drug
use	O
has	O
also	O
been	O
associated	O
with	O
aphasia.	O

American	O
pharmaceutical	O
company	O
Gilead	O
sought	O
and	O
obtained	O
orphan	O
drug	O
status	O
for	O
remdesivir	B-Drug
from	O
the	O
US	O
Food	O
Drug	O
Administration	O
(FDA)	O
on	O
23	O
March	O
2020.	O

The	O
released	O
serotonin	O
binds	O
to	O
various	O
receptors	O
and	O
activates	O
them	O
in	O
excess,	O
which	O
is	O
the	O
primary	O
mechanism	O
through	O
MDMA	B-Drug
causes	O
intoxication.	O

Between	O
July	O
2009	O
and	O
February	O
2010,	O
UK	O
health	O
professionals	O
accessed	O
the	O
National	O
Poisons	O
Information	O
Service's	O
(NPIS)	O
entry	O
on	O
mephedrone	B-Drug
1664	O
times	O
made	O
157	O
telephone	O
inquiries;	O
requests	O
increased	O
month	O
over	O
this	O
period.	O

Diseases	O
that	O
may	O
present	O
similar	O
to	O
an	O
anxiety	O
disorder,	O
including	O
certain	O
endocrine	O
diseases	O
(hypo-	O
and	O
hyperthyroidism,	O
hyperprolactinemia),	O
metabolic	O
disorders	O
(diabetes),	O
deficiency	O
states	O
(low	O
levels	O
of	O
vitamin	O
D,	O
B2,	O
B12,	O
folic	O
acid),	O
gastrointestinal	O
(celiac	O
disease,	O
non-celiac	O
gluten	O
sensitivity,	O
inflammatory	O
bowel	O
disease),	O
heart	O
diseases,	O
blood	O
(anemia),	O
brain	O
degenerative	O
(Parkinson's	O
dementia,	O
multiple	O
sclerosis,	O
Huntington's	O
disease).Also,	O
several	O
drugs	O
can	O
cause	O
or	O
worsen	O
anxiety,	O
whether	O
in	O
intoxication,	O
withdrawal,	O
from	O
chronic	O
use.	O
B12	B-Drug

Remifentanil	B-Drug
is	O
used	O
for	O
sedation	O
as	O
well	O
combined	O
with	O
other	O
medications	O
use	O
in	O
general	O
anesthesia.	O

Heroin	B-Drug
was	O
made	O
an	O
illegal	O
drug	O
with	O
the	O
Anti-Heroin	O
Act	O
of	O
1924,	O
in	O
which	O
US	O
Congress	O
banned	O
sale,	O
importation,	O
or	O
manufacture	O
heroin.	O
heroin	B-Drug

Psychedelic	O
research	O
pioneer	O
Alexander	O
Shulgin	O
said	O
he	O
was	O
first	O
inspired	O
to	O
explore	O
psychedelic	O
compounds	O
by	O
a	O
mescaline	B-Drug
experience.	O

A	O
high	O
dosage	O
of	O
20	O
mg/day	O
norethisterone	B-Drug
or	O
NETA	O
has	O
been	O
found	O
to	O
significantly	O
stimulate	O
the	O
sebaceous	O
glands,	O
whereas	O
lower	O
dosages	O
5	O
and	O
2.5	O
NETA,	O
respectively,	O
did	O
not	O
sebum	O
production	O
were	O
consequently	O
regarded	O
as	O
devoid	O
significant	O
androgenicity.	O

The	O
rod	O
contains	O
68	O
mg	O
of	O
etonogestrel	B-Drug
(sometimes	O
called	O
3-keto-destrogestrel),	O
a	O
type	O
progestin.	O

Like	O
many	O
other	O
drugs,	O
PCP	B-Drug
has	O
been	O
known	O
to	O
alter	O
mood	O
states	O
in	O
an	O
unpredictable	O
fashion,	O
causing	O
some	O
individuals	O
become	O
detached,	O
and	O
others	O
animated.	O

The	O
secondary	O
pathway	O
involves	O
conversion	O
of	O
17-hydroxyprogesterone,	O
most	O
often	O
a	O
precursor	O
to	O
cortisol,	O
androstenedione	B-Drug
directly	O
by	O
way	O
17,20-lyase.	O

Naltrexone	B-Drug
should	O
not	O
be	O
used	O
by	O
persons	O
with	O
acute	O
hepatitis	O
or	O
liver	O
failure,	O
those	O
recent	O
opioid	O
use	O
(typically	O
710	O
days).	O

Other	O
isomers	O
of	O
codeine	B-Drug
include	O
allocodeine,	O
pseudocodeine,	O
heterocodeine	B-Drug
and	O
substances	O
with	O
intermediate	O
qualities	O
such	O
as	O
pseudoallocodeine	O
formylallocodeine	O
can	O
be	O
prepared	O
in	O
the	O
laboratory.	O

At	O
sufficiently	O
high	O
doses,	O
users	O
may	O
experience	O
what	O
is	O
called	O
the	O
"K-hole",	O
a	O
state	O
of	O
dissociation	O
with	O
visual	O
and	O
auditory	O
hallucinations.	O
K-hole	B-Drug

In	O
March	O
2016	O
a	O
district	O
court	O
found	O
that	O
alirocumab	B-Drug
infringed	O
Amgen's	O
patents;	O
Amgen	O
then	O
requested	O
an	O
injunction	O
barring	O
Regeneron	O
and	O
Sanofi	O
from	O
marketing	O
alirocumab,	O
which	O
was	O
granted	O
in	O
January	O
2017.	O

Strychnine	O
has	O
indeed	O
rarely	O
been	O
discovered	O
mixed	O
with	O
LSD	B-Drug
and	O
other	O
drugs	O
in	O
a	O
few	O
samples	O
recovered	O
by	O
law	O
enforcement	O
agencies,	O
but	O
these	O
were	O
all	O
found	O
murder	O
or	O
attempted	O
investigations	O
where	O
someone	O
was	O
being	O
specifically	O
targeted	O
for	O
poisoning,	O
not	O
associated	O
recreational	O
use.	O

THC	B-Drug
also	O
potentiates	O
the	O
effects	O
of	O
glycine	O
receptors.	O

Because	O
of	O
the	O
high	O
level	O
physical	O
activity	O
and	O
relative	O
imperviousness	O
to	O
pain	O
induced	O
by	O
PCP,	O
some	O
deaths	O
have	O
been	O
reported	O
due	O
release	O
myoglobin	O
from	O
ruptured	O
muscle	O
cells.	O
PCP	B-Drug

Multiple-substance	O
exposures	O
were	O
associated	O
with	O
a	O
higher	O
number	O
of	O
hospitalizations	O
than	O
single-substance	O
exposures,	O
and	O
involved	O
11	O
deaths,	O
including	O
two	O
due	O
to	O
kratom	B-Drug
alone.	O

Other	O
studies	O
examined	O
the	O
use	O
of	O
temazepam	B-Drug
over	O
six	O
days	O
and	O
saw	O
no	O
evidence	O
tolerance.	O

According	O
to	O
a	O
2014	O
survey,	O
25I-NBOMe	B-Drug
was	O
the	O
most	O
frequently	O
used	O
of	O
NBOMe	O
series.	O

The	O
primary	O
area	O
for	O
concern	O
is	O
patients	O
who	O
may	O
develop	O
prostate	O
cancer	O
whilst	O
taking	O
dutasteride	B-Drug
benign	O
prostatic	O
hyperplasia,	O
which	O
in	O
turn	O
could	O
delay	O
diagnosis	O
and	O
early	O
treatment	O
of	O
the	O
cancer,	O
thereby	O
potentially	O
increasing	O
risk	O
these	O
developing	O
high-grade	O
cancer.	O

The	O
average	O
THC	B-Drug
level	O
in	O
coffee	O
shops	O
the	O
Netherlands	O
is	O
about	O
1819%.The	O
levels	O
of	O
cannabis	O
sold	O
United	O
States	O
rose	O
dramatically	O
between	O
1970s	O
and	O
2000.	O

Celecoxib	B-Drug
had	O
already	O
been	O
approved	O
for	O
this	O
indication,	O
and	O
it	O
was	O
hoped	O
to	O
add	O
the	O
indications	O
rofecoxib	O
as	O
well.	O

Antiandrogens	O
like	O
spironolactone	B-Drug
are	O
male-specific	O
teratogens	O
which	O
can	O
feminize	O
male	O
fetuses	O
due	O
to	O
their	O
antiandrogenic	O
effects.	O

Intranasal	O
fentanyl	B-Drug
appears	O
to	O
be	O
as	O
equally	O
effective	O
IV	O
morphine	B-Drug
and	O
superior	O
intramuscular	O
for	O
management	O
of	O
acute	O
hospital	O
pain.	O

However,	O
some	O
users	O
report	O
that	O
O-acetylpsilocin's	O
subjective	O
effects	O
differ	O
from	O
those	O
of	O
psilocybin	O
and	O
psilocin.	O
O-acetylpsilocin	B-Drug
psilocin	B-Drug

Examples	O
of	O
notable	O
designer	O
steroids	O
include	O
1-testosterone	B-Drug
(dihydroboldenone),	O
methasterone,	O
trenbolone	O
enanthate,	O
desoxymethyltestosterone,	O
tetrahydrogestrinone,	O
and	O
methylstenbolone.	O
methasterone	B-Drug
desoxymethyltestosterone	B-Drug
tetrahydrogestrinone	B-Drug

CYP3A4	O
inhibitors	O
such	O
as	O
cimetidine,	O
erythromycin,	O
norfluoxetine,	O
fluvoxamine,	O
itraconazole,	O
ketoconazole,	O
nefazodone,	O
propoxyphene,	O
and	O
ritonavir	B-Drug
delay	O
the	O
hepatic	O
clearance	O
of	O
alprazolam,	O
which	O
may	O
result	O
in	O
its	O
accumulation	O
increased	O
severity	O
side	O
effects.	O
cimetidine	B-Drug
erythromycin	B-Drug
fluvoxamine	B-Drug
itraconazole	B-Drug
ketoconazole	B-Drug
nefazodone	B-Drug
propoxyphene	B-Drug
alprazolam	B-Drug

Methadone	B-Drug
causes	O
dry	O
mouth,	O
reducing	O
the	O
protective	O
role	O
of	O
saliva	O
in	O
preventing	O
decay.	O

The	O
following	O
BischlerNapieralski	O
reaction	O
produces	O
papaverine.	O
papaverine	B-Drug

All	O
of	O
these	O
derivatives	O
are	O
likely	O
to	O
share	O
some	O
their	O
psychoactive	O
effects	O
with	O
PCP	B-Drug
itself,	O
although	O
a	O
range	O
potencies	O
and	O
varying	O
mixtures	O
anesthetic,	O
dissociative,	O
stimulant	O
known,	O
depending	O
on	O
the	O
particular	O
drug	O
its	O
substituents.	O

Diazepam	B-Drug
has	O
a	O
number	O
of	O
uses	O
including:	O
Treatment	O
anxiety,	O
panic	O
attacks,	O
and	O
states	O
agitation	O
neurovegetative	O
symptoms	O
associated	O
with	O
vertigo	O
the	O
alcohol,	O
opiate,	O
benzodiazepine	O
withdrawal	O
Short-term	O
treatment	O
insomnia	O
muscle	O
spasms	O
tetanus,	O
together	O
other	O
measures	O
intensive	O
Adjunctive	O
spastic	O
muscular	O
paresis	O
(paraplegia/tetraplegia)	O
caused	O
by	O
cerebral	O
or	O
spinal	O
cord	O
conditions	O
such	O
as	O
stroke,	O
multiple	O
sclerosis,	O
injury	O
(long-term	O
is	O
coupled	O
rehabilitative	O
measures)	O

Breastfeeding:	O
The	O
manufacturer	O
does	O
not	O
recommend	O
breastfeeding	O
since	O
low	O
concentrations	O
of	O
phenytoin	B-Drug
are	O
excreted	O
in	O
breast	O
milk.	O

For	O
premenopausal	O
women	O
with	O
hormone-receptorpositive	O
breast	O
cancer,	O
adjuvant	O
treatment	O
ovarian	O
suppression	O
plus	O
the	O
aromatase	O
inhibitor	O
exemestane,	O
as	O
compared	O
tamoxifen,	O
provides	O
a	O
new	O
option	O
that	O
reduces	O
risk	O
of	O
recurrence.	O
exemestane	B-Drug
tamoxifen	B-Drug

Tibolone	B-Drug
is	O
used	O
in	O
the	O
treatment	O
of	O
menopausal	O
symptoms	O
like	O
hot	O
flashes	O
and	O
vaginal	O
atrophy,	O
postmenopausal	O
osteoporosis,	O
endometriosis.	O

Zopiclone	B-Drug
induces	O
impairment	O
of	O
psychomotor	O
function.	O

Nicotinic	B-Drug
acid	I-Drug
can	O
be	O
synthesized	O
from	O
tryptophan	O
or	O
aspartic	O
acid.	O

Pregabalin	B-Drug
was	O
synthesized	O
in	O
1990	O
as	O
an	O
anticonvulsant.	O

Tamoxifen	B-Drug
function	O
can	O
be	O
regulated	O
by	O
a	O
number	O
of	O
different	O
variables	O
including	O
growth	O
factors.	O

As	O
an	O
AAS,	O
metenolone	B-Drug
enanthate	O
is	O
antigonadotropic	O
and	O
can	O
suppress	O
the	O
hypothalamicpituitarygonadal	O
axis	O
produce	O
reversible	O
hypogonadism	O
infertility.	O

the	O
following	O
phenethylamine	B-Drug
derivatives,	O
namely:	O
(c)	O

Narconon	O
states	O
that	O
other	O
synthetic	O
drugs	O
used	O
in	O
clubs,	O
or	O
which	O
are	O
sold	O
as	O
"Ecstasy"	O
include	O
harmaline;	O
piperazines	O
(e.g.,	O
BZP	B-Drug
and	O
TFMPP);	O
PMA/PMMA;	O
harmaline	B-Drug
TFMPP	B-Drug
PMA	B-Drug
PMMA	B-Drug

Nortriptyline	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
1964.	O

Danazol	B-Drug
possesses	O
a	O
complex	O
pharmacology,	O
with	O
multiple	O
mechanisms	O
of	O
action.	O

Amphetamine	B-Drug
withdrawal	O
symptoms	O
can	O
include	O
anxiety,	O
drug	O
craving,	O
depressed	O
mood,	O
fatigue,	O
increased	O
appetite,	O
movement	O
or	O
decreased	O
movement,	O
lack	O
of	O
motivation,	O
sleeplessness	O
sleepiness,	O
and	O
lucid	O
dreams.	O

Brazilian	O
footballer	O
assistant	O
Robson	O
Oliveira	O
was	O
arrested	O
in	O
2019	O
upon	O
arriving	O
Russia	O
with	O
methadone	B-Drug
tablets	O
sold	O
legally	O
other	O
countries	O
and	O
has	O
been	O
jail	O
since	O
then	O
for	O
what	O
considered	O
drug	O
trafficking	O
under	O
Russian	O
law.	O

Also,	O
cross-sensitization	O
is	O
not	O
unique	O
to	O
marijuana.	O
marijuana	B-Drug

Mirtazapine	B-Drug
also	O
has	O
some	O
veterinary	O
use	O
in	O
cats	O
and	O
dogs.	O

In	O
2020,	O
the	O
label	O
for	O
Epidiolex	B-Drug
in	O
US	O
was	O
expanded	O
to	O
include	O
treatment	O
of	O
seizures	O
associated	O
with	O
tuberous	O
sclerosis	O
complex.	O

In	O
the	O
US,	O
celecoxib	B-Drug
was	O
covered	O
by	O
three	O
patents,	O
two	O
of	O
which	O
expired	O
on	O
May	O
30,	O
2014,	O
and	O
one	O
(US	O
RE44048)	O
due	O
to	O
expire	O
December	O
2,	O
2015.	O

Flutamide	O
has	O
been	O
found	O
to	O
be	O
similarly	O
effective	O
in	O
the	O
treatment	O
of	O
prostate	O
cancer	O
bicalutamide,	O
although	O
indications	O
inferior	O
efficacy,	O
including	O
greater	O
compensatory	O
increases	O
testosterone	O
levels	O
and	O
reductions	O
PSA	O
with	O
were	O
observed.	O
bicalutamide	B-Drug

Dexamethasone	B-Drug
may	O
be	O
given	O
to	O
women	O
at	O
risk	O
of	O
delivering	O
prematurely	O
promote	O
maturation	O
the	O
fetus'	O
lungs.	O

The	O
fentanyl	B-Drug
patch	O
is	O
one	O
of	O
a	O
few	O
medications	O
that	O
may	O
be	O
especially	O
harmful,	O
and	O
in	O
some	O
cases	O
fatal,	O
with	O
just	O
dose,	O
if	O
used	O
by	O
someone	O
other	O
than	O
the	O
person	O
for	O
whom	O
medication	O
was	O
prescribed.	O

In	O
the	O
United	O
Kingdom,	O
it	O
is	O
available	O
in	O
5	O
mg	O
instant	O
release	O
sulfate	O
tablets	O
under	O
generic	O
name	O
dexamfetamine	B-Drug
as	O
well	O
10	O
and	O
20	O
strength	O
brand	O
Amfexa.	O

Together	O
with	O
25CN-NBOH,	O
2S,6S-DMBMPP	O
is	O
the	O
only	O
known	O
5-HT2A	O
agonist	O
to	O
exhibit	O
this	O
level	O
of	O
selectivity.	O
25CN-NBOH	B-Drug

Some	O
otolaryngology	O
(ENT)	O
specialists	O
occasionally	O
use	O
cocaine	B-Drug
within	O
the	O
practice	O
when	O
performing	O
procedures	O
such	O
as	O
nasal	O
cauterization.	O

The	O
skin	O
of	O
many	O
toad	O
species	O
the	O
genus	O
Bufo	O
contains	O
a	O
derivative	O
tryptamine,	O
bufotenin,	O
and	O
venom	O
alvarius	O
(Colorado	O
River	O
toad)	O
5-MeO-DMT.	O
bufotenin	B-Drug
5-MeO-DMT	B-Drug

Physiological	O
and	O
psychotropic	O
effects	O
from	O
nasally	O
insufflated	O
cocaine	B-Drug
are	O
sustained	O
for	O
approximately	O
4060	O
minutes	O
after	O
the	O
peak	O
attained.	O

Mefenamic	B-Drug
acid	I-Drug
and	O
its	O
metabolites	O
are	O
excreted	O
via	O
the	O
urine	O
(5267%)	O
faeces	O
(2025%,	O
or	O
less	O
than	O
20%	O
following	O
another	O
source).	O

However,	O
natural	O
cocaine	B-Drug
remains	O
the	O
lowest	O
cost	O
and	O
highest	O
quality	O
supply	O
of	O
cocaine.	O

Similar	O
anxiety-ridden	O
reports	O
appeared	O
throughout	O
cities	O
in	O
the	O
South,	O
leading	O
some	O
to	O
declare	O
that	O
"the	O
cocaine	B-Drug
habit	O
has	O
assumed	O
proportions	O
of	O
an	O
epidemic	O
among	O
colored	O
people".	O

The	O
muscle	O
relaxant	O
properties	O
of	O
diazepam	B-Drug
are	O
produced	O
via	O
inhibition	O
polysynaptic	O
pathways	O
in	O
the	O
spinal	O
cord.	O

However,	O
diprenorphine	O
is	O
not	O
generally	O
available	O
in	O
hospitals;	O
instead	O
a	O
vial	O
of	O
supplied	O
with	O
etorphine	B-Drug
or	O
carfentanil	B-Drug
specifically	O
for	O
reversing	O
the	O
effects	O
drug,	O
so	O
use	O
treating	O
buprenorphine	B-Drug
overdose	O
usually	O
carried	O
out	O
practice.	O

cocaine,	O
heroin	B-Drug
Fringe	O
series	O
LSD,	O
unidentified	O
psychoactive	O
drugs	O
cocaine	B-Drug
LSD	B-Drug

As	O
of	O
2015,	O
increased	O
rates	O
recreational	O
use	O
and	O
addiction	O
were	O
attributed	O
to	O
over-prescription	O
opioid	O
medications	O
inexpensive	O
illicit	O
heroin.	O
heroin	B-Drug

cocaine,	O
possibly	O
heroinThe	O
Five	O
Heartbeats	O
Gambling,	O
Gods	O
and	O
LSD	B-Drug
(2002)	O
cocaine	B-Drug

THC,	O
the	O
principal	O
psychoactive	O
constituent	O
of	O
cannabis	O
plant,	O
has	O
low	O
toxicity.	O
THC	B-Drug

Sveriges	O
riksdags	O
health	O
ministry	O
Statens	O
folkhlsoinstitut	O
classified	O
5-MeO-MT	O
as	O
"health	O
hazard"	O
under	O
the	O
act	O
Lagen	O
om	O
frbud	O
mot	O
vissa	O
hlsofarliga	O
varor	O
(translated	O
Act	O
on	O
Prohibition	O
of	O
Certain	O
Goods	O
Dangerous	O
to	O
Health)	O
Oct	O
1,	O
2004,	O
in	O
their	O
regulation	O
SFS	O
2004:696	O
listed	O
5-metoxi-alfametyltryptamin	O
(5-MeO-AMT),	O
making	O
it	O
illegal	O
sell	O
or	O
possess.	O
5-MeO-AMT	B-Drug

The	O
International	O
Olympic	O
Committee	O
in	O
1997	O
banned	O
androstenedione	B-Drug
and	O
placed	O
it	O
under	O
the	O
category	O
of	O
androgenic-anabolic	O
steroids.	O

Soon	O
after	O
its	O
introduction	O
to	O
the	O
Old	O
World,	O
tobacco	B-Drug
came	O
under	O
frequent	O
criticism	O
from	O
state	O
and	O
religious	O
leaders.	O

Intravenous	O
fentanyl	B-Drug
is	O
often	O
used	O
for	O
anesthesia	O
and	O
to	O
treat	O
pain.	O

Goserelin/bicalutamide	O
(ZolaCos	O
CP)	O
bicalutamide	B-Drug

Cannabis	O
tea,	O
which	O
contains	O
relatively	O
small	O
concentrations	O
of	O
THC	B-Drug
because	O
is	O
an	O
oil	O
(lipophilic)	O
and	O
only	O
slightly	O
water-soluble	O
(with	O
a	O
solubility	O
2.8	O
mg	O
per	O
liter).	O

Only	O
if	O
the	O
person	O
has	O
symptomatic	O
hyperkalemia,	O
then	O
rocuronium	B-Drug
should	O
be	O
considered.	O

It	O
can	O
increase	O
the	O
kidney	O
toxicity	O
of	O
ciclosporin	B-Drug
and	O
tacrolimus.	O
tacrolimus	B-Drug

The	O
retinol	B-Drug
form	O
functions	O
as	O
a	O
storage	O
of	O
the	O
vitamin,	O
and	O
can	O
be	O
converted	O
to	O
from	O
its	O
visually	O
active	O
aldehyde	O
form,	O
retinal.	O

Budesonide	B-Drug
assists	O
in	O
the	O
induction	O
of	O
remission	O
people	O
with	O
active	O
ulcerative	O
colitis.	O

Oxycodone	B-Drug
is	O
available	O
in	O
a	O
variety	O
of	O
formulations	O
for	O
by	O
mouth	O
or	O
under	O
the	O
tongue:	O
Immediate-release	O
oxycodone	B-Drug
(OxyFast,	O
OxyIR,	O
OxyNorm,	O
Roxicodone)	O
Roxicodone	B-Drug

Chemically,	O
MDMA	B-Drug
is	O
classified	O
as	O
a	O
substituted	O
amphetamine	O
(which	O
includes	O
stimulants	O
like	O
dextroamphetamine	B-Drug
and	O
psychedelics	O
2,5-dimethoxy-4-methylamphetamine),	O
which	O
makes	O
phenethylamine	O
other	O
methylphenidate	B-Drug
mescaline)	O
by	O
the	O
definition	O
of	O
amphetamine.	O
mescaline	B-Drug

Bupropion	B-Drug
is	O
a	O
reuptake	O
inhibitor	O
and	O
releasing	O
agent	O
of	O
both	O
norepinephrine	O
dopamine,	O
nicotinic	O
acetylcholine	O
receptor	O
antagonist,	O
it	O
activates	O
proopiomelanocortin	O
(POMC)	O
neurons	O
in	O
the	O
hypothalamus	O
which	O
give	O
an	O
effect	O
downstream,	O
resulting	O
loss	O
appetite	O
increased	O
energy	O
output.	O

In	O
the	O
United	O
States,	O
cannabidiol	B-Drug
drug	O
Epidiolex	B-Drug
was	O
approved	O
by	O
Food	O
and	O
Drug	O
Administration	O
in	O
2018	O
for	O
treatment	O
of	O
two	O
epilepsy	O
disorders.	O

(i.e.	O
the	O
isopropyl	O
instead	O
of	O
t-butyl	O
analogue	O
MDMB-CHMINACA)	O
has	O
been	O
identified	O
on	O
designer	O
drug	O
market	O
in	O
2015	O
as	O
AMB-CHMINACA.	O
MDMB-CHMINACA	B-Drug
AMB-CHMINACA	B-Drug

Antihistamines	O
(e.g.	O
fexofenadine)	O
fexofenadine	B-Drug

Consumption	O
of	O
dried	O
kratom	B-Drug
leaves	O
yields	O
different	O
responses	O
depending	O
on	O
the	O
dose	O
consumed.	O

Drugs	O
such	O
as	O
ephedrine,	O
pseudoephedrine,	O
amphetamine	B-Drug
and	O
methylphenidate	B-Drug
have	O
well	O
documented	O
ergogenic	O
effects,	O
while	O
cocaine	B-Drug
has	O
the	O
opposite	O
effect.	O
ephedrine	B-Drug
pseudoephedrine	B-Drug

/DarkNetMarkets	O
citing	O
new	O
changes	O
to	O
their	O
content	O
policy	O
that	O
forbids	O
the	O
sale	O
of	O
"Drugs,	O
including	O
alcohol	O
and	O
tobacco,	O
or	O
any	O
controlled	O
substances".	O
tobacco	B-Drug

The	O
disposition	O
of	O
MDMA	B-Drug
may	O
also	O
be	O
stereoselective,	O
with	O
the	O
S-enantiomer	O
having	O
a	O
shorter	O
elimination	O
half-life	O
and	O
greater	O
excretion	O
than	O
R-enantiomer.	O

Desogestrel,	O
sold	O
under	O
the	O
brand	O
names	O
Cerazette	O
and	O
Mircette	O
among	O
many	O
others,	O
is	O
a	O
progestin	O
medication	O
which	O
used	O
in	O
birth	O
control	O
pills	O
for	O
women.	O
Desogestrel	B-Drug

Beginning	O
in	O
2015,	O
Canada	O
has	O
seen	O
a	O
number	O
of	O
fentanyl	B-Drug
overdoses.	O

Examples	O
of	O
GABAA	O
PAMs	O
include	O
alcohol	O
(ethanol),	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug
(Valium)	O
and	O
alprazolam	B-Drug
(Xanax),	O
Z-drugs	O
zolpidem	B-Drug
(Ambien)	O
the	O
barbiturate	O
drugs.	O
Valium	B-Drug
Xanax	B-Drug
Ambien	B-Drug

They	O
are	O
also	O
responsible	O
for	O
the	O
androgenic	O
side	O
effects	O
of	O
tibolone	B-Drug
such	O
as	O
acne	O
and	O
increased	O
hair	O
growth	O
in	O
some	O
women.	O

However,	O
entactogens	O
such	O
as	O
MDMA	B-Drug
that	O
release	O
neurotransmitters	O
may	O
stimulate	O
increased	O
formation	O
of	O
free	O
radicals	O
possibly	O
formed	O
from	O
released	O
the	O
synaptic	O
vesicle.	O

Ketamine	B-Drug
is	O
frequently	O
used	O
in	O
severely	O
injured	O
people	O
and	O
appears	O
to	O
be	O
safe	O
this	O
group.	O

Between	O
1997	O
and	O
2008,	O
Grnenthal	O
declined	O
further	O
payments	O
to	O
thalidomide	B-Drug
victims.	O

Attempts	O
to	O
eradicate	O
coca	B-Drug
fields	O
through	O
the	O
use	O
of	O
defoliants	O
have	O
devastated	O
part	O
farming	O
economy	O
in	O
some	O
growing	O
regions	O
Colombia,	O
and	O
strains	O
appear	O
been	O
developed	O
that	O
are	O
more	O
resistant	O
or	O
immune	O
their	O
use.	O

In	O
1972,	O
it	O
was	O
the	O
sixth-bestselling	O
sedative	O
in	O
US,	O
where	O
legal	O
under	O
brand	O
name	O
Quaalude.	O
Quaalude	B-Drug

The	O
effects	O
of	O
this	O
and	O
related	O
mescaline	B-Drug
analogues	O
in	O
humans	O
were	O
first	O
described	O
by	O
Alexander	O
Shulgin.	O

However,	O
Hall	O
and	O
Carter	O
have	O
argued	O
that	O
many	O
such	O
objections	O
are	O
"based	O
on	O
wildly	O
exaggerated	O
unrealistic	O
scenarios	O
ignore	O
the	O
limited	O
action	O
of	O
propranolol	B-Drug
in	O
affecting	O
memory,	O
underplay	O
debilitating	O
impact	O
PTSD	O
has	O
those	O
who	O
suffer	O
from	O
it,	O
fail	O
to	O
acknowledge	O
extent	O
which	O
drugs	O
like	O
alcohol	O
already	O
used	O
for	O
this	O
purpose."	O

It	O
may	O
also	O
be	O
mixed	O
with	O
cannabis	O
or	O
tobacco.	O
tobacco	B-Drug

In	O
the	O
horror	O
video-game	O
Amnesia:	O
Rebirth	O
(2020),	O
laudanum	B-Drug
can	O
be	O
found	O
scarcely,	O
and	O
used	O
to	O
decrease	O
player	O
character's	O
fear.	O

Ro15-4513	O
was	O
somewhat	O
less	O
effective	O
than	O
flumazenil	B-Drug
at	O
blocking	O
the	O
effects	O
of	O
benzodiazepines,	O
but	O
instead	O
selectively	O
blocked	O
ethanol.	O

In	O
addition	O
to	O
its	O
medical	O
use,	O
mesterolone	B-Drug
has	O
been	O
used	O
improve	O
physique	O
and	O
performance,	O
although	O
it	O
is	O
not	O
commonly	O
for	O
such	O
purposes	O
due	O
weak	O
anabolic	O
effects.	O

It	O
takes	O
at	O
least	O
a	O
month	O
of	O
little	O
to	O
no	O
vitamin	B-Drug
C	I-Drug
in	O
the	O
diet	O
before	O
symptoms	O
occur.	O

According	O
to	O
the	O
Summer	O
1998	O
Pulse	O
Check,	O
published	O
by	O
U.S.	O
Office	O
of	O
National	O
Drug	O
Control	O
Policy,	O
cocaine	B-Drug
use	O
had	O
stabilized	O
across	O
country,	O
with	O
a	O
few	O
increases	O
reported	O
in	O
San	O
Diego,	O
Bridgeport,	O
Miami,	O
and	O
Boston.	O

Moore	O
received	O
a	O
lethal	O
injection,	O
administered	O
as	O
an	O
intravenous	O
series	O
of	O
four	O
drugs	O
that	O
included	O
fentanyl	B-Drug
citrate	O
to	O
inhibit	O
breathing	O
and	O
render	O
the	O
subject	O
unconscious.	O

In	O
2019,	O
the	O
European	O
Commission	O
announced	O
that	O
CBD	B-Drug
and	O
other	O
cannabinoids	O
would	O
be	O
classified	O
as	O
"novel	O
foods",	O
meaning	O
products	O
require	O
authorization	O
under	O
EU	O
Novel	O
Food	O
Regulation	O
stating	O
because	O
"this	O
product	O
was	O
not	O
used	O
a	O
food	O
or	O
ingredient	O
before	O
May	O
15,	O
1997,	O
it	O
may	O
placed	O
on	O
market	O
in	O
ingredient,	O
safety	O
assessment	O
is	O
required.	O

Clonazepam	B-Drug
is	O
not	O
recommended	O
for	O
use	O
in	O
those	O
under	O
18.	O

Hydrocodone/paracetamol,	O
also	O
known	O
as	O
hydrocodone/acetaminophen,	O
is	O
the	O
combination	O
of	O
pain	O
medications	O
hydrocodone	B-Drug
and	O
paracetamol	B-Drug
(acetaminophen).	O
Hydrocodone/paracetamol	B-Drug
acetaminophen	B-Drug

Pentobarbital-induced	O
coma	O
has	O
been	O
advocated	O
in	O
patients	O
with	O
acute	O
liver	O
failure	O
refractory	O
to	O
mannitol.	O
mannitol	B-Drug

When	O
interpreting	O
the	O
results	O
of	O
a	O
test,	O
it	O
is	O
important	O
to	O
consider	O
diamorphine	B-Drug
usage	O
history	O
individual,	O
since	O
chronic	O
user	O
can	O
develop	O
tolerance	O
doses	O
that	O
would	O
incapacitate	O
an	O
opiate-naive	O
and	O
often	O
has	O
high	O
baseline	O
values	O
these	O
metabolites	O
in	O
his	O
system.	O

Nichols	O
studied	O
thereby	O
molecules	O
with	O
similar	O
structure,	O
including	O
4-MTA.	O
4-MTA	B-Drug

Pfizer	O
Inc.	O
Eletriptan	B-Drug
was	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
on	O
December	O
26,	O
2002,	O
for	O
acute	O
treatment	O
of	O
migraine	O
with	O
or	O
without	O
aura	O
in	O
adults.	O

The	O
incident	O
was	O
described	O
by	O
Donald	O
A.	O
Cooper	O
of	O
the	O
DEA	O
thus:	O
"Given	O
world	O
wide	O
ready	O
availability	O
marijuana,	O
it	O
is	O
somewhat	O
difficult	O
to	O
produce	O
a	O
viable	O
argument	O
for	O
making	O
[controlled	O
substance	O
analogs	O
(CsA's)]	O
cannabinoids.	O
CsA	B-Drug

PCE	B-Drug
was	O
reported	O
in	O
1953	O
and	O
PCMo	O
1954,	O
with	O
the	O
latter	O
compound	O
described	O
as	O
a	O
potent	O
sedative.	O

In	O
premenopausal	O
women,	O
the	O
adrenal	O
glands	O
and	O
ovaries	O
each	O
produce	O
about	O
half	O
of	O
total	O
androstenedione	B-Drug
(about	O
3	O
mg/day).	O

Brand	O
names	O
include	O
Sublimaze,	O
Actiq,	O
Durogesic,	O
Duragesic,	O
Fentora,	O
Matrifen,	O
Haldid,	O
Onsolis,	O
Instanyl,	O
Abstral,	O
Lazanda	B-Drug
and	O
others.	O
Actiq	B-Drug
Duragesic	B-Drug

Tegretol	B-Drug
(carbamazepine)	O
an	O
anticonvulsant	O
used	O
as	O
a	O
mood	O
stabilizer.	O
carbamazepine	B-Drug

This	O
allows	O
GW	O
Pharmaceuticals	O
to	O
sell	O
Epidiolex,	O
but	O
it	O
does	O
not	O
apply	O
broadly	O
and	O
all	O
other	O
CBD-containing	O
products	O
remain	O
Schedule	O
Epidiolex	B-Drug

The	O
widespread	O
use	O
of	O
fentanyl	B-Drug
triggered	O
the	O
production	O
citrate	O
(the	O
salt	O
formed	O
by	O
combining	O
and	O
citric	O
acid	O
in	O
a	O
1:1	O
stoichiometric	O
ratio).	O

The	O
resulting	O
compound	O
is	O
called	O
psilocin,	O
which	O
responsible	O
for	O
the	O
psychedelic	O
effects.	O
psilocin	B-Drug

Neal	O
Benowitz,	O
a	O
professor	O
of	O
medicine	O
at	O
UC	O
San	O
Francisco	O
who	O
is	O
an	O
expert	O
on	O
ephedrine	B-Drug
and	O
other	O
stimulants,	O
agreed	O
that	O
"These	O
[levels]	O
are	O
what	O
you'd	O
see	O
from	O
someone	O
taking	O
cold	O
or	O
allergy	O
medicines	O
unlikely	O
to	O
have	O
any	O
effect	O
performance."Following	O

Unlike	O
other	O
benzodiazepines,	O
pyrazolam	B-Drug
does	O
not	O
appear	O
to	O
undergo	O
metabolism,	O
instead	O
being	O
excreted	O
unchanged	O
in	O
the	O
urine.	O

Sleep	O
apnea	O
may	O
be	O
worsened	O
by	O
lorazepam's	O
central	O
nervous	O
system	O
depressant	O
effects.	O
lorazepam	B-Drug

Studies	O
from	O
the	O
2000s	O
and	O
2010s	O
are	O
conflicted	O
on	O
whether	O
PCE	O
adolescents	O
at	O
greater	O
risk	O
for	O
use	O
of	O
drugs	O
such	O
as	O
cocaine,	O
alcohol,	O
marijuana.	O
cocaine	B-Drug

In	O
2017,	O
doctors	O
in	O
the	O
UK	O
began	O
first	O
clinical	O
study	O
of	O
MDMA	B-Drug
alcohol	O
use	O
disorder.	O

Due	O
to	O
the	O
risks	O
of	O
tolerance	O
and	O
withdrawal	O
seizures,	O
clonazepam	B-Drug
is	O
generally	O
not	O
recommended	O
for	O
long-term	O
management	O
epilepsies.	O

Thalidomide	B-Drug
did	O
not	O
damage	O
the	O
fetus	O
if	O
taken	O
after	O
42	O
days	O
gestation.	O

The	O
method	O
for	O
synthesis	O
of	O
nicomorphine,	O
which	O
involves	O
treating	O
anhydrous	O
morphine	B-Drug
base	O
with	O
nicotinic	O
anhydride	O
at	O
130	O
C,	O
was	O
published	O
by	O
Pongratz	O
and	O
Zirm	O
in	O
Monatshefte	O
fr	O
Chemie	O
1957,	O
simultaneously	O
the	O
two	O
analogues	O
nicocodeine	B-Drug
nicodicodeine	B-Drug
an	O
article	O
about	O
amides	O
esters	O
various	O
organic	O
acids.	O
nicomorphine	B-Drug

Phencyclidine	B-Drug
or	O
phenylcyclohexyl	O
piperidine	O
(PCP),	O
also	O
known	O
as	O
angel	B-Drug
dust	I-Drug
among	O
other	O
names,	O
is	O
a	O
drug	O
used	O
for	O
its	O
mind-altering	O
effects.	O
PCP	B-Drug

Steppe	O
eagles	O
have	O
the	O
same	O
vulnerability	O
to	O
diclofenac	B-Drug
as	O
vultures	O
and	O
may	O
also	O
fall	O
victim	O
it.	O

In	O
addition,	O
a	O
study	O
found	O
that	O
combination	O
of	O
125	O
mg/day	O
flutamide	O
with	O
finasteride	B-Drug
was	O
no	O
more	O
effective	O
than	O
alone	O
in	O
the	O
treatment	O
hirsutism.	O

Ocfentanil	B-Drug
is	O
a	O
Schedule	O
I	O
controlled	O
drug	O
in	O
the	O
USA	O
since	O
1.	O

Remifentanil	B-Drug
is	O
patented	O
by	O
Glaxo	O
Wellcome	O
Inc.	O
and	O
was	O
FDA	O
approved	O
on	O
July	O
12,	O
1996.	O

In	O
a	O
separate	O
study	O
conducted	O
by	O
the	O
CDC,	O
82%	O
of	O
fentanyl	B-Drug
overdose	O
deaths	O
involved	O
illegally	O
manufactured	O
fentanyl,	O
while	O
only	O
4%	O
were	O
suspected	O
to	O
originate	O
from	O
prescription.	O

Alvimopan	B-Drug
is	O
only	O
approved	O
for	O
short	O
term	O
use	O
of	O
no	O
more	O
than	O
15	O
doses.	O

Similar	O
to	O
delta-9-THC,	O
a	O
majority	O
of	O
CBD	B-Drug
is	O
excreted	O
in	O
feces	O
and	O
some	O
the	O
urine.	O
delta-9-THC	B-Drug

Some	O
of	O
his	O
artist	O
patients	O
painted	O
numerous	O
paintings	O
while	O
on	O
LSD.	O
LSD	B-Drug

As	O
adequate	O
concentrations	O
of	O
thyroid	O
hormone	O
are	O
required	O
to	O
maintain	O
normal	O
lactation,	O
appropriate	O
levothyroxine	B-Drug
doses	O
should	O
be	O
administered	O
during	O
breastfeeding.	O

Mary	O
Todd	O
Lincoln,	O
for	O
example,	O
the	O
wife	O
of	O
US	O
president	O
Abraham	O
was	O
a	O
laudanum	B-Drug
addict,	O
as	O
English	O
poet	O
Samuel	O
Taylor	O
Coleridge,	O
who	O
famously	O
interrupted	O
in	O
middle	O
an	O
opium-induced	O
writing	O
session	O
Kubla	O
Khan	O
by	O
"person	O
from	O
Porlock".	O

Oral	O
exemestane	B-Drug
25	O
mg/day	O
for	O
23	O
years	O
of	O
adjuvant	O
therapy	O
was	O
generally	O
more	O
effective	O
than	O
5	O
continuous	O
tamoxifen	B-Drug
in	O
the	O
treatment	O
postmenopausal	O
women	O
with	O
early-stage	O
estrogen	O
receptor-positive/unknown	O
receptor	O
status	O
breast	O
a	O
large	O
well-designed	O
trial.	O

The	O
Amendment	O
also	O
contained	O
measures	O
to	O
improve	O
treatment	O
and	O
care	O
for	O
people	O
dependent	O
on	O
drugs,	O
opened	O
up	O
the	O
processing	O
of	O
opium	B-Drug
concentrated	O
poppy	O
straw	O
private	O
sector,	O
strengthened	O
provisions	O
related	O
forfeiture	O
property	O
persons	O
arraigned	O
charges	O
drug	O
trafficking.	O

Acute	O
nicotine	B-Drug
intoxication	O
has	O
been	O
found	O
to	O
significantly	O
reduce	O
total	O
sleep	O
time	O
and	O
increase	O
REM	O
latency,	O
onset	O
non-rapid	O
eye	O
movement	O
(NREM)	O
stage	O
2	O
time.	O

Metandienone	B-Drug
was	O
introduced	O
and	O
formerly	O
sold	O
primarily	O
under	O
the	O
brand	O
name	O
Dianabol.	O
Dianabol	B-Drug

(See	O
for	O
example	O
Lysergic	B-Drug
acid	I-Drug
diethylamide	I-Drug
effects)	O

Taiminen	O
and	O
Jskelinen	O
(2001)	O
reported	O
the	O
case	O
of	O
an	O
otherwise	O
healthy	O
male	O
who	O
started	O
experiencing	O
intense	O
recurrent	O
sensations	O
dj	O
vu	O
upon	O
taking	O
drugs	O
amantadine	B-Drug
phenylpropanolamine	B-Drug
together	O
to	O
relieve	O
flu	O
symptoms.	O

In	O
organic	O
chemistry,	O
amphetamine	B-Drug
is	O
an	O
excellent	O
chiral	O
ligand	O
for	O
the	O
stereoselective	O
synthesis	O
of	O
1,1'-bi-2-naphthol.	O

The	O
racetams	O
have	O
poorly	O
understood	O
mechanisms,	O
although	O
piracetam	B-Drug
and	O
aniracetam	B-Drug
are	O
known	O
to	O
act	O
as	O
positive	O
allosteric	O
modulators	O
of	O
AMPA	O
receptors	O
appear	O
modulate	O
cholinergic	O
systems.	O

Besides	O
Afghanistan,	O
smaller	O
quantities	O
of	O
opium	B-Drug
are	O
produced	O
in	O
Pakistan,	O
the	O
Golden	O
Triangle	O
region	O
Southeast	O
Asia	O
(particularly	O
Burma),	O
Colombia,	O
Guatemala,	O
and	O
Mexico.	O

Mark	O
McCloud	O
is	O
a	O
recognized	O
authority	O
on	O
the	O
history	O
of	O
LSD	B-Drug
blotter	O
art.	O

American	O
rapper	O
Lil	O
Peep	O
also	O
died	O
of	O
an	O
accidental	O
fentanyl	B-Drug
overdose	O
on	O
November	O
15,	O
2017.	O

If	O
heroin	B-Drug
were	O
legal	O
today,	O
as	O
it	O
was	O
in	O
1953,	O
society	O
would	O
not	O
have	O
a	O
drug	O
problem.	O

Accutane/RoAccutane	O
(isotretinoin),	O
for	O
severe	O
(nodular)	O
acne	O
vulgaris	O
-	O
no	O
longer	O
sold	O
under	O
Accutane	B-Drug
brand	O
name	O
but	O
is	O
still	O
available	O
as	O
RoAccutane,	O
other	O
names	O
and	O
Isotretinoin	B-Drug
generics.	O
RoAccutane	B-Drug
isotretinoin	B-Drug

(Atropa	O
belladonna)	O
Hyoscyamine,	O
the	O
levo-isomer	O
of	O
atropine,	O
from	O
henbane	O
Hyoscyamine	B-Drug

As	O
of	O
2015	O
the	O
health	O
effects	O
using	O
hash	B-Drug
oil	I-Drug
were	O
poorly	O
documented.	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco,	O
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine.	O
tobacco	B-Drug
cocaine	B-Drug

Carlin's	O
resignation	O
was	O
specifically	O
linked	O
to	O
the	O
criminalisation	O
of	O
mephedrone,	O
he	O
stated:	O
"We	O
need	O
review	O
our	O
entire	O
approach	O
drugs,	O
dumping	O
idea	O
that	O
legally-sanctioned	O
punishments	O
for	O
drug	O
users	O
should	O
constitute	O
a	O
main	O
part	O
armoury	O
in	O
helping	O
solve	O
countrys	O
problems.	O
mephedrone	B-Drug

The	O
Harvard	O
researchers	O
developed	O
a	O
specific	O
protocol	O
for	O
golden	O
retriever	O
named	O
Navy	O
who	O
was	O
cancer-free	O
after	O
receiving	O
the	O
prescribed	O
cocktail	O
of	O
celecoxib,	O
doxycycline,	O
and	O
tamoxifen	B-Drug
celecoxib	B-Drug
doxycycline	B-Drug

Transmucosal	O
(diffusion	O
through	O
a	O
mucous	O
membrane),	O
e.g.	O
insufflation	O
(snorting)	O
of	O
cocaine,	O
sublingual,	O
i.e.	O
under	O
the	O
tongue,	O
sublabial,	O
between	O
lips	O
and	O
gingiva,	O
nitroglycerine,	O
vaginal	O
suppositories.	O
cocaine	B-Drug

In	O
1952,	O
thalidomide	B-Drug
was	O
synthesised	O
by	O
Chemical	O
Industry	O
Basel	O
(CIBA),	O
but	O
found	O
"to	O
have	O
no	O
effect	O
on	O
animals	O
and	O
discarded"	O
that	O
basis.	O

The	O
symptoms	O
of	O
zopiclone	B-Drug
addiction	O
can	O
include	O
depression,	O
dysphoria,	O
hopelessness,	O
slow	O
thoughts,	O
social	O
isolation,	O
worrying,	O
sexual	O
anhedonia,	O
and	O
nervousness.	O

In	O
the	O
United	O
States,	O
dextromethamphetamine	B-Drug
hydrochloride,	O
under	O
trade	O
name	O
Desoxyn,	O
has	O
been	O
approved	O
by	O
FDA	O
for	O
treating	O
ADHD	O
and	O
obesity	O
in	O
both	O
adults	O
children;	O
however,	O
also	O
indicates	O
that	O
limited	O
therapeutic	O
usefulness	O
of	O
methamphetamine	B-Drug
should	O
be	O
weighed	O
against	O
inherent	O
risks	O
associated	O
with	O
its	O
use.	O
Desoxyn	B-Drug

Hydrocodone	B-Drug
is	O
second	O
among	O
the	O
list	O
of	O
top	O
prescribed	O
opioid	O
painkillers,	O
but	O
it	O
also	O
high	O
on	O
most	O
abused.	O

LSD,	O
mescaline,	O
psilocybin,	O
and	O
PCP	B-Drug
are	O
drugs	O
that	O
cause	O
hallucinations,	O
which	O
can	O
alter	O
a	O
person's	O
perception	O
of	O
reality.	O
LSD	B-Drug
mescaline	B-Drug

Also,	O
coca	B-Drug
leaves	O
have	O
been	O
used	O
by	O
South	O
American	O
Indians	O
since	O
ancient	O
times.	O

Tibolone	B-Drug
is	O
metabolized	O
in	O
the	O
liver	O
and	O
intestines.	O

In	O
Vanda's	O
Room	O
(2000)	O
heroin	B-Drug
Inauguration	O
of	O
the	O
Pleasure	O
Dome	O
(1954)	O
ayahuasca	O
Ingrid	O
Goes	O
West	O
(2017)	O

However,	O
androstenedione	B-Drug
was	O
legally	O
defined	O
as	O
an	O
anabolic	O
steroid,	O
even	O
though	O
there	O
is	O
scant	O
evidence	O
that	O
itself	O
in	O
nature.	O

Methamphetamine	B-Drug
has	O
also	O
been	O
manufactured	O
in	O
North	O
Korea	O
and	O
brought	O
into	O
the	O
Philippines.	O

A	O
2009	O
publication	O
reported	O
using	O
HPLC	O
to	O
quickly	O
separate	O
forensically	O
important	O
illicit	O
drugs	O
including	O
psilocybin	O
and	O
psilocin,	O
which	O
were	O
identifiable	O
within	O
about	O
half	O
a	O
minute	O
of	O
analysis	O
time.	O
psilocin	B-Drug

Basuco	O
users	O
may	O
take	O
other	O
psychoactive	O
agents,	O
like	O
industrial	O
alcohol	O
and	O
MDMA	B-Drug
to	O
manage	O
the	O
drug	O
effects,	O
high	O
paranoia.	O

Loperamide	B-Drug
is	O
not	O
recommended	O
in	O
the	O
United	O
Kingdom	O
for	O
use	O
during	O
pregnancy	O
or	O
by	O
nursing	O
mothers.	O

ONDCP	O
stated	O
in	O
April	O
2011	O
that	O
there	O
has	O
been	O
a	O
46	O
percent	O
drop	O
cocaine	B-Drug
use	O
among	O
young	O
adults	O
over	O
the	O
past	O
five	O
years,	O
and	O
65	O
rate	O
of	O
people	O
testing	O
positive	O
for	O
workplace	O
since	O
2006.	O

Ethinylestradiol/dienogest	O
(Valette)	O
Ethinylestradiol/dimethisterone	O
(Oracon)	O
Ethinylestradiol/drospirenone	O
(Yasmin,	O
Yasminelle,	O
Yaz)	O
dienogest	B-Drug

Pethidine	B-Drug
is	O
the	O
prototype	O
of	O
a	O
large	O
family	O
analgesics	O
including	O
pethidine	B-Drug
4-phenylpiperidines	O
(piminodine,	O
anileridine	B-Drug
and	O
others),	O
prodines	O
(alphaprodine,	O
MPPP,	O
etc.),	O
bemidones	O
(ketobemidone,	O
etc.)	O
others	O
more	O
distant,	O
diphenoxylate	B-Drug
analogues.	O
alphaprodine	B-Drug
MPPP	B-Drug
ketobemidone	B-Drug

Treatment	O
of	O
heroin	B-Drug
addiction	O
often	O
includes	O
behavioral	O
therapy	O
and	O
medications.	O

Naltrexone	B-Drug
is	O
not	O
as	O
widely	O
used	O
buprenorphine	B-Drug
or	O
methadone	B-Drug
for	O
OUD	O
due	O
to	O
low	O
rates	O
of	O
patient	O
acceptance,	O
non-adherence	O
daily	O
dosing,	O
and	O
difficulty	O
achieving	O
abstinence	O
from	O
opioids	O
before	O
beginning	O
treatment.	O

heroin,	O
pills	O
Belly	O
(1998)	O
heroin	B-Drug

Transcranial	O
magnetic	O
stimulation	O
(TMS)	O
is	O
being	O
studied	O
as	O
a	O
treatment	O
for	O
cocaine	B-Drug
addiction,	O
although	O
definitive	O
evidence	O
efficacy	O
does	O
not	O
yet	O
exist.	O

Levonorgestrel	B-Drug
stimulates	O
the	O
proliferation	O
of	O
MCF-7	O
breast	O
cancer	O
cells	O
in	O
vitro,	O
an	O
action	O
that	O
is	O
independent	O
classical	O
PRs	O
and	O
instead	O
mediated	O
via	O
progesterone	O
receptor	O
membrane	O
component-1	O
(PGRMC1).	O

Cocaine's	O
binding	O
properties	O
are	O
such	O
that	O
it	O
attaches	O
so	O
this	O
hydrogen	O
bond	O
will	O
not	O
form	O
and	O
is	O
blocked	O
from	O
formation	O
due	O
to	O
the	O
tightly	O
locked	O
orientation	O
of	O
cocaine	B-Drug
molecule.	O
Cocaine	B-Drug

Breast	O
development	O
and	O
gynecomastia	O
induced	O
by	O
bicalutamide	B-Drug
is	O
thought	O
to	O
be	O
mediated	O
increased	O
activation	O
of	O
the	O
ER	O
secondary	O
blockade	O
AR	O
(resulting	O
in	O
disinhibition	O
breast	O
tissue)	O
levels	O
estradiol.	O

Gabapentin	B-Drug
is	O
approved	O
for	O
the	O
former	O
indication	O
in	O
US.	O

However,	O
since	O
dopamine-releasing	O
neurons	O
are	O
abundant	O
on	O
nicotine	B-Drug
receptors,	O
dopamine	O
is	O
released;	O
and,	O
in	O
the	O
nucleus	O
accumbens,	O
associated	O
with	O
motivation	O
causing	O
reinforcing	O
behavior.	O

It	O
was	O
developed	O
by	O
screening	O
chemicals	O
similar	O
to	O
pethidine	B-Drug
(meperidine)	O
for	O
opioid	O
activity.	O
meperidine	B-Drug

Toxic	O
epidermal	O
necrolysis	O
has	O
occurred	O
from	O
the	O
use	O
of	O
tetrazepam	B-Drug
including	O
at	O
least	O
one	O
reported	O
death.	O

Their	O
stage	O
performance	O
involved	O
the	O
use	O
of	O
strobe	O
lights	O
to	O
reproduce	O
LSD's	O
"surrealistic	O
fragmenting"	O
or	O
"vivid	O
isolating	O
caught	O
moments".	O
LSD	B-Drug

PCP	B-Drug
not	O
only	O
produced	O
symptoms	O
similar	O
to	O
schizophrenia,	O
it	O
also	O
yielded	O
electroencephalogram	O
changes	O
in	O
the	O
thalamocortical	O
pathway	O
(increased	O
delta	O
decreased	O
alpha)	O
and	O
hippocampus	O
(increase	O
theta	O
bursts)	O
that	O
were	O
those	O
schizophrenia.	O

A	O
"whistleblower	O
suit"	O
was	O
filed	O
in	O
2005	O
against	O
Wyeth,	O
which	O
acquired	O
by	O
Pfizer	O
2009,	O
alleging	O
that	O
the	O
company	O
illegally	O
marketed	O
their	O
drug	O
Rapamune.	O
Rapamune	B-Drug

The	O
serotonin	O
releasing	O
effects	O
of	O
tramadol	B-Drug
could	O
be	O
blocked	O
by	O
sufficiently	O
high	O
concentrations	O
the	O
reuptake	O
inhibitor	O
6-nitroquipazine,	O
which	O
is	O
in	O
accordance	O
with	O
other	O
agents	O
such	O
as	O
fenfluramine	B-Drug
and	O
MDMA.	O
MDMA	B-Drug

As	O
of	O
May	O
2020,	O
there	O
is	O
a	O
phase-2	O
clinical	O
trial	O
Ibogaine	B-Drug
for	O
the	O
treatment	O
alcoholism	O
scheduled	O
August	O
2020	O
in	O
Brazil.	O

Cocaine	B-Drug
was	O
introduced	O
into	O
clinical	O
use	O
as	O
a	O
local	O
anesthetic	O
in	O
Germany	O
1884,	O
about	O
the	O
same	O
time	O
Sigmund	O
Freud	O
published	O
his	O
work	O
ber	O
Coca,	O
which	O
he	O
wrote	O
that	O
cocaine	B-Drug
causes:	O
Exhilaration	O
and	O
lasting	O
euphoria,	O
no	O
way	O
differs	O
from	O
normal	O
euphoria	O
of	O
healthy	O
person.	O

A	O
form	O
of	O
buprenorphine	B-Drug
for	O
the	O
treatment	O
opioid	O
dependence	O
is	O
also	O
available	O
as	O
an	O
injectable	O
implant.	O

In	O
2004,	O
the	O
FDA	O
issued	O
a	O
"Patient	O
Safety"	O
news	O
bulletin	O
stating	O
that	O
"To	O
help	O
resolve	O
confusion	O
[between	O
opium	B-Drug
tincture	O
and	O
paregoric],	O
will	O
be	O
working	O
with	O
manufacturers	O
of	O
these	O
two	O
drugs	O
to	O
clarify	O
labeling	O
on	O
containers	O
in	O
package	O
inserts."	O

A	O
blunt	O
is	O
cannabis	O
rolled	O
with	O
a	O
cigar	O
wrapper	O
(usually	O
tobacco	B-Drug
leaf,	O
which	O
contains	O
nicotine).	O
nicotine	B-Drug

Surez	O
had	O
a	O
fleet	O
of	O
aircraft,	O
primarily	O
the	O
Cessna	O
206	O
and	O
Douglas	O
DC-3,	O
which	O
flew	O
cocaine	B-Drug
shipments	O
from	O
Bolivian	O
Amazon	O
to	O
Colombia,	O
selling	O
at	O
$9,000	O
per	O
kilogram.	O

However,	O
benzodiazepines	O
with	O
intermediate	O
half-lives	O
like	O
lorazepam	B-Drug
may	O
be	O
safer	O
in	O
people	O
liver	O
problems.	O

Individuals	O
with	O
an	O
opioid	O
use	O
disorder	O
are	O
often	O
treated	O
replacement	O
therapy	O
using	O
methadone	B-Drug
or	O
buprenorphine.	O
buprenorphine	B-Drug

Heroin	B-Drug
is	O
also	O
known	O
by	O
many	O
street	O
names	O
including	O
dope,	O
H,	O
smack,	O
junk,	O
horse,	O
scag,	O
and	O
brown,	O
among	O
others.	O
smack	B-Drug

In	O
1985	O
the	O
World	O
Health	O
Organization's	O
Expert	O
Committee	O
on	O
Drug	O
Dependence	O
recommended	O
that	O
MDMA	B-Drug
be	O
placed	O
in	O
Schedule	O
I	O
of	O
1971	O
United	O
Nations	O
Convention	O
Psychotropic	O
Substances.	O

Compared	O
to	O
heroin,	O
it	O
is	O
more	O
potent,	O
has	O
higher	O
profit	O
margins	O
and,	O
because	O
compact,	O
simpler	O
logistics.	O
heroin	B-Drug

However,	O
athletes	O
and	O
bodybuilders	O
have	O
been	O
using	O
trenbolone	B-Drug
acetate	O
as	O
a	O
physique-	O
performance-enhancing	O
drug	O
for	O
decades.	O

,	O
RCS-4,	O
RCS-4	B-Drug
butyl	O
homologue,	O
JWH-210,	O
JWH-081,	O
JWH-210	B-Drug
JWH-081	B-Drug

Mianserin	B-Drug
can	O
make	O
antihistamines	O
and	O
antimuscarinics	O
have	O
stronger	O
effects.	O

In	O
children	O
and	O
adolescents,	O
risperidone	B-Drug
may	O
be	O
more	O
effective	O
than	O
lithium	O
or	O
divalproex,	O
but	O
has	O
metabolic	O
side	O
effects.	O
divalproex	B-Drug

the	O
Netherlands,	O
fentanyl	B-Drug
is	O
a	O
List	O

Vendors	O
would	O
import	O
25I-NBOMe	B-Drug
in	O
bulk	O
(E.G	O
1	O
kilogram	O
containers)	O
and	O
resell	O
individual	O
doses	O
for	O
a	O
considerable	O
profit.	O

Noretynodrel,	O
an	O
isomer	O
of	O
norethisterone,	O
was	O
synthesized	O
in	O
1952	O
by	O
Frank	O
B.	O
Colton	O
at	O
Searle	O
Skokie,	O
Illinois	O
and	O
used	O
as	O
the	O
progestin	O
Enovid,	O
marketed	O
U.S.	O
1957	O
approved	O
first	O
oral	O
contraceptive	O
1960.	O
norethisterone	B-Drug

The	O
potent	O
agonism	O
of	O
the	O
5-HT2B	O
receptor	O
makes	O
it	O
likely	O
that	O
6-APB	B-Drug
would	O
be	O
cardiotoxic	O
with	O
chronic	O
or	O
long-term	O
use,	O
as	O
seen	O
other	O
agonists	O
such	O
withdrawn	O
serotonergic	O
anorectic	O
fenfluramine.	O
fenfluramine	B-Drug

Activated	O
charcoal	O
can	O
be	O
used	O
to	O
decrease	O
absorption	O
of	O
paracetamol	B-Drug
if	O
the	O
person	O
comes	O
hospital	O
soon	O
after	O
overdose.	O

Contraindications	O
of	O
dienogest	B-Drug
include	O
active	O
venous	O
thromboembolism,	O
previous	O
or	O
current	O
cardiovascular	O
disease,	O
diabetes	O
with	O
complications,	O
severe	O
liver	O
disease	O
tumors,	O
hormone-dependent	O
cancers	O
such	O
as	O
breast	O
cancer,	O
and	O
undiagnosed	O
vaginal	O
bleeding.	O

5-Reductase	O
inhibitors	O
like	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
can	O
prevent	O
the	O
inactivation	O
of	O
nandrolone	B-Drug
in	O
so-called	O
"androgenic"	O
tissues	O
skin,	O
hair	O
follicles,	O
prostate	O
gland	O
may	O
therefore	O
considerably	O
increase	O
its	O
androgenic	O
side	O
effects.	O

As	O
mentioned	O
below	O
under	O
pharmacology,	O
cases	O
of	O
scleroderma-like	O
illness	O
have	O
been	O
reported	O
in	O
patients	O
using	O
carbidopa	B-Drug
and	O
5-HTP.Oral	O
5-HTP	O
results	O
an	O
increase	O
urinary	O
5-HIAA,	O
a	O
serotonin	O
metabolite,	O
indicating	O
that	O
is	O
peripherally	O
metabolized	O
to	O
serotonin,	O
which	O
then	O
metabolized.	O

Transporters	O
from	O
Mexico	O
usually	O
were	O
given	O
35%	O
to	O
50%	O
of	O
each	O
cocaine	B-Drug
shipment.	O

Cannabis	O
cultivation	O
died	O
off	O
in	O
Panama	O
with	O
the	O
rise	O
of	O
cocaine	B-Drug
trafficking.	O

It	O
is	O
as	O
effective	O
for	O
this	O
indication	O
gabapentine	O
or	O
pregabalin	B-Drug
but	O
less	O
well	O
tolerated.	O

On	O
11	O
November,	O
she	O
took	O
an	O
ecstasy	B-Drug
(MDMA)	O
tablet,	O
and	O
then	O
drank	O
approximately	O
7	O
litres	O
(12	O
imp	O
pt;	O
1.8	O
US	O
gal)	O
of	O
water	O
in	O
a	O
90	O
minute	O
period.	O
MDMA	B-Drug

Currently	O
approved	O
azapirones	O
include	O
buspirone	B-Drug
(Buspar)	O
and	O
tandospirone	O
(Sediel).	O
Buspar	B-Drug

Unlike	O
19-nortestosterone	B-Drug
progestins	O
like	O
levonorgestrel,	O
CMA	O
does	O
not	O
antagonize	O
the	O
EE-induced	O
increase	O
in	O
SHBG	O
levels.	O
levonorgestrel	B-Drug

Methamphetamine	B-Drug
is	O
most	O
structurally	O
similar	O
to	O
amphetamine.	O
amphetamine	B-Drug

Typically,	O
the	O
base	O
for	O
lean	O
has	O
been	O
prescription	O
cold	O
medicine,	O
specifically	O
cough	O
syrup,	O
one	O
that	O
contains	O
both	O
promethazine	B-Drug
and	O
codeine,	O
but	O
over-the-counter	O
medicine	O
lists	O
dextromethorphan	B-Drug
as	O
active	O
ingredient	O
also	O
used,	O
it	O
can	O
produce	O
similar	O
effects	O
eliminate	O
need	O
a	O
doctor's	O
visit.	O
codeine	B-Drug

Finasteride	B-Drug
is	O
extensively	O
metabolized	O
in	O
the	O
liver,	O
first	O
by	O
hydroxylation	O
via	O
CYP3A4	O

This	O
greatly	O
reduced	O
the	O
clinical	O
research	O
about	O
LSD,	O
although	O
limited	O
experiments	O
continued	O
to	O
take	O
place,	O
such	O
as	O
those	O
conducted	O
by	O
Reese	O
Jones	O
in	O
San	O
Francisco.	O
LSD	B-Drug

A	O
key	O
figure	O
in	O
this	O
phenomenon	O
the	O
UK	O
was	O
British	O
academic	O
Michael	O
Hollingshead,	O
who	O
first	O
tried	O
LSD	B-Drug
America	O
1961	O
while	O
he	O
Executive	O
Secretary	O
for	O
Institute	O
of	O
British-American	O
Cultural	O
Exchange.	O

Because	O
significant	O
tolerance	O
to	O
respiratory	O
depression	O
develops	O
quickly	O
with	O
continued	O
use	O
and	O
is	O
lost	O
just	O
as	O
during	O
withdrawal,	O
it	O
often	O
difficult	O
determine	O
whether	O
a	O
heroin	B-Drug
lethal	O
overdose	O
was	O
accidental,	O
suicide	O
or	O
homicide.	O

Despite	O
its	O
low	O
affinity	O
for	O
the	O
PR	O
however,	O
dienogest	B-Drug
has	O
high	O
progestogenic	O
activity	O
in	O
vivo.	O

Nitrazepam	B-Drug
has	O
demonstrated	O
cortisol-suppressing	O
properties	O
in	O
humans.	O

A	O
review	O
of	O
the	O
details	O
194	O
deaths	O
attributed	O
to	O
or	O
related	O
GHB	B-Drug
over	O
a	O
ten-year	O
period	O
found	O
that	O
most	O
were	O
from	O
respiratory	O
depression	O
caused	O
by	O
interaction	O
with	O
alcohol	O
other	O
drugs.	O

Phenobarbital	B-Drug
(5-ethyl-5-phenylbarbituric	O
acid)	O

Octreotide	B-Drug
has	O
also	O
been	O
investigated	O
in	O
people	O
with	O
pain	O
from	O
chronic	O
pancreatitis.	O

Cetrorelix	B-Drug
can	O
be	O
mixed	O
with	O
follitropin	O
alpha	O
without	O
compromising	O
their	O
reported	O
safety	O
and	O
efficacy.	O

The	O
cultivation	O
of	O
opium	B-Drug
[in	O
Afghanistan]	O
reached	O
its	O
peak	O
in	O
1999,	O
when	O
350	O
square	O
miles	O
(910	O
km2)	O
poppies	O
were	O
sown	O
...	O

The	O
drug	O
has	O
been	O
shown	O
to	O
be	O
similarly	O
effective	O
in	O
the	O
treatment	O
of	O
generalized	O
anxiety	O
disorder	O
(GAD)	O
benzodiazepines	O
including	O
diazepam,	O
alprazolam,	O
lorazepam,	O
and	O
clorazepate.	O
diazepam	B-Drug
alprazolam	B-Drug
lorazepam	B-Drug
clorazepate	B-Drug

However,	O
due	O
to	O
the	O
federal	O
ban	O
on	O
androstenedione	B-Drug
supplements,	O
it	O
is	O
difficult	O
carry	O
out	O
new	O
research	O
its	O
effects.	O

Progesterone	O
in	O
turn	O
is	O
the	O
precursor	O
of	O
mineralocorticoid	O
aldosterone,	O
and	O
after	O
conversion	O
to	O
17-hydroxyprogesterone,	O
cortisol	O
androstenedione.	O
androstenedione	B-Drug

Due	O
to	O
clomethiazole's	O
action	O
at	O
the	O
barbiturate	O
complex	O
benzodiazepine	O
antidote	O
flumazenil	B-Drug
cannot	O
reverse	O
effects	O
of	O
overdose;	O
overdose	O
treatment	O
is	O
restricted	O
application	O
a	O
mechanical	O
ventilation	O
apparatus	O
until	O
enough	O
drug	O
has	O
been	O
metabolized	O
and/or	O
excreted	O
for	O
patient	O
breathe	O
sufficiently	O
without	O
assistance.	O

According	O
to	O
Ryan,	O
chemical	O
analysis	O
identified	O
the	O
active	O
ingredient	O
as	O
"100	O
percent	O
phenazepam".	O
phenazepam	B-Drug

Trenbolone	O
acetate	O
is	O
a	O
modified	O
form	O
of	O
nandrolone.	O
nandrolone	B-Drug

In	O
response,	O
New	O
Zealand	O
experts	O
called	O
for	O
wider	O
availability	O
of	O
naloxone.	O
naloxone	B-Drug

The	O
most	O
popular	O
method	O
for	O
reducing	O
ephedrine	B-Drug
to	O
methamphetamine	B-Drug
is	O
similar	O
the	O
Birch	O
reduction,	O
in	O
that	O
it	O
uses	O
anhydrous	O
ammonia	O
and	O
lithium	O
metal	O
reaction.	O

Aspirin,	O
other	O
NSAIDs,	O
and	O
paracetamol	B-Drug
(acetaminophen)	O
had	O
no	O
effect	O
on	O
the	O
risk	O
for	O
Parkinson's.	O
Aspirin	B-Drug
acetaminophen	B-Drug

During	O
the	O
18th	O
century,	O
opium	B-Drug
was	O
found	O
to	O
be	O
a	O
good	O
remedy	O
for	O
nervous	O
disorders.	O

Boldenone	B-Drug
(17-hydroxyandrosta-1,4-dien-3-one)	O
Bolenol	O
(19-nor-17-pregn-5-en-17-ol)	O

Medications	O
such	O
as	O
phenelzine,	O
have	O
been	O
used	O
to	O
cause	O
an	O
"aversion	O
reaction"	O
when	O
administered	O
with	O
cocaine.	O
phenelzine	B-Drug
cocaine	B-Drug

Fentanyl	B-Drug
analogues	O
may	O
be	O
hundreds	O
of	O
times	O
more	O
potent	O
than	O
heroin.	O
heroin	B-Drug

This	O
has	O
been	O
observed	O
already	O
with	O
resistance	O
genes	O
for	O
triclosan,	O
tetracycline,	O
and	O
trimethoprim.	O
trimethoprim	B-Drug

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms,	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O

In	O
1978,	O
People	O
magazine	O
and	O
Mike	O
Wallace	O
of	O
60	O
Minutes	O
called	O
PCP	B-Drug
the	O
country's	O
"number	O
one"	O
drug	O
problem.	O

Previously	O
a	O
relatively	O
unknown	O
drug	O
to	O
North	O
American	O
athletes,	O
Furazabol	B-Drug
gained	O
notoriety	O
in	O
the	O
Commission	O
of	O
Inquiry	O
into	O
Use	O
Drugs	O
and	O
Banned	O
Practices	O
Intended	O
Increase	O
Athletic	O
Performance	O
(known	O
colloquially	O
as	O
The	O
Dubin	O
Inquiry).	O

(MENT	O
acetate)	O
and	O
7-methylestr-4-en-17-ol-3-one	O
17-acetate)	O
is	O
a	O
synthetic	O
injected	O
anabolicandrogenic	O
steroid	O
(AAS)	O
derivative	O
of	O
nandrolone	B-Drug
(19-nortestosterone)	O
which	O
was	O
never	O
marketed.	O
19-nortestosterone	B-Drug

As	O
a	O
glucocorticoid,	O
dexamethasone	B-Drug
is	O
an	O
agonist	O
of	O
the	O
glucocorticoid	O
receptor	O
(GR).	O

To	O
get	O
butylone	B-Drug
a	O
drop	O
of	O
ether	O
and	O
HCl	O
solution	O
was	O
added.	O

In	O
May,	O
onasemnogene	B-Drug
abeparvovec	I-Drug
(Zolgensma)	O
was	O
approved	O
by	O
the	O
European	O
Union	O
for	O
treatment	O
of	O
spinal	O
muscular	O
atrophy	O
in	O
people	O
who	O
either	O
have	O
clinical	O
symptoms	O
SMA	O
type	O
1	O
or	O
2	O
3	O
copies	O
SMN2	O
gene,	O
irrespective	O
body	O
weight	O
age.	O
Zolgensma	B-Drug

It	O
is	O
similar	O
to	O
tramadol	B-Drug
in	O
its	O
dual	O
mechanism	O
of	O
action;	O
namely,	O
ability	O
activate	O
the	O
mu	O
opioid	O
receptor	O
and	O
inhibit	O
reuptake	O
norepinephrine.	O

By	O
the	O
early	O
1980s	O
MDMA	B-Drug
was	O
being	O
used	O
in	O
Boston	O
and	O
New	O
York	O
City	O
nightclubs	O
such	O
as	O
Studio	O
54	O
Paradise	O
Garage.	O

From	O
1989	O
to	O
1994,	O
in	O
the	O
midst	O
of	O
public	O
outcry	O
about	O
cocaine	B-Drug
babies,	O
Medical	O
University	O
South	O
Carolina	O
tested	O
pregnant	O
women	O
for	O
cocaine,	O
reporting	O
those	O
who	O
positive	O
police.	O

First	O
synthesized	O
in	O
Germany	O
1940	O
and	O
patented	O
the	O
US	O
1952,	O
it	O
has	O
a	O
high	O
potential	O
for	O
abuse	O
as	O
with	O
any	O
potent	O
opioid	O
agonist,	O
is	O
sometimes	O
found	O
along	O
desomorphine	B-Drug
component	O
of	O
home-made	O
mixture	O
known	O
"Krokodil"	O
used	O
Russia	O
neighboring	O
former	O
Soviet	O
republics.	O

helped	O
fund	O
another	O
study	O
exploring	O
the	O
link	O
between	O
HIV	O
infection	O
and	O
injection	O
use	O
of	O
oxymorphone	B-Drug
in	O
Indiana	O
from	O
2014	O
to	O
2015.The	O
results	O
these	O
studies	O

Ketamine	B-Drug
appears	O
not	O
to	O
produce	O
sedation	O
or	O
aneasthesia	O
in	O
snails.	O

Szra,	O
who	O
later	O
worked	O
for	O
the	O
US	O
National	O
Institutes	O
of	O
Health,	O
had	O
turned	O
his	O
attention	O
to	O
DMT	O
after	O
order	O
LSD	B-Drug
from	O
Swiss	O
company	O
Sandoz	O
Laboratories	O
was	O
rejected	O
on	O
grounds	O
that	O
powerful	O
psychotropic	O
could	O
be	O
dangerous	O
in	O
hands	O
a	O
communist	O
country.	O

As	O
opposed	O
to	O
Adderall,	O
which	O
contains	O
roughly	O
equal	O
parts	O
of	O
racemic	O
amphetamine	B-Drug
and	O
dextroamphetamine	B-Drug
salts,	O
lisdexamfetamine	B-Drug
is	O
a	O
single-enantiomer	O
formula.	O
Adderall	B-Drug

Selegiline	B-Drug
has	O
also	O
been	O
used	O
off-label	O
as	O
a	O
palliative	O
treatment	O
for	O
dementia	O
in	O
Alzheimer's	O
disease.	O

Less	O
frequently,	O
in	O
3-10%	O
of	O
people,	O
fentanyl	B-Drug
can	O
cause	O
abdominal	O
pain,	O
headache,	O
fatigue,	O
anorexia	O
and	O
weight	O
loss,	O
dizziness,	O
nervousness,	O
hallucinations,	O
anxiety,	O
depression,	O
flu-like	O
symptoms,	O
dyspepsia	O
(indigestion),	O
shortness	O
breath,	O
hypoventilation,	O
apnoea,	O
urinary	O
retention.	O

In	O
this	O
paper	O
he	O
declared	O
coca	B-Drug
and	O
cocaine	B-Drug
(at	O
the	O
time	O
they	O
were	O
assumed	O
to	O
be	O
same)	O
as	O
being	O
useful	O
medicinally,	O
in	O
treatment	O
of	O
"a	O
furred	O
tongue	O
morning,	O
flatulence,	O
whitening	O
teeth.	O

Mirtazapine	B-Drug
itself	O
blocks	O
these	O
same	O
alpha-2	O
autoreceptors,	O
so	O
the	O
effect	O
of	O
adding	O
mirtazapine	B-Drug
to	O
a	O
patient	O
stabilized	O
on	O
clonidine	B-Drug
may	O
precipitate	O
withdrawal	O
symptoms.	O

According	O
to	O
the	O
United	O
Nations	O
Office	O
on	O
Drugs	O
and	O
Crime	O
(UNODC),	O
there	O
are	O
an	O
estimated	O
18	O
million	O
users	O
of	O
cocaine	B-Drug
globally.	O

In	O
Canada,	O
fentanyl	B-Drug
is	O
considered	O
a	O
Schedule	O
I	O
drug	O
as	O
listed	O
in	O
Canada's	O
Controlled	O
Drugs	O
and	O
Substances	O
Act.	O

Pentazocine	B-Drug
was	O
originally	O
unclassified	O
under	O
the	O
Controlled	O
Substances	O
Act.	O

Ketoconazole	B-Drug
and	O
sulfaphenazole	O
interfere	O
with	O
the	O
metabolism	O
of	O
zopiclone.	O
zopiclone	B-Drug

The	O
elimination	O
half-life	O
of	O
levonorgestrel	B-Drug
is	O
24	O
to	O
32	O
hours,	O
although	O
values	O
as	O
short	O
8	O
hours	O
and	O
great	O
45	O
have	O
been	O
reported.	O

However,	O
propofol	B-Drug
can	O
induce	O
hypotension	O
and	O
bradycardia	O
due	O
to	O
its	O
calcium	O
channel	O
blocker	O
beta	O
properties.	O

and	O
JWH-122	B-Drug
were	O
banned	O
in	O
Sweden	O
on	O
1	O
October	O
2010	O
as	O
hazardous	O
goods	O
harmful	O
to	O
health,	O
after	O
being	O
identified	O
ingredients	O
"herbal"	O
synthetic	O
cannabis	O
products.	O

According	O
to	O
anecdotal	O
reports	O
from	O
the	O
substance's	O
entry	O
in	O
PiHKAL,	O
3C-BZ's	O
effects	O
can	O
vary	O
significantly,	O
ranging	O
intensified	O
emotions	O
and	O
strange	O
dreams,	O
similar	O
those	O
of	O
LSD	B-Drug
or	O
TMA.	O

Fludrocortisone	B-Drug
(Florinef)	O
is	O
a	O
synthetic	O
mineralocorticoid.	O

Metenolone	O
enanthate,	O
or	O
methenolone	B-Drug
sold	O
under	O
the	O
brand	O
names	O
Primobolan	O
Depot	O
and	O
Nibal	O
Injection,	O
is	O
an	O
androgen	O
anabolic	O
steroid	O
(AAS)	O
medication	O
which	O
used	O
mainly	O
in	O
treatment	O
of	O
anemia	O
due	O
to	O
bone	O
marrow	O
failure.	O

Meprodine	B-Drug
is	O
an	O
opioid	O
analgesic	O
that	O
analogue	O
of	O
pethidine	B-Drug
(meperidine).	O
meperidine	B-Drug

Propofol	B-Drug

The	O
dose	O
of	O
THC	B-Drug
needed	O
to	O
kill	O
50%	O
tested	O
rodents	O
is	O
extremely	O
high.	O

Heroin	B-Drug
is	O
Schedule	O
1	O
on	O
the	O
California	O
Uniform	O
Controlled	O
Substances	O
Act.	O

CBN	B-Drug
acts	O
as	O
a	O
partial	O
agonist	O
at	O
the	O
CB1	O
receptors,	O
but	O
has	O
higher	O
affinity	O
to	O
CB2	O
receptors;	O
however,	O
it	O
lower	O
affinities	O
relative	O
THC.	O
THC	B-Drug

Faced	O
with	O
the	O
problem	O
that	O
many	O
Chinese	O
associated	O
Christianity	O
opium,	O
partly	O
due	O
to	O
arrival	O
of	O
early	O
Protestant	O
missionaries	O
on	O
opium	B-Drug
clippers,	O
at	O
1890	O
Shanghai	O
Missionary	O
Conference,	O
they	O
agreed	O
establish	O
Permanent	O
Committee	O
for	O
Promotion	O
Anti-Opium	O
Societies	O
in	O
an	O
attempt	O
overcome	O
this	O
and	O
arouse	O
public	O
opinion	O
against	O
trade.	O

Britain's	O
All-India	O
Opium	O
Act	O
of	O
1878	O
formalized	O
ethnic	O
restrictions	O
on	O
the	O
use	O
opium,	O
limiting	O
recreational	O
opium	B-Drug
sales	O
to	O
registered	O
Indian	O
opium-eaters	O
and	O
Chinese	O
opium-smokers	O
only	O
prohibiting	O
its	O
sale	O
workers	O
from	O
Burma.	O

This	O
is	O
notably	O
not	O
the	O
case	O
with	O
combined	O
oral	O
contraceptives	O
that	O
contain	O
norethisterone	B-Drug
and	O
EE,	O
however.	O

The	O
medicinal	O
chemistry	O
work	O
turned	O
to	O
improving	O
the	O
lead	O
compound	O
into	O
a	O
suitable	O
drug:	O
result	O
was	O
thalidomide.	O
thalidomide	B-Drug

Prednisolone	B-Drug
sodium	I-Drug
phosphate	I-Drug
oral	O
dissolving	O
tablets	O
(Orapred	O
ODT)	O
Orapred	B-Drug

Desomorphine	B-Drug
abuse	O
in	O
Russia	O
attracted	O
international	O
attention	O
2010	O
due	O
to	O
an	O
increase	O
clandestine	O
production,	O
presumably	O
its	O
relatively	O
simple	O
synthesis	O
from	O
codeine	B-Drug
available	O
over-the-counter.	O

Naltrexone	B-Drug
is	O
metabolized	O
in	O
the	O
liver	O
mainly	O
to	O
6-naltrexol	O
by	O
enzyme	O
dihydrodiol	O
dehydrogenase.	O

A	O
chemical	O
synthesis	O
of	O
methyltestosterone	B-Drug
from	O
dehydroepiandrosterone	O
(DHEA)	O
with	O
methandriol	O
as	O
an	O
intermediate	O
proceeds	O
follows:	O
Methyltestosterone	B-Drug
was	O
first	O
synthesized	O
in	O
1935	O
along	O
and	O
mestanolone.	O
mestanolone	B-Drug

Work	O
in	O
the	O
laboratory	O
of	O
Mark	O
Molliver	O
at	O
Johns	O
Hopkins	O
indicated	O
degeneration	O
cerebellar	O
Purkinje	O
cells	O
observed	O
rats	O
given	O
substantially	O
larger	O
dosages	O
ibogaine	B-Drug
than	O
those	O
used	O
to	O
study	O
drug	O
self-administration	O
and	O
withdrawal.	O

Special	O
provisions	O
relating	O
to	O
coca	B-Drug
plant	O
and	O
leaves	O
for	O
use	O
in	O
the	O
preparation	O
of	O
flavoring	O
agentNotwithstanding	O
anything	O
contained	O
section	O
8,	O
Central	O
Government	O
may	O
permit,	O
with	O
or	O
without	O
conditions,	O
on	O
behalf	O
Government,	O
cultivation	O
any	O
gathering	O
portion	O
thereof	O
production,	O
possession,	O
sale,	O
purchase,	O
transport,	O
import	O
inter-State,	O
export	O
inter-State	O
into	O
India	O
agent	O
which	O
shall	O
not	O
contain	O
alkaloid	O
extent	O
necessary	O
such	O
use.	O

The	O
Japanese	O
motorcycle	O
racer	O
Noriyuki	O
Haga	O
tested	O
positive	O
for	O
ephedrine	B-Drug
in	O
2000,	O
being	O
disqualified	O
from	O
two	O
races	O
and	O
banned	O
more	O
as	O
a	O
result.	O

Methimazole	B-Drug
Propylthiouracil	O
Lugol's	O
solution	O
Potassium	B-Drug
iodide	I-Drug
Tuberculin,	O
purified	B-Drug
protein	I-Drug
derivative	I-Drug
(	O
Tuberculin	B-Drug

As	O
of	O
September	O
2018,	O
zolpidem	B-Drug
was	O
marketed	O
under	O
many	O
brands:	O
Adorma,	O
Albapax,	O
Ambien,	O
Atrimon,	O
Belbien,	O
Bikalm,	O
Cymerion,	O
Dactive,	O
Dalparan,	O
Damixan,	O
Dormeben,	O
Dormilam,	O
Dormilan,	O
Dormizol,	O
Eanox,	O
Edluar,	O
Flazinil,	O
Fulsadem,	O
Hypnogen,	O
Hypnonorm,	O
Intermezzo,	O
Inzofresh,	O
Ivadal,	O
Ivedal,	O
Le	O
Tan,	O
Lioram,	O
Lunata,	O
Medploz,	O
Mondeal,	O
Myslee,	O
Nasen,	O
Niterest,	O
Nocte,	O
Nottem,	O
Noxidem,	O
Noxizol,	O
Nuo	O
Bin,	O
Nytamel,	O
Nyxe,	O
Olpitric,	O
Onirex,	O
Opsycon,	O
Patz,	O
Polsen,	O
Sanval,	O
Semi-Nax,	O
Sleepman,	O
Somex,	O
Somidem,	O
Somit,	O
Somnil,	O
Somnipax,	O
Somnipron,	O
Somno,	O
Somnogen,	O
Somnor,	O
Sonirem,	O
Sove,	O
Soza,	O
Stilnoct,	O
Stilnox,	O
Stilpidem,	O
Stimin,	O
Sublinox,	O
Sucedal,	O
Sumenan,	O
Vicknox,	O
Viradex,	O
Xentic,	O
Zasan,	O
Zaviana,	O
Ziohex,	O
Zipsoon,	O
Zodem,	O
Zodenox,	O
Zodium,	O
Zodorm,	O
Zolcent,	O
Zoldem,	O
Zoldorm,	O
Zoldox,	O
Zolep,	O
Zolfresh,	O
Zolip,	O
Zolman,	O
Zolmia,	O
Zolnox,	O
Zolnoxs,	O
Zolodorm,	O
Zolnyt,	O
Zolpeduar,	O
Zolpel,	O
Zolpi,	O
Zolpi-Q,	O
Zolpic,	O
Zolpidem,	O
Zolpidem	B-Drug
tartrate,	O
Zolpidemi	O
tartras,	O
Zolpidemtartraat,	O
Zolpidemtartrat,	O
Zolpidemum,	O
Zolpigen,	O
Zolpihexal,	O
Zolpimist,	O
Zolpineo,	O
Zolpinox,	O
Zolpirest,	O
Zolpistar,	O
Zolpitop,	O
Zolpitrac,	O
Zolpium,	O
Zolprem,	O
Zolsana,	O
Zolta,	O
Zoltar,	O
Zolway,	O
Zomnia,	O
Zonadin,	O
Zonoct,	O
Zopid,	O
Zopidem,	O
Zopim,	O
and	O
Zorimin.	O
Ambien	B-Drug
Stilnox	B-Drug

Ibogaine	B-Drug
-	O
Natural	O
Tramadol"	O
(2021)	O
Tramadol	B-Drug

A	O
photoactivatable	O
form	O
of	O
nicotine,	O
which	O
releases	O
nicotine	B-Drug
when	O
exposed	O
to	O
ultraviolet	O
light	O
with	O
certain	O
conditions,	O
has	O
been	O
developed	O
for	O
studying	O
nicotinic	O
acetylcholine	O
receptors	O
in	O
brain	O
tissue.	O

However,	O
the	O
effects	O
were	O
significantly	O
less	O
than	O
those	O
of	O
methyltestosterone.	O
methyltestosterone	B-Drug

As	O
part	O
of	O
the	O
REMS	O
requirements,	O
prescribers	O
and	O
patients	O
must	O
adhere	O
to	O
required	O
cardiac	O
monitoring	O
with	O
echocardiograms	O
receive	O
fenfluramine.	O
fenfluramine	B-Drug

If	O
withdrawal	O
occurs,	O
naltrexone	B-Drug
should	O
not	O
be	O
started.	O

Premazepam	O
produces	O
more	O
slow	O
wave	O
and	O
less	O
fast	O
EEG	O
changes	O
than	O
diazepam.	O
diazepam	B-Drug

Alcohol	O
and	O
nicotine	B-Drug
also	O
prime	O
the	O
brain	O
for	O
a	O
heightened	O
response	O
to	O
other	O
drugs	O
are,	O
like	O
marijuana,	O
typically	O
used	O
before	O
person	O
progresses	O
other,	O
more	O
harmful	O
substances.	O

Although	O
Ziegler	O
prescribed	O
only	O
small	O
doses	O
to	O
athletes,	O
he	O
soon	O
discovered	O
that	O
those	O
having	O
abused	O
Dianabol	B-Drug
suffered	O
from	O
enlarged	O
prostates	O
and	O
atrophied	O
testes.	O

Fentanyl	B-Drug
is	O
sometimes	O
given	O
intrathecally	O
as	O
part	O
of	O
spinal	O
anesthesia	O
or	O
epidurally	O
for	O
epidural	O
anaesthesia	O
and	O
analgesia.	O

In	O
2016,	O
deaths	O
from	O
fatal	O
fentanyl	B-Drug
overdoses	O
in	O
the	O
province	O
of	O
British	O
Columbia	O
averaged	O
two	O
persons	O
per	O
day.	O

In	O
the	O
United	O
States	O
eszopiclone	B-Drug
is	O
a	O
schedule	O
IV	O
controlled	O
substance	O
under	O
Controlled	O
Substances	O
Act.	O

Some	O
slang	O
terms	O
for	O
opium	B-Drug
include:	O
"Big	O
O",	O
"Shanghai	O
Sally",	O
"dope",	O
"hop",	O
"midnight	O
oil",	O
"O.P.",	O
and	O
"tar".	O
"	O

In	O
the	O
United	O
States,	O
nicotine	B-Drug
products	O
and	O
Nicotine	O
Replacement	O
Therapy	O
like	O
Nicotrol	O
are	O
only	O
available	O
to	O
persons	O
21	O
above;	O
proof	O
of	O
age	O
is	O
required;	O
not	O
for	O
sale	O
in	O
vending	O
machine	O
or	O
from	O
any	O
source	O
where	O
cannot	O
be	O
verified.	O

In	O
1947,	O
David	O
Lester	O
and	O
Leon	O
Greenberg	O
found	O
strong	O
evidence	O
that	O
paracetamol	B-Drug
was	O
a	O
major	O
metabolite	O
of	O
acetanilide	O
in	O
human	O
blood,	O
subsequent	O
study	O
they	O
reported	O
large	O
doses	O
given	O
to	O
albino	O
rats	O
did	O
not	O
cause	O
methemoglobinemia.	O

The	O
study	O
found	O
the	O
combination	O
to	O
significantly	O
improve	O
negative	O
schizophrenia	O
symptoms,	O
and	O
people	O
taking	O
both	O
drugs	O
experienced	O
fewer	O
of	O
adverse	O
effects	O
commonly	O
associated	O
with	O
haloperidol.	O
haloperidol	B-Drug

In	O
extreme	O
cases	O
and,	O
in	O
particular,	O
where	O
severe	O
addiction	O
and/or	O
abuse	O
is	O
manifested,	O
an	O
inpatient	O
detoxification	O
may	O
be	O
required,	O
with	O
flumazenil	B-Drug
as	O
a	O
possible	O
tool.	O

In	O
the	O
1930s	O
and	O
early	O
1940s,	O
while	O
still	O
working	O
closely	O
with	O
SKF,	O
he	O
produced	O
hallucinogens	O
related	O
to	O
amphetamine	B-Drug
mescaline,	O
including	O
MDA,	O
for	O
firm	O
test	O
in	O
low	O
doses	O
as	O
diet	O
drugs	O
antidepressants.	O
mescaline	B-Drug

Therefore,	O
there	O
is	O
no	O
plausible	O
motivation	O
for	O
a	O
drug	O
dealer	O
to	O
distribute	O
LSD	B-Drug
in	O
this	O
manner.	O

GW	O
Pharmaceuticals	O
is	O
studying	O
plant-derived	O
tetrahydrocannabivarin	O
(as	O
GWP42004)	O
for	O
type	O
2	O
diabetes	O
in	O
addition	O
to	O
metformin.	O
metformin	B-Drug

Like	O
other	O
2C-X-NBOMe	O
molecules,	O
25I-NBOMe	B-Drug
is	O
a	O
derivative	O
of	O
the	O
2C	O
family	O
phenethylamines	O
described	O
by	O
chemist	O
Alexander	O
Shulgin	O
in	O
his	O
book	O
PiHKAL.	O

the	O
Blue	O
(1980)	O
Outland	O
(1981)	O
amphetamine-type	O
drug	O
Outside	O
Providence	O
(1999)	O
cannabis	O
and	O
Quaaludes	B-Drug

As	O
of	O
October	O
2015	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

On	O
15	O
September	O
2014	O
the	O
Turkey	O
government	O
banned	O
sale	O
of	O
MN-18.	O
MN-18	B-Drug

In	O
addition,	O
glucose	O
metabolites	O
produce	O
all	O
nonessential	O
amino	O
acids,	O
sugar	O
alcohols	O
such	O
as	O
mannitol	B-Drug
and	O
sorbitol,	O
fatty	O
cholesterol	O
nucleic	O
acids.	O

heroin,	O
LSD	B-Drug
Tomorrow,	O
When	O
the	O
War	O
Began	O
(2010)	O
heroin	B-Drug

Ranitidine	B-Drug
and	O
other	O
histamine	O
H2	O
receptor	O
antagonists	O
may	O
increase	O
the	O
risk	O
of	O
pneumonia	O
in	O
hospitalised	O
patients.	O

Very-high-dose	O
progestogen	O
therapy,	O
including	O
with	O
medroxyprogesterone	B-Drug
acetate,	O
megestrol	O
and	O
cyproterone	O
has	O
been	O
associated	O
activation	O
of	O
coagulation	O
a	O
dose-dependent	O
increased	O
risk	O
VTE.	O
acetate	I-Drug

In	O
2020,	O
an	O
internet	O
challenge	O
emerged	O
on	O
social	O
media	O
platform	O
TikTok	O
involving	O
deliberately	O
overdosing	O
diphenhydramine;	O
dubbed	O
the	O
Benadryl	O
challenge,	O
requires	O
participants	O
to	O
overdose	O
for	O
purpose	O
of	O
filming	O
resultant	O
psychoactive	O
effects,	O
and	O
has	O
been	O
implicated	O
in	O
several	O
hospitalisations	O
at	O
least	O
one	O
death.	O
diphenhydramine	B-Drug

Indeed,	O
in	O
2005,	O
labels	O
for	O
opium	B-Drug
tincture	O
began	O
to	O
include	O
the	O
concentration	O
of	O
morphine	B-Drug
(10	O
mg/mL)	O
large	O
text	O
beneath	O
words	O
"Opium	O
Tincture".	O

One	O
poorly	O
absorbable	O
antibiotic	O
is	O
vancomycin,	O
which	O
recommended	O
by	O
mouth	O
as	O
a	O
treatment	O
for	O
severe	O
Clostridium	O
difficile	O
colitis.	O
vancomycin	B-Drug

Prior	O
to	O
the	O
ban	O
taking	O
effect,	O
mephedrone	B-Drug
was	O
not	O
covered	O
by	O
Misuse	O
of	O
Drugs	O
Act	O
1971.	O

As	O
of	O
July	O
2014	O
lisdexamfetamine	B-Drug
was	O
sold	O
under	O
the	O
following	O
brands:	O
Elvanse,	O
Samexid,	O
Tyvense,	O
Venvanse,	O
and	O
Vyvanse.	O
Vyvanse	B-Drug

CBD	B-Drug
is	O
a	O
5-HT1A	O
receptor	O
agonist,	O
which	O
under	O
laboratory	O
research	O
to	O
determine	O
if	O
it	O
has	O
an	O
anxiolytic	O
effect.	O

Lisdexamfetamine	B-Drug
is	O
an	O
inactive	O
prodrug	O
that	O
converted	O
in	O
the	O
body	O
to	O
dextroamphetamine,	O
a	O
pharmacologically	O
active	O
compound	O
which	O
responsible	O
for	O
drug's	O
activity.	O
dextroamphetamine	B-Drug

Under	O
normal	O
circumstances,	O
the	O
patch	O
will	O
reach	O
its	O
full	O
effect	O
within	O
12	O
to	O
24	O
hours;	O
thus,	O
fentanyl	B-Drug
patches	O
are	O
often	O
prescribed	O
with	O
a	O
fast-acting	O
opioid	O
(such	O
as	O
morphine	B-Drug
or	O
oxycodone)	O
handle	O
breakthrough	O
pain.	O
oxycodone	B-Drug

It	O
is	O
formed	O
either	O
through	O
the	O
addition	O
of	O
acetic	O
anhydride,	O
which	O
can	O
only	O
acetylate	O
6	O
position	O
on	O
codeine	B-Drug
or	O
as	O
a	O
result	O
acid	O
with	O
catalyst	O
in	O
an	O
attempt	O
to	O
create	O
6-monoacetylmorphine,	O
equivalent	O
ester	O
morphine	B-Drug
slightly	O
more	O
potent	O
than	O
heroin	B-Drug
itself.	O
6-monoacetylmorphine	B-Drug

As	O
of	O
2005,	O
India	O
was	O
the	O
only	O
country	O
producing	O
licit	O
opium	B-Drug
(opium	O
gum)	O
for	O
both	O
domestic	O
use	O
and	O
export.	O

However,	O
using	O
more	O
accurate	O
techniques,	O
Papac	O
and	O
Foltz	O
(1990)	O
reported	O
that	O
1	O
g/kg	O
oral	O
LSD	B-Drug
given	O
to	O
a	O
single	O
male	O
volunteer	O
had	O
an	O
apparent	O
plasma	O
half-life	O
of	O
5.1	O
hours,	O
with	O
peak	O
concentration	O
5	O
ng	O

It	O
takes	O
15	O
to	O
60	O
minutes	O
for	O
the	O
effects	O
of	O
PCP	B-Drug
manifest.	O

He	O
had	O
some	O
psychiatric	O
patients	O
that	O
claimed	O
they	O
only	O
smoked	O
pot	O
but	O
their	O
drug	O
tests	O
were	O
positive	O
for	O
methamphetamine	B-Drug
use.	O

Newer	O
drugs	O
such	O
as	O
BIMU-8	O
and	O
CX-546	B-Drug
may	O
be	O
much	O
more	O
effective.	O

PCP	B-Drug
is	O
most	O
commonly	O
used	O
in	O
the	O
United	O
States.	O

In	O
tests	O
against	O
a	O
control,	O
Sprague-Dawley	O
rats	O
given	O
free	O
access	O
to	O
less-preferred	O
rat	O
chow	O
and	O
trained	O
operate	O
lever	O
repeatedly	O
obtain	O
preferred	O
performed	O
additional	O
work	O
when	O
methylphenidate,	O
d-amphetamine,	O
phenylpiracetam.	O
methylphenidate	B-Drug
d-amphetamine	B-Drug
phenylpiracetam	B-Drug

This	O
activity	O
may	O
be	O
associated	O
with	O
some	O
of	O
the	O
other	O
more	O
psychotic	O
features	O
PCP	B-Drug
intoxication,	O
which	O
is	O
evidenced	O
by	O
successful	O
use	O
D2	O
receptor	O
antagonists	O
(such	O
as	O
haloperidol)	O
in	O
treatment	O
psychosis.	O
haloperidol	B-Drug

PCP	B-Drug
is	O
self-administered	O
and	O
induces	O
FosB	O
expression	O
in	O
the	O
D1-type	O
medium	O
spiny	O
neurons	O
of	O
nucleus	O
accumbens,	O
accordingly,	O
excessive	O
use	O
known	O
to	O
cause	O
addiction.	O

In	O
the	O
mid-1990s,	O
Janssen	O
Pharmaceutica	O
developed	O
and	O
introduced	O
into	O
clinical	O
trials	O
Duragesic	B-Drug
patch,	O
which	O
is	O
a	O
formulation	O
of	O
an	O
inert	O
alcohol	O
gel	O
infused	O
with	O
select	O
fentanyl	B-Drug
doses,	O
are	O
worn	O
to	O
provide	O
constant	O
administration	O
opioid	O
over	O
period	O
48	O
72	O
hours.	O

Unlike	O
17-alkylated	O
AAS	O
such	O
as	O
methyltestosterone,	O
nandrolone	B-Drug
decanoate	I-Drug
is	O
not	O
associated	O
with	O
liver	O
toxicity.	O
methyltestosterone	B-Drug

However,	O
some	O
products	O
branded	O
as	O
Ivory	O
Wave	O
possibly	O
do	O
not	O
contain	O
MDPV.	O
MDPV	B-Drug

Ketobemidone	B-Drug
is	O
mostly	O
used	O
in	O
the	O
Scandinavian	O
countries,	O
with	O
Denmark	O
topping	O
statistics.	O

Respiratory	O
depression,	O
euphoria,	O
excessive	O
sedation	O
and	O
somnolence	O
(so-called	O
'nodding'	O
by	O
recreational	O
opioid	O
users),	O
constipation,	O
miosis	O
(pinpoint	O
pupils),	O
nausea,	O
bradycardia,	O
behavioral	O
disturbances,	O
severe	O
physical	O
psychological	O
dependence	O
on	O
morphine	B-Drug
is	O
more	O
likely	O
with	O
the	O
use	O
of	O
versus	O
dipropanoylmorphine.	O
dipropanoylmorphine	B-Drug

Until	O
the	O
early	O
1990s,	O
U.S.	O
market	O
for	O
methamphetamine	B-Drug
was	O
supplied	O
mostly	O
by	O
labs	O
run	O
drug	O
traffickers	O
in	O
both	O
Mexico	O
and	O
California.	O

THC	B-Drug
acetate	O
ester	O
was	O
investigated	O
as	O
a	O
possible	O
non-lethal	O
incapacitating	O
agent	O
part	O
of	O
the	O
Edgewood	O
Arsenal	O
experiments	O
at	O
some	O
point	O
between	O
1949	O
and	O
1975.	O

Sweden's	O
public	O
health	O
agency	O
suggested	O
classifying	O
5-MeO-MALT	B-Drug
as	O
a	O
hazardous	O
substance,	O
on	O
May	O
15,	O
2019.	O

However,	O
barbiturates	O
are	O
still	O
used	O
as	O
anticonvulsants	O
(e.g.,	O
phenobarbital	B-Drug
and	O
primidone)	O
general	O
anesthetics	O
sodium	B-Drug
thiopental).	O
primidone	B-Drug
thiopental	I-Drug

Lorazepam's	O
anticonvulsant	O
and	O
CNS	O
depressant	O
properties	O
are	O
useful	O
for	O
the	O
treatment	O
prevention	O
of	O
alcohol	O
withdrawal	O
syndrome.	O
Lorazepam	B-Drug

A	O
study	O
released	O
in	O
1997	O
examined	O
the	O
addictive	O
nature	O
of	O
both	O
crack	O
and	O
powder	O
cocaine	B-Drug
concluded	O
that	O
one	O
was	O
no	O
more	O
than	O
other.	O

N-acylethanolamines	O
such	O
as	O
PEA	B-Drug
often	O
act	O
signaling	O
molecules,	O
activating	O
receptors	O
and	O
regulating	O
a	O
variety	O
of	O
physiological	O
functions.	O

In	O
2020,	O
Bulgaria	O
became	O
the	O
first	O
country	O
in	O
European	O
Union	O
to	O
allow	O
retail	O
sales	O
of	O
food	O
products	O
and	O
supplements	O
containing	O
CBD,	O
despite	O
ongoing	O
discussion	O
within	O
EU	O
about	O
classification	O
CBD	B-Drug
as	O
a	O
novel	O
food.	O

An	O
analysis	O
of	O
samples	O
acquired	O
four	O
weeks	O
after	O
the	O
German	O
prohibition	O
JWH-018	B-Drug
took	O
place	O
found	O
that	O
manufacturers	O
had	O
shortened	O
alkyl	O
chain	O
by	O
one	O
carbon	O
to	O
circumvent	O
ban.	O

Butyrfentanyl	B-Drug
is	O
illegal	O
in	O
the	O
United	O
Kingdom	O
as	O
it	O
a	O
modification	O
of	O
fentanyl	B-Drug
"by	O
replacement	O
N-propionyl	O
group	O
by	O
another	O
acyl	O
group".	O

Ketoconazole	B-Drug
has	O
also	O
been	O
found	O
to	O
decrease	O
levels	O
of	O
endogenous	O
corticosteroids,	O
such	O
as	O
cortisol,	O
corticosterone,	O
and	O
aldosterone,	O
well	O
vitamin	O
D.Ketoconazole	O
displace	O
dihydrotestosterone	O
estradiol	O
from	O
sex	O
hormone-binding	O
globulin	O
in	O
vitro,	O
but	O
this	O
was	O
not	O
be	O
relevant	O
vivo.	O

GHB	B-Drug
has	O
at	O
least	O
two	O
distinct	O
binding	O
sites	O
in	O
the	O
central	O
nervous	O
system.	O

Additionally,	O
dosing	O
naltrexone	B-Drug
after	O
recent	O
opioid	O
use	O
could	O
lead	O
to	O
precipitated	O
withdrawal.	O

The	O
indazole	O
carboxamide	O
group,	O
including	O
APINACA	B-Drug
(AKB-48),	O
an	O
adamantyl	O
carboxamide,	O
and	O
AB-PINACA,	O
aminocarbonyl	O
is	O
example	O
of	O
a	O
new	O
group	O
synthetic	O
cannabinoids.	O
AKB-48	B-Drug
AB-PINACA	B-Drug

Atomoxetine,	O
nisoxetine	O
and	O
reboxetine	B-Drug
all	O
have	O
a	O
substitution	O
group	O
in	O
the	O
2'	O
position	O
are	O
selective	O
NRIs	O
while	O
compounds	O
that	O
4'	O
(like	O
fluoxetine	B-Drug
paroxetine)	O
SSRIs.	O
Atomoxetine	B-Drug
paroxetine	B-Drug

Phenytoin	B-Drug
may	O
increase	O
risk	O
of	O
suicidal	O
thoughts	O
or	O
behavior.	O

In	O
this	O
scenario	O
dissolved	O
cocaine	B-Drug
is	O
soaked	O
into	O
a	O
ball	O
of	O
cotton	O
wool,	O
which	O
placed	O
in	O
the	O
nostril	O
for	O
1015	O
minutes	O
immediately	O
before	O
procedure,	O
thus	O
performing	O
dual	O
role	O
both	O
numbing	O
area	O
to	O
be	O
cauterized,	O
and	O
vasoconstriction.	O

Mannitol	B-Drug
can	O
be	O
used	O
to	O
form	O
a	O
complex	O
with	O
boric	O
acid.	O

However,	O
PCP	B-Drug
may	O
also	O
interact	O
with	O
allosteric	O
sites	O
on	O
the	O
monoamine	O
transporters	O
to	O
produce	O
inhibition	O
of	O
reuptake.	O

Symptoms	O
of	O
overdose	O
mephobarbital	B-Drug
include	O
confusion,	O
decrease	O
in	O
or	O
loss	O
reflexes,	O
somnolence,	O
fever,	O
irritability,	O
hypothermia,	O
poor	O
judgment,	O
shortness	O
breath	O
slow/troubled	O
breathing,	O
slow	O
heartbeat,	O
slurred	O
speech,	O
staggering,	O
trouble	O
sleeping,	O
unusual	O
movements	O
the	O
eyes,	O
weakness.	O

The	O
drug	O
is	O
most	O
commonly	O
taken	O
orally	O
as	O
an	O
elixir,	O
tablet,	O
or	O
capsule,	O
although	O
rectal	O
and	O
subcutaneous	O
administration	O
has	O
the	O
same	O
advantages	O
with	O
hydrocodone	B-Drug
would	O
taking	O
a	O
tablet	O
powder	O
liquid	O
concentrate	O
buccally	O
sublingually.	O

Various	O
surveys	O
conducted	O
between	O
2015	O
and	O
2019	O
found	O
that	O
many	O
users	O
of	O
cannabis	O
substitute	O
it	O
for	O
prescription	O
drugs	O
(including	O
opioids),	O
alcohol,	O
tobacco;	O
most	O
those	O
who	O
used	O
in	O
place	O
alcohol	O
or	O
tobacco	B-Drug
either	O
reduced	O
stopped	O
their	O
intake	O
the	O
latter	O
substances.	O

Deaths	O
with	O
tramadol	B-Drug
overdose	O
have	O
been	O
reported	O
and	O
are	O
increasing	O
in	O
frequency	O
Northern	O
Ireland;	O
the	O
majority	O
of	O
these	O
overdoses	O
involves	O
other	O
drugs	O
including	O
alcohol.	O

The	O
average	O
THC	B-Drug
level	O
in	O
coffee	O
shops	O
the	O
Netherlands	O
is	O
about	O
1819%.The	O
levels	O
of	O
cannabis	O
sold	O
United	O
States	O
rose	O
dramatically	O
between	O
1970s	O
and	O
2000.	O

The	O
combination	O
of	O
fenfluramine	B-Drug
and	O
phentermine	B-Drug
was	O
proposed	O
in	O
1984.	O

Clonazepam	B-Drug
has	O
also	O
been	O
found	O
effective	O
in	O
treating	O
other	O
anxiety	O
disorders,	O
such	O
as	O
social	O
phobia,	O
but	O
this	O
is	O
an	O
off-label	O
use.	O

On	O
the	O
basis	O
of	O
preceding	O
knowledge,	O
it	O
has	O
been	O
proposed	O
that	O
inhibition	O
claustrum	O
(as	O
well	O
as,	O
"additionally,	O
deep	O
layers	O
cortex,	O
mainly	O
in	O
prefrontal	O
areas")	O
by	O
activation	O
KORs	O
these	O
areas	O
is	O
primarily	O
responsible	O
for	O
profound	O
consciousness-altering/dissociative	O
hallucinogen	O
effects	O
salvinorin	B-Drug
A	I-Drug
and	O
other	O
KOR	O
agonists.	O

Hydromorphone	B-Drug
was	O
patented	O
in	O
1923.	O

In	O
1999,	O
Burma,	O
the	O
heartland	O
of	O
Golden	O
Triangle,	O
was	O
second-largest	O
producer	O
heroin,	O
after	O
Afghanistan.	O
heroin	B-Drug

Folkman	O
persuaded	O
the	O
patient's	O
doctor	O
to	O
try	O
thalidomide,	O
and	O
that	O
conducted	O
a	O
clinical	O
trial	O
of	O
thalidomide	B-Drug
for	O
people	O
with	O
multiple	O
myeloma	O
in	O
which	O
about	O
third	O
subjects	O
responded	O
treatment.	O

Research	O
is	O
starting	O
to	O
show	O
that	O
morphine	B-Drug
and	O
related	O
drugs	O
may	O
indeed	O
have	O
peripheral	O
effects	O
as	O
well,	O
such	O
gel	O
working	O
on	O
burns.	O

Another	O
study	O
conducted	O
in	O
January	O
2013	O
found	O
that	O
Ligandrol	B-Drug
can	O
help	O
increase	O
lean	O
muscle	O
mass,	O
and	O
was	O
generally	O
well	O
tolerated	O
by	O
test	O
subjects.	O

Between	O
1998	O
and	O
2004,	O
13%	O
of	O
emergency-room	O
admissions	O
for	O
"poisoning	O
with	O
criminal	O
intentions"	O
in	O
a	O
clinic	O
Bogot,	O
Colombia	O
have	O
been	O
attributed	O
to	O
hyoscine,	O
44%	O
benzodiazepines.	O
hyoscine	B-Drug

In	O
many	O
countries,	O
underprescription	O
of	O
morphine	B-Drug
is	O
rampant	O
because	O
the	O
high	O
prices	O
and	O
lack	O
training	O
in	O
prescription	O
poppy-based	O
drugs.	O

Desogestrel	B-Drug
(via	O
etonogestrel)	O
is	O
a	O
very	O
potent	O
progestogen	O
and	O
inhibits	O
ovulation	O
at	O
low	O
doses,	O
in	O
the	O
microgram	O
range.	O
etonogestrel	B-Drug

Methyltestosterone	B-Drug
is	O
used	O
in	O
the	O
treatment	O
of	O
delayed	O
puberty,	O
hypogonadism,	O
cryptorchidism,	O
and	O
erectile	O
dysfunction	O
males,	O
low	O
doses	O
to	O
treat	O
menopausal	O
symptoms	O
(specifically	O
for	O
osteoporosis,	O
hot	O
flashes,	O
increase	O
libido	O
energy),	O
postpartum	O
breast	O
pain	O
engorgement,	O
cancer	O
women.	O

Medications	O
containing	O
desogestrel	B-Drug
as	O
the	O
only	O
active	O
ingredient	O
(as	O
opposed	O
to	O
being	O
used	O
in	O
conjunction	O
with	O
ethinylestradiol,	O
like	O
combined	O
oral	O
contraceptives)	O
do	O
not	O
show	O
an	O
increased	O
thrombosis	O
risk	O
and	O
are	O
therefore	O
safer	O
than	O
second-generation	O
birth-control	O
pills	O
regards	O
thrombosis.	O

In	O
the	O
six	O
years	O
from	O
2000	O
to	O
2006,	O
U.S.	O
spent	O
$4.7	O
billion	O
on	O
Plan	O
Colombia,	O
an	O
effort	O
eradicate	O
coca	B-Drug
production	O
in	O
Colombia.	O

Enzalutamide	B-Drug
is	O
primarily	O
bound	O
to	O
albumin.	O

The	O
average	O
half-life	O
of	O
hydrocodone	B-Drug
is	O
4.5	O
hours.	O

Apalutamide	B-Drug
has	O
a	O
high	O
potential	O
for	O
drug	O
interactions.	O

In	O
addition	O
to	O
binding	O
serotonin	O
receptors,	O
buspirone	B-Drug
is	O
an	O
antagonist	O
of	O
the	O
dopamine	O
D2	O
receptor	O
with	O
weak	O
affinity.	O

Currently,	O
dihydrocodeine	B-Drug
and	O
nicocodeine	B-Drug
are	O
used	O
as	O
second-line	O
codeine	B-Drug
replacements.	O

In	O
the	O
US,	O
outpatient	O
treatment	O
programs	O
must	O
be	O
certified	O
by	O
federal	O
Substance	O
Abuse	O
and	O
Mental	O
Health	O
Services	O
Administration	O
(SAMHSA)	O
registered	O
Drug	O
Enforcement	O
(DEA)	O
in	O
order	O
to	O
prescribe	O
methadone	B-Drug
for	O
opioid	O
addiction.	O

It	O
has	O
similar	O
activity	O
to	O
that	O
of	O
apalutamide	B-Drug
and,	O
with	O
therapy,	O
circulates	O
at	O
concentrations	O
those	O
steady	O
state.	O

As	O
of	O
2015	O
China	O
had	O
the	O
largest	O
methadone	B-Drug
maintenance	O
treatment	O
program	O
with	O
over	O
250,000	O
people	O
in	O
650	O
clinics	O
27	O
provinces.	O

Other	O
studies	O
have	O
indicated	O
the	O
risk	O
of	O
a	O
scleroderma-like	O
condition	O
resulting	O
from	O
combination	O
5-HTP	O
and	O
carbidopa.	O
carbidopa	B-Drug

In	O
addition	O
to	O
its	O
affinity	O
for	O
the	O
PR,	O
trimegestone	O
has	O
moderate	O
mineralocorticoid	O
receptor	O
(42120%	O
of	O
that	O
aldosterone),	O
weak	O
very	O
glucocorticoid	O
and	O
androgen	O
receptors	O
(913%	O
dexamethasone	B-Drug
12.4%	O
testosterone,	O
respectively),	O
no	O
estrogen	O
(less	O
than	O
0.02%	O
estradiol).	O

Due	O
to	O
its	O
high	O
rates	O
of	O
abuse,	O
the	O
Drug	O
Enforcement	O
Administration	O
(DEA)	O
reclassified	O
codeine	B-Drug
as	O
Schedule	O
III	O
for	O
increased	O
meticulous	O
monitoring.	O

Estrogen	O
receptors	O
(ER)	O
like	O
ER	O
and	O
include	O
activation	O
function	O
1	O
(AF1)	O
domain	O
2	O
(AF2)	O
in	O
which	O
SERMS	O
act	O
as	O
antagonists	O
for	O
the	O
AF2	O
domain,	O
while	O
pure	O
antiestrogens	O
ICI	B-Drug
182,780	I-Drug
164,384	O
are	O
AF1	O
domains.	O

These	O
include	O
pergolide	O
and	O
cabergoline,	O
but	O
not	O
the	O
more	O
dopamine-specific	O
lisuride.	O
cabergoline	B-Drug

Much	O
pharmaceutical	O
drug	O
design	O
has	O
attempted	O
to	O
focus	O
on	O
selective	O
COX-2	O
inhibition	O
as	O
a	O
way	O
minimize	O
the	O
gastrointestinal	O
side	O
effects	O
of	O
NSAIDs	O
such	O
aspirin.	O
aspirin	B-Drug

Serotonin	O
depletion	O
following	O
MDMA	B-Drug
use	O
can	O
cause	O
depression	O
in	O
subsequent	O
days.	O

In	O
the	O
United	O
States	O
in	O
1937,	O
Marihuana	B-Drug
Tax	O
Act	O
was	O
passed,	O
and	O
prohibited	O
production	O
of	O
hemp	O
addition	O
to	O
cannabis.	O

Nabiximols	B-Drug
is	O
a	O
branded	O
product	O
name	O
from	O
tincture	O
manufacturing	O
pharmaceutical	O
company.	O

The	O
only	O
European	O
countries	O
that	O
now	O
use	O
the	O
brand	O
Palfium	B-Drug
are	O
Netherlands,	O
Ireland	O
and	O
Luxembourg.	O

The	O
74	O
kb	O
mupirocin	B-Drug
gene	O
cluster	O
contains	O
six	O
multi-domain	O
enzymes	O
and	O
twenty-six	O
other	O
peptides	O
(Table	O
1).	O

JWH-193	B-Drug
has	O
a	O
binding	O
affinity	O
at	O
the	O
CB1	O
receptor	O
of	O
6	O
nM,	O
around	O
seven	O
times	O
more	O
tightly	O
than	O
parent	O
compound	O
JWH-200,	O
JWH-200	B-Drug

Imovane	O
(zopiclone)	O
a	O
non-benzodiazepine	O
hypnotic.	O
zopiclone	B-Drug

Another	O
drug	O
para-Methoxyamphetamine	B-Drug
(4-MA)	O
also	O
known	O
as	O
pink	O
ecstasy,	O
PMA,	O
"Death"	O
or	O
"Dr.	O
Death",	O
it	O
is	O
similar	O
to	O
MDMA	B-Drug
but	O
they	O
can	O
take	O
up	O
an	O
hour	O
produce	O
effects,	O
which	O
result	O
in	O
hyperthermia	O
and	O
subsequently,	O
organ	O
failure.	O
ecstasy	B-Drug
PMA	B-Drug

Many	O
of	O
these	O
individual	O
genes	O
are	O
directly	O
related	O
to	O
aspects	O
addiction	O
associated	O
with	O
cocaine	B-Drug
exposure.	O

Prednisone	B-Drug
is	O
a	O
synthetic	O
glucocorticoid	O
used	O
for	O
its	O
anti-inflammatory	O
and	O
immunosuppressive	O
properties.	O

Similar	O
experiments	O
performed	O
by	O
Edward	O
Jenner	O
over	O
his	O
smallpox	B-Drug
vaccine	I-Drug
were	O
equally	O
conceptually	O
flawed.	O

Conversely,	O
Australian	O
anaesthetists	O
have	O
requested	O
a	O
ban	O
on	O
pholcodine	B-Drug
due	O
to	O
the	O
high	O
anaphylaxis	O
rate	O
in	O
country.	O

Therefore,	O
preventing	O
a	O
withdrawal	O
syndrome	O
requires	O
that	O
prolonged	O
infusion	O
be	O
gradually	O
withdrawn,	O
and	O
sometimes,	O
continued	O
tapering	O
of	O
dose	O
with	O
an	O
oral	O
long-acting	O
benzodiazepine	O
such	O
as	O
clorazepate	B-Drug
dipotassium.	O
dipotassium	I-Drug

Dutasteride	B-Drug
has	O
been	O
studied	O
in	O
combination	O
with	O
bicalutamide	B-Drug
the	O
treatment	O
of	O
prostate	O
cancer.	O

More	O
specifically,	O
a	O
report	O
by	O
the	O
United	O
Nations	O
Office	O
on	O
Drugs	O
and	O
Crime	O
(UNODC)	O
stated	O
that	O
there	O
were	O
significant	O
quantities	O
of	O
heroin	B-Drug
being	O
seized	O
in	O
areas	O
along	O
east	O
coast	O
Africa	O
with	O
most	O
originating	O
from	O
Afghanistan.	O

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression.	O

Prior	O
to	O
the	O
availability	O
of	O
sofosbuvir,	O
hepatitis	O
C	O
treatments	O
involved	O
6	O
12	O
months	O
treatment	O
with	O
an	O
interferon-based	O
regimen	O
that	O
provided	O
cure	O
rates	O
70%	O
or	O
less	O
and	O
was	O
associated	O
severe	O
side	O
effects	O
including	O
anemia,	O
depression,	O
rash,	O
nausea,	O
diarrhea,	O
fatigue.	O
sofosbuvir	B-Drug

There	O
was	O
a	O
new	O
discussion	O
about	O
its	O
fate	O
on	O
April	O
23,	O
2012,	O
where	O
it	O
decided	O
that	O
the	O
bill	O
would	O
be	O
rewritten	O
and	O
phenazepam	B-Drug
still	O
banned.	O

The	O
higher	O
prevalence	O
of	O
central	O
nervous	O
system	O
side	O
effects	O
in	O
African	O
as	O
compared	O
to	O
American	O
and	O
European	O
patients	O
treated	O
with	O
efavirenz	B-Drug
has	O
been	O
attributed	O
the	O
frequency	O
CYP2B6	O
slow	O
metabolizer	O
phenotype	O
sub-Saharan	O
populations.	O

A	O
California	O
laboratory	O
that	O
analyzed	O
confidentially	O
submitted	O
drug	O
samples	O
first	O
detected	O
MDMA	B-Drug
in	O
1975.	O

Based	O
on	O
a	O
systematic	O
review,	O
paracetamol	B-Drug
was	O
recommended	O
by	O
the	O
American	O
College	O
of	O
Physicians	O
and	O
Pain	O
Society	O
as	O
first-line	O
treatment	O
for	O
lower	O
back	O
pain.	O

Ephedrine	B-Drug
also	O
decreases	O
gastric	O
emptying.	O

Tamoxifen	B-Drug
is	O
useful	O
in	O
the	O
treatment	O
of	O
peripheral	O
precocious	O
puberty,	O
for	O
instance	O
due	O
to	O
McCuneAlbright	O
syndrome,	O
both	O
girls	O
and	O
boys.	O

(JWH-302)	O
JWH-302	B-Drug

In	O
the	O
1980s	O
and	O
1990s	O
formula	O
changed	O
to	O
using	O
codeine	B-Drug
promethazine	B-Drug
cough	O
syrup,	O
somewhat	O
like	O
Glutethimide	B-Drug
combination	O
that	O
was	O
popular	O
from	O
seventies	O
up	O
early	O
nineties.	O

cannabis,	O
cocaine	B-Drug
Adventureland	O
(2009)	O
cannabis	O
Air	O
America	O
(1990)	O

Amitriptyline	B-Drug
is	O
readily	O
absorbed	O
from	O
the	O
gastrointestinal	O
tract	O
(90-95%).	O

The	O
process	O
gave	O
rise	O
to	O
various	O
concentrations	O
of	O
hydromorphone,	O
dihydromorphine,	O
hydromorphinol,	O
and	O
oxymorphone	B-Drug
during	O
the	O
experiments.	O
hydromorphone	B-Drug
dihydromorphine	B-Drug
hydromorphinol	B-Drug

As	O
discussed	O
the	O
main	O
addictive	O
component	O
is	O
heroin.	O
heroin	B-Drug

All	O
drugs	O
in	O
the	O
NBOMe	O
series,	O
including	O
25I-NBOMe,	O
became	O
illegal	O
Russia	O
October	O
2011.	O
25I-NBOMe	B-Drug

They	O
can	O
be	O
thought	O
of	O
as	O
the	O
functional	O
opposites	O
AR	O
agonists,	O
for	O
instance	O
androgens	O
and	O
anabolic	O
steroids	O
(AAS)	O
like	O
testosterone,	O
DHT,	O
nandrolone	B-Drug
selective	O
androgen	O
receptor	O
modulators	O
(SARMs)	O
enobosarm.	O
enobosarm	B-Drug

This	O
was	O
the	O
conclusion	O
of	O
a	O
2017	O
hybrid	O
systematic	O
review	O
studies	O
spironolactone	B-Drug
for	O
acne	O
in	O
women	O
as	O
well,	O
which	O
found	O
that	O
hyperkalemia	O
rare	O
and	O
invariably	O
mild	O
clinically	O
insignificant.	O

The	O
average	O
THC	B-Drug
level	O
in	O
coffee	O
shops	O
the	O
Netherlands	O
is	O
about	O
1819%.The	O
levels	O
of	O
cannabis	O
sold	O
United	O
States	O
rose	O
dramatically	O
between	O
1970s	O
and	O
2000.	O

This	O
group	O
included	O
opium	B-Drug
derivatives,	O
like	O
heroin,	O
as	O
well	O
LSD.In	O
1969,	O
fearing	O
that	O
low	O
punishments	O
would	O
attract	O
international	O
drug	O
traffickers,	O
the	O
government	O
increased	O
for	O
crimes	O
involving	O
most	O
gross	O
degree,	O
and	O
corresponding	O
laws	O
on	O
smuggling	O
were	O
to	O
a	O
maximum	O
penalty	O
of	O
six	O
years.	O
heroin	B-Drug

In	O
addition	O
to	O
functioning	O
as	O
an	O
endogenous	O
prohormone,	O
androstenedione	B-Drug
also	O
has	O
weak	O
androgenic	O
activity	O
in	O
its	O
own	O
right.	O

In	O
2016,	O
fentanyl	B-Drug
and	O
analogues	O
were	O
the	O
most	O
common	O
cause	O
of	O
overdose	O
deaths	O
in	O
United	O
States	O
at	O
more	O
than	O
20,000,	O
about	O
half	O
all	O
opioid-related	O
deaths.	O

Tetrahydrocannabinol	B-Drug
(THC)	O
is	O
the	O
primary	O
psychoactive	O
component	O
of	O
Cannabis	O
plant.	O
THC	B-Drug

Methadone	B-Drug
and	O
its	O
major	O
metabolite,	O
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine	O
(EDDP),	O
are	O
often	O
measured	O
in	O
urine	O
as	O
part	O
of	O
a	O
drug	O
abuse	O
testing	O
program,	O
plasma	O
or	O
serum	O
to	O
confirm	O
diagnosis	O
poisoning	O
hospitalized	O
victims,	O
whole	O
blood	O
assist	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
violation	O
case	O
sudden	O
death.	O

The	O
positions	O
of	O
major	O
tobacco	B-Drug
companies	O
on	O
the	O
issue	O
secondhand	O
smoke	O
is	O
somewhat	O
varied.	O

Conversely,	O
naltrexone	B-Drug
antagonism	O
at	O
the	O
opioid	O
receptor	O
can	O
be	O
overcome	O
with	O
higher	O
doses	O
of	O
opioids.	O

Cole	O
Memorandum	O
Congressional	O
Cannabis	O
Caucus	O
Legality	O
of	O
cannabis	O
by	O
U.S.	O
jurisdiction	O
on	O
American	O
Indian	O
reservations	O
Decriminalization	O
non-medical	O
in	O
the	O
United	O
States	O
Marihuana	B-Drug
Tax	O
Act	O
1937	O
and	O
military	O
Removal	O
from	O
Schedule	O
I	O
Controlled	O
Substances	O

In	O
a	O
comparative	O
study,	O
flutamide	O
significantly	O
improved	O
scalp	O
hair	O
growth	O
(21%	O
reduction	O
in	O
Ludwig	O
scores)	O
hyperandrogenic	O
women	O
after	O
1	O
year	O
of	O
treatment,	O
whereas	O
cyproterone	O
acetate	O
and	O
finasteride	B-Drug
were	O
ineffective.	O

The	O
ethynyl	O
group	O
of	O
norethisterone	B-Drug
is	O
preserved	O
in	O
approximately	O
90%	O
all	O
its	O
metabolites.	O

In	O
2018,	O
results	O
were	O
first	O
published	O
which	O
suggested	O
that	O
thalidomide's	O
teratogenic	O
effects	O
are	O
mediated	O
through	O
degradation	O
of	O
the	O
transcription	O
factor,	O
SALL4,	O
an	O
as	O
yet	O
unverified	O
finding.	O
thalidomide	B-Drug

The	O
long	O
term	O
safety	O
and	O
effectiveness	O
of	O
modafinil	B-Drug
have	O
not	O
been	O
determined.	O

The	O
onset	O
of	O
heroin's	O
effects	O
depends	O
upon	O
the	O
route	O
administration.	O
heroin	B-Drug

It	O
produces	O
effects	O
in	O
animals	O
similar	O
to	O
those	O
of	O
tetrahydrocannabinol	B-Drug
(THC),	O
a	O
cannabinoid	O
naturally	O
present	O
cannabis,	O
leading	O
its	O
use	O
synthetic	O
cannabis	O
products	O
that	O
some	O
countries	O
are	O
sold	O
legally	O
as	O
"incense	O
blends".	O
THC	B-Drug

Phenytoin	B-Drug
is	O
believed	O
to	O
protect	O
against	O
seizures	O
by	O
causing	O
voltage-dependent	O
block	O
of	O
voltage	O
gated	O
sodium	O
channels.	O

Ciclosporin	B-Drug
blocks	O
the	O
formation	O
of	O
mitochondrial	O
permeability	O
transition	O
pore,	O
which	O
has	O
been	O
found	O
to	O
cause	O
much	O
damage	O
associated	O
with	O
head	O
injury	O
and	O
neurodegenerative	O
diseases.	O

Inhalation	O
by	O
smoking	O
cocaine	B-Drug
is	O
one	O
of	O
the	O
several	O
ways	O
drug	O
consumed.	O

Clonazepam	B-Drug
is	O
generally	O
not	O
recommended	O
for	O
use	O
in	O
elderly	O
people	O
insomnia	O
due	O
to	O
its	O
high	O
potency	O
relative	O
other	O
benzodiazepines.	O

The	O
commercial	O
product	O
contains	O
no	O
codeine	B-Drug
or	O
promethazine,	O
but	O
claims	O
to	O
"Slow	O
Your	O
Roll"	O
with	O
a	O
combination	O
of	O
herbal	O
ingredients	O
such	O
as	O
valerian	O
root	O
and	O
rose	O
hips	O
well	O
the	O
hormone	O
melatonin.	O
promethazine	B-Drug
melatonin	B-Drug

Medical	O
examiners	O
concluded	O
that	O
musician	O
Prince	O
died	O
on	O
April	O
21,	O
2016,	O
from	O
an	O
accidental	O
fentanyl	B-Drug
overdose.	O

Blood	O
or	O
plasma	O
fentanyl	B-Drug
concentrations	O
are	O
expected	O
to	O
be	O
in	O
a	O
range	O
of	O
0.33.0	O
g/L	O
persons	O
using	O
the	O
medication	O
therapeutically,	O
110	O
intoxicated	O
people	O
and	O
3300	O
victims	O
acute	O
overdosage.	O

The	O
benzodiazepine	O
of	O
choice	O
in	O
North	O
America	O
for	O
initial	O
treatment	O
is	O
lorazepam,	O
due	O
to	O
its	O
relatively	O
long	O
duration	O
action	O
(28	O
hours)	O
when	O
injected,	O
and	O
rapid	O
onset	O
action,	O
which	O
thought	O
be	O
high	O
affinity	O
GABA	O
receptors	O
low	O
lipid	O
solubility,	O
causes	O
it	O
remain	O
the	O
vascular	O
compartment.	O
lorazepam	B-Drug

Factors	O
such	O
as	O
poverty	O
that	O
are	O
frequently	O
associated	O
with	O
PCE	O
have	O
a	O
much	O
stronger	O
influence	O
on	O
children's	O
intellectual	O
and	O
academic	O
abilities	O
than	O
does	O
exposure	O
to	O
cocaine	B-Drug
in	O
isolation.	O

Naloxone	B-Drug
can	O
completely	O
or	O
partially	O
reverse	O
an	O
opioid	O
overdose.	O

Infrequent	O
adverse	O
reactions	O
in	O
patients	O
taking	O
opioids	O
for	O
pain	O
relief	O
include:	O
dose-related	O
respiratory	O
depression	O
(especially	O
with	O
more	O
potent	O
opioids),	O
confusion,	O
hallucinations,	O
delirium,	O
urticaria,	O
hypothermia,	O
bradycardia/tachycardia,	O
orthostatic	O
hypotension,	O
dizziness,	O
headache,	O
urinary	O
retention,	O
ureteric	O
or	O
biliary	O
spasm,	O
muscle	O
rigidity,	O
myoclonus	O
(with	O
high	O
doses),	O
and	O
flushing	O
(due	O
to	O
histamine	O
release,	O
except	O
fentanyl	B-Drug
remifentanil).	O
remifentanil	B-Drug

The	O
psychotomimetic	O
(psychosis-mimicking)	O
effects	O
of	O
psilocin	B-Drug
can	O
be	O
blocked	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
the	O
5-HT2A	O
antagonist	O
drug	O
ketanserin.	O

Believing	O
MDMA	B-Drug
allowed	O
users	O
to	O
strip	O
away	O
habits	O
and	O
perceive	O
the	O
world	O
clearly,	O
Shulgin	O
called	O
drug	O
window.	O

Boldenone	B-Drug
undecylenate	I-Drug

THC	B-Drug
targets	O
receptors	O
in	O
a	O
manner	O
far	O
less	O
selective	O
than	O
endocannabinoid	O
molecules	O
released	O
during	O
retrograde	O
signaling,	O
as	O
the	O
drug	O
has	O
relatively	O
low	O
cannabinoid	O
receptor	O
affinity.	O

The	O
results	O
of	O
that	O
trial	O
were	O
published	O
in	O
the	O
New	O
England	O
Journal	O
Medicine	O
1999.After	O
further	O
work	O
was	O
done	O
by	O
Celgene	O
and	O
others,	O
2006	O
U.S.	O
Food	O
Drug	O
Administration	O
granted	O
accelerated	O
approval	O
for	O
thalidomide	B-Drug
combination	O
with	O
dexamethasone	B-Drug
treatment	O
newly	O
diagnosed	O
multiple	O
myeloma	O
patients.	O

A	O
2014	O
systematic	O
review	O
noted	O
that	O
low	O
doses	O
of	O
amphetamine	B-Drug
also	O
improve	O
memory	O
consolidation,	O
in	O
turn	O
leading	O
to	O
improved	O
recall	O
information	O
non-ADHD	O
youth.	O

The	O
precise	O
mechanism	O
of	O
action	O
for	O
thalidomide	B-Drug
is	O
not	O
known,	O
although	O
efforts	O
to	O
identify	O
thalidomide's	O
teratogenic	O
generated	O
2,000	O
research	O
papers	O
and	O
the	O
proposal	O
15	O
or	O
16	O
plausible	O
mechanisms	O
by	O
year	O
2000.	O

Since	O
diprenorphine	O
also	O
has	O
partial	O
agonistic	O
properties	O
of	O
its	O
own,	O
it	O
should	O
not	O
be	O
used	O
on	O
humans	O
in	O
the	O
event	O
that	O
they	O
are	O
accidentally	O
exposed	O
to	O
etorphine	B-Drug
or	O
carfentanil.	O
carfentanil	B-Drug

Remifentanil	B-Drug
is	O
a	O
Schedule	O
II	O
narcotic	O
controlled	O
substance	O
in	O
the	O
United	O
States	O
with	O
DEA	O
ACSCN	O
of	O
9739	O
and	O
2013	O
annual	O
aggregate	O
manufacturing	O
quota	O
3750	O
grams,	O
unchanged	O
from	O
prior	O
year.	O

The	O
methodology	O
of	O
clinical	O
trials	O
was	O
further	O
developed	O
by	O
Sir	O
Austin	O
Bradford	O
Hill,	O
who	O
had	O
been	O
involved	O
in	O
the	O
streptomycin	B-Drug
trials.	O

Oscar-winning	O
British	O
actor	O
George	O
Sanders	O
died	O
of	O
a	O
suicidal	O
overdose	O
Nembutal	B-Drug
in	O
Spain.	O

Due	O
to	O
these	O
reports,	O
some	O
physicians	O
may	O
check	O
liver	O
function	O
tests	O
prior	O
starting	O
naltrexone,	O
and	O
periodically	O
thereafter.	O
naltrexone	B-Drug

For	O
those	O
with	O
bronchospasm,	O
propofol	B-Drug
also	O
has	O
mild	O
bronchodilating	O
effect.	O

Medical	O
Hypotheses	O
suggested	O
leuprorelin	B-Drug
as	O
a	O
possible	O
treatment	O
for	O
autism,	O
the	O
hypothetical	O
method	O
of	O
action	O
being	O
now	O
defunct	O
hypothesis	O
that	O
autism	O
is	O
caused	O
by	O
mercury,	O
with	O
additional	O
unfounded	O
assumption	O
mercury	O
binds	O
irreversibly	O
to	O
testosterone	O
and	O
therefore	O
can	O
help	O
cure	O
lowering	O
levels	O
thereby	O
levels.	O

It	O
was	O
initially	O
put	O
forward	O
in	O
the	O
media	O
that	O
ecstasy	B-Drug
tablet	O
taken	O
by	O
Wood	O
probably	O
laced	O
with	O
heroin	B-Drug
or	O
morphine,	O
purported	O
cause	O
of	O
her	O
death,	O
but	O
coroner's	O
report	O
determined	O
only	O
MDMA	B-Drug
present	O
Wood's	O
body.	O
morphine	B-Drug

Cocaine	B-Drug
possession	O
is	O
illegal	O
across	O
the	O
U.S.	O

These	O
metabolites	O
are	O
the	O
chemicals	O
recognized	O
by	O
common	O
antibody-based	O
"drug	O
tests";	O
in	O
case	O
of	O
THC	B-Drug
or	O
others,	O
these	O
loads	O
do	O
not	O
represent	O
intoxication	O
(compare	O
to	O
ethanol	O
breath	O
tests	O
that	O
measure	O
instantaneous	O
blood	O
alcohol	O
levels),	O
but	O
an	O
integration	O
past	O
consumption	O
over	O
approximately	O
month-long	O
window.	O

Australia's	O
National	O
Cannabis	O
Prevention	O
and	O
Information	O
Centre	O
(NCPIC)	O
states	O
that	O
the	O
buds	O
(infructescences)	O
of	O
female	O
cannabis	O
plant	O
contain	O
highest	O
concentration	O
THC,	O
followed	O
by	O
leaves.	O
THC	B-Drug

Nalorphine	B-Drug
and	O
nalmefene	B-Drug
are	O
dual	O
MOR	O
antagonists	O
KOR	O
agonists	O
that	O
have	O
been	O
used	O
clinically	O
as	O
antidotes	O
for	O
opioid	O
overdose,	O
although	O
the	O
specific	O
role	O
significance	O
of	O
activation	O
in	O
this	O
indication,	O
if	O
any,	O
is	O
uncertain.	O

5-reductase	O
inhibitors	O
like	O
finasteride	B-Drug
have	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
(excessive	O
facial	O
and/or	O
body	O
hair	O
growth)	O
women.	O

One	O
example	O
is	O
the	O
case	O
of	O
Big	O
Lurch,	O
a	O
former	O
rapper	O
with	O
history	O
violent	O
crime,	O
who	O
was	O
convicted	O
murdering	O
and	O
cannibalizing	O
his	O
roommate	O
while	O
under	O
influence	O
PCP.	O
PCP	B-Drug

Tibolone,	O
3-hydroxytibolone,	O
and	O
3-hydroxytibolone	O
act	O
as	O
antagonists	O
of	O
the	O
glucocorticoid	O
mineralocorticoid	O
receptors,	O
with	O
preference	O
for	O
receptor.	O
Tibolone	B-Drug

Brands	O
include	O
Adepril,	O
ADT,	O
Ambival,	O
Amicon,	O
Amilavil,	O
Amilin,	O
Amiline,	O
Amineurin,	O
Amiplin,	O
Amirol,	O
Amit,	O
Amitin,	O
Amitone,	O
Amitrac,	O
Amitrip,	O
Amitriptilina,	O
Amitriptilino,	O
Amitriptilins,	O
Amitriptine,	O
Amitriptylin,	O
Amitriptyline,	O
Amitriptylinhydrochlorid,	O
Amitriptylini,	O
Amitriptylinum,	O
Amitryp,	O
Amotrip,	O
Amyline,	O
Amypres,	O
Amytril,	O
Amyzol,	O
Anapsique,	O
Arpidox,	O
Deprelio,	O
Elatrol,	O
Elatrolet,	O
Elavil,	O
Endep,	O
Fiorda,	O
Laroxyl,	O
Latilin,	O
Levate,	O
Maxitrip,	O
Maxivalet,	O
Mitryp,	O
Modup,	O
Normaln,	O
Odep,	O
Pinsaun,	O
Polytanol,	O
Protanol,	O
Qualitriptine,	O
Redomex,	O
Saroten,	O
Sarotex,	O
Stelminal,	O
Syneudon,	O
Teperin,	O
Trepiline,	O
Triamyl,	O
Trilin,	O
Trip,	O
Tripta,	O
Triptiline,	O
Triptizol,	O
Triptric,	O
Triptyl,	O
Triptyline,	O
Tripyline,	O
Trynol,	O
Tryptalgin,	O
Tryptanol,	O
Tryptin,	O
Tryptizol,	O
Tryptomer,	O
and	O
Vanatrip.	O
Amitriptyline	B-Drug
Elavil	B-Drug

The	O
buprenorphine/naloxone	B-Drug
sublingual	O
film	O
(e.g.	O
trade	O
name	O
Suboxone)	O
achieves	O
higher	O
buprenorphine	B-Drug
maximum	O
plasma	O
concentrations	O
(Cmax)	O
and	O
area	O
under	O
the	O
curve	O
(AUC,	O
a	O
measure	O
of	O
total	O
drug	O
exposure)	O
than	O
original	O
tablets	O
at	O
equal	O
doses.	O

The	O
risk	O
of	O
hepatotoxicity	O
with	O
flutamide	O
treatment	O
is	O
far	O
higher	O
than	O
nilutamide	O
or	O
bicalutamide.	O
bicalutamide	B-Drug

Pure	O
salts	O
of	O
LSD	B-Drug
are	O
triboluminescent,	O
emitting	O
small	O
flashes	O
white	O
light	O
when	O
shaken	O
in	O
the	O
dark.	O

Diazepam	B-Drug
is	O
a	O
good	O
choice	O
for	O
tapering	O
those	O
using	O
high	O
doses	O
of	O
other	O
benzodiazepines	O
since	O
it	O
has	O
long	O
half-life	O
thus	O
withdrawal	O
symptoms	O
are	O
tolerable.	O

Cannabinoidergics	O
(CB-1	O
receptor	O
agonists	O
or	O
atypical	O
psychedelics)	O
such	O
as	O
THC	B-Drug
from	O
cannabis	O
(Cannabis)	O

However,	O
the	O
elimination	O
half-life	O
of	O
naloxone	B-Drug
can	O
be	O
shorter	O
than	O
that	O
opioid	O
itself,	O
so	O
repeat	O
dosing	O
or	O
continuous	O
infusion	O
may	O
required,	O
a	O
longer	O
acting	O
antagonist	O
such	O
as	O
nalmefene	B-Drug
used.	O

However,	O
PCP	B-Drug
may	O
also	O
interact	O
with	O
allosteric	O
sites	O
on	O
the	O
monoamine	O
transporters	O
to	O
produce	O
inhibition	O
of	O
reuptake.	O

Conversely,	O
cocaine	B-Drug
use	O
appears	O
to	O
be	O
increasing	O
in	O
Europe	O
with	O
the	O
highest	O
prevalences	O
Spain,	O
United	O
Kingdom,	O
Italy,	O
and	O
Ireland.	O

The	O
elimination	O
half	O
life	O
of	O
estazolam	B-Drug
is	O
an	O
average	O
19	O
hours,	O
with	O
a	O
range	O
831	O
hours.	O

Tasmania	O
also	O
had	O
25%	O
of	O
the	O
world's	O
opium	B-Drug
and	O
codeine	B-Drug
production.	O

Chlorthalidone	B-Drug
is	O
the	O
official	O
name	O
of	O
medication	O
according	O
to	O
(USAN),	O
which	O
naming	O
system	O
coordinated	O
by	O
USAN	O
Council,	O
co-sponsored	O
American	O
Medical	O
Association	O
(AMA),	O
United	O
States	O
Pharmacopeial	O
Convention	O
(USP),	O
and	O
Pharmacists	O
(APhA).	O

Many	O
were	O
based	O
on	O
fentanyl	B-Drug
or	O
meperidine.	O
meperidine	B-Drug

Finasteride	B-Drug
is	O
most	O
effective	O
on	O
the	O
crown	O
but	O
can	O
reduce	O
hair	O
loss	O
in	O
all	O
areas	O
of	O
scalp.	O

Tamoxifen	B-Drug
did	O
eventually	O
receive	O
marketing	O
approval	O
as	O
a	O
fertility	O
treatment,	O
but	O
the	O
class	O
of	O
compounds	O
never	O
proved	O
useful	O
in	O
human	O
contraception.	O

The	O
mupirocin	B-Drug
pathway	O
also	O
contains	O
several	O
tandem	O
acyl	O
carrier	O
protein	O
doublets	O
or	O
triplets.	O

Methorphan	B-Drug
comes	O
in	O
two	O
isomeric	O
forms,	O
each	O
with	O
differing	O
pharmacology	O
and	O
effects:	O
Dextromethorphan	B-Drug
-	O
An	O
over-the-counter	O
cough	O
suppressant,	O
as	O
well	O
dissociative	O
hallucinogen.	O

Temazepam	B-Drug
is	O
a	O
white,	O
crystalline	O
substance,	O
very	O
slightly	O
soluble	O
in	O
water,	O
and	O
sparingly	O
alcohol.	O

Thalidomide,	O
sold	O
under	O
the	O
brand	O
names	O
Contergan	B-Drug
and	O
Thalomid	B-Drug
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
number	O
of	O
cancers	O
(including	O
multiple	O
myeloma),	O
graft-versus-host	O
disease,	O
skin	O
conditions	O
including	O
complications	O
leprosy.	O
Thalidomide	B-Drug

In	O
1997,	O
in	O
response	O
to	O
mounting	O
concern	O
over	O
serious	O
side	O
effects	O
of	O
ephedra,	O
the	O
FDA	O
proposed	O
a	O
ban	O
on	O
products	O
containing	O
8	O
mg	O
or	O
more	O
ephedrine	B-Drug
alkaloids	O
and	O
stricter	O
labeling	O
low-dose	O
ephedra	O
supplements.	O

In	O
August	O
2004	O
the	O
synthesis	O
and	O
effects	O
of	O
5-MeO-DALT	B-Drug
were	O
published	O
by	O
Erowid.	O

MAOIs	O
appear	O
to	O
be	O
particularly	O
indicated	O
for	O
outpatients	O
with	O
dysthymia	O
complicated	O
by	O
panic	O
disorder	O
or	O
hysteroid	O
dysphoriaNewer	O
such	O
as	O
selegiline	B-Drug
(typically	O
used	O
in	O
the	O
treatment	O
of	O
Parkinson's	O
disease)	O
and	O
reversible	O
MAOI	O
moclobemide	B-Drug
provide	O
a	O
safer	O
alternative	O
are	O
now	O
sometimes	O
first-line	O
therapy.	O

His	O
cellmate	O
Diego	O
Delgado	O
has	O
contacts	O
in	O
the	O
Medellin	O
cartel	O
and	O
convinces	O
George	O
to	O
help	O
him	O
go	O
into	O
cocaine	B-Drug
business.	O

Cannabidiol	B-Drug
(CBD)	O
is	O
another	O
major	O
constituent	O
of	O
the	O
plant.	O
CBD	B-Drug

There	O
is	O
some	O
mixed	O
evidence	O
that	O
agomelatine,	O
a	O
5-HT2C	O
antagonist,	O
an	O
effective	O
antidepressant.	O
agomelatine	B-Drug

Lefetamine	B-Drug
(Santenol)	O
is	O
a	O
drug	O
which	O
stimulant	O
and	O
also	O
an	O
analgesic	O
with	O
effects	O
comparable	O
to	O
codeine.	O
codeine	B-Drug

There	O
are	O
also	O
data	O
associating	O
spontaneous	O
abortion	O
with	O
cocaine	B-Drug
use.	O

(developmental	O
code	O
name	O
HRP-002),	O
or	O
levonorgestrel	B-Drug
17-butanoate,	O
is	O
a	O
steroidal	O
progestin	O
of	O
the	O
19-nortestosterone	B-Drug
group	O
which	O
was	O
developed	O
by	O
World	O
Health	O
Organization	O
(WHO)	O
in	O
collaboration	O
with	O
Contraceptive	O
Development	O
Branch	O
(CDB)	O
National	O
Institute	O
Child	O
and	O
Human	O
as	O
long-acting	O
injectable	O
contraceptive.	O

People	O
with	O
normal	O
vitamin	B-Drug
B12	I-Drug
levels	O
have	O
stores	O
to	O
make	O
the	O
effects	O
of	O
nitrous	O
oxide	O
insignificant,	O
unless	O
exposure	O
is	O
repeated	O
and	O
prolonged	O
(nitrous	O
abuse).	O

This	O
often	O
included	O
complementary	O
businesses,	O
such	O
as	O
pharmacy	O
and	O
chemical	O
manufacturing,	O
which	O
provided	O
a	O
cover	O
for	O
the	O
purchase	O
of	O
chemicals	O
needed	O
to	O
refine	O
coca-paste	O
purchased	O
in	O
coca-growing	O
regions	O
into	O
cocaine	B-Drug
export	O
USA.	O

Naproxen	B-Drug
may	O
have	O
antiviral	O
activity	O
against	O
influenza.	O

Parecoxib	B-Drug
is	O
a	O
COX2	O
selective	O
inhibitor.	O

Semorphone	O
(Mr	O
2264)	O
is	O
an	O
opiate	O
analogue	O
that	O
N-substituted	O
derivative	O
of	O
oxymorphone.	O
oxymorphone	B-Drug

Sexual	O
dysfunction,	O
including	O
erectile	O
loss	O
of	O
libido,	O
and	O
reduced	O
ejaculate	O
volume,	O
may	O
occur	O
in	O
3.4	O
to	O
15.8%	O
men	O
treated	O
with	O
finasteride	B-Drug
or	O
dutasteride.	O
dutasteride	B-Drug

Clotiazepam	B-Drug
has	O
a	O
short	O
elimination	O
half-life	O
and	O
is	O
less	O
prone	O
to	O
accumulation	O
after	O
repeated	O
dosing	O
compared	O
longer-acting	O
benzodiazepine	O
agents.	O

As	O
such,	O
there	O
is	O
a	O
considerable	O
separation	O
in	O
the	O
ratios	O
of	O
androgenic	O
and	O
progestogenic	O
activity	O
for	O
ethisterone	O
norethisterone.	O
norethisterone	B-Drug

MDMA	B-Drug
became	O
one	O
of	O
the	O
four	O
most	O
widely	O
used	O
illicit	O
drugs	O
in	O
US,	O
along	O
with	O
cocaine,	O
heroin,	O
and	O
cannabis.	O
cocaine	B-Drug
heroin	B-Drug

In	O
the	O
EU,	O
bevacizumab	B-Drug
in	O
combination	O
with	O
fluoropyrimidine-based	O
chemotherapy	O
is	O
indicated	O
for	O
treatment	O
of	O
adults	O
metastatic	O
carcinoma	O
colon	O
or	O
rectum.	O

Metenolone	B-Drug
esters	O
are	O
used	O
mainly	O
in	O
the	O
treatment	O
of	O
anemia	O
due	O
to	O
bone	O
marrow	O
failure.	O

Nandrolone	B-Drug
has	O
strong	O
anabolic	O
effects	O
and	O
weak	O
androgenic	O
effects,	O
which	O
give	O
them	O
a	O
mild	O
side	O
effect	O
profile	O
make	O
especially	O
suitable	O
for	O
use	O
in	O
women	O
children.	O

hashish,	O
codeine,	O
LSD	B-Drug
and	O
cannabis,	O
references	O
to	O
heroin	B-Drug
Midsommar	O
(2019)	O
psilocybin	O
mushrooms	O
A	O
Midsummer	O
Night's	O
Rave	O
(2002)	O
hashish	B-Drug
codeine	B-Drug

The	O
wall	O
is	O
thickened,	O
and	O
the	O
functional	O
bladder	O
capacity	O
as	O
low	O
10150	O
mL.Management	O
of	O
ketamine-induced	O
cystitis	O
involves	O
ketamine	B-Drug
cessation	O
first	O
step.	O

In	O
2017	O
it	O
was	O
found	O
that	O
some	O
pills	O
being	O
sold	O
as	O
MDMA	B-Drug
contained	O
pentylone,	O
which	O
can	O
cause	O
very	O
unpleasant	O
agitation	O
and	O
paranoia.	O
pentylone	B-Drug

Chests	O
of	O
opium	B-Drug
were	O
sold	O
in	O
auctions	O
Calcutta	O
with	O
the	O
understanding	O
that	O
independent	O
purchasers	O
would	O
then	O
smuggle	O
it	O
into	O
China.	O

GHB	B-Drug
has	O
been	O
used	O
as	O
a	O
club	O
drug,	O
apparently	O
starting	O
in	O
the	O
1990s,	O
small	O
doses	O
of	O
can	O
act	O
euphoriant	O
and	O
are	O
believed	O
to	O
be	O
aphrodisiac.	O

TFMFly	B-Drug

The	O
pH	O
of	O
gastrointestinal	O
content	O
and	O
urine	O
affects	O
the	O
absorption	O
excretion	O
methamphetamine.	O
methamphetamine	B-Drug

In	O
2003,	O
a	O
team	O
led	O
by	O
Oda	O
Manami	O
at	O
Oita	O
Medical	O
University	O
reported	O
that	O
CYP3A4,	O
member	O
of	O
the	O
Cytochrome	O
P450	O
family,	O
was	O
not	O
responsible	O
enzyme	O
since	O
itraconazole,	O
known	O
inhibitor	O
did	O
affect	O
its	O
metabolism.	O
itraconazole	B-Drug

The	O
minister	O
stressed	O
that	O
the	O
drug	O
fentanyl	B-Drug
used	O
in	O
gas,	O
which	O
is	O
widely	O
as	O
a	O
pain	O
medication,	O
"cannot	O
itself	O
be	O
called	O
lethal".	O

LSD	B-Drug
is	O
a	O
chiral	O
compound	O
with	O
two	O
stereocenters	O
at	O
the	O
carbon	O
atoms	O

AM-2201	B-Drug

Ibogaine	B-Drug
has	O
also	O
been	O
reported	O
in	O
multiple	O
small-study	O
cohorts	O
to	O
reduce	O
cravings	O
for	O
methamphetamine.	O
methamphetamine	B-Drug

Most	O
MDMA	B-Drug
enters	O
Australia	O
from	O
the	O
Netherlands,	O
UK,	O
Asia,	O
and	O
US.	O

People	O
with	O
cancer	O
undergoing	O
chemotherapy	O
are	O
often	O
given	O
dexamethasone	B-Drug
to	O
counteract	O
certain	O
side	O
effects	O
of	O
their	O
antitumor	O
treatments.	O

The	O
bioavailability	O
of	O
intranasal	O
fentanyl	B-Drug
is	O
about	O
7090%,	O
but	O
with	O
some	O
imprecision	O
due	O
to	O
clotted	O
nostrils,	O
pharyngeal	O
swallow	O
and	O
incorrect	O
administration.	O

Despite	O
the	O
similarity	O
in	O
name,	O
MDMA	B-Drug
and	O
MPPP	B-Drug
are	O
unrelated	O
should	O
not	O
be	O
conflated.	O

The	O
generic	O
name	O
of	O
the	O
unesterified	O
form	O
drug	O
is	O
drostanolone	B-Drug
or	O
dromostanolone	O
and	O
former	O
its	O
INN,	O
BAN,	O
DCF	O
while	O
there	O
no	O
USAN.	O

Mirtazapine	B-Drug
significantly	O
improves	O
pre-existing	O
symptoms	O
of	O
nausea,	O
vomiting,	O
diarrhea,	O
and	O
irritable	O
bowel	O
syndrome	O
in	O
afflicted	O
individuals.	O

US	O
production	O
of	O
Methysergide,	O
(Sansert),	O
was	O
discontinued	O
on	O
the	O
manufacturer's	O
own	O
behalf	O
in	O
2002.	O
Methysergide	B-Drug

Nalbuphine	B-Drug
was	O
initially	O
designated	O
as	O
a	O
Schedule	O
II	O
controlled	O
substance	O
in	O
the	O
United	O
States	O
along	O
with	O
other	O
opioids	O
upon	O
introduction	O
of	O
1970	O
Controlled	O
Substances	O
Act.	O

Boldenone	B-Drug
cypionate	O
(Equilon	O
100)	O

Unprocessed	O
cocaine,	O
such	O
as	O
coca	B-Drug
leaves,	O
are	O
occasionally	O
purchased	O
and	O
sold,	O
but	O
this	O
is	O
exceedingly	O
rare	O
it	O
much	O
easier	O
more	O
profitable	O
to	O
conceal	O
smuggle	O
in	O
powdered	O
form.	O
cocaine	B-Drug

Naloxone	B-Drug
can	O
completely	O
or	O
partially	O
reverse	O
an	O
opioid	O
overdose.	O

In	O
addition,	O
MDMA	B-Drug
has	O
immunosuppressive	O
effects	O
in	O
the	O
peripheral	O
nervous	O
system	O
and	O
pro-inflammatory	O
central	O
system.	O

Integrating	O
Medication-Assisted	O
Treatment	O
into	O
outpatient	O
primary	O
care	O
practices	O
improves	O
patient	O
access	O
to	O
Suboxone.	O
Suboxone	B-Drug

Amphetamine	B-Drug
and	O
other	O
dopaminergic	O
drugs	O
also	O
increase	O
power	O
output	O
at	O
fixed	O
levels	O
of	O
perceived	O
exertion	O
by	O
overriding	O
a	O
"safety	O
switch",	O
allowing	O
the	O
core	O
temperature	O
limit	O
to	O
in	O
order	O
access	O
reserve	O
capacity	O
that	O
is	O
normally	O
off-limits.	O

Flunitrazepam	B-Drug
and	O
other	O
sedative	O
hypnotic	O
drugs	O
are	O
detected	O
frequently	O
in	O
cases	O
of	O
people	O
suspected	O
driving	O
under	O
the	O
influence	O
drugs.	O

However,	O
urinalysis	O
conducted	O
by	O
the	O
Department	O
of	O
Defense	O
has	O
been	O
challenged	O
for	O
reliability	O
testing	O
metabolite	O
cocaine.	O
cocaine	B-Drug

It	O
is	O
the	O
4-propylthio	O
analog	O
of	O
mescaline.	O
mescaline	B-Drug

Ergine	B-Drug
(lysergic	O
acid	I-Drug
amide),	O
listed	O
as	O
a	O
sedative	O
but	O
considered	O
by	O
some	O
to	O
be	O
psychedelic.	O
lysergic	B-Drug
amide	I-Drug

In	O
addition	O
to	O
being	O
5-HT1B	O
agonists,	O
triptans	O
(i.e.	O
sumatriptan,	O
almotriptan,	O
zolmitriptan,	O
naratriptan,	O
eletriptan,	O
frovatriptan	O
and	O
rizatriptan)	O
are	O
also	O
agonists	O
at	O
the	O
5-HT1D	O
receptor,	O
which	O
contributes	O
their	O
antimigraine	O
effect	O
caused	O
by	O
vasoconstriction	O
of	O
blood	O
vessels	O
in	O
brain.	O
sumatriptan	B-Drug
almotriptan	B-Drug
zolmitriptan	B-Drug
eletriptan	B-Drug

In	O
the	O
United	O
Kingdom,	O
MDMA	B-Drug
was	O
made	O
illegal	O
in	O
1977	O
by	O
a	O
modification	O
order	O
to	O
existing	O
Misuse	O
of	O
Drugs	O
Act	O
1971.	O

A	O
seizure	O
of	O
a	O
record	O
amount	O
fentanyl	B-Drug
occurred	O
on	O
February	O
2,	O
2019,	O
by	O
U.S.	O
Customs	O
and	O
Border	O
Protection	O
in	O
Nogales,	O
Arizona.	O

Fludrocortisone	B-Drug
is	O
marketed	O
mainly	O
under	O
the	O
brand	O
names	O
Astonin	O
and	O
Astonin-H,	O
whereas	O
more	O
widely	O
used	O
fludrocortisone	B-Drug
acetate	I-Drug
sold	O
as	O
Florinef	O
but	O
also	O
several	O
other	O
including	O
Cortineff,	O
Florinefe,	O
Fludrocortison.	O

You	O
are	O
seizing	O
and	O
consuming	O
coca	B-Drug
leaves	O
that	O
were	O
probably	O
grown	O
processed	O
in	O
2003	O
2002."Other	O
observers	O
say	O
this	O
points	O
to	O
the	O
ultimate	O
ineffectiveness	O
of	O
Plan	O
stopping	O
flow	O
drugs	O
addressing	O
more	O
important	O
or	O
underlying	O
issues	O
like	O
providing	O
a	O
viable	O
alternative	O
for	O
landless	O
other	O
peasants,	O
who	O
turn	O
cultivation	O
due	O
lack	O
economic	O
possibilities,	O
addition	O
having	O
deal	O
with	O
tumultuous	O
civil	O
conflict	O
between	O
state,	O
guerrillas	O
paramilitaries.	O

Testosterone	O
enanthate,	O
sold	O
under	O
the	O
brand	O
names	O
Delatestryl	B-Drug
and	O
Xyosted	O
among	O
others,	O
is	O
an	O
androgen	O
anabolic	O
steroid	O
(AAS)	O
medication	O
which	O
used	O
mainly	O
in	O
treatment	O
of	O
low	O
testosterone	O
levels	O
men.	O

Loperamide	B-Drug
metabolizes	O
into	O
an	O
MPTP-like	O
compound,	O
but	O
is	O
unlikely	O
to	O
exert	O
neurotoxicity.	O

Extracts	O
such	O
as	O
hashish	B-Drug
and	O
hash	B-Drug
oil	I-Drug
typically	O
contain	O
more	O
THC	B-Drug
than	O
high	O
potency	O
cannabis	O
infructescences.	O

Nabilone	B-Drug
was	O
approved	O
in	O
Austria	O
to	O
treat	O
chemotherapy-induced	O
nausea	O
2013;	O
it	O
already	O
Spain	O
for	O
the	O
same	O
indication	O
and	O
legal	O
Belgium	O
glaucoma,	O
spasticity	O
multiple	O
sclerosis,	O
wasting	O
due	O
AIDS,	O
chronic	O
pain.	O

Blockade	O
of	O
the	O
AR	O
by	O
bicalutamide	B-Drug
in	O
pituitary	O
gland	O
and	O
hypothalamus	O
results	O
prevention	O
negative	O
feedback	O
androgens	O
on	O
hypothalamicpituitarygonadal	O
axis	O
(HPG	O
axis)	O
males	O
consequent	O
disinhibition	O
luteinizing	O
hormone	O
(LH)	O
secretion.	O

For	O
example,	O
white	O
blood	O
cells	O
of	O
people	O
who	O
had	O
been	O
given	O
LSD	B-Drug
in	O
a	O
clinical	O
setting	O
were	O
examined	O
for	O
visible	O
chromosomal	O
abnormalities;	O
overall,	O
there	O
appeared	O
to	O
be	O
no	O
lasting	O
changes.	O

5-MeO-MPT	O
5-MeO-MiPT,	O
also	O
known	O
as	O
'Moxy';	O
has	O
entactogenic	O
properties	O
5-MeO-MALT	B-Drug
5-MeO-DET	B-Drug
5-MeO	O
5-MeO-MiPT	B-Drug

Acute	O
stress	O
elevates	O
the	O
levels	O
of	O
inhibitory	O
neurosteroids	O
like	O
allopregnanolone,	O
and	O
these	O
are	O
known	O
to	O
counteract	O
many	O
effects	O
stress.	O
allopregnanolone	B-Drug

Known	O
colloquially	O
as	O
"Laborit's	O
drug",	O
chlorpromazine	B-Drug
was	O
released	O
onto	O
the	O
market	O
in	O
1953	O
by	O
Rhne-Poulenc	O
and	O
given	O
trade	O
name	O
Largactil,	O
derived	O
from	O
large	O
"broad"	O
acti*	O
"activity.	O
Largactil	B-Drug

MDMA:	O
The	O
"euphoriant	O
drugs	O
such	O
as	O
MDMA	B-Drug
('ecstasy')	O
and	O
MDEA	O
('eve')"	O
are	O
popular	O
among	O
young	O
adults.	O
ecstasy	B-Drug

Adjunctive	O
to	O
morphine	B-Drug
or	O
on	O
its	O
own,	O
ketamine	B-Drug
reduces	O
use,	O
pain	O
level,	O
nausea,	O
and	O
vomiting	O
after	O
surgery.	O

These	O
results	O
suggest	O
that	O
PCP	B-Drug
is	O
a	O
highly	O
selective	O
ligand	O
of	O
the	O
NMDAR	O
and	O
2	O
receptor.	O

The	O
risk	O
of	O
venous	O
thromboembolisms	O
with	O
thalidomide	B-Drug
seems	O
to	O
be	O
increased	O
when	O
patients	O
are	O
treated	O
oral	O
contraceptives	O
or	O
other	O
cytotoxic	O
agents	O
(including	O
doxorubicin	B-Drug
and	O
melphalan)	O
concurrently.	O

Some	O
signs	O
of	O
an	O
overdose	O
cocaine	B-Drug
are	O
difficulty	O
breathing,	O
loss	O
urine	O
control,	O
bluish	O
color	O
the	O
skin,	O
awareness	O
or	O
surroundings,	O
and	O
high	O
blood	O
pressure.	O

Naltrexone	B-Drug
can	O
be	O
described	O
as	O
a	O
substituted	O
oxymorphone	B-Drug
here	O

The	O
group	O
of	O
men	O
responsible	O
travelled	O
from	O
New	O
Zealand	O
to	O
a	O
'mothership'	O
in	O
the	O
South	O
Pacific	O
Ocean	O
on	O
yacht	O
where	O
they	O
collected	O
cocaine	B-Drug
and	O
attempted	O
sail	O
into	O
Australia,	O
but	O
were	O
intercepted	O
south	O
coast	O
Australia.	O

Pemoline	B-Drug
is	O
synthesized	O
by	O
the	O
condensation	O
of	O
racemic	O
ethyl	O
mandelate	O
with	O
guanidine.	O

In	O
the	O
United	O
States,	O
meloxicam	B-Drug
is	O
approved	O
for	O
use	O
only	O
in	O
canines,	O
whereas	O
(due	O
to	O
concerns	O
about	O
liver	O
damage)	O
it	O
carries	O
warnings	O
against	O
its	O
cats	O
except	O
one-time	O
during	O
surgery.	O

By	O
the	O
18th	O
century,	O
medicinal	O
properties	O
of	O
opium	B-Drug
and	O
laudanum	B-Drug
were	O
well	O
known,	O
term	O
"laudanum"	O
came	O
to	O
refer	O
any	O
combination	O
alcohol.	O

25CN-NBOH	B-Drug
(sometimes	O
also	O
referred	O
to	O
as	O
NBOH-2C-CN)	O
is	O
a	O
compound	O
indirectly	O
derived	O
from	O
the	O
phenethylamine	B-Drug
series	O
of	O
hallucinogens,	O
which	O
was	O
discovered	O
in	O
2014	O
by	O
group	O
researchers	O
at	O
University	O
Copenhagen.	O
NBOH-2C-CN	B-Drug

They	O
feature	O
a	O
phenethylamine	B-Drug
core	O
with	O
methyl	O
group	O
attached	O
to	O
the	O
alpha	O
carbon	O
resulting	O
in	O
amphetamine,	O
along	O
additional	O
substitutions.	O

Cocaine,	O
heroin,	O
cannabis,	O
and	O
other	O
such	O
drugs	O
continued	O
to	O
be	O
legally	O
available	O
without	O
prescription	O
as	O
long	O
they	O
were	O
labeled.	O
Cocaine	B-Drug
heroin	B-Drug

Mephedrone	B-Drug
was	O
reported	O
as	O
having	O
been	O
sold	O
ecstasy	B-Drug
in	O
the	O
Australian	O
city	O
of	O
Cairns,	O
along	O
with	O
ethylcathinone,	O
2008.	O

When	O
assayed	O
in	O
mice,	O
repeated	O
exposure	O
to	O
MDPV	B-Drug
causes	O
not	O
only	O
an	O
anxiogenic	O
effect	O
but	O
also	O
increased	O
aggressive	O
behaviour,	O
a	O
feature	O
that	O
has	O
already	O
been	O
observed	O
humans.	O

Naltrexone	B-Drug
is	O
available	O
and	O
most	O
commonly	O
used	O
in	O
the	O
form	O
of	O
an	O
oral	O
tablet	O
(50	O
mg).	O

stipulate	O
that	O
methadone	B-Drug
treatment	O
can	O
be	O
initiated	O
by	O
centers	O
whereas	O
buprenorphine	B-Drug
any	O
medical	O
doctor,	O
specialized	O
doctors	O
and	O
centers.	O

Because	O
THC	B-Drug
production	O
drops	O
off	O
once	O
pollination	O
occurs,	O
the	O
male	O
plants	O
(which	O
produce	O
little	O
themselves)	O
are	O
eliminated	O
before	O
they	O
shed	O
pollen	O
to	O
prevent	O
pollination,	O
thus	O
inducing	O
development	O
of	O
parthenocarpic	O
fruits	O
gathered	O
in	O
dense	O
infructescences.	O

In	O
the	O
Philippines,	O
alprazolam	B-Drug
is	O
legally	O
classified	O
as	O
a	O
"dangerous	O
drug"	O
under	O
Comprehensive	O
Dangerous	O
Drugs	O
Act	O
of	O
2002,	O
along	O
with	O
other	O
schedule	O
drugs	O
listed	O
in	O
1971	O
Convention	O
on	O
Psychotropic	O
Substances.	O

Wu	O
told	O
the	O
coroner	O
he	O
believed	O
death	O
was	O
due	O
to	O
hypersensitivity	O
either	O
cannabis	O
or	O
equagesic.	O
equagesic	B-Drug

Rocephin	B-Drug
(ceftriaxone),	O
a	O
broad-spectrum	O
cephalosporin	O
antibiotic.	O
ceftriaxone	B-Drug

In	O
these	O
early	O
years,	O
Purdue	O
Pharma	O
was	O
aware	O
of	O
OxyContin	B-Drug
abuse,	O
including	O
"reports	O
that	O
the	O
pills	O
were	O
being	O
crushed	O
and	O
snorted;	O
stolen	O
from	O
pharmacies;	O
some	O
doctors	O
charged	O
with	O
selling	O
prescriptions,"	O
according	O
to	O
The	O
New	O
York	O
Times,	O
based	O
on	O
a	O
confidential	O
Justice	O
Department	O
report	O
revealed	O
in	O
May	O
2018.	O

JWH-018	B-Drug
has	O
been	O
shown	O
to	O
cause	O
profound	O
changes	O
in	O
CB1	O
receptor	O
density	O
following	O
administration,	O
causing	O
desensitization	O
its	O
effects	O
more	O
rapidly	O
than	O
related	O
cannabinoids.	O

The	O
tetrahydrocannabinol	B-Drug
(THC)	O
and	O
other	O
cannabinoids	O
dissolve	O
into	O
the	O
alcohol.	O
THC	B-Drug

Due	O
to	O
its	O
progestogenic	O
activity,	O
levonorgestrel	B-Drug
has	O
antigonadotropic	O
effects,	O
and	O
is	O
able	O
suppress	O
fertility	O
gonadal	O
sex	O
hormone	O
production	O
in	O
both	O
women	O
men.	O

While	O
Rock	O
'n'	O
roll	O
music	O
has	O
been	O
described	O
as	O
"steeped	O
in	O
rebellion,"	O
there	O
is	O
a	O
long	O
list	O
of	O
musicians	O
who	O
have	O
abused	O
heroin,	O
including	O
John	O
Lennon,	O
Keith	O
Richards,	O
Bob	O
Dylan,	O
Buffy	O
Sainte-Marie,	O
Jim	O
Morrison,	O
Jerry	O
Garcia,	O
Jimi	O
Hendrix,	O
Janis	O
Joplin	O
and	O
Eric	O
Clapton,	O
Kurt	O
Cobain,	O
Shannon	O
Hoon,	O
Courtney	O
Love,	O
Scott	O
Weiland,	O
Anthony	O
Kiedis,	O
Layne	O
Staley,	O
David	O
Gahan	O
others.	O
heroin	B-Drug

Given	O
the	O
known	O
metabolic	O
liberation	O
(and	O
presence	O
as	O
an	O
impurity)	O
of	O
amantadine	B-Drug
in	O
related	O
compound	O
APINACA,	O
it	O
is	O
suspected	O
that	O
hydrolysis	O
amide	O
group	O
APICA	O
may	O
also	O
release	O
amantadine.	O
APINACA	B-Drug

The	O
risk	O
of	O
abuse	O
lorazepam	B-Drug
is	O
increased	O
in	O
dependent	O
people.	O

Other	O
progestogens	O
such	O
as	O
medroxyprogesterone	B-Drug
acetate,	O
hydroxyprogesterone	O
caproate,	O
and	O
gestonorone	O
caproate	O
have	O
also	O
been	O
studied,	O
but	O
inadequate	O
effectiveness.	O
acetate	I-Drug

Approximately	O
17	O
million	O
Europeans	O
(5.1%)	O
have	O
used	O
cocaine	B-Drug
at	O
least	O
once	O
and	O
3.5	O
(1.1%)	O
in	O
the	O
last	O
year.	O

